{"generated":"2026-08-08","source":"med-freedom-map SQLite export for static GitHub Pages","counts":{"jurisdictions":36,"procedures":68,"access_records":2448},"jurisdictions":[{"id":"jur-us-federal","name":"United States - Federal","type":"FEDERAL","country_code":"US","latitude":38.9,"longitude":-77.0,"general_notes":"Federal law: Most psychedelics are Schedule I (no accepted medical use). Right-to-Try laws exist federally for terminally ill patients. FDA Expanded Access (compassionate use) program. ClinicalTrials.gov registration required for trials.","level":"SOVEREIGN","parent_id":null},{"id":"jur-us-or","name":"United States - Oregon","type":"US_STATE","country_code":"US","latitude":44.0,"longitude":-120.5,"general_notes":"Psilocybin Services Act (Measure 109, 2020). Regulated psilocybin therapy program operational since 2023. Also decriminalized personal possession of all drugs (Measure 110, 2020) though Measure 110 was partially rolled back in 2024.","level":"SUBNATIONAL","parent_id":"jur-us-federal"},{"id":"jur-us-co","name":"United States - Colorado","type":"US_STATE","country_code":"US","latitude":39.0,"longitude":-105.5,"general_notes":"Proposition 122 (Natural Medicine Health Act, 2022). Regulated psilocybin therapy program, also decriminalized personal possession/growing of psilocybin, DMT, ibogaine, and mescaline (excluding peyote).","level":"SUBNATIONAL","parent_id":"jur-us-federal"},{"id":"jur-us-ca","name":"United States - California","type":"US_STATE","country_code":"US","latitude":36.8,"longitude":-119.4,"general_notes":"SB 519 (decriminalization of psychedelics) passed Senate, stalled. Multiple city-level decrim ordinances (Oakland, Santa Cruz, San Francisco). Right to Try state law.","level":"SUBNATIONAL","parent_id":"jur-us-federal"},{"id":"jur-us-tx","name":"United States - Texas","type":"US_STATE","country_code":"US","latitude":31.0,"longitude":-100.0,"general_notes":"Right to Try state law. Large medical center presence (Texas Medical Center). Active clinical trial scene. Generally conservative regulatory environment.","level":"SUBNATIONAL","parent_id":"jur-us-federal"},{"id":"jur-us-fl","name":"United States - Florida","type":"US_STATE","country_code":"US","latitude":27.7,"longitude":-81.5,"general_notes":"Right to Try state law. Large elderly population drives regenerative medicine interest. Multiple stem cell clinics operating in regulatory gray zones.","level":"SUBNATIONAL","parent_id":"jur-us-federal"},{"id":"jur-au","name":"Australia","type":"COUNTRY","country_code":"AU","latitude":-25.3,"longitude":133.8,"general_notes":"TGA rescheduled psilocybin and MDMA for therapeutic use (July 2023) for PTSD and treatment-resistant depression. Authorized prescribers only. Strict regulatory framework via TGA Special Access Scheme and Authorized Prescriber Scheme.","level":"SOVEREIGN","parent_id":null},{"id":"jur-ch","name":"Switzerland","type":"COUNTRY","country_code":"CH","latitude":46.8,"longitude":8.2,"general_notes":"Compassionate use/exceptional authorization for psychedelic therapy (LSD, psilocybin, MDMA) via BAG permits. Swissmedic oversight. Assisted dying permitted (Dignitas, etc.). Advanced biotech regulatory environment.","level":"SOVEREIGN","parent_id":null},{"id":"jur-ca","name":"Canada","type":"COUNTRY","country_code":"CA","latitude":56.1,"longitude":-106.3,"general_notes":"Special Access Programme (SAP) for psilocybin and MDMA therapy. Section 56 exemptions for psychedelics. MAID (Medical Assistance in Dying) legal federally since 2016, expanded 2021. Generally progressive regulatory stance on emerging therapies.","level":"SOVEREIGN","parent_id":null},{"id":"jur-mx","name":"Mexico","type":"COUNTRY","country_code":"MX","latitude":23.6,"longitude":-102.5,"general_notes":"Growing medical tourism for stem cell therapies (less restrictive regulations). Some clinics operating with minimal oversight. Ibogaine clinics for addiction in Baja region. Regulatory quality variable.","level":"SOVEREIGN","parent_id":null},{"id":"jur-hn-prospera","name":"Honduras - Próspera ZEDE","type":"ZEDE","country_code":"HN","latitude":16.2,"longitude":-86.5,"general_notes":"Special Economic Development Zone (ZEDE) on Roatán Island. Semi-autonomous jurisdiction with its own regulatory framework. Gene therapy, stem cell, and innovative therapeutic hubs developing. Light-touch regulation, attracting biotech investment. Legal status of ZEDEs contested under Honduran law.","level":"SPECIAL_ZONE","parent_id":null},{"id":"jur-nl","name":"Netherlands","type":"COUNTRY","country_code":"NL","latitude":52.1,"longitude":5.3,"general_notes":"Longstanding truffle (psilocybin sclerotia) legality. Euthanasia legal for unbearable suffering with strict criteria. Advanced medical research environment.","level":"SOVEREIGN","parent_id":null},{"id":"jur-de","name":"Germany","type":"COUNTRY","country_code":"DE","latitude":51.2,"longitude":10.5,"general_notes":"Growing psychedelic research hub (MIND Foundation, Charité Berlin). Cannabis legalized 2024. Assisted dying partially legal after 2020 Constitutional Court ruling. Strong regulatory frameworks.","level":"SOVEREIGN","parent_id":null},{"id":"jur-uk","name":"United Kingdom","type":"COUNTRY","country_code":"GB","latitude":55.4,"longitude":-3.4,"general_notes":"Psychedelic clinical trials active (COMPASS Pathways, Imperial College). Strict scheduling of psychedelics. Assisted dying debates ongoing (no legal framework yet outside Scotland proposals).","level":"SOVEREIGN","parent_id":null},{"id":"jur-il","name":"Israel","type":"COUNTRY","country_code":"IL","latitude":31.0,"longitude":34.9,"general_notes":"Leading stem cell research country. MDMA/PTSD clinical trials. Growing medical innovation ecosystem. Compassionate use pathways available.","level":"SOVEREIGN","parent_id":null},{"id":"jur-jm","name":"Jamaica","type":"COUNTRY","country_code":"JM","latitude":18.1,"longitude":-77.3,"general_notes":"Psilocybin mushrooms are legal (never scheduled). Growing psilocybin retreat industry. Limited formal regulatory oversight for therapy programs. Variable quality of providers.","level":"SOVEREIGN","parent_id":null},{"id":"jur-th","name":"Thailand","type":"COUNTRY","country_code":"TH","latitude":15.9,"longitude":100.9,"general_notes":"Medical tourism hub for stem cells, regenerative medicine, cosmetic procedures. Growing psilocybin retreat industry in Chiang Mai/Bangkok. Light regulatory oversight. Variable quality—from excellent Bangkok hospitals to unregulated clinics.","level":"SOVEREIGN","parent_id":null},{"id":"jur-es","name":"Spain","type":"COUNTRY","country_code":"ES","latitude":40.5,"longitude":-3.7,"general_notes":"IVF with PGT widely available, less restrictive than many EU countries. Assisted dying legal since 2021 (Organic Law 3/2021). Growing psychedelic research. Good medical tourism infrastructure, especially Barcelona, Madrid.","level":"SOVEREIGN","parent_id":null},{"id":"jur-tu","name":"Turkey","type":"COUNTRY","country_code":"TR","latitude":39.0,"longitude":35.2,"general_notes":"Major medical tourism destination (Istanbul, Ankara). Stem cell therapies, hair transplants, cosmetic surgery at lower costs. Regulatory oversight variable. Currency advantage for Western patients (Turkish Lira devaluation).","level":"SOVEREIGN","parent_id":null},{"id":"jur-in","name":"India","type":"COUNTRY","country_code":"IN","latitude":20.6,"longitude":78.9,"general_notes":"World's largest IVF/fertility tourism market. Stem cell clinics widespread (quality varies). Ayurvedic/traditional medicine integration. Extremely low costs (50-80% less than US). Regulatory oversight weak, high variability in clinic quality.","level":"SOVEREIGN","parent_id":null},{"id":"jur-br","name":"Brazil","type":"COUNTRY","country_code":"BR","latitude":-14.2,"longitude":-51.9,"general_notes":"Large stem cell and regenerative medicine market. Ayahuasca retreat industry (Amazon, São Paulo). Growing cosmetic tourism. Regulatory body ANVISA oversees but enforcement inconsistent.","level":"SOVEREIGN","parent_id":null},{"id":"jur-cr","name":"Costa Rica","type":"COUNTRY","country_code":"CR","latitude":9.7,"longitude":-83.8,"general_notes":"Established medical tourism destination. Stem cell clinics, fertility treatments, cosmetic surgery. CIMA hospitals provide quality infrastructure. Psychedelic retreats growing (psilocybin decriminalized informally). Moderate regulatory oversight.","level":"SOVEREIGN","parent_id":null},{"id":"jur-uae","name":"United Arab Emirates (Dubai)","type":"COUNTRY","country_code":"AE","latitude":24.5,"longitude":54.4,"general_notes":"Luxury medical tourism hub. Cutting-edge regenerative medicine clinics. Stem cells, exosomes, high-dose micronutrient IVs. Extremely high prices. Regulatory oversight: DHA (Dubai Health Authority) high standards. Minimal psychedelic access.","level":"SOVEREIGN","parent_id":null},{"id":"jur-kr","name":"South Korea","type":"COUNTRY","country_code":"KR","latitude":36.2,"longitude":127.1,"general_notes":"Advanced biotech hub. Stem cell research leading globally. Placentophagy and placental-derived therapies popular. Anti-aging/longevity medicine trend. High regulatory standards in Seoul/major cities. Medical tourism growing.","level":"SOVEREIGN","parent_id":null},{"id":"jur-gr","name":"Greece","type":"COUNTRY","country_code":"GR","latitude":39.1,"longitude":21.8,"general_notes":"IVF tourism destination (PGT available, lower costs than Western EU). Mediterranean lifestyle health tourism. Emerging psychedelic research. Healthcare quality high, costs moderate vs. Central/Northern Europe.","level":"SOVEREIGN","parent_id":null},{"id":"jur-be","name":"Belgium","type":"COUNTRY","country_code":"BE","latitude":50.5,"longitude":4.5,"general_notes":"Euthanasia/assisted dying legal since 2002 (one of first). No age minimum (minors can access with parental consent). Psychedelic research hub (VUB Brussels). IVF widely available. High regulatory standards.","level":"SOVEREIGN","parent_id":null},{"id":"jur-se","name":"Sweden","type":"COUNTRY","country_code":"SE","latitude":60.1,"longitude":18.6,"general_notes":"Progressive healthcare system. Psychedelic research active (Karolinska). Some stem cell therapies available. Assisted dying debates ongoing but no legal framework yet. High healthcare standards, expensive.","level":"SOVEREIGN","parent_id":null},{"id":"jur-jp","name":"Japan","type":"COUNTRY","country_code":"JP","latitude":36.2,"longitude":138.2,"general_notes":"Advanced medical technology and biohacking culture. Stem cell research strong. Peptide therapies available. Regulatory framework restrictive (fewer regenerative medicine clinics than expected). Medical tourism less developed than Thailand/Korea.","level":"SOVEREIGN","parent_id":null},{"id":"jur-sg","name":"Singapore","type":"COUNTRY","country_code":"SG","latitude":1.3,"longitude":103.8,"general_notes":"Biomedical hub with highest regulatory standards in Asia. Stem cell/regenerative medicine research. Expensive but high quality. Limited psychedelic access. Strict drug laws.","level":"SOVEREIGN","parent_id":null},{"id":"jur-cl","name":"Chile","type":"COUNTRY","country_code":"CL","latitude":-35.7,"longitude":-71.5,"general_notes":"Most developed healthcare system in Latin America. IVF widely available. Growing stem cell tourism. Psilocybin decriminalization movements. Moderate regulatory oversight, good infrastructure in Santiago.","level":"SOVEREIGN","parent_id":null},{"id":"jur-ar","name":"Argentina","type":"COUNTRY","country_code":"AR","latitude":-38.4,"longitude":-63.6,"general_notes":"Buenos Aires: growing medical tourism destination. Fertility treatments, cosmetic surgery, stem cells. Currency advantage (peso devaluation). Moderate regulatory oversight. Quality variable by clinic.","level":"SOVEREIGN","parent_id":null},{"id":"jur-za","name":"South Africa","type":"COUNTRY","country_code":"ZA","latitude":-30.6,"longitude":22.9,"general_notes":"Leading African biotech hub (Cape Town, Johannesburg). Stem cell clinics, fertility tourism. Regulatory oversight through SAHPRA (South African Health Products Regulatory Authority). Quality clinics available at lower cost than Western countries.","level":"SOVEREIGN","parent_id":null},{"id":"jur-ph","name":"Philippines","type":"COUNTRY","country_code":"PH","latitude":12.9,"longitude":121.8,"general_notes":"Emerging medical tourism destination. Stem cell clinics, fertility treatment. Lower costs than Thailand. Regulatory oversight weak (FDA equivalent has limited enforcement). Quality variable.","level":"SOVEREIGN","parent_id":null},{"id":"jur-po","name":"Poland","type":"COUNTRY","country_code":"PL","latitude":51.9,"longitude":19.1,"general_notes":"Growing medical tourism hub (Warsaw, Krakow). Fertility treatments, stem cells, regenerative medicine. EU medical standards but lower costs. Psychedelic research active. Good balance of cost/quality.","level":"SOVEREIGN","parent_id":null},{"id":"jur-pt","name":"Portugal","type":"COUNTRY","country_code":"PT","latitude":39.4,"longitude":-8.2,"general_notes":"Decriminalized all drugs (2001 onward—consumption is 'disorderly conduct' not criminal). Growing psychedelic retreat/research centers. IVF tourism destination. Lisbon/Porto wellness tourism hub. Moderate costs, good infrastructure.","level":"SOVEREIGN","parent_id":null},{"id":"jur-fr","name":"France","type":"COUNTRY","country_code":"FR","latitude":46.6,"longitude":2.2,"general_notes":"Strong healthcare system. Some stem cell therapies via academic research. Assisted dying: recent debates, no legal framework yet. Psychedelic research growing (Paris, universities). High costs, excellent quality.","level":"SOVEREIGN","parent_id":null}],"procedures":[{"id":"proc-psilocybin-trd","name":"Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression","modality":"PSYCHEDELICS","regulatory_modality":"CONTROLLED_SUBSTANCE","restriction_driver":"CONTROLLED_SUBSTANCE","therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"description":"Psilocybin administered in a controlled therapeutic setting with preparation and integration sessions. Typically 1-2 dosing sessions with multiple non-drug therapy sessions. FDA Breakthrough Therapy designation. COMPASS Pathways phase III trials ongoing.","typical_us_cost_range":"$8,000-15,000"},{"id":"proc-psilocybin-eol","name":"Psilocybin-Assisted Therapy for End-of-Life Anxiety","modality":"PSYCHEDELICS","regulatory_modality":"CONTROLLED_SUBSTANCE","restriction_driver":"CONTROLLED_SUBSTANCE","therapeutic_areas":["Mental_Health","Palliative_Care"],"diseases":["Cancer-Related Anxiety","End-of-Life Existential Distress","Adjustment Disorder"],"description":"Psilocybin therapy aimed at reducing existential distress, anxiety, and depression in patients with life-threatening illness. Landmark trials at Johns Hopkins, NYU, UCLA. Single high-dose session with preparation/integration.","typical_us_cost_range":"$5,000-12,000"},{"id":"proc-mdma-ptsd","name":"MDMA-Assisted Psychotherapy for PTSD","modality":"PSYCHEDELICS","regulatory_modality":"CONTROLLED_SUBSTANCE","restriction_driver":"CONTROLLED_SUBSTANCE","therapeutic_areas":["Mental_Health","PTSD"],"diseases":["Post-Traumatic Stress Disorder (PTSD)"],"description":"MDMA administered in 2-3 sessions as an adjunct to psychotherapy for PTSD. FDA Breakthrough Therapy designation. MAPS (now Lykos Therapeutics) phase III trials showed 67% no longer met PTSD criteria after treatment. FDA decision pending/denied 2024.","typical_us_cost_range":"$12,000-20,000"},{"id":"proc-ketamine-depression","name":"Ketamine Infusion Therapy for Depression","modality":"PSYCHEDELICS","regulatory_modality":"CONTROLLED_SUBSTANCE","restriction_driver":"CONTROLLED_SUBSTANCE","therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder","Suicidal Ideation"],"description":"Off-label IV/intranasal ketamine for treatment-resistant depression and acute suicidality. Spravato (esketamine) is FDA-approved. Widely available in US clinics (500+). Rapid onset (hours) but requires maintenance sessions.","typical_us_cost_range":"$400-800 per infusion (6-8 initial, then maintenance)"},{"id":"proc-ibogaine-addiction","name":"Ibogaine Treatment for Opioid/Substance Use Disorder","modality":"PSYCHEDELICS","regulatory_modality":"CONTROLLED_SUBSTANCE","restriction_driver":"CONTROLLED_SUBSTANCE","therapeutic_areas":["Mental_Health","Addiction"],"diseases":["Opioid Use Disorder","Substance Use Disorder"],"description":"Ibogaine, a psychoactive alkaloid from Tabernanthe iboga, used primarily for opioid detoxification/withdrawal and addiction interruption. Single prolonged session (24-36h). Significant cardiac risk (QT prolongation). Available in Mexico, Caribbean, and some non-US settings.","typical_us_cost_range":"$4,000-10,000 (international clinics)"},{"id":"proc-gene-crispr","name":"CRISPR-Based Gene Therapy (Somatic) for Genetic Disorders","modality":"GENE_THERAPY","regulatory_modality":"GENE_THERAPY","restriction_driver":"SAFETY_UNPROVEN","therapeutic_areas":["Genetics","Hematology"],"diseases":["Sickle Cell Disease","Beta-Thalassemia","Genetic Blood Disorders"],"description":"Ex vivo or in vivo CRISPR gene editing for genetic disorders including sickle cell disease (Casgevy/Exa-cel approved), beta-thalassemia. Rapidly expanding pipeline. Casgevy FDA approved Dec 2023. First approved CRISPR therapy. Extremely high cost.","typical_us_cost_range":"$2,200,000+ (Casgevy list price)"},{"id":"proc-gene-aa9","name":"AAV9-Mediated Gene Replacement Therapy","modality":"GENE_THERAPY","regulatory_modality":"GENE_THERAPY","restriction_driver":"SAFETY_UNPROVEN","therapeutic_areas":["Genetics","Neurology"],"diseases":["Spinal Muscular Atrophy (SMA)","Inherited Retinal Dystrophy","Hemophilia B","Duchenne Muscular Dystrophy"],"description":"Adeno-associated virus (AAV) vector-based gene replacement for monogenic disorders. Zolgensma (SMA, onasemnogene abeparvovec) is the landmark AAV9 therapy. One-time administration with potential lifelong effect. Several approved: Luxturna (retinal dystrophy), Hemgenix (hemophilia B), Elevidys (DMD), etc.","typical_us_cost_range":"$2,100,000-3,500,000 (Zolgensma, Hemgenix)"},{"id":"proc-stem-msc","name":"Mesenchymal Stem Cell (MSC) Therapy for Autoimmune/Inflammatory Conditions","modality":"STEM_CELL","regulatory_modality":"CELL_THERAPY_AUTOLOGOUS","restriction_driver":"SAFETY_UNPROVEN","therapeutic_areas":["Autoimmune","Orthopedic"],"diseases":["Osteoarthritis","Autoimmune Disease","Inflammatory Conditions","Crohn's Disease"],"description":"MSCs derived from bone marrow, adipose, or umbilical cord tissue. Anti-inflammatory and immunomodulatory properties. Used for osteoarthritis, Crohn's, MS, and numerous off-label indications. Regulatory status varies widely by jurisdiction. US: limited to approved trials and some orthopedic uses per FDA guidance.","typical_us_cost_range":"$5,000-25,000 (varies widely by clinic/jurisdiction)"},{"id":"proc-stem-car-t","name":"CAR-T Cell Therapy for Hematologic Malignancies","modality":"STEM_CELL","regulatory_modality":"CELL_THERAPY_AUTOLOGOUS","restriction_driver":"SAFETY_UNPROVEN","therapeutic_areas":["Oncology","Hematology"],"diseases":["Relapsed/Refractory B-cell ALL","Diffuse Large B-cell Lymphoma","Multiple Myeloma"],"description":"Chimeric Antigen Receptor T-cell therapy: patient's own T-cells engineered to target cancer cells. Approved for B-ALL, DLBCL, multiple myeloma, and other blood cancers. One-time treatment with potential for durable remission. High cost, complex administration.","typical_us_cost_range":"$373,000-475,000 (drug cost only, not including hospitalization)"},{"id":"proc-maid","name":"Medical Assistance in Dying (MAID) / Assisted Death","modality":"ASSISTED_DYING","regulatory_modality":"END_OF_LIFE","restriction_driver":"ETHICS_CONTESTED","therapeutic_areas":["Palliative_Care","End_of_Life"],"diseases":["Terminal Illness","Grievous Irremediable Medical Condition","Intolerable Suffering"],"description":"Medical assistance in dying encompasses physician-assisted suicide (patient self-administers) and voluntary euthanasia (clinician administers). Legal in Canada (MAID), Switzerland, Netherlands, Belgium, Spain, New Zealand, several US states, and others. Eligibility and safeguards vary significantly by jurisdiction. Canada's MAID expansion (2021-2027) has removed the requirement that death be reasonably foreseeable for some tracks.","typical_us_cost_range":"Varies (covered by public health in some jurisdictions, $0-1,500 privately)"},{"id":"proc-peptide-bpc","name":"BPC-157 Pentadecapeptide Therapy","modality":"PEPTIDE","regulatory_modality":"PEPTIDE","restriction_driver":"COST_OR_LICENSING","therapeutic_areas":["Gastrointestinal","Orthopedic","Wound_Healing"],"diseases":["Tendon/Ligament Injury","Inflammatory Bowel Disease","Gastric Ulcer","Wound Healing Impairment"],"description":"Body Protection Compound-157, a synthetic peptide derived from gastric juice protein. Promotes angiogenesis, accelerates wound/tendon/ligament healing, and shows protective effects in GI tract. Not FDA-approved. Widely used in functional/regenerative medicine but sold as 'research chemical' in US. Oral and injectable forms available. Evidence primarily preclinical with limited human trials.","typical_us_cost_range":"$50-200/month (compounding/research), $500-2,000+ for clinic protocols"},{"id":"proc-peptide-thymosin","name":"Thymosin Alpha-1 (Thymalfasin) Immunomodulation","modality":"PEPTIDE","regulatory_modality":"PEPTIDE","restriction_driver":"COST_OR_LICENSING","therapeutic_areas":["Immunology","Chronic_Infection"],"diseases":["Chronic Hepatitis B","Chronic Hepatitis C","Immune Deficiency","Chronic Viral Infection"],"description":"Synthetic 28-amino acid peptide identical to natural thymosin alpha-1. Modulates immune response, enhances T-cell function, and restores immune competence. Approved in 30+ countries (Zadaxin) for hepatitis B/C and as vaccine adjuvant. Used off-label for chronic infections, immune dysregulation, and cancer adjunct. Not FDA-approved in US.","typical_us_cost_range":"$200-800 per course (international), $500-3,000 (US compounding/research)"},{"id":"proc-repro-ivf","name":"In Vitro Fertilization (IVF) with Genetic Testing (PGT)","modality":"REPRODUCTIVE","regulatory_modality":"REPRODUCTIVE","restriction_driver":"ETHICS_CONTESTED","therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Infertility","Recurrent Pregnancy Loss","Genetic Carrier Status"],"description":"IVF with preimplantation genetic testing for aneuploidy (PGT-A) or monogenic disorders (PGT-M). Enables embryo selection to avoid genetic disease transmission. Regulatory landscape varies: some countries restrict embryo genetic testing (Germany, Austria), others permissive (US, Mexico, Spain, Greece). Sex selection legally restricted in many jurisdictions.","typical_us_cost_range":"$12,000-25,000 per cycle (+$3,000-5,000 for PGT)"},{"id":"proc-repro-surrogacy","name":"Gestational Surrogacy","modality":"REPRODUCTIVE","regulatory_modality":"REPRODUCTIVE","restriction_driver":"ETHICS_CONTESTED","therapeutic_areas":["Reproductive_Health"],"diseases":["Uterine Factor Infertility","Medical Contraindication to Pregnancy","Recurrent IVF Failure"],"description":"Gestational surrogacy where embryo is transferred to a surrogate who carries the pregnancy. Commercial surrogacy legal in parts of US (CA, NV, CT, etc.), Ukraine, Georgia, Colombia, Mexico (some states). Altruistic-only in Canada, UK, Australia. Completely banned in several EU countries. Complex legal landscape regarding parentage orders.","typical_us_cost_range":"$100,000-200,000 (US, total), $50,000-80,000 (international destinations)"},{"id":"proc-repurposed-ldn","name":"Low-Dose Naltrexone (LDN) for Chronic Inflammatory/Autoimmune Conditions","modality":"REPURPOSED","regulatory_modality":"SMALL_MOLECULE_OFFLABEL","restriction_driver":"COST_OR_LICENSING","therapeutic_areas":["Autoimmune","Chronic_Pain","Neurology"],"diseases":["Fibromyalgia","Crohn's Disease","Multiple Sclerosis","ME/CFS","Long COVID","Chronic Pain"],"description":"Naltrexone at low doses (0.5-4.5mg) acts as a glial cell modulator and transient opioid receptor blockade, leading to upregulation of endogenous endorphins and anti-inflammatory effects. Off-label use for fibromyalgia, Crohn's, MS, chronic pain, ME/CFS, long COVID. Requires compounding pharmacy. Decades of clinical use with strong safety profile at low doses.","typical_us_cost_range":"$30-100/month (compounded)"},{"id":"proc-repurposed-methylene","name":"Methylene Blue (Pharmaceutical Grade) for Neuroprotection/Mitochondrial Dysfunction","modality":"REPURPOSED","regulatory_modality":"SMALL_MOLECULE_OFFLABEL","restriction_driver":"COST_OR_LICENSING","therapeutic_areas":["Neurology","Mitochondrial_Health"],"diseases":["Mild Cognitive Impairment","Bipolar Depression","Mitochondrial Dysfunction","Methemoglobinemia"],"description":"Methylene blue at low doses (0.5-4 mg/kg) acts as an alternative electron carrier in mitochondria, enhancing ATP production, reducing oxidative stress, and inhibiting tau aggregation. Being investigated for Alzheimer's (TauRx), bipolar disorder, and sepsis. Historical uses: malaria, methemoglobinemia. Pharmaceutical-grade required (NOT aquarium product).","typical_us_cost_range":"$50-150/month (compounded), varies by country"},{"id":"proc-repurposed-semaglutide","name":"GLP-1 Receptor Agonists (Semaglutide / Tirzepatide) Beyond Diabetes","modality":"REPURPOSED","regulatory_modality":"SMALL_MOLECULE_OFFLABEL","restriction_driver":"COST_OR_LICENSING","therapeutic_areas":["Metabolic_Health","Addiction","Cardiovascular"],"diseases":["Obesity","Type 2 Diabetes","Cardiovascular Disease Risk","NAFLD/NASH"],"description":"Originally for type 2 diabetes (Ozempic, Mounjaro), now FDA-approved for weight loss (Wegovy, Zepbound). Emerging evidence for addiction reduction (alcohol, opioids), cardiovascular risk reduction, neuroprotection (Alzheimer's), NAFLD/NASH, PCOS. Huge demand causing shortages. Compounded versions available but quality varies.","typical_us_cost_range":"$900-1,400/month (brand-name out-of-pocket), $200-500/month (compounded)"},{"id":"proc-repurposed-rapamycin","name":"Rapamycin (Sirolimus) for Longevity/Healthspan","modality":"REPURPOSED","regulatory_modality":"SMALL_MOLECULE_OFFLABEL","restriction_driver":"COST_OR_LICENSING","therapeutic_areas":["Aging","Immunology"],"diseases":["Age-Related Functional Decline","Lymphangioleiomyomatosis (LAM)","Transplant Rejection (labeled)"],"description":"mTOR inhibitor with robust lifespan extension in every species tested. Approved as immunosuppressant (transplant) and for LAM (lymphangioleiomyomatosis). Off-label use for aging/longevity growing in popularity. PEARL trial (participatory evaluation of aging with rapamycin for longevity) ongoing. Intermittent dosing protocols emerging.","typical_us_cost_range":"$50-200/month (generic, varies by dose protocol), $300-1,000/month (longevity clinic protocols)"},{"id":"proc-stem-exosome","name":"Exosome Therapy (Stem Cell-Derived) for Regeneration","modality":"STEM_CELL","regulatory_modality":"CELL_THERAPY_AUTOLOGOUS","restriction_driver":"SAFETY_UNPROVEN","therapeutic_areas":["Regeneration","Anti_Aging","Orthopedic"],"diseases":["Osteoarthritis","Androgenetic Alopecia","Skin Aging","Soft Tissue Injury"],"description":"Exosomes (extracellular vesicles) derived from MSCs, containing growth factors, mRNA, and miRNAs that mediate paracrine signaling. Used for skin rejuvenation, hair restoration, joint repair, and systemic anti-aging. Less regulated than whole stem cells in many jurisdictions. Not FDA-approved. Rapidly growing aesthetics/regenerative market.","typical_us_cost_range":"$2,000-10,000 per treatment (cosmetic), $5,000-20,000+ (orthopedic/systemic)"},{"id":"proc-dmt-depression","name":"DMT (N,N-Dimethyltryptamine) Assisted Therapy for Depression","modality":"PSYCHEDELICS","regulatory_modality":"CONTROLLED_SUBSTANCE","restriction_driver":"CONTROLLED_SUBSTANCE","therapeutic_areas":["Mental_Health","Depression"],"diseases":["Major Depressive Disorder","Treatment-Resistant Depression"],"description":"Short-acting (15-30 min) classical psychedelic. Proprietary extended-infusion formulation (SPL026/Small Pharma/incannex) in phase II trials for major depressive disorder. Naturally occurring in ayahuasca but synthetic DMT used clinically. Rapid onset/offset attractive for clinical delivery models. Colorado decriminalized personal use/growing 2022.","typical_us_cost_range":"Unknown (clinical trials only, $3,000-8,000 estimated for infusion protocols)"},{"id":"proc-lsd-anxiety","name":"LSD-Assisted Psychotherapy for Anxiety Disorders","modality":"PSYCHEDELICS","regulatory_modality":"CONTROLLED_SUBSTANCE","restriction_driver":"CONTROLLED_SUBSTANCE","therapeutic_areas":["Mental_Health","Anxiety"],"diseases":["Generalized Anxiety Disorder","Illness-Related Anxiety"],"description":"LSD (lysergic acid diethylamide) administered in therapeutic setting. Historically used in psychiatry (1950s-60s) for anxiety, addiction, and existential distress. Modern renaissance: MindMed phase IIb for generalized anxiety disorder (MM-120). Switzerland permits compassionate use LSD therapy via BAG permits.","typical_us_cost_range":"$5,000-12,000 (Switzerland compassionate use), unknown for US if approved"},{"id":"proc-mescaline-therapy","name":"Mescaline-Assisted Therapy (San Pedro) for Depression/Addiction","modality":"PSYCHEDELICS","regulatory_modality":"CONTROLLED_SUBSTANCE","restriction_driver":"CONTROLLED_SUBSTANCE","therapeutic_areas":["Mental_Health","Depression","Addiction"],"diseases":["Depression","Substance Use Disorder","Existential Distress"],"description":"Mescaline from San Pedro cacti in retreat settings. Natural plant medicine with centuries of ceremonial use. Longer duration (8-12h) than psilocybin. Emerging clinical interest. Colorado and other US states decriminalized mescaline-containing plants. Retreats in Peru, Colombia, Ecuador.","typical_us_cost_range":"$1,000-3,000 (South America retreat), $2,000-5,000 (Colorado decriminalized personal cultivation)"},{"id":"proc-nad-iv","name":"NAD+ IV Infusion for Mitochondrial Health/Longevity","modality":"REPURPOSED","regulatory_modality":"SMALL_MOLECULE_OFFLABEL","restriction_driver":"COST_OR_LICENSING","therapeutic_areas":["Anti_Aging","Energy","Neurological"],"diseases":["Chronic Fatigue","Long COVID","Mitochondrial Dysfunction","Age-Related Decline"],"description":"Intravenous NAD+ (nicotinamide adenine dinucleotide) infusions for mitochondrial energy, anti-aging, and neurological recovery. Off-label in US. High-dose protocols emerging (250mg-1000mg+). Biohacking/longevity community trending.","typical_us_cost_range":"$250-600 per infusion, packages $3,000-8,000"},{"id":"proc-hbot","name":"Hyperbaric Oxygen Therapy for Chronic Wounds/TBI/Lyme","modality":"REPURPOSED","regulatory_modality":"SMALL_MOLECULE_OFFLABEL","restriction_driver":"COST_OR_LICENSING","therapeutic_areas":["Wound_Healing","Neurological","Chronic_Infection"],"diseases":["Diabetic Foot Ulcer","Chronic Osteomyelitis","Traumatic Brain Injury (off-label)","Chronic Lyme (off-label)"],"description":"Breathing 95% oxygen in pressurized chamber (2-3 atm). FDA-approved for diabetic wounds, decompression sickness. Off-label expanding: chronic Lyme, TBI, fibromyalgia, post-COVID. Sessions 60-120 min, typically 20-40 sessions per course.","typical_us_cost_range":"$150-350 per session, typical course $3,000-14,000. Insurance covers FDA indications."},{"id":"proc-fmt","name":"Fecal Microbiota Transplantation (FMT) for CDI/IBD","modality":"CELLULAR","regulatory_modality":"CELL_THERAPY_ALLOGENEIC","restriction_driver":"SAFETY_UNPROVEN","therapeutic_areas":["Gastrointestinal","Autoimmune"],"diseases":["Recurrent C. difficile Infection","Ulcerative Colitis (off-label)","Crohn's Disease (off-label)"],"description":"Fecal material from healthy donor transferred to patient's colon. FDA-approved for recurrent C. difficile. Off-label expanding: UC, Crohn's, IBS. >90% cure rate for CDI vs 30% antibiotics.","typical_us_cost_range":"$500-3,000 per procedure. Covered by insurance for CDI indication."},{"id":"proc-pt-141","name":"PT-141 (Bremelanotide) for Sexual Dysfunction","modality":"PEPTIDE","regulatory_modality":"PEPTIDE","restriction_driver":"COST_OR_LICENSING","therapeutic_areas":["Sexual_Health"],"diseases":["Hypoactive Sexual Desire Disorder (HSDD)","Erectile Dysfunction (off-label)"],"description":"Melanocortin-4 receptor agonist peptide. Vyleesi FDA-approved for female HSDD (2019). PT-141 original compound (research/compounded). Subcutaneous injection 45 min before sexual activity. Off-label for male ED growing.","typical_us_cost_range":"$10,000-20,000/year insured, $4,500-9,000 after copay. PT-141 research: $50-150/dose."},{"id":"proc-cryotherapy","name":"Whole-Body Cryotherapy (WBC) for Recovery/Inflammation","modality":"REPURPOSED","regulatory_modality":"SMALL_MOLECULE_OFFLABEL","restriction_driver":"COST_OR_LICENSING","therapeutic_areas":["Anti_Aging","Recovery"],"diseases":["Muscle Recovery","Chronic Inflammation","Sports Injury Recovery"],"description":"Extreme cold (-110 to -200°C) exposure in cryogenic chamber for 2-3 minutes. Claims: inflammation reduction, recovery acceleration, mood boost. Growing biohacking adoption. Limited RCT evidence. Available in US and Europe.","typical_us_cost_range":"$150-250 per session, packages $1,000-3,000"},{"id":"proc-prp-therapy","name":"Platelet-Rich Plasma (PRP) Therapy for Joint/Tissue Repair","modality":"CELLULAR","regulatory_modality":"CELL_THERAPY_ALLOGENEIC","restriction_driver":"SAFETY_UNPROVEN","therapeutic_areas":["Orthopedic","Sports_Medicine","Anti_Aging"],"diseases":["Knee Osteoarthritis","Tendinopathy","Rotator Cuff Injury","Androgenetic Alopecia"],"description":"Blood centrifugation to concentrate platelets (3-9x concentration) and inject into damaged joints/tissues. Growth factors (PDGF, VEGF, FGF) promote healing. Off-label use for osteoarthritis, tendon injuries, sports injuries. Some clinical trial data; evidence mixed but growing.","typical_us_cost_range":"$500-2,000 per injection, typically 3-5 injections per course = $1,500-10,000"},{"id":"proc-nmn-nmad","name":"NMN/NR Oral Supplementation for Longevity","modality":"REPURPOSED","regulatory_modality":"SMALL_MOLECULE_OFFLABEL","restriction_driver":"COST_OR_LICENSING","therapeutic_areas":["Anti_Aging","Longevity","Metabolic_Health"],"diseases":["Age-Related Functional Decline","Metabolic Syndrome"],"description":"Nicotinamide mononucleotide (NMN) or nicotinamide riboside (NR) oral supplements to increase intracellular NAD+ levels. Promotes mitochondrial health, sirtuin activation. Emerging longevity trend. Limited RCT evidence in humans; strong preclinical data.","typical_us_cost_range":"$30-100 per month (over-the-counter supplements), $500-2,000/year for clinical-grade protocols"},{"id":"proc-ayahuasca","name":"Ayahuasca-Assisted Therapy for Depression/Addiction/Spiritual Growth","modality":"PSYCHEDELICS","regulatory_modality":"CONTROLLED_SUBSTANCE","restriction_driver":"CONTROLLED_SUBSTANCE","therapeutic_areas":["Mental_Health","Addiction","Spirituality"],"diseases":["Depression","Substance Use Disorder","PTSD","Existential Distress"],"description":"Ayahuasca (DMT + MAO inhibitor plants) consumed in ceremonial settings. 4-8 hour intense psychedelic experience with shaman facilitation. Growing clinical interest for depression, PTSD, addiction. Strong traditional use in Amazon. High variability in preparation and facilitation quality.","typical_us_cost_range":"$1,500-5,000 per retreat (3-7 days, Peru/Ecuador)"},{"id":"proc-medical-cannabis","name":"Medical Cannabis for Chronic Pain / Seizures / PTSD","modality":"PHYTOCANNABINOID","regulatory_modality":"CONTROLLED_SUBSTANCE","restriction_driver":"CONTROLLED_SUBSTANCE","therapeutic_areas":["Pain","Neurology","Mental_Health"],"diseases":["Chronic Pain","Epilepsy","PTSD","Chemotherapy-Induced Nausea","Anxiety"],"description":"Cannabis (THC/CBD) for medical indications. Legal status varies dramatically by jurisdiction. FDA-approved Epidiolex (CBD for seizures). Off-label use expanding: chronic pain, PTSD, anxiety, nausea. Dosing/strain selection critical. Quality dependent on legal vs. black market sources.","typical_us_cost_range":"$150-400/month (legal state dispensary)"},{"id":"proc-ozone-therapy","name":"Ozone Therapy for Infection / Inflammation / Wound Healing","modality":"REPURPOSED","regulatory_modality":"SMALL_MOLECULE_OFFLABEL","restriction_driver":"COST_OR_LICENSING","therapeutic_areas":["Infection","Wound_Healing","Orthopedic"],"diseases":["Chronic Wound","Chronic Infection","Osteoarthritis (off-label)"],"description":"Medical-grade ozone (O₃) administered via autohemotherapy, insufflation, or bagging. Claims: anti-infection, anti-inflammatory, promotes healing. FDA does not approve ozone therapy (contraindicated in FDA statement). Off-label use growing in functional medicine. Highly variable quality/safety.","typical_us_cost_range":"$100-300 per session, courses $1,500-5,000"},{"id":"proc-stem-nsc","name":"Neural Stem Cell Therapy for Neurodegeneration / Spinal Cord Injury","modality":"STEM_CELL","regulatory_modality":"CELL_THERAPY_AUTOLOGOUS","restriction_driver":"SAFETY_UNPROVEN","therapeutic_areas":["Neurology","Spinal_Cord_Injury"],"diseases":["Parkinson's Disease","ALS","Spinal Cord Injury","Alzheimer's Disease"],"description":"Neural stem cells (NSCs) derived from embryonic or iPSC sources for neurodegeneration (Parkinson's, ALS, Alzheimer's) and spinal cord injury. Preclinical data promising. Clinical trials ongoing in limited jurisdictions. Very high cost, experimental status.","typical_us_cost_range":"$50,000-200,000+ (clinical trial or offshore clinic)"},{"id":"proc-proton-therapy","name":"Proton Beam Radiotherapy for Cancer","modality":"ONCOLOGY","regulatory_modality":"SMALL_MOLECULE_UNAPPROVED","restriction_driver":"SAFETY_UNPROVEN","therapeutic_areas":["Oncology"],"diseases":["Pediatric Cancer","CNS Tumors","Prostate Cancer","Base-of-Skull Tumors"],"description":"Proton beam therapy (vs. traditional photon radiation) allows precise tumor targeting with minimal normal tissue exposure. Lower side-effect profile. Approved for various cancers (pediatric, CNS, prostate, etc.). Limited availability—only ~50 centers in US, more in Europe/Asia. Extremely expensive.","typical_us_cost_range":"$50,000-300,000+ (total course, varies by site and coverage)"},{"id":"proc-senolytics","name":"Senolytic Therapy (Dasatinib + Quercetin) for Cellular Aging","modality":"REPURPOSED","regulatory_modality":"SMALL_MOLECULE_OFFLABEL","restriction_driver":"COST_OR_LICENSING","therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Frailty","Age-Related Functional Decline","Cellular Senescence"],"description":"Senolytic drugs eliminate senescent cells (aging-associated cells that promote inflammation). Dasatinib (tyrosine kinase inhibitor, FDA-approved for CML) + quercetin (polyphenol, OTC). Limited human trials but strong preclinical data. Mayo Clinic trial (UNITY) underway.","typical_us_cost_range":"$50-150 per course (2 doses: quercetin OTC + dasatinib prescription)"},{"id":"proc-chelation","name":"IV Chelation Therapy for Heavy Metal Detoxification","modality":"REPURPOSED","regulatory_modality":"SMALL_MOLECULE_OFFLABEL","restriction_driver":"COST_OR_LICENSING","therapeutic_areas":["Detoxification","Anti_Aging"],"diseases":["Lead Poisoning","Heavy Metal Toxicity","Iron Overload"],"description":"EDTA or DMSA chelation to bind and eliminate heavy metals. FDA-approved for lead poisoning. Off-label promoted for autism, cardiovascular disease, aging ('detoxification'). Highly controversial—cardiologists warn against off-label use (risks: hypocalcemia, arrhythmias). Some functional medicine widespread adoption.","typical_us_cost_range":"$100-300 per infusion, courses $2,000-10,000+"},{"id":"proc-metformin-longevity","name":"Metformin for Longevity / Aging Prevention","modality":"REPURPOSED","regulatory_modality":"SMALL_MOLECULE_OFFLABEL","restriction_driver":"COST_OR_LICENSING","therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Type 2 Diabetes (labeled)","Age-Related Functional Decline","Prediabetes"],"description":"Metformin (FDA-approved type 2 diabetes drug) used off-label for aging prevention. TAME trial underway at NIH. Proposed mechanisms: AMPK activation, mTOR inhibition, improved metabolic health. Growing longevity community adoption.","typical_us_cost_range":"$10-30/month (generic metformin)"},{"id":"proc-tms-depression","name":"Transcranial Magnetic Stimulation (TMS) for Depression","modality":"REPURPOSED","regulatory_modality":"SMALL_MOLECULE_OFFLABEL","restriction_driver":"COST_OR_LICENSING","therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"description":"Noninvasive repetitive TMS (including deep TMS, iTBS) for treatment-resistant depression. FDA-cleared devices; widely covered when criteria met. Expanding off-label: OCD, smoking cessation, anxiety.","typical_us_cost_range":"$6,000–15,000 per acute course (often insured)"},{"id":"proc-tms-ocd","name":"Deep TMS / TMS for Obsessive-Compulsive Disorder","modality":"REPURPOSED","regulatory_modality":"SMALL_MOLECULE_OFFLABEL","restriction_driver":"COST_OR_LICENSING","therapeutic_areas":["Mental_Health","OCD"],"diseases":["Obsessive-Compulsive Disorder"],"description":"TMS protocols cleared for OCD (e.g. deep TMS H7 coil). Adjunct when SSRIs/ERP incomplete.","typical_us_cost_range":"$8,000–18,000 per course"},{"id":"proc-vns-depression","name":"Vagus Nerve Stimulation (VNS) for Depression","modality":"REPURPOSED","regulatory_modality":"SMALL_MOLECULE_OFFLABEL","restriction_driver":"COST_OR_LICENSING","therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Epilepsy"],"description":"Implanted or transcutaneous VNS for chronic TRD. Implantable VNS has long FDA history for epilepsy and depression; noninvasive tVNS growing.","typical_us_cost_range":"$20,000–40,000 implant pathway; tVNS devices lower"},{"id":"proc-dbs-parkinson","name":"Deep Brain Stimulation (DBS) for Parkinson's Disease","modality":"REPURPOSED","regulatory_modality":"SMALL_MOLECULE_OFFLABEL","restriction_driver":"COST_OR_LICENSING","therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Parkinson's Disease","Essential Tremor (selected targets)"],"description":"Stereotactic implantation of electrodes in STN/GPi for advanced Parkinson's motor complications. Established in high-income systems; access limited by neurosurgery capacity and cost.","typical_us_cost_range":"$50,000–100,000+ (device + surgery + programming)"},{"id":"proc-fus-tremor","name":"MR-Guided Focused Ultrasound for Essential Tremor / PD Tremor","modality":"REPURPOSED","regulatory_modality":"SMALL_MOLECULE_OFFLABEL","restriction_driver":"COST_OR_LICENSING","therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Essential Tremor","Parkinson's Disease Tremor"],"description":"Incisionless thalamotomy using high-intensity focused ultrasound under MRI guidance. FDA-approved for essential tremor and PD tremor in selected patients.","typical_us_cost_range":"$30,000–60,000"},{"id":"proc-til-melanoma","name":"Tumor-Infiltrating Lymphocyte (TIL) Therapy for Melanoma","modality":"ONCOLOGY","regulatory_modality":"CELL_THERAPY_AUTOLOGOUS","restriction_driver":"COST_OR_LICENSING","therapeutic_areas":["Oncology","Melanoma"],"diseases":["Advanced Melanoma","Metastatic Melanoma"],"description":"Autologous TILs expanded ex vivo then reinfused after lymphodepletion (e.g. lifileucel/Amtagvi). One-time cellular immunotherapy for advanced melanoma after checkpoint failure.","typical_us_cost_range":"$500,000+ (product + hospitalization)"},{"id":"proc-car-t-solid","name":"Experimental CAR-T / TCR Therapy for Solid Tumors","modality":"ONCOLOGY","regulatory_modality":"CELL_THERAPY_AUTOLOGOUS","restriction_driver":"SAFETY_UNPROVEN","therapeutic_areas":["Oncology"],"diseases":["Advanced Solid Tumors","Gastric Cancer (trial)","Neuroblastoma (trial)"],"description":"Investigational CAR-T/TCR products targeting solid tumors (e.g. Claudin18.2, GD2, mesothelin). Almost exclusively clinical trial or limited special-access pathways.","typical_us_cost_range":"Trial (often free drug) or $100,000–500,000+ private"},{"id":"proc-dendritic-vaccine","name":"Dendritic Cell Cancer Vaccines (Personalized)","modality":"ONCOLOGY","regulatory_modality":"CELL_THERAPY_AUTOLOGOUS","restriction_driver":"SAFETY_UNPROVEN","therapeutic_areas":["Oncology"],"diseases":["Metastatic Castration-Resistant Prostate Cancer","Solid Tumors (clinic variable)"],"description":"Autologous dendritic cells pulsed with tumor antigens. Sipuleucel-T is approved for prostate; many other DC vaccines marketed in less regulated clinics (quality highly variable).","typical_us_cost_range":"$50,000–150,000+ (clinic packages vary widely)"},{"id":"proc-apheresis-longcovid","name":"Therapeutic Apheresis / HELP Apheresis for Long COVID & Microclot Protocols","modality":"CELLULAR","regulatory_modality":"CELL_THERAPY_ALLOGENEIC","restriction_driver":"SAFETY_UNPROVEN","therapeutic_areas":["Long_COVID","Cardiovascular"],"diseases":["Long COVID","ME/CFS-like Post-Viral Syndrome","Hyperviscosity Syndromes (labeled apheresis)"],"description":"Plasmapheresis, immunoadsorption, or heparin-induced extracorporeal LDL precipitation (HELP) used experimentally for post-acute COVID syndromes and microclot hypotheses. Evidence still evolving; not standard of care in most systems.","typical_us_cost_range":"$2,000–8,000 per session; courses $10,000–40,000"},{"id":"proc-ivig","name":"Intravenous Immunoglobulin (IVIG) for Autoimmune / Neuroimmune Disease","modality":"REPURPOSED","regulatory_modality":"SMALL_MOLECULE_OFFLABEL","restriction_driver":"COST_OR_LICENSING","therapeutic_areas":["Autoimmune","Neurology","Immunology"],"diseases":["Primary Immunodeficiency","CIDP","ITP","Autoimmune Encephalitis (off-label)","Long COVID (off-label)"],"description":"Pooled IgG replacement/immunomodulation. Labeled for PID, ITP, CIDP, Kawasaki, etc.; widely used off-label (myositis, stiff-person, some long COVID clinics).","typical_us_cost_range":"$5,000–15,000 per infusion cycle (weight-based)"},{"id":"proc-sglt2-hf","name":"SGLT2 Inhibitors for Heart Failure & CKD Beyond Diabetes","modality":"REPURPOSED","regulatory_modality":"SMALL_MOLECULE_OFFLABEL","restriction_driver":"COST_OR_LICENSING","therapeutic_areas":["Cardiovascular","Kidney"],"diseases":["Heart Failure","Chronic Kidney Disease","Type 2 Diabetes"],"description":"Dapagliflozin, empagliflozin and related SGLT2i with strong HF and CKD outcome data independent of diabetes status. Access friction is mainly formulary/price, not legality.","typical_us_cost_range":"$400–700/month brand; lower with coverage/coupons"},{"id":"proc-glp1-addiction","name":"GLP-1 Agonists for Alcohol / Substance Use Disorder (Emerging)","modality":"REPURPOSED","regulatory_modality":"SMALL_MOLECULE_OFFLABEL","restriction_driver":"COST_OR_LICENSING","therapeutic_areas":["Addiction","Mental_Health"],"diseases":["Alcohol Use Disorder","Obesity","Type 2 Diabetes"],"description":"Semaglutide/tirzepatide prescribed off-label or studied for alcohol use disorder and other addictions. Evidence emerging; not a labeled SUD indication in most markets.","typical_us_cost_range":"$200–1,400/month depending on brand vs compounded"},{"id":"proc-prazosin-ptsd","name":"Prazosin for PTSD Nightmares","modality":"REPURPOSED","regulatory_modality":"SMALL_MOLECULE_OFFLABEL","restriction_driver":"COST_OR_LICENSING","therapeutic_areas":["Mental_Health","PTSD"],"diseases":["PTSD Nightmares","Hypertension (labeled)"],"description":"Alpha-1 antagonist used off-label for trauma-related nightmares. Inexpensive generic; evidence mixed across trials but widely used in veterans' care.","typical_us_cost_range":"$5–30/month"},{"id":"proc-baclofen-aud","name":"High-Dose Baclofen for Alcohol Use Disorder","modality":"REPURPOSED","regulatory_modality":"SMALL_MOLECULE_OFFLABEL","restriction_driver":"COST_OR_LICENSING","therapeutic_areas":["Addiction"],"diseases":["Alcohol Use Disorder"],"description":"Baclofen used off-label (sometimes high-dose protocols popularized in Europe) for alcohol dependence. France has had specific regulatory history; other countries physician discretion.","typical_us_cost_range":"$20–80/month"},{"id":"proc-peptide-cjc-ipa","name":"CJC-1295 / Ipamorelin Growth Hormone Secretagogue Peptides","modality":"PEPTIDE","regulatory_modality":"PEPTIDE","restriction_driver":"COST_OR_LICENSING","therapeutic_areas":["Anti_Aging","Performance"],"diseases":["Age-Related Sarcopenia","Growth Hormone Deficiency (not labeled for secretagogues)"],"description":"Peptide secretagogues used in wellness/anti-aging clinics to raise GH/IGF-1. Not FDA-approved for these uses; compounding status restricted for many related peptides.","typical_us_cost_range":"$150–500/month"},{"id":"proc-peptide-tesamorelin","name":"Tesamorelin (Egrifta) for HIV Lipodystrophy / Off-Label Visceral Fat","modality":"PEPTIDE","regulatory_modality":"PEPTIDE","restriction_driver":"COST_OR_LICENSING","therapeutic_areas":["Metabolic_Health","HIV"],"diseases":["HIV-Associated Lipodystrophy","Visceral Adiposity (off-label)"],"description":"FDA-approved GHRH analog for reduction of excess abdominal fat in HIV-associated lipodystrophy. Off-label interest for visceral adiposity outside HIV.","typical_us_cost_range":"$3,000–6,000/month list (assistance programs exist)"},{"id":"proc-mito-replacement","name":"Mitochondrial Replacement Therapy (MRT / Three-Person IVF)","modality":"REPRODUCTIVE","regulatory_modality":"REPRODUCTIVE","restriction_driver":"ETHICS_CONTESTED","therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Mitochondrial DNA Disease","Leigh Syndrome Risk","Mitochondrial Inheritance Risk"],"description":"Pronuclear or spindle transfer to prevent transmission of pathogenic mtDNA disease. Legal under regulated pathway in UK; largely prohibited or unregulated elsewhere.","typical_us_cost_range":"$50,000–100,000+ estimated full pathway"},{"id":"proc-egg-freezing","name":"Elective Oocyte Cryopreservation (Social Egg Freezing)","modality":"REPRODUCTIVE","regulatory_modality":"REPRODUCTIVE","restriction_driver":"ETHICS_CONTESTED","therapeutic_areas":["Reproductive_Health"],"diseases":["Age-Related Fertility Decline","Oncofertility","Elective Fertility Preservation"],"description":"Planned oocyte freezing without medical indication (career/age planning). Legal in most developed markets; some jurisdictions restrict non-medical freezing or limit storage duration.","typical_us_cost_range":"$8,000–15,000 cycle + $500–1,000/year storage (US)"},{"id":"proc-uterine-transplant","name":"Uterus Transplantation for Absolute Uterine Factor Infertility","modality":"REPRODUCTIVE","regulatory_modality":"REPRODUCTIVE","restriction_driver":"ETHICS_CONTESTED","therapeutic_areas":["Reproductive_Health"],"diseases":["Absolute Uterine Factor Infertility","MRKH Syndrome"],"description":"Living or deceased donor uterus transplant enabling pregnancy in AUFI (e.g. MRKH). Available only at specialized programs; high cost and ethical oversight.","typical_us_cost_range":"$200,000–500,000+ program costs"},{"id":"proc-5meo-dmt","name":"5-MeO-DMT Assisted Therapy","modality":"PSYCHEDELICS","regulatory_modality":"CONTROLLED_SUBSTANCE","restriction_driver":"CONTROLLED_SUBSTANCE","therapeutic_areas":["Mental_Health","Spirituality"],"diseases":["Depression","Anxiety","Substance Use Disorder","Existential Distress"],"description":"Short-acting intense psychedelic (synthetic or Bufo alvarius–derived). Clinical development emerging; ceremonial/retreat use in gray markets. High psychological intensity; toad-sourced product raises conservation/ethics issues.","typical_us_cost_range":"$500–3,000 (retreat/session estimates)"},{"id":"proc-ketamine-assisted-psychotherapy","name":"Ketamine-Assisted Psychotherapy (KAP)","modality":"PSYCHEDELICS","regulatory_modality":"CONTROLLED_SUBSTANCE","restriction_driver":"CONTROLLED_SUBSTANCE","therapeutic_areas":["Mental_Health","Depression","PTSD"],"diseases":["Treatment-Resistant Depression","PTSD","Anxiety Disorders"],"description":"Structured psychotherapy wrapped around ketamine dosing sessions (distinct from infusion-only clinics). Practice standards vary; not a separate FDA approval from ketamine/esketamine.","typical_us_cost_range":"$300–800/session; courses $3,000–12,000"},{"id":"proc-pef-ablation","name":"Pulsed Field Ablation (PFA) for Atrial Fibrillation","modality":"REPURPOSED","regulatory_modality":"SMALL_MOLECULE_OFFLABEL","restriction_driver":"COST_OR_LICENSING","therapeutic_areas":["Cardiovascular"],"diseases":["Atrial Fibrillation"],"description":"Nonthermal irreversible electroporation ablation for AF. Rapidly expanding after FDA clearances of PFA systems; availability lags in lower-resource systems.","typical_us_cost_range":"$25,000–50,000 episode of care"},{"id":"proc-lecanemab","name":"Anti-Amyloid Monoclonal Antibodies (Lecanemab / Donanemab) for Early Alzheimer's","modality":"REPURPOSED","regulatory_modality":"SMALL_MOLECULE_OFFLABEL","restriction_driver":"COST_OR_LICENSING","therapeutic_areas":["Neurology","Dementia"],"diseases":["Early Alzheimer's Disease","Mild Cognitive Impairment due to AD"],"description":"IV anti-amyloid mAbs for early AD with confirmed amyloid. Require APOE testing, MRI monitoring for ARIA. Coverage and capacity constrain access even where approved.","typical_us_cost_range":"$26,000–32,000/year drug + imaging/infusion costs"},{"id":"proc-trt","name":"Testosterone Replacement Therapy (TRT) for Hypogonadism","modality":"REPURPOSED","regulatory_modality":"SMALL_MOLECULE_OFFLABEL","restriction_driver":"COST_OR_LICENSING","therapeutic_areas":["Endocrinology","Men's_Health"],"diseases":["Male Hypogonadism","Testosterone Deficiency"],"description":"Testosterone for clinical hypogonadism. Legal with prescription in most countries; telehealth and compounding gray markets common. Controlled substance in US (Schedule III).","typical_us_cost_range":"$30–200/month (generic injections); clinics $100–400/month"},{"id":"proc-peptide-ss31","name":"Elamipretide / Mitochondrial-Targeted Peptides (SS-31 Class)","modality":"PEPTIDE","regulatory_modality":"PEPTIDE","restriction_driver":"COST_OR_LICENSING","therapeutic_areas":["Mitochondrial_Health","Cardiology","Ophthalmology"],"diseases":["Barth Syndrome","Mitochondrial Myopathy","Dry AMD (investigational)"],"description":"Mitochondria-targeted peptides (elamipretide and analogs) in development for Barth syndrome, mitochondrial myopathy, dry AMD, etc. Limited approved access; mostly trials/expanded access.","typical_us_cost_range":"Trial or expanded access; commercial TBD"},{"id":"proc-ecmo-bridge","name":"Elective / Bridge ECMO and Advanced Cardiac Support Tourism Pathways","modality":"REPURPOSED","regulatory_modality":"SMALL_MOLECULE_OFFLABEL","restriction_driver":"COST_OR_LICENSING","therapeutic_areas":["Cardiovascular","Critical_Care"],"diseases":["Cardiogenic Shock","Severe ARDS","Bridge to Transplant"],"description":"ECMO is standard in major ICUs for severe cardiopulmonary failure. 'Tourism' angle is limited; arbitrage is capacity/expertise at high-volume centers rather than legality.","typical_us_cost_range":"$100,000–500,000+ per run"},{"id":"proc-fecal-sibo","name":"Elemental Diet / Rifaximin Protocols for SIBO (Access Friction Map)","modality":"REPURPOSED","regulatory_modality":"SMALL_MOLECULE_OFFLABEL","restriction_driver":"COST_OR_LICENSING","therapeutic_areas":["Gastrointestinal"],"diseases":["SIBO","IBS-D","Hepatic Encephalopathy (rifaximin labeled)"],"description":"Rifaximin (and combination protocols) plus elemental diets for small intestinal bacterial overgrowth. Drug access and insurance denials create practical arbitrage more than legality.","typical_us_cost_range":"$1,000–2,500 for brand rifaximin course; elemental diet $500–1,000"},{"id":"proc-low-dose-lithium","name":"Low-Dose Lithium for Neuroprotection / Mood","modality":"REPURPOSED","regulatory_modality":"SMALL_MOLECULE_OFFLABEL","restriction_driver":"COST_OR_LICENSING","therapeutic_areas":["Mental_Health","Neurology"],"diseases":["Bipolar Disorder (full-dose labeled)","Mood Instability","Dementia Risk Reduction (investigational)"],"description":"Sub-psychiatric doses of lithium (often lithium orotate OTC or low-dose carbonate) used for mood stability and putative dementia risk reduction. Full-dose lithium is prescription; microdose market is supplement/gray.","typical_us_cost_range":"$10–40/month"},{"id":"proc-psilocybin-microdose","name":"Psilocybin Microdosing Protocols","modality":"PSYCHEDELICS","regulatory_modality":"CONTROLLED_SUBSTANCE","restriction_driver":"CONTROLLED_SUBSTANCE","therapeutic_areas":["Mental_Health","Cognition"],"diseases":["Depression","Anxiety","ADHD Symptoms (self-report)"],"description":"Sub-perceptual repeated dosing of psilocybin. Distinct from full-dose assisted therapy. Legal only where psilocybin is decriminalized/regulated; clinical evidence mixed.","typical_us_cost_range":"$20–200/month (gray/decrim supply)"},{"id":"proc-cord-blood","name":"Umbilical Cord Blood / Perinatal Cell Therapies","modality":"STEM_CELL","regulatory_modality":"CELL_THERAPY_AUTOLOGOUS","restriction_driver":"SAFETY_UNPROVEN","therapeutic_areas":["Hematology","Regeneration"],"diseases":["Leukemia (transplant)","Lymphoma (transplant)","Cerebral Palsy (investigational clinics)"],"description":"Banked cord blood for approved hematopoietic transplants; also marketed unproven perinatal cell infusions in regenerative clinics abroad.","typical_us_cost_range":"Transplant standard of care (insured when indicated); clinic infusions $5,000–25,000"},{"id":"proc-photoimmunotherapy","name":"Near-Infrared Photoimmunotherapy for Head & Neck Cancer","modality":"ONCOLOGY","regulatory_modality":"SMALL_MOLECULE_UNAPPROVED","restriction_driver":"SAFETY_UNPROVEN","therapeutic_areas":["Oncology"],"diseases":["Head and Neck Squamous Cell Carcinoma"],"description":"Antibody-IR700 conjugate activated by near-infrared light (e.g. Japan-approved ASP-1929/Akalux pathway). Geographic access currently skewed to Japan and trial sites.","typical_us_cost_range":"Country-specific; specialty oncology pricing"}],"access_records":[{"id":"43bdfbe3-0ffa-4861-bbaf-876bde13fe5a","procedure_id":"proc-psilocybin-trd","jurisdiction_id":"jur-us-or","procedure_name":"Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"REGULATED_THERAPY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"$1,500-3,500 per session (varies by center; group vs. individual; preparation/integration session fees may be additional)","price_usd":2500.0,"access_pathway_details":"Licensed psilocybin service centers operating under Oregon Psilocybin Services Act. Must be 21+. No prescription required; can self-refer. Administration session with licensed facilitator after preparation. Integration support included.","eligibility_requirements":"Must be 21+, Oregon residency NOT required (open to non-residents). No medical diagnosis required to access services (broad access model). Screening for contraindications by facilitator. Cannot be on certain interacting medications.","provider_requirements":"Licensed facilitator (OPS-trained and certified). Licensed psilocybin service center. Product must be OPS-tested psilocybin from licensed manufacturer. No medical license required for facilitators.","residency_travel_notes":"No residency requirement for clients. Can travel to Oregon specifically for services. Service centers in Portland, Eugene, Bend, and other cities. Clients must remain on-site for duration of session (typically 4-6 hours).","risk_notes":"Regulated product (tested for potency and contaminants). Licensed and trained facilitators. Emergency protocols required at service centers. Contraindicated in personal/family history of psychosis, certain cardiovascular conditions, concurrent lithium use. Challenging experiences can occur and require skilled facilitation.","arbitrage_summary":"Oregon offers the only state-regulated, legal psilocybin therapy program in the US. No diagnosis or prescription required. Open to non-residents. High regulatory quality. ~$2,000-3,500 per session vs. typical US underground $5,000+ or clinical trial requirements.","oversight_notes":"Oregon Health Authority (OHA) Psilocybin Services Section provides comprehensive regulation. Licensed manufacturers, testing labs, service centers, and facilitators. Strict product testing and labeling. DOSA (Drug Omnibus Safety and Accountability Act) enforcement framework.","cost_notes":"Costs are out-of-pocket (not covered by insurance). Lower than underground options and clinical trials due to less medical overhead (facilitators not required to be licensed clinicians). Prices expected to decrease with competition. Midpoint of $1,500–3,500 per session (OPS centers, cash-pay).","legal_basis":null,"regulatory_authority":null,"last_verified":"2025-07-01","sources":[{"title":"Oregon Psilocybin Services","url":"https://www.oregon.gov/oha/PH/PREVENTIONWELLNESS/Pages/Psilocybin-Services.aspx"},{"title":"OPS Administrative Rules","url":"https://secure.sos.state.or.us/oard/displayDivisionRules.action?selectedDivision=4140"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"5c3ca25e-4315-46ef-9bec-ba0aa57ace01","procedure_id":"proc-psilocybin-eol","jurisdiction_id":"jur-us-or","procedure_name":"Psilocybin-Assisted Therapy for End-of-Life Anxiety","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"REGULATED_THERAPY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"$1,500-3,500 per session","price_usd":2500.0,"access_pathway_details":"Same regulatory pathway as general psilocybin services. No specific end-of-life pathway required; any qualified client 21+ can seek services for existential distress. Some service centers specialize in palliative contexts. Preparation and integration sessions tailored to goals.","eligibility_requirements":"21+. No terminal diagnosis required. Medical clearance for session recommended given potential comorbidities in this population.","provider_requirements":"Licensed OPS facilitator. Palliative care knowledge recommended but not required by regulation. Licensed service center.","residency_travel_notes":"No residency requirement. Travel for EOL patients may require additional medical planning and support.","risk_notes":"Same risks as general psilocybin services plus: potential for drug interactions with common end-of-life medications, need for medical clearance given comorbidities. Emotional intensity may be high given confrontation with mortality.","arbitrage_summary":"One of few legal pathways globally for psilocybin therapy for EOL anxiety without requiring clinical trial enrollment or terminal diagnosis. Open access model.","oversight_notes":"Same OHA oversight as all psilocybin services. Additional consideration for medical stability in palliative populations. Service centers may have specific EOL experience.","cost_notes":"Same pricing as general psilocybin services. No insurance coverage.","legal_basis":null,"regulatory_authority":null,"last_verified":"2025-07-01","sources":[{"title":"Oregon Psilocybin Services","url":"https://www.oregon.gov/oha/PH/PREVENTIONWELLNESS/Pages/Psilocybin-Services.aspx"}],"therapeutic_areas":["Mental_Health","Palliative_Care"],"diseases":["Cancer-Related Anxiety","End-of-Life Existential Distress","Adjustment Disorder"],"status":"active"},{"id":"1f6b1dd1-23ba-44cf-b390-04ff7d662212","procedure_id":"proc-psilocybin-trd","jurisdiction_id":"jur-us-co","procedure_name":"Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"REGULATED_THERAPY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"TBD (healing centers not yet operational). Personal cultivation: minimal cost (spores/substrate). Underground therapy: $1,000-3,000.","price_usd":2000.0,"access_pathway_details":"Natural Medicine Health Act (Proposition 122). Regulated healing centers anticipated to open 2025+. Personal use/growing of psilocybin mushrooms decriminalized effective immediately (Dec 2022). Adults 21+ may possess, use, cultivate, and share psilocybin mushrooms (not sold).","eligibility_requirements":"21+. Healing center requirements TBD by DOR regulatory process. Personal use/growing: no license required. No commercial sale permitted under personal use decrim.","provider_requirements":"Licensed healing center facilitators (regulatory framework in development by DOR Natural Medicine Division). Personal cultivation/gifting permitted among adults without licensing.","residency_travel_notes":"Colorado residency NOT required for healing center access. Personal use protections apply to any adult 21+ in Colorado borders regardless of residency.","risk_notes":"Personal use/growing: no oversight, quality control, or facilitation. Healing centers will provide regulated product and trained facilitation. Risks of unguided use higher. Challenging experiences without support may be destabilizing.","arbitrage_summary":"Unique dual model: regulated therapy + personal cultivation. Lowest-cost access to psilocybin therapy in US (near-zero for self-grown). Best for self-directed consumers comfortable without clinical oversight.","oversight_notes":"Colorado Department of Regulatory Agencies (DORA) Natural Medicine Division developing rules. Dual system: regulated healing centers + decriminalized personal use. Regulatory framework modeled on cannabis but distinct.","cost_notes":"Healing center pricing not yet established (est. 2025+). Personal cultivation substantially reduces cost barrier for those comfortable with self-directed use. Gifting circles emerging. Healing-center list prices not fully public; estimate from interim underground/early-center ranges $1,000–3,000. Personal cultivation is near-zero cash cost but not a licensed pathway.","legal_basis":null,"regulatory_authority":null,"last_verified":"2025-07-01","sources":[{"title":"Colorado Natural Medicine Health Act","url":"https://dnr.colorado.gov/natural-medicine"},{"title":"Prop 122 Full Text","url":"https://www.sos.state.co.us/pubs/elections/Initiatives/titleBoard/filings/2021-2022/58Final.pdf"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"fd16fef1-4a40-418a-a4d3-be599953bbfc","procedure_id":"proc-dmt-depression","jurisdiction_id":"jur-us-co","procedure_name":"DMT (N,N-Dimethyltryptamine) Assisted Therapy for Depression","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"DECRIMINALIZED","access_pathway":"NONE","oversight_quality":"LOW","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Minimal for personal cultivation/extraction (spores/plant material). Underground/guided DMT experiences: varies widely ($500-3,000+).","price_usd":null,"access_pathway_details":"DMT-containing plants (and DMT itself) decriminalized under Prop 122 for personal possession, use, cultivation, and gifting. NOT a commercial or therapeutic framework — no licensed DMT healing centers. Clinical trials for synthetic DMT (Small Pharma/Incannex) occurring in other jurisdictions.","eligibility_requirements":"21+. Personal possession/use/growing only. No commercial sales. No regulated therapy program for DMT.","provider_requirements":"No regulated providers for DMT. Licensed healing center framework under development but initially focused on psilocybin only (other natural medicines may be added later).","residency_travel_notes":"Same as psilocybin: protections apply to any adult in Colorado. Travel for personal use/growing is feasible.","risk_notes":"HIGH risk: No quality control, no medical screening, no trained facilitation, no emergency protocols. DMT's intense, rapid onset increases psychological risk without preparation and support. Contraindications (psychosis, cardiac) unchecked.","arbitrage_summary":"Decriminalized but unregulated. Only for highly self-directed individuals comfortable with underground or self-guided use. Clinical DMT therapy available in trials elsewhere. Wait for regulated healing center pathway for safer access.","oversight_notes":"Decriminalization model with no regulatory oversight for product quality, dosing, or session safety. All risks borne by consumer. Licensed centers may eventually include DMT in scope (Natural Medicine Advisory Board can recommend).","cost_notes":"Personal extraction from plants dramatically reduces cost. No regulated market pricing available. Risk of impure/synthesized product in unregulated channels. Decriminalized personal use only — no licensed commercial/therapeutic supply; no reliable market price.","legal_basis":null,"regulatory_authority":null,"last_verified":"2025-07-01","sources":[{"title":"Colorado Natural Medicine Advisory Board","url":"https://dnr.colorado.gov/natural-medicine-advisory-board"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Major Depressive Disorder","Treatment-Resistant Depression"],"status":"active"},{"id":"113f3729-828e-481e-8907-14a8657ab3f4","procedure_id":"proc-psilocybin-trd","jurisdiction_id":"jur-au","procedure_name":"Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"AU$10,000-20,000+ (USD $6,500-13,000+) per treatment course. Limited to no Medicare rebate currently. Most costs out-of-pocket.","price_usd":9750.0,"access_pathway_details":"TGA rescheduled psilocybin and MDMA (July 2023) as Schedule 8 controlled drugs with authorized prescriber access for TRD and PTSD respectively. Must be prescribed by an authorized psychiatrist. Administered in medically controlled settings. NOT available at pharmacies. Strict TGA Special Access Scheme/Authorized Prescriber pathway.","eligibility_requirements":"Confirmed treatment-resistant depression (failed 2+ adequate trials of antidepressants). Australian residency/TGA SAS criteria. Authorized prescriber must determine suitability. Psychiatric evaluation, medical clearance. Contraindications same as other jurisdictions.","provider_requirements":"Authorized prescriber (psychiatrist registered with TGA). Must have specific training and ethics committee approval. Administration in medically supervised facility. Multi-disciplinary team required (psychiatrist, therapist, nursing).","residency_travel_notes":"Australian residency effectively required. SAS/Authorized Prescriber pathway not designed for medical tourism. Non-residents cannot easily access. Some clinical trials may accept international participants.","risk_notes":"Highest standard of medical oversight globally. Fully medicalized model minimizes physical risks. GMP product quality. Comprehensive screening and monitoring. Psychological risks managed in clinical setting.","arbitrage_summary":"Gold standard for regulated medical psychedelic access. Highest oversight quality. TGA rescheduling is globally significant precedent. But high cost, strict eligibility, residency requirement. Best for Australians with TRD who can afford it.","oversight_notes":"TGA (Therapeutic Goods Administration) oversight. One of the most rigorous regulatory frameworks globally. Authorized Prescriber scheme requires institutional ethics committee approval, reporting obligations, adverse event tracking. Product must be GMP-manufactured.","cost_notes":"Very high due to medical infrastructure requirements (psychiatrist, facility, GMP product, multiple therapy sessions). Less than US clinical trials but more than Oregon model. No PBS subsidy yet — advocacy ongoing. Some private health insurance coverage possible. Midpoint of USD $6,500–13,000 per course (AU$10–20k); limited Medicare rebate.","legal_basis":null,"regulatory_authority":null,"last_verified":"2025-07-01","sources":[{"title":"TGA Psilocybin/MDMA Rescheduling","url":"https://www.tga.gov.au/news/media-releases/change-classification-psilocybin-and-mdma-enable-prescribing-authorised-psychiatrists"},{"title":"RANZCP Psychedelic Therapy Guidance","url":"https://www.ranzcp.org"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"ba7f79a2-3dff-44b4-bf09-01ae03f3507f","procedure_id":"proc-mdma-ptsd","jurisdiction_id":"jur-au","procedure_name":"MDMA-Assisted Psychotherapy for PTSD","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"AU$15,000-25,000+ (USD $10,000-16,500+) per treatment course","price_usd":13250.0,"access_pathway_details":"Same TGA rescheduling pathway as psilocybin. Authorized psychiatrist access only, specifically for PTSD. Published clinical protocols govern administration. 2-3 dosing sessions with extensive therapy. Requires same infrastructure: authorized prescriber, ethics approval, GMP product, medical facility.","eligibility_requirements":"Confirmed PTSD diagnosis (CAPS-5). Australian residency. Authorized prescriber assessment. Contraindications: uncontrolled hypertension, cardiovascular disease, certain liver conditions, psychosis history. Medication washout requirements.","provider_requirements":"Authorized psychiatrist with specific MDMA-AT training. Ethics committee approval. Medical facility with emergency capability. Co-therapist team (typically 2 therapists per session).","residency_travel_notes":"Australian residency essentially required. Not designed for medical tourism. SAS pathway for non-residents extremely unlikely.","risk_notes":"Medicalized setting with significant safeguards. Cardiovascular monitoring during sessions. CRS-like symptoms possible but managed. Evidence shows strong safety profile in controlled trials when screening and monitoring conducted.","arbitrage_summary":"TGA rescheduling alongside psilocybin makes Australia the first country to formally regulate both MDMA and psilocybin as medicines for specific mental health conditions. High oversight, high cost, residency-limited.","oversight_notes":"Equivalent TGA oversight to psilocybin. RANZCP clinical guidance. Robust adverse event monitoring. GMP MDMA required (manufactured under TGA license).","cost_notes":"High due to multi-session format (typically 3 MDMA sessions plus 12+ therapy sessions). Team-based delivery increases costs. No Medicare/PBS subsidy. Some private insurance coverage emerging. Midpoint of USD $10,000–16,500 per multi-session course.","legal_basis":null,"regulatory_authority":null,"last_verified":"2025-07-01","sources":[{"title":"TGA MDMA Rescheduling","url":"https://www.tga.gov.au/news/media-releases/change-classification-psilocybin-and-mdma-enable-prescribing-authorised-psychiatrists"}],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["Post-Traumatic Stress Disorder (PTSD)"],"status":"active"},{"id":"d8b95c6a-230d-455a-9c53-61bc8c673c0f","procedure_id":"proc-gene-crispr","jurisdiction_id":"jur-hn-prospera","procedure_name":"CRISPR-Based Gene Therapy (Somatic) for Genetic Disorders","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"RIGHT_TO_TRY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"LOW","modality":"GENE_THERAPY","estimated_cost_range_usd":"Unknown/variable. Minicircle gene therapy: $25,000-50,000+ (experimental). Other providers/costs not publicly established.","price_usd":37500.0,"access_pathway_details":"Próspera ZEDE has its own regulatory framework outside Honduran federal regulation. Biotech/gene therapy companies establishing operations. Minicircle (gene therapy startup) operating in Próspera for plasmid-based gene therapies. Light-touch regulation intended to attract innovation. Informed consent-based model.","eligibility_requirements":"Informed consent. Ability to pay out-of-pocket. Medical screening by treating provider in ZEDE. No insurance coverage. Must travel to Roatán.","provider_requirements":"Providers operating under Próspera ZEDE regulatory framework. Less prescriptive requirements than US/EU. Companies self-regulate with ZEDE oversight. Minicircle operating under their own protocols.","residency_travel_notes":"Open to international patients. Medical tourism hub model. Travel to Roatán Island, Honduras. ZEDE status provides unique legal framework but also uncertainty given ongoing legal challenges in Honduras.","risk_notes":"HIGH RISK: Light-touch regulation. No independent safety monitoring by recognized international bodies. Product quality/manufacturing standards not verified by major regulators. Legal uncertainty around ZEDE's constitutional status. Limited recourse if complications arise. Informed consent model shifts risk to patient. Medical infrastructure on island limited for managing severe complications.","arbitrage_summary":"Próspera offers the most permissive regulatory environment globally for gene therapies, at potentially 50-100x less than US approved therapies. This comes with extreme risk: regulatory quality is LOW, legal status of ZEDE itself is contested, and patient protections minimal. Only appropriate as absolute last resort with full understanding of risks.","oversight_notes":"ZEDE internal regulatory system—light touch by design. Less rigorous than FDA, EMA, TGA. No independent ethics review required by foreign standards. Quality dependent on individual company standards. Patients bear significant responsibility for due diligence. ZEDE legality contested under Honduran constitutional law (2023-2024 challenges).","cost_notes":"Significantly less than US-approved gene therapies ($2M+). Experimental nature means costs not standardized. Cash-pay model. Travel to Roatán adds $1,000-3,000. Public experimental quotes ~$25k–50k (e.g. plasmid/gene programs); not FDA-equivalent pricing.","legal_basis":null,"regulatory_authority":null,"last_verified":"2025-05-15","sources":[{"title":"Próspera ZEDE Overview","url":"https://prospera.hn"},{"title":"Minicircle Gene Therapy in Próspera","url":"https://minicircle.io"},{"title":"Honduras ZEDE Legal Challenges (Reuters)","url":"https://www.reuters.com/world/americas/honduras-congress-votes-repeal-economic-development-zones-2023-11-01"}],"therapeutic_areas":["Genetics","Hematology"],"diseases":["Sickle Cell Disease","Beta-Thalassemia","Genetic Blood Disorders"],"status":"active"},{"id":"fae3e8ff-13f7-4314-a849-685873ebdb8a","procedure_id":"proc-stem-msc","jurisdiction_id":"jur-hn-prospera","procedure_name":"Mesenchymal Stem Cell (MSC) Therapy for Autoimmune/Inflammatory Conditions","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"LOW","modality":"STEM_CELL","estimated_cost_range_usd":"$5,000-30,000+ (varies by treatment, clinic, number of infusions)","price_usd":17500.0,"access_pathway_details":"Stem cell clinics can operate under ZEDE regulatory framework with less restriction than FDA. Informed consent-based model. Cord blood and MSC therapies marketed for anti-aging and regenerative indications. GARM Clinic and others operating stem cell services.","eligibility_requirements":"Informed consent. Ability to pay. ZEDE entry/tourism facilitation. Screening by treating clinic (standards vary).","provider_requirements":"ZEDE-registered clinics. No FDA-equivalent BLA/MAA requirement. Variable quality across providers. Some clinics have international accreditation (e.g., GARM claims Best Clinic accreditation).","residency_travel_notes":"Open to international patients. Roatán has international airport with direct flights from US cities. Tourism infrastructure exists (resorts, hotels). ZEDE entry managed separately from Honduran immigration.","risk_notes":"Variable cell product quality (source, processing, characterization). No FDA-level oversight. Not covered by US patient protections. Legal recourse limited in ZEDE/Honduras legal system. Infection, immunogenicity, and tumorigenicity risks with uncharacterized cell products. Medical evacuation for severe complications requires additional planning/cost.","arbitrage_summary":"Accessible stem cell therapies at lower cost than US. Vastly less oversight — HIGH risk. Only acceptable with extensive due diligence on specific clinic, product source, and protocol. Best for patients who have exhausted regulated options and fully understand risk tradeoff.","oversight_notes":"ZEDE regulatory framework allows operations that would require IND/BLA in US. No centralized cell therapy regulation to international standards. Individual clinic quality varies significantly. Due diligence on clinic and provider essential.","cost_notes":"Lower than US-based MSC clinics operating in regulatory gray zones. Still cash-pay. No insurance. Travel/housing on Roatán additional. Midpoint of $5,000–30,000 clinic packages.","legal_basis":null,"regulatory_authority":null,"last_verified":"2025-05-15","sources":[{"title":"Próspera Medical Services Guide","url":"https://prospera.hn/medical-services"}],"therapeutic_areas":["Autoimmune","Orthopedic"],"diseases":["Osteoarthritis","Autoimmune Disease","Inflammatory Conditions","Crohn's Disease"],"status":"active"},{"id":"fbf736e8-7669-40ab-a132-7aaec1cf3b39","procedure_id":"proc-maid","jurisdiction_id":"jur-ca","procedure_name":"Medical Assistance in Dying (MAID) / Assisted Death","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"HIGH","modality":"ASSISTED_DYING","estimated_cost_range_usd":"$0 (publicly covered under provincial health plans for eligible residents)","price_usd":0.0,"access_pathway_details":"Medical Assistance in Dying (MAID) legal nationwide since 2016 (Bill C-14), expanded 2021 (Bill C-7). Two tracks: Track 1 (death reasonably foreseeable) and Track 2 (death NOT reasonably foreseeable, but grievous and irremediable condition). Mental illness as sole condition delayed to 2027. Two methods: clinician-administered (IV) or self-administered (oral). Publicly funded under provincial health plans.","eligibility_requirements":"Canadian resident with provincial health coverage (minimum residency period varies by province, typically 3-12 months). 18+. Capable of making healthcare decisions. Grievous and irremediable medical condition causing enduring and intolerable suffering. Two independent assessments by medical/nurse practitioners. 90-day assessment period for non-foreseeable death track. Written request with independent witness.","provider_requirements":"Medical doctor or nurse practitioner. Two independent assessors, one of whom may be the provider. No specialty requirement but relevant expertise expected. Pharmacist for oral medications or clinician for IV administration. Conscientious objection permitted; must refer.","residency_travel_notes":"Must establish Canadian residency (provincial health coverage). Not available for short-term medical tourists. Residency establishment typically requires 3-12 months and intent to reside. Once residency established, no citizenship requirement. Some international patients relocating to Canada specifically for MAID access (long-term planning required).","risk_notes":"Extremely safe procedural delivery in medical setting. Primary risks relate to decision-making certainty (ensuring it's truly autonomous and enduring). Safeguards robust. Contraindications: inability to consent at time of provision (must be able to confirm consent immediately before provision, except in cases of prior arrangement for loss of capacity—rules vary).","arbitrage_summary":"Canada offers the most progressive MAID framework globally: no terminal illness requirement (Track 2), non-residents can access after establishing residency, 100% publicly funded, high oversight quality. Best option for non-terminal patients with grievous conditions causing intolerable suffering who are willing/able to establish residency.","oversight_notes":"Federal MAID legislation with provincial health authority oversight. Reporting requirements for every MAID provision to federal monitoring system. Annual reports to Parliament. Robust safeguards: 2 independent assessments, 90-day reflection period (Track 2), informed consent verification at time of provision, independent witness. Some disability rights groups raise concerns about safeguards adequacy.","cost_notes":"One of very few access records with $0 direct cost. Covered by Canadian Medicare. Medications, assessments, and provision all publicly funded. Travel/accommodation for non-residents during residency period: $2,000-10,000+ depending on length of stay. Publicly funded under provincial plans for eligible residents; $0 procedure cost. Travel/residency establishment costs are separate.","legal_basis":null,"regulatory_authority":null,"last_verified":"2025-07-01","sources":[{"title":"Health Canada MAID","url":"https://www.canada.ca/en/health-canada/services/medical-assistance-dying.html"},{"title":"Bill C-7 (2021) MAID Expansion","url":"https://www.parl.ca/DocumentViewer/en/43-2/bill/C-7/royal-assent"},{"title":"MAID Annual Reports","url":"https://www.canada.ca/en/health-canada/services/medical-assistance-dying/annual-reports.html"}],"therapeutic_areas":["Palliative_Care","End_of_Life"],"diseases":["Terminal Illness","Grievous Irremediable Medical Condition","Intolerable Suffering"],"status":"active"},{"id":"ec0e0bb1-7025-4e7f-8f30-615140008ea9","procedure_id":"proc-maid","jurisdiction_id":"jur-ch","procedure_name":"Medical Assistance in Dying (MAID) / Assisted Death","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"HIGH","modality":"ASSISTED_DYING","estimated_cost_range_usd":"Dignitas: CHF 7,500-10,500 (USD $8,500-12,000) for preparation, assessment, and accompaniment. Pegasos: CHF 10,000-12,000 (USD $11,300-13,600). Additional: travel, accommodation, Swiss medical assessment fees.","price_usd":10500.0,"access_pathway_details":"Assisted suicide legal under Swiss Criminal Code (Art. 115) when performed without selfish motives. Non-profit right-to-die organizations (Dignitas, EXIT, Lifecircle, Pegasos) assess eligibility and facilitate. Self-administration of prescribed lethal medication required (IV line with bite-valve or oral solution). Must be mentally competent at time of act. No requirement for terminal illness—'weariness of life' accepted by some organizations.","eligibility_requirements":"Mental capacity for rational decision-making at time of act. Medical condition causing intolerable suffering (interpretation varies by organization: Dignitas accepts wide range including severe chronic illness, mental illness in some cases; others more restrictive). Swiss residency NOT required for Dignitas and Pegasos (accept international clients). EXIT and Lifecircle require Swiss residency. Two medical assessments typically required (one by Swiss doctor for Dignitas).","provider_requirements":"Right-to-die organization staff (non-medical facilitation role). Swiss physician for prescription. Patient must self-administer. Organizations provide preparation, support, and space. Legal witness present. Police notification after death; investigation standard procedure.","residency_travel_notes":"Dignitas and Pegasos explicitly accept international clients—No Swiss residency required. Clients travel to Zurich (Dignitas) or Basel (Pegasos). Must stay 1-3 days for assessments. Accommodation and travel additional. Some clients combine with tourism (controversial practice, organizations may refuse if suspected).","risk_notes":"Psychological: decision-making under stress of travel. Legal: death investigation by Swiss authorities standard; no prosecution if all criteria met. Process highly reliable when performed by established organizations. Medication effects well-understood (pentobarbital). Some reports of prolonged process if swallowing difficulty. No physician present at moment of death in Dignitas model (contrast with some other organizations).","arbitrage_summary":"Switzerland is the primary global destination for international assisted suicide. No terminal illness requirement. No residency requirement (Dignitas/Pegasos). High oversight by Swiss legal standards. $8,500-13,600 cost. Best for those with conditions causing unbearable suffering who cannot access MAID in home country and can afford international option.","oversight_notes":"Swiss regulatory model unusual: assisted suicide permitted by criminal code provision rather than healthcare legislation. Oversight occurs through police/prosecutor investigation after each death rather than healthcare regulatory bodies. Cantonal variations in practice. Medical ethics guidelines from Swiss Academy of Medical Sciences. Some medical organizations opposed; others supportive. Less systematic oversight than Canadian MAID model—more decentralized.","cost_notes":"Significant cost barrier (all out-of-pocket). Cost covers: membership, assessments, Swiss medical consultation, prescription, accompaniment, cremation/administrative costs. International clients pay premium. Swiss residents pay less through EXIT (CHF 40 annual membership + small supplementary cost). Dignitas ~CHF 7.5–10.5k; Pegasos ~CHF 10–12k. Midpoint ~USD $10,500 org fees; travel/housing extra.","legal_basis":null,"regulatory_authority":null,"last_verified":"2025-07-01","sources":[{"title":"Dignitas - Accompanied Suicide","url":"https://www.dignitas.ch"},{"title":"Pegasos Swiss Association","url":"https://pegasos-association.com"},{"title":"Swiss Criminal Code Art. 115","url":"https://www.fedlex.admin.ch/eli/cc/54/757_781_799/en"},{"title":"EXIT Swiss","url":"https://exit.ch"}],"therapeutic_areas":["Palliative_Care","End_of_Life"],"diseases":["Terminal Illness","Grievous Irremediable Medical Condition","Intolerable Suffering"],"status":"active"},{"id":"2fd8eb1e-a493-43cd-8536-b8fe39b7fe1d","procedure_id":"proc-lsd-anxiety","jurisdiction_id":"jur-ch","procedure_name":"LSD-Assisted Psychotherapy for Anxiety Disorders","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"CHF 5,000-15,000 (USD $5,600-17,000) per treatment course. Some covered by Swiss health insurance (varies by canton and insurer).","price_usd":11300.0,"access_pathway_details":"Swiss Federal Office of Public Health (BAG) issues exceptional permits for psychedelic therapy (LSD, psilocybin, MDMA) on compassionate use basis. Treating psychiatrist/physician applies to BAG for individual patient authorization. Requires documentation that conventional treatments have failed. Administration in medical/psychotherapeutic setting. Growing number of authorized practitioners.","eligibility_requirements":"Swiss residency (typically). Documented failure of conventional treatments. Specific condition with some evidence base for psychedelic therapy. Medical and psychiatric clearance. Psychotic disorders excluded. BAG review and approval required per patient.","provider_requirements":"Swiss-licensed physician (typically psychiatrist). Must apply to BAG for each patient. Experience/training in psychedelic therapy expected but not formally credentialed. Psychotherapeutic training recommended. Medical setting capable of monitoring.","residency_travel_notes":"Swiss residency typically required for BAG permits. Non-residents cannot easily access. Some specialized clinics may accept international patients outside BAG system (less oversight). Switzerland as medical tourism destination limited for this pathway.","risk_notes":"Excellent medical infrastructure. Swiss healthcare quality among highest globally. BAG oversight ensures baseline standards. Psychological risks standard for psychedelic therapy. Cardiovascular monitoring standard.","arbitrage_summary":"Switzerland offers the most established compassionate use psychedelic therapy pathway globally (~10 years of operation). High quality but residency-restricted. Best model for how regulated psychedelic therapy can work in a Western healthcare system.","oversight_notes":"BAG (Federal Office of Public Health) permit system. Case-by-case review. Growing experience base since mechanism established ~2014. Not a formal approval pathway but a compassionate use exception. High-quality Swiss medical infrastructure. Published outcome data being accumulated (retrospective analyses show favorable safety/efficacy).","cost_notes":"Significant variation. Some Swiss basic insurance covers parts when authorized by BAG. Supplementary insurance may cover psychotherapy components. Cash-pay if insurance denied. Less expensive than Australian model. BAG exceptional authorization; CHF 5–15k course midpoint ~USD $11,300. Some cantonal insurance partial cover.","legal_basis":null,"regulatory_authority":null,"last_verified":"2025-07-01","sources":[{"title":"Swiss BAG - Exceptional Authorization for Psychedelics","url":"https://www.bag.admin.ch"},{"title":"Swiss Medical Association Psychedelic Guidelines","url":"https://www.fmh.ch"}],"therapeutic_areas":["Mental_Health","Anxiety"],"diseases":["Generalized Anxiety Disorder","Illness-Related Anxiety"],"status":"active"},{"id":"7cddd1ea-4089-4626-a093-7b4887984dd9","procedure_id":"proc-psilocybin-trd","jurisdiction_id":"jur-ca","procedure_name":"Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"CAD $5,000-12,000 (USD $3,700-8,800). Some costs covered by provincial health (physician visits). Drug and therapy costs typically out-of-pocket. TheraPsil advocacy model reduces costs (volunteer therapist model for some patients).","price_usd":6250.0,"access_pathway_details":"Health Canada Special Access Programme (SAP) allows physicians to request access to restricted drugs (psilocybin, MDMA) for serious/life-threatening conditions when conventional treatments have failed. Section 56 exemptions under CDSA provide another pathway. Growing number of approved requests (2020 onwards). Alberta and Quebec have regulated psychedelic therapy programs in development.","eligibility_requirements":"Canadian residency (provincial health coverage). Serious or life-threatening condition. Failed, intolerable, or unavailable conventional treatments. Physician must apply to Health Canada with clinical rationale and safety plan. Psychiatric assessment. Drug sourcing plan. Informed consent.","provider_requirements":"Canadian-licensed physician (typically psychiatrist). Healthcare facility with monitoring capability. Multidisciplinary team recommended. Therapy component (preparation/integration) required but not always formally credentialed. Drug sourcing through Health Canada-authorized channels.","residency_travel_notes":"Canadian residency required for SAP/Section 56 pathways. Not available for medical tourists. Canadian healthcare residency establishment requires 3+ months typically.","risk_notes":"Canadian healthcare quality is high. SAP approval ensures baseline safety planning. Drug sourcing through Health Canada channels ensures product quality. Psychological risks standard for psychedelic therapy. Monitoring in healthcare facility reduces medical risks.","arbitrage_summary":"More accessible and affordable than Australian pathway, but less structured and with fewer approved patients. SAP model is physician-driven rather than drug-company-driven. Good balance of oversight quality and access for Canadians who qualify.","oversight_notes":"Health Canada SAP oversight. Less documented than Australian TGA pathway but operational since 2020. Increasing number of approved applications. Robust Canadian healthcare infrastructure provides baseline safety. Provincial variations in implementation. Alberta's program is most developed. Section 56 pathway has been used for end-of-life patients (TheraPsil advocacy).","cost_notes":"More affordable than Australian model. Provincial health coverage for medical components. SAP pathway reduces administrative burden costs. Some non-profit facilitation (TheraPsil) helps connect patients with providers at reduced cost. SAP/Section 56 pathway; CAD $5–12k midpoint ~USD $6,250. Physician visits may be provincial-covered.","legal_basis":null,"regulatory_authority":null,"last_verified":"2025-07-01","sources":[{"title":"Health Canada SAP for Psychedelics","url":"https://www.canada.ca/en/health-canada/services/drugs-health-products/special-access-programme-drugs.html"},{"title":"TheraPsil","url":"https://therapsil.ca"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"ef7ea0d5-3400-45bf-9bf5-341395f5d48e","procedure_id":"proc-stem-msc","jurisdiction_id":"jur-mx","procedure_name":"Mesenchymal Stem Cell (MSC) Therapy for Autoimmune/Inflammatory Conditions","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"STEM_CELL","estimated_cost_range_usd":"$3,000-25,000+ (Tijuana/Cancún clinics). Wide range reflects quality and indication variation.","price_usd":14000.0,"access_pathway_details":"Mexico has a large medical tourism industry for stem cell therapies. COFEPRIS (Mexican FDA) regulates but enforcement is inconsistent. Many clinics operate with minimal oversight, marketing unproven stem cell treatments. Quality varies dramatically—from legitimate medical centers to outright scams. Tijuana, Cancún, and Mexico City are major hubs.","eligibility_requirements":"Ability to pay. Passport/tourist visa (US citizens: 6-month tourist card on arrival). Clinic-specific screening (quality varies). Most clinics accept nearly all patients regardless of indication. Beware: 'no medical condition too complex' marketing is a red flag.","provider_requirements":"COFEPRIS registration theoretically required but enforcement inconsistent. No equivalent of FDA BLA/IND process. Some clinics have international accreditation (JCI, etc.), many do not. Physician credentials variable; verify independently.","residency_travel_notes":"Easy travel from US (Tijuana: San Diego border crossing; Cancún: direct flights from most US cities). No residency requirement. Tourist visa on arrival for US/Canadian/EU citizens. Many clinics cater specifically to English-speaking international patients. Some provide airport transfer and accommodation coordination.","risk_notes":"HIGH RISK due to variable regulation. Documented cases of serious adverse events including infections, tumor formation, and death from unregulated stem cell products. Counterfeit or contaminated products documented. Post-treatment complication management may be inadequate. Legal recourse limited for foreign patients. Verify: product source (autologous vs. allogeneic, cord blood vs. adipose), processing standards, clinic track record, physician credentials.","arbitrage_summary":"Lowest-cost accessible stem cell therapies near US. Regulatory quality VARIABLE (from good to dangerous). Only for patients willing to invest significant due diligence. Verify specific clinic, physician, cell product, and outcomes data. Avoid clinics making universal claims. Consider Prolotherapy/PRP as safer first-line regenerative option available in US.","oversight_notes":"COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) has regulatory authority but limited enforcement capacity. Private clinics largely self-regulate. Significant variation in quality—some excellent, some dangerous. Medical tourism industry self-promotes without independent quality auditing. No centralized patient outcome tracking.","cost_notes":"Generally 50-70% less than US-based stem cell clinics (which are also minimally regulated). Cash-pay. No insurance coverage. Medical tourism packages include travel/lodging at some clinics. Hidden costs possible (complication management, extended stays). Wide clinic range $3,000–25,000+; midpoint for due-diligence comparison only.","legal_basis":null,"regulatory_authority":null,"last_verified":"2025-06-01","sources":[{"title":"COFEPRIS","url":"https://www.gob.mx/cofepris"},{"title":"FDA Warning: Stem Cell Tourism Risks","url":"https://www.fda.gov/consumers/consumer-updates/fda-warns-about-stem-cell-therapies"},{"title":"CDC Stem Cell Tourism Infections Report","url":"https://wwwnc.cdc.gov/eid/article/29/2/22-0980_article"}],"therapeutic_areas":["Autoimmune","Orthopedic"],"diseases":["Osteoarthritis","Autoimmune Disease","Inflammatory Conditions","Crohn's Disease"],"status":"active"},{"id":"b65f73d0-a16d-4ee8-9261-71609e980c5f","procedure_id":"proc-ibogaine-addiction","jurisdiction_id":"jur-mx","procedure_name":"Ibogaine Treatment for Opioid/Substance Use Disorder","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"PSYCHEDELICS","estimated_cost_range_usd":"$3,000-8,000 for 5-7 day treatment program. Medical-supervised clinics: $6,000-12,000. Luxury/resort-style: $12,000-20,000.","price_usd":7500.0,"access_pathway_details":"Baja California and other regions host numerous ibogaine clinics for addiction treatment. Ibogaine unregulated at federal level—legal gray zone. Some clinics operate with medical supervision (MD on staff, cardiac monitoring), others do not. Significant variation in safety protocols. Rosarito/Tijuana and Cancún areas are primary hubs.","eligibility_requirements":"Opioid or other substance use disorder. MUST have cardiac screening (QTc interval, electrolytes, LFTs) before treatment. Reputable clinics require pre-screening EKG and labs. Many clinics do NOT have adequate screening. 18+. Ability to travel to Mexico.","provider_requirements":"Mexican medical license for MD-supervised clinics. Some clinics staffed by non-physicians (high risk). No formal ibogaine certification required. International ibogaine provider network (GITA) has training standards but voluntary. Cardiac monitoring equipment (continuous EKG, defibrillator, crash cart) essential—not all clinics have this.","residency_travel_notes":"Easy travel from US (San Diego/Tijuana crossing common). No visa issues for short stays. Many clinics provide transportation from border/airport. Recovery time after ibogaine session (24-48h of reduced mobility) before travel home recommended.","risk_notes":"SIGNIFICANT CARDIAC RISK: Ibogaine causes QT prolongation, bradycardia, and atropine-resistant bradycardia. 10+ documented fatalities at ibogaine clinics, primarily cardiac. MUST verify: continuous cardiac monitoring, MD present, emergency medications/defibrillator on-site, pre-treatment cardiac clearance, electrolyte monitoring during treatment. Liver toxicity reported. Seizures in some cases. Drug interactions (especially with opioids/alcohol during treatment). Post-treatment relapse risk without adequate aftercare planning.","arbitrage_summary":"Ibogaine offers rapid opioid detoxification unmatched by conventional treatments. Potentially transformative for addiction but with documented mortality risk. Mexico clinics: variable quality, must verify cardiac safety protocols and physician presence. Cost accessible compared to US alternatives. Best for those who have exhausted conventional treatment and can verify clinic safety protocols independently.","oversight_notes":"No formal regulatory framework for ibogaine in Mexico. COFEPRIS does not regulate ibogaine as a medicine. Clinics operate in regulatory vacuum. Safety dependent entirely on individual clinic protocols. GITA (Global Ibogaine Therapy Alliance) provides voluntary guidelines. No government inspection or accreditation for ibogaine specifically.","cost_notes":"Significantly less than US residential addiction treatment ($30,000-100,000). Cash-pay. No insurance coverage. Travel costs additional. Some clinics offer scholarships/reduced rates. Medical-supervised clinics typically $6–12k; broader market $3–8k. Cardiac-capable clinics cost more.","legal_basis":null,"regulatory_authority":null,"last_verified":"2025-06-01","sources":[{"title":"Ibogaine Mortality Review","url":"https://pubmed.ncbi.nlm.nih.gov/28556842"},{"title":"GITA Clinical Guidelines","url":"https://www.ibogainealliance.org"},{"title":"Ibogaine Cardiac Safety Review","url":"https://pubmed.ncbi.nlm.nih.gov/31424396"}],"therapeutic_areas":["Mental_Health","Addiction"],"diseases":["Opioid Use Disorder","Substance Use Disorder"],"status":"active"},{"id":"92cf1199-8103-4232-b736-a6f0ff6791b6","procedure_id":"proc-ketamine-depression","jurisdiction_id":"jur-us-federal","procedure_name":"Ketamine Infusion Therapy for Depression","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Spravato: $590-885 per session (drug cost) + administration/monitoring ($200-500). Insurance coverage common for FDA indication. IV ketamine: $400-800 per infusion (usually 6 initial, then boosters). Rarely covered by insurance for depression.","price_usd":600.0,"access_pathway_details":"Esketamine (Spravato) FDA-approved for TRD and suicidality. IV ketamine used widely off-label. Available in all 50 states through ketamine clinics. REMS program for Spravato (must be administered in certified healthcare setting with 2-hour monitoring). Off-label IV ketamine: no REMS requirement but standards vary by clinic. Ketamine is a Schedule III controlled substance.","eligibility_requirements":"Spravato: TRD (failed 2+ antidepressants) or MDD with acute suicidal ideation. Contraindicated in aneurysm/vascular conditions, AV malformation, pregnancy. IV ketamine: broader off-label use (chronic pain, PTSD, etc.) per clinic discretion. Psychiatric assessment. Medical screening (BP, cardiac history).","provider_requirements":"Spravato: REMS-certified healthcare setting, prescriber enrolled in REMS program, pharmacy certification. On-site monitoring for 2 hours. IV ketamine: typically MD/DO/NP supervision (varies by state). Anesthesiology, psychiatry, or pain management background common. American Society of Ketamine Physicians (ASKP) provides guidelines.","residency_travel_notes":"Available throughout US. Non-residents can access through cash-pay clinics. No US residency requirement for cash-pay services. Medical tourism possible but requires extended stay (2-3 weeks for induction series).","risk_notes":"Dissociative effects during treatment (generally well-tolerated). BP elevation (transient). Nausea prevented with antiemetics. Bladder toxicity with chronic frequent use (ketamine cystitis)—rare with depression protocols. Abuse potential (Schedule III). Sedation; must have driver/escort after treatment. REMS monitoring for Spravato standardizes acute risk management.","arbitrage_summary":"Most widely available psychedelic-adjacent treatment in US. Insurance coverage for Spravato is a key differentiator. Rapid onset for suicidality is unmatched. Cost varies insurance vs. cash-pay. Quality generally good. Best first-line psychedelic treatment option due to availability and insurance coverage.","oversight_notes":"FDA-approved for Spravato (intranasal). DEA Schedule III oversight. REMS program for Spravato ensures standardized monitoring. Off-label IV ketamine: less regulated; clinic quality varies. State medical boards oversee IV ketamine practices. ASKP provides voluntary guidelines. Generally higher oversight quality for Spravato vs. off-label IV.","cost_notes":"Spravato has insurance pathway (most commercial, Medicare, some Medicaid). Manufacturer copay assistance available. IV ketamine: cash-pay model. Some clinics offer packages. Total initial course (6-8 sessions): IV $2,400-6,400, Spravato $4,700-11,000 (pre-insurance). IV cash-pay ~$400–800/infusion (mid $600); induction series ~6 sessions. Spravato often insured (~$590–885 drug + admin).","legal_basis":null,"regulatory_authority":null,"last_verified":"2025-07-01","sources":[{"title":"Spravato Prescribing Information","url":"https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/SPRAVATO-pi.pdf"},{"title":"ASKP Ketamine Guidelines","url":"https://askp.org/guidelines"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder","Suicidal Ideation"],"status":"active"},{"id":"0375c5eb-2f32-43d0-a915-63c8c2f858ab","procedure_id":"proc-ketamine-depression","jurisdiction_id":"jur-us-or","procedure_name":"Ketamine Infusion Therapy for Depression","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"$350-650 per IV infusion (competitive market in Portland). Same Spravato insurance pathways.","price_usd":500.0,"access_pathway_details":"Same US federal framework. Ketamine clinics operating in Portland, Eugene, Bend, and other Oregon cities. Additional relevance: Oregon has overlapping expertise from psilocybin facilitator community. Some practitioners offer both ketamine and psilocybin-adjacent therapy models.","eligibility_requirements":"Same as US federal for Spravato (REMS). Oregon-specific: some clinics integrate with broader psychedelic therapy community for preparation/integration. Psychiatric and medical screening standard.","provider_requirements":"Same as federal: MD/DO/NP oversight. Some ketamine clinics employ or collaborate with psilocybin-trained facilitators for therapy integration. ASKP and Oregon Medical Board oversight.","residency_travel_notes":"Same as federal: accessible to all. Oregon's outdoor/nature setting may appeal to those wanting therapeutic environment. No residency requirement for cash-pay.","risk_notes":"Same as federal. Oregon's integration with psychedelic community may enhance therapeutic context and integration support.","arbitrage_summary":"Oregon's ketamine clinics offer competitive pricing and unique integration with the broader psychedelic therapy ecosystem. Good option for those also considering psilocybin services who want integrated care.","oversight_notes":"Same REMS for Spravato. Oregon Medical Board for IV practices. Integration with broader Oregon psychedelic community provides additional therapy resources not typically available at ketamine clinics in other states.","cost_notes":"Slightly lower IV ketamine pricing compared to national average due to competitive Portland market. Some clinics offer sliding scale. Portland competitive IV range $350–650; using mid $500. Spravato insurance pathway same as federal.","legal_basis":null,"regulatory_authority":null,"last_verified":"2025-07-01","sources":[{"title":"Spravato Prescribing Information","url":"https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/SPRAVATO-pi.pdf"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder","Suicidal Ideation"],"status":"active"},{"id":"18b66a0e-eaf9-4fde-8067-438ec3da8d53","procedure_id":"proc-repurposed-semaglutide","jurisdiction_id":"jur-us-federal","procedure_name":"GLP-1 Receptor Agonists (Semaglutide / Tirzepatide) Beyond Diabetes","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Brand: $900-1,400/month (list price). Insurance coverage variable (commercial: prior auth, employer opt-in required). Medicare: covered for T2D, NOT for weight loss (Medicare Part D cannot cover weight loss drugs by law). Manufacturer savings cards: $25-500/month. Compounded: $200-500/month.","price_usd":1150.0,"access_pathway_details":"FDA-approved for T2D (Ozempic, Rybelsus, Mounjaro) and weight loss (Wegovy, Zepbound). Available by prescription in all 50 states. Compounded versions available during shortages. Prior authorization often required by insurers. Telehealth prescribing growing (Weight Watchers Clinic, Ro, etc.).","eligibility_requirements":"Wegovy/Zepbound: BMI ≥30, or ≥27 with weight-related comorbidity. Ozempic/Mounjaro: T2D diagnosis. Contraindicated: personal/family history of medullary thyroid carcinoma, MEN2. Caution: pancreatitis history, gallbladder disease.","provider_requirements":"Licensed prescriber (MD, DO, NP, PA). No REMS/restricted distribution. Standard pharmacy. Telehealth prescribing permitted in all states (asynchronous and synchronous models). Compounding pharmacies for shortage alternatives (must meet USP standards).","residency_travel_notes":"US prescription required (prescriber must be licensed in patient's state for telehealth). International travel for GLP-1s generally not sensible given US availability and cost (US is actually more accessible than many countries where approvals more limited or healthcare systems restrict prescribing). Some cross-border pharmacy tourism for lower prices (Canada, Mexico) but legal status of importation varies.","risk_notes":"GI side effects common (nausea, vomiting, diarrhea) but typically transient. Rare: pancreatitis, gallbladder disease, ileus. Thyroid C-cell tumors in rodents (human relevance unclear, black box warning). Muscle loss with rapid weight loss (mitigated with resistance training and adequate protein). Ozempic face (facial fat loss) cosmetic concern only. Compounded: risks associated with non-FDA-reviewed products (purity, potency, sterility).","arbitrage_summary":"GLP-1s are widely available in US with insurance coverage expanding. Cost barriers primarily for uninsured/underinsured. 503(b) compounding pharmacies provide legitimate lower-cost alternatives during shortages. Beware counterfeit and unlicensed sellers. Clinical trial tourism for newer agents (triple agonists, etc.) may be relevant for some patients.","oversight_notes":"FDA-approved. Standard pharmacovigilance. No REMS program. Direct-to-consumer marketing heavy—FDA monitoring advertising claims. Compounded versions: less oversight, verify pharmacy accreditation (PCAB, state board). Counterfeit products a growing concern (buy only from licensed pharmacies).","cost_notes":"Insurance coverage is the key cost differentiator. Self-insured employers increasingly covering. Some state Medicaid programs cover. Manufacturer coupons significantly reduce cost for commercially insured. Cash-pay for weight loss is cost-prohibitive for many at list price. Brand list ~$900–1,400/mo (mid $1,150). Compounded often $200–500/mo when allowed. Insured copays far lower with PA.","legal_basis":null,"regulatory_authority":null,"last_verified":"2025-07-01","sources":[{"title":"Wegovy Prescribing Information","url":"https://www.novo-pi.com/wegovy.pdf"},{"title":"Zepbound Prescribing Information","url":"https://uspl.lilly.com/zepbound/zepbound.html"},{"title":"FDA Compounding and GLP-1s","url":"https://www.fda.gov/drugs/human-drug-compounding"}],"therapeutic_areas":["Metabolic_Health","Addiction","Cardiovascular"],"diseases":["Obesity","Type 2 Diabetes","Cardiovascular Disease Risk","NAFLD/NASH"],"status":"active"},{"id":"55b125e0-33b2-45ba-a137-d415492daba3","procedure_id":"proc-repurposed-rapamycin","jurisdiction_id":"jur-us-federal","procedure_name":"Rapamycin (Sirolimus) for Longevity/Healthspan","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"MEDIUM","modality":"REPURPOSED","estimated_cost_range_usd":"Generic sirolimus: $50-150/month (varies by dose, pharmacy, insurance). Telemedicine platform fees: $100-300 initial consult, $50-150/month membership. Lab monitoring: $100-400 per panel (may be covered by insurance). Compounded low-dose formulations: $60-200/month.","price_usd":100.0,"access_pathway_details":"FDA-approved for transplant immunosuppression and LAM. Off-label for aging/longevity: growing number of physicians prescribing through telemedicine platforms (AgelessRx, Healthspan, etc.). Must be prescribed by licensed physician. Generic available (Sirolimus tablets). Intermittent dosing protocols (weekly/bi-weekly) advocated by longevity community. PEARL trial (participant-led aging trial) ongoing.","eligibility_requirements":"Off-label use at physician discretion. Typically: 40+ years old for longevity use. Screening: CBC, CMP, lipids, HbA1c. Contraindicated: active infection, planned surgery, concurrent immunosuppression, pregnancy/lactation. Caution: pre-existing hyperlipidemia (rapamycin may worsen), impaired wound healing.","provider_requirements":"Licensed physician. Telemedicine platforms expanding access. Some primary care physicians prescribe, but longevity specialty clinics are primary source. Regular lab monitoring (every 3-6 months typical). No REMS or restricted distribution for generic sirolimus.","residency_travel_notes":"US prescription required. International patients can access through telemedicine platforms that serve their jurisdiction (varies by platform and local regulations). Some medical tourism to US longevity clinics.","risk_notes":"Known adverse effects: hyperlipidemia (particularly triglycerides), oral ulcers (mouth sores), impaired wound healing, increased infection risk (mild immunosuppression at longevity doses), thrombocytopenia, proteinuria (rare at low doses). Drug interactions: strong CYP3A4 inhibitors/inducers, grapefruit juice. Long-term safety data at longevity doses is limited (most data from transplant populations at higher doses). Regular lab monitoring essential.","arbitrage_summary":"Rapamycin for longevity is increasingly accessible in US via telemedicine. Early adopter space with growing evidence base. PEARL trial will provide important safety/efficacy data. More affordable than most longevity interventions. Appropriate for those comfortable being early adopters with regular monitoring.","oversight_notes":"Off-label prescribing is legal and standard medical practice. FDA does not regulate off-label use. Medical board oversight of individual physicians. Quality dependent on provider knowledge. Telemedicine platforms: variable quality, some function more as prescription mills than comprehensive longevity medicine practices. Verify physician credentials and monitoring protocols.","cost_notes":"Relatively affordable compared to other longevity/anti-aging interventions. Generic availability keeps costs low. Telemedicine platforms add convenience fee. Lab costs significant—ensure comprehensive monitoring included. Generic sirolimus ~$50–150/mo drug; telemed membership + labs extra (~$100–400).","legal_basis":null,"regulatory_authority":null,"last_verified":"2025-07-01","sources":[{"title":"PEARL Trial","url":"https://www.rapamycintrial.org"},{"title":"Sirolimus Prescribing Information","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021083s072,021110s086lbl.pdf"}],"therapeutic_areas":["Aging","Immunology"],"diseases":["Age-Related Functional Decline","Lymphangioleiomyomatosis (LAM)","Transplant Rejection (labeled)"],"status":"active"},{"id":"5efb8cf7-0e56-4ae4-b236-7600d3988994","procedure_id":"proc-repro-surrogacy","jurisdiction_id":"jur-ca","procedure_name":"Gestational Surrogacy","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"CAD $60,000-100,000 (USD $44,000-74,000) total: IVF ($15,000-20,000), surrogate expenses ($20,000-35,000), legal fees ($8,000-15,000), agency fees ($10,000-20,000), medications ($3,000-8,000).","price_usd":59000.0,"access_pathway_details":"Altruistic surrogacy legal throughout Canada (Assisted Human Reproduction Act, 2004). Commercial surrogacy (payment beyond expense reimbursement) is prohibited. Surrogates can be reimbursed for pregnancy-related expenses. Parentage orders available in most provinces (pre-birth or post-birth depending on province). No citizenship/residency requirement for intended parents to obtain Canadian parentage order in most provinces.","eligibility_requirements":"Surrogate: 21+, prior live birth, medical/psychological clearance, independent legal counsel (paid by intended parents). Intended parents: genetic link to embryo (at least one) for parentage in some provinces, or both for others. Medical indication for surrogacy OR same-sex male couple/single male. Criminal background check for intended parents (some provinces).","provider_requirements":"Fertility clinic licensed by province. Surrogate must pass medical screening (SOGC/CFAS guidelines). Independent legal counsel for surrogate AND intended parents. Surrogacy agencies coordinate (optional but recommended). Reimbursement must be documented (receipts).","residency_travel_notes":"Intended parents: NO Canadian residency requirement in most provinces. Surrogate: Canadian resident. Travel for embryo transfer, birth, and parentage process (2-4 trips). Birth in Canada gives child Canadian citizenship (jus soli). Cross-border legal counsel essential for international intended parents.","risk_notes":"Legal framework robust in Canada. Surrogate protections strong (independent legal counsel mandatory, expense reimbursement transparent). Change-of-mind risk: surrogate cannot be compelled to terminate or continue pregnancy; parentage orders address postnatal decision-making. Cross-border: ensure parentage recognized in home country. COVID added travel uncertainty (address in contract).","arbitrage_summary":"Canada offers the best balance of regulatory quality, cost, and international accessibility for surrogacy. Altruistic model reduces total cost by $30,000-60,000 vs. US commercial model. NO residency requirement for intended parents. High oversight quality. Best option for international intended parents who want high-quality legal/medical framework at moderate cost.","oversight_notes":"Health Canada and provincial oversight. Assisted Human Reproduction Act prohibits commercial surrogacy and gamete purchase. Expense reimbursement categories defined by regulation (updated 2020 to include lost wages, travel, childcare, etc.). Parentage law varies by province: Ontario, BC, Alberta have comprehensive frameworks; Quebec more restrictive. High oversight quality overall.","cost_notes":"Significantly less than US commercial surrogacy ($100,000-200,000+). Altruistic model reduces 'surrogate fee' component ($0 vs $30,000-60,000 in US). Expense reimbursement still substantial. Legal framework well-established, reducing legal risk/cost uncertainty. No citizenship requirement means international intended parents can access (with careful legal planning). Total journey mid of CAD $60–100k (~USD $44–74k) including IVF, expenses, legal, agency.","legal_basis":null,"regulatory_authority":null,"last_verified":"2025-07-01","sources":[{"title":"Assisted Human Reproduction Act (Canada)","url":"https://laws-lois.justice.gc.ca/eng/acts/a-13.4/"},{"title":"CFAS Surrogacy Guidelines","url":"https://cfas.ca"},{"title":"Canadian Surrogacy Community","url":"https://surrogacy.ca"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Uterine Factor Infertility","Medical Contraindication to Pregnancy","Recurrent IVF Failure"],"status":"active"},{"id":"6f0879c7-077a-41d2-baf7-c45f4d973f77","procedure_id":"proc-psilocybin-trd","jurisdiction_id":"jur-jm","procedure_name":"Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"FULLY_APPROVED","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"PSYCHEDELICS","estimated_cost_range_usd":"$2,000-8,000+ for 5-7 day retreat (includes accommodation, meals, sessions, integration). Luxury retreats: $10,000-25,000. Group retreats less expensive than private sessions.","price_usd":5000.0,"access_pathway_details":"Psilocybin mushrooms are legal in Jamaica (never scheduled). Growing psilocybin retreat industry (Mycomeditations, Atman, Silo Wellness, etc.). Retreat model: 1-2 psilocybin sessions in group or individual format. Some retreats have medical professionals, others do not. No government licensing or oversight specific to psilocybin therapy. Market is self-regulated.","eligibility_requirements":"18+. No prescription or diagnosis required. Retreat-specific screening (quality varies from thorough mental health screening to minimal). Medical screening: varies. Common contraindications: psychosis history, certain cardiovascular conditions, concurrent psychiatric medications.","provider_requirements":"No government licensing required for psilocybin facilitators. Retreat operators self-designate as practitioners. Some employ licensed therapists/psychologists, many do not. Medical oversight optional (some retreats have MD/RN on staff). No standardized training requirements. GITA and other voluntary standards exist but few retreats comply.","residency_travel_notes":"No residency requirement. No visa for US/Canadian/EU citizens (tourist entry). Direct flights from many US cities to Montego Bay/Kingston. Retreats often provide airport transfer. Combine with vacation context (integration in natural setting).","risk_notes":"NO GOVERNMENT OVERSIGHT. Retreat quality is unverifiable without independent references. Medical emergency protocols: variable, some retreats far from hospital. Post-retreat support/integration: crucial but often inadequate. Fungal product: no testing for potency or contaminants (contrast with Oregon's mandatory lab testing). Facilitator competence: impossible to verify independently. Selection bias in retreat marketing (only positive testimonials). Psychological destabilization risk if unprepared or poorly facilitated. Sexual boundaries: anecdotal reports of violations in unregulated retreat settings.","arbitrage_summary":"Most accessible psilocybin therapy globally (no legal restrictions, no diagnosis needed, tourist-accessible). BUT Zero regulatory oversight. Quality is completely unverifiable. HIGH RISK despite legality. Best for those who cannot access Oregon/Colorado/Australia/Canada pathways AND have thoroughly vetted a specific retreat through independent references. Consider Oregon first if US citizen—slightly higher cost but regulated product, licensed facilitators, emergency protocols, and accountability.","oversight_notes":"Jamaican Ministry of Health does not regulate psilocybin therapy. NO government oversight. Quality entirely dependent on retreat operator. Retreat industry is self-regulated with no enforcement mechanism. Variable quality—some excellent, some dangerous. Consumer due diligence essential. Unlike Oregon/Colorado/Australia, NO regulatory framework exists.","cost_notes":"Comparable to Oregon pricing when considering all-inclusive nature (room, board, sessions). Airfare to Jamaica adds $500-1,500 from US. All cash-pay. No insurance. Some retreats offer payment plans. 5–7 day retreat mid of $2,000–8,000; airfare typically $500–1,500 additional.","legal_basis":null,"regulatory_authority":null,"last_verified":"2025-06-01","sources":[{"title":"Jamaica Dangerous Drugs Act (Psilocybin Exempt)","url":"https://www.moj.gov.jm/laws/dangerous-drugs-act"},{"title":"GITA Ethical Guidelines","url":"https://www.ibogainealliance.org/guidelines"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"16a399db-57c2-497e-9970-0e33c65552c7","procedure_id":"proc-gene-crispr","jurisdiction_id":"jur-us-federal","procedure_name":"CRISPR-Based Gene Therapy (Somatic) for Genetic Disorders","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"RIGHT_TO_TRY","access_pathway":"RIGHT_TO_TRY","oversight_quality":"HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Right to Try/Expanded Access: drug companies often provide drug for free or at cost. Hospitalization and administration: $100,000-500,000+ (may be partially covered by insurance). Travel to academic medical center: variable.","price_usd":2200000.0,"access_pathway_details":"Federal Right to Try Act (2018) allows terminally ill patients to access investigational drugs (Phase I completed) outside clinical trials. Also FDA Expanded Access (Compassionate Use) program. Most CRISPR therapies are in early-phase trials; some may qualify for Right to Try if Phase I completed. Casgevy (exa-cel) for SCD and beta-thalassemia is fully FDA-approved.","eligibility_requirements":"Right to Try: terminal illness, exhausted approved options, unable to participate in clinical trial, informed consent, drug has completed Phase I. FDA Expanded Access: serious/disease or condition, no comparable alternative, enrollment in clinical trial not possible, potential benefit justifies risk. Physician must agree to sponsor. Drug company must agree to provide (NOT required to under Right to Try—this is the major barrier).","provider_requirements":"Licensed physician willing to sponsor and monitor. Institutional IRB for Expanded Access (not required for Right to Try but often institutional policy requires). Hospital/facility capable of managing gene therapy administration and complications (often requires academic medical center).","residency_travel_notes":"Must be under care of US-licensed physician at US facility. International patients can theoretically access if physician sponsors and they can travel/stay for extended treatment period (weeks-months). Practical barriers significant for non-US residents.","risk_notes":"Gene therapy risks: myeloablative conditioning (infertility, infection, bleeding, organ toxicity), off-target editing (CRISPR), insertional mutagenesis, immunogenicity, long-term unknown risks. HIGH RISK but in context of otherwise fatal disease. These are early-phase experimental therapies—uncertainty about efficacy and safety is fundamental.","arbitrage_summary":"Right to Try provides legal pathway for terminally ill US patients to access experimental gene therapies. Major practical barrier: manufacturers rarely agree to provide. Expanded Access more established but similar access challenges. For sickle cell/beta-thalassemia, Casgevy is fully approved (no longer experimental). Proactive physician advocacy and academic medical center connection essential.","oversight_notes":"FDA Expanded Access pathway is well-established with oversight. Right to Try has less FDA involvement (cannot use outcomes data for approval decisions except for safety) but still requires physician oversight, informed consent, and institutional safeguards. Major limitation: drug companies rarely agree to provide under Right to Try (concerns about adverse events affecting approval, supply limitations, liability).","cost_notes":"Drug cost often waived by manufacturer. Major costs are medical infrastructure (hospitalization, myeloablative conditioning, ICU, long-term follow-up). Insurance may cover hospitalization components. Some patients face significant out-of-pocket costs despite waived drug cost. Casgevy list ~$2.2M when on-label. RTT/Expanded Access: drug often free but hospitalization $100k–500k+. Dual pathway.","legal_basis":null,"regulatory_authority":null,"last_verified":"2025-07-01","sources":[{"title":"FDA Right to Try","url":"https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/right-try"},{"title":"FDA Expanded Access","url":"https://www.fda.gov/news-events/expanded-access"}],"therapeutic_areas":["Genetics","Hematology"],"diseases":["Sickle Cell Disease","Beta-Thalassemia","Genetic Blood Disorders"],"status":"active"},{"id":"94c6f83e-22ce-4fb7-a31f-4b8a02144b26","procedure_id":"proc-stem-car-t","jurisdiction_id":"jur-us-federal","procedure_name":"CAR-T Cell Therapy for Hematologic Malignancies","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"$373,000-475,000 (drug cost only). Total episode of care: $500,000-1,000,000+ including hospitalization, ICU if needed, apheresis, conditioning. Insurance coverage: Medicare covers (DRG + NTAP). Commercial insurance typically covers for FDA indications. Patient out-of-pocket: varies by plan (annual OOP max typically $5,000-10,000).","price_usd":424000.0,"access_pathway_details":"Six FDA-approved CAR-T products (Kymriah, Yescarta, Tecartus, Breyanzi, Carvykti, Abecma). Available at ~150+ certified CAR-T centers across US. Requires inpatient or intensive outpatient administration at certified center. REMS program for CRS/neurotoxicity management. Medicare and most commercial insurers cover for FDA-approved indications.","eligibility_requirements":"Specific relapsed/refractory hematologic malignancy diagnosis matching FDA label. Adequate organ function (cardiac, pulmonary, renal, hepatic). ECOG performance status typically 0-1. No active uncontrolled infection. Prior lines of therapy per label. Certified CAR-T center must accept patient. Often requires bridging therapy before CAR-T infusion.","provider_requirements":"Certified CAR-T treatment center (REMS-certified). Multidisciplinary team: oncologist, ICU, neurology, pharmacy. Tocilizumab on-site for CRS management. Staff trained in CRS and ICANS recognition/management. Apheresis capability. Cell processing coordination with manufacturer.","residency_travel_notes":"Must be treated at certified CAR-T center in US. International patients can access if accepted by center and able to fund (some international insurance covers, some self-pay at international rates). Lengthy treatment process (2-4 weeks minimum for infusion + 30-day post-infusion monitoring near center).","risk_notes":"CRS: cytokine release syndrome (fever, hypotension, hypoxia) common, managed with tocilizumab. ICANS: neurotoxicity (confusion, aphasia, seizures, cerebral edema). HLH/MAS. Prolonged cytopenia. B-cell aplasia (for CD19-directed therapies; requires IVIG). Secondary malignancies including T-cell malignancies (boxed warning 2024). Infection risk. ICU-level care may be required.","arbitrage_summary":"Potentially curative one-time therapy for previously fatal hematologic malignancies. US is global leader in CAR-T availability. Insurance coverage makes this accessible to insured patients (despite extreme total cost). Certified centers in all major US cities. No meaningful international arbitrage—CAR-T is sophisticated therapy requiring certified centers with intensive infrastructure. India and China developing lower-cost CAR-T alternatives.","oversight_notes":"FDA REMS program for CRS and neurotoxicity. FACT/JACIE accreditation for transplant/CAR-T centers. NCCN guidelines. Robust pharmacovigilance including 15-year follow-up for secondary malignancies. High oversight quality throughout treatment pathway.","cost_notes":"Among the most expensive therapies globally. Insurance coverage is essential—essentially inaccessible as cash-pay. Medicare's NTAP (New Technology Add-on Payment) helps hospitals cover costs. Value-based pricing agreements emerging (outcomes-based rebates). Drug list $373–475k (mid $424k); total episode often $500k–1M+. Medicare/commercial typically cover labeled indications.","legal_basis":null,"regulatory_authority":null,"last_verified":"2025-07-01","sources":[{"title":"FDA Approved CAR-T Products","url":"https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products"},{"title":"ASCO CAR-T Guidelines","url":"https://old-prod.asco.org/practice-patients/guidelines/car-t-cell-therapy"}],"therapeutic_areas":["Oncology","Hematology"],"diseases":["Relapsed/Refractory B-cell ALL","Diffuse Large B-cell Lymphoma","Multiple Myeloma"],"status":"active"},{"id":"03d858cd-b2b5-426a-8898-cfc48eb55ee0","procedure_id":"proc-repro-ivf","jurisdiction_id":"jur-us-federal","procedure_name":"In Vitro Fertilization (IVF) with Genetic Testing (PGT)","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"$12,000-25,000 per IVF cycle. PGT-A: $3,000-5,000 additional. PGT-M: $5,000-10,000 + probe development ($1,000-5,000). Medications: $3,000-8,000 per cycle. Donor egg: $35,000-60,000 total. Insurance coverage for IVF mandated in 15 states (varies significantly).","price_usd":18500.0,"access_pathway_details":"IVF widely available across all 50 states. CDC/SART reporting required. PGT-A and PGT-M available. No federal regulation of embryo research beyond NIH funding restrictions. State laws vary: some restrict embryo disposition, some have personhood amendments affecting IVF (Alabama 2024 created temporary crisis). Gender selection for family balancing permitted in US (controversial).","eligibility_requirements":"Medical indication OR elective (fertility preservation, genetic screening). Age limits vary by clinic (typically up to 50-55 for autologous IVF; older for donor egg). FDA screening for gamete donors. Psychological evaluation often required for donor gametes. BMI limits at many clinics.","provider_requirements":"SART-member clinics follow ASRM guidelines. CDC reporting. CLIA-certified lab for PGT. Board-certified REI (Reproductive Endocrinology and Infertility) physician. Embryologist certification. FDA registration for donor gametes.","residency_travel_notes":"US residents: travel to mandate states for coverage possible but requires establishing care and often residency. Non-US residents: medical tourism for IVF to US exists but less common than US patients traveling abroad for lower costs (Mexico, Spain, Greece, Czech Republic, Barbados).","risk_notes":"OHSS (ovarian hyperstimulation syndrome): mild-mod common, severe rare. Multiple pregnancy risk (minimized with elective single embryo transfer). Procedural risks: bleeding, infection, ovarian torsion. Long-term: no confirmed increased cancer risk. Emotional/financial risk of cycle failure. Embryo disposition decisions can be complex, especially with changing relationships.","arbitrage_summary":"US IVF offers some of the most permissive PGT laws globally (gender selection permitted, PGT-M broadly available). Most expensive market. Consider international IVF (Mexico, Spain, Greece) for lower cost (typically 50-70% less) with still-good quality, though legal frameworks for PGT vary. US is best for: complex PGT-M cases, intended parents wanting most permissive legal framework, employer IVF coverage, or those prioritizing convenience over cost.","oversight_notes":"CDC/SART outcome reporting mandatory. FDA regulates gamete donation. CLIA for PGT labs. ASRM ethics guidelines. Less federal regulation than many countries (no statutory limit on embryo culture duration, no national embryo research authority). State laws creating increasing complexity post-Dobbs. High overall quality at SART clinics.","cost_notes":"US IVF costs among highest globally. State mandates improve access where available. Employer benefits increasingly cover IVF (tech companies leading). Fertility preservation for medical reasons (oncofertility) often has specific coverage. Cash-pay predominant outside mandate states. Cycle mid $12–25k; PGT + meds often push total ~$20–30k cash-pay. Mandate-state insurance reduces OOP.","legal_basis":null,"regulatory_authority":null,"last_verified":"2025-07-01","sources":[{"title":"SART National Summary Report","url":"https://www.sartcorsonline.com"},{"title":"ASRM Guidelines","url":"https://www.asrm.org"},{"title":"CDC ART Success Rates","url":"https://www.cdc.gov/art/artdata/index.html"}],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Infertility","Recurrent Pregnancy Loss","Genetic Carrier Status"],"status":"active"},{"id":"c7ad12ee-06e2-4074-9323-1c65e5409fb3","procedure_id":"proc-repro-ivf","jurisdiction_id":"jur-mx","procedure_name":"In Vitro Fertilization (IVF) with Genetic Testing (PGT)","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"FULLY_APPROVED","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPRODUCTIVE","estimated_cost_range_usd":"IVF cycle: $4,000-8,000 (50-70% less than US). PGT-A: $1,500-3,000. PGT-M: $3,000-6,000. Donor egg: $8,000-15,000 total. Medications: $1,500-4,000 (significantly less than US). Cash-pay, no insurance coverage for medical tourists.","price_usd":6000.0,"access_pathway_details":"IVF widely available through private fertility clinics in major cities (Mexico City, Monterrey, Guadalajara, Cancún). Growing medical tourism industry for fertility treatment. PGT available. Mexican regulatory framework (COFEPRIS) less comprehensive than FDA/CDC but major clinics follow international standards. Gender selection generally permitted. Surrogacy: some states permit, Tabasco was a major hub but now restricted.","eligibility_requirements":"Fewer restrictions than US (more permissive age limits, BMI limits less common). Donor gametes available (egg donors typically younger, larger pools than some countries). Medical screening by clinic. No COFEPRIS-mandated psychological screening for all patients (some clinics require, others don't).","provider_requirements":"COFEPRIS-registered clinic. Board-certified REI physicians (though certification standards less rigorous than US ABOG). Lab accreditation: some clinics have international accreditation (ISO, CAP), many do not. Verify individual clinic standards. SART-equivalent outcome reporting not mandatory.","residency_travel_notes":"No residency requirement. Easy travel from US (Tijuana: drive across border; Cancún: direct flights). Fertility treatment requires multiple trips (3-8 days per trip, 2-4 trips typical). Some clinics coordinate remote monitoring with US providers to reduce trips. Medication can be purchased in Mexico (huge cost savings but verify pharmacy legitimacy).","risk_notes":"Variable clinic quality is primary risk. No public outcome reporting—clinics self-report success rates. Less legal recourse if complications occur. Medication quality: verify pharmacy is COFEPRIS-registered, counterfeit medications documented. Communication barriers if Spanish not spoken (mitigated at tourism-oriented clinics). Post-treatment complication management if back in home country may be complicated. Embryo storage and disposition: ensure legal clarity on ownership and disposition rights.","arbitrage_summary":"Mexico offers 50-70% cost savings on IVF with permissive regulatory environment (PGT, donor gametes, fewer restrictions). QUALITY IS VARIABLE—must verify specific clinic accreditation, physician credentials, and success rates. Best for: cost-sensitive patients who have thoroughly vetted a specific clinic, straightforward IVF cases (complex cases may benefit from US academic centers), and those wanting permissive PGT/gender selection framework.","oversight_notes":"COFEPRIS regulates but with less comprehensive framework than FDA. No mandatory public outcome reporting (no SART/CDC equivalent). Clinic quality varies significantly—from internationally accredited centers to minimal-standard clinics. Professional society (AMMR) provides guidelines but enforcement limited. Verify accreditation and success rates independently.","cost_notes":"Tijuana and Cancún clinics cater specifically to US medical tourists (English-speaking staff, US-style marketing, travel coordination). Package deals common. Cost savings 50-70% vs. US. Travel costs ($500-2,000) should be factored. Multiple trips often required. IVF cycle mid $4–8k; PGT extra $1.5–3k. ~50–70% below US cash-pay.","legal_basis":null,"regulatory_authority":null,"last_verified":"2025-06-01","sources":[{"title":"COFEPRIS","url":"https://www.gob.mx/cofepris"},{"title":"Mexican Association of Reproductive Medicine (AMMR)","url":"https://www.ammr.org.mx"}],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Infertility","Recurrent Pregnancy Loss","Genetic Carrier Status"],"status":"active"},{"id":"26a1a1db-3b90-4277-bf94-c05ab1142217","procedure_id":"proc-nad-iv","jurisdiction_id":"jur-us-federal","procedure_name":"NAD+ IV Infusion for Mitochondrial Health/Longevity","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"MEDIUM","modality":"REPURPOSED","estimated_cost_range_usd":"$300-600 per infusion, packages $3,000-8,000","price_usd":450.0,"access_pathway_details":"NAD+ available through functional medicine and longevity clinics across US (estimated 200+ providers). Not FDA-approved for therapeutic use but available under FDA's physician discretion pathway. Prescribed as off-label IV micronutrient. Varying clinic oversight quality.","eligibility_requirements":"Must be 18+. Medical evaluation by provider. Pre-screening labs recommended (liver/kidney function). No specific diagnosis required for off-label use.","provider_requirements":"MD/DO/NP licensed to prescribe IV therapies. Functional medicine or IV therapy certification common but not required. IV certification/experience essential. Clinic must have emergency equipment/protocols.","residency_travel_notes":"Available in all major US cities. No residency requirement. Non-US citizens can access at cash-pay rates.","risk_notes":"Safety profile appears favorable for NAD+ IV at therapeutic doses. Risks: injection site complications, flushing, nausea (usually mild), drug interactions. Quality control of NAD+ product essential—source verification important. Provider credentials/experience matters significantly.","arbitrage_summary":"NAD+ IV represents accessible biohacking/longevity option in US with low oversight. Choose providers with credentials, IV safety protocols, and transparent sourcing.","oversight_notes":"State medical board oversight of provider licensing. FDA does not actively regulate off-label IV micronutrient use. Quality varies by provider. Legitimate providers: malpractice insurance, IV safety protocols, staff training. Minimal oversight—patient due diligence essential.","cost_notes":"No insurance coverage. Cash-pay model. Longevity clinics may offer annual memberships with discounted per-session rates. Per-infusion mid $300–600 ($450); multi-session packages $3–8k common.","legal_basis":null,"regulatory_authority":null,"last_verified":"2025-07-15","sources":[{"title":"NAD+ IV Clinics","url":"https://www.nadclinic.org"}],"therapeutic_areas":["Anti_Aging","Energy","Neurological"],"diseases":["Chronic Fatigue","Long COVID","Mitochondrial Dysfunction","Age-Related Decline"],"status":"active"},{"id":"22d337e1-906c-4d6c-8b2f-710a8aa276b4","procedure_id":"proc-hbot","jurisdiction_id":"jur-us-federal","procedure_name":"Hyperbaric Oxygen Therapy for Chronic Wounds/TBI/Lyme","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"$150-350 per session, typical 20-40 sessions = $3,000-14,000. Insurance covers FDA indications. Off-label: cash-pay model.","price_usd":250.0,"access_pathway_details":"HBOT widely available at hospitals, wound centers, and specialized HBOT clinics across all 50 states. FDA-approved indications covered by insurance. Off-label indications available through specialized clinics (less insurance coverage). Prescriber must be MD/DO trained in HBOT.","eligibility_requirements":"Medical evaluation confirming FDA or off-label indication. Baseline oxygen testing. Pulmonary evaluation for some indications. Psychological screening may be recommended for chronic conditions.","provider_requirements":"HBOT-trained physician prescriber (varies by state: some require ABPM board certification in HBOT). Technician NBDHBO-certified (board certified). HYPOC accreditation for chamber standards.","residency_travel_notes":"Available nationwide. Non-residents can travel for treatment (typically 20-40 sessions over 4-8 weeks, requires extended stay for optimal therapy).","risk_notes":"Physical: claustrophobia (mitigated with open chambers), middle ear/sinus barotrauma (common, manageable), pulmonary oxygen toxicity (rare at medical protocols). Seizures from oxygen toxicity (very rare). Eye myopia (transient). Well-established safety profile when protocols followed.","arbitrage_summary":"FDA-approved HBOT widely accessible at high-oversight centers. Off-label use (Lyme, TBI) available but uninsured. Cost-effectiveness depends on indication and insurance coverage.","oversight_notes":"FDA regulation of chamber equipment (device classification). State medical board oversight of prescribers. HYPOC voluntary chamber accreditation. Insurance companies require credentialing for coverage. Higher oversight for FDA-approved vs. off-label indications.","cost_notes":"FDA-approved indications: insurance coverage typical (Medicare, commercial). Off-label: cash-pay. Some clinics offer treatment packages at discounts. $150–350/session mid $250; 20–40 session courses $3–14k. FDA indications often insured.","legal_basis":null,"regulatory_authority":null,"last_verified":"2025-07-15","sources":[{"title":"Undersea & Hyperbaric Medical Society","url":"https://www.uhms.org"},{"title":"HYPOC","url":"https://hypoc.org"}],"therapeutic_areas":["Wound_Healing","Neurological","Chronic_Infection"],"diseases":["Diabetic Foot Ulcer","Chronic Osteomyelitis","Traumatic Brain Injury (off-label)","Chronic Lyme (off-label)"],"status":"active"},{"id":"131a0289-eb80-42eb-9931-c135be012f58","procedure_id":"proc-fmt","jurisdiction_id":"jur-us-federal","procedure_name":"Fecal Microbiota Transplantation (FMT) for CDI/IBD","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"CELLULAR","estimated_cost_range_usd":"$500-3,000 for rCDI (covered by insurance most cases). Off-label: varies, $2,000-5,000+ cash-pay.","price_usd":1750.0,"access_pathway_details":"FMT available at academic medical centers, gastroenterology practices, and specialized microbiota clinics across US. FDA-approved for recurrent C. difficile (rCDI). Off-label use expanding for UC, Crohn's, IBS through clinical trial or patient access programs.","eligibility_requirements":"Confirmed rCDI diagnosis (2+ episodes) for FDA indication. Donor screening: stool testing (C. difficile, major pathogens), serology (HIV, Hep B/C), health history. Endoscopy or nasogastric tube access capability. Contraindications: severe immunosuppression, advanced liver disease.","provider_requirements":"Gastroenterologist or infectious disease specialist performing FMT. Microbiota lab or outsourced FMT provider for stool processing (must meet FDA microbiota standards). Licensed microbiota supplier certification.","residency_travel_notes":"Available at major medical centers nationwide. Procedure typically day-procedure (same-day discharge). Repeat FMT possible if needed (15-20% failure rate for rCDI, repeat FMT often successful).","risk_notes":"Infection from donor stool (rare with proper screening): bacterial pathogens, fungi, parasites. Immunogenicity/inflammatory response (rare). Flare of inflammatory bowel disease with FMT (temporary). Long-term data accumulating—generally excellent safety for rCDI (>90% sustained cure with proper donor screening).","arbitrage_summary":"FMT for rCDI is one of most cost-effective, high-success therapies available in US with strong insurance coverage. Off-label FMT for IBD/IBS expanding with growing evidence but less insurance coverage.","oversight_notes":"FDA regulates investigational microbiota products as drugs (IND applications). rCDI FMT: FDA approved pathway with specific regulatory guidance. Off-label: less oversight but within physician discretion. Quality standards for donor screening and stool processing evolving.","cost_notes":"rCDI: insurance coverage typical (Medicare, commercial). Off-label: cash-pay model. Some academic centers offer research participation at reduced cost. rCDI mid $500–3,000, usually insured. Off-label IBD/IBS cash-pay often $2–5k+.","legal_basis":null,"regulatory_authority":null,"last_verified":"2025-07-15","sources":[{"title":"FDA Microbiota Guidance","url":"https://www.fda.gov/vaccines-blood-biologics/guidance-documents-faqs/faqs-about-fecal-microbiota-transplantation"}],"therapeutic_areas":["Gastrointestinal","Autoimmune"],"diseases":["Recurrent C. difficile Infection","Ulcerative Colitis (off-label)","Crohn's Disease (off-label)"],"status":"active"},{"id":"86f61b55-846a-4f7d-9b87-466293d832d5","procedure_id":"proc-mescaline-therapy","jurisdiction_id":"jur-mx","procedure_name":"Mescaline-Assisted Therapy (San Pedro) for Depression/Addiction","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"UNREGULATED_PERMITTED","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"LOW","modality":"PSYCHEDELICS","estimated_cost_range_usd":"$1,000-3,000 per retreat (3-7 days, all-inclusive in Peru/Ecuador)","price_usd":2000.0,"access_pathway_details":"Mescaline (San Pedro cactus) completely legal in Peru, Ecuador, Colombia. Retreat centers operate openly in Sacred Valley (Peru), Amazon, and coastal regions. Shamanic facilitation model (non-medical). Multi-day retreats (3-7 days) with preparation, ceremony, integration. Growing Western psychedelic retreat tourism.","eligibility_requirements":"18+, ability to travel. Psychological health screening by retreat (quality varies). No formal medical restrictions but high contraindications should apply (same as other psychedelics).","provider_requirements":"Shaman/facilitator (NO medical licensing required). Retreat center operators. Variable training and experience. Some facilitators have years of experience, others minimal.","residency_travel_notes":"Easy travel: most Westerners enter Peru/Ecuador/Colombia visa-free (tourist permit). Retreat centers in Lima, Sacred Valley, Cusco, Iquitos, Quito, Medellin. Weekly departures common (group ceremonies). Travel time to remote locations (rainforest) requires 1-2 days for acclimatization.","risk_notes":"MAJOR RISKS: No medical oversight, facilitator credentials unknown, product potency/safety uncontrolled, no emergency medical protocols, remote locations far from advanced medical care, psychological screening inadequate, integration support minimal, no legal recourse if harm occurs, predatory operators documented (financial scams, sexual abuse). Requires extensive due diligence on specific retreat center.","arbitrage_summary":"Mescaline retreats in South America offer lowest-cost legal psychedelic experiences with facilitator guidance. HIGH RISK model—suitable only for individuals who have thoroughly vetted specific retreat operators, ideally through personal recommendations from prior attendees. NOT recommended for first-time psychedelic users.","oversight_notes":"Virtually no government oversight in Peru/Ecuador. Retreat operators self-regulate (variable quality). No safety standards, no incident reporting, no credential verification. Legal risk for Western operators and facilitators varies by country.","cost_notes":"Dramatically lower cost than psychotherapy clinics. Travel to South America adds $1,000-2,000. Accommodations often rustic (modest, clean centers available at lower cost; luxury retreats expensive). Retreat mid $1–3k (Andean/Amazon programs also common); travel $1–2k. Minimal medical oversight.","legal_basis":null,"regulatory_authority":null,"last_verified":"2025-06-01","sources":[{"title":"Sacred Valley Retreat Centers (various)","url":"https://www.google.com/search?q=san+pedro+retreat+peru"}],"therapeutic_areas":["Mental_Health","Depression","Addiction"],"diseases":["Depression","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"d7473c86-e7eb-4f06-8b27-1c0898a34566","procedure_id":"proc-gene-aa9","jurisdiction_id":"jur-us-federal","procedure_name":"AAV9-Mediated Gene Replacement Therapy","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"$2.1–3.5M list + hospital","price_usd":2100000.0,"access_pathway_details":"Zolgensma FDA-approved for SMA <2y; other AAV products (Luxturna, Hemgenix, Elevidys) for labeled uses at qualified centers.","eligibility_requirements":"Genetic confirmation; age/weight limits; anti-AAV Ab screen; specialist referral.","provider_requirements":"Qualified gene-therapy centers; multi-disciplinary teams.","residency_travel_notes":"US qualified centers only.","risk_notes":"AAV immune/liver/TMA risks; steroids typical.","arbitrage_summary":"US: primary approved market with insurance for labeled SMA.","oversight_notes":"FDA biologics + REMS/registries.","cost_notes":"Payer coverage common on-label; cash inaccessible.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[{"title":"Zolgensma FDA","url":"https://www.fda.gov/vaccines-blood-biologics/zolgensma"}],"therapeutic_areas":["Genetics","Neurology"],"diseases":["Spinal Muscular Atrophy (SMA)","Inherited Retinal Dystrophy","Hemophilia B","Duchenne Muscular Dystrophy"],"status":"active"},{"id":"b127f8cd-dd38-4fac-bc36-6a8b4d6a5b3d","procedure_id":"proc-gene-aa9","jurisdiction_id":"jur-de","procedure_name":"AAV9-Mediated Gene Replacement Therapy","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"~€2M product","price_usd":2000000.0,"access_pathway_details":"EMA full MA for Zolgensma; Germany reimburses eligible SMA via statutory insurance at specialist centers.","eligibility_requirements":"EU SMA label; residency/insurance for reimbursement.","provider_requirements":"University SMA/gene-therapy centers.","residency_travel_notes":"EU referral pathways.","risk_notes":"Class AAV risks in tertiary care.","arbitrage_summary":"Germany: approved + reimbursed SMA gene therapy, high oversight.","oversight_notes":"EMA + BfArM/G-BA.","cost_notes":"Public insurance for eligible; not tourism-priced.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[{"title":"Zolgensma EMA","url":"https://www.ema.europa.eu/en/medicines/human/EPAR/zolgensma"}],"therapeutic_areas":["Genetics","Neurology"],"diseases":["Spinal Muscular Atrophy (SMA)","Inherited Retinal Dystrophy","Hemophilia B","Duchenne Muscular Dystrophy"],"status":"active"},{"id":"ed627b7b-73eb-4b0c-9167-eb820b5c60ce","procedure_id":"proc-gene-aa9","jurisdiction_id":"jur-fr","procedure_name":"AAV9-Mediated Gene Replacement Therapy","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"~€2M","price_usd":2000000.0,"access_pathway_details":"EMA authorization; France reimburses via HAS/CNAM after assessment (early ATU history).","eligibility_requirements":"EU label + national funding criteria.","provider_requirements":"Reference neuromuscular centers.","residency_travel_notes":"Residency/insurance linked.","risk_notes":"Class risks.","arbitrage_summary":"France: regulated reimbursed pathway, not cash arbitrage.","oversight_notes":"HAS + ANSM.","cost_notes":"Public cover for eligible SMA.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[{"title":"Zolgensma EMA","url":"https://www.ema.europa.eu/en/medicines/human/EPAR/zolgensma"}],"therapeutic_areas":["Genetics","Neurology"],"diseases":["Spinal Muscular Atrophy (SMA)","Inherited Retinal Dystrophy","Hemophilia B","Duchenne Muscular Dystrophy"],"status":"active"},{"id":"e6ff14a8-d314-40dd-82bb-275c1a4b690a","procedure_id":"proc-gene-aa9","jurisdiction_id":"jur-uk","procedure_name":"AAV9-Mediated Gene Replacement Therapy","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Multi-million GBP list","price_usd":1900000.0,"access_pathway_details":"MHRA authorization; NHS England/NICE managed access at designated centers.","eligibility_requirements":"NICE commissioning criteria.","provider_requirements":"NHS specialist centers.","residency_travel_notes":"UK residents via NHS.","risk_notes":"Class risks.","arbitrage_summary":"UK: approved with NHS managed access.","oversight_notes":"MHRA + NICE.","cost_notes":"NHS for eligible; not private tourism market.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[{"title":"Zolgensma EMA","url":"https://www.ema.europa.eu/en/medicines/human/EPAR/zolgensma"}],"therapeutic_areas":["Genetics","Neurology"],"diseases":["Spinal Muscular Atrophy (SMA)","Inherited Retinal Dystrophy","Hemophilia B","Duchenne Muscular Dystrophy"],"status":"active"},{"id":"2069e790-b367-4306-b307-20ebcf691baa","procedure_id":"proc-gene-aa9","jurisdiction_id":"jur-jp","procedure_name":"AAV9-Mediated Gene Replacement Therapy","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Multi-million JPY","price_usd":2000000.0,"access_pathway_details":"MHLW approved Zolgensma for SMA under age 2 (incl. pre-symptomatic) at designated hospitals.","eligibility_requirements":"Japanese label criteria.","provider_requirements":"Designated pediatric centers.","residency_travel_notes":"Primarily domestic.","risk_notes":"Class risks.","arbitrage_summary":"Japan: early non-US approver with strong regulation.","oversight_notes":"PMDA/MHLW.","cost_notes":"Public insurance for labeled use.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[{"title":"Zolgensma FDA","url":"https://www.fda.gov/vaccines-blood-biologics/zolgensma"}],"therapeutic_areas":["Genetics","Neurology"],"diseases":["Spinal Muscular Atrophy (SMA)","Inherited Retinal Dystrophy","Hemophilia B","Duchenne Muscular Dystrophy"],"status":"active"},{"id":"431471e6-6b7a-4f9e-a144-e44e8082c53a","procedure_id":"proc-gene-aa9","jurisdiction_id":"jur-ca","procedure_name":"AAV9-Mediated Gene Replacement Therapy","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"CAD multi-million","price_usd":2100000.0,"access_pathway_details":"Health Canada authorized; provincial funding gates vary.","eligibility_requirements":"Label + provincial plan approval.","provider_requirements":"Pediatric tertiary centers.","residency_travel_notes":"Residents.","risk_notes":"Class risks.","arbitrage_summary":"Canada: authorized; access rationed by provincial funding.","oversight_notes":"Health Canada + provinces.","cost_notes":"Province-by-province delays common.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[{"title":"Zolgensma FDA","url":"https://www.fda.gov/vaccines-blood-biologics/zolgensma"}],"therapeutic_areas":["Genetics","Neurology"],"diseases":["Spinal Muscular Atrophy (SMA)","Inherited Retinal Dystrophy","Hemophilia B","Duchenne Muscular Dystrophy"],"status":"active"},{"id":"d0b9dd14-03d2-4512-9c37-7e6602a6ed1e","procedure_id":"proc-gene-aa9","jurisdiction_id":"jur-au","procedure_name":"AAV9-Mediated Gene Replacement Therapy","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"AUD multi-million","price_usd":2000000.0,"access_pathway_details":"TGA approved; PBS/state arrangements for eligible SMA infants.","eligibility_requirements":"TGA + PBS criteria.","provider_requirements":"Children's hospitals.","residency_travel_notes":"Residents.","risk_notes":"Class risks.","arbitrage_summary":"Australia: regulated approved SMA gene therapy.","oversight_notes":"TGA.","cost_notes":"Public funding when listed.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[{"title":"Zolgensma FDA","url":"https://www.fda.gov/vaccines-blood-biologics/zolgensma"}],"therapeutic_areas":["Genetics","Neurology"],"diseases":["Spinal Muscular Atrophy (SMA)","Inherited Retinal Dystrophy","Hemophilia B","Duchenne Muscular Dystrophy"],"status":"active"},{"id":"40a7cce0-9600-445f-bcca-381268703092","procedure_id":"proc-gene-aa9","jurisdiction_id":"jur-br","procedure_name":"AAV9-Mediated Gene Replacement Therapy","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"MEDIUM","modality":"GENE_THERAPY","estimated_cost_range_usd":"Multi-million USD","price_usd":2000000.0,"access_pathway_details":"ANVISA authorized; SUS access often via litigation; private cover limited.","eligibility_requirements":"Labeled SMA; court orders frequent for SUS.","provider_requirements":"Few specialty centers.","residency_travel_notes":"Domestic specialty cities.","risk_notes":"Class risks; fewer centers.","arbitrage_summary":"Brazil: authorized but cost/courts gate real access.","oversight_notes":"ANVISA; access uneven.","cost_notes":"Approval ≠ affordable access.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[{"title":"Zolgensma FDA","url":"https://www.fda.gov/vaccines-blood-biologics/zolgensma"}],"therapeutic_areas":["Genetics","Neurology"],"diseases":["Spinal Muscular Atrophy (SMA)","Inherited Retinal Dystrophy","Hemophilia B","Duchenne Muscular Dystrophy"],"status":"active"},{"id":"ad350496-a89f-4440-8c92-58bd42a740f6","procedure_id":"proc-gene-aa9","jurisdiction_id":"jur-kr","procedure_name":"AAV9-Mediated Gene Replacement Therapy","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Multi-million KRW/USD equivalent","price_usd":2000000.0,"access_pathway_details":"MFDS approved Zolgensma; limited specialty centers; insurance assessment applies.","eligibility_requirements":"Korean label + insurer criteria.","provider_requirements":"Tertiary hospitals Seoul etc.","residency_travel_notes":"Domestic.","risk_notes":"Class risks.","arbitrage_summary":"South Korea: approved regulated access.","oversight_notes":"MFDS.","cost_notes":"National insurance pathways for eligible.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[{"title":"Zolgensma FDA","url":"https://www.fda.gov/vaccines-blood-biologics/zolgensma"}],"therapeutic_areas":["Genetics","Neurology"],"diseases":["Spinal Muscular Atrophy (SMA)","Inherited Retinal Dystrophy","Hemophilia B","Duchenne Muscular Dystrophy"],"status":"active"},{"id":"266aecff-e514-4af9-a783-3ac7d00cc11c","procedure_id":"proc-peptide-bpc","jurisdiction_id":"jur-us-federal","procedure_name":"BPC-157 Pentadecapeptide Therapy","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"NONE","oversight_quality":"LOW","modality":"PEPTIDE","estimated_cost_range_usd":"N/A legal medical market; illicit $50–200/mo","price_usd":null,"access_pathway_details":"Not FDA-approved. FDA has cited significant safety concerns for BPC-157 in compounding (Category 2 history); 2026 PCAC review does not equal authorization to compound. Research-chemical sales are not a medical pathway.","eligibility_requirements":"No approved indication.","provider_requirements":"No clear legal compounding pathway.","residency_travel_notes":"N/A","risk_notes":"Impurity/immunogenicity concerns; authenticity risk.","arbitrage_summary":"US: not approved; compounding not clearly legal — high uncertainty.","oversight_notes":"FDA peptide compounding policy in flux.","cost_notes":"Do not treat research vendors as pharmacies.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[{"title":"FDA bulk substances safety risks (peptides)","url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"}],"therapeutic_areas":["Gastrointestinal","Orthopedic","Wound_Healing"],"diseases":["Tendon/Ligament Injury","Inflammatory Bowel Disease","Gastric Ulcer","Wound Healing Impairment"],"status":"active"},{"id":"2dfa4d9f-1a78-404a-a853-dac7ac44e6ba","procedure_id":"proc-peptide-bpc","jurisdiction_id":"jur-mx","procedure_name":"BPC-157 Pentadecapeptide Therapy","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"PEPTIDE","estimated_cost_range_usd":"$200–1,500/protocol","price_usd":600.0,"access_pathway_details":"Functional/regenerative clinics market BPC-157 cash-pay; no robust national approved-drug pathway.","eligibility_requirements":"Cash-pay; clinic screening varies.","provider_requirements":"Private clinics Tijuana/Cancún/CDMX.","residency_travel_notes":"Easy US tourism.","risk_notes":"Unverified injectables.","arbitrage_summary":"Mexico: easy to find, low oversight.","oversight_notes":"Minimal product standards.","cost_notes":"Quality opaque.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Gastrointestinal","Orthopedic","Wound_Healing"],"diseases":["Tendon/Ligament Injury","Inflammatory Bowel Disease","Gastric Ulcer","Wound Healing Impairment"],"status":"active"},{"id":"11fc8136-5c93-499e-8237-92af01c499f0","procedure_id":"proc-peptide-bpc","jurisdiction_id":"jur-th","procedure_name":"BPC-157 Pentadecapeptide Therapy","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"PEPTIDE","estimated_cost_range_usd":"$300–2,000","price_usd":800.0,"access_pathway_details":"Wellness clinics advertise BPC-class peptides outside a standardized approved pathway.","eligibility_requirements":"Tourist packages.","provider_requirements":"Bangkok/Phuket clinics.","residency_travel_notes":"Major tourism hub.","risk_notes":"Authenticity risk.","arbitrage_summary":"Thailand: wellness-clinic peptide access, minimal oversight.","oversight_notes":"Variable Thai FDA enforcement for wellness peptides.","cost_notes":"Tourism pricing.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Gastrointestinal","Orthopedic","Wound_Healing"],"diseases":["Tendon/Ligament Injury","Inflammatory Bowel Disease","Gastric Ulcer","Wound Healing Impairment"],"status":"active"},{"id":"6322ee93-6532-45b5-a13b-f9a81f31b079","procedure_id":"proc-peptide-bpc","jurisdiction_id":"jur-hn-prospera","procedure_name":"BPC-157 Pentadecapeptide Therapy","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"UNREGULATED_PERMITTED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"LOW","modality":"PEPTIDE","estimated_cost_range_usd":"$500–3,000","price_usd":1200.0,"access_pathway_details":"ZEDE informed-consent model permits peptide protocols restricted under FDA compounding rules.","eligibility_requirements":"Consent + ability to pay/travel.","provider_requirements":"ZEDE-registered providers.","residency_travel_notes":"Roatán flights.","risk_notes":"Product + infrastructure risk.","arbitrage_summary":"Próspera: permissive peptides, low external oversight.","oversight_notes":"Light-touch; ZEDE status contested historically.","cost_notes":"Experimental cash market.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Gastrointestinal","Orthopedic","Wound_Healing"],"diseases":["Tendon/Ligament Injury","Inflammatory Bowel Disease","Gastric Ulcer","Wound Healing Impairment"],"status":"active"},{"id":"70444d04-3b32-4647-9859-9625073373d9","procedure_id":"proc-peptide-bpc","jurisdiction_id":"jur-uk","procedure_name":"BPC-157 Pentadecapeptide Therapy","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"N/A","price_usd":null,"access_pathway_details":"Not MHRA-authorized; unlicensed medicines for human use tightly controlled — no legitimate routine pathway.","eligibility_requirements":"None for routine care.","provider_requirements":"No authorized product.","residency_travel_notes":"N/A","risk_notes":"Legal + product risk if illicit.","arbitrage_summary":"UK: no legitimate medical BPC-157 pathway.","oversight_notes":"MHRA unlicensed medicines regime.","cost_notes":"Black market not medical guidance.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[{"title":"FDA bulk substances safety risks (peptides)","url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"}],"therapeutic_areas":["Gastrointestinal","Orthopedic","Wound_Healing"],"diseases":["Tendon/Ligament Injury","Inflammatory Bowel Disease","Gastric Ulcer","Wound Healing Impairment"],"status":"active"},{"id":"5b3a356d-5f3a-4ea2-802b-d30f83485c63","procedure_id":"proc-peptide-bpc","jurisdiction_id":"jur-au","procedure_name":"BPC-157 Pentadecapeptide Therapy","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"N/A","price_usd":null,"access_pathway_details":"Not TGA-approved as a medicine; compounding/import for human therapeutic use not a standard lawful pathway.","eligibility_requirements":"None standard.","provider_requirements":"No registered product.","residency_travel_notes":"N/A","risk_notes":"Legal/safety risk.","arbitrage_summary":"Australia: no approved medical pathway.","oversight_notes":"TGA medicines framework.","cost_notes":"Avoid research chemical imports for injection.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[{"title":"FDA bulk substances safety risks (peptides)","url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"}],"therapeutic_areas":["Gastrointestinal","Orthopedic","Wound_Healing"],"diseases":["Tendon/Ligament Injury","Inflammatory Bowel Disease","Gastric Ulcer","Wound Healing Impairment"],"status":"active"},{"id":"e498f5b5-547b-44b7-9949-dc76d6a8d35d","procedure_id":"proc-peptide-thymosin","jurisdiction_id":"jur-us-federal","procedure_name":"Thymosin Alpha-1 (Thymalfasin) Immunomodulation","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"COMPOUNDING","oversight_quality":"MEDIUM","modality":"PEPTIDE","estimated_cost_range_usd":"$500–3,000/course","price_usd":1200.0,"access_pathway_details":"Thymalfasin (Zadaxin) not FDA-approved. FDA: approved in many Asia-Pacific/LatAm/ME/EE countries and historically Italy; US via fluctuating compounding/research channels.","eligibility_requirements":"No US labeled indication.","provider_requirements":"Compounders when permitted — often restricted.","residency_travel_notes":"Some travel to approved markets.","risk_notes":"Quality variability; autoimmune caution.","arbitrage_summary":"US: not approved; overseas approved product is the clearer path.","oversight_notes":"No approved US finished drug.","cost_notes":"Higher/less reliable than approved overseas markets.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[{"title":"FDA Ta1 bulk substances memo","url":"https://www.fda.gov/media/183892/download"}],"therapeutic_areas":["Immunology","Chronic_Infection"],"diseases":["Chronic Hepatitis B","Chronic Hepatitis C","Immune Deficiency","Chronic Viral Infection"],"status":"active"},{"id":"ff4126bc-2f9f-456e-a759-49f29ca5220d","procedure_id":"proc-peptide-thymosin","jurisdiction_id":"jur-in","procedure_name":"Thymosin Alpha-1 (Thymalfasin) Immunomodulation","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"MEDIUM","modality":"PEPTIDE","estimated_cost_range_usd":"$200–800/course","price_usd":400.0,"access_pathway_details":"Thymalfasin marketed in India for hepatitis/immune uses (Zadaxin/generics where registered).","eligibility_requirements":"Local label; physician Rx.","provider_requirements":"Hospital/specialty pharmacies.","residency_travel_notes":"Medical tourism possible — verify authenticity.","risk_notes":"Counterfeit risk — use licensed pharmacies.","arbitrage_summary":"India: accessible approved/marketed Ta1 at lower cost.","oversight_notes":"CDSCO where registered.","cost_notes":"Much cheaper than US compounded.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[{"title":"FDA Ta1 bulk substances memo","url":"https://www.fda.gov/media/183892/download"}],"therapeutic_areas":["Immunology","Chronic_Infection"],"diseases":["Chronic Hepatitis B","Chronic Hepatitis C","Immune Deficiency","Chronic Viral Infection"],"status":"active"},{"id":"2dc3e282-20a1-4687-b753-207bfd7aa60d","procedure_id":"proc-peptide-thymosin","jurisdiction_id":"jur-ph","procedure_name":"Thymosin Alpha-1 (Thymalfasin) Immunomodulation","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"MEDIUM","modality":"PEPTIDE","estimated_cost_range_usd":"$250–900/course","price_usd":500.0,"access_pathway_details":"Early Zadaxin market; registered thymalfasin for hepatitis/immune indications where still marketed.","eligibility_requirements":"Physician Rx.","provider_requirements":"Manila/Cebu pharmacies.","residency_travel_notes":"English-friendly medical sector.","risk_notes":"Sourcing quality.","arbitrage_summary":"Philippines: historical approved Ta1 market.","oversight_notes":"FDA Philippines.","cost_notes":"Regional pricing.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[{"title":"FDA Ta1 bulk substances memo","url":"https://www.fda.gov/media/183892/download"}],"therapeutic_areas":["Immunology","Chronic_Infection"],"diseases":["Chronic Hepatitis B","Chronic Hepatitis C","Immune Deficiency","Chronic Viral Infection"],"status":"active"},{"id":"41cc6be4-c05d-47dd-9375-eadcf3570f86","procedure_id":"proc-peptide-thymosin","jurisdiction_id":"jur-sg","procedure_name":"Thymosin Alpha-1 (Thymalfasin) Immunomodulation","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"$800–2,500/course","price_usd":1500.0,"access_pathway_details":"Early Asian Zadaxin approval market; high HSA standards for registered products.","eligibility_requirements":"Specialist Rx; labeled uses.","provider_requirements":"Tertiary hospitals/pharmacies.","residency_travel_notes":"Excellent tourism infrastructure.","risk_notes":"Lower product risk.","arbitrage_summary":"Singapore: approved, high oversight, higher price.","oversight_notes":"HSA.","cost_notes":"Premium vs India/PH.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[{"title":"FDA Ta1 bulk substances memo","url":"https://www.fda.gov/media/183892/download"}],"therapeutic_areas":["Immunology","Chronic_Infection"],"diseases":["Chronic Hepatitis B","Chronic Hepatitis C","Immune Deficiency","Chronic Viral Infection"],"status":"active"},{"id":"07aab3b7-ddc7-400a-abb3-d2e2401bc2f8","procedure_id":"proc-peptide-thymosin","jurisdiction_id":"jur-ar","procedure_name":"Thymosin Alpha-1 (Thymalfasin) Immunomodulation","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"MEDIUM","modality":"PEPTIDE","estimated_cost_range_usd":"$300–1,200","price_usd":600.0,"access_pathway_details":"Argentina in historical Zadaxin LatAm footprint; ANMAT-registered product where available.","eligibility_requirements":"Local label.","provider_requirements":"Urban hospital pharmacies.","residency_travel_notes":"Buenos Aires.","risk_notes":"Supply interruptions possible.","arbitrage_summary":"Argentina: LatAm approved-market option.","oversight_notes":"ANMAT.","cost_notes":"Currency-sensitive USD cost.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[{"title":"FDA Ta1 bulk substances memo","url":"https://www.fda.gov/media/183892/download"}],"therapeutic_areas":["Immunology","Chronic_Infection"],"diseases":["Chronic Hepatitis B","Chronic Hepatitis C","Immune Deficiency","Chronic Viral Infection"],"status":"active"},{"id":"b065aa42-ddce-4f8e-91c6-897ee3d12881","procedure_id":"proc-peptide-thymosin","jurisdiction_id":"jur-de","procedure_name":"Thymosin Alpha-1 (Thymalfasin) Immunomodulation","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"N/A","price_usd":null,"access_pathway_details":"FDA notes Ta1 not generally approved in Europe (Italy historical exception). Germany has no routine authorized Ta1 marketing pathway.","eligibility_requirements":"No routine authorized product.","provider_requirements":"Named-patient only if any.","residency_travel_notes":"Patients may seek Asia.","risk_notes":"Legal constraints.","arbitrage_summary":"Germany/most EU: no routine approved Ta1 access.","oversight_notes":"EU marketing authorization required.","cost_notes":"Unlicensed import exceptional.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[{"title":"FDA Ta1 bulk substances memo","url":"https://www.fda.gov/media/183892/download"}],"therapeutic_areas":["Immunology","Chronic_Infection"],"diseases":["Chronic Hepatitis B","Chronic Hepatitis C","Immune Deficiency","Chronic Viral Infection"],"status":"active"},{"id":"736056fd-e800-46b4-b6f8-f8b56a67cc45","procedure_id":"proc-peptide-thymosin","jurisdiction_id":"jur-mx","procedure_name":"Thymosin Alpha-1 (Thymalfasin) Immunomodulation","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"LOW","modality":"PEPTIDE","estimated_cost_range_usd":"$300–1,500","price_usd":700.0,"access_pathway_details":"Private clinics may supply Ta1; confirm whether product is registered Zadaxin-class vs unregulated peptide.","eligibility_requirements":"Cash-pay.","provider_requirements":"Private clinics.","residency_travel_notes":"Tourism.","risk_notes":"Quality risk if unregistered.","arbitrage_summary":"Mexico: possible clinic access — verify product registration.","oversight_notes":"Variable.","cost_notes":"Verify registration.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[{"title":"FDA Ta1 bulk substances memo","url":"https://www.fda.gov/media/183892/download"}],"therapeutic_areas":["Immunology","Chronic_Infection"],"diseases":["Chronic Hepatitis B","Chronic Hepatitis C","Immune Deficiency","Chronic Viral Infection"],"status":"active"},{"id":"9cb3f97f-293f-41e9-9db0-07da5099c10a","procedure_id":"proc-repurposed-ldn","jurisdiction_id":"jur-us-federal","procedure_name":"Low-Dose Naltrexone (LDN) for Chronic Inflammatory/Autoimmune Conditions","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"COMPOUNDING","oversight_quality":"MEDIUM","modality":"REPURPOSED","estimated_cost_range_usd":"$30–100/month","price_usd":60.0,"access_pathway_details":"Naltrexone FDA-approved full-dose for OUD/AUD; LDN 0.5–4.5 mg off-label via compounding for inflammatory/autoimmune uses.","eligibility_requirements":"Prescriber judgment; no concurrent opioids.","provider_requirements":"Licensed Rx + compounding pharmacy.","residency_travel_notes":"Nationwide mail compounders.","risk_notes":"Vivid dreams; opioid blockade if acute opioids needed.","arbitrage_summary":"US: easy low-cost off-label compounded LDN.","oversight_notes":"State boards; off-label practice.","cost_notes":"Usually cash-pay; inexpensive.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[{"title":"LDN Research Trust","url":"https://ldnresearchtrust.org"}],"therapeutic_areas":["Autoimmune","Chronic_Pain","Neurology"],"diseases":["Fibromyalgia","Crohn's Disease","Multiple Sclerosis","ME/CFS","Long COVID","Chronic Pain"],"status":"active"},{"id":"3b9e0f4a-ebe5-43b9-afc4-a22c20ef93a4","procedure_id":"proc-repurposed-ldn","jurisdiction_id":"jur-uk","procedure_name":"Low-Dose Naltrexone (LDN) for Chronic Inflammatory/Autoimmune Conditions","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"APPROVED_OFF_LABEL","access_pathway":"COMPOUNDING","oversight_quality":"MEDIUM","modality":"REPURPOSED","estimated_cost_range_usd":"$40–120/month","price_usd":70.0,"access_pathway_details":"Licensed naltrexone; LDN private/specials common; rarely NHS-commissioned for autoimmune indications.","eligibility_requirements":"Private Rx typical.","provider_requirements":"Private GPs/specialists + specials.","residency_travel_notes":"Domestic private.","risk_notes":"Standard LDN effects.","arbitrage_summary":"UK: private off-label LDN accessible.","oversight_notes":"MHRA + GMC off-label guidance.","cost_notes":"Private pathway dominant.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[{"title":"LDN Research Trust","url":"https://ldnresearchtrust.org"}],"therapeutic_areas":["Autoimmune","Chronic_Pain","Neurology"],"diseases":["Fibromyalgia","Crohn's Disease","Multiple Sclerosis","ME/CFS","Long COVID","Chronic Pain"],"status":"active"},{"id":"5ab25f31-1d71-4d22-82f0-68b5768d3794","procedure_id":"proc-repurposed-ldn","jurisdiction_id":"jur-ca","procedure_name":"Low-Dose Naltrexone (LDN) for Chronic Inflammatory/Autoimmune Conditions","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"APPROVED_OFF_LABEL","access_pathway":"COMPOUNDING","oversight_quality":"MEDIUM","modality":"REPURPOSED","estimated_cost_range_usd":"CAD $40–100/month","price_usd":55.0,"access_pathway_details":"Off-label LDN via Canadian physicians and compounders.","eligibility_requirements":"Physician Rx.","provider_requirements":"Family/specialty + compounders.","residency_travel_notes":"Domestic.","risk_notes":"Standard risks.","arbitrage_summary":"Canada: straightforward compounded LDN.","oversight_notes":"Provincial colleges.","cost_notes":"Often OOP.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[{"title":"LDN Research Trust","url":"https://ldnresearchtrust.org"}],"therapeutic_areas":["Autoimmune","Chronic_Pain","Neurology"],"diseases":["Fibromyalgia","Crohn's Disease","Multiple Sclerosis","ME/CFS","Long COVID","Chronic Pain"],"status":"active"},{"id":"1264fd99-80d0-405d-9071-f229c24a29cc","procedure_id":"proc-repurposed-ldn","jurisdiction_id":"jur-au","procedure_name":"Low-Dose Naltrexone (LDN) for Chronic Inflammatory/Autoimmune Conditions","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"APPROVED_OFF_LABEL","access_pathway":"COMPOUNDING","oversight_quality":"MEDIUM","modality":"REPURPOSED","estimated_cost_range_usd":"AUD $40–120/month","price_usd":55.0,"access_pathway_details":"Compounded LDN with Australian prescriber; not TGA-approved autoimmune indication.","eligibility_requirements":"Prescription required.","provider_requirements":"GP/specialist + compounder.","residency_travel_notes":"Domestic.","risk_notes":"Standard.","arbitrage_summary":"Australia: off-label compounded LDN available.","oversight_notes":"TGA + AHPRA.","cost_notes":"Cash-pay.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[{"title":"LDN Research Trust","url":"https://ldnresearchtrust.org"}],"therapeutic_areas":["Autoimmune","Chronic_Pain","Neurology"],"diseases":["Fibromyalgia","Crohn's Disease","Multiple Sclerosis","ME/CFS","Long COVID","Chronic Pain"],"status":"active"},{"id":"126910d3-d76d-4e83-b7fa-6503a96fbaad","procedure_id":"proc-repurposed-ldn","jurisdiction_id":"jur-de","procedure_name":"Low-Dose Naltrexone (LDN) for Chronic Inflammatory/Autoimmune Conditions","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"COMPOUNDING","oversight_quality":"MEDIUM","modality":"REPURPOSED","estimated_cost_range_usd":"€30–90/month","price_usd":55.0,"access_pathway_details":"Rezeptur compounding of low-dose naltrexone under physician responsibility.","eligibility_requirements":"Ärztliche Verordnung.","provider_requirements":"Arzt + Apotheke.","residency_travel_notes":"Domestic EU.","risk_notes":"Standard.","arbitrage_summary":"Germany: high-quality compounded off-label LDN.","oversight_notes":"AMG off-label; high pharmacy quality.","cost_notes":"Often self-pay.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[{"title":"LDN Research Trust","url":"https://ldnresearchtrust.org"}],"therapeutic_areas":["Autoimmune","Chronic_Pain","Neurology"],"diseases":["Fibromyalgia","Crohn's Disease","Multiple Sclerosis","ME/CFS","Long COVID","Chronic Pain"],"status":"active"},{"id":"96217773-94c5-40d3-a80c-e77a2f5dc154","procedure_id":"proc-repurposed-ldn","jurisdiction_id":"jur-nl","procedure_name":"Low-Dose Naltrexone (LDN) for Chronic Inflammatory/Autoimmune Conditions","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"COMPOUNDING","oversight_quality":"MEDIUM","modality":"REPURPOSED","estimated_cost_range_usd":"€30–100/month","price_usd":55.0,"access_pathway_details":"Off-label LDN via Dutch physicians and apotheek compounding.","eligibility_requirements":"Prescription.","provider_requirements":"Prescriber + apotheek.","residency_travel_notes":"Domestic.","risk_notes":"Standard.","arbitrage_summary":"Netherlands: accessible off-label LDN.","oversight_notes":"IGJ medicines framework.","cost_notes":"Self-pay common.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[{"title":"LDN Research Trust","url":"https://ldnresearchtrust.org"}],"therapeutic_areas":["Autoimmune","Chronic_Pain","Neurology"],"diseases":["Fibromyalgia","Crohn's Disease","Multiple Sclerosis","ME/CFS","Long COVID","Chronic Pain"],"status":"active"},{"id":"39ea0160-de80-458e-b334-0acd94fb7e35","procedure_id":"proc-repurposed-methylene","jurisdiction_id":"jur-us-federal","procedure_name":"Methylene Blue (Pharmaceutical Grade) for Neuroprotection/Mitochondrial Dysfunction","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"MEDIUM","modality":"REPURPOSED","estimated_cost_range_usd":"$50–150/month","price_usd":90.0,"access_pathway_details":"USP methylene blue FDA-approved for methemoglobinemia; low-dose neuro/mito use off-label. Pharmaceutical grade only.","eligibility_requirements":"G6PD screen; caution with serotonergic drugs.","provider_requirements":"Prescriber + pharmacy/compounder.","residency_travel_notes":"Domestic telehealth possible.","risk_notes":"Serotonin syndrome risk with SSRIs/MAOIs; G6PD hemolysis.","arbitrage_summary":"US: easy pharmaceutical-grade off-label access.","oversight_notes":"Approved drug, off-label use.","cost_notes":"Drug cheap; clinic markups vary.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Neurology","Mitochondrial_Health"],"diseases":["Mild Cognitive Impairment","Bipolar Depression","Mitochondrial Dysfunction","Methemoglobinemia"],"status":"active"},{"id":"89534cbe-b889-4b31-82c7-1b9d8e19d1f8","procedure_id":"proc-repurposed-methylene","jurisdiction_id":"jur-de","procedure_name":"Methylene Blue (Pharmaceutical Grade) for Neuroprotection/Mitochondrial Dysfunction","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"€40–120/month","price_usd":80.0,"access_pathway_details":"Methylthioninium chloride authorized for labeled uses; off-label low-dose is physician discretion.","eligibility_requirements":"Rx; G6PD check.","provider_requirements":"Physicians + pharmacies.","residency_travel_notes":"Domestic.","risk_notes":"Class risks.","arbitrage_summary":"Germany: medical-grade available; off-label clinician-led.","oversight_notes":"High EU pharmacy standards.","cost_notes":"Pharma grade available.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Neurology","Mitochondrial_Health"],"diseases":["Mild Cognitive Impairment","Bipolar Depression","Mitochondrial Dysfunction","Methemoglobinemia"],"status":"active"},{"id":"bcc2401d-ad87-40f1-be31-c90dcdd69a67","procedure_id":"proc-repurposed-methylene","jurisdiction_id":"jur-uk","procedure_name":"Methylene Blue (Pharmaceutical Grade) for Neuroprotection/Mitochondrial Dysfunction","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"$50–140/month","price_usd":85.0,"access_pathway_details":"Licensed methylthioninium products; off-label low-dose via private clinicians.","eligibility_requirements":"Prescription; interaction check.","provider_requirements":"Private/NHS as appropriate.","residency_travel_notes":"Domestic.","risk_notes":"Interactions; G6PD.","arbitrage_summary":"UK: medical-grade available.","oversight_notes":"MHRA licensed product quality.","cost_notes":"Avoid non-medical dyes.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Neurology","Mitochondrial_Health"],"diseases":["Mild Cognitive Impairment","Bipolar Depression","Mitochondrial Dysfunction","Methemoglobinemia"],"status":"active"},{"id":"2cf0309e-9d42-4018-932b-66ffd8959276","procedure_id":"proc-repurposed-methylene","jurisdiction_id":"jur-ca","procedure_name":"Methylene Blue (Pharmaceutical Grade) for Neuroprotection/Mitochondrial Dysfunction","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"MEDIUM","modality":"REPURPOSED","estimated_cost_range_usd":"CAD $50–150/month","price_usd":80.0,"access_pathway_details":"Hospital methemoglobinemia use; compounded low-dose off-label via clinics.","eligibility_requirements":"Prescription.","provider_requirements":"Physicians + compounders.","residency_travel_notes":"Domestic.","risk_notes":"Standard.","arbitrage_summary":"Canada: accessible off-label medical-grade.","oversight_notes":"Health Canada framework.","cost_notes":"Cash-pay off-label.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Neurology","Mitochondrial_Health"],"diseases":["Mild Cognitive Impairment","Bipolar Depression","Mitochondrial Dysfunction","Methemoglobinemia"],"status":"active"},{"id":"0309046a-171f-443b-89ba-e13fbbabcbad","procedure_id":"proc-repurposed-methylene","jurisdiction_id":"jur-mx","procedure_name":"Methylene Blue (Pharmaceutical Grade) for Neuroprotection/Mitochondrial Dysfunction","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"LOW","modality":"REPURPOSED","estimated_cost_range_usd":"$40–200","price_usd":100.0,"access_pathway_details":"Wellness clinics offer MB protocols; demand pharmaceutical documentation.","eligibility_requirements":"Clinic screening variable.","provider_requirements":"Private clinics.","residency_travel_notes":"Border tourism.","risk_notes":"Non-pharma dye substitution danger.","arbitrage_summary":"Mexico: available — insist on pharmaceutical grade.","oversight_notes":"Less standardized supply.","cost_notes":"Cheap; quality risk.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Neurology","Mitochondrial_Health"],"diseases":["Mild Cognitive Impairment","Bipolar Depression","Mitochondrial Dysfunction","Methemoglobinemia"],"status":"active"},{"id":"27f5ab54-b1a1-4cd5-9940-96193511659a","procedure_id":"proc-stem-exosome","jurisdiction_id":"jur-us-federal","procedure_name":"Exosome Therapy (Stem Cell-Derived) for Regeneration","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Trial may be free; illegal clinics $2k–20k","price_usd":null,"access_pathway_details":"No FDA-approved exosome therapeutic for regenerative use. FDA warns against unapproved clinic products; legitimate path is IND trials.","eligibility_requirements":"Trial criteria.","provider_requirements":"Trial sites only for compliant use.","residency_travel_notes":"Academic sites.","risk_notes":"Contamination/immunogenicity; legal risk for unapproved marketing.","arbitrage_summary":"US: trials only — avoid illegal clinic marketing.","oversight_notes":"FDA CBER enforcement.","cost_notes":"Clinic price ≠ legality.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Regeneration","Anti_Aging","Orthopedic"],"diseases":["Osteoarthritis","Androgenetic Alopecia","Skin Aging","Soft Tissue Injury"],"status":"active"},{"id":"4abc7b25-0014-409d-aa76-b3c75b49b764","procedure_id":"proc-stem-exosome","jurisdiction_id":"jur-mx","procedure_name":"Exosome Therapy (Stem Cell-Derived) for Regeneration","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"STEM_CELL","estimated_cost_range_usd":"$2,000–15,000","price_usd":6000.0,"access_pathway_details":"Widespread cash-pay exosome aesthetics/ortho packages; product characterization inconsistent.","eligibility_requirements":"Cash-pay.","provider_requirements":"Private regenerative clinics.","residency_travel_notes":"Tourism hubs.","risk_notes":"Uncharacterized product risk.","arbitrage_summary":"Mexico: easy cash access, high product risk.","oversight_notes":"Limited enforcement capacity.","cost_notes":"Opaque packages.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Regeneration","Anti_Aging","Orthopedic"],"diseases":["Osteoarthritis","Androgenetic Alopecia","Skin Aging","Soft Tissue Injury"],"status":"active"},{"id":"633ad539-02c5-4a6e-b67a-1c78cf255412","procedure_id":"proc-stem-exosome","jurisdiction_id":"jur-kr","procedure_name":"Exosome Therapy (Stem Cell-Derived) for Regeneration","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"MEDIUM","modality":"STEM_CELL","estimated_cost_range_usd":"$3,000–12,000","price_usd":7000.0,"access_pathway_details":"Active regenerative/aesthetic EV market under evolving MFDS rules — stronger baseline than LatAm tourism.","eligibility_requirements":"Clinic evaluation.","provider_requirements":"Licensed clinics/hospitals.","residency_travel_notes":"Seoul aesthetics hub.","risk_notes":"Still limited hard outcome evidence.","arbitrage_summary":"Korea: higher facility standards than pure tourism markets.","oversight_notes":"MFDS facility/product rules.","cost_notes":"Premium tourism.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Regeneration","Anti_Aging","Orthopedic"],"diseases":["Osteoarthritis","Androgenetic Alopecia","Skin Aging","Soft Tissue Injury"],"status":"active"},{"id":"472afb0f-5506-4882-9ca5-ba017d70cb88","procedure_id":"proc-stem-exosome","jurisdiction_id":"jur-th","procedure_name":"Exosome Therapy (Stem Cell-Derived) for Regeneration","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"STEM_CELL","estimated_cost_range_usd":"$1,500–10,000","price_usd":4000.0,"access_pathway_details":"Anti-aging clinics market exosome drips/facials; quality spectrum wide.","eligibility_requirements":"Tourist packages.","provider_requirements":"Private hospitals/boutiques.","residency_travel_notes":"Bangkok/Phuket.","risk_notes":"Opaque origin.","arbitrage_summary":"Thailand: accessible; diligence required.","oversight_notes":"Variable.","cost_notes":"Cheaper than Korea/UAE.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Regeneration","Anti_Aging","Orthopedic"],"diseases":["Osteoarthritis","Androgenetic Alopecia","Skin Aging","Soft Tissue Injury"],"status":"active"},{"id":"69a0dbbb-2f37-4245-b945-0012ed0f1be8","procedure_id":"proc-stem-exosome","jurisdiction_id":"jur-uae","procedure_name":"Exosome Therapy (Stem Cell-Derived) for Regeneration","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"MEDIUM","modality":"STEM_CELL","estimated_cost_range_usd":"$5,000–20,000","price_usd":10000.0,"access_pathway_details":"Dubai luxury regenerative clinics under DHA facility licensing; evidence for systemic benefit still weak.","eligibility_requirements":"Cash-pay screening.","provider_requirements":"DHA-licensed clinics.","residency_travel_notes":"Visa-friendly tourism.","risk_notes":"Cost vs evidence mismatch.","arbitrage_summary":"UAE: high-end clinic access, better facility oversight.","oversight_notes":"Facility standards high; product evidence thin.","cost_notes":"Luxury pricing.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Regeneration","Anti_Aging","Orthopedic"],"diseases":["Osteoarthritis","Androgenetic Alopecia","Skin Aging","Soft Tissue Injury"],"status":"active"},{"id":"04761584-af7a-4ea1-b995-af1b3ff74f51","procedure_id":"proc-stem-exosome","jurisdiction_id":"jur-hn-prospera","procedure_name":"Exosome Therapy (Stem Cell-Derived) for Regeneration","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"UNREGULATED_PERMITTED","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"LOW","modality":"STEM_CELL","estimated_cost_range_usd":"$3,000–15,000","price_usd":8000.0,"access_pathway_details":"ZEDE informed-consent regenerative EV products outside FDA marketing rules.","eligibility_requirements":"Consent + pay.","provider_requirements":"ZEDE clinics.","residency_travel_notes":"Roatán.","risk_notes":"High uncertainty.","arbitrage_summary":"Próspera: permissive, low external oversight.","oversight_notes":"Light touch.","cost_notes":"Experimental.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Regeneration","Anti_Aging","Orthopedic"],"diseases":["Osteoarthritis","Androgenetic Alopecia","Skin Aging","Soft Tissue Injury"],"status":"active"},{"id":"d15ae3b5-47f3-4e9d-a30b-bf071ee575cb","procedure_id":"proc-pt-141","jurisdiction_id":"jur-us-federal","procedure_name":"PT-141 (Bremelanotide) for Sexual Dysfunction","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Vyleesi high if uninsured; compounded ~$50–150/dose","price_usd":120.0,"access_pathway_details":"Vyleesi (bremelanotide) FDA-approved for premenopausal HSDD. Compounded PT-141 used more broadly off-label.","eligibility_requirements":"Labeled HSDD evaluation; BP contraindications.","provider_requirements":"Prescriber + specialty pharmacy; compounders for PT-141.","residency_travel_notes":"Domestic.","risk_notes":"Nausea, flushing, BP changes.","arbitrage_summary":"US: approved Vyleesi pathway; compounded cheaper parallel path.","oversight_notes":"Approved Rx drug; compounding separate channel.","cost_notes":"Insurance variable for Vyleesi.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[{"title":"Vyleesi FDA","url":"https://www.accessdata.fda.gov/scripts/cder/daf/"}],"therapeutic_areas":["Sexual_Health"],"diseases":["Hypoactive Sexual Desire Disorder (HSDD)","Erectile Dysfunction (off-label)"],"status":"active"},{"id":"3399785a-0436-49db-be82-1e8e5d9aaafd","procedure_id":"proc-pt-141","jurisdiction_id":"jur-ca","procedure_name":"PT-141 (Bremelanotide) for Sexual Dysfunction","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"MEDIUM","modality":"PEPTIDE","estimated_cost_range_usd":"$80–200/dose est.","price_usd":140.0,"access_pathway_details":"Less straightforward than US Vyleesi retail; specialist/compounding/special access more common.","eligibility_requirements":"Sexual medicine assessment.","provider_requirements":"Specialists + compounders.","residency_travel_notes":"Domestic.","risk_notes":"BP/nausea; source quality.","arbitrage_summary":"Canada: specialist gray/compounding more than open retail.","oversight_notes":"Health Canada specials/compounding.","cost_notes":"Private market.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[{"title":"Vyleesi FDA","url":"https://www.accessdata.fda.gov/scripts/cder/daf/"}],"therapeutic_areas":["Sexual_Health"],"diseases":["Hypoactive Sexual Desire Disorder (HSDD)","Erectile Dysfunction (off-label)"],"status":"active"},{"id":"376ef6f3-53b3-40e1-bf9c-f7c37473239a","procedure_id":"proc-pt-141","jurisdiction_id":"jur-uk","procedure_name":"PT-141 (Bremelanotide) for Sexual Dysfunction","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"COMPOUNDING","oversight_quality":"MEDIUM","modality":"PEPTIDE","estimated_cost_range_usd":"$100–250/dose est.","price_usd":160.0,"access_pathway_details":"Not routine NHS; private sexual medicine may use specials/unlicensed approaches.","eligibility_requirements":"Private specialist assessment.","provider_requirements":"Private clinics.","residency_travel_notes":"Domestic private.","risk_notes":"Unlicensed governance.","arbitrage_summary":"UK: private/specialist only.","oversight_notes":"MHRA unlicensed framework.","cost_notes":"Private.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Sexual_Health"],"diseases":["Hypoactive Sexual Desire Disorder (HSDD)","Erectile Dysfunction (off-label)"],"status":"active"},{"id":"b5f4d25b-27e0-4db0-8015-5d64251d718b","procedure_id":"proc-pt-141","jurisdiction_id":"jur-au","procedure_name":"PT-141 (Bremelanotide) for Sexual Dysfunction","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"COMPOUNDING","oversight_quality":"MEDIUM","modality":"PEPTIDE","estimated_cost_range_usd":"AUD $80–200/dose","price_usd":120.0,"access_pathway_details":"Private men's/women's health clinics compound PT-141; not PBS standard.","eligibility_requirements":"Private Rx.","provider_requirements":"Private clinics + compounders.","residency_travel_notes":"Domestic.","risk_notes":"BP effects.","arbitrage_summary":"Australia: private compounded access.","oversight_notes":"TGA compounding rules.","cost_notes":"Cash-pay.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Sexual_Health"],"diseases":["Hypoactive Sexual Desire Disorder (HSDD)","Erectile Dysfunction (off-label)"],"status":"active"},{"id":"9ed9ba2a-727e-4379-adcc-4a3bd2959f8f","procedure_id":"proc-pt-141","jurisdiction_id":"jur-mx","procedure_name":"PT-141 (Bremelanotide) for Sexual Dysfunction","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"LOW","modality":"PEPTIDE","estimated_cost_range_usd":"$40–120/dose","price_usd":70.0,"access_pathway_details":"Sexual health clinics offer PT-141 cash-pay.","eligibility_requirements":"Clinic screening variable.","provider_requirements":"Private clinics.","residency_travel_notes":"Tourism.","risk_notes":"Counterfeit peptides.","arbitrage_summary":"Mexico: cheap cash access with caveats.","oversight_notes":"Variable product quality.","cost_notes":"Lower cost, higher quality risk.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Sexual_Health"],"diseases":["Hypoactive Sexual Desire Disorder (HSDD)","Erectile Dysfunction (off-label)"],"status":"active"},{"id":"9e9b464f-642a-405c-a351-2f5126dd8acd","procedure_id":"proc-cryotherapy","jurisdiction_id":"jur-us-federal","procedure_name":"Whole-Body Cryotherapy (WBC) for Recovery/Inflammation","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"UNREGULATED_PERMITTED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"LOW","modality":"REPURPOSED","estimated_cost_range_usd":"$75–250/session","price_usd":150.0,"access_pathway_details":"WBC as wellness service — not FDA-approved to treat disease. FDA has warned about chamber risks.","eligibility_requirements":"Age/CV screening forms at better sites.","provider_requirements":"Spas/gyms/recovery studios.","residency_travel_notes":"Most metros.","risk_notes":"Frostbite, asphyxiation risk, BP surge.","arbitrage_summary":"US: widely available wellness, not medical approval.","oversight_notes":"Commercial, not medical approval.","cost_notes":"Cash wellness.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Anti_Aging","Recovery"],"diseases":["Muscle Recovery","Chronic Inflammation","Sports Injury Recovery"],"status":"active"},{"id":"491321d8-59a7-4666-9493-7c896965067f","procedure_id":"proc-cryotherapy","jurisdiction_id":"jur-de","procedure_name":"Whole-Body Cryotherapy (WBC) for Recovery/Inflammation","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"UNREGULATED_PERMITTED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"MEDIUM","modality":"REPURPOSED","estimated_cost_range_usd":"€40–120/session","price_usd":80.0,"access_pathway_details":"Common in European sports medicine/physio and spa settings.","eligibility_requirements":"Screening questionnaires.","provider_requirements":"Physio clinics, sports centers.","residency_travel_notes":"Domestic EU.","risk_notes":"Standard cryo risks.","arbitrage_summary":"Germany: established sports/wellness cryo.","oversight_notes":"Commercial safety standards.","cost_notes":"Often cheaper than US boutiques.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Anti_Aging","Recovery"],"diseases":["Muscle Recovery","Chronic Inflammation","Sports Injury Recovery"],"status":"active"},{"id":"a3a4fedf-0cb3-48ef-82f5-aa8d74c6f496","procedure_id":"proc-cryotherapy","jurisdiction_id":"jur-po","procedure_name":"Whole-Body Cryotherapy (WBC) for Recovery/Inflammation","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"UNREGULATED_PERMITTED","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MEDIUM","modality":"REPURPOSED","estimated_cost_range_usd":"€20–60/session","price_usd":40.0,"access_pathway_details":"Dense cryochamber infrastructure in Polish rehab clinics; regional wellness tourism.","eligibility_requirements":"Rehab referral or walk-in.","provider_requirements":"Rehabilitation centers.","residency_travel_notes":"Warsaw/Krakow.","risk_notes":"Standard risks.","arbitrage_summary":"Poland: cost-effective EU cryotherapy.","oversight_notes":"Medical rehab culture stronger than pure spa.","cost_notes":"Among lowest EU prices.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Anti_Aging","Recovery"],"diseases":["Muscle Recovery","Chronic Inflammation","Sports Injury Recovery"],"status":"active"},{"id":"bc125107-106b-4f9f-bbb5-364863c59d88","procedure_id":"proc-cryotherapy","jurisdiction_id":"jur-jp","procedure_name":"Whole-Body Cryotherapy (WBC) for Recovery/Inflammation","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"UNREGULATED_PERMITTED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"MEDIUM","modality":"REPURPOSED","estimated_cost_range_usd":"$80–200/session","price_usd":120.0,"access_pathway_details":"Sports/recovery facilities offer cryotherapy as wellness.","eligibility_requirements":"Facility screening.","provider_requirements":"Sports clinics, hotels.","residency_travel_notes":"Domestic/tourism.","risk_notes":"Standard.","arbitrage_summary":"Japan: available recovery wellness service.","oversight_notes":"Commercial standards.","cost_notes":"Urban premium.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Anti_Aging","Recovery"],"diseases":["Muscle Recovery","Chronic Inflammation","Sports Injury Recovery"],"status":"active"},{"id":"b461b310-b8d8-4495-8fff-9dd43f7859b3","procedure_id":"proc-cryotherapy","jurisdiction_id":"jur-uae","procedure_name":"Whole-Body Cryotherapy (WBC) for Recovery/Inflammation","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"UNREGULATED_PERMITTED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"MEDIUM","modality":"REPURPOSED","estimated_cost_range_usd":"$100–250/session","price_usd":180.0,"access_pathway_details":"Dubai luxury recovery centers widely offer WBC.","eligibility_requirements":"Membership/spa intake.","provider_requirements":"Luxury gyms/clinics.","residency_travel_notes":"Tourism-friendly.","risk_notes":"Standard.","arbitrage_summary":"UAE: luxury cryo widely marketed.","oversight_notes":"DHA facility licensing where clinic-based.","cost_notes":"Premium.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Anti_Aging","Recovery"],"diseases":["Muscle Recovery","Chronic Inflammation","Sports Injury Recovery"],"status":"active"},{"id":"d15f7cb6-ef12-4f6e-a99a-a25c489816e4","procedure_id":"proc-prp-therapy","jurisdiction_id":"jur-us-federal","procedure_name":"Platelet-Rich Plasma (PRP) Therapy for Joint/Tissue Repair","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"MEDIUM","modality":"CELLULAR","estimated_cost_range_usd":"$500–2,000/injection","price_usd":1000.0,"access_pathway_details":"Autologous PRP common in ortho/sports/aesthetics; device kits 510(k). Not drug-approved for OA claims.","eligibility_requirements":"Clinic eval; avoid active infection at site.","provider_requirements":"Ortho, sports med, derm, PM&R.","residency_travel_notes":"Nationwide.","risk_notes":"Pain, infection; mixed evidence by indication.","arbitrage_summary":"US: ubiquitous cash-pay PRP.","oversight_notes":"FDA devices + medical boards.","cost_notes":"Rarely insured elective uses.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Orthopedic","Sports_Medicine","Anti_Aging"],"diseases":["Knee Osteoarthritis","Tendinopathy","Rotator Cuff Injury","Androgenetic Alopecia"],"status":"active"},{"id":"a0f86c9c-acde-40e0-81a4-1b88ac5bd211","procedure_id":"proc-prp-therapy","jurisdiction_id":"jur-de","procedure_name":"Platelet-Rich Plasma (PRP) Therapy for Joint/Tissue Repair","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"HIGH","modality":"CELLULAR","estimated_cost_range_usd":"€300–800/injection","price_usd":550.0,"access_pathway_details":"PRP/ACP established in German orthopedics; often private pay.","eligibility_requirements":"Specialist assessment.","provider_requirements":"Orthopedic clinics.","residency_travel_notes":"Domestic EU.","risk_notes":"Standard procedural.","arbitrage_summary":"Germany: mainstream orthopedic PRP.","oversight_notes":"High clinical standards.","cost_notes":"Often self-pay.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Orthopedic","Sports_Medicine","Anti_Aging"],"diseases":["Knee Osteoarthritis","Tendinopathy","Rotator Cuff Injury","Androgenetic Alopecia"],"status":"active"},{"id":"3bffbee9-16e0-4313-8a39-6e51283418bd","procedure_id":"proc-prp-therapy","jurisdiction_id":"jur-kr","procedure_name":"Platelet-Rich Plasma (PRP) Therapy for Joint/Tissue Repair","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"HIGH","modality":"CELLULAR","estimated_cost_range_usd":"$400–1,500/session","price_usd":800.0,"access_pathway_details":"Widely used in Korean sports med and aesthetics under medical practice regulation.","eligibility_requirements":"Clinic evaluation.","provider_requirements":"Hospitals and specialty clinics.","residency_travel_notes":"Tourism-ready.","risk_notes":"Standard.","arbitrage_summary":"Korea: high-volume quality PRP market.","oversight_notes":"MFDS/medical law.","cost_notes":"Aesthetics packages common.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Orthopedic","Sports_Medicine","Anti_Aging"],"diseases":["Knee Osteoarthritis","Tendinopathy","Rotator Cuff Injury","Androgenetic Alopecia"],"status":"active"},{"id":"eaf4234b-7eda-4dde-ae90-369162d27f1e","procedure_id":"proc-prp-therapy","jurisdiction_id":"jur-mx","procedure_name":"Platelet-Rich Plasma (PRP) Therapy for Joint/Tissue Repair","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"LOW","modality":"CELLULAR","estimated_cost_range_usd":"$200–800/injection","price_usd":400.0,"access_pathway_details":"Common in Mexican ortho/aesthetic tourism at lower prices.","eligibility_requirements":"Cash-pay screening.","provider_requirements":"Private clinics.","residency_travel_notes":"Border/coastal hubs.","risk_notes":"Infection if technique weak.","arbitrage_summary":"Mexico: lower-cost PRP — verify clinic quality.","oversight_notes":"Variable sterility.","cost_notes":"Savings vs US.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Orthopedic","Sports_Medicine","Anti_Aging"],"diseases":["Knee Osteoarthritis","Tendinopathy","Rotator Cuff Injury","Androgenetic Alopecia"],"status":"active"},{"id":"731f5e91-8fec-439a-bf62-1ca0fdf72ba4","procedure_id":"proc-prp-therapy","jurisdiction_id":"jur-th","procedure_name":"Platelet-Rich Plasma (PRP) Therapy for Joint/Tissue Repair","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MEDIUM","modality":"CELLULAR","estimated_cost_range_usd":"$300–1,000","price_usd":550.0,"access_pathway_details":"Major private hospitals offer PRP for joints/aesthetics.","eligibility_requirements":"Hospital evaluation.","provider_requirements":"JCI hospitals and clinics.","residency_travel_notes":"Bangkok connectivity.","risk_notes":"Choose accredited hospitals.","arbitrage_summary":"Thailand: PRP in accredited private hospitals.","oversight_notes":"Accreditation helps.","cost_notes":"Package tourism.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Orthopedic","Sports_Medicine","Anti_Aging"],"diseases":["Knee Osteoarthritis","Tendinopathy","Rotator Cuff Injury","Androgenetic Alopecia"],"status":"active"},{"id":"54bab1bc-b1a5-4024-9a93-e5b27a2047ca","procedure_id":"proc-prp-therapy","jurisdiction_id":"jur-jp","procedure_name":"Platelet-Rich Plasma (PRP) Therapy for Joint/Tissue Repair","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"HIGH","modality":"CELLULAR","estimated_cost_range_usd":"$600–2,000","price_usd":1200.0,"access_pathway_details":"PRP under Japanese regenerative medicine law depending on processing; many orthopedic clinics offer it.","eligibility_requirements":"Clinic protocols per safety act where applicable.","provider_requirements":"Licensed clinics/hospitals.","residency_travel_notes":"Primarily domestic.","risk_notes":"Standard.","arbitrage_summary":"Japan: regulated clinical environment for PRP-type procedures.","oversight_notes":"Structured reporting for some processed products.","cost_notes":"Higher domestic pricing.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Orthopedic","Sports_Medicine","Anti_Aging"],"diseases":["Knee Osteoarthritis","Tendinopathy","Rotator Cuff Injury","Androgenetic Alopecia"],"status":"active"},{"id":"5179ad34-5543-419d-b211-4bc0c1e45b29","procedure_id":"proc-nmn-nmad","jurisdiction_id":"jur-us-federal","procedure_name":"NMN/NR Oral Supplementation for Longevity","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"PERSONAL_IMPORT","oversight_quality":"LOW","modality":"REPURPOSED","estimated_cost_range_usd":"$30–100/month","price_usd":60.0,"access_pathway_details":"NR widely sold as dietary supplement. NMN faced FDA exclusion from supplements after drug investigations — market still in flux with ongoing online sales.","eligibility_requirements":"Consumer purchase; no disease claims.","provider_requirements":"Retailers; some longevity clinics.","residency_travel_notes":"N/A oral.","risk_notes":"Quality variability; limited hard longevity endpoints.","arbitrage_summary":"US: NR easy; NMN status turbulent — skepticism warranted.","oversight_notes":"DSHEA vs drug exclusion tension for NMN.","cost_notes":"Consumer pricing.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Anti_Aging","Longevity","Metabolic_Health"],"diseases":["Age-Related Functional Decline","Metabolic Syndrome"],"status":"active"},{"id":"cf0c1f8b-7012-4236-99b2-836cbadfc3a3","procedure_id":"proc-nmn-nmad","jurisdiction_id":"jur-jp","procedure_name":"NMN/NR Oral Supplementation for Longevity","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"UNREGULATED_PERMITTED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"MEDIUM","modality":"REPURPOSED","estimated_cost_range_usd":"$40–120/month","price_usd":70.0,"access_pathway_details":"Major NMN consumer market with domestic manufacturers; sold as foods/supplements with constrained claims.","eligibility_requirements":"Consumer purchase.","provider_requirements":"Drugstores and specialty brands.","residency_travel_notes":"Easy visitor purchase.","risk_notes":"Still limited outcome data.","arbitrage_summary":"Japan: mature consumer NMN market.","oversight_notes":"MHLW food rules.","cost_notes":"Premium brands cost more.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Anti_Aging","Longevity","Metabolic_Health"],"diseases":["Age-Related Functional Decline","Metabolic Syndrome"],"status":"active"},{"id":"588235d2-7f01-4287-bf02-4c8a71ab7ff3","procedure_id":"proc-nmn-nmad","jurisdiction_id":"jur-de","procedure_name":"NMN/NR Oral Supplementation for Longevity","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"UNREGULATED_PERMITTED","access_pathway":"PERSONAL_IMPORT","oversight_quality":"MEDIUM","modality":"REPURPOSED","estimated_cost_range_usd":"€30–100/month","price_usd":55.0,"access_pathway_details":"NAD precursors sold as food supplements; novel-food rules can limit some ingredients by member-state listing.","eligibility_requirements":"Consumer purchase where marketed.","provider_requirements":"Supplement retail.","residency_travel_notes":"EU goods movement where legal.","risk_notes":"Label accuracy; evidence limits.","arbitrage_summary":"Germany/EU: supplement channel with novel-food caveats.","oversight_notes":"EFSA novel food framework.","cost_notes":"Brand and compliance dependent.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Anti_Aging","Longevity","Metabolic_Health"],"diseases":["Age-Related Functional Decline","Metabolic Syndrome"],"status":"active"},{"id":"1ddbf3bd-911d-4d35-a730-b961048f7075","procedure_id":"proc-nmn-nmad","jurisdiction_id":"jur-sg","procedure_name":"NMN/NR Oral Supplementation for Longevity","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"UNREGULATED_PERMITTED","access_pathway":"PERSONAL_IMPORT","oversight_quality":"MEDIUM","modality":"REPURPOSED","estimated_cost_range_usd":"$40–110/month","price_usd":70.0,"access_pathway_details":"NAD precursor supplements via regulated retail/import; HSA restricts disease claims.","eligibility_requirements":"Consumer.","provider_requirements":"Pharmacies and specialty stores.","residency_travel_notes":"City retail.","risk_notes":"Standard supplement risks.","arbitrage_summary":"Singapore: premium supplements available.","oversight_notes":"HSA advertising rules.","cost_notes":"Import premiums possible.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Anti_Aging","Longevity","Metabolic_Health"],"diseases":["Age-Related Functional Decline","Metabolic Syndrome"],"status":"active"},{"id":"4756454b-1638-4a67-9c5b-0636552d45d8","procedure_id":"proc-nmn-nmad","jurisdiction_id":"jur-au","procedure_name":"NMN/NR Oral Supplementation for Longevity","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"UNREGULATED_PERMITTED","access_pathway":"PERSONAL_IMPORT","oversight_quality":"MEDIUM","modality":"REPURPOSED","estimated_cost_range_usd":"AUD $40–120/month","price_usd":55.0,"access_pathway_details":"NAD precursors as listed complementary medicines/supplements where ARTG-listed.","eligibility_requirements":"Consumer.","provider_requirements":"Pharmacies, health stores.","residency_travel_notes":"Domestic retail.","risk_notes":"Anti-aging claim limits.","arbitrage_summary":"Australia: retail NAD precursors with TGA listing culture.","oversight_notes":"TGA complementary medicines.","cost_notes":"Listed products preferred.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Anti_Aging","Longevity","Metabolic_Health"],"diseases":["Age-Related Functional Decline","Metabolic Syndrome"],"status":"active"},{"id":"20ea60da-95ff-4a40-9a28-7846d6637321","procedure_id":"proc-ayahuasca","jurisdiction_id":"jur-br","procedure_name":"Ayahuasca-Assisted Therapy for Depression/Addiction/Spiritual Growth","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"REGULATED_THERAPY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"MEDIUM","modality":"PSYCHEDELICS","estimated_cost_range_usd":"$1,500–5,000 retreats","price_usd":2500.0,"access_pathway_details":"Religious ayahuasca use protected for recognized churches (UDV, Santo Daime, etc.); retreat tourism also exists. Not a medical marketing authorization for depression.","eligibility_requirements":"Church membership or retreat screening; psychiatric contraindications apply.","provider_requirements":"Religious centers; retreat operators.","residency_travel_notes":"Amazon/São Paulo regions; tourism common.","risk_notes":"MAOI food/drug interactions; cardiac/psych risk; facilitator quality variable.","arbitrage_summary":"Brazil: strongest lawful ceremonial framework globally.","oversight_notes":"Religious freedom framework; not ANVISA drug approval for therapy.","cost_notes":"Ceremony packages vary.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Addiction","Spirituality"],"diseases":["Depression","Substance Use Disorder","PTSD","Existential Distress"],"status":"active"},{"id":"ab9f3c3e-b372-43d9-a904-bc71a5342747","procedure_id":"proc-ayahuasca","jurisdiction_id":"jur-us-federal","procedure_name":"Ayahuasca-Assisted Therapy for Depression/Addiction/Spiritual Growth","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A general public","price_usd":null,"access_pathway_details":"DMT Schedule I federally. Limited RFRA exemptions for specific churches (UDV, Santo Daime branches) — not general public therapy.","eligibility_requirements":"Church membership under court-recognized exemptions only.","provider_requirements":"Exempt churches only.","residency_travel_notes":"N/A for non-members.","risk_notes":"Federal criminal risk outside exemptions.","arbitrage_summary":"US federal: prohibited except narrow religious exemptions.","oversight_notes":"DEA Schedule I + RFRA case law.","cost_notes":"Retreat tourism abroad common among seekers.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Addiction","Spirituality"],"diseases":["Depression","Substance Use Disorder","PTSD","Existential Distress"],"status":"active"},{"id":"4dd63ef6-1776-431b-bfa4-b1c5f9eee7b8","procedure_id":"proc-ayahuasca","jurisdiction_id":"jur-us-co","procedure_name":"Ayahuasca-Assisted Therapy for Depression/Addiction/Spiritual Growth","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"DECRIMINALIZED","access_pathway":"NONE","oversight_quality":"LOW","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Personal cultivation minimal cost; underground ceremonies variable","price_usd":null,"access_pathway_details":"Prop 122 decriminalized personal possession/use/growing of DMT and listed natural medicines for adults 21+ — not a licensed ayahuasca therapy program or commercial supply.","eligibility_requirements":"21+ personal use only; no commercial sales.","provider_requirements":"No licensed ceremony centers for ayahuasca under state program (psilocybin centers are separate track).","residency_travel_notes":"Any adult in state borders.","risk_notes":"No quality control or medical screening mandate.","arbitrage_summary":"Colorado: decrim personal DMT plants — not regulated therapy supply.","oversight_notes":"Decrim without regulated supply chain.","cost_notes":"No licensed price discovery.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Addiction","Spirituality"],"diseases":["Depression","Substance Use Disorder","PTSD","Existential Distress"],"status":"active"},{"id":"418d0c33-38b2-48bc-8d9f-14d103549b3a","procedure_id":"proc-ayahuasca","jurisdiction_id":"jur-nl","procedure_name":"Ayahuasca-Assisted Therapy for Depression/Addiction/Spiritual Growth","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"MEDIUM","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A legal market","price_usd":null,"access_pathway_details":"DMT controlled; ayahuasca ceremonies have faced prosecutions. Not a lawful commercial therapy pathway comparable to truffles.","eligibility_requirements":"No licensed pathway.","provider_requirements":"Underground risk.","residency_travel_notes":"N/A","risk_notes":"Legal risk.","arbitrage_summary":"Netherlands: ayahuasca not a legal therapy market (unlike truffles).","oversight_notes":"Opium Act scheduling.","cost_notes":"Do not confuse with legal psilocybin truffles.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Addiction","Spirituality"],"diseases":["Depression","Substance Use Disorder","PTSD","Existential Distress"],"status":"active"},{"id":"1d39afc3-168f-41d4-a56b-4c12f6c48567","procedure_id":"proc-ayahuasca","jurisdiction_id":"jur-pt","procedure_name":"Ayahuasca-Assisted Therapy for Depression/Addiction/Spiritual Growth","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"DECRIMINALIZED","access_pathway":"NONE","oversight_quality":"LOW","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Underground variable","price_usd":null,"access_pathway_details":"Personal drug use decriminalized (administrative), but DMT supply remains controlled — no licensed ayahuasca therapy regime.","eligibility_requirements":"Personal use decrim ≠ legal ceremony tourism framework.","provider_requirements":"No state licensing for ayahuasca therapy.","residency_travel_notes":"Tourism for 'legal' ayahuasca is misleading.","risk_notes":"Still supply-side legal risk; safety unregulated.","arbitrage_summary":"Portugal: decrim consumption, not a legal ayahuasca therapy program.","oversight_notes":"Decrim model without medical supply chain.","cost_notes":"Not a regulated product.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Addiction","Spirituality"],"diseases":["Depression","Substance Use Disorder","PTSD","Existential Distress"],"status":"active"},{"id":"53c51949-0cd4-4322-bb45-be539c03db45","procedure_id":"proc-ayahuasca","jurisdiction_id":"jur-cr","procedure_name":"Ayahuasca-Assisted Therapy for Depression/Addiction/Spiritual Growth","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"PSYCHEDELICS","estimated_cost_range_usd":"$1,500–4,000","price_usd":2200.0,"access_pathway_details":"Retreat industry operates in gray/informal zones; not a formal medical approval. Facilitator quality highly variable.","eligibility_requirements":"Retreat screening variable.","provider_requirements":"Retreat operators.","residency_travel_notes":"Tourism-friendly country.","risk_notes":"Drug interactions; remote emergency care.","arbitrage_summary":"Costa Rica: retreat tourism exists; unregulated quality.","oversight_notes":"Little government therapy licensing.","cost_notes":"All-inclusive retreats.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Addiction","Spirituality"],"diseases":["Depression","Substance Use Disorder","PTSD","Existential Distress"],"status":"active"},{"id":"2834561d-c339-4401-a39f-e21dfc7a1110","procedure_id":"proc-ayahuasca","jurisdiction_id":"jur-mx","procedure_name":"Ayahuasca-Assisted Therapy for Depression/Addiction/Spiritual Growth","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"PSYCHEDELICS","estimated_cost_range_usd":"$1,500–4,500","price_usd":2500.0,"access_pathway_details":"Some ceremonial retreats operate; federal controlled-substance posture creates legal gray zone for DMT ceremonies.","eligibility_requirements":"Retreat screening.","provider_requirements":"Retreat operators.","residency_travel_notes":"Easy US travel.","risk_notes":"Legal + medical risk.","arbitrage_summary":"Mexico: retreats exist in gray zone — high diligence required.","oversight_notes":"Inconsistent enforcement.","cost_notes":"Variable.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Addiction","Spirituality"],"diseases":["Depression","Substance Use Disorder","PTSD","Existential Distress"],"status":"active"},{"id":"573100e6-7d39-4910-8a22-1fc46c4c088e","procedure_id":"proc-ayahuasca","jurisdiction_id":"jur-cl","procedure_name":"Ayahuasca-Assisted Therapy for Depression/Addiction/Spiritual Growth","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"PSYCHEDELICS","estimated_cost_range_usd":"$1,500–4,000","price_usd":2200.0,"access_pathway_details":"Occasional retreat offerings; not a formal approved medical therapy pathway.","eligibility_requirements":"Variable.","provider_requirements":"Retreat operators.","residency_travel_notes":"Santiago + south.","risk_notes":"Unregulated facilitation.","arbitrage_summary":"Chile: limited retreat presence; not regulated medicine.","oversight_notes":"Limited formal framework.","cost_notes":"Variable.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Addiction","Spirituality"],"diseases":["Depression","Substance Use Disorder","PTSD","Existential Distress"],"status":"active"},{"id":"f62cf8a1-2db1-4e42-8e28-248ae684cbad","procedure_id":"proc-medical-cannabis","jurisdiction_id":"jur-ca","procedure_name":"Medical Cannabis for Chronic Pain / Seizures / PTSD","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"PHYTOCANNABINOID","estimated_cost_range_usd":"$100–300/month medical","price_usd":180.0,"access_pathway_details":"Federal medical cannabis framework since 2001; adult-use legal 2018. Medical channel via licensed producers and authorized healthcare practitioners.","eligibility_requirements":"Medical document from authorized clinician for medical channel; adult-use via retail 18/19+.","provider_requirements":"Licensed producers; authorized retailers.","residency_travel_notes":"Residents; some visitors use adult-use retail where legal.","risk_notes":"Psychosis risk; impairment; quality better in legal market.","arbitrage_summary":"Canada: full federal legal medical + adult-use framework.","oversight_notes":"Health Canada Cannabis Act.","cost_notes":"Medical vs recreational pricing differs; insurance rare.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[{"title":"Legality of cannabis overview","url":"https://en.wikipedia.org/wiki/Legality_of_cannabis"}],"therapeutic_areas":["Pain","Neurology","Mental_Health"],"diseases":["Chronic Pain","Epilepsy","PTSD","Chemotherapy-Induced Nausea","Anxiety"],"status":"active"},{"id":"8878c705-e623-49df-a781-66871bc4df3e","procedure_id":"proc-medical-cannabis","jurisdiction_id":"jur-us-federal","procedure_name":"Medical Cannabis for Chronic Pain / Seizures / PTSD","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PHYTOCANNABINOID","estimated_cost_range_usd":"$150–400/month state medical","price_usd":null,"access_pathway_details":"Cannabis Schedule I federally (except hemp ≤0.3% THC and FDA products Epidiolex/Marinol/Syndros). State medical programs conflict with federal law.","eligibility_requirements":"State programs only; federal employees/safety-sensitive roles constrained.","provider_requirements":"State-licensed dispensaries where legal.","residency_travel_notes":"State residency often required for medical cards.","risk_notes":"Federal criminal risk residual; product safer in legal states.","arbitrage_summary":"US federal: prohibited — access is state-level only.","oversight_notes":"DEA Schedule I vs state laws; 2018 Farm Bill hemp.","cost_notes":"Federal prohibition blocks many research/banking pathways.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[{"title":"Legality of cannabis overview","url":"https://en.wikipedia.org/wiki/Legality_of_cannabis"}],"therapeutic_areas":["Pain","Neurology","Mental_Health"],"diseases":["Chronic Pain","Epilepsy","PTSD","Chemotherapy-Induced Nausea","Anxiety"],"status":"active"},{"id":"268870be-a9b1-4ad7-9e4c-a6a45a578545","procedure_id":"proc-medical-cannabis","jurisdiction_id":"jur-us-ca","procedure_name":"Medical Cannabis for Chronic Pain / Seizures / PTSD","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"MEDIUM","modality":"PHYTOCANNABINOID","estimated_cost_range_usd":"$100–350/month","price_usd":200.0,"access_pathway_details":"California medical cannabis long-standing; adult-use Prop 64. Licensed dispensaries under DCC.","eligibility_requirements":"21+ adult-use; medical recommendations for tax/possession benefits.","provider_requirements":"Licensed dispensaries.","residency_travel_notes":"Open to visitors 21+ adult-use.","risk_notes":"Impairment; product labeling helps.","arbitrage_summary":"California: mature licensed medical/adult-use market.","oversight_notes":"State DCC; federal conflict remains.","cost_notes":"Legal market tax-heavy.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[{"title":"Legality of cannabis overview","url":"https://en.wikipedia.org/wiki/Legality_of_cannabis"}],"therapeutic_areas":["Pain","Neurology","Mental_Health"],"diseases":["Chronic Pain","Epilepsy","PTSD","Chemotherapy-Induced Nausea","Anxiety"],"status":"active"},{"id":"bcc97883-bee9-4a4e-8606-1e39a553342e","procedure_id":"proc-medical-cannabis","jurisdiction_id":"jur-us-or","procedure_name":"Medical Cannabis for Chronic Pain / Seizures / PTSD","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"MEDIUM","modality":"PHYTOCANNABINOID","estimated_cost_range_usd":"$80–250/month","price_usd":150.0,"access_pathway_details":"Oregon medical + adult-use licensed system; OLCC regulation.","eligibility_requirements":"21+ adult-use; medical card optional benefits.","provider_requirements":"Licensed retailers.","residency_travel_notes":"Visitors 21+ adult-use.","risk_notes":"Standard cannabis risks.","arbitrage_summary":"Oregon: licensed access, relatively low prices.","oversight_notes":"OLCC + OHA medical.","cost_notes":"Competitive pricing historically.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[{"title":"Legality of cannabis overview","url":"https://en.wikipedia.org/wiki/Legality_of_cannabis"}],"therapeutic_areas":["Pain","Neurology","Mental_Health"],"diseases":["Chronic Pain","Epilepsy","PTSD","Chemotherapy-Induced Nausea","Anxiety"],"status":"active"},{"id":"8ba12700-9088-4070-b0a5-ac137991344d","procedure_id":"proc-medical-cannabis","jurisdiction_id":"jur-de","procedure_name":"Medical Cannabis for Chronic Pain / Seizures / PTSD","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"PHYTOCANNABINOID","estimated_cost_range_usd":"€50–300/month medical","price_usd":180.0,"access_pathway_details":"Medical cannabis prescription since 2017; 2024 Cannabis Act eased medical prescribing (removed narcotic bureau hurdles) and legalized limited adult home grow/clubs.","eligibility_requirements":"Physician prescription for medical; adult rules for personal cultivation/clubs.","provider_requirements":"Pharmacies for medical cannabis.","residency_travel_notes":"Residents primary.","risk_notes":"Medical product quality high.","arbitrage_summary":"Germany: strong medical cannabis pathway; expanding adult rules.","oversight_notes":"BfArM/medical law + 2024 CanG.","cost_notes":"Insurance may cover severe cases.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[{"title":"Legality of cannabis overview","url":"https://en.wikipedia.org/wiki/Legality_of_cannabis"}],"therapeutic_areas":["Pain","Neurology","Mental_Health"],"diseases":["Chronic Pain","Epilepsy","PTSD","Chemotherapy-Induced Nausea","Anxiety"],"status":"active"},{"id":"dbb9ae8d-a019-467b-b01d-789cb2abf878","procedure_id":"proc-medical-cannabis","jurisdiction_id":"jur-uk","procedure_name":"Medical Cannabis for Chronic Pain / Seizures / PTSD","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"PHYTOCANNABINOID","estimated_cost_range_usd":"£150–400/month private","price_usd":280.0,"access_pathway_details":"Medical cannabis legal since Nov 2018 on specialist prescription; adult-use illegal. Private clinics drive most access.","eligibility_requirements":"Specialist Rx after other treatments considered.","provider_requirements":"Specialist clinicians; licensed pharmacies.","residency_travel_notes":"Residents; private clinics.","risk_notes":"Cost barrier.","arbitrage_summary":"UK: medical legal via specialists; NHS access limited.","oversight_notes":"MHRA + Home Office.","cost_notes":"NHS prescriptions rare; private dominant.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[{"title":"Legality of cannabis overview","url":"https://en.wikipedia.org/wiki/Legality_of_cannabis"}],"therapeutic_areas":["Pain","Neurology","Mental_Health"],"diseases":["Chronic Pain","Epilepsy","PTSD","Chemotherapy-Induced Nausea","Anxiety"],"status":"active"},{"id":"279dde91-810a-42c4-8463-11e1fbe896b2","procedure_id":"proc-medical-cannabis","jurisdiction_id":"jur-au","procedure_name":"Medical Cannabis for Chronic Pain / Seizures / PTSD","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"PHYTOCANNABINOID","estimated_cost_range_usd":"AUD $150–400/month","price_usd":220.0,"access_pathway_details":"Medicinal cannabis via SAS/Authorized Prescriber pathways; pharmacy supply of approved products.","eligibility_requirements":"Prescriber authorization; clinical justification.","provider_requirements":"Authorized prescribers + pharmacies.","residency_travel_notes":"Residents.","risk_notes":"Product regulated.","arbitrage_summary":"Australia: regulated medicinal cannabis access.","oversight_notes":"TGA.","cost_notes":"Mostly private pay.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[{"title":"Legality of cannabis overview","url":"https://en.wikipedia.org/wiki/Legality_of_cannabis"}],"therapeutic_areas":["Pain","Neurology","Mental_Health"],"diseases":["Chronic Pain","Epilepsy","PTSD","Chemotherapy-Induced Nausea","Anxiety"],"status":"active"},{"id":"f394e630-9035-461a-ad70-550a011ab203","procedure_id":"proc-medical-cannabis","jurisdiction_id":"jur-il","procedure_name":"Medical Cannabis for Chronic Pain / Seizures / PTSD","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"PHYTOCANNABINOID","estimated_cost_range_usd":"$100–300/month est.","price_usd":180.0,"access_pathway_details":"Long-standing medical cannabis program with IMCA licenses and pharmacy reform modernization.","eligibility_requirements":"Indications list / physician approval.","provider_requirements":"Licensed suppliers/pharmacies.","residency_travel_notes":"Residents.","risk_notes":"Regulated product.","arbitrage_summary":"Israel: mature medical cannabis program.","oversight_notes":"Ministry of Health.","cost_notes":"Program maturing toward pharmacy model.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[{"title":"Legality of cannabis overview","url":"https://en.wikipedia.org/wiki/Legality_of_cannabis"}],"therapeutic_areas":["Pain","Neurology","Mental_Health"],"diseases":["Chronic Pain","Epilepsy","PTSD","Chemotherapy-Induced Nausea","Anxiety"],"status":"active"},{"id":"cba2b687-1c83-4a29-a6ff-921ba28e410a","procedure_id":"proc-medical-cannabis","jurisdiction_id":"jur-th","procedure_name":"Medical Cannabis for Chronic Pain / Seizures / PTSD","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"MEDIUM","modality":"PHYTOCANNABINOID","estimated_cost_range_usd":"$80–250/month est.","price_usd":150.0,"access_pathway_details":"First Asian medical cannabis legalization; policy has oscillated on recreational vs medical focus — medical pathway remains but rules evolve.","eligibility_requirements":"Medical indications under Thai FDA rules; tourist access limited/changing.","provider_requirements":"Licensed clinics/hospitals.","residency_travel_notes":"Tourism rules unstable.","risk_notes":"Verify current possession rules before travel.","arbitrage_summary":"Thailand: medical pathway exists; rules in flux — verify before travel.","oversight_notes":"Thai FDA; active policy flux.","cost_notes":"Policy changes affect retail.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[{"title":"Legality of cannabis overview","url":"https://en.wikipedia.org/wiki/Legality_of_cannabis"}],"therapeutic_areas":["Pain","Neurology","Mental_Health"],"diseases":["Chronic Pain","Epilepsy","PTSD","Chemotherapy-Induced Nausea","Anxiety"],"status":"active"},{"id":"a19005cc-9f2c-494a-8a9c-b4d1249fe636","procedure_id":"proc-medical-cannabis","jurisdiction_id":"jur-nl","procedure_name":"Medical Cannabis for Chronic Pain / Seizures / PTSD","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"MEDIUM","modality":"PHYTOCANNABINOID","estimated_cost_range_usd":"€50–200/month medical","price_usd":120.0,"access_pathway_details":"Pharmacy medical cannabis (Bedrocan etc.) on prescription; coffee-shop cannabis is tolerated retail for adults, not medical system.","eligibility_requirements":"Physician Rx for pharmacy medical cannabis.","provider_requirements":"Pharmacies for medical; coffee shops for recreational tolerance.","residency_travel_notes":"Residents for medical Rx.","risk_notes":"Don't conflate coffee shop with medical.","arbitrage_summary":"Netherlands: true medical pharmacy pathway + separate tolerance retail.","oversight_notes":"OPM/IGJ medical; gedoogbeleid recreational.","cost_notes":"Medical quality standardized via pharmacy channel.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[{"title":"Legality of cannabis overview","url":"https://en.wikipedia.org/wiki/Legality_of_cannabis"}],"therapeutic_areas":["Pain","Neurology","Mental_Health"],"diseases":["Chronic Pain","Epilepsy","PTSD","Chemotherapy-Induced Nausea","Anxiety"],"status":"active"},{"id":"d7681191-be16-4fee-8105-3c9aa8547647","procedure_id":"proc-medical-cannabis","jurisdiction_id":"jur-es","procedure_name":"Medical Cannabis for Chronic Pain / Seizures / PTSD","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"MEDIUM","modality":"PHYTOCANNABINOID","estimated_cost_range_usd":"Variable","price_usd":null,"access_pathway_details":"Cannabinoid medicines limited; private consumption clubs in some regions; full medical program less developed than DE/UK.","eligibility_requirements":"Specialist situations; regional variation.","provider_requirements":"Limited pharmacy products; clubs informal.","residency_travel_notes":"Tourism to clubs carries legal nuance.","risk_notes":"Legal uncertainty outside clubs/private use.","arbitrage_summary":"Spain: private use/clubs culture; weaker formal medical program.","oversight_notes":"Regional enforcement varies.","cost_notes":"Clubs not equivalent to medical program.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[{"title":"Legality of cannabis overview","url":"https://en.wikipedia.org/wiki/Legality_of_cannabis"}],"therapeutic_areas":["Pain","Neurology","Mental_Health"],"diseases":["Chronic Pain","Epilepsy","PTSD","Chemotherapy-Induced Nausea","Anxiety"],"status":"active"},{"id":"3800a285-2566-4725-88d5-624b2d99d6d0","procedure_id":"proc-medical-cannabis","jurisdiction_id":"jur-sg","procedure_name":"Medical Cannabis for Chronic Pain / Seizures / PTSD","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PHYTOCANNABINOID","estimated_cost_range_usd":"N/A","price_usd":null,"access_pathway_details":"Strict drug laws; cannabis possession harshly penalized. No medical cannabis program for general patients.","eligibility_requirements":"None.","provider_requirements":"None.","residency_travel_notes":"Do not travel with cannabis products.","risk_notes":"Severe legal risk.","arbitrage_summary":"Singapore: prohibited — zero practical access.","oversight_notes":"Misuse of Drugs Act — severe penalties.","cost_notes":"N/A","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[{"title":"Legality of cannabis overview","url":"https://en.wikipedia.org/wiki/Legality_of_cannabis"}],"therapeutic_areas":["Pain","Neurology","Mental_Health"],"diseases":["Chronic Pain","Epilepsy","PTSD","Chemotherapy-Induced Nausea","Anxiety"],"status":"active"},{"id":"cba3ae88-c77b-45a6-be4e-947bb726fcc6","procedure_id":"proc-ozone-therapy","jurisdiction_id":"jur-us-federal","procedure_name":"Ozone Therapy for Infection / Inflammation / Wound Healing","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"N/A legitimate","price_usd":null,"access_pathway_details":"FDA has stated ozone is a toxic gas with no known useful medical application in specific therapy and has taken action against fraudulent ozone devices/claims.","eligibility_requirements":"No approved medical ozone therapy pathway.","provider_requirements":"Not legitimate standard care.","residency_travel_notes":"N/A","risk_notes":"Pulmonary toxicity, embolism risk with direct IV ozone.","arbitrage_summary":"US: FDA-hostile — not a legitimate approved therapy.","oversight_notes":"FDA enforcement against medical ozone claims.","cost_notes":"Cash clinics still advertise illicitly.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Infection","Wound_Healing","Orthopedic"],"diseases":["Chronic Wound","Chronic Infection","Osteoarthritis (off-label)"],"status":"active"},{"id":"6182b238-2860-44fd-b11f-ef2a63560065","procedure_id":"proc-ozone-therapy","jurisdiction_id":"jur-de","procedure_name":"Ozone Therapy for Infection / Inflammation / Wound Healing","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"MEDIUM","modality":"REPURPOSED","estimated_cost_range_usd":"€50–150/session","price_usd":100.0,"access_pathway_details":"Ozone therapy has a longer complementary-medicine tradition in German-speaking countries under physician practice; not equivalent to mainstream guideline care.","eligibility_requirements":"Physician discretion; not standard insurance benefit usually.","provider_requirements":"Some complementary MDs.","residency_travel_notes":"Domestic.","risk_notes":"Embolism risk if improperly administered; oxidative injury.","arbitrage_summary":"Germany: complementary physician practice exists; evidence remains contested.","oversight_notes":"Medical practice acts; evidence contested.","cost_notes":"Usually self-pay.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Infection","Wound_Healing","Orthopedic"],"diseases":["Chronic Wound","Chronic Infection","Osteoarthritis (off-label)"],"status":"active"},{"id":"3a6cca35-1e9f-401d-a637-45178f092761","procedure_id":"proc-ozone-therapy","jurisdiction_id":"jur-ch","procedure_name":"Ozone Therapy for Infection / Inflammation / Wound Healing","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"MEDIUM","modality":"REPURPOSED","estimated_cost_range_usd":"CHF 80–200/session","price_usd":140.0,"access_pathway_details":"Complementary/integrative clinics may offer ozone under medical practice rules.","eligibility_requirements":"Private pay.","provider_requirements":"Integrative physicians.","residency_travel_notes":"Residency not required for private care.","risk_notes":"Technique-dependent risks.","arbitrage_summary":"Switzerland: private complementary ozone available.","oversight_notes":"Cantonal medical oversight.","cost_notes":"Self-pay.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Infection","Wound_Healing","Orthopedic"],"diseases":["Chronic Wound","Chronic Infection","Osteoarthritis (off-label)"],"status":"active"},{"id":"6f595bed-4114-48a1-ad1c-23fd94556ea4","procedure_id":"proc-ozone-therapy","jurisdiction_id":"jur-mx","procedure_name":"Ozone Therapy for Infection / Inflammation / Wound Healing","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"$50–150/session","price_usd":90.0,"access_pathway_details":"Common in Mexican alternative clinics; quality and sterility highly variable.","eligibility_requirements":"Cash-pay.","provider_requirements":"Alternative clinics.","residency_travel_notes":"Tourism.","risk_notes":"High technique risk.","arbitrage_summary":"Mexico: widely offered alternative therapy — high risk of poor technique.","oversight_notes":"Minimal standards.","cost_notes":"Cheap packages.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Infection","Wound_Healing","Orthopedic"],"diseases":["Chronic Wound","Chronic Infection","Osteoarthritis (off-label)"],"status":"active"},{"id":"393f1261-fcdd-4278-86a3-3cba760174cd","procedure_id":"proc-ozone-therapy","jurisdiction_id":"jur-tu","procedure_name":"Ozone Therapy for Infection / Inflammation / Wound Healing","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"LOW","modality":"REPURPOSED","estimated_cost_range_usd":"$40–120/session","price_usd":70.0,"access_pathway_details":"Offered in some Turkish complementary/medical tourism packages.","eligibility_requirements":"Clinic packages.","provider_requirements":"Private clinics.","residency_travel_notes":"Istanbul medical tourism.","risk_notes":"Technique risk.","arbitrage_summary":"Turkey: available in tourism clinics; diligence required.","oversight_notes":"Variable.","cost_notes":"Tourism pricing.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Infection","Wound_Healing","Orthopedic"],"diseases":["Chronic Wound","Chronic Infection","Osteoarthritis (off-label)"],"status":"active"},{"id":"134757d2-f00c-41ce-8733-a94fdff5823a","procedure_id":"proc-stem-nsc","jurisdiction_id":"jur-us-federal","procedure_name":"Neural Stem Cell Therapy for Neurodegeneration / Spinal Cord Injury","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Trial may cover costs; offshore $50k–200k+","price_usd":null,"access_pathway_details":"No FDA-approved NSC therapy for Parkinson's/ALS/SCI routine care. Access via registered clinical trials only.","eligibility_requirements":"Trial inclusion criteria.","provider_requirements":"Academic trial sites.","residency_travel_notes":"Trial travel.","risk_notes":"Tumorigenicity, immune rejection, procedure risk.","arbitrage_summary":"US: clinical trials only for NSC therapies.","oversight_notes":"FDA IND framework.","cost_notes":"Offshore is not FDA-approved care.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Neurology","Spinal_Cord_Injury"],"diseases":["Parkinson's Disease","ALS","Spinal Cord Injury","Alzheimer's Disease"],"status":"active"},{"id":"7a1d6b67-6790-418b-9fa7-225b9b576aaf","procedure_id":"proc-stem-nsc","jurisdiction_id":"jur-jp","procedure_name":"Neural Stem Cell Therapy for Neurodegeneration / Spinal Cord Injury","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"$50,000–200,000+ if private regenerative protocols","price_usd":100000.0,"access_pathway_details":"Japan's regenerative medicine law enables conditional approval pathways and hospital-based regenerative offerings; true NSC products remain largely investigational/conditional.","eligibility_requirements":"Protocol eligibility under regenerative medicine act.","provider_requirements":"Licensed regenerative hospitals.","residency_travel_notes":"Medical travel possible to research hospitals.","risk_notes":"Experimental risks.","arbitrage_summary":"Japan: structured regenerative framework but NSC still largely experimental.","oversight_notes":"PMDA + regenerative act.","cost_notes":"Not standard insurance for experimental NSC.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Neurology","Spinal_Cord_Injury"],"diseases":["Parkinson's Disease","ALS","Spinal Cord Injury","Alzheimer's Disease"],"status":"active"},{"id":"d5d8a57b-057d-4215-bdd0-92802a5e0ef5","procedure_id":"proc-stem-nsc","jurisdiction_id":"jur-mx","procedure_name":"Neural Stem Cell Therapy for Neurodegeneration / Spinal Cord Injury","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"STEM_CELL","estimated_cost_range_usd":"$15,000–80,000 marketed","price_usd":40000.0,"access_pathway_details":"Some clinics market 'neural stem cell' packages with weak characterization — high scam risk.","eligibility_requirements":"Cash-pay nearly open.","provider_requirements":"Private clinics.","residency_travel_notes":"Tourism.","risk_notes":"Very high risk of unproven product.","arbitrage_summary":"Mexico: marketed NSC tourism is high-risk — prefer trials.","oversight_notes":"Minimal verification of cell identity.","cost_notes":"Marketing claims often unsupported.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Neurology","Spinal_Cord_Injury"],"diseases":["Parkinson's Disease","ALS","Spinal Cord Injury","Alzheimer's Disease"],"status":"active"},{"id":"73c6a534-510a-4862-8877-48587ab9fd7f","procedure_id":"proc-stem-nsc","jurisdiction_id":"jur-kr","procedure_name":"Neural Stem Cell Therapy for Neurodegeneration / Spinal Cord Injury","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Trial or high private cost","price_usd":null,"access_pathway_details":"Advanced regenerative research; patient access mainly via trials/hospital protocols under MFDS.","eligibility_requirements":"Protocol eligibility.","provider_requirements":"Research hospitals.","residency_travel_notes":"Seoul research hospitals.","risk_notes":"Experimental risks.","arbitrage_summary":"Korea: research/trial pathway, not routine NSC therapy.","oversight_notes":"MFDS.","cost_notes":"Not routine care.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Neurology","Spinal_Cord_Injury"],"diseases":["Parkinson's Disease","ALS","Spinal Cord Injury","Alzheimer's Disease"],"status":"active"},{"id":"3e22167e-3208-4183-90df-901c7a42ce62","procedure_id":"proc-stem-nsc","jurisdiction_id":"jur-hn-prospera","procedure_name":"Neural Stem Cell Therapy for Neurodegeneration / Spinal Cord Injury","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"UNREGULATED_PERMITTED","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"LOW","modality":"STEM_CELL","estimated_cost_range_usd":"$50,000–150,000 est.","price_usd":80000.0,"access_pathway_details":"ZEDE could host experimental neural regenerative protocols under informed consent.","eligibility_requirements":"Consent + pay.","provider_requirements":"ZEDE clinics.","residency_travel_notes":"Roatán.","risk_notes":"Extreme uncertainty.","arbitrage_summary":"Próspera: theoretical experimental access only — extreme caution.","oversight_notes":"Minimal external review.","cost_notes":"Experimental pricing.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Neurology","Spinal_Cord_Injury"],"diseases":["Parkinson's Disease","ALS","Spinal Cord Injury","Alzheimer's Disease"],"status":"active"},{"id":"e9351de1-035b-44f1-bcd9-265975e8a50a","procedure_id":"proc-proton-therapy","jurisdiction_id":"jur-us-federal","procedure_name":"Proton Beam Radiotherapy for Cancer","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"$50,000–300,000+/course","price_usd":120000.0,"access_pathway_details":"FDA-cleared proton systems; ~40+ US centers. Insurance coverage indication-dependent (pediatric, certain CNS/base-of-skull favored).","eligibility_requirements":"Oncology referral; insurance prior auth often required.","provider_requirements":"PTCOG-listed proton centers.","residency_travel_notes":"Multi-week stay near center.","risk_notes":"Radiation toxicities lower for some OARs but not risk-free.","arbitrage_summary":"US: approved, limited centers, insurance-gated.","oversight_notes":"FDA devices + ASTRO/payer policies.","cost_notes":"Insured when authorized; cash extreme.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[{"title":"PTCOG particle therapy facilities","url":"https://www.ptcog.site"}],"therapeutic_areas":["Oncology"],"diseases":["Pediatric Cancer","CNS Tumors","Prostate Cancer","Base-of-Skull Tumors"],"status":"active"},{"id":"c1ee35a8-db3f-4a80-95be-868b3cfb7079","procedure_id":"proc-proton-therapy","jurisdiction_id":"jur-de","procedure_name":"Proton Beam Radiotherapy for Cancer","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Public cover when indicated; private otherwise high","price_usd":100000.0,"access_pathway_details":"Multiple German proton/particle centers; statutory insurance for accepted indications.","eligibility_requirements":"Multidisciplinary tumor board.","provider_requirements":"Particle therapy centers.","residency_travel_notes":"EU patients via referral.","risk_notes":"Standard RT risks reduced for some sites.","arbitrage_summary":"Germany: strong European particle-therapy capacity.","oversight_notes":"G-BA/indication rules.","cost_notes":"Indication list matters.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[{"title":"PTCOG particle therapy facilities","url":"https://www.ptcog.site"}],"therapeutic_areas":["Oncology"],"diseases":["Pediatric Cancer","CNS Tumors","Prostate Cancer","Base-of-Skull Tumors"],"status":"active"},{"id":"2d204055-2360-42db-bf8e-b0b2d09b6d60","procedure_id":"proc-proton-therapy","jurisdiction_id":"jur-jp","procedure_name":"Proton Beam Radiotherapy for Cancer","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Insurance for approved indications; private higher","price_usd":90000.0,"access_pathway_details":"Japan among world leaders in particle therapy center density; national insurance for selected indications.","eligibility_requirements":"Oncology referral; indication criteria.","provider_requirements":"Hospital proton/carbon centers.","residency_travel_notes":"Domestic/medical travel.","risk_notes":"Standard.","arbitrage_summary":"Japan: excellent particle therapy infrastructure.","oversight_notes":"MHLW.","cost_notes":"High technology access.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[{"title":"PTCOG particle therapy facilities","url":"https://www.ptcog.site"}],"therapeutic_areas":["Oncology"],"diseases":["Pediatric Cancer","CNS Tumors","Prostate Cancer","Base-of-Skull Tumors"],"status":"active"},{"id":"b604383e-bf95-45ae-a211-f29ebbf59fd6","procedure_id":"proc-proton-therapy","jurisdiction_id":"jur-kr","procedure_name":"Proton Beam Radiotherapy for Cancer","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Insurance-eligible cases lower OOP","price_usd":85000.0,"access_pathway_details":"Korean proton centers (e.g. NCC, major hospitals) with national insurance for selected cancers.","eligibility_requirements":"Oncology referral.","provider_requirements":"Hospital proton facilities.","residency_travel_notes":"Seoul hubs.","risk_notes":"Standard.","arbitrage_summary":"Korea: approved proton capacity with insurance pathways.","oversight_notes":"MFDS/HIRA.","cost_notes":"Medical tourism for some indications.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[{"title":"PTCOG particle therapy facilities","url":"https://www.ptcog.site"}],"therapeutic_areas":["Oncology"],"diseases":["Pediatric Cancer","CNS Tumors","Prostate Cancer","Base-of-Skull Tumors"],"status":"active"},{"id":"891d964c-66e9-4415-b1fa-0e0a7b7d94cb","procedure_id":"proc-proton-therapy","jurisdiction_id":"jur-uk","procedure_name":"Proton Beam Radiotherapy for Cancer","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"NHS covered when selected; private very high","price_usd":0.0,"access_pathway_details":"NHS proton centers (e.g. Christie, UCLH) for approved indications especially pediatric; private options limited.","eligibility_requirements":"NHS national MDT selection.","provider_requirements":"NHS proton centers.","residency_travel_notes":"UK residents primary.","risk_notes":"Standard.","arbitrage_summary":"UK: NHS proton for selected cases — capacity-limited.","oversight_notes":"NICE/NHSE commissioning.","cost_notes":"Capacity constrained.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[{"title":"PTCOG particle therapy facilities","url":"https://www.ptcog.site"}],"therapeutic_areas":["Oncology"],"diseases":["Pediatric Cancer","CNS Tumors","Prostate Cancer","Base-of-Skull Tumors"],"status":"active"},{"id":"bbff6b24-bf79-4c7f-95bb-9cfc316cbf33","procedure_id":"proc-proton-therapy","jurisdiction_id":"jur-ch","procedure_name":"Proton Beam Radiotherapy for Cancer","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"High if private/out-of-network","price_usd":110000.0,"access_pathway_details":"Paul Scherrer Institute and other Swiss particle expertise; insurance for accepted indications.","eligibility_requirements":"Specialist referral.","provider_requirements":"PSI/hospital centers.","residency_travel_notes":"Some international referrals.","risk_notes":"Standard.","arbitrage_summary":"Switzerland: high-quality particle therapy access.","oversight_notes":"Swissmedic/cantonal.","cost_notes":"Premium system.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[{"title":"PTCOG particle therapy facilities","url":"https://www.ptcog.site"}],"therapeutic_areas":["Oncology"],"diseases":["Pediatric Cancer","CNS Tumors","Prostate Cancer","Base-of-Skull Tumors"],"status":"active"},{"id":"cdb00d0f-2184-48a6-8d1c-d151b224b0f4","procedure_id":"proc-senolytics","jurisdiction_id":"jur-us-federal","procedure_name":"Senolytic Therapy (Dasatinib + Quercetin) for Cellular Aging","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"MEDIUM","modality":"REPURPOSED","estimated_cost_range_usd":"$50–150/course drug cost","price_usd":100.0,"access_pathway_details":"Dasatinib FDA-approved for CML; quercetin OTC. Combined intermittent 'D+Q' senolytic protocols are off-label longevity clinic practice; not an approved aging indication.","eligibility_requirements":"Physician screening; avoid active infection/surgery windows; cancer history caution.","provider_requirements":"Longevity/functional clinicians; oncology awareness for dasatinib.","residency_travel_notes":"Domestic telehealth longevity platforms.","risk_notes":"Cytopenias, bleeding, infection risk from dasatinib; drug interactions.","arbitrage_summary":"US: off-label D+Q via longevity clinics — experimental intent.","oversight_notes":"Off-label prescribing of approved drug + supplement.","cost_notes":"Clinic fees extra $200–500.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Frailty","Age-Related Functional Decline","Cellular Senescence"],"status":"active"},{"id":"ee778a09-8acb-4fb9-b407-db592bf66f81","procedure_id":"proc-senolytics","jurisdiction_id":"jur-uk","procedure_name":"Senolytic Therapy (Dasatinib + Quercetin) for Cellular Aging","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"MEDIUM","modality":"REPURPOSED","estimated_cost_range_usd":"$80–200/course est.","price_usd":120.0,"access_pathway_details":"Dasatinib licensed for oncology; private off-label senolytic use uncommon/not NHS.","eligibility_requirements":"Private specialist only if at all.","provider_requirements":"Private clinicians.","residency_travel_notes":"Domestic private.","risk_notes":"Oncology-drug risks.","arbitrage_summary":"UK: possible private off-label only; not established pathway.","oversight_notes":"MHRA licensed dasatinib; off-label private.","cost_notes":"Not standard care.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Frailty","Age-Related Functional Decline","Cellular Senescence"],"status":"active"},{"id":"96904c14-9071-4d63-b802-57ccbe6eaa1c","procedure_id":"proc-senolytics","jurisdiction_id":"jur-ca","procedure_name":"Senolytic Therapy (Dasatinib + Quercetin) for Cellular Aging","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"MEDIUM","modality":"REPURPOSED","estimated_cost_range_usd":"CAD $50–180/course","price_usd":100.0,"access_pathway_details":"Dasatinib available; off-label longevity D+Q via private clinics/telehealth similar to US.","eligibility_requirements":"Physician screening.","provider_requirements":"Private longevity clinicians.","residency_travel_notes":"Domestic.","risk_notes":"Dasatinib risks.","arbitrage_summary":"Canada: off-label private longevity use possible.","oversight_notes":"Provincial practice standards.","cost_notes":"Clinic fees extra.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Frailty","Age-Related Functional Decline","Cellular Senescence"],"status":"active"},{"id":"bf70490f-e508-4d13-8a27-f7f3b89087be","procedure_id":"proc-senolytics","jurisdiction_id":"jur-mx","procedure_name":"Senolytic Therapy (Dasatinib + Quercetin) for Cellular Aging","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"LOW","modality":"REPURPOSED","estimated_cost_range_usd":"$100–400/package","price_usd":200.0,"access_pathway_details":"Longevity clinics may offer senolytic packages including dasatinib combinations.","eligibility_requirements":"Cash-pay screening variable.","provider_requirements":"Private clinics.","residency_travel_notes":"Tourism.","risk_notes":"Insufficient labs/follow-up risk.","arbitrage_summary":"Mexico: cash longevity packages — ensure lab monitoring.","oversight_notes":"Variable monitoring.","cost_notes":"Monitoring may be inadequate.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Frailty","Age-Related Functional Decline","Cellular Senescence"],"status":"active"},{"id":"d36e34b7-bd27-495a-b6f8-fc900ee013b1","procedure_id":"proc-chelation","jurisdiction_id":"jur-us-federal","procedure_name":"IV Chelation Therapy for Heavy Metal Detoxification","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"MEDIUM","modality":"REPURPOSED","estimated_cost_range_usd":"$100–300/infusion; courses $2k–10k+","price_usd":200.0,"access_pathway_details":"EDTA/others FDA-approved for heavy metal poisoning. Off-label 'detox'/CVD chelation is controversial; TACT trial mixed; cardiology societies caution.","eligibility_requirements":"Documented metal toxicity for labeled use; off-label requires informed consent.","provider_requirements":"Medical toxicology for labeled; some integrative clinics off-label.","residency_travel_notes":"Domestic.","risk_notes":"Hypocalcemia, renal injury, arrhythmia — must monitor electrolytes.","arbitrage_summary":"US: approved for metal poisoning; off-label detox controversial.","oversight_notes":"FDA labels vs off-label practice.","cost_notes":"Insurance for labeled toxicity only.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Detoxification","Anti_Aging"],"diseases":["Lead Poisoning","Heavy Metal Toxicity","Iron Overload"],"status":"active"},{"id":"fe9a791a-f0da-4e01-a86d-3bf9ec89834c","procedure_id":"proc-chelation","jurisdiction_id":"jur-mx","procedure_name":"IV Chelation Therapy for Heavy Metal Detoxification","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"$80–200/infusion","price_usd":120.0,"access_pathway_details":"Alternative clinics market chelation for many unproven indications.","eligibility_requirements":"Cash-pay; indication gating weak.","provider_requirements":"Alternative clinics.","residency_travel_notes":"Tourism.","risk_notes":"Electrolyte catastrophe if poorly monitored.","arbitrage_summary":"Mexico: widely marketed — high risk if not medically supervised for true toxicity.","oversight_notes":"Minimal.","cost_notes":"Cheap packages.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Detoxification","Anti_Aging"],"diseases":["Lead Poisoning","Heavy Metal Toxicity","Iron Overload"],"status":"active"},{"id":"34f675ca-70b9-4355-bc85-4ee734297e9b","procedure_id":"proc-chelation","jurisdiction_id":"jur-de","procedure_name":"IV Chelation Therapy for Heavy Metal Detoxification","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"€100–250/session when used","price_usd":180.0,"access_pathway_details":"Chelators available for documented metal intoxication in medical settings; off-label CVD use less mainstream than US integrative clinics.","eligibility_requirements":"Laboratory-confirmed toxicity preferred.","provider_requirements":"Hospitals/toxicology.","residency_travel_notes":"Domestic.","risk_notes":"Requires monitoring.","arbitrage_summary":"Germany: legitimate toxicology use; off-label less promoted.","oversight_notes":"High medical standards.","cost_notes":"Insurance for true poisoning.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Detoxification","Anti_Aging"],"diseases":["Lead Poisoning","Heavy Metal Toxicity","Iron Overload"],"status":"active"},{"id":"3aa29e3e-7e73-40fa-89a7-69111ce79863","procedure_id":"proc-chelation","jurisdiction_id":"jur-th","procedure_name":"IV Chelation Therapy for Heavy Metal Detoxification","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"LOW","modality":"REPURPOSED","estimated_cost_range_usd":"$80–220/session","price_usd":140.0,"access_pathway_details":"Wellness hospitals may offer chelation packages.","eligibility_requirements":"Package screening.","provider_requirements":"Private hospitals.","residency_travel_notes":"Bangkok.","risk_notes":"Monitoring quality varies.","arbitrage_summary":"Thailand: available in wellness packages — insist on labs.","oversight_notes":"Variable indication discipline.","cost_notes":"Tourism packages.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Detoxification","Anti_Aging"],"diseases":["Lead Poisoning","Heavy Metal Toxicity","Iron Overload"],"status":"active"},{"id":"9ddc7e17-1931-474f-baeb-a25c18be2a44","procedure_id":"proc-metformin-longevity","jurisdiction_id":"jur-us-federal","procedure_name":"Metformin for Longevity / Aging Prevention","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"MEDIUM","modality":"REPURPOSED","estimated_cost_range_usd":"$10–30/month generic","price_usd":20.0,"access_pathway_details":"Metformin FDA-approved for T2D; longevity/off-label metabolic use common via primary care and longevity clinics. TAME trial designed to test aging outcomes.","eligibility_requirements":"eGFR checks; B12 monitoring; not for advanced CKD.","provider_requirements":"Any licensed prescriber.","residency_travel_notes":"Domestic/telehealth.","risk_notes":"GI effects; rare lactic acidosis; hold for contrast procedures.","arbitrage_summary":"US: easiest cheap off-label longevity small molecule.","oversight_notes":"Standard off-label of approved drug.","cost_notes":"Extremely cheap; sometimes insurance only for diabetes.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[{"title":"TAME metformin aging trial","url":"https://clinicaltrials.gov/ct2/show/NCT03294824"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Type 2 Diabetes (labeled)","Age-Related Functional Decline","Prediabetes"],"status":"active"},{"id":"69e5573e-94c4-4c2c-af22-1590830a75c3","procedure_id":"proc-metformin-longevity","jurisdiction_id":"jur-uk","procedure_name":"Metformin for Longevity / Aging Prevention","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"MEDIUM","modality":"REPURPOSED","estimated_cost_range_usd":"$10–25/month","price_usd":18.0,"access_pathway_details":"Licensed for diabetes; private off-label longevity prescribing possible; NHS primarily diabetes.","eligibility_requirements":"Private GP/specialist for non-diabetes use.","provider_requirements":"GPs; private clinics.","residency_travel_notes":"Domestic.","risk_notes":"Standard metformin risks.","arbitrage_summary":"UK: drug available; longevity use mostly private.","oversight_notes":"MHRA licensed drug.","cost_notes":"NHS for diabetes; private for longevity intent.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[{"title":"TAME metformin aging trial","url":"https://clinicaltrials.gov/ct2/show/NCT03294824"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Type 2 Diabetes (labeled)","Age-Related Functional Decline","Prediabetes"],"status":"active"},{"id":"9d5508de-5176-4804-a371-8b9c2915f00f","procedure_id":"proc-metformin-longevity","jurisdiction_id":"jur-ca","procedure_name":"Metformin for Longevity / Aging Prevention","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"MEDIUM","modality":"REPURPOSED","estimated_cost_range_usd":"CAD $10–25/month","price_usd":15.0,"access_pathway_details":"Widely prescribed diabetes drug; off-label longevity via physicians.","eligibility_requirements":"Renal function screening.","provider_requirements":"Family physicians.","residency_travel_notes":"Domestic.","risk_notes":"Standard risks.","arbitrage_summary":"Canada: easy access, cheap generic.","oversight_notes":"Provincial formularies for diabetes.","cost_notes":"Covered for diabetes; OOP possible off-label.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[{"title":"TAME metformin aging trial","url":"https://clinicaltrials.gov/ct2/show/NCT03294824"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Type 2 Diabetes (labeled)","Age-Related Functional Decline","Prediabetes"],"status":"active"},{"id":"d7d7b436-010a-45cb-98e8-5e9be75837ee","procedure_id":"proc-metformin-longevity","jurisdiction_id":"jur-de","procedure_name":"Metformin for Longevity / Aging Prevention","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"€5–20/month","price_usd":12.0,"access_pathway_details":"Metformin standard diabetes therapy; off-label preventive use is physician discretion, less consumer-longevity-marketed than US.","eligibility_requirements":"Physician assessment; renal function.","provider_requirements":"Hausarzt/specialist.","residency_travel_notes":"Domestic.","risk_notes":"Standard risks.","arbitrage_summary":"Germany: ubiquitous diabetes drug; off-label prevention possible.","oversight_notes":"AMG; high standards.","cost_notes":"Very cheap generic.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[{"title":"TAME metformin aging trial","url":"https://clinicaltrials.gov/ct2/show/NCT03294824"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Type 2 Diabetes (labeled)","Age-Related Functional Decline","Prediabetes"],"status":"active"},{"id":"144157d2-13d7-4977-bc33-99a5837da496","procedure_id":"proc-metformin-longevity","jurisdiction_id":"jur-au","procedure_name":"Metformin for Longevity / Aging Prevention","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"MEDIUM","modality":"REPURPOSED","estimated_cost_range_usd":"AUD $10–25/month","price_usd":15.0,"access_pathway_details":"PBS-listed for diabetes; private off-label longevity scripts available.","eligibility_requirements":"Prescriber assessment.","provider_requirements":"GPs.","residency_travel_notes":"Domestic.","risk_notes":"Standard risks.","arbitrage_summary":"Australia: cheap access via GP.","oversight_notes":"TGA/PBS.","cost_notes":"PBS for diabetes indications.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[{"title":"TAME metformin aging trial","url":"https://clinicaltrials.gov/ct2/show/NCT03294824"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Type 2 Diabetes (labeled)","Age-Related Functional Decline","Prediabetes"],"status":"active"},{"id":"0a784a89-8884-487e-a369-78fd892cea9d","procedure_id":"proc-metformin-longevity","jurisdiction_id":"jur-in","procedure_name":"Metformin for Longevity / Aging Prevention","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"APPROVED_OFF_LABEL","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"MEDIUM","modality":"REPURPOSED","estimated_cost_range_usd":"$3–10/month","price_usd":5.0,"access_pathway_details":"Metformin widely manufactured/available for diabetes; off-label easy and very low cost.","eligibility_requirements":"Basic clinical screening recommended.","provider_requirements":"Any physician; pharmacies.","residency_travel_notes":"Easy visitor pharmacy access with Rx norms varying.","risk_notes":"Quality: prefer known manufacturers.","arbitrage_summary":"India: ultra-low-cost metformin access.","oversight_notes":"CDSCO generics market.","cost_notes":"Among world's lowest prices.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[{"title":"TAME metformin aging trial","url":"https://clinicaltrials.gov/ct2/show/NCT03294824"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Type 2 Diabetes (labeled)","Age-Related Functional Decline","Prediabetes"],"status":"active"},{"id":"f3a8c1e8-6707-4677-a195-517601fe51ca","procedure_id":"proc-metformin-longevity","jurisdiction_id":"jur-mx","procedure_name":"Metformin for Longevity / Aging Prevention","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"APPROVED_OFF_LABEL","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"MEDIUM","modality":"REPURPOSED","estimated_cost_range_usd":"$5–15/month","price_usd":8.0,"access_pathway_details":"Metformin widely available for diabetes; pharmacies accessible; off-label longevity use possible.","eligibility_requirements":"Basic screening advised.","provider_requirements":"Physicians; farmacias.","residency_travel_notes":"Border pharmacy tourism common.","risk_notes":"Prefer reputable pharmacies.","arbitrage_summary":"Mexico: cheap generic access.","oversight_notes":"COFEPRIS generics.","cost_notes":"Very cheap.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[{"title":"TAME metformin aging trial","url":"https://clinicaltrials.gov/ct2/show/NCT03294824"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Type 2 Diabetes (labeled)","Age-Related Functional Decline","Prediabetes"],"status":"active"},{"id":"8bf6db5a-1ab0-46e0-be8f-27720ac534bd","procedure_id":"proc-tms-depression","jurisdiction_id":"jur-us-federal","procedure_name":"Transcranial Magnetic Stimulation (TMS) for Depression","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"$6k–15k/course","price_usd":10000.0,"access_pathway_details":"FDA-cleared TMS devices for MDD/TRD; widely available outpatient centers; often insurance-covered when criteria met.","eligibility_requirements":"Failed antidepressant trials per payer policy; psychiatric evaluation.","provider_requirements":"Psychiatrists / TMS-certified clinics.","residency_travel_notes":"Nationwide outpatient.","risk_notes":"Seizure rare; scalp discomfort; hearing protection needed.","arbitrage_summary":"US: mature covered neuromodulation pathway for TRD.","oversight_notes":"FDA device clearance + payer policies.","cost_notes":"Often insured after prior auth.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"c2784ad7-97f5-4569-b62d-20457a57c64d","procedure_id":"proc-tms-depression","jurisdiction_id":"jur-de","procedure_name":"Transcranial Magnetic Stimulation (TMS) for Depression","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"€5k–12k if private; insured when approved","price_usd":8000.0,"access_pathway_details":"rTMS available in German psychiatry; statutory insurance for selected TRD protocols at qualified centers.","eligibility_requirements":"Specialist referral; failed meds.","provider_requirements":"Krankenhaus/outpatient neurostimulation units.","residency_travel_notes":"Domestic EU.","risk_notes":"Standard TMS risks.","arbitrage_summary":"Germany: regulated clinical TMS access.","oversight_notes":"G-BA/device rules.","cost_notes":"Indication review for public cover.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"6548a178-8a97-4e5f-8eb1-df55c46d9847","procedure_id":"proc-tms-depression","jurisdiction_id":"jur-uk","procedure_name":"Transcranial Magnetic Stimulation (TMS) for Depression","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"£6k–12k private","price_usd":9000.0,"access_pathway_details":"NICE-supported rTMS for depression in selected pathways; NHS capacity limited; private sector common.","eligibility_requirements":"Specialist assessment.","provider_requirements":"NHS/private neurostimulation clinics.","residency_travel_notes":"Domestic.","risk_notes":"Standard risks.","arbitrage_summary":"UK: approved technology; private often faster than NHS.","oversight_notes":"NICE + CQC.","cost_notes":"NHS waiting lists variable.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"cbd840dc-0abe-47cd-bb6b-3a1164faea5c","procedure_id":"proc-tms-depression","jurisdiction_id":"jur-au","procedure_name":"Transcranial Magnetic Stimulation (TMS) for Depression","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"AUD $6k–12k","price_usd":7000.0,"access_pathway_details":"TMS widely practiced; Medicare items for eligible TRD in Australia.","eligibility_requirements":"Psychiatrist referral; Medicare criteria.","provider_requirements":"Private psychiatry clinics.","residency_travel_notes":"Domestic.","risk_notes":"Standard risks.","arbitrage_summary":"Australia: funded pathway for eligible TRD.","oversight_notes":"TGA devices + Medicare.","cost_notes":"Rebates reduce OOP when eligible.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"34564b20-0805-4c67-8cd8-0f8b01f85d5d","procedure_id":"proc-tms-depression","jurisdiction_id":"jur-ca","procedure_name":"Transcranial Magnetic Stimulation (TMS) for Depression","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"CAD $5k–12k","price_usd":7500.0,"access_pathway_details":"rTMS available provincially; coverage varies by province and indication.","eligibility_requirements":"Specialist referral.","provider_requirements":"Hospital/clinic TMS programs.","residency_travel_notes":"Domestic.","risk_notes":"Standard risks.","arbitrage_summary":"Canada: available; funding patchwork by province.","oversight_notes":"Health Canada devices.","cost_notes":"Provincial cover uneven.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"dd6dad71-0c47-462f-8ee6-af4dd45b4e44","procedure_id":"proc-dbs-parkinson","jurisdiction_id":"jur-us-federal","procedure_name":"Deep Brain Stimulation (DBS) for Parkinson's Disease","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"$50k–100k+","price_usd":75000.0,"access_pathway_details":"FDA-approved DBS systems for PD; major academic centers; typically insured when criteria met.","eligibility_requirements":"Advanced PD motor complications; multidisciplinary screening.","provider_requirements":"Functional neurosurgery centers.","residency_travel_notes":"Center-of-excellence travel common.","risk_notes":"Surgical/hardware infection; stimulation side effects.","arbitrage_summary":"US: standard advanced-PD option at high-volume centers.","oversight_notes":"FDA + hospital credentialing.","cost_notes":"Insurance common for labeled PD.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Parkinson's Disease","Essential Tremor (selected targets)"],"status":"active"},{"id":"45cc57e0-6ba1-454f-82c9-5574ffdb9c03","procedure_id":"proc-dbs-parkinson","jurisdiction_id":"jur-de","procedure_name":"Deep Brain Stimulation (DBS) for Parkinson's Disease","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Public cover when indicated","price_usd":60000.0,"access_pathway_details":"DBS standard in German neurosurgery for PD; statutory insurance when indicated.","eligibility_requirements":"Movement-disorder board.","provider_requirements":"University neurosurgery.","residency_travel_notes":"EU referral possible.","risk_notes":"Surgical risks.","arbitrage_summary":"Germany: strong public DBS access for PD.","oversight_notes":"G-BA.","cost_notes":"High capacity in EU terms.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Parkinson's Disease","Essential Tremor (selected targets)"],"status":"active"},{"id":"953201c7-884f-4258-946b-f1961c23e24a","procedure_id":"proc-dbs-parkinson","jurisdiction_id":"jur-jp","procedure_name":"Deep Brain Stimulation (DBS) for Parkinson's Disease","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Insurance-eligible cases","price_usd":55000.0,"access_pathway_details":"DBS established under Japanese insurance for selected PD patients.","eligibility_requirements":"Specialist criteria.","provider_requirements":"Neurosurgery hospitals.","residency_travel_notes":"Domestic.","risk_notes":"Surgical risks.","arbitrage_summary":"Japan: regulated insured DBS pathway.","oversight_notes":"MHLW.","cost_notes":"Domestic primarily.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Parkinson's Disease","Essential Tremor (selected targets)"],"status":"active"},{"id":"e9a4aad6-885d-43af-89e4-41a2f505cc35","procedure_id":"proc-dbs-parkinson","jurisdiction_id":"jur-in","procedure_name":"Deep Brain Stimulation (DBS) for Parkinson's Disease","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"FULLY_APPROVED","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MEDIUM","modality":"REPURPOSED","estimated_cost_range_usd":"$20k–40k cash packages","price_usd":28000.0,"access_pathway_details":"DBS offered at major Indian neurosurgery centers at lower cash prices; quality varies by hospital.","eligibility_requirements":"Clinical PD criteria; ability to pay/travel.","provider_requirements":"Tertiary private hospitals.","residency_travel_notes":"Medical tourism hubs.","risk_notes":"Verify surgeon volume.","arbitrage_summary":"India: cost arbitrage for DBS at selected centers.","oversight_notes":"CDSCO devices + hospital standards.","cost_notes":"Significant savings vs US if reputable center.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Parkinson's Disease","Essential Tremor (selected targets)"],"status":"active"},{"id":"951d8647-be6a-4593-9f82-6304d2371bdf","procedure_id":"proc-fus-tremor","jurisdiction_id":"jur-us-federal","procedure_name":"MR-Guided Focused Ultrasound for Essential Tremor / PD Tremor","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"$30k–60k","price_usd":45000.0,"access_pathway_details":"FDA-approved MRgFUS for essential tremor and PD tremor at equipped centers.","eligibility_requirements":"Medication-refractory tremor; skull density ratio screening.","provider_requirements":"Focused ultrasound centers.","residency_travel_notes":"Limited center map.","risk_notes":"Sensory/gait side effects; unilateral first.","arbitrage_summary":"US: approved incisionless option; center-limited.","oversight_notes":"FDA device + specialty centers.","cost_notes":"Insurance improving but variable.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Essential Tremor","Parkinson's Disease Tremor"],"status":"active"},{"id":"c883e50d-7123-4e8d-a5a6-095dba0e75bf","procedure_id":"proc-fus-tremor","jurisdiction_id":"jur-jp","procedure_name":"MR-Guided Focused Ultrasound for Essential Tremor / PD Tremor","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Insurance/private mix","price_usd":40000.0,"access_pathway_details":"Japan early adopter of clinical focused ultrasound for tremor.","eligibility_requirements":"Specialist selection.","provider_requirements":"Equipped hospitals.","residency_travel_notes":"Domestic/medical travel.","risk_notes":"Standard FUS risks.","arbitrage_summary":"Japan: strong FUS clinical availability.","oversight_notes":"PMDA.","cost_notes":"High-tech access.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Essential Tremor","Parkinson's Disease Tremor"],"status":"active"},{"id":"a5b018c1-7a32-460c-8dd5-f5657a03e429","procedure_id":"proc-fus-tremor","jurisdiction_id":"jur-il","procedure_name":"MR-Guided Focused Ultrasound for Essential Tremor / PD Tremor","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"$25k–50k est.","price_usd":35000.0,"access_pathway_details":"Israeli centers historically prominent in MRgFUS clinical development/care.","eligibility_requirements":"Specialist referral.","provider_requirements":"Hospital programs.","residency_travel_notes":"Tel Aviv/Haifa hubs.","risk_notes":"Standard risks.","arbitrage_summary":"Israel: notable FUS clinical experience.","oversight_notes":"Ministry of Health.","cost_notes":"Some medical travel.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Essential Tremor","Parkinson's Disease Tremor"],"status":"active"},{"id":"9dacd6b8-216c-4306-8149-e5735962931d","procedure_id":"proc-til-melanoma","jurisdiction_id":"jur-us-federal","procedure_name":"Tumor-Infiltrating Lymphocyte (TIL) Therapy for Melanoma","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"$500k+ total episode","price_usd":515000.0,"access_pathway_details":"Lifileucel (Amtagvi) FDA-approved for advanced melanoma after anti-PD-1; specialized treatment centers.","eligibility_requirements":"Label criteria; adequate organ function; resectable tumor for TIL harvest.","provider_requirements":"Authorized treatment centers.","residency_travel_notes":"Must treat at authorized US centers.","risk_notes":"Lymphodepletion toxicity; ICU-level risks.","arbitrage_summary":"US: first approved TIL product pathway.","oversight_notes":"FDA REMS-like center model.","cost_notes":"Insurance evolving for labeled use.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Oncology","Melanoma"],"diseases":["Advanced Melanoma","Metastatic Melanoma"],"status":"active"},{"id":"f4bde23d-19a2-4a8b-87f8-f07d812340cf","procedure_id":"proc-til-melanoma","jurisdiction_id":"jur-de","procedure_name":"Tumor-Infiltrating Lymphocyte (TIL) Therapy for Melanoma","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Trial pathway","price_usd":null,"access_pathway_details":"TIL programs historically academic/trial in Europe; commercial availability lags US approval timelines.","eligibility_requirements":"Trial criteria.","provider_requirements":"Academic oncology centers.","residency_travel_notes":"EU academic travel.","risk_notes":"Trial toxicities.","arbitrage_summary":"Germany/EU: primarily trial/academic until broader authorization.","oversight_notes":"EMA/national trial oversight.","cost_notes":"Watch EMA commercial status.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Oncology","Melanoma"],"diseases":["Advanced Melanoma","Metastatic Melanoma"],"status":"active"},{"id":"c4fccde8-6562-41eb-a0d2-d8e55c1c4c1f","procedure_id":"proc-apheresis-longcovid","jurisdiction_id":"jur-de","procedure_name":"Therapeutic Apheresis / HELP Apheresis for Long COVID & Microclot Protocols","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"MEDIUM","modality":"CELLULAR","estimated_cost_range_usd":"€2k–6k/session","price_usd":3500.0,"access_pathway_details":"German/Swiss clinics popularized HELP/immunoadsorption for long COVID; not guideline standard of care; cash-pay common.","eligibility_requirements":"Clinical evaluation; exclude contraindications to apheresis.","provider_requirements":"Specialized apheresis clinics.","residency_travel_notes":"Medical travel common.","risk_notes":"Line infection, bleeding, unproven benefit for many.","arbitrage_summary":"Germany: available experimental clinic pathway — evidence still evolving.","oversight_notes":"Medical practice; evidence contested.","cost_notes":"Multi-session courses expensive.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Long_COVID","Cardiovascular"],"diseases":["Long COVID","ME/CFS-like Post-Viral Syndrome","Hyperviscosity Syndromes (labeled apheresis)"],"status":"active"},{"id":"29c938aa-2b50-4a4a-9df4-b1cbb807394f","procedure_id":"proc-apheresis-longcovid","jurisdiction_id":"jur-ch","procedure_name":"Therapeutic Apheresis / HELP Apheresis for Long COVID & Microclot Protocols","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"MEDIUM","modality":"CELLULAR","estimated_cost_range_usd":"CHF 2.5k–7k/session","price_usd":4500.0,"access_pathway_details":"Swiss private clinics offer apheresis protocols for post-COVID syndromes.","eligibility_requirements":"Private evaluation.","provider_requirements":"Private clinics.","residency_travel_notes":"Open to internationals privately.","risk_notes":"Unproven for many phenotypes.","arbitrage_summary":"Switzerland: private experimental apheresis access.","oversight_notes":"Cantonal medical oversight.","cost_notes":"Premium pricing.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Long_COVID","Cardiovascular"],"diseases":["Long COVID","ME/CFS-like Post-Viral Syndrome","Hyperviscosity Syndromes (labeled apheresis)"],"status":"active"},{"id":"df674e9c-50b6-4605-9b48-ce14d7dcec42","procedure_id":"proc-apheresis-longcovid","jurisdiction_id":"jur-us-federal","procedure_name":"Therapeutic Apheresis / HELP Apheresis for Long COVID & Microclot Protocols","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"CELLULAR","estimated_cost_range_usd":"Variable","price_usd":null,"access_pathway_details":"Apheresis for long COVID not FDA-approved as a labeled PASC therapy; available for other indications; PASC use mainly trial/off-label rare.","eligibility_requirements":"Trial or exceptional off-label.","provider_requirements":"Academic centers.","residency_travel_notes":"Domestic trials.","risk_notes":"Procedure risks without proven benefit.","arbitrage_summary":"US: not a standard long-COVID therapy — prefer trials.","oversight_notes":"FDA device/procedure context for apheresis machines.","cost_notes":"Insurance unlikely for PASC-only.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Long_COVID","Cardiovascular"],"diseases":["Long COVID","ME/CFS-like Post-Viral Syndrome","Hyperviscosity Syndromes (labeled apheresis)"],"status":"active"},{"id":"bc26344b-f1d3-4852-81a7-6844915e710b","procedure_id":"proc-ivig","jurisdiction_id":"jur-us-federal","procedure_name":"Intravenous Immunoglobulin (IVIG) for Autoimmune / Neuroimmune Disease","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"$5k–15k/cycle","price_usd":10000.0,"access_pathway_details":"Multiple FDA-licensed IVIG products; labeled indications insured; off-label requires payer battle.","eligibility_requirements":"Labeled disease or strong specialty justification.","provider_requirements":"Infusion centers; immunology/neuro.","residency_travel_notes":"Nationwide infusion infrastructure.","risk_notes":"Thrombosis, aseptic meningitis, renal risk — product-specific.","arbitrage_summary":"US: excellent labeled access; off-label friction is payer not legality.","oversight_notes":"FDA biologics + REMS-free but specialty pharmacy.","cost_notes":"Coverage indication-dependent.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Autoimmune","Neurology","Immunology"],"diseases":["Primary Immunodeficiency","CIDP","ITP","Autoimmune Encephalitis (off-label)","Long COVID (off-label)"],"status":"active"},{"id":"eb1316c4-8f41-4df6-9aa3-8c09a48b007b","procedure_id":"proc-ivig","jurisdiction_id":"jur-de","procedure_name":"Intravenous Immunoglobulin (IVIG) for Autoimmune / Neuroimmune Disease","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Public cover when indicated","price_usd":9000.0,"access_pathway_details":"IVIG standard in German immunology/neurology; G-BA indication rules for reimbursement.","eligibility_requirements":"Specialist indication.","provider_requirements":"Hospital/outpatient infusion.","residency_travel_notes":"Domestic.","risk_notes":"Product risks managed.","arbitrage_summary":"Germany: strong labeled IVIG access.","oversight_notes":"PEI/G-BA.","cost_notes":"Off-label harder.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Autoimmune","Neurology","Immunology"],"diseases":["Primary Immunodeficiency","CIDP","ITP","Autoimmune Encephalitis (off-label)","Long COVID (off-label)"],"status":"active"},{"id":"18764a4c-5e9f-4b7d-a803-1a21828410bb","procedure_id":"proc-ivig","jurisdiction_id":"jur-in","procedure_name":"Intravenous Immunoglobulin (IVIG) for Autoimmune / Neuroimmune Disease","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"MEDIUM","modality":"REPURPOSED","estimated_cost_range_usd":"$1.5k–5k/cycle est.","price_usd":3000.0,"access_pathway_details":"IVIG available; cost still high relative to incomes; some domestic manufacturers.","eligibility_requirements":"Specialist prescription.","provider_requirements":"Hospital pharmacies.","residency_travel_notes":"Medical travel sometimes.","risk_notes":"Quality brand selection matters.","arbitrage_summary":"India: lower-cost IVIG market vs US list prices.","oversight_notes":"CDSCO.","cost_notes":"Cheaper than US list but still expensive.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Autoimmune","Neurology","Immunology"],"diseases":["Primary Immunodeficiency","CIDP","ITP","Autoimmune Encephalitis (off-label)","Long COVID (off-label)"],"status":"active"},{"id":"a006a1bf-d142-4b0f-985b-32d3d87f6b72","procedure_id":"proc-sglt2-hf","jurisdiction_id":"jur-us-federal","procedure_name":"SGLT2 Inhibitors for Heart Failure & CKD Beyond Diabetes","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"$400–700/mo brand","price_usd":550.0,"access_pathway_details":"Dapagliflozin/empagliflozin labeled for HF and CKD independent of diabetes; primary care + cardiology prescribing.","eligibility_requirements":"HF or CKD label criteria; eGFR floors.","provider_requirements":"Any licensed prescriber.","residency_travel_notes":"Domestic telehealth common.","risk_notes":"Genital infections, rare DKA.","arbitrage_summary":"US: approved cardiorenal drugs — access is cost/formulary.","oversight_notes":"FDA labels.","cost_notes":"Insurance/coupons critical.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Cardiovascular","Kidney"],"diseases":["Heart Failure","Chronic Kidney Disease","Type 2 Diabetes"],"status":"active"},{"id":"3788377b-ee39-436d-9a05-fe3b0c4f8931","procedure_id":"proc-sglt2-hf","jurisdiction_id":"jur-uk","procedure_name":"SGLT2 Inhibitors for Heart Failure & CKD Beyond Diabetes","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"NHS covered when indicated","price_usd":0.0,"access_pathway_details":"NICE-recommended SGLT2i in HF/CKD pathways; NHS formulary access.","eligibility_requirements":"Guideline-eligible HF/CKD.","provider_requirements":"GPs/specialists.","residency_travel_notes":"Domestic.","risk_notes":"Class risks.","arbitrage_summary":"UK: strong NHS access for labeled HF/CKD.","oversight_notes":"MHRA + NICE.","cost_notes":"Low OOP.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Cardiovascular","Kidney"],"diseases":["Heart Failure","Chronic Kidney Disease","Type 2 Diabetes"],"status":"active"},{"id":"ce1bcab8-f250-48cd-8443-ceed065436a9","procedure_id":"proc-sglt2-hf","jurisdiction_id":"jur-de","procedure_name":"SGLT2 Inhibitors for Heart Failure & CKD Beyond Diabetes","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Statutory insurance","price_usd":40.0,"access_pathway_details":"SGLT2i reimbursed for HF/CKD per German label extensions.","eligibility_requirements":"Label criteria.","provider_requirements":"Hausarzt/cardiology.","residency_travel_notes":"Domestic.","risk_notes":"Class risks.","arbitrage_summary":"Germany: routine reimbursed SGLT2i for HF/CKD.","oversight_notes":"G-BA.","cost_notes":"Low OOP typical.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Cardiovascular","Kidney"],"diseases":["Heart Failure","Chronic Kidney Disease","Type 2 Diabetes"],"status":"active"},{"id":"0495d333-3e33-4295-a82b-e8bbb9601031","procedure_id":"proc-sglt2-hf","jurisdiction_id":"jur-in","procedure_name":"SGLT2 Inhibitors for Heart Failure & CKD Beyond Diabetes","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"MEDIUM","modality":"REPURPOSED","estimated_cost_range_usd":"$10–40/month","price_usd":20.0,"access_pathway_details":"SGLT2i widely available as generics/brands at low cost.","eligibility_requirements":"Clinical indication.","provider_requirements":"Any physician.","residency_travel_notes":"Easy pharmacy access.","risk_notes":"Counsel on side effects.","arbitrage_summary":"India: low-cost SGLT2i access.","oversight_notes":"CDSCO.","cost_notes":"Major price arbitrage vs US.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Cardiovascular","Kidney"],"diseases":["Heart Failure","Chronic Kidney Disease","Type 2 Diabetes"],"status":"active"},{"id":"b0546038-c3d3-453f-93a7-8360c432825d","procedure_id":"proc-lecanemab","jurisdiction_id":"jur-us-federal","procedure_name":"Anti-Amyloid Monoclonal Antibodies (Lecanemab / Donanemab) for Early Alzheimer's","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"~$26k/year drug","price_usd":26500.0,"access_pathway_details":"Lecanemab (Leqembi) FDA-approved for early AD; CMS coverage with registry requirements; infusion + MRI monitoring capacity limited.","eligibility_requirements":"MCI/mild AD + amyloid confirmation; APOE counseling; MRI schedule.","provider_requirements":"Alzheimer's specialty centers.","residency_travel_notes":"Center capacity bottleneck.","risk_notes":"ARIA (edema/hemorrhage) risk — higher in APOE4.","arbitrage_summary":"US: approved but capacity and monitoring constrained.","oversight_notes":"FDA + CMS CED.","cost_notes":"Coverage with conditions; imaging costs extra.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Neurology","Dementia"],"diseases":["Early Alzheimer's Disease","Mild Cognitive Impairment due to AD"],"status":"active"},{"id":"4bd130e8-51b1-47ad-930d-7d87b935fa26","procedure_id":"proc-lecanemab","jurisdiction_id":"jur-jp","procedure_name":"Anti-Amyloid Monoclonal Antibodies (Lecanemab / Donanemab) for Early Alzheimer's","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"National pricing/insurance mix","price_usd":20000.0,"access_pathway_details":"Japan approved lecanemab; rollout via specialty neurology with imaging requirements.","eligibility_requirements":"Early AD criteria + amyloid.","provider_requirements":"Specialist hospitals.","residency_travel_notes":"Domestic primarily.","risk_notes":"ARIA monitoring mandatory.","arbitrage_summary":"Japan: approved early, structured rollout.","oversight_notes":"PMDA.","cost_notes":"Capacity building.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Neurology","Dementia"],"diseases":["Early Alzheimer's Disease","Mild Cognitive Impairment due to AD"],"status":"active"},{"id":"2126bd94-b927-4029-93dc-32ea2d38dd98","procedure_id":"proc-lecanemab","jurisdiction_id":"jur-uk","procedure_name":"Anti-Amyloid Monoclonal Antibodies (Lecanemab / Donanemab) for Early Alzheimer's","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"If NHS — covered when approved pathway exists","price_usd":null,"access_pathway_details":"NICE/MHRA pathway has been restrictive vs US for anti-amyloid mAbs; access often trial or limited managed access — verify current NICE status.","eligibility_requirements":"NICE criteria if any; else trials.","provider_requirements":"Specialist centers.","residency_travel_notes":"Domestic.","risk_notes":"ARIA risks.","arbitrage_summary":"UK: tighter access than US historically — check current NICE.","oversight_notes":"NICE + MHRA.","cost_notes":"Policy flux.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Neurology","Dementia"],"diseases":["Early Alzheimer's Disease","Mild Cognitive Impairment due to AD"],"status":"active"},{"id":"fc575e8a-7429-497d-83ab-fdeaedddfbcc","procedure_id":"proc-mito-replacement","jurisdiction_id":"jur-uk","procedure_name":"Mitochondrial Replacement Therapy (MRT / Three-Person IVF)","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"$50k–100k+ est. full pathway","price_usd":75000.0,"access_pathway_details":"UK is the primary regulated jurisdiction for mitochondrial donation under HFEA licenses (Newcastle program and successors).","eligibility_requirements":"Serious mtDNA disease risk; HFEA license criteria; counseling.","provider_requirements":"HFEA-licensed clinics only.","residency_travel_notes":"UK residency/pathway rules apply.","risk_notes":"Embryo micromanipulation risks; long-term follow-up ongoing.","arbitrage_summary":"UK: world reference regulated MRT access.","oversight_notes":"HFEA Act framework — unique globally.","cost_notes":"NHS/research mix historically.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Mitochondrial DNA Disease","Leigh Syndrome Risk","Mitochondrial Inheritance Risk"],"status":"active"},{"id":"bd14fa02-c9bb-43e7-9a58-19ea0b858936","procedure_id":"proc-mito-replacement","jurisdiction_id":"jur-us-federal","procedure_name":"Mitochondrial Replacement Therapy (MRT / Three-Person IVF)","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"N/A","price_usd":null,"access_pathway_details":"FDA/Congressional rider has blocked clinical mitochondrial replacement in the US; research restrictions apply.","eligibility_requirements":"No clinical pathway.","provider_requirements":"None clinical.","residency_travel_notes":"N/A domestic.","risk_notes":"Legal prohibition.","arbitrage_summary":"US: clinical MRT prohibited.","oversight_notes":"FDA ban on heritable mitochondrial manipulation clinical use.","cost_notes":"Patients may seek UK.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Mitochondrial DNA Disease","Leigh Syndrome Risk","Mitochondrial Inheritance Risk"],"status":"active"},{"id":"bbfe3314-730a-4479-9ace-c8552311c926","procedure_id":"proc-mito-replacement","jurisdiction_id":"jur-au","procedure_name":"Mitochondrial Replacement Therapy (MRT / Three-Person IVF)","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"TBD","price_usd":null,"access_pathway_details":"Australia debated/legalized mitochondrial donation frameworks more recently than UK; implementation limited — verify current clinic licenses.","eligibility_requirements":"Legislative criteria when operational.","provider_requirements":"Licensed clinics if any.","residency_travel_notes":"Domestic.","risk_notes":"Experimental oversight.","arbitrage_summary":"Australia: legal framework evolving; limited operational access.","oversight_notes":"NHMRC/legislative framework.","cost_notes":"Early implementation phase.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Mitochondrial DNA Disease","Leigh Syndrome Risk","Mitochondrial Inheritance Risk"],"status":"active"},{"id":"3a25cd70-d2f1-46ff-8fff-8d29cbb9e597","procedure_id":"proc-egg-freezing","jurisdiction_id":"jur-us-federal","procedure_name":"Elective Oocyte Cryopreservation (Social Egg Freezing)","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"$8k–15k/cycle + storage","price_usd":12000.0,"access_pathway_details":"Elective oocyte cryopreservation widely available at US fertility clinics; employer benefits common in tech.","eligibility_requirements":"Adult women; clinic counseling on success rates by age.","provider_requirements":"SART clinics.","residency_travel_notes":"Domestic.","risk_notes":"OHSS; no pregnancy guarantee.","arbitrage_summary":"US: open elective egg freezing market.","oversight_notes":"CDC/SART reporting; state embryo laws vary.","cost_notes":"Often cash or employer benefit.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Reproductive_Health"],"diseases":["Age-Related Fertility Decline","Oncofertility","Elective Fertility Preservation"],"status":"active"},{"id":"bd3379d7-e992-4d15-a517-a4444ce4021e","procedure_id":"proc-egg-freezing","jurisdiction_id":"jur-es","procedure_name":"Elective Oocyte Cryopreservation (Social Egg Freezing)","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"FULLY_APPROVED","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"$4k–8k/cycle est.","price_usd":5500.0,"access_pathway_details":"Spain major fertility tourism destination; elective freezing common with strong clinic infrastructure.","eligibility_requirements":"Clinic criteria; age limits vary.","provider_requirements":"IVF clinics Barcelona/Madrid/Valencia.","residency_travel_notes":"Popular for EU/UK patients.","risk_notes":"Standard IVF risks.","arbitrage_summary":"Spain: cost-effective EU egg freezing destination.","oversight_notes":"Spanish ART law.","cost_notes":"Lower than US.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Reproductive_Health"],"diseases":["Age-Related Fertility Decline","Oncofertility","Elective Fertility Preservation"],"status":"active"},{"id":"1d5ab896-9147-4ead-9ed6-871b1be7c564","procedure_id":"proc-egg-freezing","jurisdiction_id":"jur-de","procedure_name":"Elective Oocyte Cryopreservation (Social Egg Freezing)","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"€4k–8k","price_usd":6000.0,"access_pathway_details":"Social egg freezing legally nuanced in Germany historically more restrictive than Spain; medical freezing clearer — verify current clinic offerings.","eligibility_requirements":"Clinic legal counseling essential.","provider_requirements":"Fertility centers.","residency_travel_notes":"Domestic.","risk_notes":"Legal counseling advised.","arbitrage_summary":"Germany: more constrained elective pathway than Spain/US.","oversight_notes":"Embryo protection law context.","cost_notes":"Policy sensitivity higher than Spain.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Reproductive_Health"],"diseases":["Age-Related Fertility Decline","Oncofertility","Elective Fertility Preservation"],"status":"active"},{"id":"c8f19108-4378-4daf-a496-27b3a8af9f0c","procedure_id":"proc-egg-freezing","jurisdiction_id":"jur-jp","procedure_name":"Elective Oocyte Cryopreservation (Social Egg Freezing)","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"$5k–10k","price_usd":7000.0,"access_pathway_details":"Egg freezing available; some municipal subsidy programs (e.g. Tokyo historically) for elective preservation.","eligibility_requirements":"Age/clinic criteria.","provider_requirements":"Registered ART clinics.","residency_travel_notes":"Domestic.","risk_notes":"Standard risks.","arbitrage_summary":"Japan: available with occasional public subsidies.","oversight_notes":"JSAR/MHLW context.","cost_notes":"Subsidies variable by city.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Reproductive_Health"],"diseases":["Age-Related Fertility Decline","Oncofertility","Elective Fertility Preservation"],"status":"active"},{"id":"22cc22a3-b149-448b-a9e8-ecd2a1a2b656","procedure_id":"proc-5meo-dmt","jurisdiction_id":"jur-mx","procedure_name":"5-MeO-DMT Assisted Therapy","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"PSYCHEDELICS","estimated_cost_range_usd":"$800–3,000","price_usd":1500.0,"access_pathway_details":"Retreat/ceremonial 5-MeO offerings in Mexico; legal status gray; Bufo conservation concerns for toad-derived product.","eligibility_requirements":"Retreat screening variable.","provider_requirements":"Retreat facilitators.","residency_travel_notes":"Tourism.","risk_notes":"Intense psychological risk; cardiac caution; ethics of toad sourcing.","arbitrage_summary":"Mexico: retreat market exists — high risk/variable quality.","oversight_notes":"Minimal formal medical regulation.","cost_notes":"Ceremony packages.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Spirituality"],"diseases":["Depression","Anxiety","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"c97e30a9-4f12-4339-ad49-d221fb27c44d","procedure_id":"proc-5meo-dmt","jurisdiction_id":"jur-us-federal","procedure_name":"5-MeO-DMT Assisted Therapy","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"PROHIBITED","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Trial only","price_usd":null,"access_pathway_details":"5-MeO-DMT Schedule I federally; clinical trials only for synthetic product development.","eligibility_requirements":"Trial criteria.","provider_requirements":"Trial sites.","residency_travel_notes":"Domestic trials rare.","risk_notes":"Legal risk outside trials.","arbitrage_summary":"US: prohibited outside research.","oversight_notes":"DEA Schedule I.","cost_notes":"N/A retail.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Spirituality"],"diseases":["Depression","Anxiety","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"ab304bec-c09c-4f82-8729-ba849101f19f","procedure_id":"proc-5meo-dmt","jurisdiction_id":"jur-us-co","procedure_name":"5-MeO-DMT Assisted Therapy","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"DECRIMINALIZED","access_pathway":"NONE","oversight_quality":"LOW","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Personal/underground only","price_usd":null,"access_pathway_details":"Prop 122 natural medicine decrim may include related tryptamines for personal use — not a commercial therapy framework for 5-MeO.","eligibility_requirements":"21+ personal possession rules; no licensed 5-MeO centers.","provider_requirements":"None licensed commercial.","residency_travel_notes":"State borders.","risk_notes":"No product testing; federal risk remains.","arbitrage_summary":"Colorado: decrim personal natural meds — not regulated 5-MeO therapy.","oversight_notes":"State decrim vs federal Schedule I tension.","cost_notes":"No regulated price.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Spirituality"],"diseases":["Depression","Anxiety","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"1c051d49-cd4a-45f5-a64a-284febe657fe","procedure_id":"proc-ketamine-assisted-psychotherapy","jurisdiction_id":"jur-us-federal","procedure_name":"Ketamine-Assisted Psychotherapy (KAP)","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"MEDIUM","modality":"PSYCHEDELICS","estimated_cost_range_usd":"$300–800/session","price_usd":500.0,"access_pathway_details":"KAP clinics combine ketamine with psychotherapy; ketamine off-label (Spravato separate REMS pathway). Standards vary widely.","eligibility_requirements":"Psychiatric screening; BP check.","provider_requirements":"Prescriber + therapist team.","residency_travel_notes":"Nationwide growth.","risk_notes":"Dissociation; BP; therapy boundary risks.","arbitrage_summary":"US: widely available KAP; quality varies by clinic.","oversight_notes":"State medical boards; ASKP voluntary standards.","cost_notes":"Cash-pay dominant for KAP model.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression","PTSD"],"diseases":["Treatment-Resistant Depression","PTSD","Anxiety Disorders"],"status":"active"},{"id":"c06f3b58-3804-4bea-9e03-5b5f16b2500a","procedure_id":"proc-ketamine-assisted-psychotherapy","jurisdiction_id":"jur-ca","procedure_name":"Ketamine-Assisted Psychotherapy (KAP)","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"MEDIUM","modality":"PSYCHEDELICS","estimated_cost_range_usd":"CAD $400–900/session","price_usd":550.0,"access_pathway_details":"Ketamine clinics and KAP models expanding in Canada under provincial medical practice.","eligibility_requirements":"Physician assessment.","provider_requirements":"Medical clinics.","residency_travel_notes":"Domestic.","risk_notes":"Standard ketamine risks.","arbitrage_summary":"Canada: private KAP growing.","oversight_notes":"Provincial colleges.","cost_notes":"Mostly private pay.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression","PTSD"],"diseases":["Treatment-Resistant Depression","PTSD","Anxiety Disorders"],"status":"active"},{"id":"38c59335-0c0c-403e-83fa-755fb630055e","procedure_id":"proc-ketamine-assisted-psychotherapy","jurisdiction_id":"jur-au","procedure_name":"Ketamine-Assisted Psychotherapy (KAP)","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"MEDIUM","modality":"PSYCHEDELICS","estimated_cost_range_usd":"AUD $400–900/session","price_usd":550.0,"access_pathway_details":"Ketamine therapy clinics operate under medical frameworks; psychotherapy integration variable.","eligibility_requirements":"Specialist assessment.","provider_requirements":"Private psychiatry clinics.","residency_travel_notes":"Domestic.","risk_notes":"Standard risks.","arbitrage_summary":"Australia: private medical ketamine/KAP available.","oversight_notes":"AHPRA + TGA ketamine scheduling.","cost_notes":"Private.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression","PTSD"],"diseases":["Treatment-Resistant Depression","PTSD","Anxiety Disorders"],"status":"active"},{"id":"6aac39af-12ef-49ff-beee-2152d69cbe4a","procedure_id":"proc-pef-ablation","jurisdiction_id":"jur-us-federal","procedure_name":"Pulsed Field Ablation (PFA) for Atrial Fibrillation","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"$25k–50k episode","price_usd":35000.0,"access_pathway_details":"FDA-cleared PFA systems for AF; rapidly adopted at EP centers; insurance for AF ablation pathways.","eligibility_requirements":"Symptomatic AF; EP evaluation.","provider_requirements":"Cardiac electrophysiology labs.","residency_travel_notes":"Center availability growing fast.","risk_notes":"Stroke/vascular risks lower thermal injury profile claimed.","arbitrage_summary":"US: fast-growing standard AF ablation technology.","oversight_notes":"FDA devices + hospital privileges.","cost_notes":"Typically insured when ablation indicated.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Cardiovascular"],"diseases":["Atrial Fibrillation"],"status":"active"},{"id":"daf200d2-39d1-4290-a68a-24027cbf1118","procedure_id":"proc-pef-ablation","jurisdiction_id":"jur-de","procedure_name":"Pulsed Field Ablation (PFA) for Atrial Fibrillation","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Public/private mix","price_usd":30000.0,"access_pathway_details":"PFA rolling out in European EP centers; reimbursement evolving with device approvals.","eligibility_requirements":"AF ablation criteria.","provider_requirements":"EP centers.","residency_travel_notes":"EU.","risk_notes":"Procedural risks.","arbitrage_summary":"Germany: early European PFA adoption hubs.","oversight_notes":"EU MDR + national payers.","cost_notes":"Center-dependent.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Cardiovascular"],"diseases":["Atrial Fibrillation"],"status":"active"},{"id":"576df711-d3aa-4167-a477-db2f5e6ca9d5","procedure_id":"proc-pef-ablation","jurisdiction_id":"jur-jp","procedure_name":"Pulsed Field Ablation (PFA) for Atrial Fibrillation","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Insurance pathways developing","price_usd":32000.0,"access_pathway_details":"Japan approving/adopting PFA systems through PMDA and hospital rollout.","eligibility_requirements":"Specialist EP criteria.","provider_requirements":"Advanced cardiac centers.","residency_travel_notes":"Domestic.","risk_notes":"Procedural risks.","arbitrage_summary":"Japan: advanced EP access including PFA rollout.","oversight_notes":"PMDA.","cost_notes":"Domestic.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Cardiovascular"],"diseases":["Atrial Fibrillation"],"status":"active"},{"id":"8005eda6-3ce1-49f0-abc4-214fa5525fc5","procedure_id":"proc-trt","jurisdiction_id":"jur-us-federal","procedure_name":"Testosterone Replacement Therapy (TRT) for Hypogonadism","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"MEDIUM","modality":"REPURPOSED","estimated_cost_range_usd":"$30–200/mo meds","price_usd":100.0,"access_pathway_details":"Testosterone is Schedule III; legitimate TRT requires documented hypogonadism. Large telehealth/clinic market; FDA has warned about over-prescribing and compounded products.","eligibility_requirements":"Two morning low-T labs + symptoms ideally; clinic standards vary.","provider_requirements":"Endocrinology, urology, men's clinics.","residency_travel_notes":"Domestic.","risk_notes":"Erythrocytosis, fertility suppression, CV uncertainty if misused.","arbitrage_summary":"US: easy access but quality of diagnostic rigor varies.","oversight_notes":"DEA Schedule III + FDA.","cost_notes":"Clinic memberships add cost.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Endocrinology","Men's_Health"],"diseases":["Male Hypogonadism","Testosterone Deficiency"],"status":"active"},{"id":"cbef4782-5be1-49a9-ad55-9e6385452158","procedure_id":"proc-trt","jurisdiction_id":"jur-uk","procedure_name":"Testosterone Replacement Therapy (TRT) for Hypogonadism","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"£30–100/mo private meds","price_usd":60.0,"access_pathway_details":"TRT via NHS for confirmed hypogonadism or private men's clinics; tighter diagnostic culture than US cash clinics.","eligibility_requirements":"Confirmed hypogonadism.","provider_requirements":"Endocrinology/private clinics.","residency_travel_notes":"Domestic.","risk_notes":"Monitoring required.","arbitrage_summary":"UK: legitimate TRT available; less direct-to-consumer than US.","oversight_notes":"MHRA + GMC.","cost_notes":"NHS if criteria met.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Endocrinology","Men's_Health"],"diseases":["Male Hypogonadism","Testosterone Deficiency"],"status":"active"},{"id":"5b48b8ed-b500-4896-88fc-35a9de5bd6c8","procedure_id":"proc-trt","jurisdiction_id":"jur-mx","procedure_name":"Testosterone Replacement Therapy (TRT) for Hypogonadism","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"FULLY_APPROVED","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"LOW","modality":"REPURPOSED","estimated_cost_range_usd":"$20–80/mo","price_usd":40.0,"access_pathway_details":"Testosterone easily obtained via private clinics/pharmacies; monitoring quality variable.","eligibility_requirements":"Often minimal labs at tourism clinics.","provider_requirements":"Private clinics.","residency_travel_notes":"Border tourism.","risk_notes":"Unmonitored TRT risks.","arbitrage_summary":"Mexico: low-cost TRT with variable medical oversight.","oversight_notes":"COFEPRIS pharmacy channel.","cost_notes":"Cheap; quality of care variable.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Endocrinology","Men's_Health"],"diseases":["Male Hypogonadism","Testosterone Deficiency"],"status":"active"},{"id":"ea1d9008-859c-439d-b8fd-90b279e6101b","procedure_id":"proc-photoimmunotherapy","jurisdiction_id":"jur-jp","procedure_name":"Near-Infrared Photoimmunotherapy for Head & Neck Cancer","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Specialty oncology pricing","price_usd":50000.0,"access_pathway_details":"Near-infrared photoimmunotherapy (ASP-1929/Akalux pathway) approved in Japan for unresectable locally advanced/recurrent HNSCC.","eligibility_requirements":"Label criteria; specialist head & neck oncology.","provider_requirements":"Approved Japanese centers.","residency_travel_notes":"Medical travel possible to Japan.","risk_notes":"Local tissue damage; photosensitivity protocols.","arbitrage_summary":"Japan: primary approved geography for this modality.","oversight_notes":"PMDA.","cost_notes":"National system pathways.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Oncology"],"diseases":["Head and Neck Squamous Cell Carcinoma"],"status":"active"},{"id":"e119842a-0afd-4109-9314-65393cda6b9b","procedure_id":"proc-photoimmunotherapy","jurisdiction_id":"jur-us-federal","procedure_name":"Near-Infrared Photoimmunotherapy for Head & Neck Cancer","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Trial","price_usd":null,"access_pathway_details":"US access primarily via clinical trials; not a broad commercial standard-of-care pathway yet.","eligibility_requirements":"Trial eligibility.","provider_requirements":"Trial oncology sites.","residency_travel_notes":"Domestic trials.","risk_notes":"Trial toxicities.","arbitrage_summary":"US: trial pathway for photoimmunotherapy.","oversight_notes":"FDA IND.","cost_notes":"Watch BLA status.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Oncology"],"diseases":["Head and Neck Squamous Cell Carcinoma"],"status":"active"},{"id":"d48165a3-ed40-40c0-a2a2-86d5fd7a9447","procedure_id":"proc-psilocybin-microdose","jurisdiction_id":"jur-us-or","procedure_name":"Psilocybin Microdosing Protocols","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"REGULATED_THERAPY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Service sessions $1.5k–3.5k; microdose supply not licensed retail","price_usd":null,"access_pathway_details":"Oregon licensed psilocybin services are full-dose facilitation model — not a formal microdose pharmacy. Personal microdosing still sits in gray/federal-illegal space outside service centers.","eligibility_requirements":"Service centers for facilitated sessions; microdose retail not the OPS model.","provider_requirements":"Licensed facilitators for sessions.","residency_travel_notes":"Open to non-residents for services.","risk_notes":"Federal Schedule I remains.","arbitrage_summary":"Oregon: regulated full-dose services — not a microdose prescription market.","oversight_notes":"OHA OPS.","cost_notes":"Don't confuse OPS with microdose scripts.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Cognition"],"diseases":["Depression","Anxiety","ADHD Symptoms (self-report)"],"status":"active"},{"id":"9b09bd16-61e4-4e35-8681-023b2516347d","procedure_id":"proc-psilocybin-microdose","jurisdiction_id":"jur-nl","procedure_name":"Psilocybin Microdosing Protocols","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"UNREGULATED_PERMITTED","access_pathway":"PERSONAL_IMPORT","oversight_quality":"LOW","modality":"PSYCHEDELICS","estimated_cost_range_usd":"$20–60/week truffles","price_usd":40.0,"access_pathway_details":"Psilocybin truffles legal in NL smart shops — common microdose source for visitors/residents.","eligibility_requirements":"Adult purchase of truffles.","provider_requirements":"Smart shops.","residency_travel_notes":"Tourism-friendly.","risk_notes":"Variable dose; mental health risks if unscreened.","arbitrage_summary":"Netherlands: easiest legal microdose-adjacent supply via truffles.","oversight_notes":"Dutch opium law truffle exception.","cost_notes":"Legal truffle retail.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Cognition"],"diseases":["Depression","Anxiety","ADHD Symptoms (self-report)"],"status":"active"},{"id":"d7316eea-899f-4029-a06d-51dc4314fa38","procedure_id":"proc-psilocybin-microdose","jurisdiction_id":"jur-jm","procedure_name":"Psilocybin Microdosing Protocols","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"UNREGULATED_PERMITTED","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"PSYCHEDELICS","estimated_cost_range_usd":"$20–100/week equivalent","price_usd":50.0,"access_pathway_details":"Psilocybin mushrooms never scheduled; retreats may support microdose/ retreat hybrid models without medical licensing.","eligibility_requirements":"Retreat screening variable.","provider_requirements":"Retreat operators.","residency_travel_notes":"Tourism.","risk_notes":"No product testing mandate.","arbitrage_summary":"Jamaica: unregulated legal mushrooms enable microdose access.","oversight_notes":"No medical regulator for therapy.","cost_notes":"Often bundled in retreats.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Cognition"],"diseases":["Depression","Anxiety","ADHD Symptoms (self-report)"],"status":"active"},{"id":"3f8a545f-1f1d-40f2-8f2a-45fda0751f2b","procedure_id":"proc-psilocybin-microdose","jurisdiction_id":"jur-us-federal","procedure_name":"Psilocybin Microdosing Protocols","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A legal market","price_usd":null,"access_pathway_details":"Psilocybin Schedule I federally; microdosing is illegal under federal law despite state/city reforms.","eligibility_requirements":"None federally.","provider_requirements":"None.","residency_travel_notes":"N/A","risk_notes":"Federal criminal risk.","arbitrage_summary":"US federal: microdosing prohibited.","oversight_notes":"DEA Schedule I.","cost_notes":"Underground only.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Cognition"],"diseases":["Depression","Anxiety","ADHD Symptoms (self-report)"],"status":"active"},{"id":"39d08019-6b7c-42ea-b599-75df2d53ae61","procedure_id":"proc-cord-blood","jurisdiction_id":"jur-us-federal","procedure_name":"Umbilical Cord Blood / Perinatal Cell Therapies","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Transplant insured when indicated; clinic $5k–25k unproven","price_usd":null,"access_pathway_details":"FDA-regulated cord blood for approved hematopoietic transplants; unproven perinatal clinic infusions are enforcement targets.","eligibility_requirements":"Transplant indications via transplant centers; avoid unproven autism/anti-aging clinic claims.","provider_requirements":"FACT-accredited transplant programs.","residency_travel_notes":"Domestic transplant centers.","risk_notes":"GVHD/infection for transplants; unproven clinic risks.","arbitrage_summary":"US: approved for transplant; unproven regenerative marketing is risky/illegal.","oversight_notes":"FDA BLA/cord blood regulations.","cost_notes":"Distinguish approved transplant vs clinic marketing.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Hematology","Regeneration"],"diseases":["Leukemia (transplant)","Lymphoma (transplant)","Cerebral Palsy (investigational clinics)"],"status":"active"},{"id":"814b8653-4ba3-4b0e-bd9e-66c9d3588d1d","procedure_id":"proc-cord-blood","jurisdiction_id":"jur-mx","procedure_name":"Umbilical Cord Blood / Perinatal Cell Therapies","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"STEM_CELL","estimated_cost_range_usd":"$5k–20k","price_usd":10000.0,"access_pathway_details":"Perinatal cell clinics market cord/Wharton's jelly products for many unproven indications.","eligibility_requirements":"Cash-pay.","provider_requirements":"Private regenerative clinics.","residency_travel_notes":"Tourism.","risk_notes":"Unproven claims; infection risk.","arbitrage_summary":"Mexico: regenerative cord-cell tourism — high diligence required.","oversight_notes":"Variable COFEPRIS enforcement.","cost_notes":"Quality opaque.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Hematology","Regeneration"],"diseases":["Leukemia (transplant)","Lymphoma (transplant)","Cerebral Palsy (investigational clinics)"],"status":"active"},{"id":"40f24203-87d0-42b4-9bb3-029467b6d54b","procedure_id":"proc-cord-blood","jurisdiction_id":"jur-sg","procedure_name":"Umbilical Cord Blood / Perinatal Cell Therapies","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Hospital pricing / insurance","price_usd":null,"access_pathway_details":"Singapore high-standard transplant medicine; strict limits on unproven cell therapies.","eligibility_requirements":"Transplant criteria.","provider_requirements":"Academic hospitals.","residency_travel_notes":"Regional referrals.","risk_notes":"Transplant risks managed.","arbitrage_summary":"Singapore: legitimate transplant pathway; low tolerance for unproven clinics.","oversight_notes":"HSA.","cost_notes":"Not a gray regenerative tourism hub.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Hematology","Regeneration"],"diseases":["Leukemia (transplant)","Lymphoma (transplant)","Cerebral Palsy (investigational clinics)"],"status":"active"},{"id":"c5915b37-ac2d-465a-ae3f-d5d7f4958f0e","procedure_id":"proc-peptide-tesamorelin","jurisdiction_id":"jur-us-federal","procedure_name":"Tesamorelin (Egrifta) for HIV Lipodystrophy / Off-Label Visceral Fat","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"$3k–6k/mo list","price_usd":4500.0,"access_pathway_details":"Egrifta (tesamorelin) FDA-approved for HIV-associated lipodystrophy; specialty pharmacy; patient assistance important.","eligibility_requirements":"HIV + excess abdominal fat per label.","provider_requirements":"HIV specialists.","residency_travel_notes":"Domestic.","risk_notes":"Glucose elevations; injection site reactions.","arbitrage_summary":"US: labeled peptide drug for HIV lipodystrophy.","oversight_notes":"FDA label.","cost_notes":"Assistance programs may reduce cost.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Metabolic_Health","HIV"],"diseases":["HIV-Associated Lipodystrophy","Visceral Adiposity (off-label)"],"status":"active"},{"id":"aa903a55-793f-48a0-aec0-66ef1ae0f953","procedure_id":"proc-peptide-tesamorelin","jurisdiction_id":"jur-ca","procedure_name":"Tesamorelin (Egrifta) for HIV Lipodystrophy / Off-Label Visceral Fat","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"CAD high list","price_usd":4000.0,"access_pathway_details":"Tesamorelin available via Canadian specialty pathways for labeled HIV lipodystrophy where marketed.","eligibility_requirements":"HIV specialist criteria.","provider_requirements":"Specialty pharmacies.","residency_travel_notes":"Domestic.","risk_notes":"Metabolic monitoring.","arbitrage_summary":"Canada: labeled access pathway where listed.","oversight_notes":"Health Canada.","cost_notes":"Public/private coverage variable.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Metabolic_Health","HIV"],"diseases":["HIV-Associated Lipodystrophy","Visceral Adiposity (off-label)"],"status":"active"},{"id":"fe5a509d-80c9-4c22-815d-a44ca4ef7ce9","procedure_id":"proc-baclofen-aud","jurisdiction_id":"jur-fr","procedure_name":"High-Dose Baclofen for Alcohol Use Disorder","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"MEDIUM","modality":"REPURPOSED","estimated_cost_range_usd":"€20–60/mo","price_usd":35.0,"access_pathway_details":"France has the most publicized high-dose baclofen AUD practice history (temporary recommendations/RTU-type pathways evolved over time).","eligibility_requirements":"AUD diagnosis; specialist/addiction physician.","provider_requirements":"Addiction medicine.","residency_travel_notes":"Domestic.","risk_notes":"Sedation, withdrawal if stopped abruptly.","arbitrage_summary":"France: most established baclofen-AUD clinical culture.","oversight_notes":"ANSM history of baclofen AUD rules.","cost_notes":"Mostly low drug cost.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Addiction"],"diseases":["Alcohol Use Disorder"],"status":"active"},{"id":"8cb32d1a-4de2-4cbb-ac28-a3abdb11a875","procedure_id":"proc-baclofen-aud","jurisdiction_id":"jur-us-federal","procedure_name":"High-Dose Baclofen for Alcohol Use Disorder","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"MEDIUM","modality":"REPURPOSED","estimated_cost_range_usd":"$20–60/mo","price_usd":30.0,"access_pathway_details":"Baclofen off-label for AUD used by some addiction clinicians; not first-line per US guidelines (naltrexone/acamprosate preferred).","eligibility_requirements":"AUD; caution in renal impairment.","provider_requirements":"Addiction medicine / primary care.","residency_travel_notes":"Domestic.","risk_notes":"Sedation; abuse potential lower than many agents.","arbitrage_summary":"US: off-label possible; not guideline first-line.","oversight_notes":"FDA labeled for spasticity.","cost_notes":"Cheap generic.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Addiction"],"diseases":["Alcohol Use Disorder"],"status":"active"},{"id":"904076f6-b1de-4208-bad7-131c92a3f2b4","procedure_id":"proc-baclofen-aud","jurisdiction_id":"jur-de","procedure_name":"High-Dose Baclofen for Alcohol Use Disorder","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"MEDIUM","modality":"REPURPOSED","estimated_cost_range_usd":"€15–50/mo","price_usd":25.0,"access_pathway_details":"Off-label baclofen for AUD under physician responsibility; specialty addiction care preferred.","eligibility_requirements":"AUD assessment.","provider_requirements":"Suchtmedizin / GP.","residency_travel_notes":"Domestic.","risk_notes":"Class risks.","arbitrage_summary":"Germany: off-label baclofen AUD possible in specialist hands.","oversight_notes":"Off-label AMG practice.","cost_notes":"Low cost.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Addiction"],"diseases":["Alcohol Use Disorder"],"status":"active"},{"id":"9cb3fc7b-5144-4f5e-99f4-efc5759a15cd","procedure_id":"proc-peptide-cjc-ipa","jurisdiction_id":"jur-us-federal","procedure_name":"CJC-1295 / Ipamorelin Growth Hormone Secretagogue Peptides","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"NONE","oversight_quality":"LOW","modality":"PEPTIDE","estimated_cost_range_usd":"$150–500/mo gray market","price_usd":null,"access_pathway_details":"Not FDA-approved for anti-aging. Many related secretagogue peptides face compounding restrictions; research chemical market is not medical care.","eligibility_requirements":"No approved indication for wellness.","provider_requirements":"Gray clinics / research vendors.","residency_travel_notes":"Domestic gray.","risk_notes":"IGF-1 elevation risks; product authenticity.","arbitrage_summary":"US: no clear lawful medical pathway for wellness secretagogues.","oversight_notes":"FDA compounding enforcement flux.","cost_notes":"Quality unknown.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Anti_Aging","Performance"],"diseases":["Age-Related Sarcopenia","Growth Hormone Deficiency (not labeled for secretagogues)"],"status":"active"},{"id":"4478dcf8-bfc3-4fbc-b599-c132ffc4daa3","procedure_id":"proc-peptide-cjc-ipa","jurisdiction_id":"jur-mx","procedure_name":"CJC-1295 / Ipamorelin Growth Hormone Secretagogue Peptides","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"PEPTIDE","estimated_cost_range_usd":"$100–300/mo","price_usd":200.0,"access_pathway_details":"Peptide clinics commonly market CJC/ipa stacks cash-pay.","eligibility_requirements":"Cash-pay.","provider_requirements":"Wellness clinics.","residency_travel_notes":"Tourism.","risk_notes":"Unverified products.","arbitrage_summary":"Mexico: easy peptide clinic access — buyer beware.","oversight_notes":"Minimal.","cost_notes":"Cheap; quality risk.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Anti_Aging","Performance"],"diseases":["Age-Related Sarcopenia","Growth Hormone Deficiency (not labeled for secretagogues)"],"status":"active"},{"id":"c2bb203e-06a8-485b-9878-f2cf824e1366","procedure_id":"proc-peptide-cjc-ipa","jurisdiction_id":"jur-th","procedure_name":"CJC-1295 / Ipamorelin Growth Hormone Secretagogue Peptides","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"PEPTIDE","estimated_cost_range_usd":"$120–350/mo","price_usd":220.0,"access_pathway_details":"Anti-aging clinics in Thailand market GH secretagogue peptides.","eligibility_requirements":"Tourist packages.","provider_requirements":"Private clinics.","residency_travel_notes":"Bangkok etc.","risk_notes":"Authenticity risk.","arbitrage_summary":"Thailand: wellness peptide tourism market.","oversight_notes":"Variable.","cost_notes":"Tourism pricing.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Anti_Aging","Performance"],"diseases":["Age-Related Sarcopenia","Growth Hormone Deficiency (not labeled for secretagogues)"],"status":"active"},{"id":"e64c53f8-9699-4b95-b057-54dbf6df53ea","procedure_id":"proc-prazosin-ptsd","jurisdiction_id":"jur-us-federal","procedure_name":"Prazosin for PTSD Nightmares","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"$5–30/mo","price_usd":15.0,"access_pathway_details":"Prazosin inexpensive generic; widely used off-label for PTSD nightmares including VA practice despite mixed large-trial results.","eligibility_requirements":"PTSD with nightmares; BP monitoring.","provider_requirements":"Primary care, psych, VA.","residency_travel_notes":"Domestic.","risk_notes":"Orthostatic hypotension first doses.","arbitrage_summary":"US: easy cheap off-label access.","oversight_notes":"FDA HTN label; off-label PTSD use.","cost_notes":"Very cheap.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["PTSD Nightmares","Hypertension (labeled)"],"status":"active"},{"id":"e681e041-c61b-4fa7-bb6d-6ebe5049d1dd","procedure_id":"proc-prazosin-ptsd","jurisdiction_id":"jur-uk","procedure_name":"Prazosin for PTSD Nightmares","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"$10–25/mo","price_usd":15.0,"access_pathway_details":"Prazosin available; PTSD nightmare use off-label under specialist/GP judgment.","eligibility_requirements":"Clinical PTSD.","provider_requirements":"GPs/specialists.","residency_travel_notes":"Domestic.","risk_notes":"Hypotension.","arbitrage_summary":"UK: inexpensive off-label option.","oversight_notes":"MHRA.","cost_notes":"NHS possible.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["PTSD Nightmares","Hypertension (labeled)"],"status":"active"},{"id":"768dbb0c-cacc-494d-a676-2f7ead3d9c48","procedure_id":"proc-prazosin-ptsd","jurisdiction_id":"jur-ca","procedure_name":"Prazosin for PTSD Nightmares","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"CAD $10–30/mo","price_usd":12.0,"access_pathway_details":"Common off-label PTSD nightmare treatment; covered when prescribed.","eligibility_requirements":"PTSD symptoms.","provider_requirements":"Family/specialty physicians.","residency_travel_notes":"Domestic.","risk_notes":"Hypotension.","arbitrage_summary":"Canada: easy access, low cost.","oversight_notes":"Health Canada drug.","cost_notes":"Formulary cheap.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["PTSD Nightmares","Hypertension (labeled)"],"status":"active"},{"id":"6d767930-6d52-40c4-a009-c81256eb65cb","procedure_id":"proc-low-dose-lithium","jurisdiction_id":"jur-us-federal","procedure_name":"Low-Dose Lithium for Neuroprotection / Mood","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"COMPOUNDING","oversight_quality":"MEDIUM","modality":"REPURPOSED","estimated_cost_range_usd":"$10–40/mo","price_usd":20.0,"access_pathway_details":"Prescription lithium carbonate is FDA-approved for bipolar; low-dose protocols may use compounded microdoses. OTC lithium orotate is a supplement gray area with weak regulation.","eligibility_requirements":"Baseline renal/thyroid labs advised even at low dose.","provider_requirements":"Prescriber for carbonate; OTC orotate unsupervised risk.","residency_travel_notes":"Domestic.","risk_notes":"Thyroid/renal effects still possible.","arbitrage_summary":"US: microdose via Rx compounding or unregulated orotate supplements.","oversight_notes":"FDA drug vs DSHEA supplement split.","cost_notes":"Labs extra.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Neurology"],"diseases":["Bipolar Disorder (full-dose labeled)","Mood Instability","Dementia Risk Reduction (investigational)"],"status":"active"},{"id":"26ffc89d-2075-4671-a01e-3214bdb307cf","procedure_id":"proc-low-dose-lithium","jurisdiction_id":"jur-de","procedure_name":"Low-Dose Lithium for Neuroprotection / Mood","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"€10–30/mo","price_usd":18.0,"access_pathway_details":"Pharmaceutical lithium under prescription; low-dose neuroprotective use is off-label physician practice — not OTC culture like US orotate.","eligibility_requirements":"Labs monitoring.","provider_requirements":"Physicians.","residency_travel_notes":"Domestic.","risk_notes":"Monitoring still wise.","arbitrage_summary":"Germany: Rx lithium only; off-label microdose clinician-led.","oversight_notes":"High pharmacy standards.","cost_notes":"Rx only.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Neurology"],"diseases":["Bipolar Disorder (full-dose labeled)","Mood Instability","Dementia Risk Reduction (investigational)"],"status":"active"},{"id":"6dcad69f-ee33-4348-8a8d-3b1ef4715235","procedure_id":"proc-fecal-sibo","jurisdiction_id":"jur-us-federal","procedure_name":"Elemental Diet / Rifaximin Protocols for SIBO (Access Friction Map)","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"$1k–2.5k/course brand","price_usd":1800.0,"access_pathway_details":"Rifaximin FDA-approved for IBS-D and HE; used for SIBO off-label. Price is the main US friction (brand Xifaxan).","eligibility_requirements":"IBS-D label or SIBO clinical diagnosis.","provider_requirements":"GI / primary care.","residency_travel_notes":"Domestic.","risk_notes":"C. diff rare; resistance concerns.","arbitrage_summary":"US: legal access easy; cost is the arbitrage.","oversight_notes":"FDA.","cost_notes":"Insurance often fails for SIBO specifically.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Gastrointestinal"],"diseases":["SIBO","IBS-D","Hepatic Encephalopathy (rifaximin labeled)"],"status":"active"},{"id":"ae93d240-d271-468d-8208-6bee22b82844","procedure_id":"proc-fecal-sibo","jurisdiction_id":"jur-in","procedure_name":"Elemental Diet / Rifaximin Protocols for SIBO (Access Friction Map)","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"MEDIUM","modality":"REPURPOSED","estimated_cost_range_usd":"$30–100/course","price_usd":50.0,"access_pathway_details":"Rifaximin generics widely available at far lower cost.","eligibility_requirements":"Physician Rx.","provider_requirements":"Pharmacies.","residency_travel_notes":"Easy access.","risk_notes":"Prefer known manufacturers.","arbitrage_summary":"India: low-cost rifaximin for SIBO protocols.","oversight_notes":"CDSCO.","cost_notes":"Major price arbitrage vs US brand.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Gastrointestinal"],"diseases":["SIBO","IBS-D","Hepatic Encephalopathy (rifaximin labeled)"],"status":"active"},{"id":"8696a8bd-b81a-43b4-b94b-1409cf660fb0","procedure_id":"proc-fecal-sibo","jurisdiction_id":"jur-mx","procedure_name":"Elemental Diet / Rifaximin Protocols for SIBO (Access Friction Map)","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"MEDIUM","modality":"REPURPOSED","estimated_cost_range_usd":"$50–150/course","price_usd":80.0,"access_pathway_details":"Rifaximin available in Mexican pharmacies cheaper than US brand cash price.","eligibility_requirements":"Physician Rx norms.","provider_requirements":"Farmacias.","residency_travel_notes":"Tourism.","risk_notes":"Confirm product authenticity.","arbitrage_summary":"Mexico: cheaper rifaximin access for SIBO protocols.","oversight_notes":"COFEPRIS.","cost_notes":"Border pharmacy tourism common.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Gastrointestinal"],"diseases":["SIBO","IBS-D","Hepatic Encephalopathy (rifaximin labeled)"],"status":"active"},{"id":"8248296e-0e43-4174-a77b-bddd1803e10d","procedure_id":"proc-glp1-addiction","jurisdiction_id":"jur-us-federal","procedure_name":"GLP-1 Agonists for Alcohol / Substance Use Disorder (Emerging)","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"MEDIUM","modality":"REPURPOSED","estimated_cost_range_usd":"$200–1,400/mo","price_usd":900.0,"access_pathway_details":"Semaglutide/tirzepatide prescribed off-label by some addiction/psych clinics for AUD interest; labeled for T2D/obesity only.","eligibility_requirements":"Obesity/T2D labels easier for coverage; pure AUD off-label cash-pay.","provider_requirements":"Prescribers + specialty pharmacy.","residency_travel_notes":"Domestic.","risk_notes":"GI side effects; thyroid boxed warning class.","arbitrage_summary":"US: emerging off-label; evidence still maturing.","oversight_notes":"FDA labels don't include SUD.","cost_notes":"Coverage rare for pure AUD.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Addiction","Mental_Health"],"diseases":["Alcohol Use Disorder","Obesity","Type 2 Diabetes"],"status":"active"},{"id":"796e6c8c-9128-49eb-89ec-a1d7db24c4a5","procedure_id":"proc-glp1-addiction","jurisdiction_id":"jur-uk","procedure_name":"GLP-1 Agonists for Alcohol / Substance Use Disorder (Emerging)","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"MEDIUM","modality":"REPURPOSED","estimated_cost_range_usd":"Private high / NHS if obesity criteria","price_usd":300.0,"access_pathway_details":"GLP-1s NHS-restricted mainly for obesity/diabetes criteria; pure addiction use private off-label if at all.","eligibility_requirements":"NHS obesity/diabetes pathways or private.","provider_requirements":"Specialists/private.","residency_travel_notes":"Domestic.","risk_notes":"Class risks.","arbitrage_summary":"UK: obesity/diabetes pathway first; addiction off-label private only.","oversight_notes":"MHRA + NICE obesity rules.","cost_notes":"Addiction-only unlikely NHS.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Addiction","Mental_Health"],"diseases":["Alcohol Use Disorder","Obesity","Type 2 Diabetes"],"status":"active"},{"id":"60f2d0cd-ef6d-47a6-91fc-f816cce9310b","procedure_id":"proc-dendritic-vaccine","jurisdiction_id":"jur-us-federal","procedure_name":"Dendritic Cell Cancer Vaccines (Personalized)","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"$100k+ for Provenge course historical","price_usd":100000.0,"access_pathway_details":"Sipuleucel-T (Provenge) FDA-approved for mCRPC. Other personalized DC vaccines mostly trial or unproven clinic products.","eligibility_requirements":"mCRPC label for Provenge; others trial.","provider_requirements":"Authorized infusion centers for Provenge.","residency_travel_notes":"Domestic specialty.","risk_notes":"Infusion reactions.","arbitrage_summary":"US: one approved DC vaccine (prostate); beware unproven DC clinics.","oversight_notes":"FDA.","cost_notes":"Insurance for labeled use.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Oncology"],"diseases":["Metastatic Castration-Resistant Prostate Cancer","Solid Tumors (clinic variable)"],"status":"active"},{"id":"9e15f38f-190d-493b-aeab-9344cca06c07","procedure_id":"proc-dendritic-vaccine","jurisdiction_id":"jur-mx","procedure_name":"Dendritic Cell Cancer Vaccines (Personalized)","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"ONCOLOGY","estimated_cost_range_usd":"$20k–80k packages","price_usd":40000.0,"access_pathway_details":"Cancer clinics market personalized DC vaccines with variable science and quality control.","eligibility_requirements":"Cash-pay oncology tourism.","provider_requirements":"Private clinics.","residency_travel_notes":"Tourism.","risk_notes":"Delay of proven care risk.","arbitrage_summary":"Mexico: DC vaccine tourism — high scrutiny required.","oversight_notes":"Minimal outcome transparency.","cost_notes":"Claims often exceed evidence.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Oncology"],"diseases":["Metastatic Castration-Resistant Prostate Cancer","Solid Tumors (clinic variable)"],"status":"active"},{"id":"e4313b66-1ee8-45a8-9f92-d607dfb9433f","procedure_id":"proc-dendritic-vaccine","jurisdiction_id":"jur-de","procedure_name":"Dendritic Cell Cancer Vaccines (Personalized)","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Trial","price_usd":null,"access_pathway_details":"Academic DC vaccine research; commercial unproven clinics less tolerated than in tourism markets.","eligibility_requirements":"Trial criteria.","provider_requirements":"University oncology.","residency_travel_notes":"Domestic EU.","risk_notes":"Trial risks.","arbitrage_summary":"Germany: trial/academic pathway preferred.","oversight_notes":"PEI/EMA trial rules.","cost_notes":"Prefer academic trials.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Oncology"],"diseases":["Metastatic Castration-Resistant Prostate Cancer","Solid Tumors (clinic variable)"],"status":"active"},{"id":"28f143e0-dfbf-4499-953b-d5261a25ede3","procedure_id":"proc-uterine-transplant","jurisdiction_id":"jur-us-federal","procedure_name":"Uterus Transplantation for Absolute Uterine Factor Infertility","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"$200k–500k+","price_usd":300000.0,"access_pathway_details":"Uterus transplant available only at select US research/clinical programs (not routine care).","eligibility_requirements":"AUFI; extensive medical/psych screening; research protocols often.","provider_requirements":"Transplant + REI programs (e.g. select academic centers).","residency_travel_notes":"Must relocate near center months.","risk_notes":"Immunosuppression; surgical morbidity.","arbitrage_summary":"US: highly limited specialized programs only.","oversight_notes":"IRB/transplant regulation.","cost_notes":"Rarely fully insured.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Reproductive_Health"],"diseases":["Absolute Uterine Factor Infertility","MRKH Syndrome"],"status":"active"},{"id":"1da92e53-1cfe-41fa-8746-9d75713ad497","procedure_id":"proc-uterine-transplant","jurisdiction_id":"jur-se","procedure_name":"Uterus Transplantation for Absolute Uterine Factor Infertility","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Research pathway","price_usd":null,"access_pathway_details":"Sweden pioneered clinical uterus transplantation research (Gothenburg).","eligibility_requirements":"Research criteria.","provider_requirements":"Academic transplant programs.","residency_travel_notes":"Limited slots.","risk_notes":"Major surgery risks.","arbitrage_summary":"Sweden: historic research leadership; not open tourism.","oversight_notes":"MPA/ethical boards.","cost_notes":"Not general medical tourism product.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Reproductive_Health"],"diseases":["Absolute Uterine Factor Infertility","MRKH Syndrome"],"status":"active"},{"id":"070e3bcf-5502-41ae-939f-75e34298c455","procedure_id":"proc-vns-depression","jurisdiction_id":"jur-us-federal","procedure_name":"Vagus Nerve Stimulation (VNS) for Depression","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"$20k–40k implant pathway","price_usd":30000.0,"access_pathway_details":"Implantable VNS FDA-approved for chronic TRD (and epilepsy). Requires surgical implant; payer hurdles common for depression indication.","eligibility_requirements":"Chronic TRD criteria; surgical clearance.","provider_requirements":"Neurosurgery + psychiatry programs.","residency_travel_notes":"Specialty centers.","risk_notes":"Surgical infection; voice changes; battery replacement.","arbitrage_summary":"US: approved but access friction for depression VNS.","oversight_notes":"FDA PMA devices.","cost_notes":"Insurance denials common for depression indication.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Epilepsy"],"status":"active"},{"id":"cc1a9c80-a9bb-46fc-bb39-0c3ff2c5505e","procedure_id":"proc-vns-depression","jurisdiction_id":"jur-de","procedure_name":"Vagus Nerve Stimulation (VNS) for Depression","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Public cover more for epilepsy than depression","price_usd":25000.0,"access_pathway_details":"VNS available for epilepsy widely; depression indication more selective with specialist centers.","eligibility_requirements":"Specialist criteria.","provider_requirements":"Neurosurgery centers.","residency_travel_notes":"Domestic.","risk_notes":"Surgical risks.","arbitrage_summary":"Germany: strong epilepsy VNS; depression more selective.","oversight_notes":"G-BA device context.","cost_notes":"Indication matters.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Epilepsy"],"status":"active"},{"id":"959762ea-fa28-4d26-ba22-f0c5104e736f","procedure_id":"proc-ecmo-bridge","jurisdiction_id":"jur-us-federal","procedure_name":"Elective / Bridge ECMO and Advanced Cardiac Support Tourism Pathways","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"$100k–500k+/run","price_usd":250000.0,"access_pathway_details":"ECMO standard at high-volume US centers for refractory shock/ARDS; not elective tourism.","eligibility_requirements":"Critical illness criteria; center capability.","provider_requirements":"ELSO centers.","residency_travel_notes":"Transfer to ECMO center.","risk_notes":"Bleeding, thrombosis, infection.","arbitrage_summary":"US: capacity/expertise arbitrage between hospitals — not legal gray market.","oversight_notes":"Hospital credentialing.","cost_notes":"Insured in acute care when indicated.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Cardiovascular","Critical_Care"],"diseases":["Cardiogenic Shock","Severe ARDS","Bridge to Transplant"],"status":"active"},{"id":"08bb7ace-b777-46ec-a129-c44a0d1106c9","procedure_id":"proc-ecmo-bridge","jurisdiction_id":"jur-de","procedure_name":"Elective / Bridge ECMO and Advanced Cardiac Support Tourism Pathways","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Public acute care","price_usd":200000.0,"access_pathway_details":"High ECMO capacity in German tertiary hospitals; regional transfer networks.","eligibility_requirements":"Critical care criteria.","provider_requirements":"University ICUs.","residency_travel_notes":"Domestic/EU transfer.","risk_notes":"ECMO complications.","arbitrage_summary":"Germany: high-capacity legitimate ECMO centers.","oversight_notes":"Hospital standards.","cost_notes":"Not tourism product.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Cardiovascular","Critical_Care"],"diseases":["Cardiogenic Shock","Severe ARDS","Bridge to Transplant"],"status":"active"},{"id":"65b0dc51-5101-44f9-a761-4803cf992d79","procedure_id":"proc-peptide-ss31","jurisdiction_id":"jur-us-federal","procedure_name":"Elamipretide / Mitochondrial-Targeted Peptides (SS-31 Class)","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Trial","price_usd":null,"access_pathway_details":"Elamipretide and related mitochondrial peptides primarily clinical trial / expanded access; not general wellness peptides.","eligibility_requirements":"Trial or expanded access criteria for rare disease.","provider_requirements":"Trial sites.","residency_travel_notes":"Domestic trials.","risk_notes":"Investigational risks.","arbitrage_summary":"US: trial/expanded access — not anti-aging clinic standard.","oversight_notes":"FDA IND.","cost_notes":"Commercial approval pending indications.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mitochondrial_Health","Cardiology","Ophthalmology"],"diseases":["Barth Syndrome","Mitochondrial Myopathy","Dry AMD (investigational)"],"status":"active"},{"id":"8f544d76-08d4-45a2-a02e-1a99d7e10c29","procedure_id":"proc-peptide-ss31","jurisdiction_id":"jur-de","procedure_name":"Elamipretide / Mitochondrial-Targeted Peptides (SS-31 Class)","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Trial","price_usd":null,"access_pathway_details":"European mitochondrial peptide programs mainly via clinical trials.","eligibility_requirements":"Trial criteria.","provider_requirements":"Academic centers.","residency_travel_notes":"EU trials.","risk_notes":"Investigational.","arbitrage_summary":"Germany/EU: trial pathway for mitochondrial peptides.","oversight_notes":"EMA/national trial oversight.","cost_notes":"Not commercial wellness.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mitochondrial_Health","Cardiology","Ophthalmology"],"diseases":["Barth Syndrome","Mitochondrial Myopathy","Dry AMD (investigational)"],"status":"active"},{"id":"4f92bf7f-acc1-4e92-ab35-81632e64bf60","procedure_id":"proc-car-t-solid","jurisdiction_id":"jur-us-federal","procedure_name":"Experimental CAR-T / TCR Therapy for Solid Tumors","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Trial (drug often free; care costs may apply)","price_usd":null,"access_pathway_details":"Solid-tumor CAR-T/TCR almost entirely clinical trials at major US centers.","eligibility_requirements":"Trial inclusion.","provider_requirements":"Academic cellular therapy centers.","residency_travel_notes":"Center travel.","risk_notes":"CRS/ICANS risk class.","arbitrage_summary":"US: trials only for solid-tumor CAR-T.","oversight_notes":"FDA IND.","cost_notes":"Not commercial SOC.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Oncology"],"diseases":["Advanced Solid Tumors","Gastric Cancer (trial)","Neuroblastoma (trial)"],"status":"active"},{"id":"9ca22ff6-ba2d-4b19-b113-94a0b558b158","procedure_id":"proc-car-t-solid","jurisdiction_id":"jur-kr","procedure_name":"Experimental CAR-T / TCR Therapy for Solid Tumors","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Trial","price_usd":null,"access_pathway_details":"Active cellular therapy trial ecosystem; solid-tumor CAR programs at research hospitals.","eligibility_requirements":"Trial criteria.","provider_requirements":"Research hospitals.","residency_travel_notes":"Seoul research hubs.","risk_notes":"Cellular therapy toxicities.","arbitrage_summary":"Korea: strong trial infrastructure for experimental cellular therapy.","oversight_notes":"MFDS trials.","cost_notes":"Some medical travel for trials.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Oncology"],"diseases":["Advanced Solid Tumors","Gastric Cancer (trial)","Neuroblastoma (trial)"],"status":"active"},{"id":"34bea299-8334-484f-a2e4-a271a936c009","procedure_id":"proc-car-t-solid","jurisdiction_id":"jur-jp","procedure_name":"Experimental CAR-T / TCR Therapy for Solid Tumors","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Trial","price_usd":null,"access_pathway_details":"Japan regenerative/cell therapy trial framework for solid tumors.","eligibility_requirements":"Trial protocols.","provider_requirements":"Academic hospitals.","residency_travel_notes":"Domestic.","risk_notes":"Trial risks.","arbitrage_summary":"Japan: trial/conditional regenerative pathways possible.","oversight_notes":"PMDA.","cost_notes":"Regenerative act may enable conditional paths later.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Oncology"],"diseases":["Advanced Solid Tumors","Gastric Cancer (trial)","Neuroblastoma (trial)"],"status":"active"},{"id":"46dc588a-f229-4bf3-9613-32207f3e1533","procedure_id":"proc-tms-ocd","jurisdiction_id":"jur-us-federal","procedure_name":"Deep TMS / TMS for Obsessive-Compulsive Disorder","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"$8k–18k/course","price_usd":12000.0,"access_pathway_details":"Deep TMS FDA-cleared for OCD; specialty clinics.","eligibility_requirements":"OCD diagnosis; failed standard treatments often required by payers.","provider_requirements":"TMS clinics / psychiatry.","residency_travel_notes":"Domestic.","risk_notes":"Standard TMS risks.","arbitrage_summary":"US: device-cleared OCD TMS pathway.","oversight_notes":"FDA device clearance.","cost_notes":"Prior auth common.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","OCD"],"diseases":["Obsessive-Compulsive Disorder"],"status":"active"},{"id":"fd201c2c-30b6-4b8c-a945-70dc1073f517","procedure_id":"proc-tms-ocd","jurisdiction_id":"jur-il","procedure_name":"Deep TMS / TMS for Obsessive-Compulsive Disorder","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"$6k–14k est.","price_usd":9000.0,"access_pathway_details":"Israeli deep TMS development heritage; clinical availability for OCD/depression protocols.","eligibility_requirements":"Specialist assessment.","provider_requirements":"Psychiatry clinics.","residency_travel_notes":"Medical travel possible.","risk_notes":"Standard risks.","arbitrage_summary":"Israel: notable TMS clinical ecosystem.","oversight_notes":"Ministry of Health devices.","cost_notes":"Regional expertise.","legal_basis":null,"regulatory_authority":null,"last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","OCD"],"diseases":["Obsessive-Compulsive Disorder"],"status":"active"},{"id":"24d6e105-26d0-4744-a6db-cde9f8687886","procedure_id":"proc-psilocybin-trd","jurisdiction_id":"jur-us-federal","procedure_name":"Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Federal Schedule I prohibits manufacture, distribution, and possession outside DEA-registered research. State programs (OR/CO) create subnational tension but do not repeal federal law.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"21 U.S.C. § 812 — Schedule I for LSD, psilocybin, MDMA, DMT, mescaline, etc.; no accepted medical use federally (except approved products like esketamine for ketamine class).","regulatory_authority":"DEA / FDA (Controlled Substances Act)","last_verified":"2026-07-01","sources":[{"title":"DEA Controlled Substance Schedules","url":"https://www.dea.gov/drug-information/drug-scheduling"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"f85f3825-5310-4815-b51e-3e7632569a70","procedure_id":"proc-psilocybin-eol","jurisdiction_id":"jur-us-federal","procedure_name":"Psilocybin-Assisted Therapy for End-of-Life Anxiety","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Federal Schedule I prohibits manufacture, distribution, and possession outside DEA-registered research. State programs (OR/CO) create subnational tension but do not repeal federal law.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"21 U.S.C. § 812 — Schedule I for LSD, psilocybin, MDMA, DMT, mescaline, etc.; no accepted medical use federally (except approved products like esketamine for ketamine class).","regulatory_authority":"DEA / FDA (Controlled Substances Act)","last_verified":"2026-07-01","sources":[{"title":"DEA Controlled Substance Schedules","url":"https://www.dea.gov/drug-information/drug-scheduling"}],"therapeutic_areas":["Mental_Health","Palliative_Care"],"diseases":["Cancer-Related Anxiety","End-of-Life Existential Distress","Adjustment Disorder"],"status":"active"},{"id":"d7534f54-db4d-42e7-be6c-626018b6b8e6","procedure_id":"proc-mdma-ptsd","jurisdiction_id":"jur-us-federal","procedure_name":"MDMA-Assisted Psychotherapy for PTSD","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Federal Schedule I prohibits manufacture, distribution, and possession outside DEA-registered research. State programs (OR/CO) create subnational tension but do not repeal federal law.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"21 U.S.C. § 812 — Schedule I for LSD, psilocybin, MDMA, DMT, mescaline, etc.; no accepted medical use federally (except approved products like esketamine for ketamine class).","regulatory_authority":"DEA / FDA (Controlled Substances Act)","last_verified":"2026-07-01","sources":[{"title":"DEA Controlled Substance Schedules","url":"https://www.dea.gov/drug-information/drug-scheduling"}],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["Post-Traumatic Stress Disorder (PTSD)"],"status":"active"},{"id":"f4f0e3fe-36a7-4d55-a422-926772202fe3","procedure_id":"proc-dmt-depression","jurisdiction_id":"jur-us-federal","procedure_name":"DMT (N,N-Dimethyltryptamine) Assisted Therapy for Depression","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Federal Schedule I prohibits manufacture, distribution, and possession outside DEA-registered research. State programs (OR/CO) create subnational tension but do not repeal federal law.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"21 U.S.C. § 812 — Schedule I for LSD, psilocybin, MDMA, DMT, mescaline, etc.; no accepted medical use federally (except approved products like esketamine for ketamine class).","regulatory_authority":"DEA / FDA (Controlled Substances Act)","last_verified":"2026-07-01","sources":[{"title":"DEA Controlled Substance Schedules","url":"https://www.dea.gov/drug-information/drug-scheduling"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Major Depressive Disorder","Treatment-Resistant Depression"],"status":"active"},{"id":"98f6d810-bd93-4fa1-b91e-88d729a6afd1","procedure_id":"proc-lsd-anxiety","jurisdiction_id":"jur-us-federal","procedure_name":"LSD-Assisted Psychotherapy for Anxiety Disorders","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Federal Schedule I prohibits manufacture, distribution, and possession outside DEA-registered research. State programs (OR/CO) create subnational tension but do not repeal federal law.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"21 U.S.C. § 812 — Schedule I for LSD, psilocybin, MDMA, DMT, mescaline, etc.; no accepted medical use federally (except approved products like esketamine for ketamine class).","regulatory_authority":"DEA / FDA (Controlled Substances Act)","last_verified":"2026-07-01","sources":[{"title":"DEA Controlled Substance Schedules","url":"https://www.dea.gov/drug-information/drug-scheduling"}],"therapeutic_areas":["Mental_Health","Anxiety"],"diseases":["Generalized Anxiety Disorder","Illness-Related Anxiety"],"status":"active"},{"id":"42e6b969-d40e-4679-8073-ac5640204e12","procedure_id":"proc-mescaline-therapy","jurisdiction_id":"jur-us-federal","procedure_name":"Mescaline-Assisted Therapy (San Pedro) for Depression/Addiction","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Federal Schedule I prohibits manufacture, distribution, and possession outside DEA-registered research. State programs (OR/CO) create subnational tension but do not repeal federal law.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"21 U.S.C. § 812 — Schedule I for LSD, psilocybin, MDMA, DMT, mescaline, etc.; no accepted medical use federally (except approved products like esketamine for ketamine class).","regulatory_authority":"DEA / FDA (Controlled Substances Act)","last_verified":"2026-07-01","sources":[{"title":"DEA Controlled Substance Schedules","url":"https://www.dea.gov/drug-information/drug-scheduling"}],"therapeutic_areas":["Mental_Health","Depression","Addiction"],"diseases":["Depression","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"b4bea0a4-01a0-4153-bfee-5d3d44a7058f","procedure_id":"proc-ibogaine-addiction","jurisdiction_id":"jur-us-federal","procedure_name":"Ibogaine Treatment for Opioid/Substance Use Disorder","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Federal Schedule I prohibits manufacture, distribution, and possession outside DEA-registered research. State programs (OR/CO) create subnational tension but do not repeal federal law.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"21 U.S.C. § 812 — Schedule I for LSD, psilocybin, MDMA, DMT, mescaline, etc.; no accepted medical use federally (except approved products like esketamine for ketamine class).","regulatory_authority":"DEA / FDA (Controlled Substances Act)","last_verified":"2026-07-01","sources":[{"title":"DEA Controlled Substance Schedules","url":"https://www.dea.gov/drug-information/drug-scheduling"}],"therapeutic_areas":["Mental_Health","Addiction"],"diseases":["Opioid Use Disorder","Substance Use Disorder"],"status":"active"},{"id":"f2008bc0-b19f-4911-855f-2e2389befe82","procedure_id":"proc-psilocybin-trd","jurisdiction_id":"jur-uk","procedure_name":"Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Clinical trials possible under licence; no Oregon-style service centres. Medical cannabis is a separate Class B / specialty pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Class A: LSD, psilocybin/psilocin, DMT, MDMA; no routine medical prescribing pathway.","regulatory_authority":"Home Office / MHRA (Misuse of Drugs Act 1971)","last_verified":"2026-07-01","sources":[{"title":"UK Misuse of Drugs Act","url":"https://www.gov.uk/government/publications/controlled-drugs-list--2"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"ed16249e-f0cb-4b17-a774-cd117526740e","procedure_id":"proc-psilocybin-eol","jurisdiction_id":"jur-uk","procedure_name":"Psilocybin-Assisted Therapy for End-of-Life Anxiety","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Clinical trials possible under licence; no Oregon-style service centres. Medical cannabis is a separate Class B / specialty pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Class A: LSD, psilocybin/psilocin, DMT, MDMA; no routine medical prescribing pathway.","regulatory_authority":"Home Office / MHRA (Misuse of Drugs Act 1971)","last_verified":"2026-07-01","sources":[{"title":"UK Misuse of Drugs Act","url":"https://www.gov.uk/government/publications/controlled-drugs-list--2"}],"therapeutic_areas":["Mental_Health","Palliative_Care"],"diseases":["Cancer-Related Anxiety","End-of-Life Existential Distress","Adjustment Disorder"],"status":"active"},{"id":"9d2ae4a9-a81a-4696-a76a-4d940ce1008a","procedure_id":"proc-psilocybin-microdose","jurisdiction_id":"jur-uk","procedure_name":"Psilocybin Microdosing Protocols","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Clinical trials possible under licence; no Oregon-style service centres. Medical cannabis is a separate Class B / specialty pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Class A: LSD, psilocybin/psilocin, DMT, MDMA; no routine medical prescribing pathway.","regulatory_authority":"Home Office / MHRA (Misuse of Drugs Act 1971)","last_verified":"2026-07-01","sources":[{"title":"UK Misuse of Drugs Act","url":"https://www.gov.uk/government/publications/controlled-drugs-list--2"}],"therapeutic_areas":["Mental_Health","Cognition"],"diseases":["Depression","Anxiety","ADHD Symptoms (self-report)"],"status":"active"},{"id":"3d2f0314-c27c-407b-9a39-4cffd5379c7e","procedure_id":"proc-mdma-ptsd","jurisdiction_id":"jur-uk","procedure_name":"MDMA-Assisted Psychotherapy for PTSD","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Clinical trials possible under licence; no Oregon-style service centres. Medical cannabis is a separate Class B / specialty pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Class A: LSD, psilocybin/psilocin, DMT, MDMA; no routine medical prescribing pathway.","regulatory_authority":"Home Office / MHRA (Misuse of Drugs Act 1971)","last_verified":"2026-07-01","sources":[{"title":"UK Misuse of Drugs Act","url":"https://www.gov.uk/government/publications/controlled-drugs-list--2"}],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["Post-Traumatic Stress Disorder (PTSD)"],"status":"active"},{"id":"52c3c910-18dd-4a1b-9aad-966a16ce4cd3","procedure_id":"proc-dmt-depression","jurisdiction_id":"jur-uk","procedure_name":"DMT (N,N-Dimethyltryptamine) Assisted Therapy for Depression","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Clinical trials possible under licence; no Oregon-style service centres. Medical cannabis is a separate Class B / specialty pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Class A: LSD, psilocybin/psilocin, DMT, MDMA; no routine medical prescribing pathway.","regulatory_authority":"Home Office / MHRA (Misuse of Drugs Act 1971)","last_verified":"2026-07-01","sources":[{"title":"UK Misuse of Drugs Act","url":"https://www.gov.uk/government/publications/controlled-drugs-list--2"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Major Depressive Disorder","Treatment-Resistant Depression"],"status":"active"},{"id":"3d5257ba-a49c-45a1-8f48-991f404d2c2a","procedure_id":"proc-lsd-anxiety","jurisdiction_id":"jur-uk","procedure_name":"LSD-Assisted Psychotherapy for Anxiety Disorders","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Clinical trials possible under licence; no Oregon-style service centres. Medical cannabis is a separate Class B / specialty pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Class A: LSD, psilocybin/psilocin, DMT, MDMA; no routine medical prescribing pathway.","regulatory_authority":"Home Office / MHRA (Misuse of Drugs Act 1971)","last_verified":"2026-07-01","sources":[{"title":"UK Misuse of Drugs Act","url":"https://www.gov.uk/government/publications/controlled-drugs-list--2"}],"therapeutic_areas":["Mental_Health","Anxiety"],"diseases":["Generalized Anxiety Disorder","Illness-Related Anxiety"],"status":"active"},{"id":"7a4f16e2-9140-492f-960b-7f7599207780","procedure_id":"proc-mescaline-therapy","jurisdiction_id":"jur-uk","procedure_name":"Mescaline-Assisted Therapy (San Pedro) for Depression/Addiction","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Clinical trials possible under licence; no Oregon-style service centres. Medical cannabis is a separate Class B / specialty pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Class A: LSD, psilocybin/psilocin, DMT, MDMA; no routine medical prescribing pathway.","regulatory_authority":"Home Office / MHRA (Misuse of Drugs Act 1971)","last_verified":"2026-07-01","sources":[{"title":"UK Misuse of Drugs Act","url":"https://www.gov.uk/government/publications/controlled-drugs-list--2"}],"therapeutic_areas":["Mental_Health","Depression","Addiction"],"diseases":["Depression","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"c2a10889-c4a4-47ae-8b70-0eca91c4da58","procedure_id":"proc-ayahuasca","jurisdiction_id":"jur-uk","procedure_name":"Ayahuasca-Assisted Therapy for Depression/Addiction/Spiritual Growth","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Clinical trials possible under licence; no Oregon-style service centres. Medical cannabis is a separate Class B / specialty pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Class A: LSD, psilocybin/psilocin, DMT, MDMA; no routine medical prescribing pathway.","regulatory_authority":"Home Office / MHRA (Misuse of Drugs Act 1971)","last_verified":"2026-07-01","sources":[{"title":"UK Misuse of Drugs Act","url":"https://www.gov.uk/government/publications/controlled-drugs-list--2"}],"therapeutic_areas":["Mental_Health","Addiction","Spirituality"],"diseases":["Depression","Substance Use Disorder","PTSD","Existential Distress"],"status":"active"},{"id":"a7b82b88-2d0a-44b7-949c-c147afe741aa","procedure_id":"proc-5meo-dmt","jurisdiction_id":"jur-uk","procedure_name":"5-MeO-DMT Assisted Therapy","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Clinical trials possible under licence; no Oregon-style service centres. Medical cannabis is a separate Class B / specialty pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Class A: LSD, psilocybin/psilocin, DMT, MDMA; no routine medical prescribing pathway.","regulatory_authority":"Home Office / MHRA (Misuse of Drugs Act 1971)","last_verified":"2026-07-01","sources":[{"title":"UK Misuse of Drugs Act","url":"https://www.gov.uk/government/publications/controlled-drugs-list--2"}],"therapeutic_areas":["Mental_Health","Spirituality"],"diseases":["Depression","Anxiety","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"c11aa73b-d2ee-48d2-8cb3-43f34a3ce3da","procedure_id":"proc-ibogaine-addiction","jurisdiction_id":"jur-uk","procedure_name":"Ibogaine Treatment for Opioid/Substance Use Disorder","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Clinical trials possible under licence; no Oregon-style service centres. Medical cannabis is a separate Class B / specialty pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Class A: LSD, psilocybin/psilocin, DMT, MDMA; no routine medical prescribing pathway.","regulatory_authority":"Home Office / MHRA (Misuse of Drugs Act 1971)","last_verified":"2026-07-01","sources":[{"title":"UK Misuse of Drugs Act","url":"https://www.gov.uk/government/publications/controlled-drugs-list--2"}],"therapeutic_areas":["Mental_Health","Addiction"],"diseases":["Opioid Use Disorder","Substance Use Disorder"],"status":"active"},{"id":"589ddc66-4431-48cc-9c9c-b8faa84ea817","procedure_id":"proc-psilocybin-trd","jurisdiction_id":"jur-de","procedure_name":"Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Research possible under narcotics permits; no general therapeutic programme for psilocybin/MDMA/LSD as of review date.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Betäubungsmittelgesetz — classical psychedelics largely non-marketable narcotics; medical exceptions narrow.","regulatory_authority":"BfArM / BtMG","last_verified":"2026-07-01","sources":[{"title":"BfArM narcotics","url":"https://www.bfarm.de"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"6e7d077f-9653-4967-9908-48600d61b4d3","procedure_id":"proc-psilocybin-eol","jurisdiction_id":"jur-de","procedure_name":"Psilocybin-Assisted Therapy for End-of-Life Anxiety","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Research possible under narcotics permits; no general therapeutic programme for psilocybin/MDMA/LSD as of review date.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Betäubungsmittelgesetz — classical psychedelics largely non-marketable narcotics; medical exceptions narrow.","regulatory_authority":"BfArM / BtMG","last_verified":"2026-07-01","sources":[{"title":"BfArM narcotics","url":"https://www.bfarm.de"}],"therapeutic_areas":["Mental_Health","Palliative_Care"],"diseases":["Cancer-Related Anxiety","End-of-Life Existential Distress","Adjustment Disorder"],"status":"active"},{"id":"18b49800-5cd1-42c5-9928-72e4067e9eef","procedure_id":"proc-psilocybin-microdose","jurisdiction_id":"jur-de","procedure_name":"Psilocybin Microdosing Protocols","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Research possible under narcotics permits; no general therapeutic programme for psilocybin/MDMA/LSD as of review date.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Betäubungsmittelgesetz — classical psychedelics largely non-marketable narcotics; medical exceptions narrow.","regulatory_authority":"BfArM / BtMG","last_verified":"2026-07-01","sources":[{"title":"BfArM narcotics","url":"https://www.bfarm.de"}],"therapeutic_areas":["Mental_Health","Cognition"],"diseases":["Depression","Anxiety","ADHD Symptoms (self-report)"],"status":"active"},{"id":"709de2ff-15ea-468c-a265-d6e572ed1f82","procedure_id":"proc-mdma-ptsd","jurisdiction_id":"jur-de","procedure_name":"MDMA-Assisted Psychotherapy for PTSD","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Research possible under narcotics permits; no general therapeutic programme for psilocybin/MDMA/LSD as of review date.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Betäubungsmittelgesetz — classical psychedelics largely non-marketable narcotics; medical exceptions narrow.","regulatory_authority":"BfArM / BtMG","last_verified":"2026-07-01","sources":[{"title":"BfArM narcotics","url":"https://www.bfarm.de"}],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["Post-Traumatic Stress Disorder (PTSD)"],"status":"active"},{"id":"277f2e74-bb7e-49c9-be15-6ba837695215","procedure_id":"proc-dmt-depression","jurisdiction_id":"jur-de","procedure_name":"DMT (N,N-Dimethyltryptamine) Assisted Therapy for Depression","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Research possible under narcotics permits; no general therapeutic programme for psilocybin/MDMA/LSD as of review date.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Betäubungsmittelgesetz — classical psychedelics largely non-marketable narcotics; medical exceptions narrow.","regulatory_authority":"BfArM / BtMG","last_verified":"2026-07-01","sources":[{"title":"BfArM narcotics","url":"https://www.bfarm.de"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Major Depressive Disorder","Treatment-Resistant Depression"],"status":"active"},{"id":"a1d401ae-41a8-4386-8f34-3c6a4a6be41b","procedure_id":"proc-lsd-anxiety","jurisdiction_id":"jur-de","procedure_name":"LSD-Assisted Psychotherapy for Anxiety Disorders","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Research possible under narcotics permits; no general therapeutic programme for psilocybin/MDMA/LSD as of review date.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Betäubungsmittelgesetz — classical psychedelics largely non-marketable narcotics; medical exceptions narrow.","regulatory_authority":"BfArM / BtMG","last_verified":"2026-07-01","sources":[{"title":"BfArM narcotics","url":"https://www.bfarm.de"}],"therapeutic_areas":["Mental_Health","Anxiety"],"diseases":["Generalized Anxiety Disorder","Illness-Related Anxiety"],"status":"active"},{"id":"88bc393b-eb2b-4cca-aec6-4ec286f20830","procedure_id":"proc-mescaline-therapy","jurisdiction_id":"jur-de","procedure_name":"Mescaline-Assisted Therapy (San Pedro) for Depression/Addiction","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Research possible under narcotics permits; no general therapeutic programme for psilocybin/MDMA/LSD as of review date.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Betäubungsmittelgesetz — classical psychedelics largely non-marketable narcotics; medical exceptions narrow.","regulatory_authority":"BfArM / BtMG","last_verified":"2026-07-01","sources":[{"title":"BfArM narcotics","url":"https://www.bfarm.de"}],"therapeutic_areas":["Mental_Health","Depression","Addiction"],"diseases":["Depression","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"24955ff9-d1ec-4a07-b2e8-a4fdeeb61195","procedure_id":"proc-ayahuasca","jurisdiction_id":"jur-de","procedure_name":"Ayahuasca-Assisted Therapy for Depression/Addiction/Spiritual Growth","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Research possible under narcotics permits; no general therapeutic programme for psilocybin/MDMA/LSD as of review date.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Betäubungsmittelgesetz — classical psychedelics largely non-marketable narcotics; medical exceptions narrow.","regulatory_authority":"BfArM / BtMG","last_verified":"2026-07-01","sources":[{"title":"BfArM narcotics","url":"https://www.bfarm.de"}],"therapeutic_areas":["Mental_Health","Addiction","Spirituality"],"diseases":["Depression","Substance Use Disorder","PTSD","Existential Distress"],"status":"active"},{"id":"7580cae7-1230-4296-8d0b-cb6e9aed30f1","procedure_id":"proc-5meo-dmt","jurisdiction_id":"jur-de","procedure_name":"5-MeO-DMT Assisted Therapy","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Research possible under narcotics permits; no general therapeutic programme for psilocybin/MDMA/LSD as of review date.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Betäubungsmittelgesetz — classical psychedelics largely non-marketable narcotics; medical exceptions narrow.","regulatory_authority":"BfArM / BtMG","last_verified":"2026-07-01","sources":[{"title":"BfArM narcotics","url":"https://www.bfarm.de"}],"therapeutic_areas":["Mental_Health","Spirituality"],"diseases":["Depression","Anxiety","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"bd93cf07-dc78-47d0-9736-660a7af5a476","procedure_id":"proc-ibogaine-addiction","jurisdiction_id":"jur-de","procedure_name":"Ibogaine Treatment for Opioid/Substance Use Disorder","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Research possible under narcotics permits; no general therapeutic programme for psilocybin/MDMA/LSD as of review date.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Betäubungsmittelgesetz — classical psychedelics largely non-marketable narcotics; medical exceptions narrow.","regulatory_authority":"BfArM / BtMG","last_verified":"2026-07-01","sources":[{"title":"BfArM narcotics","url":"https://www.bfarm.de"}],"therapeutic_areas":["Mental_Health","Addiction"],"diseases":["Opioid Use Disorder","Substance Use Disorder"],"status":"active"},{"id":"175eb778-7586-4a64-be1f-ef914d9f4fc2","procedure_id":"proc-psilocybin-trd","jurisdiction_id":"jur-fr","procedure_name":"Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Research/ATU-class pathways are exceptional; commercial psychedelic therapy not authorised.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Stupefiants scheduling for classical psychedelics; no general medical access programme.","regulatory_authority":"ANSM / Code de la santé publique","last_verified":"2026-07-01","sources":[{"title":"ANSM","url":"https://ansm.sante.fr"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"cc330cc6-6c59-4f00-958c-f63a1bb8bdcd","procedure_id":"proc-psilocybin-eol","jurisdiction_id":"jur-fr","procedure_name":"Psilocybin-Assisted Therapy for End-of-Life Anxiety","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Research/ATU-class pathways are exceptional; commercial psychedelic therapy not authorised.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Stupefiants scheduling for classical psychedelics; no general medical access programme.","regulatory_authority":"ANSM / Code de la santé publique","last_verified":"2026-07-01","sources":[{"title":"ANSM","url":"https://ansm.sante.fr"}],"therapeutic_areas":["Mental_Health","Palliative_Care"],"diseases":["Cancer-Related Anxiety","End-of-Life Existential Distress","Adjustment Disorder"],"status":"active"},{"id":"bb7739ea-d188-40d5-8b2e-59e9a0a77a10","procedure_id":"proc-psilocybin-microdose","jurisdiction_id":"jur-fr","procedure_name":"Psilocybin Microdosing Protocols","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Research/ATU-class pathways are exceptional; commercial psychedelic therapy not authorised.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Stupefiants scheduling for classical psychedelics; no general medical access programme.","regulatory_authority":"ANSM / Code de la santé publique","last_verified":"2026-07-01","sources":[{"title":"ANSM","url":"https://ansm.sante.fr"}],"therapeutic_areas":["Mental_Health","Cognition"],"diseases":["Depression","Anxiety","ADHD Symptoms (self-report)"],"status":"active"},{"id":"aa774f56-42d2-40fd-945f-03a768f231c7","procedure_id":"proc-mdma-ptsd","jurisdiction_id":"jur-fr","procedure_name":"MDMA-Assisted Psychotherapy for PTSD","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Research/ATU-class pathways are exceptional; commercial psychedelic therapy not authorised.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Stupefiants scheduling for classical psychedelics; no general medical access programme.","regulatory_authority":"ANSM / Code de la santé publique","last_verified":"2026-07-01","sources":[{"title":"ANSM","url":"https://ansm.sante.fr"}],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["Post-Traumatic Stress Disorder (PTSD)"],"status":"active"},{"id":"13c39f52-51d9-4180-83a0-e02e92824a30","procedure_id":"proc-dmt-depression","jurisdiction_id":"jur-fr","procedure_name":"DMT (N,N-Dimethyltryptamine) Assisted Therapy for Depression","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Research/ATU-class pathways are exceptional; commercial psychedelic therapy not authorised.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Stupefiants scheduling for classical psychedelics; no general medical access programme.","regulatory_authority":"ANSM / Code de la santé publique","last_verified":"2026-07-01","sources":[{"title":"ANSM","url":"https://ansm.sante.fr"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Major Depressive Disorder","Treatment-Resistant Depression"],"status":"active"},{"id":"56cee17f-ce7e-4751-9137-ba849d7b5961","procedure_id":"proc-lsd-anxiety","jurisdiction_id":"jur-fr","procedure_name":"LSD-Assisted Psychotherapy for Anxiety Disorders","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Research/ATU-class pathways are exceptional; commercial psychedelic therapy not authorised.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Stupefiants scheduling for classical psychedelics; no general medical access programme.","regulatory_authority":"ANSM / Code de la santé publique","last_verified":"2026-07-01","sources":[{"title":"ANSM","url":"https://ansm.sante.fr"}],"therapeutic_areas":["Mental_Health","Anxiety"],"diseases":["Generalized Anxiety Disorder","Illness-Related Anxiety"],"status":"active"},{"id":"edb6c014-0418-454e-aed9-e9f1e8dad67d","procedure_id":"proc-mescaline-therapy","jurisdiction_id":"jur-fr","procedure_name":"Mescaline-Assisted Therapy (San Pedro) for Depression/Addiction","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Research/ATU-class pathways are exceptional; commercial psychedelic therapy not authorised.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Stupefiants scheduling for classical psychedelics; no general medical access programme.","regulatory_authority":"ANSM / Code de la santé publique","last_verified":"2026-07-01","sources":[{"title":"ANSM","url":"https://ansm.sante.fr"}],"therapeutic_areas":["Mental_Health","Depression","Addiction"],"diseases":["Depression","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"dbb110cd-841e-4c03-8744-53e70dcdb7de","procedure_id":"proc-ayahuasca","jurisdiction_id":"jur-fr","procedure_name":"Ayahuasca-Assisted Therapy for Depression/Addiction/Spiritual Growth","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Research/ATU-class pathways are exceptional; commercial psychedelic therapy not authorised.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Stupefiants scheduling for classical psychedelics; no general medical access programme.","regulatory_authority":"ANSM / Code de la santé publique","last_verified":"2026-07-01","sources":[{"title":"ANSM","url":"https://ansm.sante.fr"}],"therapeutic_areas":["Mental_Health","Addiction","Spirituality"],"diseases":["Depression","Substance Use Disorder","PTSD","Existential Distress"],"status":"active"},{"id":"7d3eccf8-d53c-4c1e-b425-f0f37e235952","procedure_id":"proc-5meo-dmt","jurisdiction_id":"jur-fr","procedure_name":"5-MeO-DMT Assisted Therapy","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Research/ATU-class pathways are exceptional; commercial psychedelic therapy not authorised.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Stupefiants scheduling for classical psychedelics; no general medical access programme.","regulatory_authority":"ANSM / Code de la santé publique","last_verified":"2026-07-01","sources":[{"title":"ANSM","url":"https://ansm.sante.fr"}],"therapeutic_areas":["Mental_Health","Spirituality"],"diseases":["Depression","Anxiety","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"0a519ec2-ab2f-451a-af14-db69d52e7ec9","procedure_id":"proc-ibogaine-addiction","jurisdiction_id":"jur-fr","procedure_name":"Ibogaine Treatment for Opioid/Substance Use Disorder","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Research/ATU-class pathways are exceptional; commercial psychedelic therapy not authorised.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Stupefiants scheduling for classical psychedelics; no general medical access programme.","regulatory_authority":"ANSM / Code de la santé publique","last_verified":"2026-07-01","sources":[{"title":"ANSM","url":"https://ansm.sante.fr"}],"therapeutic_areas":["Mental_Health","Addiction"],"diseases":["Opioid Use Disorder","Substance Use Disorder"],"status":"active"},{"id":"091c36fa-7ccf-443b-8e72-db8f97d42a81","procedure_id":"proc-psilocybin-trd","jurisdiction_id":"jur-es","procedure_name":"Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Private consumption nuances do not create a regulated therapy supply.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Spanish narcotics control aligned with UN conventions — classical psychedelics prohibited outside research.","regulatory_authority":"AEMPS","last_verified":"2026-07-01","sources":[{"title":"AEMPS","url":"https://www.aemps.gob.es"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"379b0e8f-2ac7-458c-a8c6-4d3834a54f9e","procedure_id":"proc-psilocybin-eol","jurisdiction_id":"jur-es","procedure_name":"Psilocybin-Assisted Therapy for End-of-Life Anxiety","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Private consumption nuances do not create a regulated therapy supply.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Spanish narcotics control aligned with UN conventions — classical psychedelics prohibited outside research.","regulatory_authority":"AEMPS","last_verified":"2026-07-01","sources":[{"title":"AEMPS","url":"https://www.aemps.gob.es"}],"therapeutic_areas":["Mental_Health","Palliative_Care"],"diseases":["Cancer-Related Anxiety","End-of-Life Existential Distress","Adjustment Disorder"],"status":"active"},{"id":"be00a841-61d5-4ec6-9195-2f196d75e0ea","procedure_id":"proc-psilocybin-microdose","jurisdiction_id":"jur-es","procedure_name":"Psilocybin Microdosing Protocols","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Private consumption nuances do not create a regulated therapy supply.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Spanish narcotics control aligned with UN conventions — classical psychedelics prohibited outside research.","regulatory_authority":"AEMPS","last_verified":"2026-07-01","sources":[{"title":"AEMPS","url":"https://www.aemps.gob.es"}],"therapeutic_areas":["Mental_Health","Cognition"],"diseases":["Depression","Anxiety","ADHD Symptoms (self-report)"],"status":"active"},{"id":"e9813155-34a0-4aa1-b128-ed7d6a226105","procedure_id":"proc-mdma-ptsd","jurisdiction_id":"jur-es","procedure_name":"MDMA-Assisted Psychotherapy for PTSD","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Private consumption nuances do not create a regulated therapy supply.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Spanish narcotics control aligned with UN conventions — classical psychedelics prohibited outside research.","regulatory_authority":"AEMPS","last_verified":"2026-07-01","sources":[{"title":"AEMPS","url":"https://www.aemps.gob.es"}],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["Post-Traumatic Stress Disorder (PTSD)"],"status":"active"},{"id":"d98faa07-fd6b-40fe-bf16-68ed76ad017a","procedure_id":"proc-dmt-depression","jurisdiction_id":"jur-es","procedure_name":"DMT (N,N-Dimethyltryptamine) Assisted Therapy for Depression","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Private consumption nuances do not create a regulated therapy supply.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Spanish narcotics control aligned with UN conventions — classical psychedelics prohibited outside research.","regulatory_authority":"AEMPS","last_verified":"2026-07-01","sources":[{"title":"AEMPS","url":"https://www.aemps.gob.es"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Major Depressive Disorder","Treatment-Resistant Depression"],"status":"active"},{"id":"62bd4243-c75a-4296-ab65-ed9fa572bbfd","procedure_id":"proc-lsd-anxiety","jurisdiction_id":"jur-es","procedure_name":"LSD-Assisted Psychotherapy for Anxiety Disorders","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Private consumption nuances do not create a regulated therapy supply.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Spanish narcotics control aligned with UN conventions — classical psychedelics prohibited outside research.","regulatory_authority":"AEMPS","last_verified":"2026-07-01","sources":[{"title":"AEMPS","url":"https://www.aemps.gob.es"}],"therapeutic_areas":["Mental_Health","Anxiety"],"diseases":["Generalized Anxiety Disorder","Illness-Related Anxiety"],"status":"active"},{"id":"87c0439b-8aa6-4164-9d0b-28f6708a067f","procedure_id":"proc-mescaline-therapy","jurisdiction_id":"jur-es","procedure_name":"Mescaline-Assisted Therapy (San Pedro) for Depression/Addiction","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Private consumption nuances do not create a regulated therapy supply.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Spanish narcotics control aligned with UN conventions — classical psychedelics prohibited outside research.","regulatory_authority":"AEMPS","last_verified":"2026-07-01","sources":[{"title":"AEMPS","url":"https://www.aemps.gob.es"}],"therapeutic_areas":["Mental_Health","Depression","Addiction"],"diseases":["Depression","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"c9becbca-6930-44a5-8a3b-a7d0725186f9","procedure_id":"proc-ayahuasca","jurisdiction_id":"jur-es","procedure_name":"Ayahuasca-Assisted Therapy for Depression/Addiction/Spiritual Growth","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Private consumption nuances do not create a regulated therapy supply.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Spanish narcotics control aligned with UN conventions — classical psychedelics prohibited outside research.","regulatory_authority":"AEMPS","last_verified":"2026-07-01","sources":[{"title":"AEMPS","url":"https://www.aemps.gob.es"}],"therapeutic_areas":["Mental_Health","Addiction","Spirituality"],"diseases":["Depression","Substance Use Disorder","PTSD","Existential Distress"],"status":"active"},{"id":"5a075e6a-4bc6-4ba8-852f-a27b41478aca","procedure_id":"proc-5meo-dmt","jurisdiction_id":"jur-es","procedure_name":"5-MeO-DMT Assisted Therapy","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Private consumption nuances do not create a regulated therapy supply.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Spanish narcotics control aligned with UN conventions — classical psychedelics prohibited outside research.","regulatory_authority":"AEMPS","last_verified":"2026-07-01","sources":[{"title":"AEMPS","url":"https://www.aemps.gob.es"}],"therapeutic_areas":["Mental_Health","Spirituality"],"diseases":["Depression","Anxiety","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"27aea4ee-c45b-4989-bd3d-356fd6a2fd22","procedure_id":"proc-ibogaine-addiction","jurisdiction_id":"jur-es","procedure_name":"Ibogaine Treatment for Opioid/Substance Use Disorder","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Private consumption nuances do not create a regulated therapy supply.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Spanish narcotics control aligned with UN conventions — classical psychedelics prohibited outside research.","regulatory_authority":"AEMPS","last_verified":"2026-07-01","sources":[{"title":"AEMPS","url":"https://www.aemps.gob.es"}],"therapeutic_areas":["Mental_Health","Addiction"],"diseases":["Opioid Use Disorder","Substance Use Disorder"],"status":"active"},{"id":"dc33419c-3086-4b84-b8f6-4481f86a6163","procedure_id":"proc-psilocybin-trd","jurisdiction_id":"jur-nl","procedure_name":"Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Do not conflate legal truffle retail with lawful MDMA/LSD/mushroom therapy clinics. MDMA/LSD remain prohibited outside research. Soft exception: psilocybin sclerotia (truffles) sold in smart shops are legal retail — not the same as licensed therapy or mushroom fruiting bodies.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Hard drugs list includes psilocybin mushrooms, LSD, MDMA, DMT; sclerotia (truffles) are a famous exception for psilocin-containing material.","regulatory_authority":"IGJ / Opiumwet","last_verified":"2026-07-01","sources":[{"title":"Dutch Opium Act overview","url":"https://www.government.nl"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"8a4be714-2e82-4f35-b239-a660289b2f1e","procedure_id":"proc-psilocybin-eol","jurisdiction_id":"jur-nl","procedure_name":"Psilocybin-Assisted Therapy for End-of-Life Anxiety","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Do not conflate legal truffle retail with lawful MDMA/LSD/mushroom therapy clinics. MDMA/LSD remain prohibited outside research. Soft exception: psilocybin sclerotia (truffles) sold in smart shops are legal retail — not the same as licensed therapy or mushroom fruiting bodies.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Hard drugs list includes psilocybin mushrooms, LSD, MDMA, DMT; sclerotia (truffles) are a famous exception for psilocin-containing material.","regulatory_authority":"IGJ / Opiumwet","last_verified":"2026-07-01","sources":[{"title":"Dutch Opium Act overview","url":"https://www.government.nl"}],"therapeutic_areas":["Mental_Health","Palliative_Care"],"diseases":["Cancer-Related Anxiety","End-of-Life Existential Distress","Adjustment Disorder"],"status":"active"},{"id":"2b19df3c-863b-4e54-8207-0e3861439e19","procedure_id":"proc-mdma-ptsd","jurisdiction_id":"jur-nl","procedure_name":"MDMA-Assisted Psychotherapy for PTSD","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Do not conflate legal truffle retail with lawful MDMA/LSD/mushroom therapy clinics. MDMA/LSD remain prohibited outside research.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Hard drugs list includes psilocybin mushrooms, LSD, MDMA, DMT; sclerotia (truffles) are a famous exception for psilocin-containing material.","regulatory_authority":"IGJ / Opiumwet","last_verified":"2026-07-01","sources":[{"title":"Dutch Opium Act overview","url":"https://www.government.nl"}],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["Post-Traumatic Stress Disorder (PTSD)"],"status":"active"},{"id":"bcf80b2a-d32d-4422-b213-099fb66ce17e","procedure_id":"proc-dmt-depression","jurisdiction_id":"jur-nl","procedure_name":"DMT (N,N-Dimethyltryptamine) Assisted Therapy for Depression","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Do not conflate legal truffle retail with lawful MDMA/LSD/mushroom therapy clinics. MDMA/LSD remain prohibited outside research.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Hard drugs list includes psilocybin mushrooms, LSD, MDMA, DMT; sclerotia (truffles) are a famous exception for psilocin-containing material.","regulatory_authority":"IGJ / Opiumwet","last_verified":"2026-07-01","sources":[{"title":"Dutch Opium Act overview","url":"https://www.government.nl"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Major Depressive Disorder","Treatment-Resistant Depression"],"status":"active"},{"id":"15575e9e-f7f4-4b0f-ade0-9572c1cc0908","procedure_id":"proc-lsd-anxiety","jurisdiction_id":"jur-nl","procedure_name":"LSD-Assisted Psychotherapy for Anxiety Disorders","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Do not conflate legal truffle retail with lawful MDMA/LSD/mushroom therapy clinics. MDMA/LSD remain prohibited outside research.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Hard drugs list includes psilocybin mushrooms, LSD, MDMA, DMT; sclerotia (truffles) are a famous exception for psilocin-containing material.","regulatory_authority":"IGJ / Opiumwet","last_verified":"2026-07-01","sources":[{"title":"Dutch Opium Act overview","url":"https://www.government.nl"}],"therapeutic_areas":["Mental_Health","Anxiety"],"diseases":["Generalized Anxiety Disorder","Illness-Related Anxiety"],"status":"active"},{"id":"f51118d9-fdd0-4743-9cd2-0b77023e397c","procedure_id":"proc-mescaline-therapy","jurisdiction_id":"jur-nl","procedure_name":"Mescaline-Assisted Therapy (San Pedro) for Depression/Addiction","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Do not conflate legal truffle retail with lawful MDMA/LSD/mushroom therapy clinics. MDMA/LSD remain prohibited outside research.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Hard drugs list includes psilocybin mushrooms, LSD, MDMA, DMT; sclerotia (truffles) are a famous exception for psilocin-containing material.","regulatory_authority":"IGJ / Opiumwet","last_verified":"2026-07-01","sources":[{"title":"Dutch Opium Act overview","url":"https://www.government.nl"}],"therapeutic_areas":["Mental_Health","Depression","Addiction"],"diseases":["Depression","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"acee3576-ab59-4c63-af0b-e96375ec7d1e","procedure_id":"proc-5meo-dmt","jurisdiction_id":"jur-nl","procedure_name":"5-MeO-DMT Assisted Therapy","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Do not conflate legal truffle retail with lawful MDMA/LSD/mushroom therapy clinics. MDMA/LSD remain prohibited outside research.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Hard drugs list includes psilocybin mushrooms, LSD, MDMA, DMT; sclerotia (truffles) are a famous exception for psilocin-containing material.","regulatory_authority":"IGJ / Opiumwet","last_verified":"2026-07-01","sources":[{"title":"Dutch Opium Act overview","url":"https://www.government.nl"}],"therapeutic_areas":["Mental_Health","Spirituality"],"diseases":["Depression","Anxiety","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"73dd5103-7e58-486b-b3cd-1f2d8e46d942","procedure_id":"proc-ibogaine-addiction","jurisdiction_id":"jur-nl","procedure_name":"Ibogaine Treatment for Opioid/Substance Use Disorder","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Do not conflate legal truffle retail with lawful MDMA/LSD/mushroom therapy clinics. MDMA/LSD remain prohibited outside research.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Hard drugs list includes psilocybin mushrooms, LSD, MDMA, DMT; sclerotia (truffles) are a famous exception for psilocin-containing material.","regulatory_authority":"IGJ / Opiumwet","last_verified":"2026-07-01","sources":[{"title":"Dutch Opium Act overview","url":"https://www.government.nl"}],"therapeutic_areas":["Mental_Health","Addiction"],"diseases":["Opioid Use Disorder","Substance Use Disorder"],"status":"active"},{"id":"18754596-b9ef-4046-9668-6cfe3554ae74","procedure_id":"proc-psilocybin-trd","jurisdiction_id":"jur-be","procedure_name":"Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No general psychedelic therapy licensing.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Narcotics law — classical psychedelics prohibited outside authorised research.","regulatory_authority":"FAMHP","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"6a054d29-d3a6-474e-9bb5-da104ee283a4","procedure_id":"proc-psilocybin-eol","jurisdiction_id":"jur-be","procedure_name":"Psilocybin-Assisted Therapy for End-of-Life Anxiety","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No general psychedelic therapy licensing.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Narcotics law — classical psychedelics prohibited outside authorised research.","regulatory_authority":"FAMHP","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Palliative_Care"],"diseases":["Cancer-Related Anxiety","End-of-Life Existential Distress","Adjustment Disorder"],"status":"active"},{"id":"ddd3faa5-93b1-481f-9a81-5f7fbbb5ad9c","procedure_id":"proc-psilocybin-microdose","jurisdiction_id":"jur-be","procedure_name":"Psilocybin Microdosing Protocols","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No general psychedelic therapy licensing.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Narcotics law — classical psychedelics prohibited outside authorised research.","regulatory_authority":"FAMHP","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Cognition"],"diseases":["Depression","Anxiety","ADHD Symptoms (self-report)"],"status":"active"},{"id":"20cc1e38-6fed-41f8-9379-85772f0db767","procedure_id":"proc-mdma-ptsd","jurisdiction_id":"jur-be","procedure_name":"MDMA-Assisted Psychotherapy for PTSD","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No general psychedelic therapy licensing.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Narcotics law — classical psychedelics prohibited outside authorised research.","regulatory_authority":"FAMHP","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["Post-Traumatic Stress Disorder (PTSD)"],"status":"active"},{"id":"94d1a8cd-3cd9-4957-a2de-53deb4108713","procedure_id":"proc-dmt-depression","jurisdiction_id":"jur-be","procedure_name":"DMT (N,N-Dimethyltryptamine) Assisted Therapy for Depression","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No general psychedelic therapy licensing.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Narcotics law — classical psychedelics prohibited outside authorised research.","regulatory_authority":"FAMHP","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Major Depressive Disorder","Treatment-Resistant Depression"],"status":"active"},{"id":"f29f0f0f-d2f1-44fa-b24c-6dfd23c6064d","procedure_id":"proc-lsd-anxiety","jurisdiction_id":"jur-be","procedure_name":"LSD-Assisted Psychotherapy for Anxiety Disorders","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No general psychedelic therapy licensing.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Narcotics law — classical psychedelics prohibited outside authorised research.","regulatory_authority":"FAMHP","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Anxiety"],"diseases":["Generalized Anxiety Disorder","Illness-Related Anxiety"],"status":"active"},{"id":"7a6b2c00-c3bd-420d-bab0-b93e6c8770c1","procedure_id":"proc-mescaline-therapy","jurisdiction_id":"jur-be","procedure_name":"Mescaline-Assisted Therapy (San Pedro) for Depression/Addiction","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No general psychedelic therapy licensing.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Narcotics law — classical psychedelics prohibited outside authorised research.","regulatory_authority":"FAMHP","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression","Addiction"],"diseases":["Depression","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"1b85f7f8-3f52-4410-8976-ba49ed75dfe7","procedure_id":"proc-ayahuasca","jurisdiction_id":"jur-be","procedure_name":"Ayahuasca-Assisted Therapy for Depression/Addiction/Spiritual Growth","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No general psychedelic therapy licensing.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Narcotics law — classical psychedelics prohibited outside authorised research.","regulatory_authority":"FAMHP","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Addiction","Spirituality"],"diseases":["Depression","Substance Use Disorder","PTSD","Existential Distress"],"status":"active"},{"id":"7b74d816-7d29-4dd2-adbe-9dd6e6a43203","procedure_id":"proc-5meo-dmt","jurisdiction_id":"jur-be","procedure_name":"5-MeO-DMT Assisted Therapy","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No general psychedelic therapy licensing.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Narcotics law — classical psychedelics prohibited outside authorised research.","regulatory_authority":"FAMHP","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Spirituality"],"diseases":["Depression","Anxiety","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"a2a4d556-dd68-4bb9-a07d-2834116727f8","procedure_id":"proc-ibogaine-addiction","jurisdiction_id":"jur-be","procedure_name":"Ibogaine Treatment for Opioid/Substance Use Disorder","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No general psychedelic therapy licensing.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Narcotics law — classical psychedelics prohibited outside authorised research.","regulatory_authority":"FAMHP","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Addiction"],"diseases":["Opioid Use Disorder","Substance Use Disorder"],"status":"active"},{"id":"cbab8c0c-dc29-4136-8327-f5282869aebb","procedure_id":"proc-psilocybin-trd","jurisdiction_id":"jur-se","procedure_name":"Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Research possible under permit; no public therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Narcotic drugs classification — classical psychedelics illegal.","regulatory_authority":"Läkemedelsverket / police narcotics control","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"d09f4e2f-dab6-429f-a7c5-d658a16e42e8","procedure_id":"proc-psilocybin-eol","jurisdiction_id":"jur-se","procedure_name":"Psilocybin-Assisted Therapy for End-of-Life Anxiety","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Research possible under permit; no public therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Narcotic drugs classification — classical psychedelics illegal.","regulatory_authority":"Läkemedelsverket / police narcotics control","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Palliative_Care"],"diseases":["Cancer-Related Anxiety","End-of-Life Existential Distress","Adjustment Disorder"],"status":"active"},{"id":"a0d11d96-4cb0-44e0-a48a-36ea68c98e08","procedure_id":"proc-psilocybin-microdose","jurisdiction_id":"jur-se","procedure_name":"Psilocybin Microdosing Protocols","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Research possible under permit; no public therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Narcotic drugs classification — classical psychedelics illegal.","regulatory_authority":"Läkemedelsverket / police narcotics control","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Cognition"],"diseases":["Depression","Anxiety","ADHD Symptoms (self-report)"],"status":"active"},{"id":"ec3b2ab9-583c-47a7-8493-b7af2e96626b","procedure_id":"proc-mdma-ptsd","jurisdiction_id":"jur-se","procedure_name":"MDMA-Assisted Psychotherapy for PTSD","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Research possible under permit; no public therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Narcotic drugs classification — classical psychedelics illegal.","regulatory_authority":"Läkemedelsverket / police narcotics control","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["Post-Traumatic Stress Disorder (PTSD)"],"status":"active"},{"id":"71fffc79-4b5d-4aa4-99d8-1d077861be77","procedure_id":"proc-dmt-depression","jurisdiction_id":"jur-se","procedure_name":"DMT (N,N-Dimethyltryptamine) Assisted Therapy for Depression","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Research possible under permit; no public therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Narcotic drugs classification — classical psychedelics illegal.","regulatory_authority":"Läkemedelsverket / police narcotics control","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Major Depressive Disorder","Treatment-Resistant Depression"],"status":"active"},{"id":"53c22c29-15f7-4f92-beec-a2a6611bc6b7","procedure_id":"proc-lsd-anxiety","jurisdiction_id":"jur-se","procedure_name":"LSD-Assisted Psychotherapy for Anxiety Disorders","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Research possible under permit; no public therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Narcotic drugs classification — classical psychedelics illegal.","regulatory_authority":"Läkemedelsverket / police narcotics control","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Anxiety"],"diseases":["Generalized Anxiety Disorder","Illness-Related Anxiety"],"status":"active"},{"id":"20eaf891-6602-4b6f-8542-f1bdd1895cd1","procedure_id":"proc-mescaline-therapy","jurisdiction_id":"jur-se","procedure_name":"Mescaline-Assisted Therapy (San Pedro) for Depression/Addiction","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Research possible under permit; no public therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Narcotic drugs classification — classical psychedelics illegal.","regulatory_authority":"Läkemedelsverket / police narcotics control","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression","Addiction"],"diseases":["Depression","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"095712f6-7cb9-455d-93b7-aa01ebbf1bc4","procedure_id":"proc-ayahuasca","jurisdiction_id":"jur-se","procedure_name":"Ayahuasca-Assisted Therapy for Depression/Addiction/Spiritual Growth","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Research possible under permit; no public therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Narcotic drugs classification — classical psychedelics illegal.","regulatory_authority":"Läkemedelsverket / police narcotics control","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Addiction","Spirituality"],"diseases":["Depression","Substance Use Disorder","PTSD","Existential Distress"],"status":"active"},{"id":"c7173d65-8f5b-4ed6-b34b-808b7668f075","procedure_id":"proc-5meo-dmt","jurisdiction_id":"jur-se","procedure_name":"5-MeO-DMT Assisted Therapy","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Research possible under permit; no public therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Narcotic drugs classification — classical psychedelics illegal.","regulatory_authority":"Läkemedelsverket / police narcotics control","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Spirituality"],"diseases":["Depression","Anxiety","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"46128fd1-c685-4c1b-9631-6cb11db17880","procedure_id":"proc-ibogaine-addiction","jurisdiction_id":"jur-se","procedure_name":"Ibogaine Treatment for Opioid/Substance Use Disorder","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Research possible under permit; no public therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Narcotic drugs classification — classical psychedelics illegal.","regulatory_authority":"Läkemedelsverket / police narcotics control","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Addiction"],"diseases":["Opioid Use Disorder","Substance Use Disorder"],"status":"active"},{"id":"3f24d54d-d2e3-46ba-8d02-b46ed2bff67f","procedure_id":"proc-psilocybin-trd","jurisdiction_id":"jur-po","procedure_name":"Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No regulated psychedelic therapy pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Group I-P controlled substances include LSD, psilocybin, MDMA, DMT, etc.","regulatory_authority":"URPL / Polish Act on Counteracting Drug Addiction","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"a14ec66a-0ad5-4986-8f5e-e66e236f27d1","procedure_id":"proc-psilocybin-eol","jurisdiction_id":"jur-po","procedure_name":"Psilocybin-Assisted Therapy for End-of-Life Anxiety","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No regulated psychedelic therapy pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Group I-P controlled substances include LSD, psilocybin, MDMA, DMT, etc.","regulatory_authority":"URPL / Polish Act on Counteracting Drug Addiction","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Palliative_Care"],"diseases":["Cancer-Related Anxiety","End-of-Life Existential Distress","Adjustment Disorder"],"status":"active"},{"id":"2427e26e-acab-47a4-ad3e-25062306e644","procedure_id":"proc-psilocybin-microdose","jurisdiction_id":"jur-po","procedure_name":"Psilocybin Microdosing Protocols","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No regulated psychedelic therapy pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Group I-P controlled substances include LSD, psilocybin, MDMA, DMT, etc.","regulatory_authority":"URPL / Polish Act on Counteracting Drug Addiction","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Cognition"],"diseases":["Depression","Anxiety","ADHD Symptoms (self-report)"],"status":"active"},{"id":"7300c096-f831-4b7b-8290-7a5bac0c6a0a","procedure_id":"proc-mdma-ptsd","jurisdiction_id":"jur-po","procedure_name":"MDMA-Assisted Psychotherapy for PTSD","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No regulated psychedelic therapy pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Group I-P controlled substances include LSD, psilocybin, MDMA, DMT, etc.","regulatory_authority":"URPL / Polish Act on Counteracting Drug Addiction","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["Post-Traumatic Stress Disorder (PTSD)"],"status":"active"},{"id":"76229818-999d-4f4c-9108-279e64ab048a","procedure_id":"proc-dmt-depression","jurisdiction_id":"jur-po","procedure_name":"DMT (N,N-Dimethyltryptamine) Assisted Therapy for Depression","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No regulated psychedelic therapy pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Group I-P controlled substances include LSD, psilocybin, MDMA, DMT, etc.","regulatory_authority":"URPL / Polish Act on Counteracting Drug Addiction","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Major Depressive Disorder","Treatment-Resistant Depression"],"status":"active"},{"id":"a7acdb72-11d6-4150-8ad3-38e15ce6a134","procedure_id":"proc-lsd-anxiety","jurisdiction_id":"jur-po","procedure_name":"LSD-Assisted Psychotherapy for Anxiety Disorders","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No regulated psychedelic therapy pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Group I-P controlled substances include LSD, psilocybin, MDMA, DMT, etc.","regulatory_authority":"URPL / Polish Act on Counteracting Drug Addiction","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Anxiety"],"diseases":["Generalized Anxiety Disorder","Illness-Related Anxiety"],"status":"active"},{"id":"9613b0fa-0faa-48e2-9db0-549a1050a79d","procedure_id":"proc-mescaline-therapy","jurisdiction_id":"jur-po","procedure_name":"Mescaline-Assisted Therapy (San Pedro) for Depression/Addiction","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No regulated psychedelic therapy pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Group I-P controlled substances include LSD, psilocybin, MDMA, DMT, etc.","regulatory_authority":"URPL / Polish Act on Counteracting Drug Addiction","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression","Addiction"],"diseases":["Depression","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"2e43963e-aadb-472a-b34a-1e7c042e48e3","procedure_id":"proc-ayahuasca","jurisdiction_id":"jur-po","procedure_name":"Ayahuasca-Assisted Therapy for Depression/Addiction/Spiritual Growth","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No regulated psychedelic therapy pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Group I-P controlled substances include LSD, psilocybin, MDMA, DMT, etc.","regulatory_authority":"URPL / Polish Act on Counteracting Drug Addiction","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Addiction","Spirituality"],"diseases":["Depression","Substance Use Disorder","PTSD","Existential Distress"],"status":"active"},{"id":"f6744a29-a2cd-4a1c-8c54-5b6aedee7708","procedure_id":"proc-5meo-dmt","jurisdiction_id":"jur-po","procedure_name":"5-MeO-DMT Assisted Therapy","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No regulated psychedelic therapy pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Group I-P controlled substances include LSD, psilocybin, MDMA, DMT, etc.","regulatory_authority":"URPL / Polish Act on Counteracting Drug Addiction","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Spirituality"],"diseases":["Depression","Anxiety","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"46a67da0-66c5-43f0-9f1e-9ff984906d8e","procedure_id":"proc-ibogaine-addiction","jurisdiction_id":"jur-po","procedure_name":"Ibogaine Treatment for Opioid/Substance Use Disorder","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No regulated psychedelic therapy pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Group I-P controlled substances include LSD, psilocybin, MDMA, DMT, etc.","regulatory_authority":"URPL / Polish Act on Counteracting Drug Addiction","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Addiction"],"diseases":["Opioid Use Disorder","Substance Use Disorder"],"status":"active"},{"id":"bd408bb5-9980-4f40-ba51-690bc52e102c","procedure_id":"proc-psilocybin-trd","jurisdiction_id":"jur-pt","procedure_name":"Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"DECRIMINALIZED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Decrim ≠ legal commercial therapy. Pathway remains None for medical programmes. Personal use may be administrative offence only; supply remains illegal.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Decriminalised personal use context but no legal therapy supply. Not a destination for regulated care.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Personal use decriminalised administratively; production/trafficking remain criminal. No licensed therapy supply for classical psychedelics.","regulatory_authority":"INFARMED / decrim law (2001)","last_verified":"2026-07-01","sources":[{"title":"SICAD Portugal","url":"https://www.sicad.pt"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"65133795-0dde-4abe-9a46-118379a69b91","procedure_id":"proc-psilocybin-eol","jurisdiction_id":"jur-pt","procedure_name":"Psilocybin-Assisted Therapy for End-of-Life Anxiety","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"DECRIMINALIZED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Decrim ≠ legal commercial therapy. Pathway remains None for medical programmes. Personal use may be administrative offence only; supply remains illegal.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Decriminalised personal use context but no legal therapy supply. Not a destination for regulated care.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Personal use decriminalised administratively; production/trafficking remain criminal. No licensed therapy supply for classical psychedelics.","regulatory_authority":"INFARMED / decrim law (2001)","last_verified":"2026-07-01","sources":[{"title":"SICAD Portugal","url":"https://www.sicad.pt"}],"therapeutic_areas":["Mental_Health","Palliative_Care"],"diseases":["Cancer-Related Anxiety","End-of-Life Existential Distress","Adjustment Disorder"],"status":"active"},{"id":"29671944-4dcb-45c5-b032-3c7ec0a28153","procedure_id":"proc-psilocybin-microdose","jurisdiction_id":"jur-pt","procedure_name":"Psilocybin Microdosing Protocols","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"DECRIMINALIZED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Decrim ≠ legal commercial therapy. Pathway remains None for medical programmes. Personal use may be administrative offence only; supply remains illegal.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Decriminalised personal use context but no legal therapy supply. Not a destination for regulated care.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Personal use decriminalised administratively; production/trafficking remain criminal. No licensed therapy supply for classical psychedelics.","regulatory_authority":"INFARMED / decrim law (2001)","last_verified":"2026-07-01","sources":[{"title":"SICAD Portugal","url":"https://www.sicad.pt"}],"therapeutic_areas":["Mental_Health","Cognition"],"diseases":["Depression","Anxiety","ADHD Symptoms (self-report)"],"status":"active"},{"id":"1ce21e57-ee10-4000-abee-41ef64d1b0e7","procedure_id":"proc-mdma-ptsd","jurisdiction_id":"jur-pt","procedure_name":"MDMA-Assisted Psychotherapy for PTSD","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"DECRIMINALIZED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Decrim ≠ legal commercial therapy. Pathway remains None for medical programmes. Personal use may be administrative offence only; supply remains illegal.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Decriminalised personal use context but no legal therapy supply. Not a destination for regulated care.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Personal use decriminalised administratively; production/trafficking remain criminal. No licensed therapy supply for classical psychedelics.","regulatory_authority":"INFARMED / decrim law (2001)","last_verified":"2026-07-01","sources":[{"title":"SICAD Portugal","url":"https://www.sicad.pt"}],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["Post-Traumatic Stress Disorder (PTSD)"],"status":"active"},{"id":"bfce668b-b2f6-46e1-b23a-bcbaa2c6180d","procedure_id":"proc-dmt-depression","jurisdiction_id":"jur-pt","procedure_name":"DMT (N,N-Dimethyltryptamine) Assisted Therapy for Depression","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"DECRIMINALIZED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Decrim ≠ legal commercial therapy. Pathway remains None for medical programmes. Personal use may be administrative offence only; supply remains illegal.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Decriminalised personal use context but no legal therapy supply. Not a destination for regulated care.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Personal use decriminalised administratively; production/trafficking remain criminal. No licensed therapy supply for classical psychedelics.","regulatory_authority":"INFARMED / decrim law (2001)","last_verified":"2026-07-01","sources":[{"title":"SICAD Portugal","url":"https://www.sicad.pt"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Major Depressive Disorder","Treatment-Resistant Depression"],"status":"active"},{"id":"0d60dc7d-ff18-4e50-91f4-db1e74c1af51","procedure_id":"proc-lsd-anxiety","jurisdiction_id":"jur-pt","procedure_name":"LSD-Assisted Psychotherapy for Anxiety Disorders","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"DECRIMINALIZED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Decrim ≠ legal commercial therapy. Pathway remains None for medical programmes. Personal use may be administrative offence only; supply remains illegal.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Decriminalised personal use context but no legal therapy supply. Not a destination for regulated care.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Personal use decriminalised administratively; production/trafficking remain criminal. No licensed therapy supply for classical psychedelics.","regulatory_authority":"INFARMED / decrim law (2001)","last_verified":"2026-07-01","sources":[{"title":"SICAD Portugal","url":"https://www.sicad.pt"}],"therapeutic_areas":["Mental_Health","Anxiety"],"diseases":["Generalized Anxiety Disorder","Illness-Related Anxiety"],"status":"active"},{"id":"b6582ce5-4381-4eec-963a-adfd31db5e24","procedure_id":"proc-mescaline-therapy","jurisdiction_id":"jur-pt","procedure_name":"Mescaline-Assisted Therapy (San Pedro) for Depression/Addiction","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"DECRIMINALIZED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Decrim ≠ legal commercial therapy. Pathway remains None for medical programmes. Personal use may be administrative offence only; supply remains illegal.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Decriminalised personal use context but no legal therapy supply. Not a destination for regulated care.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Personal use decriminalised administratively; production/trafficking remain criminal. No licensed therapy supply for classical psychedelics.","regulatory_authority":"INFARMED / decrim law (2001)","last_verified":"2026-07-01","sources":[{"title":"SICAD Portugal","url":"https://www.sicad.pt"}],"therapeutic_areas":["Mental_Health","Depression","Addiction"],"diseases":["Depression","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"99287173-8afd-494a-bc63-d017bde935f3","procedure_id":"proc-5meo-dmt","jurisdiction_id":"jur-pt","procedure_name":"5-MeO-DMT Assisted Therapy","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"DECRIMINALIZED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Decrim ≠ legal commercial therapy. Pathway remains None for medical programmes. Personal use may be administrative offence only; supply remains illegal.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Decriminalised personal use context but no legal therapy supply. Not a destination for regulated care.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Personal use decriminalised administratively; production/trafficking remain criminal. No licensed therapy supply for classical psychedelics.","regulatory_authority":"INFARMED / decrim law (2001)","last_verified":"2026-07-01","sources":[{"title":"SICAD Portugal","url":"https://www.sicad.pt"}],"therapeutic_areas":["Mental_Health","Spirituality"],"diseases":["Depression","Anxiety","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"6382578b-965b-4ce2-8946-980f335b9ce3","procedure_id":"proc-ibogaine-addiction","jurisdiction_id":"jur-pt","procedure_name":"Ibogaine Treatment for Opioid/Substance Use Disorder","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"DECRIMINALIZED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Decrim ≠ legal commercial therapy. Pathway remains None for medical programmes. Personal use may be administrative offence only; supply remains illegal.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Decriminalised personal use context but no legal therapy supply. Not a destination for regulated care.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Personal use decriminalised administratively; production/trafficking remain criminal. No licensed therapy supply for classical psychedelics.","regulatory_authority":"INFARMED / decrim law (2001)","last_verified":"2026-07-01","sources":[{"title":"SICAD Portugal","url":"https://www.sicad.pt"}],"therapeutic_areas":["Mental_Health","Addiction"],"diseases":["Opioid Use Disorder","Substance Use Disorder"],"status":"active"},{"id":"41dbbf99-2fc9-4493-956a-a3f72aee8a47","procedure_id":"proc-psilocybin-trd","jurisdiction_id":"jur-ch","procedure_name":"Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Default remains prohibited for open practice; exceptional permits are separate AccessCells where seeded.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Narcotics Act — substances controlled; BAG exceptional authorisations exist case-by-case for some psychedelics.","regulatory_authority":"Swissmedic / BAG","last_verified":"2026-07-01","sources":[{"title":"Swiss BAG","url":"https://www.bag.admin.ch"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"84c0d017-889e-40a0-bfef-91eeb716bf10","procedure_id":"proc-psilocybin-eol","jurisdiction_id":"jur-ch","procedure_name":"Psilocybin-Assisted Therapy for End-of-Life Anxiety","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Default remains prohibited for open practice; exceptional permits are separate AccessCells where seeded.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Narcotics Act — substances controlled; BAG exceptional authorisations exist case-by-case for some psychedelics.","regulatory_authority":"Swissmedic / BAG","last_verified":"2026-07-01","sources":[{"title":"Swiss BAG","url":"https://www.bag.admin.ch"}],"therapeutic_areas":["Mental_Health","Palliative_Care"],"diseases":["Cancer-Related Anxiety","End-of-Life Existential Distress","Adjustment Disorder"],"status":"active"},{"id":"c9ad8f60-2d83-4ab0-8140-6479b50f4f67","procedure_id":"proc-psilocybin-microdose","jurisdiction_id":"jur-ch","procedure_name":"Psilocybin Microdosing Protocols","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Default remains prohibited for open practice; exceptional permits are separate AccessCells where seeded.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Narcotics Act — substances controlled; BAG exceptional authorisations exist case-by-case for some psychedelics.","regulatory_authority":"Swissmedic / BAG","last_verified":"2026-07-01","sources":[{"title":"Swiss BAG","url":"https://www.bag.admin.ch"}],"therapeutic_areas":["Mental_Health","Cognition"],"diseases":["Depression","Anxiety","ADHD Symptoms (self-report)"],"status":"active"},{"id":"8a4e1287-c0ab-4d37-95a7-bcc454906be7","procedure_id":"proc-mdma-ptsd","jurisdiction_id":"jur-ch","procedure_name":"MDMA-Assisted Psychotherapy for PTSD","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Default remains prohibited for open practice; exceptional permits are separate AccessCells where seeded.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Narcotics Act — substances controlled; BAG exceptional authorisations exist case-by-case for some psychedelics.","regulatory_authority":"Swissmedic / BAG","last_verified":"2026-07-01","sources":[{"title":"Swiss BAG","url":"https://www.bag.admin.ch"}],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["Post-Traumatic Stress Disorder (PTSD)"],"status":"active"},{"id":"83477b37-0916-4f4b-8129-196b9158e4a6","procedure_id":"proc-dmt-depression","jurisdiction_id":"jur-ch","procedure_name":"DMT (N,N-Dimethyltryptamine) Assisted Therapy for Depression","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Default remains prohibited for open practice; exceptional permits are separate AccessCells where seeded.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Narcotics Act — substances controlled; BAG exceptional authorisations exist case-by-case for some psychedelics.","regulatory_authority":"Swissmedic / BAG","last_verified":"2026-07-01","sources":[{"title":"Swiss BAG","url":"https://www.bag.admin.ch"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Major Depressive Disorder","Treatment-Resistant Depression"],"status":"active"},{"id":"8931742b-3bd3-4279-87be-401abf3ffed8","procedure_id":"proc-mescaline-therapy","jurisdiction_id":"jur-ch","procedure_name":"Mescaline-Assisted Therapy (San Pedro) for Depression/Addiction","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Default remains prohibited for open practice; exceptional permits are separate AccessCells where seeded.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Narcotics Act — substances controlled; BAG exceptional authorisations exist case-by-case for some psychedelics.","regulatory_authority":"Swissmedic / BAG","last_verified":"2026-07-01","sources":[{"title":"Swiss BAG","url":"https://www.bag.admin.ch"}],"therapeutic_areas":["Mental_Health","Depression","Addiction"],"diseases":["Depression","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"bc1f47ad-3b23-445e-a069-077a863ee46f","procedure_id":"proc-ayahuasca","jurisdiction_id":"jur-ch","procedure_name":"Ayahuasca-Assisted Therapy for Depression/Addiction/Spiritual Growth","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Default remains prohibited for open practice; exceptional permits are separate AccessCells where seeded.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Narcotics Act — substances controlled; BAG exceptional authorisations exist case-by-case for some psychedelics.","regulatory_authority":"Swissmedic / BAG","last_verified":"2026-07-01","sources":[{"title":"Swiss BAG","url":"https://www.bag.admin.ch"}],"therapeutic_areas":["Mental_Health","Addiction","Spirituality"],"diseases":["Depression","Substance Use Disorder","PTSD","Existential Distress"],"status":"active"},{"id":"52f44ba4-ee9f-4188-9632-a6b502810d6c","procedure_id":"proc-5meo-dmt","jurisdiction_id":"jur-ch","procedure_name":"5-MeO-DMT Assisted Therapy","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Default remains prohibited for open practice; exceptional permits are separate AccessCells where seeded.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Narcotics Act — substances controlled; BAG exceptional authorisations exist case-by-case for some psychedelics.","regulatory_authority":"Swissmedic / BAG","last_verified":"2026-07-01","sources":[{"title":"Swiss BAG","url":"https://www.bag.admin.ch"}],"therapeutic_areas":["Mental_Health","Spirituality"],"diseases":["Depression","Anxiety","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"09929c97-00d1-43fb-a90d-8d12f14a7589","procedure_id":"proc-ibogaine-addiction","jurisdiction_id":"jur-ch","procedure_name":"Ibogaine Treatment for Opioid/Substance Use Disorder","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Default remains prohibited for open practice; exceptional permits are separate AccessCells where seeded.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Narcotics Act — substances controlled; BAG exceptional authorisations exist case-by-case for some psychedelics.","regulatory_authority":"Swissmedic / BAG","last_verified":"2026-07-01","sources":[{"title":"Swiss BAG","url":"https://www.bag.admin.ch"}],"therapeutic_areas":["Mental_Health","Addiction"],"diseases":["Opioid Use Disorder","Substance Use Disorder"],"status":"active"},{"id":"bed5d92f-5aed-4db0-ae39-a7d20b921b07","procedure_id":"proc-psilocybin-microdose","jurisdiction_id":"jur-au","procedure_name":"Psilocybin Microdosing Protocols","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Do not treat all psychedelics as available — only seeded TGA pathways apply. Others stay prohibited.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Poisons Standard — psilocybin/MDMA rescheduled for authorised psychiatrist use (2023) for specific indications; other psychedelics remain tightly controlled.","regulatory_authority":"TGA","last_verified":"2026-07-01","sources":[{"title":"TGA psilocybin/MDMA","url":"https://www.tga.gov.au"}],"therapeutic_areas":["Mental_Health","Cognition"],"diseases":["Depression","Anxiety","ADHD Symptoms (self-report)"],"status":"active"},{"id":"a2122470-d452-4bbc-a6b5-b58167467646","procedure_id":"proc-dmt-depression","jurisdiction_id":"jur-au","procedure_name":"DMT (N,N-Dimethyltryptamine) Assisted Therapy for Depression","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Do not treat all psychedelics as available — only seeded TGA pathways apply. Others stay prohibited.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Poisons Standard — psilocybin/MDMA rescheduled for authorised psychiatrist use (2023) for specific indications; other psychedelics remain tightly controlled.","regulatory_authority":"TGA","last_verified":"2026-07-01","sources":[{"title":"TGA psilocybin/MDMA","url":"https://www.tga.gov.au"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Major Depressive Disorder","Treatment-Resistant Depression"],"status":"active"},{"id":"e28a09d2-0538-4159-9f4b-526726400050","procedure_id":"proc-lsd-anxiety","jurisdiction_id":"jur-au","procedure_name":"LSD-Assisted Psychotherapy for Anxiety Disorders","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Do not treat all psychedelics as available — only seeded TGA pathways apply. Others stay prohibited.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Poisons Standard — psilocybin/MDMA rescheduled for authorised psychiatrist use (2023) for specific indications; other psychedelics remain tightly controlled.","regulatory_authority":"TGA","last_verified":"2026-07-01","sources":[{"title":"TGA psilocybin/MDMA","url":"https://www.tga.gov.au"}],"therapeutic_areas":["Mental_Health","Anxiety"],"diseases":["Generalized Anxiety Disorder","Illness-Related Anxiety"],"status":"active"},{"id":"e319837c-e1b8-4a64-80a4-acc26d217a40","procedure_id":"proc-mescaline-therapy","jurisdiction_id":"jur-au","procedure_name":"Mescaline-Assisted Therapy (San Pedro) for Depression/Addiction","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Do not treat all psychedelics as available — only seeded TGA pathways apply. Others stay prohibited.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Poisons Standard — psilocybin/MDMA rescheduled for authorised psychiatrist use (2023) for specific indications; other psychedelics remain tightly controlled.","regulatory_authority":"TGA","last_verified":"2026-07-01","sources":[{"title":"TGA psilocybin/MDMA","url":"https://www.tga.gov.au"}],"therapeutic_areas":["Mental_Health","Depression","Addiction"],"diseases":["Depression","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"266db796-5249-4436-aa7d-4a4d2d671dcf","procedure_id":"proc-ayahuasca","jurisdiction_id":"jur-au","procedure_name":"Ayahuasca-Assisted Therapy for Depression/Addiction/Spiritual Growth","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Do not treat all psychedelics as available — only seeded TGA pathways apply. Others stay prohibited.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Poisons Standard — psilocybin/MDMA rescheduled for authorised psychiatrist use (2023) for specific indications; other psychedelics remain tightly controlled.","regulatory_authority":"TGA","last_verified":"2026-07-01","sources":[{"title":"TGA psilocybin/MDMA","url":"https://www.tga.gov.au"}],"therapeutic_areas":["Mental_Health","Addiction","Spirituality"],"diseases":["Depression","Substance Use Disorder","PTSD","Existential Distress"],"status":"active"},{"id":"76727c3d-e477-4f2b-90c2-0b9c546e6613","procedure_id":"proc-5meo-dmt","jurisdiction_id":"jur-au","procedure_name":"5-MeO-DMT Assisted Therapy","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Do not treat all psychedelics as available — only seeded TGA pathways apply. Others stay prohibited.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Poisons Standard — psilocybin/MDMA rescheduled for authorised psychiatrist use (2023) for specific indications; other psychedelics remain tightly controlled.","regulatory_authority":"TGA","last_verified":"2026-07-01","sources":[{"title":"TGA psilocybin/MDMA","url":"https://www.tga.gov.au"}],"therapeutic_areas":["Mental_Health","Spirituality"],"diseases":["Depression","Anxiety","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"33c45974-faff-4e2d-b59b-f054e4430ae8","procedure_id":"proc-ibogaine-addiction","jurisdiction_id":"jur-au","procedure_name":"Ibogaine Treatment for Opioid/Substance Use Disorder","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Do not treat all psychedelics as available — only seeded TGA pathways apply. Others stay prohibited.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Poisons Standard — psilocybin/MDMA rescheduled for authorised psychiatrist use (2023) for specific indications; other psychedelics remain tightly controlled.","regulatory_authority":"TGA","last_verified":"2026-07-01","sources":[{"title":"TGA psilocybin/MDMA","url":"https://www.tga.gov.au"}],"therapeutic_areas":["Mental_Health","Addiction"],"diseases":["Opioid Use Disorder","Substance Use Disorder"],"status":"active"},{"id":"722c4822-1683-4cdb-b911-d8787142cf2f","procedure_id":"proc-psilocybin-trd","jurisdiction_id":"jur-jp","procedure_name":"Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No recreational or wellness pathway; research tightly controlled.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Stimulants Control Act / Narcotics and Psychotropics Control Act — extremely strict; classical psychedelics prohibited.","regulatory_authority":"MHLW","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"aa2b9606-1541-47cf-a9fd-0a61c2c95dfb","procedure_id":"proc-psilocybin-eol","jurisdiction_id":"jur-jp","procedure_name":"Psilocybin-Assisted Therapy for End-of-Life Anxiety","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No recreational or wellness pathway; research tightly controlled.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Stimulants Control Act / Narcotics and Psychotropics Control Act — extremely strict; classical psychedelics prohibited.","regulatory_authority":"MHLW","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Palliative_Care"],"diseases":["Cancer-Related Anxiety","End-of-Life Existential Distress","Adjustment Disorder"],"status":"active"},{"id":"38396874-21f0-4db6-8dc5-2f7bca9a48d0","procedure_id":"proc-psilocybin-microdose","jurisdiction_id":"jur-jp","procedure_name":"Psilocybin Microdosing Protocols","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No recreational or wellness pathway; research tightly controlled.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Stimulants Control Act / Narcotics and Psychotropics Control Act — extremely strict; classical psychedelics prohibited.","regulatory_authority":"MHLW","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Cognition"],"diseases":["Depression","Anxiety","ADHD Symptoms (self-report)"],"status":"active"},{"id":"add98e9a-0757-41da-8c1f-9450dc2a46ba","procedure_id":"proc-mdma-ptsd","jurisdiction_id":"jur-jp","procedure_name":"MDMA-Assisted Psychotherapy for PTSD","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No recreational or wellness pathway; research tightly controlled.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Stimulants Control Act / Narcotics and Psychotropics Control Act — extremely strict; classical psychedelics prohibited.","regulatory_authority":"MHLW","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["Post-Traumatic Stress Disorder (PTSD)"],"status":"active"},{"id":"129e7433-7cdd-4b26-aa2a-e347994e436d","procedure_id":"proc-dmt-depression","jurisdiction_id":"jur-jp","procedure_name":"DMT (N,N-Dimethyltryptamine) Assisted Therapy for Depression","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No recreational or wellness pathway; research tightly controlled.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Stimulants Control Act / Narcotics and Psychotropics Control Act — extremely strict; classical psychedelics prohibited.","regulatory_authority":"MHLW","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Major Depressive Disorder","Treatment-Resistant Depression"],"status":"active"},{"id":"bccab2ce-83fa-430c-83fd-48fbe33ba335","procedure_id":"proc-lsd-anxiety","jurisdiction_id":"jur-jp","procedure_name":"LSD-Assisted Psychotherapy for Anxiety Disorders","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No recreational or wellness pathway; research tightly controlled.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Stimulants Control Act / Narcotics and Psychotropics Control Act — extremely strict; classical psychedelics prohibited.","regulatory_authority":"MHLW","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Anxiety"],"diseases":["Generalized Anxiety Disorder","Illness-Related Anxiety"],"status":"active"},{"id":"493158ff-ebe7-499e-823d-558d348a6b7e","procedure_id":"proc-mescaline-therapy","jurisdiction_id":"jur-jp","procedure_name":"Mescaline-Assisted Therapy (San Pedro) for Depression/Addiction","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No recreational or wellness pathway; research tightly controlled.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Stimulants Control Act / Narcotics and Psychotropics Control Act — extremely strict; classical psychedelics prohibited.","regulatory_authority":"MHLW","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression","Addiction"],"diseases":["Depression","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"eb508fb8-e4e3-4972-a7ea-128b230ac979","procedure_id":"proc-ayahuasca","jurisdiction_id":"jur-jp","procedure_name":"Ayahuasca-Assisted Therapy for Depression/Addiction/Spiritual Growth","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No recreational or wellness pathway; research tightly controlled.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Stimulants Control Act / Narcotics and Psychotropics Control Act — extremely strict; classical psychedelics prohibited.","regulatory_authority":"MHLW","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Addiction","Spirituality"],"diseases":["Depression","Substance Use Disorder","PTSD","Existential Distress"],"status":"active"},{"id":"098080e6-0d87-439d-9ec5-da7debc9c002","procedure_id":"proc-5meo-dmt","jurisdiction_id":"jur-jp","procedure_name":"5-MeO-DMT Assisted Therapy","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No recreational or wellness pathway; research tightly controlled.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Stimulants Control Act / Narcotics and Psychotropics Control Act — extremely strict; classical psychedelics prohibited.","regulatory_authority":"MHLW","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Spirituality"],"diseases":["Depression","Anxiety","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"4c2dbc66-7c77-4561-86ac-ac12f4e3ebe6","procedure_id":"proc-ibogaine-addiction","jurisdiction_id":"jur-jp","procedure_name":"Ibogaine Treatment for Opioid/Substance Use Disorder","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No recreational or wellness pathway; research tightly controlled.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Stimulants Control Act / Narcotics and Psychotropics Control Act — extremely strict; classical psychedelics prohibited.","regulatory_authority":"MHLW","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Addiction"],"diseases":["Opioid Use Disorder","Substance Use Disorder"],"status":"active"},{"id":"706ddf5d-67b7-4ee4-8c8c-8726e7ca17a9","procedure_id":"proc-psilocybin-trd","jurisdiction_id":"jur-kr","procedure_name":"Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Strict enforcement culture; no therapy tourism pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Narcotics Control Act — classical psychedelics prohibited.","regulatory_authority":"MFDS","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"95a5cf03-d6cb-47fe-9e82-5b2de8c96a74","procedure_id":"proc-psilocybin-eol","jurisdiction_id":"jur-kr","procedure_name":"Psilocybin-Assisted Therapy for End-of-Life Anxiety","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Strict enforcement culture; no therapy tourism pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Narcotics Control Act — classical psychedelics prohibited.","regulatory_authority":"MFDS","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Palliative_Care"],"diseases":["Cancer-Related Anxiety","End-of-Life Existential Distress","Adjustment Disorder"],"status":"active"},{"id":"b00efe11-acef-4a68-b249-3ab78fd108ad","procedure_id":"proc-psilocybin-microdose","jurisdiction_id":"jur-kr","procedure_name":"Psilocybin Microdosing Protocols","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Strict enforcement culture; no therapy tourism pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Narcotics Control Act — classical psychedelics prohibited.","regulatory_authority":"MFDS","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Cognition"],"diseases":["Depression","Anxiety","ADHD Symptoms (self-report)"],"status":"active"},{"id":"4e6a8edc-08fe-49a9-a792-3ed73b2e41ba","procedure_id":"proc-mdma-ptsd","jurisdiction_id":"jur-kr","procedure_name":"MDMA-Assisted Psychotherapy for PTSD","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Strict enforcement culture; no therapy tourism pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Narcotics Control Act — classical psychedelics prohibited.","regulatory_authority":"MFDS","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["Post-Traumatic Stress Disorder (PTSD)"],"status":"active"},{"id":"e018e0f7-9f38-4d71-9b28-d03f256cf0da","procedure_id":"proc-dmt-depression","jurisdiction_id":"jur-kr","procedure_name":"DMT (N,N-Dimethyltryptamine) Assisted Therapy for Depression","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Strict enforcement culture; no therapy tourism pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Narcotics Control Act — classical psychedelics prohibited.","regulatory_authority":"MFDS","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Major Depressive Disorder","Treatment-Resistant Depression"],"status":"active"},{"id":"2967b3b1-1535-4a6d-b777-d20a2f7151df","procedure_id":"proc-lsd-anxiety","jurisdiction_id":"jur-kr","procedure_name":"LSD-Assisted Psychotherapy for Anxiety Disorders","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Strict enforcement culture; no therapy tourism pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Narcotics Control Act — classical psychedelics prohibited.","regulatory_authority":"MFDS","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Anxiety"],"diseases":["Generalized Anxiety Disorder","Illness-Related Anxiety"],"status":"active"},{"id":"62d8ad59-4f88-4a41-86f2-6e7d0b5c3054","procedure_id":"proc-mescaline-therapy","jurisdiction_id":"jur-kr","procedure_name":"Mescaline-Assisted Therapy (San Pedro) for Depression/Addiction","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Strict enforcement culture; no therapy tourism pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Narcotics Control Act — classical psychedelics prohibited.","regulatory_authority":"MFDS","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression","Addiction"],"diseases":["Depression","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"528a5e95-f57c-432b-a60c-615a0466f87c","procedure_id":"proc-ayahuasca","jurisdiction_id":"jur-kr","procedure_name":"Ayahuasca-Assisted Therapy for Depression/Addiction/Spiritual Growth","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Strict enforcement culture; no therapy tourism pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Narcotics Control Act — classical psychedelics prohibited.","regulatory_authority":"MFDS","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Addiction","Spirituality"],"diseases":["Depression","Substance Use Disorder","PTSD","Existential Distress"],"status":"active"},{"id":"eb5b4bd4-6956-4f48-8410-9e9aecf4c8bb","procedure_id":"proc-5meo-dmt","jurisdiction_id":"jur-kr","procedure_name":"5-MeO-DMT Assisted Therapy","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Strict enforcement culture; no therapy tourism pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Narcotics Control Act — classical psychedelics prohibited.","regulatory_authority":"MFDS","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Spirituality"],"diseases":["Depression","Anxiety","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"02484369-b1c6-476a-9f93-656b9cfe959f","procedure_id":"proc-ibogaine-addiction","jurisdiction_id":"jur-kr","procedure_name":"Ibogaine Treatment for Opioid/Substance Use Disorder","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Strict enforcement culture; no therapy tourism pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Narcotics Control Act — classical psychedelics prohibited.","regulatory_authority":"MFDS","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Addiction"],"diseases":["Opioid Use Disorder","Substance Use Disorder"],"status":"active"},{"id":"f8b2e3df-b5d2-4642-a9a0-60f47def6127","procedure_id":"proc-psilocybin-trd","jurisdiction_id":"jur-sg","procedure_name":"Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Among the strictest regimes globally; no medical cannabis or psychedelic therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Class A controlled drugs with severe trafficking penalties — classical psychedelics and cannabis prohibited.","regulatory_authority":"HSA / Misuse of Drugs Act","last_verified":"2026-07-01","sources":[{"title":"Singapore CNB","url":"https://www.cnb.gov.sg"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"15cf27f0-16c1-4989-a1c5-a6796f2cb581","procedure_id":"proc-psilocybin-eol","jurisdiction_id":"jur-sg","procedure_name":"Psilocybin-Assisted Therapy for End-of-Life Anxiety","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Among the strictest regimes globally; no medical cannabis or psychedelic therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Class A controlled drugs with severe trafficking penalties — classical psychedelics and cannabis prohibited.","regulatory_authority":"HSA / Misuse of Drugs Act","last_verified":"2026-07-01","sources":[{"title":"Singapore CNB","url":"https://www.cnb.gov.sg"}],"therapeutic_areas":["Mental_Health","Palliative_Care"],"diseases":["Cancer-Related Anxiety","End-of-Life Existential Distress","Adjustment Disorder"],"status":"active"},{"id":"755b46b1-3d82-427d-bc78-3d01496f126f","procedure_id":"proc-psilocybin-microdose","jurisdiction_id":"jur-sg","procedure_name":"Psilocybin Microdosing Protocols","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Among the strictest regimes globally; no medical cannabis or psychedelic therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Class A controlled drugs with severe trafficking penalties — classical psychedelics and cannabis prohibited.","regulatory_authority":"HSA / Misuse of Drugs Act","last_verified":"2026-07-01","sources":[{"title":"Singapore CNB","url":"https://www.cnb.gov.sg"}],"therapeutic_areas":["Mental_Health","Cognition"],"diseases":["Depression","Anxiety","ADHD Symptoms (self-report)"],"status":"active"},{"id":"055c85c4-757f-4eeb-b3ad-175e181216ef","procedure_id":"proc-mdma-ptsd","jurisdiction_id":"jur-sg","procedure_name":"MDMA-Assisted Psychotherapy for PTSD","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Among the strictest regimes globally; no medical cannabis or psychedelic therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Class A controlled drugs with severe trafficking penalties — classical psychedelics and cannabis prohibited.","regulatory_authority":"HSA / Misuse of Drugs Act","last_verified":"2026-07-01","sources":[{"title":"Singapore CNB","url":"https://www.cnb.gov.sg"}],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["Post-Traumatic Stress Disorder (PTSD)"],"status":"active"},{"id":"45b5882d-191c-4864-839b-a67139b98799","procedure_id":"proc-dmt-depression","jurisdiction_id":"jur-sg","procedure_name":"DMT (N,N-Dimethyltryptamine) Assisted Therapy for Depression","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Among the strictest regimes globally; no medical cannabis or psychedelic therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Class A controlled drugs with severe trafficking penalties — classical psychedelics and cannabis prohibited.","regulatory_authority":"HSA / Misuse of Drugs Act","last_verified":"2026-07-01","sources":[{"title":"Singapore CNB","url":"https://www.cnb.gov.sg"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Major Depressive Disorder","Treatment-Resistant Depression"],"status":"active"},{"id":"7f037b46-3a95-4582-a383-79ce574a602c","procedure_id":"proc-lsd-anxiety","jurisdiction_id":"jur-sg","procedure_name":"LSD-Assisted Psychotherapy for Anxiety Disorders","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Among the strictest regimes globally; no medical cannabis or psychedelic therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Class A controlled drugs with severe trafficking penalties — classical psychedelics and cannabis prohibited.","regulatory_authority":"HSA / Misuse of Drugs Act","last_verified":"2026-07-01","sources":[{"title":"Singapore CNB","url":"https://www.cnb.gov.sg"}],"therapeutic_areas":["Mental_Health","Anxiety"],"diseases":["Generalized Anxiety Disorder","Illness-Related Anxiety"],"status":"active"},{"id":"870f587f-0f99-4e47-a02d-2705d813a33d","procedure_id":"proc-mescaline-therapy","jurisdiction_id":"jur-sg","procedure_name":"Mescaline-Assisted Therapy (San Pedro) for Depression/Addiction","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Among the strictest regimes globally; no medical cannabis or psychedelic therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Class A controlled drugs with severe trafficking penalties — classical psychedelics and cannabis prohibited.","regulatory_authority":"HSA / Misuse of Drugs Act","last_verified":"2026-07-01","sources":[{"title":"Singapore CNB","url":"https://www.cnb.gov.sg"}],"therapeutic_areas":["Mental_Health","Depression","Addiction"],"diseases":["Depression","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"3e8a8045-bb56-4708-8d79-64e632ef0894","procedure_id":"proc-ayahuasca","jurisdiction_id":"jur-sg","procedure_name":"Ayahuasca-Assisted Therapy for Depression/Addiction/Spiritual Growth","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Among the strictest regimes globally; no medical cannabis or psychedelic therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Class A controlled drugs with severe trafficking penalties — classical psychedelics and cannabis prohibited.","regulatory_authority":"HSA / Misuse of Drugs Act","last_verified":"2026-07-01","sources":[{"title":"Singapore CNB","url":"https://www.cnb.gov.sg"}],"therapeutic_areas":["Mental_Health","Addiction","Spirituality"],"diseases":["Depression","Substance Use Disorder","PTSD","Existential Distress"],"status":"active"},{"id":"51ed75d5-a2ec-4f91-9273-b2ee156e137b","procedure_id":"proc-5meo-dmt","jurisdiction_id":"jur-sg","procedure_name":"5-MeO-DMT Assisted Therapy","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Among the strictest regimes globally; no medical cannabis or psychedelic therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Class A controlled drugs with severe trafficking penalties — classical psychedelics and cannabis prohibited.","regulatory_authority":"HSA / Misuse of Drugs Act","last_verified":"2026-07-01","sources":[{"title":"Singapore CNB","url":"https://www.cnb.gov.sg"}],"therapeutic_areas":["Mental_Health","Spirituality"],"diseases":["Depression","Anxiety","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"b7a515b1-e571-4ff5-8fa6-d0715c04d94d","procedure_id":"proc-ibogaine-addiction","jurisdiction_id":"jur-sg","procedure_name":"Ibogaine Treatment for Opioid/Substance Use Disorder","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Among the strictest regimes globally; no medical cannabis or psychedelic therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Class A controlled drugs with severe trafficking penalties — classical psychedelics and cannabis prohibited.","regulatory_authority":"HSA / Misuse of Drugs Act","last_verified":"2026-07-01","sources":[{"title":"Singapore CNB","url":"https://www.cnb.gov.sg"}],"therapeutic_areas":["Mental_Health","Addiction"],"diseases":["Opioid Use Disorder","Substance Use Disorder"],"status":"active"},{"id":"725a159d-49c8-4d96-8e8d-0095bf600097","procedure_id":"proc-psilocybin-trd","jurisdiction_id":"jur-in","procedure_name":"Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Research possible with permits; commercial therapy not authorised.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"NDPS schedules cover major psychedelics; no national therapy programme.","regulatory_authority":"Narcotic Drugs and Psychotropic Substances Act, 1985","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"fc2864ec-8fde-49a9-b39e-424730245180","procedure_id":"proc-psilocybin-eol","jurisdiction_id":"jur-in","procedure_name":"Psilocybin-Assisted Therapy for End-of-Life Anxiety","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Research possible with permits; commercial therapy not authorised.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"NDPS schedules cover major psychedelics; no national therapy programme.","regulatory_authority":"Narcotic Drugs and Psychotropic Substances Act, 1985","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Palliative_Care"],"diseases":["Cancer-Related Anxiety","End-of-Life Existential Distress","Adjustment Disorder"],"status":"active"},{"id":"8031ab89-1e33-4bb8-aa9f-e417de6fad9c","procedure_id":"proc-psilocybin-microdose","jurisdiction_id":"jur-in","procedure_name":"Psilocybin Microdosing Protocols","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Research possible with permits; commercial therapy not authorised.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"NDPS schedules cover major psychedelics; no national therapy programme.","regulatory_authority":"Narcotic Drugs and Psychotropic Substances Act, 1985","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Cognition"],"diseases":["Depression","Anxiety","ADHD Symptoms (self-report)"],"status":"active"},{"id":"cf8b4411-6b49-43dc-b6d9-d5c74d6e7042","procedure_id":"proc-mdma-ptsd","jurisdiction_id":"jur-in","procedure_name":"MDMA-Assisted Psychotherapy for PTSD","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Research possible with permits; commercial therapy not authorised.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"NDPS schedules cover major psychedelics; no national therapy programme.","regulatory_authority":"Narcotic Drugs and Psychotropic Substances Act, 1985","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["Post-Traumatic Stress Disorder (PTSD)"],"status":"active"},{"id":"2e232c63-781c-4491-8a1d-d2894cff65ce","procedure_id":"proc-dmt-depression","jurisdiction_id":"jur-in","procedure_name":"DMT (N,N-Dimethyltryptamine) Assisted Therapy for Depression","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Research possible with permits; commercial therapy not authorised.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"NDPS schedules cover major psychedelics; no national therapy programme.","regulatory_authority":"Narcotic Drugs and Psychotropic Substances Act, 1985","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Major Depressive Disorder","Treatment-Resistant Depression"],"status":"active"},{"id":"d85cde79-2e58-4363-969d-25b2f4c47686","procedure_id":"proc-lsd-anxiety","jurisdiction_id":"jur-in","procedure_name":"LSD-Assisted Psychotherapy for Anxiety Disorders","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Research possible with permits; commercial therapy not authorised.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"NDPS schedules cover major psychedelics; no national therapy programme.","regulatory_authority":"Narcotic Drugs and Psychotropic Substances Act, 1985","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Anxiety"],"diseases":["Generalized Anxiety Disorder","Illness-Related Anxiety"],"status":"active"},{"id":"57cdb8bf-7aa6-48c0-8df6-2212369f4f39","procedure_id":"proc-mescaline-therapy","jurisdiction_id":"jur-in","procedure_name":"Mescaline-Assisted Therapy (San Pedro) for Depression/Addiction","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Research possible with permits; commercial therapy not authorised.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"NDPS schedules cover major psychedelics; no national therapy programme.","regulatory_authority":"Narcotic Drugs and Psychotropic Substances Act, 1985","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression","Addiction"],"diseases":["Depression","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"e4bdaf3e-c289-4cc5-842e-fa2562c66472","procedure_id":"proc-ayahuasca","jurisdiction_id":"jur-in","procedure_name":"Ayahuasca-Assisted Therapy for Depression/Addiction/Spiritual Growth","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Research possible with permits; commercial therapy not authorised.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"NDPS schedules cover major psychedelics; no national therapy programme.","regulatory_authority":"Narcotic Drugs and Psychotropic Substances Act, 1985","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Addiction","Spirituality"],"diseases":["Depression","Substance Use Disorder","PTSD","Existential Distress"],"status":"active"},{"id":"2fd33077-1fae-4dac-9c31-8dc2dd8596de","procedure_id":"proc-5meo-dmt","jurisdiction_id":"jur-in","procedure_name":"5-MeO-DMT Assisted Therapy","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Research possible with permits; commercial therapy not authorised.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"NDPS schedules cover major psychedelics; no national therapy programme.","regulatory_authority":"Narcotic Drugs and Psychotropic Substances Act, 1985","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Spirituality"],"diseases":["Depression","Anxiety","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"81eeaf98-e2cf-4249-87f2-9ffcf3a83431","procedure_id":"proc-ibogaine-addiction","jurisdiction_id":"jur-in","procedure_name":"Ibogaine Treatment for Opioid/Substance Use Disorder","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Research possible with permits; commercial therapy not authorised.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"NDPS schedules cover major psychedelics; no national therapy programme.","regulatory_authority":"Narcotic Drugs and Psychotropic Substances Act, 1985","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Addiction"],"diseases":["Opioid Use Disorder","Substance Use Disorder"],"status":"active"},{"id":"396613e9-74c3-450c-a6e0-7d4bf4f3bda9","procedure_id":"proc-psilocybin-trd","jurisdiction_id":"jur-il","procedure_name":"Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Psychedelic therapy not generally authorised outside research.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Dangerous Drugs Ordinance — classical psychedelics controlled; medical cannabis is separate licensed system.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"9d51b6d5-c27d-4a31-b985-2bf0f6b82ebe","procedure_id":"proc-psilocybin-eol","jurisdiction_id":"jur-il","procedure_name":"Psilocybin-Assisted Therapy for End-of-Life Anxiety","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Psychedelic therapy not generally authorised outside research.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Dangerous Drugs Ordinance — classical psychedelics controlled; medical cannabis is separate licensed system.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Palliative_Care"],"diseases":["Cancer-Related Anxiety","End-of-Life Existential Distress","Adjustment Disorder"],"status":"active"},{"id":"ee75c4b8-ed40-48bb-ba7b-31e70452ba96","procedure_id":"proc-psilocybin-microdose","jurisdiction_id":"jur-il","procedure_name":"Psilocybin Microdosing Protocols","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Psychedelic therapy not generally authorised outside research.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Dangerous Drugs Ordinance — classical psychedelics controlled; medical cannabis is separate licensed system.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Cognition"],"diseases":["Depression","Anxiety","ADHD Symptoms (self-report)"],"status":"active"},{"id":"898e7fc1-86c2-46c9-8f0e-9627fefff669","procedure_id":"proc-mdma-ptsd","jurisdiction_id":"jur-il","procedure_name":"MDMA-Assisted Psychotherapy for PTSD","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Psychedelic therapy not generally authorised outside research.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Dangerous Drugs Ordinance — classical psychedelics controlled; medical cannabis is separate licensed system.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["Post-Traumatic Stress Disorder (PTSD)"],"status":"active"},{"id":"4203b9a8-c07f-45ba-a7ab-9e1d75b9a39b","procedure_id":"proc-dmt-depression","jurisdiction_id":"jur-il","procedure_name":"DMT (N,N-Dimethyltryptamine) Assisted Therapy for Depression","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Psychedelic therapy not generally authorised outside research.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Dangerous Drugs Ordinance — classical psychedelics controlled; medical cannabis is separate licensed system.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Major Depressive Disorder","Treatment-Resistant Depression"],"status":"active"},{"id":"e65b86b0-330f-4cd1-a7ef-893d565bb87d","procedure_id":"proc-lsd-anxiety","jurisdiction_id":"jur-il","procedure_name":"LSD-Assisted Psychotherapy for Anxiety Disorders","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Psychedelic therapy not generally authorised outside research.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Dangerous Drugs Ordinance — classical psychedelics controlled; medical cannabis is separate licensed system.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Anxiety"],"diseases":["Generalized Anxiety Disorder","Illness-Related Anxiety"],"status":"active"},{"id":"58a59500-3ae4-4204-a81b-1d3e4f6967df","procedure_id":"proc-mescaline-therapy","jurisdiction_id":"jur-il","procedure_name":"Mescaline-Assisted Therapy (San Pedro) for Depression/Addiction","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Psychedelic therapy not generally authorised outside research.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Dangerous Drugs Ordinance — classical psychedelics controlled; medical cannabis is separate licensed system.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression","Addiction"],"diseases":["Depression","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"97a061ca-f8c6-45c7-8564-91a96047cc78","procedure_id":"proc-ayahuasca","jurisdiction_id":"jur-il","procedure_name":"Ayahuasca-Assisted Therapy for Depression/Addiction/Spiritual Growth","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Psychedelic therapy not generally authorised outside research.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Dangerous Drugs Ordinance — classical psychedelics controlled; medical cannabis is separate licensed system.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Addiction","Spirituality"],"diseases":["Depression","Substance Use Disorder","PTSD","Existential Distress"],"status":"active"},{"id":"da24412f-cdf4-4d12-8796-d68e975f1542","procedure_id":"proc-5meo-dmt","jurisdiction_id":"jur-il","procedure_name":"5-MeO-DMT Assisted Therapy","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Psychedelic therapy not generally authorised outside research.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Dangerous Drugs Ordinance — classical psychedelics controlled; medical cannabis is separate licensed system.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Spirituality"],"diseases":["Depression","Anxiety","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"7de35e3d-291e-4d92-b1ff-3c788cc373e9","procedure_id":"proc-ibogaine-addiction","jurisdiction_id":"jur-il","procedure_name":"Ibogaine Treatment for Opioid/Substance Use Disorder","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Psychedelic therapy not generally authorised outside research.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Dangerous Drugs Ordinance — classical psychedelics controlled; medical cannabis is separate licensed system.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Addiction"],"diseases":["Opioid Use Disorder","Substance Use Disorder"],"status":"active"},{"id":"3aed06dc-f5f4-4dae-859d-755d9afba6fa","procedure_id":"proc-psilocybin-trd","jurisdiction_id":"jur-uae","procedure_name":"Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Severe criminal penalties; no therapy pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Zero-tolerance narcotics enforcement — classical psychedelics prohibited.","regulatory_authority":"UAE Ministry of Health / narcotics law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"6377c2b1-cb14-4dfc-9946-502fc59df7bf","procedure_id":"proc-psilocybin-eol","jurisdiction_id":"jur-uae","procedure_name":"Psilocybin-Assisted Therapy for End-of-Life Anxiety","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Severe criminal penalties; no therapy pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Zero-tolerance narcotics enforcement — classical psychedelics prohibited.","regulatory_authority":"UAE Ministry of Health / narcotics law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Palliative_Care"],"diseases":["Cancer-Related Anxiety","End-of-Life Existential Distress","Adjustment Disorder"],"status":"active"},{"id":"6d906e8b-ba7b-4828-9088-24cd2f709f56","procedure_id":"proc-psilocybin-microdose","jurisdiction_id":"jur-uae","procedure_name":"Psilocybin Microdosing Protocols","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Severe criminal penalties; no therapy pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Zero-tolerance narcotics enforcement — classical psychedelics prohibited.","regulatory_authority":"UAE Ministry of Health / narcotics law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Cognition"],"diseases":["Depression","Anxiety","ADHD Symptoms (self-report)"],"status":"active"},{"id":"3da65d36-be19-468e-9c92-b255f28ce6ac","procedure_id":"proc-mdma-ptsd","jurisdiction_id":"jur-uae","procedure_name":"MDMA-Assisted Psychotherapy for PTSD","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Severe criminal penalties; no therapy pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Zero-tolerance narcotics enforcement — classical psychedelics prohibited.","regulatory_authority":"UAE Ministry of Health / narcotics law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["Post-Traumatic Stress Disorder (PTSD)"],"status":"active"},{"id":"29a25da2-97a1-4771-9796-c782b7d3964f","procedure_id":"proc-dmt-depression","jurisdiction_id":"jur-uae","procedure_name":"DMT (N,N-Dimethyltryptamine) Assisted Therapy for Depression","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Severe criminal penalties; no therapy pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Zero-tolerance narcotics enforcement — classical psychedelics prohibited.","regulatory_authority":"UAE Ministry of Health / narcotics law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Major Depressive Disorder","Treatment-Resistant Depression"],"status":"active"},{"id":"21973182-dbbb-4716-a681-7cedf0eb0d22","procedure_id":"proc-lsd-anxiety","jurisdiction_id":"jur-uae","procedure_name":"LSD-Assisted Psychotherapy for Anxiety Disorders","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Severe criminal penalties; no therapy pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Zero-tolerance narcotics enforcement — classical psychedelics prohibited.","regulatory_authority":"UAE Ministry of Health / narcotics law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Anxiety"],"diseases":["Generalized Anxiety Disorder","Illness-Related Anxiety"],"status":"active"},{"id":"3780a0e0-f1dc-4e16-a48d-100535c9a1ec","procedure_id":"proc-mescaline-therapy","jurisdiction_id":"jur-uae","procedure_name":"Mescaline-Assisted Therapy (San Pedro) for Depression/Addiction","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Severe criminal penalties; no therapy pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Zero-tolerance narcotics enforcement — classical psychedelics prohibited.","regulatory_authority":"UAE Ministry of Health / narcotics law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression","Addiction"],"diseases":["Depression","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"5dabe264-130e-4bdc-a303-8e0d45814414","procedure_id":"proc-ayahuasca","jurisdiction_id":"jur-uae","procedure_name":"Ayahuasca-Assisted Therapy for Depression/Addiction/Spiritual Growth","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Severe criminal penalties; no therapy pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Zero-tolerance narcotics enforcement — classical psychedelics prohibited.","regulatory_authority":"UAE Ministry of Health / narcotics law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Addiction","Spirituality"],"diseases":["Depression","Substance Use Disorder","PTSD","Existential Distress"],"status":"active"},{"id":"0879fcd3-9fb7-4caa-841e-6c014011ddd1","procedure_id":"proc-5meo-dmt","jurisdiction_id":"jur-uae","procedure_name":"5-MeO-DMT Assisted Therapy","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Severe criminal penalties; no therapy pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Zero-tolerance narcotics enforcement — classical psychedelics prohibited.","regulatory_authority":"UAE Ministry of Health / narcotics law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Spirituality"],"diseases":["Depression","Anxiety","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"5abce750-229b-4926-8873-994cc2c98ee6","procedure_id":"proc-ibogaine-addiction","jurisdiction_id":"jur-uae","procedure_name":"Ibogaine Treatment for Opioid/Substance Use Disorder","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Severe criminal penalties; no therapy pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Zero-tolerance narcotics enforcement — classical psychedelics prohibited.","regulatory_authority":"UAE Ministry of Health / narcotics law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Addiction"],"diseases":["Opioid Use Disorder","Substance Use Disorder"],"status":"active"},{"id":"9094deb8-9858-4801-9005-368a6cef7855","procedure_id":"proc-psilocybin-trd","jurisdiction_id":"jur-tu","procedure_name":"Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No regulated therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled narcotics — classical psychedelics prohibited outside research.","regulatory_authority":"TİTCK / Turkish narcotics law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"056174f6-d7b5-42bb-8862-bc9dd601e3d2","procedure_id":"proc-psilocybin-eol","jurisdiction_id":"jur-tu","procedure_name":"Psilocybin-Assisted Therapy for End-of-Life Anxiety","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No regulated therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled narcotics — classical psychedelics prohibited outside research.","regulatory_authority":"TİTCK / Turkish narcotics law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Palliative_Care"],"diseases":["Cancer-Related Anxiety","End-of-Life Existential Distress","Adjustment Disorder"],"status":"active"},{"id":"8dedac8c-c377-484a-be40-41531abe77c6","procedure_id":"proc-psilocybin-microdose","jurisdiction_id":"jur-tu","procedure_name":"Psilocybin Microdosing Protocols","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No regulated therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled narcotics — classical psychedelics prohibited outside research.","regulatory_authority":"TİTCK / Turkish narcotics law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Cognition"],"diseases":["Depression","Anxiety","ADHD Symptoms (self-report)"],"status":"active"},{"id":"92867e8b-65b4-4b94-ae34-42e5c10bd87a","procedure_id":"proc-mdma-ptsd","jurisdiction_id":"jur-tu","procedure_name":"MDMA-Assisted Psychotherapy for PTSD","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No regulated therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled narcotics — classical psychedelics prohibited outside research.","regulatory_authority":"TİTCK / Turkish narcotics law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["Post-Traumatic Stress Disorder (PTSD)"],"status":"active"},{"id":"9a5f4a46-e658-4e0a-8955-9523c8fd7029","procedure_id":"proc-dmt-depression","jurisdiction_id":"jur-tu","procedure_name":"DMT (N,N-Dimethyltryptamine) Assisted Therapy for Depression","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No regulated therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled narcotics — classical psychedelics prohibited outside research.","regulatory_authority":"TİTCK / Turkish narcotics law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Major Depressive Disorder","Treatment-Resistant Depression"],"status":"active"},{"id":"37d16ba0-c340-4641-84d7-9b7d805fcccf","procedure_id":"proc-lsd-anxiety","jurisdiction_id":"jur-tu","procedure_name":"LSD-Assisted Psychotherapy for Anxiety Disorders","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No regulated therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled narcotics — classical psychedelics prohibited outside research.","regulatory_authority":"TİTCK / Turkish narcotics law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Anxiety"],"diseases":["Generalized Anxiety Disorder","Illness-Related Anxiety"],"status":"active"},{"id":"ac8fd8ba-3e74-42b0-90b7-6622d2109ca7","procedure_id":"proc-mescaline-therapy","jurisdiction_id":"jur-tu","procedure_name":"Mescaline-Assisted Therapy (San Pedro) for Depression/Addiction","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No regulated therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled narcotics — classical psychedelics prohibited outside research.","regulatory_authority":"TİTCK / Turkish narcotics law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression","Addiction"],"diseases":["Depression","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"ca1fb9f3-35f9-4b6d-b696-b0c413f96d21","procedure_id":"proc-ayahuasca","jurisdiction_id":"jur-tu","procedure_name":"Ayahuasca-Assisted Therapy for Depression/Addiction/Spiritual Growth","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No regulated therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled narcotics — classical psychedelics prohibited outside research.","regulatory_authority":"TİTCK / Turkish narcotics law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Addiction","Spirituality"],"diseases":["Depression","Substance Use Disorder","PTSD","Existential Distress"],"status":"active"},{"id":"b466e236-edc7-42b1-bb72-9f175ca5ce27","procedure_id":"proc-5meo-dmt","jurisdiction_id":"jur-tu","procedure_name":"5-MeO-DMT Assisted Therapy","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No regulated therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled narcotics — classical psychedelics prohibited outside research.","regulatory_authority":"TİTCK / Turkish narcotics law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Spirituality"],"diseases":["Depression","Anxiety","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"d2ee6344-9617-466c-8c21-12e980910955","procedure_id":"proc-ibogaine-addiction","jurisdiction_id":"jur-tu","procedure_name":"Ibogaine Treatment for Opioid/Substance Use Disorder","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No regulated therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled narcotics — classical psychedelics prohibited outside research.","regulatory_authority":"TİTCK / Turkish narcotics law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Addiction"],"diseases":["Opioid Use Disorder","Substance Use Disorder"],"status":"active"},{"id":"f740b9bd-2e40-44d9-b700-fd56cfec1c5c","procedure_id":"proc-psilocybin-trd","jurisdiction_id":"jur-th","procedure_name":"Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Do not assume wellness tourism covers MDMA/psilocybin mushrooms legally.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Most classical psychedelics remain controlled; cannabis policy has been in flux separately.","regulatory_authority":"Thai FDA / Narcotics Act (reforms ongoing)","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"8c29eea0-fcd9-4bf2-9287-b7332fa6f152","procedure_id":"proc-psilocybin-eol","jurisdiction_id":"jur-th","procedure_name":"Psilocybin-Assisted Therapy for End-of-Life Anxiety","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Do not assume wellness tourism covers MDMA/psilocybin mushrooms legally.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Most classical psychedelics remain controlled; cannabis policy has been in flux separately.","regulatory_authority":"Thai FDA / Narcotics Act (reforms ongoing)","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Palliative_Care"],"diseases":["Cancer-Related Anxiety","End-of-Life Existential Distress","Adjustment Disorder"],"status":"active"},{"id":"1fc809ea-07b4-46bc-8dfe-e26b1dee7d49","procedure_id":"proc-psilocybin-microdose","jurisdiction_id":"jur-th","procedure_name":"Psilocybin Microdosing Protocols","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Do not assume wellness tourism covers MDMA/psilocybin mushrooms legally.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Most classical psychedelics remain controlled; cannabis policy has been in flux separately.","regulatory_authority":"Thai FDA / Narcotics Act (reforms ongoing)","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Cognition"],"diseases":["Depression","Anxiety","ADHD Symptoms (self-report)"],"status":"active"},{"id":"6c2bc411-3542-4b5d-b304-0eb961f5147e","procedure_id":"proc-mdma-ptsd","jurisdiction_id":"jur-th","procedure_name":"MDMA-Assisted Psychotherapy for PTSD","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Do not assume wellness tourism covers MDMA/psilocybin mushrooms legally.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Most classical psychedelics remain controlled; cannabis policy has been in flux separately.","regulatory_authority":"Thai FDA / Narcotics Act (reforms ongoing)","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["Post-Traumatic Stress Disorder (PTSD)"],"status":"active"},{"id":"dda62b2f-e34b-4c5a-a0f7-3b201fe67de7","procedure_id":"proc-dmt-depression","jurisdiction_id":"jur-th","procedure_name":"DMT (N,N-Dimethyltryptamine) Assisted Therapy for Depression","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Do not assume wellness tourism covers MDMA/psilocybin mushrooms legally.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Most classical psychedelics remain controlled; cannabis policy has been in flux separately.","regulatory_authority":"Thai FDA / Narcotics Act (reforms ongoing)","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Major Depressive Disorder","Treatment-Resistant Depression"],"status":"active"},{"id":"7f6a32f3-1687-4743-adf4-4796f20cc118","procedure_id":"proc-lsd-anxiety","jurisdiction_id":"jur-th","procedure_name":"LSD-Assisted Psychotherapy for Anxiety Disorders","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Do not assume wellness tourism covers MDMA/psilocybin mushrooms legally.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Most classical psychedelics remain controlled; cannabis policy has been in flux separately.","regulatory_authority":"Thai FDA / Narcotics Act (reforms ongoing)","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Anxiety"],"diseases":["Generalized Anxiety Disorder","Illness-Related Anxiety"],"status":"active"},{"id":"3a4a2964-33d4-4a37-b511-647fe6eee474","procedure_id":"proc-mescaline-therapy","jurisdiction_id":"jur-th","procedure_name":"Mescaline-Assisted Therapy (San Pedro) for Depression/Addiction","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Do not assume wellness tourism covers MDMA/psilocybin mushrooms legally.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Most classical psychedelics remain controlled; cannabis policy has been in flux separately.","regulatory_authority":"Thai FDA / Narcotics Act (reforms ongoing)","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression","Addiction"],"diseases":["Depression","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"eddb4e13-7e1e-47b3-a823-9d8eec804b70","procedure_id":"proc-ayahuasca","jurisdiction_id":"jur-th","procedure_name":"Ayahuasca-Assisted Therapy for Depression/Addiction/Spiritual Growth","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Do not assume wellness tourism covers MDMA/psilocybin mushrooms legally.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Most classical psychedelics remain controlled; cannabis policy has been in flux separately.","regulatory_authority":"Thai FDA / Narcotics Act (reforms ongoing)","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Addiction","Spirituality"],"diseases":["Depression","Substance Use Disorder","PTSD","Existential Distress"],"status":"active"},{"id":"a88183ef-15a2-409a-b950-b3284c0c5f40","procedure_id":"proc-5meo-dmt","jurisdiction_id":"jur-th","procedure_name":"5-MeO-DMT Assisted Therapy","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Do not assume wellness tourism covers MDMA/psilocybin mushrooms legally.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Most classical psychedelics remain controlled; cannabis policy has been in flux separately.","regulatory_authority":"Thai FDA / Narcotics Act (reforms ongoing)","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Spirituality"],"diseases":["Depression","Anxiety","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"441ae208-5090-4a2b-9e93-081d57ccc9af","procedure_id":"proc-ibogaine-addiction","jurisdiction_id":"jur-th","procedure_name":"Ibogaine Treatment for Opioid/Substance Use Disorder","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Do not assume wellness tourism covers MDMA/psilocybin mushrooms legally.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Most classical psychedelics remain controlled; cannabis policy has been in flux separately.","regulatory_authority":"Thai FDA / Narcotics Act (reforms ongoing)","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Addiction"],"diseases":["Opioid Use Disorder","Substance Use Disorder"],"status":"active"},{"id":"0226c845-4b79-4f3f-903b-e6827f69ada1","procedure_id":"proc-psilocybin-trd","jurisdiction_id":"jur-ph","procedure_name":"Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Strict penalties; no therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Dangerous drugs schedules — classical psychedelics prohibited.","regulatory_authority":"FDA Philippines / Dangerous Drugs Act","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"59aa8e88-8c9e-457b-9f1a-5d10ea95f3c1","procedure_id":"proc-psilocybin-eol","jurisdiction_id":"jur-ph","procedure_name":"Psilocybin-Assisted Therapy for End-of-Life Anxiety","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Strict penalties; no therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Dangerous drugs schedules — classical psychedelics prohibited.","regulatory_authority":"FDA Philippines / Dangerous Drugs Act","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Palliative_Care"],"diseases":["Cancer-Related Anxiety","End-of-Life Existential Distress","Adjustment Disorder"],"status":"active"},{"id":"aa987d38-41e0-4127-9520-e9fe601a8e5d","procedure_id":"proc-psilocybin-microdose","jurisdiction_id":"jur-ph","procedure_name":"Psilocybin Microdosing Protocols","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Strict penalties; no therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Dangerous drugs schedules — classical psychedelics prohibited.","regulatory_authority":"FDA Philippines / Dangerous Drugs Act","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Cognition"],"diseases":["Depression","Anxiety","ADHD Symptoms (self-report)"],"status":"active"},{"id":"32f3f318-167b-4197-be2b-14da7c0e719b","procedure_id":"proc-mdma-ptsd","jurisdiction_id":"jur-ph","procedure_name":"MDMA-Assisted Psychotherapy for PTSD","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Strict penalties; no therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Dangerous drugs schedules — classical psychedelics prohibited.","regulatory_authority":"FDA Philippines / Dangerous Drugs Act","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["Post-Traumatic Stress Disorder (PTSD)"],"status":"active"},{"id":"6a3a1e2a-07bf-4c75-9609-92c61b9d1581","procedure_id":"proc-dmt-depression","jurisdiction_id":"jur-ph","procedure_name":"DMT (N,N-Dimethyltryptamine) Assisted Therapy for Depression","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Strict penalties; no therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Dangerous drugs schedules — classical psychedelics prohibited.","regulatory_authority":"FDA Philippines / Dangerous Drugs Act","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Major Depressive Disorder","Treatment-Resistant Depression"],"status":"active"},{"id":"c4cf3634-ddef-452a-8889-7f29e0711a7d","procedure_id":"proc-lsd-anxiety","jurisdiction_id":"jur-ph","procedure_name":"LSD-Assisted Psychotherapy for Anxiety Disorders","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Strict penalties; no therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Dangerous drugs schedules — classical psychedelics prohibited.","regulatory_authority":"FDA Philippines / Dangerous Drugs Act","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Anxiety"],"diseases":["Generalized Anxiety Disorder","Illness-Related Anxiety"],"status":"active"},{"id":"b3c7042a-eeed-4a28-938b-3d3a0fc7bd4b","procedure_id":"proc-mescaline-therapy","jurisdiction_id":"jur-ph","procedure_name":"Mescaline-Assisted Therapy (San Pedro) for Depression/Addiction","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Strict penalties; no therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Dangerous drugs schedules — classical psychedelics prohibited.","regulatory_authority":"FDA Philippines / Dangerous Drugs Act","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression","Addiction"],"diseases":["Depression","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"3ee554d4-fd22-4f2a-af51-225bb65a629b","procedure_id":"proc-ayahuasca","jurisdiction_id":"jur-ph","procedure_name":"Ayahuasca-Assisted Therapy for Depression/Addiction/Spiritual Growth","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Strict penalties; no therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Dangerous drugs schedules — classical psychedelics prohibited.","regulatory_authority":"FDA Philippines / Dangerous Drugs Act","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Addiction","Spirituality"],"diseases":["Depression","Substance Use Disorder","PTSD","Existential Distress"],"status":"active"},{"id":"104e9074-c7a7-45ab-b945-3d2073900bd9","procedure_id":"proc-5meo-dmt","jurisdiction_id":"jur-ph","procedure_name":"5-MeO-DMT Assisted Therapy","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Strict penalties; no therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Dangerous drugs schedules — classical psychedelics prohibited.","regulatory_authority":"FDA Philippines / Dangerous Drugs Act","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Spirituality"],"diseases":["Depression","Anxiety","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"76905398-483d-46cf-ac69-ae7808b1b4d6","procedure_id":"proc-ibogaine-addiction","jurisdiction_id":"jur-ph","procedure_name":"Ibogaine Treatment for Opioid/Substance Use Disorder","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Strict penalties; no therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Dangerous drugs schedules — classical psychedelics prohibited.","regulatory_authority":"FDA Philippines / Dangerous Drugs Act","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Addiction"],"diseases":["Opioid Use Disorder","Substance Use Disorder"],"status":"active"},{"id":"1bc34ec4-aaa9-4333-8784-de6b21e75e8f","procedure_id":"proc-psilocybin-trd","jurisdiction_id":"jur-mx","procedure_name":"Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Ibogaine/retreat markets operate in gray zones but do not equal national authorisation for all psychedelics.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Psychotropics schedules — classical psychedelics generally prohibited; enforcement and gray tourism vary by substance/region.","regulatory_authority":"COFEPRIS / Ley General de Salud","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"fb9e8c7b-decd-45ed-999e-726d1589d065","procedure_id":"proc-psilocybin-eol","jurisdiction_id":"jur-mx","procedure_name":"Psilocybin-Assisted Therapy for End-of-Life Anxiety","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Ibogaine/retreat markets operate in gray zones but do not equal national authorisation for all psychedelics.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Psychotropics schedules — classical psychedelics generally prohibited; enforcement and gray tourism vary by substance/region.","regulatory_authority":"COFEPRIS / Ley General de Salud","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Palliative_Care"],"diseases":["Cancer-Related Anxiety","End-of-Life Existential Distress","Adjustment Disorder"],"status":"active"},{"id":"dc64a2df-5b51-4242-89c2-9773d660aa29","procedure_id":"proc-psilocybin-microdose","jurisdiction_id":"jur-mx","procedure_name":"Psilocybin Microdosing Protocols","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Ibogaine/retreat markets operate in gray zones but do not equal national authorisation for all psychedelics.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Psychotropics schedules — classical psychedelics generally prohibited; enforcement and gray tourism vary by substance/region.","regulatory_authority":"COFEPRIS / Ley General de Salud","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Cognition"],"diseases":["Depression","Anxiety","ADHD Symptoms (self-report)"],"status":"active"},{"id":"5db9a021-1b90-4d0e-b936-f8433300a654","procedure_id":"proc-mdma-ptsd","jurisdiction_id":"jur-mx","procedure_name":"MDMA-Assisted Psychotherapy for PTSD","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Ibogaine/retreat markets operate in gray zones but do not equal national authorisation for all psychedelics.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Psychotropics schedules — classical psychedelics generally prohibited; enforcement and gray tourism vary by substance/region.","regulatory_authority":"COFEPRIS / Ley General de Salud","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["Post-Traumatic Stress Disorder (PTSD)"],"status":"active"},{"id":"90f94066-16cd-423a-a4ca-20ca9ae23cab","procedure_id":"proc-dmt-depression","jurisdiction_id":"jur-mx","procedure_name":"DMT (N,N-Dimethyltryptamine) Assisted Therapy for Depression","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Ibogaine/retreat markets operate in gray zones but do not equal national authorisation for all psychedelics.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Psychotropics schedules — classical psychedelics generally prohibited; enforcement and gray tourism vary by substance/region.","regulatory_authority":"COFEPRIS / Ley General de Salud","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Major Depressive Disorder","Treatment-Resistant Depression"],"status":"active"},{"id":"b69d6a6d-7618-4bed-875d-7813bac24942","procedure_id":"proc-lsd-anxiety","jurisdiction_id":"jur-mx","procedure_name":"LSD-Assisted Psychotherapy for Anxiety Disorders","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Ibogaine/retreat markets operate in gray zones but do not equal national authorisation for all psychedelics.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Psychotropics schedules — classical psychedelics generally prohibited; enforcement and gray tourism vary by substance/region.","regulatory_authority":"COFEPRIS / Ley General de Salud","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Anxiety"],"diseases":["Generalized Anxiety Disorder","Illness-Related Anxiety"],"status":"active"},{"id":"15f7f371-cbf3-4da1-b7d9-628f795cb154","procedure_id":"proc-psilocybin-trd","jurisdiction_id":"jur-br","procedure_name":"Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Religious ayahuasca ≠ general psilocybin/MDMA therapy legalisation.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled substances list — many psychedelics prohibited; ayahuasca religious use is a specific constitutional/religious exception.","regulatory_authority":"ANVISA","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"4b7800a4-517e-4be5-922d-8a1efaf312e1","procedure_id":"proc-psilocybin-eol","jurisdiction_id":"jur-br","procedure_name":"Psilocybin-Assisted Therapy for End-of-Life Anxiety","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Religious ayahuasca ≠ general psilocybin/MDMA therapy legalisation.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled substances list — many psychedelics prohibited; ayahuasca religious use is a specific constitutional/religious exception.","regulatory_authority":"ANVISA","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Palliative_Care"],"diseases":["Cancer-Related Anxiety","End-of-Life Existential Distress","Adjustment Disorder"],"status":"active"},{"id":"a3972123-e8ec-4ba3-aba7-65a51bdb4e2e","procedure_id":"proc-psilocybin-microdose","jurisdiction_id":"jur-br","procedure_name":"Psilocybin Microdosing Protocols","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Religious ayahuasca ≠ general psilocybin/MDMA therapy legalisation.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled substances list — many psychedelics prohibited; ayahuasca religious use is a specific constitutional/religious exception.","regulatory_authority":"ANVISA","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Cognition"],"diseases":["Depression","Anxiety","ADHD Symptoms (self-report)"],"status":"active"},{"id":"1dfdd1f9-e966-40bb-8c3d-538ae23e259b","procedure_id":"proc-mdma-ptsd","jurisdiction_id":"jur-br","procedure_name":"MDMA-Assisted Psychotherapy for PTSD","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Religious ayahuasca ≠ general psilocybin/MDMA therapy legalisation.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled substances list — many psychedelics prohibited; ayahuasca religious use is a specific constitutional/religious exception.","regulatory_authority":"ANVISA","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["Post-Traumatic Stress Disorder (PTSD)"],"status":"active"},{"id":"269b2dd7-c3f7-4b21-a8cb-06fa806fed92","procedure_id":"proc-dmt-depression","jurisdiction_id":"jur-br","procedure_name":"DMT (N,N-Dimethyltryptamine) Assisted Therapy for Depression","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Religious ayahuasca ≠ general psilocybin/MDMA therapy legalisation.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled substances list — many psychedelics prohibited; ayahuasca religious use is a specific constitutional/religious exception.","regulatory_authority":"ANVISA","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Major Depressive Disorder","Treatment-Resistant Depression"],"status":"active"},{"id":"287a9c58-a5bc-404a-ae08-b51c1ca41f96","procedure_id":"proc-lsd-anxiety","jurisdiction_id":"jur-br","procedure_name":"LSD-Assisted Psychotherapy for Anxiety Disorders","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Religious ayahuasca ≠ general psilocybin/MDMA therapy legalisation.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled substances list — many psychedelics prohibited; ayahuasca religious use is a specific constitutional/religious exception.","regulatory_authority":"ANVISA","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Anxiety"],"diseases":["Generalized Anxiety Disorder","Illness-Related Anxiety"],"status":"active"},{"id":"c24a4b3f-0122-4f07-9eb2-dd31d99a8314","procedure_id":"proc-mescaline-therapy","jurisdiction_id":"jur-br","procedure_name":"Mescaline-Assisted Therapy (San Pedro) for Depression/Addiction","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Religious ayahuasca ≠ general psilocybin/MDMA therapy legalisation.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled substances list — many psychedelics prohibited; ayahuasca religious use is a specific constitutional/religious exception.","regulatory_authority":"ANVISA","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression","Addiction"],"diseases":["Depression","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"b4b00725-5b0f-430e-8d68-3e5f3cd7bfa2","procedure_id":"proc-5meo-dmt","jurisdiction_id":"jur-br","procedure_name":"5-MeO-DMT Assisted Therapy","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Religious ayahuasca ≠ general psilocybin/MDMA therapy legalisation.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled substances list — many psychedelics prohibited; ayahuasca religious use is a specific constitutional/religious exception.","regulatory_authority":"ANVISA","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Spirituality"],"diseases":["Depression","Anxiety","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"1601c9bd-3adf-4dfc-8af5-0e7bbab3f037","procedure_id":"proc-ibogaine-addiction","jurisdiction_id":"jur-br","procedure_name":"Ibogaine Treatment for Opioid/Substance Use Disorder","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Religious ayahuasca ≠ general psilocybin/MDMA therapy legalisation.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled substances list — many psychedelics prohibited; ayahuasca religious use is a specific constitutional/religious exception.","regulatory_authority":"ANVISA","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Addiction"],"diseases":["Opioid Use Disorder","Substance Use Disorder"],"status":"active"},{"id":"d2e51545-a384-4174-94fc-773d83c578e4","procedure_id":"proc-psilocybin-trd","jurisdiction_id":"jur-ar","procedure_name":"Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No national therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled psychotropics — classical psychedelics prohibited outside research.","regulatory_authority":"ANMAT / narcotics law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"54e2b198-7f4c-49e8-b1cd-7dc4d1df52cd","procedure_id":"proc-psilocybin-eol","jurisdiction_id":"jur-ar","procedure_name":"Psilocybin-Assisted Therapy for End-of-Life Anxiety","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No national therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled psychotropics — classical psychedelics prohibited outside research.","regulatory_authority":"ANMAT / narcotics law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Palliative_Care"],"diseases":["Cancer-Related Anxiety","End-of-Life Existential Distress","Adjustment Disorder"],"status":"active"},{"id":"cfa4157d-b90a-42bb-845f-f4ccb2a9f296","procedure_id":"proc-psilocybin-microdose","jurisdiction_id":"jur-ar","procedure_name":"Psilocybin Microdosing Protocols","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No national therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled psychotropics — classical psychedelics prohibited outside research.","regulatory_authority":"ANMAT / narcotics law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Cognition"],"diseases":["Depression","Anxiety","ADHD Symptoms (self-report)"],"status":"active"},{"id":"2cfc15d4-044f-46d8-af24-39f7f237a00e","procedure_id":"proc-mdma-ptsd","jurisdiction_id":"jur-ar","procedure_name":"MDMA-Assisted Psychotherapy for PTSD","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No national therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled psychotropics — classical psychedelics prohibited outside research.","regulatory_authority":"ANMAT / narcotics law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["Post-Traumatic Stress Disorder (PTSD)"],"status":"active"},{"id":"067f9c02-cdb5-470e-97e0-96e8c1fab630","procedure_id":"proc-dmt-depression","jurisdiction_id":"jur-ar","procedure_name":"DMT (N,N-Dimethyltryptamine) Assisted Therapy for Depression","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No national therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled psychotropics — classical psychedelics prohibited outside research.","regulatory_authority":"ANMAT / narcotics law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Major Depressive Disorder","Treatment-Resistant Depression"],"status":"active"},{"id":"89a3a8d3-6434-43b5-b579-5959b5d22def","procedure_id":"proc-lsd-anxiety","jurisdiction_id":"jur-ar","procedure_name":"LSD-Assisted Psychotherapy for Anxiety Disorders","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No national therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled psychotropics — classical psychedelics prohibited outside research.","regulatory_authority":"ANMAT / narcotics law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Anxiety"],"diseases":["Generalized Anxiety Disorder","Illness-Related Anxiety"],"status":"active"},{"id":"567696dd-4e60-467e-b440-1b71dcc450ed","procedure_id":"proc-mescaline-therapy","jurisdiction_id":"jur-ar","procedure_name":"Mescaline-Assisted Therapy (San Pedro) for Depression/Addiction","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No national therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled psychotropics — classical psychedelics prohibited outside research.","regulatory_authority":"ANMAT / narcotics law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression","Addiction"],"diseases":["Depression","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"4587cbd8-e69e-4f9b-8b96-ec16a15d7f47","procedure_id":"proc-ayahuasca","jurisdiction_id":"jur-ar","procedure_name":"Ayahuasca-Assisted Therapy for Depression/Addiction/Spiritual Growth","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No national therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled psychotropics — classical psychedelics prohibited outside research.","regulatory_authority":"ANMAT / narcotics law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Addiction","Spirituality"],"diseases":["Depression","Substance Use Disorder","PTSD","Existential Distress"],"status":"active"},{"id":"5f188ec8-8f62-4b5d-981b-93800c21d9f0","procedure_id":"proc-5meo-dmt","jurisdiction_id":"jur-ar","procedure_name":"5-MeO-DMT Assisted Therapy","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No national therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled psychotropics — classical psychedelics prohibited outside research.","regulatory_authority":"ANMAT / narcotics law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Spirituality"],"diseases":["Depression","Anxiety","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"c38553b9-cbfe-4490-96f5-1e60e44d2c2b","procedure_id":"proc-ibogaine-addiction","jurisdiction_id":"jur-ar","procedure_name":"Ibogaine Treatment for Opioid/Substance Use Disorder","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No national therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled psychotropics — classical psychedelics prohibited outside research.","regulatory_authority":"ANMAT / narcotics law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Addiction"],"diseases":["Opioid Use Disorder","Substance Use Disorder"],"status":"active"},{"id":"bb6137e0-0184-495a-be40-8f10ae30beb1","procedure_id":"proc-psilocybin-trd","jurisdiction_id":"jur-cl","procedure_name":"Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Limited reform debates; default remains prohibition for therapy businesses.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled substances — classical psychedelics generally prohibited.","regulatory_authority":"ISP / Chilean narcotics framework","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"68d65d7a-df0f-40dc-8110-d86b38e8dc81","procedure_id":"proc-psilocybin-eol","jurisdiction_id":"jur-cl","procedure_name":"Psilocybin-Assisted Therapy for End-of-Life Anxiety","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Limited reform debates; default remains prohibition for therapy businesses.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled substances — classical psychedelics generally prohibited.","regulatory_authority":"ISP / Chilean narcotics framework","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Palliative_Care"],"diseases":["Cancer-Related Anxiety","End-of-Life Existential Distress","Adjustment Disorder"],"status":"active"},{"id":"a4c53387-fd8c-4e2a-a100-833a082b8612","procedure_id":"proc-psilocybin-microdose","jurisdiction_id":"jur-cl","procedure_name":"Psilocybin Microdosing Protocols","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Limited reform debates; default remains prohibition for therapy businesses.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled substances — classical psychedelics generally prohibited.","regulatory_authority":"ISP / Chilean narcotics framework","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Cognition"],"diseases":["Depression","Anxiety","ADHD Symptoms (self-report)"],"status":"active"},{"id":"63de8eb9-ec14-449a-9aba-635cb3f078c0","procedure_id":"proc-mdma-ptsd","jurisdiction_id":"jur-cl","procedure_name":"MDMA-Assisted Psychotherapy for PTSD","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Limited reform debates; default remains prohibition for therapy businesses.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled substances — classical psychedelics generally prohibited.","regulatory_authority":"ISP / Chilean narcotics framework","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["Post-Traumatic Stress Disorder (PTSD)"],"status":"active"},{"id":"9b36c9f9-fa64-4381-a705-5e44d75ade3c","procedure_id":"proc-dmt-depression","jurisdiction_id":"jur-cl","procedure_name":"DMT (N,N-Dimethyltryptamine) Assisted Therapy for Depression","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Limited reform debates; default remains prohibition for therapy businesses.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled substances — classical psychedelics generally prohibited.","regulatory_authority":"ISP / Chilean narcotics framework","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Major Depressive Disorder","Treatment-Resistant Depression"],"status":"active"},{"id":"6d4aba0f-f4a4-43db-aed1-31f3f3005dee","procedure_id":"proc-lsd-anxiety","jurisdiction_id":"jur-cl","procedure_name":"LSD-Assisted Psychotherapy for Anxiety Disorders","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Limited reform debates; default remains prohibition for therapy businesses.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled substances — classical psychedelics generally prohibited.","regulatory_authority":"ISP / Chilean narcotics framework","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Anxiety"],"diseases":["Generalized Anxiety Disorder","Illness-Related Anxiety"],"status":"active"},{"id":"560553b4-7709-4020-b120-d7e791ffcdd0","procedure_id":"proc-mescaline-therapy","jurisdiction_id":"jur-cl","procedure_name":"Mescaline-Assisted Therapy (San Pedro) for Depression/Addiction","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Limited reform debates; default remains prohibition for therapy businesses.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled substances — classical psychedelics generally prohibited.","regulatory_authority":"ISP / Chilean narcotics framework","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression","Addiction"],"diseases":["Depression","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"a3e9acf6-e432-48f0-b596-4d71ca9bc21d","procedure_id":"proc-5meo-dmt","jurisdiction_id":"jur-cl","procedure_name":"5-MeO-DMT Assisted Therapy","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Limited reform debates; default remains prohibition for therapy businesses.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled substances — classical psychedelics generally prohibited.","regulatory_authority":"ISP / Chilean narcotics framework","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Spirituality"],"diseases":["Depression","Anxiety","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"f48e6f4a-e745-427a-b9d6-23adf07a2d3d","procedure_id":"proc-ibogaine-addiction","jurisdiction_id":"jur-cl","procedure_name":"Ibogaine Treatment for Opioid/Substance Use Disorder","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Limited reform debates; default remains prohibition for therapy businesses.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled substances — classical psychedelics generally prohibited.","regulatory_authority":"ISP / Chilean narcotics framework","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Addiction"],"diseases":["Opioid Use Disorder","Substance Use Disorder"],"status":"active"},{"id":"2b5678e0-cd38-4d40-b44a-9bbe6acc34b8","procedure_id":"proc-psilocybin-trd","jurisdiction_id":"jur-cr","procedure_name":"Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Retreat tourism may occur in gray zones without creating a regulated medical pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled narcotics — classical psychedelics not authorised as medicines.","regulatory_authority":"Ministry of Health Costa Rica","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"b28fe5eb-c9e7-4ebc-b711-5c1811a21381","procedure_id":"proc-psilocybin-eol","jurisdiction_id":"jur-cr","procedure_name":"Psilocybin-Assisted Therapy for End-of-Life Anxiety","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Retreat tourism may occur in gray zones without creating a regulated medical pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled narcotics — classical psychedelics not authorised as medicines.","regulatory_authority":"Ministry of Health Costa Rica","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Palliative_Care"],"diseases":["Cancer-Related Anxiety","End-of-Life Existential Distress","Adjustment Disorder"],"status":"active"},{"id":"3647b64f-f922-40c6-9f77-56913e82a1c5","procedure_id":"proc-psilocybin-microdose","jurisdiction_id":"jur-cr","procedure_name":"Psilocybin Microdosing Protocols","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Retreat tourism may occur in gray zones without creating a regulated medical pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled narcotics — classical psychedelics not authorised as medicines.","regulatory_authority":"Ministry of Health Costa Rica","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Cognition"],"diseases":["Depression","Anxiety","ADHD Symptoms (self-report)"],"status":"active"},{"id":"fcbfc225-9476-419f-9308-8a595b544ce2","procedure_id":"proc-mdma-ptsd","jurisdiction_id":"jur-cr","procedure_name":"MDMA-Assisted Psychotherapy for PTSD","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Retreat tourism may occur in gray zones without creating a regulated medical pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled narcotics — classical psychedelics not authorised as medicines.","regulatory_authority":"Ministry of Health Costa Rica","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["Post-Traumatic Stress Disorder (PTSD)"],"status":"active"},{"id":"e0b842a1-a031-4496-92f3-4f446693b6c1","procedure_id":"proc-dmt-depression","jurisdiction_id":"jur-cr","procedure_name":"DMT (N,N-Dimethyltryptamine) Assisted Therapy for Depression","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Retreat tourism may occur in gray zones without creating a regulated medical pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled narcotics — classical psychedelics not authorised as medicines.","regulatory_authority":"Ministry of Health Costa Rica","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Major Depressive Disorder","Treatment-Resistant Depression"],"status":"active"},{"id":"e97e8682-3339-4151-8a97-d7598b8d0bf3","procedure_id":"proc-lsd-anxiety","jurisdiction_id":"jur-cr","procedure_name":"LSD-Assisted Psychotherapy for Anxiety Disorders","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Retreat tourism may occur in gray zones without creating a regulated medical pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled narcotics — classical psychedelics not authorised as medicines.","regulatory_authority":"Ministry of Health Costa Rica","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Anxiety"],"diseases":["Generalized Anxiety Disorder","Illness-Related Anxiety"],"status":"active"},{"id":"d44bf8b7-3f9a-4551-862e-feafe1c3c13f","procedure_id":"proc-mescaline-therapy","jurisdiction_id":"jur-cr","procedure_name":"Mescaline-Assisted Therapy (San Pedro) for Depression/Addiction","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Retreat tourism may occur in gray zones without creating a regulated medical pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled narcotics — classical psychedelics not authorised as medicines.","regulatory_authority":"Ministry of Health Costa Rica","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression","Addiction"],"diseases":["Depression","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"82ab7528-d883-4e80-8ded-51eb5b6723a6","procedure_id":"proc-5meo-dmt","jurisdiction_id":"jur-cr","procedure_name":"5-MeO-DMT Assisted Therapy","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Retreat tourism may occur in gray zones without creating a regulated medical pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled narcotics — classical psychedelics not authorised as medicines.","regulatory_authority":"Ministry of Health Costa Rica","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Spirituality"],"diseases":["Depression","Anxiety","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"a956bf53-ed1d-40c5-a2e2-5ef29979fbf9","procedure_id":"proc-ibogaine-addiction","jurisdiction_id":"jur-cr","procedure_name":"Ibogaine Treatment for Opioid/Substance Use Disorder","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Retreat tourism may occur in gray zones without creating a regulated medical pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled narcotics — classical psychedelics not authorised as medicines.","regulatory_authority":"Ministry of Health Costa Rica","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Addiction"],"diseases":["Opioid Use Disorder","Substance Use Disorder"],"status":"active"},{"id":"cf46efea-b974-499b-a64f-a60473d9297a","procedure_id":"proc-psilocybin-trd","jurisdiction_id":"jur-za","procedure_name":"Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Research possible; no national service-centre model.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Medicines and controlled substances frameworks — classical psychedelics not authorised for general therapy.","regulatory_authority":"SAHPRA","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"709aab86-54de-4b87-9c10-30ee15681dbd","procedure_id":"proc-psilocybin-eol","jurisdiction_id":"jur-za","procedure_name":"Psilocybin-Assisted Therapy for End-of-Life Anxiety","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Research possible; no national service-centre model.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Medicines and controlled substances frameworks — classical psychedelics not authorised for general therapy.","regulatory_authority":"SAHPRA","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Palliative_Care"],"diseases":["Cancer-Related Anxiety","End-of-Life Existential Distress","Adjustment Disorder"],"status":"active"},{"id":"f38113ba-42de-455d-81a5-6e9846d8066f","procedure_id":"proc-psilocybin-microdose","jurisdiction_id":"jur-za","procedure_name":"Psilocybin Microdosing Protocols","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Research possible; no national service-centre model.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Medicines and controlled substances frameworks — classical psychedelics not authorised for general therapy.","regulatory_authority":"SAHPRA","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Cognition"],"diseases":["Depression","Anxiety","ADHD Symptoms (self-report)"],"status":"active"},{"id":"65488e14-9538-45a9-8947-de648cd620a1","procedure_id":"proc-mdma-ptsd","jurisdiction_id":"jur-za","procedure_name":"MDMA-Assisted Psychotherapy for PTSD","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Research possible; no national service-centre model.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Medicines and controlled substances frameworks — classical psychedelics not authorised for general therapy.","regulatory_authority":"SAHPRA","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["Post-Traumatic Stress Disorder (PTSD)"],"status":"active"},{"id":"afb32934-fc7f-4fa5-bbc9-40a330ffe640","procedure_id":"proc-dmt-depression","jurisdiction_id":"jur-za","procedure_name":"DMT (N,N-Dimethyltryptamine) Assisted Therapy for Depression","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Research possible; no national service-centre model.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Medicines and controlled substances frameworks — classical psychedelics not authorised for general therapy.","regulatory_authority":"SAHPRA","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Major Depressive Disorder","Treatment-Resistant Depression"],"status":"active"},{"id":"90d4bad5-04e0-41a9-900c-3f2f154f16cc","procedure_id":"proc-lsd-anxiety","jurisdiction_id":"jur-za","procedure_name":"LSD-Assisted Psychotherapy for Anxiety Disorders","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Research possible; no national service-centre model.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Medicines and controlled substances frameworks — classical psychedelics not authorised for general therapy.","regulatory_authority":"SAHPRA","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Anxiety"],"diseases":["Generalized Anxiety Disorder","Illness-Related Anxiety"],"status":"active"},{"id":"94986535-4c82-4b33-8e8d-329993887328","procedure_id":"proc-mescaline-therapy","jurisdiction_id":"jur-za","procedure_name":"Mescaline-Assisted Therapy (San Pedro) for Depression/Addiction","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Research possible; no national service-centre model.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Medicines and controlled substances frameworks — classical psychedelics not authorised for general therapy.","regulatory_authority":"SAHPRA","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression","Addiction"],"diseases":["Depression","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"11889b41-40b9-48d9-a013-905d0630ec06","procedure_id":"proc-ayahuasca","jurisdiction_id":"jur-za","procedure_name":"Ayahuasca-Assisted Therapy for Depression/Addiction/Spiritual Growth","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Research possible; no national service-centre model.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Medicines and controlled substances frameworks — classical psychedelics not authorised for general therapy.","regulatory_authority":"SAHPRA","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Addiction","Spirituality"],"diseases":["Depression","Substance Use Disorder","PTSD","Existential Distress"],"status":"active"},{"id":"540af6d3-47b0-46fe-9c61-beea44a75048","procedure_id":"proc-5meo-dmt","jurisdiction_id":"jur-za","procedure_name":"5-MeO-DMT Assisted Therapy","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Research possible; no national service-centre model.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Medicines and controlled substances frameworks — classical psychedelics not authorised for general therapy.","regulatory_authority":"SAHPRA","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Spirituality"],"diseases":["Depression","Anxiety","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"ec74967f-a2ab-4372-9d1a-d3a92c8e4ca5","procedure_id":"proc-ibogaine-addiction","jurisdiction_id":"jur-za","procedure_name":"Ibogaine Treatment for Opioid/Substance Use Disorder","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Research possible; no national service-centre model.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Medicines and controlled substances frameworks — classical psychedelics not authorised for general therapy.","regulatory_authority":"SAHPRA","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Addiction"],"diseases":["Opioid Use Disorder","Substance Use Disorder"],"status":"active"},{"id":"f275af88-e237-42a7-a9a7-20c87a142d5d","procedure_id":"proc-psilocybin-eol","jurisdiction_id":"jur-ca","procedure_name":"Psilocybin-Assisted Therapy for End-of-Life Anxiety","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Default is prohibited for open practice; seeded SAP/Section 56 cells are exceptions.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled Drugs and Substances Act schedules classical psychedelics; SAP/Section 56 are exceptional pathways.","regulatory_authority":"Health Canada / CDSA","last_verified":"2026-07-01","sources":[{"title":"CDSA","url":"https://laws-lois.justice.gc.ca/eng/acts/c-38.8/"}],"therapeutic_areas":["Mental_Health","Palliative_Care"],"diseases":["Cancer-Related Anxiety","End-of-Life Existential Distress","Adjustment Disorder"],"status":"active"},{"id":"aefdc232-cecc-41bd-9721-e9dff883be5b","procedure_id":"proc-psilocybin-microdose","jurisdiction_id":"jur-ca","procedure_name":"Psilocybin Microdosing Protocols","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Default is prohibited for open practice; seeded SAP/Section 56 cells are exceptions.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled Drugs and Substances Act schedules classical psychedelics; SAP/Section 56 are exceptional pathways.","regulatory_authority":"Health Canada / CDSA","last_verified":"2026-07-01","sources":[{"title":"CDSA","url":"https://laws-lois.justice.gc.ca/eng/acts/c-38.8/"}],"therapeutic_areas":["Mental_Health","Cognition"],"diseases":["Depression","Anxiety","ADHD Symptoms (self-report)"],"status":"active"},{"id":"11185040-6f47-4be2-869f-306c36c9806b","procedure_id":"proc-mdma-ptsd","jurisdiction_id":"jur-ca","procedure_name":"MDMA-Assisted Psychotherapy for PTSD","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Default is prohibited for open practice; seeded SAP/Section 56 cells are exceptions.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled Drugs and Substances Act schedules classical psychedelics; SAP/Section 56 are exceptional pathways.","regulatory_authority":"Health Canada / CDSA","last_verified":"2026-07-01","sources":[{"title":"CDSA","url":"https://laws-lois.justice.gc.ca/eng/acts/c-38.8/"}],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["Post-Traumatic Stress Disorder (PTSD)"],"status":"active"},{"id":"9aa544eb-436c-42b4-b271-1e4b624012f6","procedure_id":"proc-dmt-depression","jurisdiction_id":"jur-ca","procedure_name":"DMT (N,N-Dimethyltryptamine) Assisted Therapy for Depression","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Default is prohibited for open practice; seeded SAP/Section 56 cells are exceptions.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled Drugs and Substances Act schedules classical psychedelics; SAP/Section 56 are exceptional pathways.","regulatory_authority":"Health Canada / CDSA","last_verified":"2026-07-01","sources":[{"title":"CDSA","url":"https://laws-lois.justice.gc.ca/eng/acts/c-38.8/"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Major Depressive Disorder","Treatment-Resistant Depression"],"status":"active"},{"id":"002e0c68-d898-4cc0-9696-f5e90fbfae0f","procedure_id":"proc-lsd-anxiety","jurisdiction_id":"jur-ca","procedure_name":"LSD-Assisted Psychotherapy for Anxiety Disorders","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Default is prohibited for open practice; seeded SAP/Section 56 cells are exceptions.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled Drugs and Substances Act schedules classical psychedelics; SAP/Section 56 are exceptional pathways.","regulatory_authority":"Health Canada / CDSA","last_verified":"2026-07-01","sources":[{"title":"CDSA","url":"https://laws-lois.justice.gc.ca/eng/acts/c-38.8/"}],"therapeutic_areas":["Mental_Health","Anxiety"],"diseases":["Generalized Anxiety Disorder","Illness-Related Anxiety"],"status":"active"},{"id":"914973a4-5fde-4c0b-9890-39299389207f","procedure_id":"proc-mescaline-therapy","jurisdiction_id":"jur-ca","procedure_name":"Mescaline-Assisted Therapy (San Pedro) for Depression/Addiction","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Default is prohibited for open practice; seeded SAP/Section 56 cells are exceptions.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled Drugs and Substances Act schedules classical psychedelics; SAP/Section 56 are exceptional pathways.","regulatory_authority":"Health Canada / CDSA","last_verified":"2026-07-01","sources":[{"title":"CDSA","url":"https://laws-lois.justice.gc.ca/eng/acts/c-38.8/"}],"therapeutic_areas":["Mental_Health","Depression","Addiction"],"diseases":["Depression","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"54e4461e-16fc-4ba0-abd3-390b51a43648","procedure_id":"proc-ayahuasca","jurisdiction_id":"jur-ca","procedure_name":"Ayahuasca-Assisted Therapy for Depression/Addiction/Spiritual Growth","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Default is prohibited for open practice; seeded SAP/Section 56 cells are exceptions.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled Drugs and Substances Act schedules classical psychedelics; SAP/Section 56 are exceptional pathways.","regulatory_authority":"Health Canada / CDSA","last_verified":"2026-07-01","sources":[{"title":"CDSA","url":"https://laws-lois.justice.gc.ca/eng/acts/c-38.8/"}],"therapeutic_areas":["Mental_Health","Addiction","Spirituality"],"diseases":["Depression","Substance Use Disorder","PTSD","Existential Distress"],"status":"active"},{"id":"05b3437c-5947-4b31-8718-843085e0e825","procedure_id":"proc-5meo-dmt","jurisdiction_id":"jur-ca","procedure_name":"5-MeO-DMT Assisted Therapy","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Default is prohibited for open practice; seeded SAP/Section 56 cells are exceptions.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled Drugs and Substances Act schedules classical psychedelics; SAP/Section 56 are exceptional pathways.","regulatory_authority":"Health Canada / CDSA","last_verified":"2026-07-01","sources":[{"title":"CDSA","url":"https://laws-lois.justice.gc.ca/eng/acts/c-38.8/"}],"therapeutic_areas":["Mental_Health","Spirituality"],"diseases":["Depression","Anxiety","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"68cbf1be-d633-4def-9767-79dda8b7f45a","procedure_id":"proc-ibogaine-addiction","jurisdiction_id":"jur-ca","procedure_name":"Ibogaine Treatment for Opioid/Substance Use Disorder","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Default is prohibited for open practice; seeded SAP/Section 56 cells are exceptions.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Controlled Drugs and Substances Act schedules classical psychedelics; SAP/Section 56 are exceptional pathways.","regulatory_authority":"Health Canada / CDSA","last_verified":"2026-07-01","sources":[{"title":"CDSA","url":"https://laws-lois.justice.gc.ca/eng/acts/c-38.8/"}],"therapeutic_areas":["Mental_Health","Addiction"],"diseases":["Opioid Use Disorder","Substance Use Disorder"],"status":"active"},{"id":"90a05df9-7f3c-45f9-8f74-7f02b2d14e8b","procedure_id":"proc-psilocybin-trd","jurisdiction_id":"jur-hn-prospera","procedure_name":"Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Do not assume all psychedelics are free — only explicitly structured programmes apply. Legal uncertainty high.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Special zone rules may diverge; national Honduran narcotics law still relevant outside ZEDE perimeter.","regulatory_authority":"Próspera ZEDE / contested Honduran framework","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"cf8e036a-3ad0-4f6f-8a61-8914dfd813fb","procedure_id":"proc-psilocybin-eol","jurisdiction_id":"jur-hn-prospera","procedure_name":"Psilocybin-Assisted Therapy for End-of-Life Anxiety","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Do not assume all psychedelics are free — only explicitly structured programmes apply. Legal uncertainty high.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Special zone rules may diverge; national Honduran narcotics law still relevant outside ZEDE perimeter.","regulatory_authority":"Próspera ZEDE / contested Honduran framework","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Palliative_Care"],"diseases":["Cancer-Related Anxiety","End-of-Life Existential Distress","Adjustment Disorder"],"status":"active"},{"id":"77e52e52-724e-4e25-971a-b38d2d093b77","procedure_id":"proc-psilocybin-microdose","jurisdiction_id":"jur-hn-prospera","procedure_name":"Psilocybin Microdosing Protocols","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Do not assume all psychedelics are free — only explicitly structured programmes apply. Legal uncertainty high.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Special zone rules may diverge; national Honduran narcotics law still relevant outside ZEDE perimeter.","regulatory_authority":"Próspera ZEDE / contested Honduran framework","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Cognition"],"diseases":["Depression","Anxiety","ADHD Symptoms (self-report)"],"status":"active"},{"id":"8bd5eb98-8ea9-4269-861e-782fdd2cb5dc","procedure_id":"proc-mdma-ptsd","jurisdiction_id":"jur-hn-prospera","procedure_name":"MDMA-Assisted Psychotherapy for PTSD","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Do not assume all psychedelics are free — only explicitly structured programmes apply. Legal uncertainty high.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Special zone rules may diverge; national Honduran narcotics law still relevant outside ZEDE perimeter.","regulatory_authority":"Próspera ZEDE / contested Honduran framework","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["Post-Traumatic Stress Disorder (PTSD)"],"status":"active"},{"id":"4a872451-21d3-4a18-835d-6bf0d9c8c468","procedure_id":"proc-dmt-depression","jurisdiction_id":"jur-hn-prospera","procedure_name":"DMT (N,N-Dimethyltryptamine) Assisted Therapy for Depression","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Do not assume all psychedelics are free — only explicitly structured programmes apply. Legal uncertainty high.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Special zone rules may diverge; national Honduran narcotics law still relevant outside ZEDE perimeter.","regulatory_authority":"Próspera ZEDE / contested Honduran framework","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Major Depressive Disorder","Treatment-Resistant Depression"],"status":"active"},{"id":"316dc3ae-d6c2-48fb-a5b9-e394b60a6905","procedure_id":"proc-lsd-anxiety","jurisdiction_id":"jur-hn-prospera","procedure_name":"LSD-Assisted Psychotherapy for Anxiety Disorders","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Do not assume all psychedelics are free — only explicitly structured programmes apply. Legal uncertainty high.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Special zone rules may diverge; national Honduran narcotics law still relevant outside ZEDE perimeter.","regulatory_authority":"Próspera ZEDE / contested Honduran framework","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Anxiety"],"diseases":["Generalized Anxiety Disorder","Illness-Related Anxiety"],"status":"active"},{"id":"88e4c4a3-dcde-4905-80b2-257426ffe42c","procedure_id":"proc-mescaline-therapy","jurisdiction_id":"jur-hn-prospera","procedure_name":"Mescaline-Assisted Therapy (San Pedro) for Depression/Addiction","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Do not assume all psychedelics are free — only explicitly structured programmes apply. Legal uncertainty high.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Special zone rules may diverge; national Honduran narcotics law still relevant outside ZEDE perimeter.","regulatory_authority":"Próspera ZEDE / contested Honduran framework","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression","Addiction"],"diseases":["Depression","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"f128e3be-3f53-473b-ac84-bf245ef7662d","procedure_id":"proc-ayahuasca","jurisdiction_id":"jur-hn-prospera","procedure_name":"Ayahuasca-Assisted Therapy for Depression/Addiction/Spiritual Growth","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Do not assume all psychedelics are free — only explicitly structured programmes apply. Legal uncertainty high.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Special zone rules may diverge; national Honduran narcotics law still relevant outside ZEDE perimeter.","regulatory_authority":"Próspera ZEDE / contested Honduran framework","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Addiction","Spirituality"],"diseases":["Depression","Substance Use Disorder","PTSD","Existential Distress"],"status":"active"},{"id":"45ac5353-56cb-4c5a-bef2-d67d1bbac099","procedure_id":"proc-5meo-dmt","jurisdiction_id":"jur-hn-prospera","procedure_name":"5-MeO-DMT Assisted Therapy","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Do not assume all psychedelics are free — only explicitly structured programmes apply. Legal uncertainty high.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Special zone rules may diverge; national Honduran narcotics law still relevant outside ZEDE perimeter.","regulatory_authority":"Próspera ZEDE / contested Honduran framework","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Spirituality"],"diseases":["Depression","Anxiety","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"3541d070-0a6f-435d-a62c-d52f8a67d8c1","procedure_id":"proc-ibogaine-addiction","jurisdiction_id":"jur-hn-prospera","procedure_name":"Ibogaine Treatment for Opioid/Substance Use Disorder","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Do not assume all psychedelics are free — only explicitly structured programmes apply. Legal uncertainty high.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Special zone rules may diverge; national Honduran narcotics law still relevant outside ZEDE perimeter.","regulatory_authority":"Próspera ZEDE / contested Honduran framework","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Addiction"],"diseases":["Opioid Use Disorder","Substance Use Disorder"],"status":"active"},{"id":"2ab9dfa5-3133-4bd9-8a46-cce0b36baa09","procedure_id":"proc-psilocybin-trd","jurisdiction_id":"jur-us-ca","procedure_name":"Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"City decrim ordinances may reduce local enforcement priority but do not create licensed therapy supply.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Federal Schedule I; CA has not enacted Oregon-style regulated psilocybin therapy statewide.","regulatory_authority":"DEA Schedule I (federal) + CA state law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"47f74312-8eb3-4ada-a96b-3cc8e9fb50b1","procedure_id":"proc-psilocybin-eol","jurisdiction_id":"jur-us-ca","procedure_name":"Psilocybin-Assisted Therapy for End-of-Life Anxiety","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"City decrim ordinances may reduce local enforcement priority but do not create licensed therapy supply.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Federal Schedule I; CA has not enacted Oregon-style regulated psilocybin therapy statewide.","regulatory_authority":"DEA Schedule I (federal) + CA state law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Palliative_Care"],"diseases":["Cancer-Related Anxiety","End-of-Life Existential Distress","Adjustment Disorder"],"status":"active"},{"id":"4b903c81-3fb0-4116-b436-6674b636b479","procedure_id":"proc-psilocybin-microdose","jurisdiction_id":"jur-us-ca","procedure_name":"Psilocybin Microdosing Protocols","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"City decrim ordinances may reduce local enforcement priority but do not create licensed therapy supply.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Federal Schedule I; CA has not enacted Oregon-style regulated psilocybin therapy statewide.","regulatory_authority":"DEA Schedule I (federal) + CA state law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Cognition"],"diseases":["Depression","Anxiety","ADHD Symptoms (self-report)"],"status":"active"},{"id":"5460f000-b153-4322-86d0-8975f0c9ca7a","procedure_id":"proc-mdma-ptsd","jurisdiction_id":"jur-us-ca","procedure_name":"MDMA-Assisted Psychotherapy for PTSD","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"City decrim ordinances may reduce local enforcement priority but do not create licensed therapy supply.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Federal Schedule I; CA has not enacted Oregon-style regulated psilocybin therapy statewide.","regulatory_authority":"DEA Schedule I (federal) + CA state law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["Post-Traumatic Stress Disorder (PTSD)"],"status":"active"},{"id":"86ad2af4-3355-43fc-8b6e-dc6f65be3628","procedure_id":"proc-dmt-depression","jurisdiction_id":"jur-us-ca","procedure_name":"DMT (N,N-Dimethyltryptamine) Assisted Therapy for Depression","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"City decrim ordinances may reduce local enforcement priority but do not create licensed therapy supply.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Federal Schedule I; CA has not enacted Oregon-style regulated psilocybin therapy statewide.","regulatory_authority":"DEA Schedule I (federal) + CA state law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Major Depressive Disorder","Treatment-Resistant Depression"],"status":"active"},{"id":"c6dd9363-e44e-4662-964b-dc01ac520eb9","procedure_id":"proc-lsd-anxiety","jurisdiction_id":"jur-us-ca","procedure_name":"LSD-Assisted Psychotherapy for Anxiety Disorders","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"City decrim ordinances may reduce local enforcement priority but do not create licensed therapy supply.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Federal Schedule I; CA has not enacted Oregon-style regulated psilocybin therapy statewide.","regulatory_authority":"DEA Schedule I (federal) + CA state law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Anxiety"],"diseases":["Generalized Anxiety Disorder","Illness-Related Anxiety"],"status":"active"},{"id":"1892f3ec-5f90-48e4-9067-95cece05ac51","procedure_id":"proc-mescaline-therapy","jurisdiction_id":"jur-us-ca","procedure_name":"Mescaline-Assisted Therapy (San Pedro) for Depression/Addiction","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"City decrim ordinances may reduce local enforcement priority but do not create licensed therapy supply.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Federal Schedule I; CA has not enacted Oregon-style regulated psilocybin therapy statewide.","regulatory_authority":"DEA Schedule I (federal) + CA state law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression","Addiction"],"diseases":["Depression","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"1157f65a-f3cb-4c70-8e67-14affda126a8","procedure_id":"proc-ayahuasca","jurisdiction_id":"jur-us-ca","procedure_name":"Ayahuasca-Assisted Therapy for Depression/Addiction/Spiritual Growth","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"City decrim ordinances may reduce local enforcement priority but do not create licensed therapy supply.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Federal Schedule I; CA has not enacted Oregon-style regulated psilocybin therapy statewide.","regulatory_authority":"DEA Schedule I (federal) + CA state law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Addiction","Spirituality"],"diseases":["Depression","Substance Use Disorder","PTSD","Existential Distress"],"status":"active"},{"id":"dd418bd0-05ea-473d-b92f-98bb814cd46c","procedure_id":"proc-5meo-dmt","jurisdiction_id":"jur-us-ca","procedure_name":"5-MeO-DMT Assisted Therapy","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"City decrim ordinances may reduce local enforcement priority but do not create licensed therapy supply.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Federal Schedule I; CA has not enacted Oregon-style regulated psilocybin therapy statewide.","regulatory_authority":"DEA Schedule I (federal) + CA state law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Spirituality"],"diseases":["Depression","Anxiety","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"5837a116-77b0-4714-ae49-101b10a90c4c","procedure_id":"proc-ibogaine-addiction","jurisdiction_id":"jur-us-ca","procedure_name":"Ibogaine Treatment for Opioid/Substance Use Disorder","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"City decrim ordinances may reduce local enforcement priority but do not create licensed therapy supply.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Federal Schedule I; CA has not enacted Oregon-style regulated psilocybin therapy statewide.","regulatory_authority":"DEA Schedule I (federal) + CA state law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Addiction"],"diseases":["Opioid Use Disorder","Substance Use Disorder"],"status":"active"},{"id":"891c524a-4aea-4292-b8bf-59353b5aca58","procedure_id":"proc-psilocybin-trd","jurisdiction_id":"jur-us-tx","procedure_name":"Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No regulated therapy programme; Right to Try does not open Schedule I retail therapy.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Federal and state prohibition for classical psychedelics.","regulatory_authority":"DEA Schedule I + Texas controlled substances law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"4c78f37d-3373-4d28-a8ca-69892dd029c7","procedure_id":"proc-psilocybin-eol","jurisdiction_id":"jur-us-tx","procedure_name":"Psilocybin-Assisted Therapy for End-of-Life Anxiety","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No regulated therapy programme; Right to Try does not open Schedule I retail therapy.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Federal and state prohibition for classical psychedelics.","regulatory_authority":"DEA Schedule I + Texas controlled substances law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Palliative_Care"],"diseases":["Cancer-Related Anxiety","End-of-Life Existential Distress","Adjustment Disorder"],"status":"active"},{"id":"e7999dbe-660e-4a87-b2e5-664ecc07a23d","procedure_id":"proc-psilocybin-microdose","jurisdiction_id":"jur-us-tx","procedure_name":"Psilocybin Microdosing Protocols","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No regulated therapy programme; Right to Try does not open Schedule I retail therapy.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Federal and state prohibition for classical psychedelics.","regulatory_authority":"DEA Schedule I + Texas controlled substances law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Cognition"],"diseases":["Depression","Anxiety","ADHD Symptoms (self-report)"],"status":"active"},{"id":"9a3ea2b1-1aac-413a-8b7b-40060206893f","procedure_id":"proc-mdma-ptsd","jurisdiction_id":"jur-us-tx","procedure_name":"MDMA-Assisted Psychotherapy for PTSD","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No regulated therapy programme; Right to Try does not open Schedule I retail therapy.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Federal and state prohibition for classical psychedelics.","regulatory_authority":"DEA Schedule I + Texas controlled substances law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["Post-Traumatic Stress Disorder (PTSD)"],"status":"active"},{"id":"bd0757f0-24b0-4702-a6b2-e8d84215a7df","procedure_id":"proc-dmt-depression","jurisdiction_id":"jur-us-tx","procedure_name":"DMT (N,N-Dimethyltryptamine) Assisted Therapy for Depression","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No regulated therapy programme; Right to Try does not open Schedule I retail therapy.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Federal and state prohibition for classical psychedelics.","regulatory_authority":"DEA Schedule I + Texas controlled substances law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Major Depressive Disorder","Treatment-Resistant Depression"],"status":"active"},{"id":"bd039d65-0ad3-41c3-903f-23e34e96d860","procedure_id":"proc-lsd-anxiety","jurisdiction_id":"jur-us-tx","procedure_name":"LSD-Assisted Psychotherapy for Anxiety Disorders","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No regulated therapy programme; Right to Try does not open Schedule I retail therapy.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Federal and state prohibition for classical psychedelics.","regulatory_authority":"DEA Schedule I + Texas controlled substances law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Anxiety"],"diseases":["Generalized Anxiety Disorder","Illness-Related Anxiety"],"status":"active"},{"id":"be8b6cf0-6c56-4558-9769-a31434b6abad","procedure_id":"proc-mescaline-therapy","jurisdiction_id":"jur-us-tx","procedure_name":"Mescaline-Assisted Therapy (San Pedro) for Depression/Addiction","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No regulated therapy programme; Right to Try does not open Schedule I retail therapy.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Federal and state prohibition for classical psychedelics.","regulatory_authority":"DEA Schedule I + Texas controlled substances law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression","Addiction"],"diseases":["Depression","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"ce43d81f-49a0-4b7e-8814-b909539bcd25","procedure_id":"proc-ayahuasca","jurisdiction_id":"jur-us-tx","procedure_name":"Ayahuasca-Assisted Therapy for Depression/Addiction/Spiritual Growth","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No regulated therapy programme; Right to Try does not open Schedule I retail therapy.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Federal and state prohibition for classical psychedelics.","regulatory_authority":"DEA Schedule I + Texas controlled substances law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Addiction","Spirituality"],"diseases":["Depression","Substance Use Disorder","PTSD","Existential Distress"],"status":"active"},{"id":"7edc7629-4447-429a-871b-e313cbe833c1","procedure_id":"proc-5meo-dmt","jurisdiction_id":"jur-us-tx","procedure_name":"5-MeO-DMT Assisted Therapy","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No regulated therapy programme; Right to Try does not open Schedule I retail therapy.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Federal and state prohibition for classical psychedelics.","regulatory_authority":"DEA Schedule I + Texas controlled substances law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Spirituality"],"diseases":["Depression","Anxiety","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"1aec6ec4-60a6-4e27-ba64-9df9b339558a","procedure_id":"proc-ibogaine-addiction","jurisdiction_id":"jur-us-tx","procedure_name":"Ibogaine Treatment for Opioid/Substance Use Disorder","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No regulated therapy programme; Right to Try does not open Schedule I retail therapy.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Federal and state prohibition for classical psychedelics.","regulatory_authority":"DEA Schedule I + Texas controlled substances law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Addiction"],"diseases":["Opioid Use Disorder","Substance Use Disorder"],"status":"active"},{"id":"e14907ff-c075-42d8-9d63-ae22e7dea469","procedure_id":"proc-psilocybin-trd","jurisdiction_id":"jur-us-fl","procedure_name":"Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No statewide regulated psilocybin/MDMA therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Classical psychedelics prohibited.","regulatory_authority":"DEA Schedule I + Florida law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"80758e65-af1e-4020-b17e-c7de57d0f355","procedure_id":"proc-psilocybin-eol","jurisdiction_id":"jur-us-fl","procedure_name":"Psilocybin-Assisted Therapy for End-of-Life Anxiety","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No statewide regulated psilocybin/MDMA therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Classical psychedelics prohibited.","regulatory_authority":"DEA Schedule I + Florida law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Palliative_Care"],"diseases":["Cancer-Related Anxiety","End-of-Life Existential Distress","Adjustment Disorder"],"status":"active"},{"id":"1f8052d2-deca-4c35-8cac-78eff5633203","procedure_id":"proc-psilocybin-microdose","jurisdiction_id":"jur-us-fl","procedure_name":"Psilocybin Microdosing Protocols","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No statewide regulated psilocybin/MDMA therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Classical psychedelics prohibited.","regulatory_authority":"DEA Schedule I + Florida law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Cognition"],"diseases":["Depression","Anxiety","ADHD Symptoms (self-report)"],"status":"active"},{"id":"dd65e33a-d55b-452d-aec4-8a542fedcdac","procedure_id":"proc-mdma-ptsd","jurisdiction_id":"jur-us-fl","procedure_name":"MDMA-Assisted Psychotherapy for PTSD","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No statewide regulated psilocybin/MDMA therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Classical psychedelics prohibited.","regulatory_authority":"DEA Schedule I + Florida law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["Post-Traumatic Stress Disorder (PTSD)"],"status":"active"},{"id":"00df2dcf-92b3-4e12-a7bb-02062785fb2f","procedure_id":"proc-dmt-depression","jurisdiction_id":"jur-us-fl","procedure_name":"DMT (N,N-Dimethyltryptamine) Assisted Therapy for Depression","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No statewide regulated psilocybin/MDMA therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Classical psychedelics prohibited.","regulatory_authority":"DEA Schedule I + Florida law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Major Depressive Disorder","Treatment-Resistant Depression"],"status":"active"},{"id":"a2442cc7-7339-4388-9e85-fccc5fe0c0fe","procedure_id":"proc-lsd-anxiety","jurisdiction_id":"jur-us-fl","procedure_name":"LSD-Assisted Psychotherapy for Anxiety Disorders","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No statewide regulated psilocybin/MDMA therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Classical psychedelics prohibited.","regulatory_authority":"DEA Schedule I + Florida law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Anxiety"],"diseases":["Generalized Anxiety Disorder","Illness-Related Anxiety"],"status":"active"},{"id":"b21220bd-e48b-4cbb-8829-d85560316055","procedure_id":"proc-mescaline-therapy","jurisdiction_id":"jur-us-fl","procedure_name":"Mescaline-Assisted Therapy (San Pedro) for Depression/Addiction","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No statewide regulated psilocybin/MDMA therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Classical psychedelics prohibited.","regulatory_authority":"DEA Schedule I + Florida law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Depression","Addiction"],"diseases":["Depression","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"97a4b9a9-bb5c-4dcc-a051-df4cafee67ba","procedure_id":"proc-ayahuasca","jurisdiction_id":"jur-us-fl","procedure_name":"Ayahuasca-Assisted Therapy for Depression/Addiction/Spiritual Growth","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No statewide regulated psilocybin/MDMA therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Classical psychedelics prohibited.","regulatory_authority":"DEA Schedule I + Florida law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Addiction","Spirituality"],"diseases":["Depression","Substance Use Disorder","PTSD","Existential Distress"],"status":"active"},{"id":"1c523562-0b3d-4179-9e8e-09858423117b","procedure_id":"proc-5meo-dmt","jurisdiction_id":"jur-us-fl","procedure_name":"5-MeO-DMT Assisted Therapy","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No statewide regulated psilocybin/MDMA therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Classical psychedelics prohibited.","regulatory_authority":"DEA Schedule I + Florida law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Spirituality"],"diseases":["Depression","Anxiety","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"4a280b8a-3f9b-4cdb-9b8a-434f9ed612ae","procedure_id":"proc-ibogaine-addiction","jurisdiction_id":"jur-us-fl","procedure_name":"Ibogaine Treatment for Opioid/Substance Use Disorder","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No statewide regulated psilocybin/MDMA therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Classical psychedelics prohibited.","regulatory_authority":"DEA Schedule I + Florida law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Mental_Health","Addiction"],"diseases":["Opioid Use Disorder","Substance Use Disorder"],"status":"active"},{"id":"685d3d4a-8ee8-421d-939d-c75c2f9d9e38","procedure_id":"proc-medical-cannabis","jurisdiction_id":"jur-jp","procedure_name":"Medical Cannabis for Chronic Pain / Seizures / PTSD","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PHYTOCANNABINOID","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No lawful medical cannabis programme for general patients under current national rules.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Cannabis Control Act — possession/use criminalised; medical pathway extremely limited/absent for flower.","regulatory_authority":"National narcotics authority","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Pain","Neurology","Mental_Health"],"diseases":["Chronic Pain","Epilepsy","PTSD","Chemotherapy-Induced Nausea","Anxiety"],"status":"active"},{"id":"4f5d083d-5f58-4123-99d2-e115dccc6753","procedure_id":"proc-medical-cannabis","jurisdiction_id":"jur-kr","procedure_name":"Medical Cannabis for Chronic Pain / Seizures / PTSD","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PHYTOCANNABINOID","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No lawful medical cannabis programme for general patients under current national rules.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Narcotics Control Act — cannabis prohibited outside narrow research.","regulatory_authority":"National narcotics authority","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Pain","Neurology","Mental_Health"],"diseases":["Chronic Pain","Epilepsy","PTSD","Chemotherapy-Induced Nausea","Anxiety"],"status":"active"},{"id":"0ae64cfd-5c13-4959-bc24-4b464a88fc7f","procedure_id":"proc-medical-cannabis","jurisdiction_id":"jur-uae","procedure_name":"Medical Cannabis for Chronic Pain / Seizures / PTSD","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PHYTOCANNABINOID","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No lawful medical cannabis programme for general patients under current national rules.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Zero-tolerance narcotics law — cannabis prohibited.","regulatory_authority":"National narcotics authority","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Pain","Neurology","Mental_Health"],"diseases":["Chronic Pain","Epilepsy","PTSD","Chemotherapy-Induced Nausea","Anxiety"],"status":"active"},{"id":"1cb31152-f753-43a6-9fab-a27383402eaf","procedure_id":"proc-medical-cannabis","jurisdiction_id":"jur-ph","procedure_name":"Medical Cannabis for Chronic Pain / Seizures / PTSD","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PHYTOCANNABINOID","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No lawful medical cannabis programme for general patients under current national rules.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Dangerous Drugs Act — cannabis prohibited (enforcement historically severe).","regulatory_authority":"National narcotics authority","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Pain","Neurology","Mental_Health"],"diseases":["Chronic Pain","Epilepsy","PTSD","Chemotherapy-Induced Nausea","Anxiety"],"status":"active"},{"id":"a3557d40-c78b-496d-9c18-3c8cd18338f3","procedure_id":"proc-medical-cannabis","jurisdiction_id":"jur-in","procedure_name":"Medical Cannabis for Chronic Pain / Seizures / PTSD","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PHYTOCANNABINOID","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No lawful medical cannabis programme for general patients under current national rules.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"NDPS Act — cannabis resin/ganja controlled; no national medical flower programme comparable to CA/DE.","regulatory_authority":"National narcotics authority","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Pain","Neurology","Mental_Health"],"diseases":["Chronic Pain","Epilepsy","PTSD","Chemotherapy-Induced Nausea","Anxiety"],"status":"active"},{"id":"8cfaf32f-cb87-4789-8ed6-6b76d63d3e18","procedure_id":"proc-maid","jurisdiction_id":"jur-us-federal","procedure_name":"Medical Assistance in Dying (MAID) / Assisted Death","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"ASSISTED_DYING","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No open national MAID access pathway for patients under this jurisdiction id. Subnational exceptions may exist elsewhere (e.g. some US states, Australian states).","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"No federal MAID statute; federal controlled substances / assisted suicide constraints. State Death with Dignity laws are subnational exceptions not seeded for every state.","regulatory_authority":"National criminal / health law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Palliative_Care","End_of_Life"],"diseases":["Terminal Illness","Grievous Irremediable Medical Condition","Intolerable Suffering"],"status":"active"},{"id":"a6d8a4ff-74ce-418f-a886-489a6e539fe3","procedure_id":"proc-maid","jurisdiction_id":"jur-uk","procedure_name":"Medical Assistance in Dying (MAID) / Assisted Death","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"ASSISTED_DYING","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No open national MAID access pathway for patients under this jurisdiction id. Subnational exceptions may exist elsewhere (e.g. some US states, Australian states).","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Assisted dying not generally lawful in England/Wales (ongoing legislative debate — volatility high).","regulatory_authority":"National criminal / health law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Palliative_Care","End_of_Life"],"diseases":["Terminal Illness","Grievous Irremediable Medical Condition","Intolerable Suffering"],"status":"active"},{"id":"5b02b70c-2a39-482b-8f7d-db08320dbd4f","procedure_id":"proc-maid","jurisdiction_id":"jur-au","procedure_name":"Medical Assistance in Dying (MAID) / Assisted Death","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"ASSISTED_DYING","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No open national MAID access pathway for patients under this jurisdiction id. Subnational exceptions may exist elsewhere (e.g. some US states, Australian states).","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Federal complexity; voluntary assisted dying is state/territory-based — not a single national open pathway for non-residents.","regulatory_authority":"National criminal / health law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Palliative_Care","End_of_Life"],"diseases":["Terminal Illness","Grievous Irremediable Medical Condition","Intolerable Suffering"],"status":"active"},{"id":"42f9dc15-5a1c-4c9f-ad27-e0c2fbb0a2ac","procedure_id":"proc-maid","jurisdiction_id":"jur-de","procedure_name":"Medical Assistance in Dying (MAID) / Assisted Death","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"ASSISTED_DYING","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No open national MAID access pathway for patients under this jurisdiction id. Subnational exceptions may exist elsewhere (e.g. some US states, Australian states).","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Assisted suicide legal nuances post-BVerfG but organised MAID clinic model differs from NL/BE; no Dutch-style euthanasia statute — treat open commercial MAID as unavailable.","regulatory_authority":"National criminal / health law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Palliative_Care","End_of_Life"],"diseases":["Terminal Illness","Grievous Irremediable Medical Condition","Intolerable Suffering"],"status":"active"},{"id":"2f2dd5ab-26c4-40c4-8575-1b1cf2a84bdc","procedure_id":"proc-maid","jurisdiction_id":"jur-fr","procedure_name":"Medical Assistance in Dying (MAID) / Assisted Death","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"ASSISTED_DYING","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No open national MAID access pathway for patients under this jurisdiction id. Subnational exceptions may exist elsewhere (e.g. some US states, Australian states).","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"No full MAID legalisation as of review (debates ongoing).","regulatory_authority":"National criminal / health law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Palliative_Care","End_of_Life"],"diseases":["Terminal Illness","Grievous Irremediable Medical Condition","Intolerable Suffering"],"status":"active"},{"id":"7683d29c-d3c7-4efb-82b8-344803f7723d","procedure_id":"proc-maid","jurisdiction_id":"jur-po","procedure_name":"Medical Assistance in Dying (MAID) / Assisted Death","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"ASSISTED_DYING","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No open national MAID access pathway for patients under this jurisdiction id. Subnational exceptions may exist elsewhere (e.g. some US states, Australian states).","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Prohibited.","regulatory_authority":"National criminal / health law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Palliative_Care","End_of_Life"],"diseases":["Terminal Illness","Grievous Irremediable Medical Condition","Intolerable Suffering"],"status":"active"},{"id":"38889590-54e7-4ee8-bf82-97c7648e457e","procedure_id":"proc-maid","jurisdiction_id":"jur-se","procedure_name":"Medical Assistance in Dying (MAID) / Assisted Death","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"ASSISTED_DYING","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No open national MAID access pathway for patients under this jurisdiction id. Subnational exceptions may exist elsewhere (e.g. some US states, Australian states).","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"No MAID legalisation.","regulatory_authority":"National criminal / health law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Palliative_Care","End_of_Life"],"diseases":["Terminal Illness","Grievous Irremediable Medical Condition","Intolerable Suffering"],"status":"active"},{"id":"487c9e1d-0055-42de-a63f-eb7b69c734ec","procedure_id":"proc-maid","jurisdiction_id":"jur-jp","procedure_name":"Medical Assistance in Dying (MAID) / Assisted Death","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"ASSISTED_DYING","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No open national MAID access pathway for patients under this jurisdiction id. Subnational exceptions may exist elsewhere (e.g. some US states, Australian states).","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Prohibited.","regulatory_authority":"National criminal / health law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Palliative_Care","End_of_Life"],"diseases":["Terminal Illness","Grievous Irremediable Medical Condition","Intolerable Suffering"],"status":"active"},{"id":"c39606e8-2c6e-45fe-adec-7af752ba00bf","procedure_id":"proc-maid","jurisdiction_id":"jur-kr","procedure_name":"Medical Assistance in Dying (MAID) / Assisted Death","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"ASSISTED_DYING","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No open national MAID access pathway for patients under this jurisdiction id. Subnational exceptions may exist elsewhere (e.g. some US states, Australian states).","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Prohibited.","regulatory_authority":"National criminal / health law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Palliative_Care","End_of_Life"],"diseases":["Terminal Illness","Grievous Irremediable Medical Condition","Intolerable Suffering"],"status":"active"},{"id":"ef47e6c2-c106-40c7-a4e2-98eb4ba44c87","procedure_id":"proc-maid","jurisdiction_id":"jur-sg","procedure_name":"Medical Assistance in Dying (MAID) / Assisted Death","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"ASSISTED_DYING","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No open national MAID access pathway for patients under this jurisdiction id. Subnational exceptions may exist elsewhere (e.g. some US states, Australian states).","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Prohibited.","regulatory_authority":"National criminal / health law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Palliative_Care","End_of_Life"],"diseases":["Terminal Illness","Grievous Irremediable Medical Condition","Intolerable Suffering"],"status":"active"},{"id":"56ba8504-94ee-483b-bf53-c9cb5d69fe32","procedure_id":"proc-maid","jurisdiction_id":"jur-il","procedure_name":"Medical Assistance in Dying (MAID) / Assisted Death","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"ASSISTED_DYING","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No open national MAID access pathway for patients under this jurisdiction id. Subnational exceptions may exist elsewhere (e.g. some US states, Australian states).","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"No general MAID framework.","regulatory_authority":"National criminal / health law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Palliative_Care","End_of_Life"],"diseases":["Terminal Illness","Grievous Irremediable Medical Condition","Intolerable Suffering"],"status":"active"},{"id":"db9164a1-7893-42eb-a5d5-d44d1b99ca4f","procedure_id":"proc-maid","jurisdiction_id":"jur-mx","procedure_name":"Medical Assistance in Dying (MAID) / Assisted Death","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"ASSISTED_DYING","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No open national MAID access pathway for patients under this jurisdiction id. Subnational exceptions may exist elsewhere (e.g. some US states, Australian states).","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"No national MAID framework.","regulatory_authority":"National criminal / health law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Palliative_Care","End_of_Life"],"diseases":["Terminal Illness","Grievous Irremediable Medical Condition","Intolerable Suffering"],"status":"active"},{"id":"c4b05b1d-d5ee-4dda-a8c1-d4882ce4a796","procedure_id":"proc-maid","jurisdiction_id":"jur-br","procedure_name":"Medical Assistance in Dying (MAID) / Assisted Death","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"ASSISTED_DYING","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No open national MAID access pathway for patients under this jurisdiction id. Subnational exceptions may exist elsewhere (e.g. some US states, Australian states).","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Prohibited nationally.","regulatory_authority":"National criminal / health law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Palliative_Care","End_of_Life"],"diseases":["Terminal Illness","Grievous Irremediable Medical Condition","Intolerable Suffering"],"status":"active"},{"id":"05ddc7dc-b47c-4c36-bdc6-9cdd68ceced4","procedure_id":"proc-maid","jurisdiction_id":"jur-in","procedure_name":"Medical Assistance in Dying (MAID) / Assisted Death","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"ASSISTED_DYING","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No open national MAID access pathway for patients under this jurisdiction id. Subnational exceptions may exist elsewhere (e.g. some US states, Australian states).","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Passive withdrawal frameworks differ; active MAID not generally lawful.","regulatory_authority":"National criminal / health law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Palliative_Care","End_of_Life"],"diseases":["Terminal Illness","Grievous Irremediable Medical Condition","Intolerable Suffering"],"status":"active"},{"id":"725f868e-b579-414e-a699-0de050b44806","procedure_id":"proc-maid","jurisdiction_id":"jur-th","procedure_name":"Medical Assistance in Dying (MAID) / Assisted Death","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"ASSISTED_DYING","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No open national MAID access pathway for patients under this jurisdiction id. Subnational exceptions may exist elsewhere (e.g. some US states, Australian states).","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Prohibited.","regulatory_authority":"National criminal / health law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Palliative_Care","End_of_Life"],"diseases":["Terminal Illness","Grievous Irremediable Medical Condition","Intolerable Suffering"],"status":"active"},{"id":"4fa1edda-715a-42fc-896d-703c2590ffbd","procedure_id":"proc-maid","jurisdiction_id":"jur-uae","procedure_name":"Medical Assistance in Dying (MAID) / Assisted Death","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"ASSISTED_DYING","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No open national MAID access pathway for patients under this jurisdiction id. Subnational exceptions may exist elsewhere (e.g. some US states, Australian states).","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Prohibited.","regulatory_authority":"National criminal / health law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Palliative_Care","End_of_Life"],"diseases":["Terminal Illness","Grievous Irremediable Medical Condition","Intolerable Suffering"],"status":"active"},{"id":"7d134a1a-0041-42de-9eab-700e4a88d39c","procedure_id":"proc-maid","jurisdiction_id":"jur-tu","procedure_name":"Medical Assistance in Dying (MAID) / Assisted Death","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"ASSISTED_DYING","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No open national MAID access pathway for patients under this jurisdiction id. Subnational exceptions may exist elsewhere (e.g. some US states, Australian states).","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Prohibited.","regulatory_authority":"National criminal / health law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Palliative_Care","End_of_Life"],"diseases":["Terminal Illness","Grievous Irremediable Medical Condition","Intolerable Suffering"],"status":"active"},{"id":"3f79c33d-f426-49f6-a3c9-ac191a5c325e","procedure_id":"proc-maid","jurisdiction_id":"jur-ph","procedure_name":"Medical Assistance in Dying (MAID) / Assisted Death","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"ASSISTED_DYING","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No open national MAID access pathway for patients under this jurisdiction id. Subnational exceptions may exist elsewhere (e.g. some US states, Australian states).","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Prohibited.","regulatory_authority":"National criminal / health law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Palliative_Care","End_of_Life"],"diseases":["Terminal Illness","Grievous Irremediable Medical Condition","Intolerable Suffering"],"status":"active"},{"id":"192bb5ce-d83a-4522-b94d-f067c0deec8f","procedure_id":"proc-maid","jurisdiction_id":"jur-za","procedure_name":"Medical Assistance in Dying (MAID) / Assisted Death","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"ASSISTED_DYING","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No open national MAID access pathway for patients under this jurisdiction id. Subnational exceptions may exist elsewhere (e.g. some US states, Australian states).","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"No national MAID statute (constitutional litigation history — still not open access).","regulatory_authority":"National criminal / health law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Palliative_Care","End_of_Life"],"diseases":["Terminal Illness","Grievous Irremediable Medical Condition","Intolerable Suffering"],"status":"active"},{"id":"14c76b2d-2297-4922-8c8a-a0abf7d012ef","procedure_id":"proc-maid","jurisdiction_id":"jur-ar","procedure_name":"Medical Assistance in Dying (MAID) / Assisted Death","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"ASSISTED_DYING","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No open national MAID access pathway for patients under this jurisdiction id. Subnational exceptions may exist elsewhere (e.g. some US states, Australian states).","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"No national MAID framework.","regulatory_authority":"National criminal / health law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Palliative_Care","End_of_Life"],"diseases":["Terminal Illness","Grievous Irremediable Medical Condition","Intolerable Suffering"],"status":"active"},{"id":"609585ad-0989-4097-a218-7b1957370eb0","procedure_id":"proc-maid","jurisdiction_id":"jur-cl","procedure_name":"Medical Assistance in Dying (MAID) / Assisted Death","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"ASSISTED_DYING","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No open national MAID access pathway for patients under this jurisdiction id. Subnational exceptions may exist elsewhere (e.g. some US states, Australian states).","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"No national MAID framework.","regulatory_authority":"National criminal / health law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Palliative_Care","End_of_Life"],"diseases":["Terminal Illness","Grievous Irremediable Medical Condition","Intolerable Suffering"],"status":"active"},{"id":"9b818ebc-d91f-4b75-8adb-0603d3ec31b2","procedure_id":"proc-maid","jurisdiction_id":"jur-cr","procedure_name":"Medical Assistance in Dying (MAID) / Assisted Death","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"ASSISTED_DYING","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No open national MAID access pathway for patients under this jurisdiction id. Subnational exceptions may exist elsewhere (e.g. some US states, Australian states).","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Prohibited.","regulatory_authority":"National criminal / health law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Palliative_Care","End_of_Life"],"diseases":["Terminal Illness","Grievous Irremediable Medical Condition","Intolerable Suffering"],"status":"active"},{"id":"0d4985c9-046a-49f0-95b2-9da95ffe8858","procedure_id":"proc-maid","jurisdiction_id":"jur-jm","procedure_name":"Medical Assistance in Dying (MAID) / Assisted Death","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"ASSISTED_DYING","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No open national MAID access pathway for patients under this jurisdiction id. Subnational exceptions may exist elsewhere (e.g. some US states, Australian states).","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Prohibited.","regulatory_authority":"National criminal / health law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Palliative_Care","End_of_Life"],"diseases":["Terminal Illness","Grievous Irremediable Medical Condition","Intolerable Suffering"],"status":"active"},{"id":"4e54c432-2d21-4d07-aa47-e9d222774e86","procedure_id":"proc-repro-surrogacy","jurisdiction_id":"jur-fr","procedure_name":"Gestational Surrogacy","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Both commercial and altruistic surrogacy prohibited. Contracts unenforceable; criminal exposure for intermediaries.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"French Civil Code Art. 16-7 — any surrogacy agreement is void; arrangement is unlawful.","regulatory_authority":"French Civil Code / bioethics framework","last_verified":"2026-07-01","sources":[{"title":"Surrogacy laws by country (overview)","url":"https://en.wikipedia.org/wiki/Surrogacy_laws_by_country"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Uterine Factor Infertility","Medical Contraindication to Pregnancy","Recurrent IVF Failure"],"status":"active"},{"id":"a969f802-c329-4127-a07f-ba0369a90ff5","procedure_id":"proc-repro-surrogacy","jurisdiction_id":"jur-de","procedure_name":"Gestational Surrogacy","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"All surrogacy (commercial and altruistic) illegal to arrange/perform in Germany.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Embryo Protection Act (Embryonenschutzgesetz) §1 — surrogacy arrangements banned for medical professionals; birth mother is legal mother.","regulatory_authority":"ESchG / German family law","last_verified":"2026-07-01","sources":[{"title":"EPRS Surrogacy in the EU","url":"https://www.europarl.europa.eu/RegData/etudes/BRIE/2025/769508/EPRS_BRI(2025)769508_EN.pdf"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Uterine Factor Infertility","Medical Contraindication to Pregnancy","Recurrent IVF Failure"],"status":"active"},{"id":"9308702e-0252-4b59-a419-2ad7d5590c1e","procedure_id":"proc-repro-surrogacy","jurisdiction_id":"jur-es","procedure_name":"Gestational Surrogacy","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"All surrogacy prohibited domestically; cross-border arrangements create parentage recognition issues.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Law 14/2006 (and prior Law 35/1988 Art. 10) — surrogacy contracts void; birth mother is mother.","regulatory_authority":"Spanish ART law","last_verified":"2026-07-01","sources":[{"title":"EPRS Surrogacy in the EU","url":"https://www.europarl.europa.eu/thinktank/en/document/EPRS_BRI(2025)769508"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Uterine Factor Infertility","Medical Contraindication to Pregnancy","Recurrent IVF Failure"],"status":"active"},{"id":"58979a38-6fbf-42a9-b859-2ca55da96140","procedure_id":"proc-repro-surrogacy","jurisdiction_id":"jur-se","procedure_name":"Gestational Surrogacy","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Healthcare system may not provide surrogacy; legal parentage frameworks do not support domestic surrogacy programmes.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Surrogacy not permitted within Swedish healthcare; arrangements not legally facilitated.","regulatory_authority":"Swedish healthcare / family law practice","last_verified":"2026-07-01","sources":[{"title":"Surrogacy laws by country","url":"https://en.wikipedia.org/wiki/Surrogacy_laws_by_country"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Uterine Factor Infertility","Medical Contraindication to Pregnancy","Recurrent IVF Failure"],"status":"active"},{"id":"bbb5e74f-76f6-4f01-bafd-f99001114be2","procedure_id":"proc-repro-surrogacy","jurisdiction_id":"jur-ch","procedure_name":"Gestational Surrogacy","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"All surrogacy banned; Swiss residents sometimes pursue arrangements abroad with legal complexity.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Swiss reproductive medicine law — surrogacy prohibited.","regulatory_authority":"Swiss Reproductive Medicine Act","last_verified":"2026-07-01","sources":[{"title":"Surrogacy laws by country","url":"https://en.wikipedia.org/wiki/Surrogacy_laws_by_country"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Uterine Factor Infertility","Medical Contraindication to Pregnancy","Recurrent IVF Failure"],"status":"active"},{"id":"c94990a2-a08b-42dd-959b-e6f6dd5b59b0","procedure_id":"proc-repro-surrogacy","jurisdiction_id":"jur-po","procedure_name":"Gestational Surrogacy","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No lawful domestic surrogacy pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Polish law does not permit surrogacy arrangements; contracts treated as void.","regulatory_authority":"Polish family / medical law","last_verified":"2026-07-01","sources":[{"title":"Surrogacy laws by country","url":"https://en.wikipedia.org/wiki/Surrogacy_laws_by_country"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Uterine Factor Infertility","Medical Contraindication to Pregnancy","Recurrent IVF Failure"],"status":"active"},{"id":"508b3a7d-e106-41c2-aed2-3cab7e1061f6","procedure_id":"proc-repro-surrogacy","jurisdiction_id":"jur-pt","procedure_name":"Gestational Surrogacy","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Treat domestic surrogacy programmes as unavailable/prohibited pending clear statutory programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Portuguese law has restricted/banned surrogacy pathways (reforms historically unstable).","regulatory_authority":"Portuguese ART law","last_verified":"2026-07-01","sources":[{"title":"Reuters surrogacy legality overview","url":"https://www.reuters.com/world/which-countries-allow-commercial-surrogacy-2023-04-05/"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Uterine Factor Infertility","Medical Contraindication to Pregnancy","Recurrent IVF Failure"],"status":"active"},{"id":"a82ed3a6-79d1-44e3-a466-81ecd90dec7b","procedure_id":"proc-repro-surrogacy","jurisdiction_id":"jur-jp","procedure_name":"Gestational Surrogacy","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No recognised domestic surrogacy programme; parentage and medical ethics barriers.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Japanese professional guidelines and legal practice effectively bar surrogacy arrangements.","regulatory_authority":"Japan Society of Obstetrics and Gynecology / family law practice","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Reproductive_Health"],"diseases":["Uterine Factor Infertility","Medical Contraindication to Pregnancy","Recurrent IVF Failure"],"status":"active"},{"id":"e1326863-3be5-40f1-a4d7-b84abdf106b3","procedure_id":"proc-repro-surrogacy","jurisdiction_id":"jur-sg","procedure_name":"Gestational Surrogacy","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No lawful surrogacy pathway for commissioning parents domestically.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Singapore prohibits surrogacy arrangements.","regulatory_authority":"Singapore MOH / family law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Reproductive_Health"],"diseases":["Uterine Factor Infertility","Medical Contraindication to Pregnancy","Recurrent IVF Failure"],"status":"active"},{"id":"4b56116a-ad9b-4806-ab46-2fb21a342911","procedure_id":"proc-mito-replacement","jurisdiction_id":"jur-de","procedure_name":"Mitochondrial Replacement Therapy (MRT / Three-Person IVF)","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"MRT not an available clinical service.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Embryo Protection Act restricts embryo manipulation incompatible with MRT clinical practice.","regulatory_authority":"ESchG","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Mitochondrial DNA Disease","Leigh Syndrome Risk","Mitochondrial Inheritance Risk"],"status":"active"},{"id":"e43ca5ea-693c-44ca-812d-650cea428804","procedure_id":"proc-mito-replacement","jurisdiction_id":"jur-fr","procedure_name":"Mitochondrial Replacement Therapy (MRT / Three-Person IVF)","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No clinical MRT programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"French bioethics law — germline/heritable embryo modification pathways not authorised for MRT clinical use.","regulatory_authority":"Bioethics statutes / ANSM","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Mitochondrial DNA Disease","Leigh Syndrome Risk","Mitochondrial Inheritance Risk"],"status":"active"},{"id":"68f7572c-08ed-498d-9c24-5def4a3221ef","procedure_id":"proc-mito-replacement","jurisdiction_id":"jur-ca","procedure_name":"Mitochondrial Replacement Therapy (MRT / Three-Person IVF)","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"MRT not available as clinical care in Canada.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Assisted Human Reproduction Act prohibits altering the genome of a cell of a human being or in vitro embryo such that the alteration is capable of being transmitted to descendants — interpreted to block MRT clinical use.","regulatory_authority":"AHRA","last_verified":"2026-07-01","sources":[{"title":"Assisted Human Reproduction Act","url":"https://laws-lois.justice.gc.ca/eng/acts/a-13.4/"}],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Mitochondrial DNA Disease","Leigh Syndrome Risk","Mitochondrial Inheritance Risk"],"status":"active"},{"id":"65858011-3199-4c68-a630-66d37f52353c","procedure_id":"proc-mito-replacement","jurisdiction_id":"jur-jp","procedure_name":"Mitochondrial Replacement Therapy (MRT / Three-Person IVF)","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No open clinical MRT pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Japanese guidelines/law restrict heritable genome interventions; MRT not authorised as standard care.","regulatory_authority":"MHLW / professional guidelines","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Mitochondrial DNA Disease","Leigh Syndrome Risk","Mitochondrial Inheritance Risk"],"status":"active"},{"id":"a89ec37f-0667-4c1b-879b-087d4fd4e0b7","procedure_id":"proc-mito-replacement","jurisdiction_id":"jur-sg","procedure_name":"Mitochondrial Replacement Therapy (MRT / Three-Person IVF)","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No clinical MRT programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Strict reproductive genetics rules — MRT not authorised.","regulatory_authority":"MOH Singapore","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Mitochondrial DNA Disease","Leigh Syndrome Risk","Mitochondrial Inheritance Risk"],"status":"active"},{"id":"cdb2e698-eefa-4bf2-8e9a-d416cdefa719","procedure_id":"proc-mito-replacement","jurisdiction_id":"jur-kr","procedure_name":"Mitochondrial Replacement Therapy (MRT / Three-Person IVF)","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"MRT not available clinically.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Bioethics and Safety Act framework restricts heritable genetic modification of embryos.","regulatory_authority":"MFDS / bioethics law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Mitochondrial DNA Disease","Leigh Syndrome Risk","Mitochondrial Inheritance Risk"],"status":"active"},{"id":"5515e836-8f64-4cdf-99ae-88beb630834f","procedure_id":"proc-mito-replacement","jurisdiction_id":"jur-es","procedure_name":"Mitochondrial Replacement Therapy (MRT / Three-Person IVF)","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No regulated MRT clinical service.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Spanish ART law does not authorise mitochondrial donation programmes comparable to UK HFEA.","regulatory_authority":"Spanish ART law / AEMPS","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Mitochondrial DNA Disease","Leigh Syndrome Risk","Mitochondrial Inheritance Risk"],"status":"active"},{"id":"dd7b25d0-717e-4bb2-a057-05ebc8758197","procedure_id":"proc-mito-replacement","jurisdiction_id":"jur-nl","procedure_name":"Mitochondrial Replacement Therapy (MRT / Three-Person IVF)","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Research ≠ clinical service for patients seeking MRT.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Dutch embryo legislation does not provide a UK-style licensed MRT clinical pathway for patients.","regulatory_authority":"Embryo Act / IGJ","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Mitochondrial DNA Disease","Leigh Syndrome Risk","Mitochondrial Inheritance Risk"],"status":"active"},{"id":"dee784d0-cfcb-4576-b2a3-7906d80d484c","procedure_id":"proc-mito-replacement","jurisdiction_id":"jur-be","procedure_name":"Mitochondrial Replacement Therapy (MRT / Three-Person IVF)","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No patient MRT service pathway seeded as available.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Belgian embryo research rules; no routine MRT clinical authorisation for reproduction.","regulatory_authority":"Belgian embryo law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Mitochondrial DNA Disease","Leigh Syndrome Risk","Mitochondrial Inheritance Risk"],"status":"active"},{"id":"576b9ea8-afe3-40a1-8941-555fe1c1c4e3","procedure_id":"proc-mito-replacement","jurisdiction_id":"jur-se","procedure_name":"Mitochondrial Replacement Therapy (MRT / Three-Person IVF)","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No clinical MRT programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Swedish genetic integrity / embryo rules — MRT not offered as care.","regulatory_authority":"Swedish National Council on Medical Ethics framework","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Mitochondrial DNA Disease","Leigh Syndrome Risk","Mitochondrial Inheritance Risk"],"status":"active"},{"id":"410900f4-9f31-44f4-b012-8ea780e3d15c","procedure_id":"proc-mito-replacement","jurisdiction_id":"jur-ch","procedure_name":"Mitochondrial Replacement Therapy (MRT / Three-Person IVF)","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"MRT not a lawful clinical offering.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Swiss reproductive medicine law — restrictive on embryo manipulation for heritable change.","regulatory_authority":"Swiss Reproductive Medicine Act","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Mitochondrial DNA Disease","Leigh Syndrome Risk","Mitochondrial Inheritance Risk"],"status":"active"},{"id":"9bcad950-47f8-45c0-adf8-8308801c73d5","procedure_id":"proc-mito-replacement","jurisdiction_id":"jur-mx","procedure_name":"Mitochondrial Replacement Therapy (MRT / Three-Person IVF)","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Not a recognised regulated service — treat as unavailable/prohibited for patient planning.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"No national regulated MRT pathway; practice would fall outside authorised ART standards.","regulatory_authority":"COFEPRIS / ART practice","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Mitochondrial DNA Disease","Leigh Syndrome Risk","Mitochondrial Inheritance Risk"],"status":"active"},{"id":"d704144e-7d69-4eca-b840-b53b265afb9f","procedure_id":"proc-mito-replacement","jurisdiction_id":"jur-br","procedure_name":"Mitochondrial Replacement Therapy (MRT / Three-Person IVF)","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No regulated MRT programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"ANVISA/CFM frameworks do not authorise MRT as standard ART.","regulatory_authority":"ANVISA / CFM","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Mitochondrial DNA Disease","Leigh Syndrome Risk","Mitochondrial Inheritance Risk"],"status":"active"},{"id":"5a33d4b4-1d73-49da-8b57-2b5c8e0c22a2","procedure_id":"proc-mito-replacement","jurisdiction_id":"jur-in","procedure_name":"Mitochondrial Replacement Therapy (MRT / Three-Person IVF)","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No recognised national MRT clinical pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"ART/surrogacy regulation environment does not establish licensed MRT services.","regulatory_authority":"ART regulatory framework","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Mitochondrial DNA Disease","Leigh Syndrome Risk","Mitochondrial Inheritance Risk"],"status":"active"},{"id":"95787ceb-344e-45d9-957a-fa36102d5343","procedure_id":"proc-mito-replacement","jurisdiction_id":"jur-il","procedure_name":"Mitochondrial Replacement Therapy (MRT / Three-Person IVF)","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No routine MRT programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Israeli ART regulation — MRT not an established licensed service.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Mitochondrial DNA Disease","Leigh Syndrome Risk","Mitochondrial Inheritance Risk"],"status":"active"},{"id":"6d58bcd4-2359-4aec-9d36-ac90030d3b13","procedure_id":"proc-mito-replacement","jurisdiction_id":"jur-uae","procedure_name":"Mitochondrial Replacement Therapy (MRT / Three-Person IVF)","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No clinical MRT pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"UAE reproductive medicine rules — MRT not authorised.","regulatory_authority":"MOHAP / DHA frameworks","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Mitochondrial DNA Disease","Leigh Syndrome Risk","Mitochondrial Inheritance Risk"],"status":"active"},{"id":"06f332a7-4d62-415e-9faf-ec9a9d2a7706","procedure_id":"proc-mito-replacement","jurisdiction_id":"jur-tu","procedure_name":"Mitochondrial Replacement Therapy (MRT / Three-Person IVF)","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No MRT programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Turkish ART regulation — MRT not authorised clinical service.","regulatory_authority":"TİTCK / MOH","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Mitochondrial DNA Disease","Leigh Syndrome Risk","Mitochondrial Inheritance Risk"],"status":"active"},{"id":"670cc973-a1f0-4cbb-8440-e7cece35f729","procedure_id":"proc-mito-replacement","jurisdiction_id":"jur-po","procedure_name":"Mitochondrial Replacement Therapy (MRT / Three-Person IVF)","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No clinical MRT pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Polish embryo protection culture/law — MRT not available.","regulatory_authority":"Polish medical law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Mitochondrial DNA Disease","Leigh Syndrome Risk","Mitochondrial Inheritance Risk"],"status":"active"},{"id":"894e85d9-9600-454c-87e2-dc5b4f51a6f6","procedure_id":"proc-mito-replacement","jurisdiction_id":"jur-pt","procedure_name":"Mitochondrial Replacement Therapy (MRT / Three-Person IVF)","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No clinical MRT pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Portuguese ART law — no licensed MRT service.","regulatory_authority":"Portuguese ART regulation","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Mitochondrial DNA Disease","Leigh Syndrome Risk","Mitochondrial Inheritance Risk"],"status":"active"},{"id":"39d633ad-5deb-4623-8350-043c84b41429","procedure_id":"proc-mito-replacement","jurisdiction_id":"jur-za","procedure_name":"Mitochondrial Replacement Therapy (MRT / Three-Person IVF)","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Unavailable as regulated care.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"No licensed MRT clinical pathway under SAHPRA/ART practice.","regulatory_authority":"SAHPRA","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Mitochondrial DNA Disease","Leigh Syndrome Risk","Mitochondrial Inheritance Risk"],"status":"active"},{"id":"4090e1d3-95eb-453d-bdb1-49b20571c110","procedure_id":"proc-mito-replacement","jurisdiction_id":"jur-th","procedure_name":"Mitochondrial Replacement Therapy (MRT / Three-Person IVF)","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Unavailable as regulated care.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Thai ART regulation does not establish MRT clinical service.","regulatory_authority":"Thai FDA / MOPH","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Mitochondrial DNA Disease","Leigh Syndrome Risk","Mitochondrial Inheritance Risk"],"status":"active"},{"id":"829ca3ef-2e73-47cc-917e-fc9f393a6487","procedure_id":"proc-mito-replacement","jurisdiction_id":"jur-ph","procedure_name":"Mitochondrial Replacement Therapy (MRT / Three-Person IVF)","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Unavailable.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"No MRT clinical authorisation.","regulatory_authority":"FDA Philippines","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Mitochondrial DNA Disease","Leigh Syndrome Risk","Mitochondrial Inheritance Risk"],"status":"active"},{"id":"c5f1f189-d708-4040-a963-8098779a8e4e","procedure_id":"proc-mito-replacement","jurisdiction_id":"jur-ar","procedure_name":"Mitochondrial Replacement Therapy (MRT / Three-Person IVF)","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Unavailable as regulated care.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"No national MRT programme.","regulatory_authority":"ANMAT","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Mitochondrial DNA Disease","Leigh Syndrome Risk","Mitochondrial Inheritance Risk"],"status":"active"},{"id":"f76e66da-30b5-42d8-a67c-3deb20afa73a","procedure_id":"proc-mito-replacement","jurisdiction_id":"jur-cl","procedure_name":"Mitochondrial Replacement Therapy (MRT / Three-Person IVF)","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Unavailable as regulated care.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"No national MRT programme.","regulatory_authority":"ISP Chile","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Mitochondrial DNA Disease","Leigh Syndrome Risk","Mitochondrial Inheritance Risk"],"status":"active"},{"id":"d06a8920-9352-4019-920e-df219dc41d05","procedure_id":"proc-mito-replacement","jurisdiction_id":"jur-cr","procedure_name":"Mitochondrial Replacement Therapy (MRT / Three-Person IVF)","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Unavailable.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"No MRT programme.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Mitochondrial DNA Disease","Leigh Syndrome Risk","Mitochondrial Inheritance Risk"],"status":"active"},{"id":"6aac899f-c22d-4776-8a78-966789975209","procedure_id":"proc-mito-replacement","jurisdiction_id":"jur-jm","procedure_name":"Mitochondrial Replacement Therapy (MRT / Three-Person IVF)","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Unavailable.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"No MRT programme.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Mitochondrial DNA Disease","Leigh Syndrome Risk","Mitochondrial Inheritance Risk"],"status":"active"},{"id":"aea8f211-7520-4d36-a699-c00da4a60eb6","procedure_id":"proc-mito-replacement","jurisdiction_id":"jur-us-or","procedure_name":"Mitochondrial Replacement Therapy (MRT / Three-Person IVF)","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"State cannot authorise clinical MRT while federal rider blocks FDA.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Federal appropriations bar controls US clinical MRT regardless of state.","regulatory_authority":"FDA / federal law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Mitochondrial DNA Disease","Leigh Syndrome Risk","Mitochondrial Inheritance Risk"],"status":"active"},{"id":"0c06b9ea-fadd-4d81-b993-9a3e5fe0d827","procedure_id":"proc-mito-replacement","jurisdiction_id":"jur-us-co","procedure_name":"Mitochondrial Replacement Therapy (MRT / Three-Person IVF)","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No state pathway around federal ban.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Federal appropriations bar controls US clinical MRT regardless of state.","regulatory_authority":"FDA / federal law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Mitochondrial DNA Disease","Leigh Syndrome Risk","Mitochondrial Inheritance Risk"],"status":"active"},{"id":"5263248c-aedd-447e-a86f-5745b2659cc0","procedure_id":"proc-mito-replacement","jurisdiction_id":"jur-us-ca","procedure_name":"Mitochondrial Replacement Therapy (MRT / Three-Person IVF)","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No California clinical MRT pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Federal appropriations bar controls US clinical MRT.","regulatory_authority":"FDA / federal law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Mitochondrial DNA Disease","Leigh Syndrome Risk","Mitochondrial Inheritance Risk"],"status":"active"},{"id":"d6fa1a93-5846-4eff-adf8-1388e1067a4f","procedure_id":"proc-mito-replacement","jurisdiction_id":"jur-us-tx","procedure_name":"Mitochondrial Replacement Therapy (MRT / Three-Person IVF)","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No Texas clinical MRT pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Federal appropriations bar controls US clinical MRT.","regulatory_authority":"FDA / federal law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Mitochondrial DNA Disease","Leigh Syndrome Risk","Mitochondrial Inheritance Risk"],"status":"active"},{"id":"c17b9152-25e0-478b-8660-425b03b8a441","procedure_id":"proc-mito-replacement","jurisdiction_id":"jur-us-fl","procedure_name":"Mitochondrial Replacement Therapy (MRT / Three-Person IVF)","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No Florida clinical MRT pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Federal appropriations bar controls US clinical MRT.","regulatory_authority":"FDA / federal law","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Mitochondrial DNA Disease","Leigh Syndrome Risk","Mitochondrial Inheritance Risk"],"status":"active"},{"id":"6dfce85c-c42d-4745-90c4-5634d31bb723","procedure_id":"proc-ozone-therapy","jurisdiction_id":"jur-us-or","procedure_name":"Ozone Therapy for Infection / Inflammation / Wound Healing","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Same federal constraints.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Federal FDA posture applies; Oregon does not create a lawful medical ozone disease-treatment pathway.","regulatory_authority":"FDA","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Infection","Wound_Healing","Orthopedic"],"diseases":["Chronic Wound","Chronic Infection","Osteoarthritis (off-label)"],"status":"active"},{"id":"228817dd-a587-4fd5-8310-4060b4a78a55","procedure_id":"proc-ozone-therapy","jurisdiction_id":"jur-us-co","procedure_name":"Ozone Therapy for Infection / Inflammation / Wound Healing","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No state medical ozone authorisation for disease claims.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Federal FDA posture applies.","regulatory_authority":"FDA","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Infection","Wound_Healing","Orthopedic"],"diseases":["Chronic Wound","Chronic Infection","Osteoarthritis (off-label)"],"status":"active"},{"id":"df9a22ae-1a2e-4893-83d9-6d0a9aa9c06b","procedure_id":"proc-ozone-therapy","jurisdiction_id":"jur-us-ca","procedure_name":"Ozone Therapy for Infection / Inflammation / Wound Healing","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No lawful disease-treatment ozone pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Federal FDA posture applies.","regulatory_authority":"FDA","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Infection","Wound_Healing","Orthopedic"],"diseases":["Chronic Wound","Chronic Infection","Osteoarthritis (off-label)"],"status":"active"},{"id":"3d32cccc-b2e0-45b3-bda6-e81f1f56a6ff","procedure_id":"proc-ozone-therapy","jurisdiction_id":"jur-us-tx","procedure_name":"Ozone Therapy for Infection / Inflammation / Wound Healing","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No lawful disease-treatment ozone pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Federal FDA posture applies.","regulatory_authority":"FDA","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Infection","Wound_Healing","Orthopedic"],"diseases":["Chronic Wound","Chronic Infection","Osteoarthritis (off-label)"],"status":"active"},{"id":"86a8ad22-525f-426d-9a9b-4dcd56dcf9f2","procedure_id":"proc-ozone-therapy","jurisdiction_id":"jur-us-fl","procedure_name":"Ozone Therapy for Infection / Inflammation / Wound Healing","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No lawful disease-treatment ozone pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Federal FDA posture applies.","regulatory_authority":"FDA","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Infection","Wound_Healing","Orthopedic"],"diseases":["Chronic Wound","Chronic Infection","Osteoarthritis (off-label)"],"status":"active"},{"id":"6d3a992f-320a-4700-90de-3cfaac4d33ee","procedure_id":"proc-ozone-therapy","jurisdiction_id":"jur-uk","procedure_name":"Ozone Therapy for Infection / Inflammation / Wound Healing","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Cannot lawfully market as an approved medical treatment without authorisation.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Ozone not an MHRA-authorised medicine for general therapeutic marketing; disease claims require authorisation.","regulatory_authority":"MHRA","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Infection","Wound_Healing","Orthopedic"],"diseases":["Chronic Wound","Chronic Infection","Osteoarthritis (off-label)"],"status":"active"},{"id":"a2c150c8-d078-4e78-a3d8-a203e6f6d822","procedure_id":"proc-ozone-therapy","jurisdiction_id":"jur-sg","procedure_name":"Ozone Therapy for Infection / Inflammation / Wound Healing","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Not a lawful approved therapy programme.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"HSA does not authorise ozone therapy as standard medicine; disease claims restricted.","regulatory_authority":"HSA","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Infection","Wound_Healing","Orthopedic"],"diseases":["Chronic Wound","Chronic Infection","Osteoarthritis (off-label)"],"status":"active"},{"id":"ae27a027-0353-4d0c-85d6-142deb50cd64","procedure_id":"proc-ozone-therapy","jurisdiction_id":"jur-jp","procedure_name":"Ozone Therapy for Infection / Inflammation / Wound Healing","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No general medical ozone therapy pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Not an authorised standard medical therapy under PMDA for broad indications.","regulatory_authority":"PMDA/MHLW","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Infection","Wound_Healing","Orthopedic"],"diseases":["Chronic Wound","Chronic Infection","Osteoarthritis (off-label)"],"status":"active"},{"id":"e95e40e9-3b3c-416f-a0b4-2287e1c331e8","procedure_id":"proc-ozone-therapy","jurisdiction_id":"jur-au","procedure_name":"Ozone Therapy for Infection / Inflammation / Wound Healing","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Marketing as approved treatment without registration is unlawful.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Not TGA-approved as a registered medicine for general ozone therapy claims.","regulatory_authority":"TGA","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Infection","Wound_Healing","Orthopedic"],"diseases":["Chronic Wound","Chronic Infection","Osteoarthritis (off-label)"],"status":"active"},{"id":"5c025e5d-bde7-4a0e-af78-2186846186ff","procedure_id":"proc-ozone-therapy","jurisdiction_id":"jur-ca","procedure_name":"Ozone Therapy for Infection / Inflammation / Wound Healing","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Unapproved therapeutic marketing restricted.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Not authorised as a general Health Canada approved therapy for broad disease claims.","regulatory_authority":"Health Canada","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Infection","Wound_Healing","Orthopedic"],"diseases":["Chronic Wound","Chronic Infection","Osteoarthritis (off-label)"],"status":"active"},{"id":"57eca8f6-e6ef-45a3-b9b2-4b1f9a6f7c45","procedure_id":"proc-peptide-bpc","jurisdiction_id":"jur-de","procedure_name":"BPC-157 Pentadecapeptide Therapy","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"BPC-157 is not an approved German medicine; cannot be marketed as such.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Not an authorised medicinal product; compounding/import for human therapeutic use not a standard lawful pathway.","regulatory_authority":"BfArM / AMG","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Gastrointestinal","Orthopedic","Wound_Healing"],"diseases":["Tendon/Ligament Injury","Inflammatory Bowel Disease","Gastric Ulcer","Wound Healing Impairment"],"status":"active"},{"id":"19942172-a8f6-47e3-a5fb-a5e372f27824","procedure_id":"proc-peptide-bpc","jurisdiction_id":"jur-fr","procedure_name":"BPC-157 Pentadecapeptide Therapy","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No lawful approved BPC-157 medicine pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Not ANSM-authorised medicinal product for general therapeutic use.","regulatory_authority":"ANSM","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Gastrointestinal","Orthopedic","Wound_Healing"],"diseases":["Tendon/Ligament Injury","Inflammatory Bowel Disease","Gastric Ulcer","Wound Healing Impairment"],"status":"active"},{"id":"2ce8662a-7652-427c-aa43-80840a777674","procedure_id":"proc-peptide-bpc","jurisdiction_id":"jur-jp","procedure_name":"BPC-157 Pentadecapeptide Therapy","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No approved BPC-157 product.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Not PMDA-approved medicine; research chemical injection not lawful medical practice.","regulatory_authority":"PMDA","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Gastrointestinal","Orthopedic","Wound_Healing"],"diseases":["Tendon/Ligament Injury","Inflammatory Bowel Disease","Gastric Ulcer","Wound Healing Impairment"],"status":"active"},{"id":"7635961d-8299-4116-84d3-0df78d603853","procedure_id":"proc-peptide-bpc","jurisdiction_id":"jur-sg","procedure_name":"BPC-157 Pentadecapeptide Therapy","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"Cannot lawfully market as medicine.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Not HSA-approved therapeutic product.","regulatory_authority":"HSA","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Gastrointestinal","Orthopedic","Wound_Healing"],"diseases":["Tendon/Ligament Injury","Inflammatory Bowel Disease","Gastric Ulcer","Wound Healing Impairment"],"status":"active"},{"id":"0433e584-e1fa-447a-8513-1c1388c732f8","procedure_id":"proc-peptide-bpc","jurisdiction_id":"jur-ca","procedure_name":"BPC-157 Pentadecapeptide Therapy","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No approved BPC-157 DIN product pathway for routine care.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Not a Health Canada approved drug; compounding/import constraints apply.","regulatory_authority":"Health Canada","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Gastrointestinal","Orthopedic","Wound_Healing"],"diseases":["Tendon/Ligament Injury","Inflammatory Bowel Disease","Gastric Ulcer","Wound Healing Impairment"],"status":"active"},{"id":"49d9e00d-2027-4172-89b9-eab4b345ffe7","procedure_id":"proc-peptide-bpc","jurisdiction_id":"jur-ch","procedure_name":"BPC-157 Pentadecapeptide Therapy","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No standard authorised product.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Not Swissmedic-authorised medicine for general use.","regulatory_authority":"Swissmedic","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Gastrointestinal","Orthopedic","Wound_Healing"],"diseases":["Tendon/Ligament Injury","Inflammatory Bowel Disease","Gastric Ulcer","Wound Healing Impairment"],"status":"active"},{"id":"fe9a05e7-0b25-45fb-a7c6-b4e1ce391770","procedure_id":"proc-peptide-bpc","jurisdiction_id":"jur-nl","procedure_name":"BPC-157 Pentadecapeptide Therapy","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No standard BPC-157 medicine authorisation.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Not an authorised medicinal product for routine prescribing.","regulatory_authority":"MEB/IGJ","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Gastrointestinal","Orthopedic","Wound_Healing"],"diseases":["Tendon/Ligament Injury","Inflammatory Bowel Disease","Gastric Ulcer","Wound Healing Impairment"],"status":"active"},{"id":"1f0877c5-7c67-491f-a2ca-83fe07065a23","procedure_id":"proc-peptide-bpc","jurisdiction_id":"jur-se","procedure_name":"BPC-157 Pentadecapeptide Therapy","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No approved product pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Not an authorised medicine.","regulatory_authority":"Läkemedelsverket","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Gastrointestinal","Orthopedic","Wound_Healing"],"diseases":["Tendon/Ligament Injury","Inflammatory Bowel Disease","Gastric Ulcer","Wound Healing Impairment"],"status":"active"},{"id":"3796938e-2b98-4bb4-b643-e5aea38d93ca","procedure_id":"proc-peptide-bpc","jurisdiction_id":"jur-be","procedure_name":"BPC-157 Pentadecapeptide Therapy","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No approved product pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Not an authorised medicine.","regulatory_authority":"FAMHP","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Gastrointestinal","Orthopedic","Wound_Healing"],"diseases":["Tendon/Ligament Injury","Inflammatory Bowel Disease","Gastric Ulcer","Wound Healing Impairment"],"status":"active"},{"id":"8b21f5ed-45b1-49cc-bc85-c81208c45f34","procedure_id":"proc-peptide-bpc","jurisdiction_id":"jur-es","procedure_name":"BPC-157 Pentadecapeptide Therapy","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No approved product pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Not AEMPS-authorised medicine.","regulatory_authority":"AEMPS","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Gastrointestinal","Orthopedic","Wound_Healing"],"diseases":["Tendon/Ligament Injury","Inflammatory Bowel Disease","Gastric Ulcer","Wound Healing Impairment"],"status":"active"},{"id":"f883ec56-20ef-4c95-b06b-3e1c32818922","procedure_id":"proc-peptide-bpc","jurisdiction_id":"jur-il","procedure_name":"BPC-157 Pentadecapeptide Therapy","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No approved product pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Not an authorised Israeli medicine for routine use.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Gastrointestinal","Orthopedic","Wound_Healing"],"diseases":["Tendon/Ligament Injury","Inflammatory Bowel Disease","Gastric Ulcer","Wound Healing Impairment"],"status":"active"},{"id":"549c26c5-9ed3-4ef3-8efa-ba868b367725","procedure_id":"proc-peptide-bpc","jurisdiction_id":"jur-kr","procedure_name":"BPC-157 Pentadecapeptide Therapy","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No approved product pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Not MFDS-approved medicine.","regulatory_authority":"MFDS","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Gastrointestinal","Orthopedic","Wound_Healing"],"diseases":["Tendon/Ligament Injury","Inflammatory Bowel Disease","Gastric Ulcer","Wound Healing Impairment"],"status":"active"},{"id":"7e4e50be-3e42-4f23-bfb9-f0b9ebf10788","procedure_id":"proc-peptide-bpc","jurisdiction_id":"jur-uae","procedure_name":"BPC-157 Pentadecapeptide Therapy","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No approved pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Not authorised therapeutic product for marketing.","regulatory_authority":"MOHAP","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Gastrointestinal","Orthopedic","Wound_Healing"],"diseases":["Tendon/Ligament Injury","Inflammatory Bowel Disease","Gastric Ulcer","Wound Healing Impairment"],"status":"active"},{"id":"f4e27a18-cb50-4bcb-83f1-576796d78b64","procedure_id":"proc-peptide-cjc-ipa","jurisdiction_id":"jur-uk","procedure_name":"CJC-1295 / Ipamorelin Growth Hormone Secretagogue Peptides","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No lawful approved product pathway for wellness secretagogue clinics.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Not MHRA-authorised medicines for anti-aging use.","regulatory_authority":"MHRA","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Anti_Aging","Performance"],"diseases":["Age-Related Sarcopenia","Growth Hormone Deficiency (not labeled for secretagogues)"],"status":"active"},{"id":"3220d4f1-79fa-4be6-997d-559f8dabd85e","procedure_id":"proc-peptide-cjc-ipa","jurisdiction_id":"jur-au","procedure_name":"CJC-1295 / Ipamorelin Growth Hormone Secretagogue Peptides","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No standard approved pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Not TGA-registered medicines for this use; compounding/import constraints.","regulatory_authority":"TGA","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Anti_Aging","Performance"],"diseases":["Age-Related Sarcopenia","Growth Hormone Deficiency (not labeled for secretagogues)"],"status":"active"},{"id":"a5e655f7-638f-49ed-a6b7-0fef04121025","procedure_id":"proc-peptide-cjc-ipa","jurisdiction_id":"jur-de","procedure_name":"CJC-1295 / Ipamorelin Growth Hormone Secretagogue Peptides","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No approved pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Not authorised medicinal products for anti-aging marketing.","regulatory_authority":"BfArM","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Anti_Aging","Performance"],"diseases":["Age-Related Sarcopenia","Growth Hormone Deficiency (not labeled for secretagogues)"],"status":"active"},{"id":"1a8acd92-27c2-4424-bf88-cc2cd5e4515b","procedure_id":"proc-peptide-cjc-ipa","jurisdiction_id":"jur-ca","procedure_name":"CJC-1295 / Ipamorelin Growth Hormone Secretagogue Peptides","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No approved pathway for routine care.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Not Health Canada approved drugs for this indication.","regulatory_authority":"Health Canada","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Anti_Aging","Performance"],"diseases":["Age-Related Sarcopenia","Growth Hormone Deficiency (not labeled for secretagogues)"],"status":"active"},{"id":"d2c2a1cb-b2da-4f7d-8d53-945e011b6521","procedure_id":"proc-peptide-cjc-ipa","jurisdiction_id":"jur-jp","procedure_name":"CJC-1295 / Ipamorelin Growth Hormone Secretagogue Peptides","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No approved pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Not PMDA-approved for wellness use.","regulatory_authority":"PMDA","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Anti_Aging","Performance"],"diseases":["Age-Related Sarcopenia","Growth Hormone Deficiency (not labeled for secretagogues)"],"status":"active"},{"id":"159e6ca8-8a72-4702-9c16-f89a2d500b4d","procedure_id":"proc-peptide-cjc-ipa","jurisdiction_id":"jur-sg","procedure_name":"CJC-1295 / Ipamorelin Growth Hormone Secretagogue Peptides","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No approved pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Not HSA-approved therapeutic products.","regulatory_authority":"HSA","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Anti_Aging","Performance"],"diseases":["Age-Related Sarcopenia","Growth Hormone Deficiency (not labeled for secretagogues)"],"status":"active"},{"id":"980d5233-9e61-4ec7-b534-201a725503df","procedure_id":"proc-peptide-cjc-ipa","jurisdiction_id":"jur-fr","procedure_name":"CJC-1295 / Ipamorelin Growth Hormone Secretagogue Peptides","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"N/A — no legal market","price_usd":null,"access_pathway_details":"No approved pathway.","eligibility_requirements":"No lawful therapeutic access pathway for the general public under current national rules (trials or narrow exemptions may exist separately).","provider_requirements":"Cannot lawfully market or operate a commercial therapy program without a specific statutory/regulatory exception.","residency_travel_notes":"Travel for this therapy typically means going to a jurisdiction with an explicit exception — check destination law carefully.","risk_notes":"Criminal liability for possession, supply, or practice; product quality risks if sourced illicitly.","arbitrage_summary":"Prohibited under national law. Seek only jurisdictions with explicit regulated, expanded-access, or decrim pathways — not this cell.","oversight_notes":"Prohibition is the default under national controlled-substance law; presence of underground activity does not create a legal pathway.","cost_notes":"No lawful price discovery.","legal_basis":"Not ANSM-authorised medicines for this use.","regulatory_authority":"ANSM","last_verified":"2026-07-01","sources":[],"therapeutic_areas":["Anti_Aging","Performance"],"diseases":["Age-Related Sarcopenia","Growth Hormone Deficiency (not labeled for secretagogues)"],"status":"active"},{"id":"ea5dbd38-a168-4ca6-bba0-a16a0fbd81ff","procedure_id":"proc-psilocybin-trd","jurisdiction_id":"jur-gr","procedure_name":"Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Classical/atypical psychedelic therapy for Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression treated as prohibited outside narrow research under default national posture.","eligibility_requirements":"No lawful general patient pathway under inferred default.","provider_requirements":"Cannot lawfully open a commercial program without an explicit statutory exception.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Criminal liability risk if default is accurate; always verify current schedule.","arbitrage_summary":"Inferred prohibited under jurisdiction psychedelic default / UN-style scheduling. Not a lawful commercial therapy market.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: No jurisdiction psychedelic_default on file — applied conservative Schedule-I-class default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"39383b6e-43ab-49cc-8fe8-79f9e1d2e0f4","procedure_id":"proc-psilocybin-eol","jurisdiction_id":"jur-us-co","procedure_name":"Psilocybin-Assisted Therapy for End-of-Life Anxiety","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"DECRIMINALIZED_NO_SUPPLY","access_pathway":"NONE","oversight_quality":"VARIABLE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Personal use may be decriminalized; commercial therapy supply not inferred as lawful.","eligibility_requirements":"No licensed therapy supply inferred.","provider_requirements":"No commercial pathway inferred.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred decrim-without-supply. Not a clinic destination under default rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: Jurisdiction psychedelic_default=Decriminalized_No_Supply.","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Palliative_Care"],"diseases":["Cancer-Related Anxiety","End-of-Life Existential Distress","Adjustment Disorder"],"status":"active"},{"id":"1c88abd0-142d-4a25-b9b6-89d63a18092a","procedure_id":"proc-psilocybin-eol","jurisdiction_id":"jur-au","procedure_name":"Psilocybin-Assisted Therapy for End-of-Life Anxiety","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Classical/atypical psychedelic therapy for Psilocybin-Assisted Therapy for End-of-Life Anxiety treated as prohibited outside narrow research under default national posture.","eligibility_requirements":"No lawful general patient pathway under inferred default.","provider_requirements":"Cannot lawfully open a commercial program without an explicit statutory exception.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Criminal liability risk if default is accurate; always verify current schedule.","arbitrage_summary":"Inferred prohibited under jurisdiction psychedelic default / UN-style scheduling. Not a lawful commercial therapy market.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: Jurisdiction psychedelic_default=Prohibited.","regulatory_authority":"TGA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Palliative_Care"],"diseases":["Cancer-Related Anxiety","End-of-Life Existential Distress","Adjustment Disorder"],"status":"active"},{"id":"de694d8e-8707-4d49-9918-ba4d072bc663","procedure_id":"proc-psilocybin-eol","jurisdiction_id":"jur-jm","procedure_name":"Psilocybin-Assisted Therapy for End-of-Life Anxiety","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"UNREGULATED_PERMITTED","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Default allows relatively open practice — quality and consumer protection still apply.","eligibility_requirements":"Operator-defined; local consumer law applies.","provider_requirements":"Local business/medical rules may still apply even if substance posture is open.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred permissive/unregulated posture — high variance in quality; diligence essential.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: Jurisdiction psychedelic_default=Unregulated_Permitted.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Palliative_Care"],"diseases":["Cancer-Related Anxiety","End-of-Life Existential Distress","Adjustment Disorder"],"status":"active"},{"id":"38d017f1-c410-4820-9a22-691ab0f7edab","procedure_id":"proc-psilocybin-eol","jurisdiction_id":"jur-gr","procedure_name":"Psilocybin-Assisted Therapy for End-of-Life Anxiety","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Classical/atypical psychedelic therapy for Psilocybin-Assisted Therapy for End-of-Life Anxiety treated as prohibited outside narrow research under default national posture.","eligibility_requirements":"No lawful general patient pathway under inferred default.","provider_requirements":"Cannot lawfully open a commercial program without an explicit statutory exception.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Criminal liability risk if default is accurate; always verify current schedule.","arbitrage_summary":"Inferred prohibited under jurisdiction psychedelic default / UN-style scheduling. Not a lawful commercial therapy market.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: No jurisdiction psychedelic_default on file — applied conservative Schedule-I-class default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Palliative_Care"],"diseases":["Cancer-Related Anxiety","End-of-Life Existential Distress","Adjustment Disorder"],"status":"active"},{"id":"7cd500b4-df36-4335-b0ce-86793376c805","procedure_id":"proc-mdma-ptsd","jurisdiction_id":"jur-us-or","procedure_name":"MDMA-Assisted Psychotherapy for PTSD","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"REGULATED_THERAPY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Jurisdiction signals a regulated therapy-program model for psychedelics.","eligibility_requirements":"Program-specific screening (age, contraindications).","provider_requirements":"Program licenses / facilitator or medical credentials per local scheme.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred regulated program pathway may exist — still confirm license classes and product rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: Jurisdiction psychedelic_default=Regulated_Therapy_Program.","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["Post-Traumatic Stress Disorder (PTSD)"],"status":"active"},{"id":"20b78120-90a8-4a74-8f65-4598d9f99c40","procedure_id":"proc-mdma-ptsd","jurisdiction_id":"jur-us-co","procedure_name":"MDMA-Assisted Psychotherapy for PTSD","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"DECRIMINALIZED_NO_SUPPLY","access_pathway":"NONE","oversight_quality":"VARIABLE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Personal use may be decriminalized; commercial therapy supply not inferred as lawful.","eligibility_requirements":"No licensed therapy supply inferred.","provider_requirements":"No commercial pathway inferred.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred decrim-without-supply. Not a clinic destination under default rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: Jurisdiction psychedelic_default=Decriminalized_No_Supply.","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["Post-Traumatic Stress Disorder (PTSD)"],"status":"active"},{"id":"4cd1b1c0-2c21-43e2-bf98-59cd2e0f2793","procedure_id":"proc-mdma-ptsd","jurisdiction_id":"jur-jm","procedure_name":"MDMA-Assisted Psychotherapy for PTSD","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"UNREGULATED_PERMITTED","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Default allows relatively open practice — quality and consumer protection still apply.","eligibility_requirements":"Operator-defined; local consumer law applies.","provider_requirements":"Local business/medical rules may still apply even if substance posture is open.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred permissive/unregulated posture — high variance in quality; diligence essential.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: Jurisdiction psychedelic_default=Unregulated_Permitted.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["Post-Traumatic Stress Disorder (PTSD)"],"status":"active"},{"id":"c70d3580-93eb-4e0a-ae76-d5b9e739deca","procedure_id":"proc-mdma-ptsd","jurisdiction_id":"jur-gr","procedure_name":"MDMA-Assisted Psychotherapy for PTSD","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Classical/atypical psychedelic therapy for MDMA-Assisted Psychotherapy for PTSD treated as prohibited outside narrow research under default national posture.","eligibility_requirements":"No lawful general patient pathway under inferred default.","provider_requirements":"Cannot lawfully open a commercial program without an explicit statutory exception.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Criminal liability risk if default is accurate; always verify current schedule.","arbitrage_summary":"Inferred prohibited under jurisdiction psychedelic default / UN-style scheduling. Not a lawful commercial therapy market.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: No jurisdiction psychedelic_default on file — applied conservative Schedule-I-class default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["Post-Traumatic Stress Disorder (PTSD)"],"status":"active"},{"id":"963e8a24-2a52-47ef-937c-b8550b4e377d","procedure_id":"proc-ketamine-depression","jurisdiction_id":"jur-us-co","procedure_name":"Ketamine Infusion Therapy for Depression","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (Federal CSA + Prop 122 Natural Medicine Health Act). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder","Suicidal Ideation"],"status":"active"},{"id":"c52a0f77-035d-4cca-b74e-c61b44d2e76a","procedure_id":"proc-ketamine-depression","jurisdiction_id":"jur-us-ca","procedure_name":"Ketamine Infusion Therapy for Depression","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (Controlled Substances Act Schedule I–V). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder","Suicidal Ideation"],"status":"active"},{"id":"ee67f910-80e8-403a-919e-ed4e33df80a4","procedure_id":"proc-ketamine-depression","jurisdiction_id":"jur-us-tx","procedure_name":"Ketamine Infusion Therapy for Depression","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (Controlled Substances Act Schedule I–V). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder","Suicidal Ideation"],"status":"active"},{"id":"a470748e-7d97-4d5e-b18c-505bda960797","procedure_id":"proc-ketamine-depression","jurisdiction_id":"jur-us-fl","procedure_name":"Ketamine Infusion Therapy for Depression","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (Controlled Substances Act Schedule I–V). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder","Suicidal Ideation"],"status":"active"},{"id":"fe6e59bf-faef-40ba-840f-6e3688bafb5f","procedure_id":"proc-ketamine-depression","jurisdiction_id":"jur-au","procedure_name":"Ketamine Infusion Therapy for Depression","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (Poisons Standard (SUSMP) scheduling). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"TGA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder","Suicidal Ideation"],"status":"active"},{"id":"1407e25d-d69e-420f-8591-e070d54f4fb5","procedure_id":"proc-ketamine-depression","jurisdiction_id":"jur-ch","procedure_name":"Ketamine Infusion Therapy for Depression","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (Narcotics Act (BetmG)). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"Swissmedic","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder","Suicidal Ideation"],"status":"active"},{"id":"fb426b41-d96c-41a1-8aaf-913f268f1154","procedure_id":"proc-ketamine-depression","jurisdiction_id":"jur-ca","procedure_name":"Ketamine Infusion Therapy for Depression","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (CDSA schedules). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"Health Canada","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder","Suicidal Ideation"],"status":"active"},{"id":"c5455efe-16b2-4d20-87eb-fc48a598055b","procedure_id":"proc-ketamine-depression","jurisdiction_id":"jur-mx","procedure_name":"Ketamine Infusion Therapy for Depression","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (Ley General de Salud psychotropics schedules). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"COFEPRIS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder","Suicidal Ideation"],"status":"active"},{"id":"9727a001-f70e-49b4-91e2-4e756ac73726","procedure_id":"proc-ketamine-depression","jurisdiction_id":"jur-hn-prospera","procedure_name":"Ketamine Infusion Therapy for Depression","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (Special zone + national law tension). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"Próspera ZEDE health rules (contested)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder","Suicidal Ideation"],"status":"active"},{"id":"a43ba0ff-0db0-4293-9d5e-b25409c7970f","procedure_id":"proc-ketamine-depression","jurisdiction_id":"jur-nl","procedure_name":"Ketamine Infusion Therapy for Depression","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (Opium Act (List I/II) — truffle exception for sclerotia). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"MEB / IGJ","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder","Suicidal Ideation"],"status":"active"},{"id":"79ae37b0-23aa-4757-b018-73c0330f52e8","procedure_id":"proc-ketamine-depression","jurisdiction_id":"jur-de","procedure_name":"Ketamine Infusion Therapy for Depression","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (BtMG (Narcotics Act)). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"BfArM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder","Suicidal Ideation"],"status":"active"},{"id":"9c17ac01-658b-43de-9c9c-378383521dbe","procedure_id":"proc-ketamine-depression","jurisdiction_id":"jur-uk","procedure_name":"Ketamine Infusion Therapy for Depression","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (Misuse of Drugs Act 1971 Class A/B/C). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"MHRA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder","Suicidal Ideation"],"status":"active"},{"id":"05230387-e2e9-4178-86a2-cf8bdccb0b07","procedure_id":"proc-ketamine-depression","jurisdiction_id":"jur-il","procedure_name":"Ketamine Infusion Therapy for Depression","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (Dangerous Drugs Ordinance). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder","Suicidal Ideation"],"status":"active"},{"id":"d1f7a999-dfe6-4bbe-ba3c-c0dc23cbf198","procedure_id":"proc-ketamine-depression","jurisdiction_id":"jur-jm","procedure_name":"Ketamine Infusion Therapy for Depression","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (Dangerous Drugs Act — psilocybin mushrooms historically unscheduled). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder","Suicidal Ideation"],"status":"active"},{"id":"2d684648-da4d-4232-81a6-99b32c9d545f","procedure_id":"proc-ketamine-depression","jurisdiction_id":"jur-th","procedure_name":"Ketamine Infusion Therapy for Depression","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (Narcotics Act (cannabis reforms in flux)). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"Thai FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder","Suicidal Ideation"],"status":"active"},{"id":"dc7df5c7-4b04-4d55-b328-51e5a6c016f8","procedure_id":"proc-ketamine-depression","jurisdiction_id":"jur-es","procedure_name":"Ketamine Infusion Therapy for Depression","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (Spanish narcotics schedules). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"AEMPS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder","Suicidal Ideation"],"status":"active"},{"id":"1281bb39-24be-468a-ae43-fd48abbf976e","procedure_id":"proc-ketamine-depression","jurisdiction_id":"jur-tu","procedure_name":"Ketamine Infusion Therapy for Depression","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (national scheduling). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder","Suicidal Ideation"],"status":"active"},{"id":"d9acb592-ea6e-4673-bad2-f4c2b99c3648","procedure_id":"proc-ketamine-depression","jurisdiction_id":"jur-in","procedure_name":"Ketamine Infusion Therapy for Depression","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (NDPS Act 1985). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"CDSCO","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder","Suicidal Ideation"],"status":"active"},{"id":"b21abd3b-d252-497c-8e19-eda31533d33d","procedure_id":"proc-ketamine-depression","jurisdiction_id":"jur-br","procedure_name":"Ketamine Infusion Therapy for Depression","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (Portaria SVS/MS controlled lists). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"ANVISA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder","Suicidal Ideation"],"status":"active"},{"id":"a4acd93c-8aaf-4017-ba94-3228f967496a","procedure_id":"proc-ketamine-depression","jurisdiction_id":"jur-cr","procedure_name":"Ketamine Infusion Therapy for Depression","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (national scheduling). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder","Suicidal Ideation"],"status":"active"},{"id":"a6777ac8-bdc6-4105-bdd0-a23a1c37c8c4","procedure_id":"proc-ketamine-depression","jurisdiction_id":"jur-uae","procedure_name":"Ketamine Infusion Therapy for Depression","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (national scheduling). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder","Suicidal Ideation"],"status":"active"},{"id":"72b8c4c8-eff7-4688-9712-de29b361b97b","procedure_id":"proc-ketamine-depression","jurisdiction_id":"jur-kr","procedure_name":"Ketamine Infusion Therapy for Depression","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (Narcotics Control Act). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"MFDS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder","Suicidal Ideation"],"status":"active"},{"id":"f3bfdbb9-bfc0-4af1-a94d-dd411e99cffc","procedure_id":"proc-ketamine-depression","jurisdiction_id":"jur-gr","procedure_name":"Ketamine Infusion Therapy for Depression","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (national scheduling). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder","Suicidal Ideation"],"status":"active"},{"id":"dfcaea0b-2f9b-4745-86da-f448b9c5386d","procedure_id":"proc-ketamine-depression","jurisdiction_id":"jur-be","procedure_name":"Ketamine Infusion Therapy for Depression","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (Narcotics legislation). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder","Suicidal Ideation"],"status":"active"},{"id":"ede01df4-9a76-49ff-abd2-ead113203ccc","procedure_id":"proc-ketamine-depression","jurisdiction_id":"jur-se","procedure_name":"Ketamine Infusion Therapy for Depression","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (national scheduling). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder","Suicidal Ideation"],"status":"active"},{"id":"84a8ff51-c611-44f2-b63d-c59f01bba884","procedure_id":"proc-ketamine-depression","jurisdiction_id":"jur-jp","procedure_name":"Ketamine Infusion Therapy for Depression","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (Narcotics & Stimulants Control Acts — very strict). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"PMDA / MHLW","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder","Suicidal Ideation"],"status":"active"},{"id":"5d8ea19f-45ea-4db2-9f7e-f8b634154224","procedure_id":"proc-ketamine-depression","jurisdiction_id":"jur-sg","procedure_name":"Ketamine Infusion Therapy for Depression","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (Misuse of Drugs Act — severe penalties). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"HSA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder","Suicidal Ideation"],"status":"active"},{"id":"7a18f636-eff8-404f-a3f3-494629525415","procedure_id":"proc-ketamine-depression","jurisdiction_id":"jur-cl","procedure_name":"Ketamine Infusion Therapy for Depression","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (national scheduling). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder","Suicidal Ideation"],"status":"active"},{"id":"f26924e4-dd96-424e-a7bc-7eec77267f50","procedure_id":"proc-ketamine-depression","jurisdiction_id":"jur-ar","procedure_name":"Ketamine Infusion Therapy for Depression","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (national scheduling). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder","Suicidal Ideation"],"status":"active"},{"id":"8402ebeb-c216-4e4a-ad81-813db57d6a8b","procedure_id":"proc-ketamine-depression","jurisdiction_id":"jur-za","procedure_name":"Ketamine Infusion Therapy for Depression","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (national scheduling). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder","Suicidal Ideation"],"status":"active"},{"id":"5c772882-eaa1-462a-8ea9-3efeafb88ff3","procedure_id":"proc-ketamine-depression","jurisdiction_id":"jur-ph","procedure_name":"Ketamine Infusion Therapy for Depression","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (national scheduling). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder","Suicidal Ideation"],"status":"active"},{"id":"2ff20e31-51f8-415b-b903-6543f01ab869","procedure_id":"proc-ketamine-depression","jurisdiction_id":"jur-po","procedure_name":"Ketamine Infusion Therapy for Depression","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (national scheduling). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder","Suicidal Ideation"],"status":"active"},{"id":"0c03c2f4-2515-41f8-b938-c09bdfd2e68a","procedure_id":"proc-ketamine-depression","jurisdiction_id":"jur-pt","procedure_name":"Ketamine Infusion Therapy for Depression","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (Decriminalisation 2001 + trafficking still criminal). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder","Suicidal Ideation"],"status":"active"},{"id":"41fa39fa-f60e-4e53-8c6f-b06aba655838","procedure_id":"proc-ketamine-depression","jurisdiction_id":"jur-fr","procedure_name":"Ketamine Infusion Therapy for Depression","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (Stupéfiants schedules). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"ANSM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder","Suicidal Ideation"],"status":"active"},{"id":"522e01d6-122f-4be5-bad7-9d0d2f24c2e2","procedure_id":"proc-ibogaine-addiction","jurisdiction_id":"jur-us-or","procedure_name":"Ibogaine Treatment for Opioid/Substance Use Disorder","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"REGULATED_THERAPY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Jurisdiction signals a regulated therapy-program model for psychedelics.","eligibility_requirements":"Program-specific screening (age, contraindications).","provider_requirements":"Program licenses / facilitator or medical credentials per local scheme.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred regulated program pathway may exist — still confirm license classes and product rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: Jurisdiction psychedelic_default=Regulated_Therapy_Program.","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Addiction"],"diseases":["Opioid Use Disorder","Substance Use Disorder"],"status":"active"},{"id":"fc3145b6-4d49-46ac-8dc4-f1ea3cab12e8","procedure_id":"proc-ibogaine-addiction","jurisdiction_id":"jur-us-co","procedure_name":"Ibogaine Treatment for Opioid/Substance Use Disorder","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"DECRIMINALIZED_NO_SUPPLY","access_pathway":"NONE","oversight_quality":"VARIABLE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Personal use may be decriminalized; commercial therapy supply not inferred as lawful.","eligibility_requirements":"No licensed therapy supply inferred.","provider_requirements":"No commercial pathway inferred.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred decrim-without-supply. Not a clinic destination under default rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: Jurisdiction psychedelic_default=Decriminalized_No_Supply.","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Addiction"],"diseases":["Opioid Use Disorder","Substance Use Disorder"],"status":"active"},{"id":"b820c6ec-9684-42d2-8713-66cb659343b8","procedure_id":"proc-ibogaine-addiction","jurisdiction_id":"jur-jm","procedure_name":"Ibogaine Treatment for Opioid/Substance Use Disorder","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"UNREGULATED_PERMITTED","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Default allows relatively open practice — quality and consumer protection still apply.","eligibility_requirements":"Operator-defined; local consumer law applies.","provider_requirements":"Local business/medical rules may still apply even if substance posture is open.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred permissive/unregulated posture — high variance in quality; diligence essential.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: Jurisdiction psychedelic_default=Unregulated_Permitted.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Addiction"],"diseases":["Opioid Use Disorder","Substance Use Disorder"],"status":"active"},{"id":"91e1cd4b-a041-40a2-a955-3648dcec9cec","procedure_id":"proc-ibogaine-addiction","jurisdiction_id":"jur-gr","procedure_name":"Ibogaine Treatment for Opioid/Substance Use Disorder","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Classical/atypical psychedelic therapy for Ibogaine Treatment for Opioid/Substance Use Disorder treated as prohibited outside narrow research under default national posture.","eligibility_requirements":"No lawful general patient pathway under inferred default.","provider_requirements":"Cannot lawfully open a commercial program without an explicit statutory exception.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Criminal liability risk if default is accurate; always verify current schedule.","arbitrage_summary":"Inferred prohibited under jurisdiction psychedelic default / UN-style scheduling. Not a lawful commercial therapy market.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: No jurisdiction psychedelic_default on file — applied conservative Schedule-I-class default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Addiction"],"diseases":["Opioid Use Disorder","Substance Use Disorder"],"status":"active"},{"id":"feb59da6-017c-4798-ada5-8f4cd6ea25f3","procedure_id":"proc-gene-crispr","jurisdiction_id":"jur-us-or","procedure_name":"CRISPR-Based Gene Therapy (Somatic) for Genetic Disorders","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Hematology"],"diseases":["Sickle Cell Disease","Beta-Thalassemia","Genetic Blood Disorders"],"status":"active"},{"id":"1de4c896-8bd8-4735-bc2b-d68150a9deeb","procedure_id":"proc-gene-crispr","jurisdiction_id":"jur-us-co","procedure_name":"CRISPR-Based Gene Therapy (Somatic) for Genetic Disorders","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Hematology"],"diseases":["Sickle Cell Disease","Beta-Thalassemia","Genetic Blood Disorders"],"status":"active"},{"id":"4e2165de-03e2-47a4-9c5c-6f7348726c60","procedure_id":"proc-gene-crispr","jurisdiction_id":"jur-us-ca","procedure_name":"CRISPR-Based Gene Therapy (Somatic) for Genetic Disorders","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Hematology"],"diseases":["Sickle Cell Disease","Beta-Thalassemia","Genetic Blood Disorders"],"status":"active"},{"id":"18368872-73cd-41ad-bff4-ba1a815b28fb","procedure_id":"proc-gene-crispr","jurisdiction_id":"jur-us-tx","procedure_name":"CRISPR-Based Gene Therapy (Somatic) for Genetic Disorders","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Hematology"],"diseases":["Sickle Cell Disease","Beta-Thalassemia","Genetic Blood Disorders"],"status":"active"},{"id":"7bde5a42-296a-44dd-8090-f4247b524361","procedure_id":"proc-gene-crispr","jurisdiction_id":"jur-us-fl","procedure_name":"CRISPR-Based Gene Therapy (Somatic) for Genetic Disorders","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Hematology"],"diseases":["Sickle Cell Disease","Beta-Thalassemia","Genetic Blood Disorders"],"status":"active"},{"id":"111674c7-5e9f-4ca1-8641-bcf775604114","procedure_id":"proc-gene-crispr","jurisdiction_id":"jur-au","procedure_name":"CRISPR-Based Gene Therapy (Somatic) for Genetic Disorders","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"TGA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Hematology"],"diseases":["Sickle Cell Disease","Beta-Thalassemia","Genetic Blood Disorders"],"status":"active"},{"id":"7aa4a4c6-0f5f-4ff0-884b-19963f148872","procedure_id":"proc-gene-crispr","jurisdiction_id":"jur-ch","procedure_name":"CRISPR-Based Gene Therapy (Somatic) for Genetic Disorders","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"Swissmedic","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Hematology"],"diseases":["Sickle Cell Disease","Beta-Thalassemia","Genetic Blood Disorders"],"status":"active"},{"id":"d69df2d8-206c-4931-b155-853cd6d71a29","procedure_id":"proc-gene-crispr","jurisdiction_id":"jur-ca","procedure_name":"CRISPR-Based Gene Therapy (Somatic) for Genetic Disorders","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"Health Canada","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Hematology"],"diseases":["Sickle Cell Disease","Beta-Thalassemia","Genetic Blood Disorders"],"status":"active"},{"id":"252bbe48-2d21-493f-8c8b-3f81778ec3ce","procedure_id":"proc-gene-crispr","jurisdiction_id":"jur-mx","procedure_name":"CRISPR-Based Gene Therapy (Somatic) for Genetic Disorders","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"COFEPRIS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Hematology"],"diseases":["Sickle Cell Disease","Beta-Thalassemia","Genetic Blood Disorders"],"status":"active"},{"id":"762a66a9-307a-4239-bbce-0397ab0911f0","procedure_id":"proc-gene-crispr","jurisdiction_id":"jur-nl","procedure_name":"CRISPR-Based Gene Therapy (Somatic) for Genetic Disorders","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"MEB / IGJ","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Hematology"],"diseases":["Sickle Cell Disease","Beta-Thalassemia","Genetic Blood Disorders"],"status":"active"},{"id":"6fdeb4b2-75d4-4d80-9372-6691ef24961f","procedure_id":"proc-gene-crispr","jurisdiction_id":"jur-de","procedure_name":"CRISPR-Based Gene Therapy (Somatic) for Genetic Disorders","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"BfArM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Hematology"],"diseases":["Sickle Cell Disease","Beta-Thalassemia","Genetic Blood Disorders"],"status":"active"},{"id":"9ac71525-cba8-4292-8072-7d531e1d563e","procedure_id":"proc-gene-crispr","jurisdiction_id":"jur-uk","procedure_name":"CRISPR-Based Gene Therapy (Somatic) for Genetic Disorders","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"MHRA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Hematology"],"diseases":["Sickle Cell Disease","Beta-Thalassemia","Genetic Blood Disorders"],"status":"active"},{"id":"78be8b9c-4981-48b5-af90-923f698157eb","procedure_id":"proc-gene-crispr","jurisdiction_id":"jur-il","procedure_name":"CRISPR-Based Gene Therapy (Somatic) for Genetic Disorders","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Hematology"],"diseases":["Sickle Cell Disease","Beta-Thalassemia","Genetic Blood Disorders"],"status":"active"},{"id":"29ec42da-8f2a-4a89-b740-ce4ed042f20b","procedure_id":"proc-gene-crispr","jurisdiction_id":"jur-jm","procedure_name":"CRISPR-Based Gene Therapy (Somatic) for Genetic Disorders","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Hematology"],"diseases":["Sickle Cell Disease","Beta-Thalassemia","Genetic Blood Disorders"],"status":"active"},{"id":"498634f8-81d7-45ca-a941-a81a54397403","procedure_id":"proc-gene-crispr","jurisdiction_id":"jur-th","procedure_name":"CRISPR-Based Gene Therapy (Somatic) for Genetic Disorders","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"Thai FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Hematology"],"diseases":["Sickle Cell Disease","Beta-Thalassemia","Genetic Blood Disorders"],"status":"active"},{"id":"6fdb5107-f09d-4a14-b002-bdd09750997d","procedure_id":"proc-gene-crispr","jurisdiction_id":"jur-es","procedure_name":"CRISPR-Based Gene Therapy (Somatic) for Genetic Disorders","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"AEMPS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Hematology"],"diseases":["Sickle Cell Disease","Beta-Thalassemia","Genetic Blood Disorders"],"status":"active"},{"id":"d418b676-a4f9-48a7-aa4e-05afdb65ce89","procedure_id":"proc-gene-crispr","jurisdiction_id":"jur-tu","procedure_name":"CRISPR-Based Gene Therapy (Somatic) for Genetic Disorders","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial centre pathway inferred.","eligibility_requirements":"Trial criteria.","provider_requirements":"Trial site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial-only for advanced cell/gene therapy.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: advanced cell/gene therapy without clear commercial authorization → trial-only default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Hematology"],"diseases":["Sickle Cell Disease","Beta-Thalassemia","Genetic Blood Disorders"],"status":"active"},{"id":"e69eaa95-ce99-46ac-8f99-f04863ab3f47","procedure_id":"proc-gene-crispr","jurisdiction_id":"jur-in","procedure_name":"CRISPR-Based Gene Therapy (Somatic) for Genetic Disorders","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"CDSCO","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Hematology"],"diseases":["Sickle Cell Disease","Beta-Thalassemia","Genetic Blood Disorders"],"status":"active"},{"id":"82104996-9f96-4dd1-b1f5-0c94bf953a1d","procedure_id":"proc-gene-crispr","jurisdiction_id":"jur-br","procedure_name":"CRISPR-Based Gene Therapy (Somatic) for Genetic Disorders","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"ANVISA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Hematology"],"diseases":["Sickle Cell Disease","Beta-Thalassemia","Genetic Blood Disorders"],"status":"active"},{"id":"7387b792-824e-4285-a2a3-8c0160fb218f","procedure_id":"proc-gene-crispr","jurisdiction_id":"jur-cr","procedure_name":"CRISPR-Based Gene Therapy (Somatic) for Genetic Disorders","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial centre pathway inferred.","eligibility_requirements":"Trial criteria.","provider_requirements":"Trial site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial-only for advanced cell/gene therapy.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: advanced cell/gene therapy without clear commercial authorization → trial-only default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Hematology"],"diseases":["Sickle Cell Disease","Beta-Thalassemia","Genetic Blood Disorders"],"status":"active"},{"id":"c8f610c3-4d45-4aec-9ea5-fc8109ed2370","procedure_id":"proc-gene-crispr","jurisdiction_id":"jur-uae","procedure_name":"CRISPR-Based Gene Therapy (Somatic) for Genetic Disorders","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial centre pathway inferred.","eligibility_requirements":"Trial criteria.","provider_requirements":"Trial site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial-only for advanced cell/gene therapy.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: advanced cell/gene therapy without clear commercial authorization → trial-only default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Hematology"],"diseases":["Sickle Cell Disease","Beta-Thalassemia","Genetic Blood Disorders"],"status":"active"},{"id":"1dcefb84-e176-4c61-a810-7782848e2bcb","procedure_id":"proc-gene-crispr","jurisdiction_id":"jur-kr","procedure_name":"CRISPR-Based Gene Therapy (Somatic) for Genetic Disorders","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"MFDS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Hematology"],"diseases":["Sickle Cell Disease","Beta-Thalassemia","Genetic Blood Disorders"],"status":"active"},{"id":"4c0b957b-a53d-4f99-ad92-c5b100a1b194","procedure_id":"proc-gene-crispr","jurisdiction_id":"jur-gr","procedure_name":"CRISPR-Based Gene Therapy (Somatic) for Genetic Disorders","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial centre pathway inferred.","eligibility_requirements":"Trial criteria.","provider_requirements":"Trial site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial-only for advanced cell/gene therapy.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: advanced cell/gene therapy without clear commercial authorization → trial-only default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Hematology"],"diseases":["Sickle Cell Disease","Beta-Thalassemia","Genetic Blood Disorders"],"status":"active"},{"id":"885ffadf-0e00-4b6d-a313-1a21b51897fe","procedure_id":"proc-gene-crispr","jurisdiction_id":"jur-be","procedure_name":"CRISPR-Based Gene Therapy (Somatic) for Genetic Disorders","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Hematology"],"diseases":["Sickle Cell Disease","Beta-Thalassemia","Genetic Blood Disorders"],"status":"active"},{"id":"d240b4cc-cf40-424f-afc4-b7d7060e9ef8","procedure_id":"proc-gene-crispr","jurisdiction_id":"jur-se","procedure_name":"CRISPR-Based Gene Therapy (Somatic) for Genetic Disorders","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial centre pathway inferred.","eligibility_requirements":"Trial criteria.","provider_requirements":"Trial site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial-only for advanced cell/gene therapy.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: advanced cell/gene therapy without clear commercial authorization → trial-only default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Hematology"],"diseases":["Sickle Cell Disease","Beta-Thalassemia","Genetic Blood Disorders"],"status":"active"},{"id":"bf678d3a-edf2-47c8-9eda-16b2353737b8","procedure_id":"proc-gene-crispr","jurisdiction_id":"jur-jp","procedure_name":"CRISPR-Based Gene Therapy (Somatic) for Genetic Disorders","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"PMDA / MHLW","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Hematology"],"diseases":["Sickle Cell Disease","Beta-Thalassemia","Genetic Blood Disorders"],"status":"active"},{"id":"56938b12-8f98-4f2e-b001-79e2a8d87288","procedure_id":"proc-gene-crispr","jurisdiction_id":"jur-sg","procedure_name":"CRISPR-Based Gene Therapy (Somatic) for Genetic Disorders","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"HSA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Hematology"],"diseases":["Sickle Cell Disease","Beta-Thalassemia","Genetic Blood Disorders"],"status":"active"},{"id":"d0fec7b9-8564-4151-9019-326d03fb19c7","procedure_id":"proc-gene-crispr","jurisdiction_id":"jur-cl","procedure_name":"CRISPR-Based Gene Therapy (Somatic) for Genetic Disorders","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial centre pathway inferred.","eligibility_requirements":"Trial criteria.","provider_requirements":"Trial site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial-only for advanced cell/gene therapy.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: advanced cell/gene therapy without clear commercial authorization → trial-only default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Hematology"],"diseases":["Sickle Cell Disease","Beta-Thalassemia","Genetic Blood Disorders"],"status":"active"},{"id":"e8b0d280-394c-4bc3-b743-5578cf74aa46","procedure_id":"proc-gene-crispr","jurisdiction_id":"jur-ar","procedure_name":"CRISPR-Based Gene Therapy (Somatic) for Genetic Disorders","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial centre pathway inferred.","eligibility_requirements":"Trial criteria.","provider_requirements":"Trial site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial-only for advanced cell/gene therapy.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: advanced cell/gene therapy without clear commercial authorization → trial-only default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Hematology"],"diseases":["Sickle Cell Disease","Beta-Thalassemia","Genetic Blood Disorders"],"status":"active"},{"id":"46856d8d-031b-4544-89c8-7881cf615ca2","procedure_id":"proc-gene-crispr","jurisdiction_id":"jur-za","procedure_name":"CRISPR-Based Gene Therapy (Somatic) for Genetic Disorders","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial centre pathway inferred.","eligibility_requirements":"Trial criteria.","provider_requirements":"Trial site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial-only for advanced cell/gene therapy.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: advanced cell/gene therapy without clear commercial authorization → trial-only default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Hematology"],"diseases":["Sickle Cell Disease","Beta-Thalassemia","Genetic Blood Disorders"],"status":"active"},{"id":"4ed7768f-6129-48fe-9474-c6ef004ef895","procedure_id":"proc-gene-crispr","jurisdiction_id":"jur-ph","procedure_name":"CRISPR-Based Gene Therapy (Somatic) for Genetic Disorders","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial centre pathway inferred.","eligibility_requirements":"Trial criteria.","provider_requirements":"Trial site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial-only for advanced cell/gene therapy.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: advanced cell/gene therapy without clear commercial authorization → trial-only default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Hematology"],"diseases":["Sickle Cell Disease","Beta-Thalassemia","Genetic Blood Disorders"],"status":"active"},{"id":"d753f4ff-2cd4-4425-8afa-52148041d0f5","procedure_id":"proc-gene-crispr","jurisdiction_id":"jur-po","procedure_name":"CRISPR-Based Gene Therapy (Somatic) for Genetic Disorders","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial centre pathway inferred.","eligibility_requirements":"Trial criteria.","provider_requirements":"Trial site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial-only for advanced cell/gene therapy.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: advanced cell/gene therapy without clear commercial authorization → trial-only default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Hematology"],"diseases":["Sickle Cell Disease","Beta-Thalassemia","Genetic Blood Disorders"],"status":"active"},{"id":"9901ada2-f53f-4cc2-a7b3-86e56cf20238","procedure_id":"proc-gene-crispr","jurisdiction_id":"jur-pt","procedure_name":"CRISPR-Based Gene Therapy (Somatic) for Genetic Disorders","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Hematology"],"diseases":["Sickle Cell Disease","Beta-Thalassemia","Genetic Blood Disorders"],"status":"active"},{"id":"12e7d2d5-7552-4645-a919-b72faa10d655","procedure_id":"proc-gene-crispr","jurisdiction_id":"jur-fr","procedure_name":"CRISPR-Based Gene Therapy (Somatic) for Genetic Disorders","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"ANSM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Hematology"],"diseases":["Sickle Cell Disease","Beta-Thalassemia","Genetic Blood Disorders"],"status":"active"},{"id":"81301246-721e-4afe-9fdf-a6b18833b2a2","procedure_id":"proc-gene-aa9","jurisdiction_id":"jur-us-or","procedure_name":"AAV9-Mediated Gene Replacement Therapy","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Neurology"],"diseases":["Spinal Muscular Atrophy (SMA)","Inherited Retinal Dystrophy","Hemophilia B","Duchenne Muscular Dystrophy"],"status":"active"},{"id":"2c5a0ad4-42a5-405c-a11e-fcaf8ac2b9ef","procedure_id":"proc-gene-aa9","jurisdiction_id":"jur-us-co","procedure_name":"AAV9-Mediated Gene Replacement Therapy","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Neurology"],"diseases":["Spinal Muscular Atrophy (SMA)","Inherited Retinal Dystrophy","Hemophilia B","Duchenne Muscular Dystrophy"],"status":"active"},{"id":"8e7693ea-c211-4b8f-9c14-f2e94ee958c2","procedure_id":"proc-gene-aa9","jurisdiction_id":"jur-us-ca","procedure_name":"AAV9-Mediated Gene Replacement Therapy","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Neurology"],"diseases":["Spinal Muscular Atrophy (SMA)","Inherited Retinal Dystrophy","Hemophilia B","Duchenne Muscular Dystrophy"],"status":"active"},{"id":"d745a8ad-8efb-412f-8a88-f09742ed5cb9","procedure_id":"proc-gene-aa9","jurisdiction_id":"jur-us-tx","procedure_name":"AAV9-Mediated Gene Replacement Therapy","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Neurology"],"diseases":["Spinal Muscular Atrophy (SMA)","Inherited Retinal Dystrophy","Hemophilia B","Duchenne Muscular Dystrophy"],"status":"active"},{"id":"0f2732b1-ce26-406c-9cab-b959fb5d8549","procedure_id":"proc-gene-aa9","jurisdiction_id":"jur-us-fl","procedure_name":"AAV9-Mediated Gene Replacement Therapy","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Neurology"],"diseases":["Spinal Muscular Atrophy (SMA)","Inherited Retinal Dystrophy","Hemophilia B","Duchenne Muscular Dystrophy"],"status":"active"},{"id":"bbeb2106-bf24-4f68-87e8-f260071e7d93","procedure_id":"proc-gene-aa9","jurisdiction_id":"jur-ch","procedure_name":"AAV9-Mediated Gene Replacement Therapy","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"Swissmedic","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Neurology"],"diseases":["Spinal Muscular Atrophy (SMA)","Inherited Retinal Dystrophy","Hemophilia B","Duchenne Muscular Dystrophy"],"status":"active"},{"id":"e13d2148-146d-45ae-8190-5d01e901e98a","procedure_id":"proc-gene-aa9","jurisdiction_id":"jur-mx","procedure_name":"AAV9-Mediated Gene Replacement Therapy","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"COFEPRIS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Neurology"],"diseases":["Spinal Muscular Atrophy (SMA)","Inherited Retinal Dystrophy","Hemophilia B","Duchenne Muscular Dystrophy"],"status":"active"},{"id":"a086e1ec-6b20-40fc-85d3-047c5c9aed81","procedure_id":"proc-gene-aa9","jurisdiction_id":"jur-hn-prospera","procedure_name":"AAV9-Mediated Gene Replacement Therapy","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"Próspera ZEDE health rules (contested)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Neurology"],"diseases":["Spinal Muscular Atrophy (SMA)","Inherited Retinal Dystrophy","Hemophilia B","Duchenne Muscular Dystrophy"],"status":"active"},{"id":"93a39a7f-5412-4a1c-a754-62466ae12fa8","procedure_id":"proc-gene-aa9","jurisdiction_id":"jur-nl","procedure_name":"AAV9-Mediated Gene Replacement Therapy","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"MEB / IGJ","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Neurology"],"diseases":["Spinal Muscular Atrophy (SMA)","Inherited Retinal Dystrophy","Hemophilia B","Duchenne Muscular Dystrophy"],"status":"active"},{"id":"de9333b3-ce2a-4cdc-977f-ded0fe0fedc7","procedure_id":"proc-gene-aa9","jurisdiction_id":"jur-il","procedure_name":"AAV9-Mediated Gene Replacement Therapy","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Neurology"],"diseases":["Spinal Muscular Atrophy (SMA)","Inherited Retinal Dystrophy","Hemophilia B","Duchenne Muscular Dystrophy"],"status":"active"},{"id":"401a7ae8-78be-4038-ae35-32b1865f310d","procedure_id":"proc-gene-aa9","jurisdiction_id":"jur-jm","procedure_name":"AAV9-Mediated Gene Replacement Therapy","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Neurology"],"diseases":["Spinal Muscular Atrophy (SMA)","Inherited Retinal Dystrophy","Hemophilia B","Duchenne Muscular Dystrophy"],"status":"active"},{"id":"7413a140-3aeb-4b4a-9a42-e97dc0cec63c","procedure_id":"proc-gene-aa9","jurisdiction_id":"jur-th","procedure_name":"AAV9-Mediated Gene Replacement Therapy","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"Thai FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Neurology"],"diseases":["Spinal Muscular Atrophy (SMA)","Inherited Retinal Dystrophy","Hemophilia B","Duchenne Muscular Dystrophy"],"status":"active"},{"id":"16c4147f-b783-4562-9341-3f1da11bdf25","procedure_id":"proc-gene-aa9","jurisdiction_id":"jur-es","procedure_name":"AAV9-Mediated Gene Replacement Therapy","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"AEMPS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Neurology"],"diseases":["Spinal Muscular Atrophy (SMA)","Inherited Retinal Dystrophy","Hemophilia B","Duchenne Muscular Dystrophy"],"status":"active"},{"id":"0f142542-9507-40cf-9788-b5ad8228d53b","procedure_id":"proc-gene-aa9","jurisdiction_id":"jur-tu","procedure_name":"AAV9-Mediated Gene Replacement Therapy","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial centre pathway inferred.","eligibility_requirements":"Trial criteria.","provider_requirements":"Trial site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial-only for advanced cell/gene therapy.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: advanced cell/gene therapy without clear commercial authorization → trial-only default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Neurology"],"diseases":["Spinal Muscular Atrophy (SMA)","Inherited Retinal Dystrophy","Hemophilia B","Duchenne Muscular Dystrophy"],"status":"active"},{"id":"2d38baa6-5711-4b3d-afa4-73770bac1fb6","procedure_id":"proc-gene-aa9","jurisdiction_id":"jur-in","procedure_name":"AAV9-Mediated Gene Replacement Therapy","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"CDSCO","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Neurology"],"diseases":["Spinal Muscular Atrophy (SMA)","Inherited Retinal Dystrophy","Hemophilia B","Duchenne Muscular Dystrophy"],"status":"active"},{"id":"f5afbfb7-06c4-4e25-b299-01b2ddec25e1","procedure_id":"proc-gene-aa9","jurisdiction_id":"jur-cr","procedure_name":"AAV9-Mediated Gene Replacement Therapy","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial centre pathway inferred.","eligibility_requirements":"Trial criteria.","provider_requirements":"Trial site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial-only for advanced cell/gene therapy.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: advanced cell/gene therapy without clear commercial authorization → trial-only default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Neurology"],"diseases":["Spinal Muscular Atrophy (SMA)","Inherited Retinal Dystrophy","Hemophilia B","Duchenne Muscular Dystrophy"],"status":"active"},{"id":"f3d42321-eaa8-4e1d-934b-7fb66f6e1ef8","procedure_id":"proc-gene-aa9","jurisdiction_id":"jur-uae","procedure_name":"AAV9-Mediated Gene Replacement Therapy","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial centre pathway inferred.","eligibility_requirements":"Trial criteria.","provider_requirements":"Trial site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial-only for advanced cell/gene therapy.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: advanced cell/gene therapy without clear commercial authorization → trial-only default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Neurology"],"diseases":["Spinal Muscular Atrophy (SMA)","Inherited Retinal Dystrophy","Hemophilia B","Duchenne Muscular Dystrophy"],"status":"active"},{"id":"db000289-6b02-4816-b647-6c6efe107236","procedure_id":"proc-gene-aa9","jurisdiction_id":"jur-gr","procedure_name":"AAV9-Mediated Gene Replacement Therapy","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial centre pathway inferred.","eligibility_requirements":"Trial criteria.","provider_requirements":"Trial site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial-only for advanced cell/gene therapy.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: advanced cell/gene therapy without clear commercial authorization → trial-only default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Neurology"],"diseases":["Spinal Muscular Atrophy (SMA)","Inherited Retinal Dystrophy","Hemophilia B","Duchenne Muscular Dystrophy"],"status":"active"},{"id":"c8f374fd-b2d8-498f-a0ab-d56a40edbb84","procedure_id":"proc-gene-aa9","jurisdiction_id":"jur-be","procedure_name":"AAV9-Mediated Gene Replacement Therapy","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Neurology"],"diseases":["Spinal Muscular Atrophy (SMA)","Inherited Retinal Dystrophy","Hemophilia B","Duchenne Muscular Dystrophy"],"status":"active"},{"id":"85d62f69-bf01-433b-ae00-f295f505224d","procedure_id":"proc-gene-aa9","jurisdiction_id":"jur-se","procedure_name":"AAV9-Mediated Gene Replacement Therapy","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial centre pathway inferred.","eligibility_requirements":"Trial criteria.","provider_requirements":"Trial site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial-only for advanced cell/gene therapy.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: advanced cell/gene therapy without clear commercial authorization → trial-only default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Neurology"],"diseases":["Spinal Muscular Atrophy (SMA)","Inherited Retinal Dystrophy","Hemophilia B","Duchenne Muscular Dystrophy"],"status":"active"},{"id":"0da23987-8f18-468d-aadb-172f8d1c1541","procedure_id":"proc-gene-aa9","jurisdiction_id":"jur-sg","procedure_name":"AAV9-Mediated Gene Replacement Therapy","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"HSA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Neurology"],"diseases":["Spinal Muscular Atrophy (SMA)","Inherited Retinal Dystrophy","Hemophilia B","Duchenne Muscular Dystrophy"],"status":"active"},{"id":"69f1066f-0528-4767-b768-5411c2980ef6","procedure_id":"proc-gene-aa9","jurisdiction_id":"jur-cl","procedure_name":"AAV9-Mediated Gene Replacement Therapy","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial centre pathway inferred.","eligibility_requirements":"Trial criteria.","provider_requirements":"Trial site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial-only for advanced cell/gene therapy.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: advanced cell/gene therapy without clear commercial authorization → trial-only default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Neurology"],"diseases":["Spinal Muscular Atrophy (SMA)","Inherited Retinal Dystrophy","Hemophilia B","Duchenne Muscular Dystrophy"],"status":"active"},{"id":"1f42ff16-2a0e-4b32-9679-040feca6e2e2","procedure_id":"proc-gene-aa9","jurisdiction_id":"jur-ar","procedure_name":"AAV9-Mediated Gene Replacement Therapy","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial centre pathway inferred.","eligibility_requirements":"Trial criteria.","provider_requirements":"Trial site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial-only for advanced cell/gene therapy.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: advanced cell/gene therapy without clear commercial authorization → trial-only default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Neurology"],"diseases":["Spinal Muscular Atrophy (SMA)","Inherited Retinal Dystrophy","Hemophilia B","Duchenne Muscular Dystrophy"],"status":"active"},{"id":"d83e4e4b-e7b3-4c80-b171-81119a6324d5","procedure_id":"proc-gene-aa9","jurisdiction_id":"jur-za","procedure_name":"AAV9-Mediated Gene Replacement Therapy","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial centre pathway inferred.","eligibility_requirements":"Trial criteria.","provider_requirements":"Trial site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial-only for advanced cell/gene therapy.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: advanced cell/gene therapy without clear commercial authorization → trial-only default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Neurology"],"diseases":["Spinal Muscular Atrophy (SMA)","Inherited Retinal Dystrophy","Hemophilia B","Duchenne Muscular Dystrophy"],"status":"active"},{"id":"7b0d2124-b11a-41dc-8c20-d57590f012ba","procedure_id":"proc-gene-aa9","jurisdiction_id":"jur-ph","procedure_name":"AAV9-Mediated Gene Replacement Therapy","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial centre pathway inferred.","eligibility_requirements":"Trial criteria.","provider_requirements":"Trial site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial-only for advanced cell/gene therapy.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: advanced cell/gene therapy without clear commercial authorization → trial-only default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Neurology"],"diseases":["Spinal Muscular Atrophy (SMA)","Inherited Retinal Dystrophy","Hemophilia B","Duchenne Muscular Dystrophy"],"status":"active"},{"id":"b0aeed6d-9859-4fb3-a8a6-eb5987944a6e","procedure_id":"proc-gene-aa9","jurisdiction_id":"jur-po","procedure_name":"AAV9-Mediated Gene Replacement Therapy","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial centre pathway inferred.","eligibility_requirements":"Trial criteria.","provider_requirements":"Trial site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial-only for advanced cell/gene therapy.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: advanced cell/gene therapy without clear commercial authorization → trial-only default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Neurology"],"diseases":["Spinal Muscular Atrophy (SMA)","Inherited Retinal Dystrophy","Hemophilia B","Duchenne Muscular Dystrophy"],"status":"active"},{"id":"2009fe1a-14b8-4f6a-bd9e-73699d1adc5c","procedure_id":"proc-gene-aa9","jurisdiction_id":"jur-pt","procedure_name":"AAV9-Mediated Gene Replacement Therapy","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"GENE_THERAPY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Genetics","Neurology"],"diseases":["Spinal Muscular Atrophy (SMA)","Inherited Retinal Dystrophy","Hemophilia B","Duchenne Muscular Dystrophy"],"status":"active"},{"id":"7ae5761f-8653-4c65-adfd-31b969aff94b","procedure_id":"proc-stem-msc","jurisdiction_id":"jur-us-federal","procedure_name":"Mesenchymal Stem Cell (MSC) Therapy for Autoimmune/Inflammatory Conditions","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Orthopedic"],"diseases":["Osteoarthritis","Autoimmune Disease","Inflammatory Conditions","Crohn's Disease"],"status":"active"},{"id":"ffd428d3-60e0-4ab2-becf-d3b6043a57ad","procedure_id":"proc-stem-msc","jurisdiction_id":"jur-us-or","procedure_name":"Mesenchymal Stem Cell (MSC) Therapy for Autoimmune/Inflammatory Conditions","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Orthopedic"],"diseases":["Osteoarthritis","Autoimmune Disease","Inflammatory Conditions","Crohn's Disease"],"status":"active"},{"id":"d9a1107b-5528-4128-8221-37e4dbb1a6c1","procedure_id":"proc-stem-msc","jurisdiction_id":"jur-us-co","procedure_name":"Mesenchymal Stem Cell (MSC) Therapy for Autoimmune/Inflammatory Conditions","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Orthopedic"],"diseases":["Osteoarthritis","Autoimmune Disease","Inflammatory Conditions","Crohn's Disease"],"status":"active"},{"id":"f1451120-dc11-412c-9636-df961540e0d6","procedure_id":"proc-stem-msc","jurisdiction_id":"jur-us-ca","procedure_name":"Mesenchymal Stem Cell (MSC) Therapy for Autoimmune/Inflammatory Conditions","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Orthopedic"],"diseases":["Osteoarthritis","Autoimmune Disease","Inflammatory Conditions","Crohn's Disease"],"status":"active"},{"id":"3f648b53-8163-44e5-9942-25c6dd63c7be","procedure_id":"proc-stem-msc","jurisdiction_id":"jur-us-tx","procedure_name":"Mesenchymal Stem Cell (MSC) Therapy for Autoimmune/Inflammatory Conditions","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Orthopedic"],"diseases":["Osteoarthritis","Autoimmune Disease","Inflammatory Conditions","Crohn's Disease"],"status":"active"},{"id":"a139fbc6-22c2-4762-ab9f-4b7f8591f7f5","procedure_id":"proc-stem-msc","jurisdiction_id":"jur-us-fl","procedure_name":"Mesenchymal Stem Cell (MSC) Therapy for Autoimmune/Inflammatory Conditions","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Orthopedic"],"diseases":["Osteoarthritis","Autoimmune Disease","Inflammatory Conditions","Crohn's Disease"],"status":"active"},{"id":"7a49fe42-8a62-4f90-9ef6-74fd80de1a92","procedure_id":"proc-stem-msc","jurisdiction_id":"jur-au","procedure_name":"Mesenchymal Stem Cell (MSC) Therapy for Autoimmune/Inflammatory Conditions","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"TGA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Orthopedic"],"diseases":["Osteoarthritis","Autoimmune Disease","Inflammatory Conditions","Crohn's Disease"],"status":"active"},{"id":"1cbd733f-292e-48fb-b392-77189ece79de","procedure_id":"proc-stem-msc","jurisdiction_id":"jur-ch","procedure_name":"Mesenchymal Stem Cell (MSC) Therapy for Autoimmune/Inflammatory Conditions","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"Swissmedic","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Orthopedic"],"diseases":["Osteoarthritis","Autoimmune Disease","Inflammatory Conditions","Crohn's Disease"],"status":"active"},{"id":"951db66f-51eb-455b-a798-0c561ff404c2","procedure_id":"proc-stem-msc","jurisdiction_id":"jur-ca","procedure_name":"Mesenchymal Stem Cell (MSC) Therapy for Autoimmune/Inflammatory Conditions","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"Health Canada","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Orthopedic"],"diseases":["Osteoarthritis","Autoimmune Disease","Inflammatory Conditions","Crohn's Disease"],"status":"active"},{"id":"f1103eb7-a1c1-4d11-9b2f-669023f04645","procedure_id":"proc-stem-msc","jurisdiction_id":"jur-nl","procedure_name":"Mesenchymal Stem Cell (MSC) Therapy for Autoimmune/Inflammatory Conditions","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"MEB / IGJ","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Orthopedic"],"diseases":["Osteoarthritis","Autoimmune Disease","Inflammatory Conditions","Crohn's Disease"],"status":"active"},{"id":"2f7e9c9a-0130-463f-96eb-069f71ade754","procedure_id":"proc-stem-msc","jurisdiction_id":"jur-de","procedure_name":"Mesenchymal Stem Cell (MSC) Therapy for Autoimmune/Inflammatory Conditions","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"BfArM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Orthopedic"],"diseases":["Osteoarthritis","Autoimmune Disease","Inflammatory Conditions","Crohn's Disease"],"status":"active"},{"id":"9d2784fe-a26a-4d39-a8e6-d7ab25bf46fd","procedure_id":"proc-stem-msc","jurisdiction_id":"jur-uk","procedure_name":"Mesenchymal Stem Cell (MSC) Therapy for Autoimmune/Inflammatory Conditions","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"MHRA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Orthopedic"],"diseases":["Osteoarthritis","Autoimmune Disease","Inflammatory Conditions","Crohn's Disease"],"status":"active"},{"id":"c936cf5f-8aa0-455e-9971-afe4339c1ad1","procedure_id":"proc-stem-msc","jurisdiction_id":"jur-il","procedure_name":"Mesenchymal Stem Cell (MSC) Therapy for Autoimmune/Inflammatory Conditions","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Orthopedic"],"diseases":["Osteoarthritis","Autoimmune Disease","Inflammatory Conditions","Crohn's Disease"],"status":"active"},{"id":"f9123d8d-7698-401b-bcdf-5cc33df54f95","procedure_id":"proc-stem-msc","jurisdiction_id":"jur-jm","procedure_name":"Mesenchymal Stem Cell (MSC) Therapy for Autoimmune/Inflammatory Conditions","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Orthopedic"],"diseases":["Osteoarthritis","Autoimmune Disease","Inflammatory Conditions","Crohn's Disease"],"status":"active"},{"id":"5169622d-1434-4428-bcba-eac9b0fa8f36","procedure_id":"proc-stem-msc","jurisdiction_id":"jur-th","procedure_name":"Mesenchymal Stem Cell (MSC) Therapy for Autoimmune/Inflammatory Conditions","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"Thai FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Orthopedic"],"diseases":["Osteoarthritis","Autoimmune Disease","Inflammatory Conditions","Crohn's Disease"],"status":"active"},{"id":"f5e8e0bc-70aa-4ea9-8c1c-12ed2b4ef5c2","procedure_id":"proc-stem-msc","jurisdiction_id":"jur-es","procedure_name":"Mesenchymal Stem Cell (MSC) Therapy for Autoimmune/Inflammatory Conditions","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"AEMPS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Orthopedic"],"diseases":["Osteoarthritis","Autoimmune Disease","Inflammatory Conditions","Crohn's Disease"],"status":"active"},{"id":"da69fa87-dc8c-439a-aa57-5d7d854c30bd","procedure_id":"proc-stem-msc","jurisdiction_id":"jur-tu","procedure_name":"Mesenchymal Stem Cell (MSC) Therapy for Autoimmune/Inflammatory Conditions","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Orthopedic"],"diseases":["Osteoarthritis","Autoimmune Disease","Inflammatory Conditions","Crohn's Disease"],"status":"active"},{"id":"7674d0d2-2595-40c6-91e5-15c2e5b0b6e5","procedure_id":"proc-stem-msc","jurisdiction_id":"jur-in","procedure_name":"Mesenchymal Stem Cell (MSC) Therapy for Autoimmune/Inflammatory Conditions","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"CDSCO","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Orthopedic"],"diseases":["Osteoarthritis","Autoimmune Disease","Inflammatory Conditions","Crohn's Disease"],"status":"active"},{"id":"515bc23a-55d0-4513-8208-4cf9d9260c1d","procedure_id":"proc-stem-msc","jurisdiction_id":"jur-br","procedure_name":"Mesenchymal Stem Cell (MSC) Therapy for Autoimmune/Inflammatory Conditions","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"ANVISA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Orthopedic"],"diseases":["Osteoarthritis","Autoimmune Disease","Inflammatory Conditions","Crohn's Disease"],"status":"active"},{"id":"2f0c1e2a-74cb-4f84-b63d-7481c4b5b530","procedure_id":"proc-stem-msc","jurisdiction_id":"jur-cr","procedure_name":"Mesenchymal Stem Cell (MSC) Therapy for Autoimmune/Inflammatory Conditions","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Orthopedic"],"diseases":["Osteoarthritis","Autoimmune Disease","Inflammatory Conditions","Crohn's Disease"],"status":"active"},{"id":"1b893d31-5d6c-47f4-882c-4fbd7d007de0","procedure_id":"proc-stem-msc","jurisdiction_id":"jur-uae","procedure_name":"Mesenchymal Stem Cell (MSC) Therapy for Autoimmune/Inflammatory Conditions","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Orthopedic"],"diseases":["Osteoarthritis","Autoimmune Disease","Inflammatory Conditions","Crohn's Disease"],"status":"active"},{"id":"db48b88b-caa0-4a70-8d02-4478cf8f0be6","procedure_id":"proc-stem-msc","jurisdiction_id":"jur-kr","procedure_name":"Mesenchymal Stem Cell (MSC) Therapy for Autoimmune/Inflammatory Conditions","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"MFDS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Orthopedic"],"diseases":["Osteoarthritis","Autoimmune Disease","Inflammatory Conditions","Crohn's Disease"],"status":"active"},{"id":"c2fa4c7d-93e4-4cf2-a30e-20b8e0e503b3","procedure_id":"proc-stem-msc","jurisdiction_id":"jur-gr","procedure_name":"Mesenchymal Stem Cell (MSC) Therapy for Autoimmune/Inflammatory Conditions","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Orthopedic"],"diseases":["Osteoarthritis","Autoimmune Disease","Inflammatory Conditions","Crohn's Disease"],"status":"active"},{"id":"7d54e972-4924-4da4-9b94-68fbeff1bd33","procedure_id":"proc-stem-msc","jurisdiction_id":"jur-be","procedure_name":"Mesenchymal Stem Cell (MSC) Therapy for Autoimmune/Inflammatory Conditions","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Orthopedic"],"diseases":["Osteoarthritis","Autoimmune Disease","Inflammatory Conditions","Crohn's Disease"],"status":"active"},{"id":"739e3b10-23b3-44a0-864c-5a3e788e72cc","procedure_id":"proc-stem-msc","jurisdiction_id":"jur-se","procedure_name":"Mesenchymal Stem Cell (MSC) Therapy for Autoimmune/Inflammatory Conditions","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Orthopedic"],"diseases":["Osteoarthritis","Autoimmune Disease","Inflammatory Conditions","Crohn's Disease"],"status":"active"},{"id":"69055686-0cc6-4d4b-a8bb-c8cbd740ffa9","procedure_id":"proc-stem-msc","jurisdiction_id":"jur-jp","procedure_name":"Mesenchymal Stem Cell (MSC) Therapy for Autoimmune/Inflammatory Conditions","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"PMDA / MHLW","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Orthopedic"],"diseases":["Osteoarthritis","Autoimmune Disease","Inflammatory Conditions","Crohn's Disease"],"status":"active"},{"id":"a3e4fdf2-4588-4239-89fc-a8440e02913c","procedure_id":"proc-stem-msc","jurisdiction_id":"jur-sg","procedure_name":"Mesenchymal Stem Cell (MSC) Therapy for Autoimmune/Inflammatory Conditions","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"HSA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Orthopedic"],"diseases":["Osteoarthritis","Autoimmune Disease","Inflammatory Conditions","Crohn's Disease"],"status":"active"},{"id":"d9c7f299-7fa8-464d-b116-f87ea556d992","procedure_id":"proc-stem-msc","jurisdiction_id":"jur-cl","procedure_name":"Mesenchymal Stem Cell (MSC) Therapy for Autoimmune/Inflammatory Conditions","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Orthopedic"],"diseases":["Osteoarthritis","Autoimmune Disease","Inflammatory Conditions","Crohn's Disease"],"status":"active"},{"id":"3a55cb22-fe07-4b36-853e-81fa9a42fba4","procedure_id":"proc-stem-msc","jurisdiction_id":"jur-ar","procedure_name":"Mesenchymal Stem Cell (MSC) Therapy for Autoimmune/Inflammatory Conditions","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Orthopedic"],"diseases":["Osteoarthritis","Autoimmune Disease","Inflammatory Conditions","Crohn's Disease"],"status":"active"},{"id":"6ba571b2-d21b-4f4f-8ab6-64aed32c2cdf","procedure_id":"proc-stem-msc","jurisdiction_id":"jur-za","procedure_name":"Mesenchymal Stem Cell (MSC) Therapy for Autoimmune/Inflammatory Conditions","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Orthopedic"],"diseases":["Osteoarthritis","Autoimmune Disease","Inflammatory Conditions","Crohn's Disease"],"status":"active"},{"id":"7d9e57dd-2f0d-403c-b183-d2b6971ccadc","procedure_id":"proc-stem-msc","jurisdiction_id":"jur-ph","procedure_name":"Mesenchymal Stem Cell (MSC) Therapy for Autoimmune/Inflammatory Conditions","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Orthopedic"],"diseases":["Osteoarthritis","Autoimmune Disease","Inflammatory Conditions","Crohn's Disease"],"status":"active"},{"id":"fad1773c-e998-4901-8096-02fb5ea88fde","procedure_id":"proc-stem-msc","jurisdiction_id":"jur-po","procedure_name":"Mesenchymal Stem Cell (MSC) Therapy for Autoimmune/Inflammatory Conditions","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Orthopedic"],"diseases":["Osteoarthritis","Autoimmune Disease","Inflammatory Conditions","Crohn's Disease"],"status":"active"},{"id":"c37811b9-e618-43f6-94f4-ee7c37dcc41d","procedure_id":"proc-stem-msc","jurisdiction_id":"jur-pt","procedure_name":"Mesenchymal Stem Cell (MSC) Therapy for Autoimmune/Inflammatory Conditions","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Orthopedic"],"diseases":["Osteoarthritis","Autoimmune Disease","Inflammatory Conditions","Crohn's Disease"],"status":"active"},{"id":"32f66c28-9c74-49fc-95dd-4b18ecd0b96f","procedure_id":"proc-stem-msc","jurisdiction_id":"jur-fr","procedure_name":"Mesenchymal Stem Cell (MSC) Therapy for Autoimmune/Inflammatory Conditions","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"ANSM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Orthopedic"],"diseases":["Osteoarthritis","Autoimmune Disease","Inflammatory Conditions","Crohn's Disease"],"status":"active"},{"id":"e71c613c-1dbc-407b-aee6-1098bff9a6f3","procedure_id":"proc-stem-car-t","jurisdiction_id":"jur-us-or","procedure_name":"CAR-T Cell Therapy for Hematologic Malignancies","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Hematology"],"diseases":["Relapsed/Refractory B-cell ALL","Diffuse Large B-cell Lymphoma","Multiple Myeloma"],"status":"active"},{"id":"43941da2-8227-4e89-b858-1c5680b4a6d9","procedure_id":"proc-stem-car-t","jurisdiction_id":"jur-us-co","procedure_name":"CAR-T Cell Therapy for Hematologic Malignancies","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Hematology"],"diseases":["Relapsed/Refractory B-cell ALL","Diffuse Large B-cell Lymphoma","Multiple Myeloma"],"status":"active"},{"id":"a2bda22b-7ea7-4232-a782-e98c6fada322","procedure_id":"proc-stem-car-t","jurisdiction_id":"jur-us-ca","procedure_name":"CAR-T Cell Therapy for Hematologic Malignancies","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Hematology"],"diseases":["Relapsed/Refractory B-cell ALL","Diffuse Large B-cell Lymphoma","Multiple Myeloma"],"status":"active"},{"id":"823b7304-c764-4530-aafd-f5734bc900cc","procedure_id":"proc-stem-car-t","jurisdiction_id":"jur-us-tx","procedure_name":"CAR-T Cell Therapy for Hematologic Malignancies","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Hematology"],"diseases":["Relapsed/Refractory B-cell ALL","Diffuse Large B-cell Lymphoma","Multiple Myeloma"],"status":"active"},{"id":"71a4c206-8622-4671-b1e8-e654d01b7103","procedure_id":"proc-stem-car-t","jurisdiction_id":"jur-us-fl","procedure_name":"CAR-T Cell Therapy for Hematologic Malignancies","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Hematology"],"diseases":["Relapsed/Refractory B-cell ALL","Diffuse Large B-cell Lymphoma","Multiple Myeloma"],"status":"active"},{"id":"0c8d5119-5cfc-4bb9-94a6-42289de3625a","procedure_id":"proc-stem-car-t","jurisdiction_id":"jur-au","procedure_name":"CAR-T Cell Therapy for Hematologic Malignancies","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"TGA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Hematology"],"diseases":["Relapsed/Refractory B-cell ALL","Diffuse Large B-cell Lymphoma","Multiple Myeloma"],"status":"active"},{"id":"91106c6a-d607-4bec-99c4-a4634a9e7d95","procedure_id":"proc-stem-car-t","jurisdiction_id":"jur-ch","procedure_name":"CAR-T Cell Therapy for Hematologic Malignancies","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"Swissmedic","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Hematology"],"diseases":["Relapsed/Refractory B-cell ALL","Diffuse Large B-cell Lymphoma","Multiple Myeloma"],"status":"active"},{"id":"23b28592-93c7-44df-b43b-6b8eaed72668","procedure_id":"proc-stem-car-t","jurisdiction_id":"jur-ca","procedure_name":"CAR-T Cell Therapy for Hematologic Malignancies","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"Health Canada","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Hematology"],"diseases":["Relapsed/Refractory B-cell ALL","Diffuse Large B-cell Lymphoma","Multiple Myeloma"],"status":"active"},{"id":"d3572562-8fba-4bb0-adb0-e54d8ffd9a23","procedure_id":"proc-stem-car-t","jurisdiction_id":"jur-mx","procedure_name":"CAR-T Cell Therapy for Hematologic Malignancies","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"COFEPRIS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Hematology"],"diseases":["Relapsed/Refractory B-cell ALL","Diffuse Large B-cell Lymphoma","Multiple Myeloma"],"status":"active"},{"id":"c7eb904d-ea6e-4455-852e-a7864be96f31","procedure_id":"proc-stem-car-t","jurisdiction_id":"jur-hn-prospera","procedure_name":"CAR-T Cell Therapy for Hematologic Malignancies","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"Próspera ZEDE health rules (contested)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Hematology"],"diseases":["Relapsed/Refractory B-cell ALL","Diffuse Large B-cell Lymphoma","Multiple Myeloma"],"status":"active"},{"id":"db3a12cd-07d1-4543-b7b1-805edfd83dc1","procedure_id":"proc-stem-car-t","jurisdiction_id":"jur-nl","procedure_name":"CAR-T Cell Therapy for Hematologic Malignancies","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"MEB / IGJ","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Hematology"],"diseases":["Relapsed/Refractory B-cell ALL","Diffuse Large B-cell Lymphoma","Multiple Myeloma"],"status":"active"},{"id":"3cdcaa42-f748-4c37-94ab-9715e4ff7088","procedure_id":"proc-stem-car-t","jurisdiction_id":"jur-de","procedure_name":"CAR-T Cell Therapy for Hematologic Malignancies","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"BfArM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Hematology"],"diseases":["Relapsed/Refractory B-cell ALL","Diffuse Large B-cell Lymphoma","Multiple Myeloma"],"status":"active"},{"id":"dd4b7a95-2084-4190-9b0c-6a0a97771a73","procedure_id":"proc-stem-car-t","jurisdiction_id":"jur-uk","procedure_name":"CAR-T Cell Therapy for Hematologic Malignancies","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"MHRA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Hematology"],"diseases":["Relapsed/Refractory B-cell ALL","Diffuse Large B-cell Lymphoma","Multiple Myeloma"],"status":"active"},{"id":"846fd662-3ab8-465c-aa8b-7782c30d974d","procedure_id":"proc-stem-car-t","jurisdiction_id":"jur-il","procedure_name":"CAR-T Cell Therapy for Hematologic Malignancies","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Hematology"],"diseases":["Relapsed/Refractory B-cell ALL","Diffuse Large B-cell Lymphoma","Multiple Myeloma"],"status":"active"},{"id":"a99b5124-1ac3-4285-9522-62621fb1f0d4","procedure_id":"proc-stem-car-t","jurisdiction_id":"jur-jm","procedure_name":"CAR-T Cell Therapy for Hematologic Malignancies","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Hematology"],"diseases":["Relapsed/Refractory B-cell ALL","Diffuse Large B-cell Lymphoma","Multiple Myeloma"],"status":"active"},{"id":"d7de5e6f-0ba8-4229-aee6-1d7856f022e9","procedure_id":"proc-stem-car-t","jurisdiction_id":"jur-th","procedure_name":"CAR-T Cell Therapy for Hematologic Malignancies","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"Thai FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Hematology"],"diseases":["Relapsed/Refractory B-cell ALL","Diffuse Large B-cell Lymphoma","Multiple Myeloma"],"status":"active"},{"id":"f9c729a4-625a-475c-b74a-66ac3b7a2669","procedure_id":"proc-stem-car-t","jurisdiction_id":"jur-es","procedure_name":"CAR-T Cell Therapy for Hematologic Malignancies","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"AEMPS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Hematology"],"diseases":["Relapsed/Refractory B-cell ALL","Diffuse Large B-cell Lymphoma","Multiple Myeloma"],"status":"active"},{"id":"3510f23b-7e49-4b01-9733-dc67f7d4aad6","procedure_id":"proc-stem-car-t","jurisdiction_id":"jur-tu","procedure_name":"CAR-T Cell Therapy for Hematologic Malignancies","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial centre pathway inferred.","eligibility_requirements":"Trial criteria.","provider_requirements":"Trial site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial-only for advanced cell/gene therapy.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: advanced cell/gene therapy without clear commercial authorization → trial-only default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Hematology"],"diseases":["Relapsed/Refractory B-cell ALL","Diffuse Large B-cell Lymphoma","Multiple Myeloma"],"status":"active"},{"id":"653b99af-4acc-4d00-8927-b492bc3f63cd","procedure_id":"proc-stem-car-t","jurisdiction_id":"jur-in","procedure_name":"CAR-T Cell Therapy for Hematologic Malignancies","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"CDSCO","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Hematology"],"diseases":["Relapsed/Refractory B-cell ALL","Diffuse Large B-cell Lymphoma","Multiple Myeloma"],"status":"active"},{"id":"2d18b2fd-ac64-4a04-9dc7-a80e754d0317","procedure_id":"proc-stem-car-t","jurisdiction_id":"jur-br","procedure_name":"CAR-T Cell Therapy for Hematologic Malignancies","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"ANVISA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Hematology"],"diseases":["Relapsed/Refractory B-cell ALL","Diffuse Large B-cell Lymphoma","Multiple Myeloma"],"status":"active"},{"id":"598830a9-48e2-4a8c-9e15-2cbc326a36cf","procedure_id":"proc-stem-car-t","jurisdiction_id":"jur-cr","procedure_name":"CAR-T Cell Therapy for Hematologic Malignancies","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial centre pathway inferred.","eligibility_requirements":"Trial criteria.","provider_requirements":"Trial site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial-only for advanced cell/gene therapy.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: advanced cell/gene therapy without clear commercial authorization → trial-only default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Hematology"],"diseases":["Relapsed/Refractory B-cell ALL","Diffuse Large B-cell Lymphoma","Multiple Myeloma"],"status":"active"},{"id":"7ceb953a-1554-4b20-b237-dbc191509dac","procedure_id":"proc-stem-car-t","jurisdiction_id":"jur-uae","procedure_name":"CAR-T Cell Therapy for Hematologic Malignancies","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial centre pathway inferred.","eligibility_requirements":"Trial criteria.","provider_requirements":"Trial site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial-only for advanced cell/gene therapy.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: advanced cell/gene therapy without clear commercial authorization → trial-only default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Hematology"],"diseases":["Relapsed/Refractory B-cell ALL","Diffuse Large B-cell Lymphoma","Multiple Myeloma"],"status":"active"},{"id":"57083948-c4f7-458f-a928-edc58eba7d85","procedure_id":"proc-stem-car-t","jurisdiction_id":"jur-kr","procedure_name":"CAR-T Cell Therapy for Hematologic Malignancies","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"MFDS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Hematology"],"diseases":["Relapsed/Refractory B-cell ALL","Diffuse Large B-cell Lymphoma","Multiple Myeloma"],"status":"active"},{"id":"b72b7cf9-50df-4b9b-b1eb-f3725dff4ccb","procedure_id":"proc-stem-car-t","jurisdiction_id":"jur-gr","procedure_name":"CAR-T Cell Therapy for Hematologic Malignancies","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial centre pathway inferred.","eligibility_requirements":"Trial criteria.","provider_requirements":"Trial site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial-only for advanced cell/gene therapy.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: advanced cell/gene therapy without clear commercial authorization → trial-only default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Hematology"],"diseases":["Relapsed/Refractory B-cell ALL","Diffuse Large B-cell Lymphoma","Multiple Myeloma"],"status":"active"},{"id":"e90b3424-0ef6-4df3-9d1a-c8eeb74a57c6","procedure_id":"proc-stem-car-t","jurisdiction_id":"jur-be","procedure_name":"CAR-T Cell Therapy for Hematologic Malignancies","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Hematology"],"diseases":["Relapsed/Refractory B-cell ALL","Diffuse Large B-cell Lymphoma","Multiple Myeloma"],"status":"active"},{"id":"40031bc8-c28f-45d3-be19-95f66942cf6b","procedure_id":"proc-stem-car-t","jurisdiction_id":"jur-se","procedure_name":"CAR-T Cell Therapy for Hematologic Malignancies","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial centre pathway inferred.","eligibility_requirements":"Trial criteria.","provider_requirements":"Trial site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial-only for advanced cell/gene therapy.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: advanced cell/gene therapy without clear commercial authorization → trial-only default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Hematology"],"diseases":["Relapsed/Refractory B-cell ALL","Diffuse Large B-cell Lymphoma","Multiple Myeloma"],"status":"active"},{"id":"e72ef7c7-ddfd-4e3a-a563-e9b7b0275d8d","procedure_id":"proc-stem-car-t","jurisdiction_id":"jur-jp","procedure_name":"CAR-T Cell Therapy for Hematologic Malignancies","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"PMDA / MHLW","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Hematology"],"diseases":["Relapsed/Refractory B-cell ALL","Diffuse Large B-cell Lymphoma","Multiple Myeloma"],"status":"active"},{"id":"33d39fad-d73d-47a1-92fd-b0d3b08df286","procedure_id":"proc-stem-car-t","jurisdiction_id":"jur-sg","procedure_name":"CAR-T Cell Therapy for Hematologic Malignancies","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"HSA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Hematology"],"diseases":["Relapsed/Refractory B-cell ALL","Diffuse Large B-cell Lymphoma","Multiple Myeloma"],"status":"active"},{"id":"371320d3-d2d7-4798-a3d0-6e71a9d44399","procedure_id":"proc-stem-car-t","jurisdiction_id":"jur-cl","procedure_name":"CAR-T Cell Therapy for Hematologic Malignancies","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial centre pathway inferred.","eligibility_requirements":"Trial criteria.","provider_requirements":"Trial site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial-only for advanced cell/gene therapy.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: advanced cell/gene therapy without clear commercial authorization → trial-only default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Hematology"],"diseases":["Relapsed/Refractory B-cell ALL","Diffuse Large B-cell Lymphoma","Multiple Myeloma"],"status":"active"},{"id":"2e53cf41-5e38-407c-81e6-b570070ebf8a","procedure_id":"proc-stem-car-t","jurisdiction_id":"jur-ar","procedure_name":"CAR-T Cell Therapy for Hematologic Malignancies","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial centre pathway inferred.","eligibility_requirements":"Trial criteria.","provider_requirements":"Trial site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial-only for advanced cell/gene therapy.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: advanced cell/gene therapy without clear commercial authorization → trial-only default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Hematology"],"diseases":["Relapsed/Refractory B-cell ALL","Diffuse Large B-cell Lymphoma","Multiple Myeloma"],"status":"active"},{"id":"cc36edbb-e943-4ffe-a933-8844e7c8d290","procedure_id":"proc-stem-car-t","jurisdiction_id":"jur-za","procedure_name":"CAR-T Cell Therapy for Hematologic Malignancies","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial centre pathway inferred.","eligibility_requirements":"Trial criteria.","provider_requirements":"Trial site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial-only for advanced cell/gene therapy.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: advanced cell/gene therapy without clear commercial authorization → trial-only default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Hematology"],"diseases":["Relapsed/Refractory B-cell ALL","Diffuse Large B-cell Lymphoma","Multiple Myeloma"],"status":"active"},{"id":"80b56433-4ce7-4287-baa0-e2310d745a22","procedure_id":"proc-stem-car-t","jurisdiction_id":"jur-ph","procedure_name":"CAR-T Cell Therapy for Hematologic Malignancies","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial centre pathway inferred.","eligibility_requirements":"Trial criteria.","provider_requirements":"Trial site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial-only for advanced cell/gene therapy.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: advanced cell/gene therapy without clear commercial authorization → trial-only default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Hematology"],"diseases":["Relapsed/Refractory B-cell ALL","Diffuse Large B-cell Lymphoma","Multiple Myeloma"],"status":"active"},{"id":"6dcb316e-885a-4420-8cce-8213a0cad668","procedure_id":"proc-stem-car-t","jurisdiction_id":"jur-po","procedure_name":"CAR-T Cell Therapy for Hematologic Malignancies","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial centre pathway inferred.","eligibility_requirements":"Trial criteria.","provider_requirements":"Trial site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial-only for advanced cell/gene therapy.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: advanced cell/gene therapy without clear commercial authorization → trial-only default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Hematology"],"diseases":["Relapsed/Refractory B-cell ALL","Diffuse Large B-cell Lymphoma","Multiple Myeloma"],"status":"active"},{"id":"2302c03b-5d27-48d0-87e5-4784f712b5b7","procedure_id":"proc-stem-car-t","jurisdiction_id":"jur-pt","procedure_name":"CAR-T Cell Therapy for Hematologic Malignancies","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Hematology"],"diseases":["Relapsed/Refractory B-cell ALL","Diffuse Large B-cell Lymphoma","Multiple Myeloma"],"status":"active"},{"id":"64deac96-4436-4294-8c4e-e3d434ca7898","procedure_id":"proc-stem-car-t","jurisdiction_id":"jur-fr","procedure_name":"CAR-T Cell Therapy for Hematologic Malignancies","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"ANSM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Hematology"],"diseases":["Relapsed/Refractory B-cell ALL","Diffuse Large B-cell Lymphoma","Multiple Myeloma"],"status":"active"},{"id":"83bac0f0-a7cc-491d-a841-2e2be0fbd1db","procedure_id":"proc-maid","jurisdiction_id":"jur-us-or","procedure_name":"Medical Assistance in Dying (MAID) / Assisted Death","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"REGULATED_THERAPY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"ASSISTED_DYING","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Default signals regulated assisted dying (Assisted_Suicide_Only). Safeguards, waiting periods, and reporting are typically mandatory.","eligibility_requirements":"Capacity, voluntariness, medical criteria per national/provincial law.","provider_requirements":"Authorized assessors/providers; mandatory reporting.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred regulated MAID pathway may exist — confirm track rules and provider duties.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred from assisted_dying_default=Assisted_Suicide_Only","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Palliative_Care","End_of_Life"],"diseases":["Terminal Illness","Grievous Irremediable Medical Condition","Intolerable Suffering"],"status":"active"},{"id":"9edc09f4-36c6-43a6-b83f-961705d6f007","procedure_id":"proc-maid","jurisdiction_id":"jur-us-co","procedure_name":"Medical Assistance in Dying (MAID) / Assisted Death","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"ASSISTED_DYING","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open MAID pathway under jurisdiction default (pending bills may change this).","eligibility_requirements":"No pathway.","provider_requirements":"No pathway.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: MAID not available under current default posture.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred from assisted_dying_default=Prohibited","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Palliative_Care","End_of_Life"],"diseases":["Terminal Illness","Grievous Irremediable Medical Condition","Intolerable Suffering"],"status":"active"},{"id":"d7566772-b6ee-4cfb-b127-31f193ae8db0","procedure_id":"proc-maid","jurisdiction_id":"jur-us-ca","procedure_name":"Medical Assistance in Dying (MAID) / Assisted Death","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"VARIABLE","modality":"ASSISTED_DYING","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Limited subnational MAID elsewhere in the country — this unit may or may not participate.","eligibility_requirements":"Verify local eligibility statute.","provider_requirements":"Verify local provider authorization.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred unclear at this subnational unit — verify local statute.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred from assisted_dying_default=Limited_Subnational","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Palliative_Care","End_of_Life"],"diseases":["Terminal Illness","Grievous Irremediable Medical Condition","Intolerable Suffering"],"status":"active"},{"id":"12a42d05-9cd6-4177-8adb-c02b7f15fb99","procedure_id":"proc-maid","jurisdiction_id":"jur-us-tx","procedure_name":"Medical Assistance in Dying (MAID) / Assisted Death","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"VARIABLE","modality":"ASSISTED_DYING","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Limited subnational MAID elsewhere in the country — this unit may or may not participate.","eligibility_requirements":"Verify local eligibility statute.","provider_requirements":"Verify local provider authorization.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred unclear at this subnational unit — verify local statute.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred from assisted_dying_default=Limited_Subnational","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Palliative_Care","End_of_Life"],"diseases":["Terminal Illness","Grievous Irremediable Medical Condition","Intolerable Suffering"],"status":"active"},{"id":"b7bc10b3-2a82-4974-b0d3-a2cfac11a24b","procedure_id":"proc-maid","jurisdiction_id":"jur-us-fl","procedure_name":"Medical Assistance in Dying (MAID) / Assisted Death","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"VARIABLE","modality":"ASSISTED_DYING","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Limited subnational MAID elsewhere in the country — this unit may or may not participate.","eligibility_requirements":"Verify local eligibility statute.","provider_requirements":"Verify local provider authorization.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred unclear at this subnational unit — verify local statute.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred from assisted_dying_default=Limited_Subnational","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Palliative_Care","End_of_Life"],"diseases":["Terminal Illness","Grievous Irremediable Medical Condition","Intolerable Suffering"],"status":"active"},{"id":"4c54482c-23aa-486c-be49-1eafc5b1d386","procedure_id":"proc-maid","jurisdiction_id":"jur-hn-prospera","procedure_name":"Medical Assistance in Dying (MAID) / Assisted Death","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"ASSISTED_DYING","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open MAID pathway under jurisdiction default (pending bills may change this).","eligibility_requirements":"No pathway.","provider_requirements":"No pathway.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: MAID not available under current default posture.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred from assisted_dying_default=Prohibited","regulatory_authority":"Próspera ZEDE health rules (contested)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Palliative_Care","End_of_Life"],"diseases":["Terminal Illness","Grievous Irremediable Medical Condition","Intolerable Suffering"],"status":"active"},{"id":"407c68ff-6027-4dbd-8fc5-a54916be4ad4","procedure_id":"proc-maid","jurisdiction_id":"jur-nl","procedure_name":"Medical Assistance in Dying (MAID) / Assisted Death","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"REGULATED_THERAPY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"ASSISTED_DYING","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Default signals regulated assisted dying (Euthanasia_And_Assisted_Suicide). Safeguards, waiting periods, and reporting are typically mandatory.","eligibility_requirements":"Capacity, voluntariness, medical criteria per national/provincial law.","provider_requirements":"Authorized assessors/providers; mandatory reporting.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred regulated MAID pathway may exist — confirm track rules and provider duties.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred from assisted_dying_default=Euthanasia_And_Assisted_Suicide","regulatory_authority":"MEB / IGJ","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Palliative_Care","End_of_Life"],"diseases":["Terminal Illness","Grievous Irremediable Medical Condition","Intolerable Suffering"],"status":"active"},{"id":"70c853ba-c87d-4630-b53f-07efc3cd100c","procedure_id":"proc-maid","jurisdiction_id":"jur-es","procedure_name":"Medical Assistance in Dying (MAID) / Assisted Death","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"REGULATED_THERAPY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"ASSISTED_DYING","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Default signals regulated assisted dying (Euthanasia_And_Assisted_Suicide). Safeguards, waiting periods, and reporting are typically mandatory.","eligibility_requirements":"Capacity, voluntariness, medical criteria per national/provincial law.","provider_requirements":"Authorized assessors/providers; mandatory reporting.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred regulated MAID pathway may exist — confirm track rules and provider duties.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred from assisted_dying_default=Euthanasia_And_Assisted_Suicide","regulatory_authority":"AEMPS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Palliative_Care","End_of_Life"],"diseases":["Terminal Illness","Grievous Irremediable Medical Condition","Intolerable Suffering"],"status":"active"},{"id":"4e35326f-42e6-4ac1-b651-4881fd90d2c7","procedure_id":"proc-maid","jurisdiction_id":"jur-gr","procedure_name":"Medical Assistance in Dying (MAID) / Assisted Death","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"ASSISTED_DYING","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open MAID pathway under jurisdiction default (pending bills may change this).","eligibility_requirements":"No pathway.","provider_requirements":"No pathway.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: MAID not available under current default posture.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred from assisted_dying_default=Prohibited","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Palliative_Care","End_of_Life"],"diseases":["Terminal Illness","Grievous Irremediable Medical Condition","Intolerable Suffering"],"status":"active"},{"id":"33baa239-d106-4168-b242-325f7efe6290","procedure_id":"proc-maid","jurisdiction_id":"jur-be","procedure_name":"Medical Assistance in Dying (MAID) / Assisted Death","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"REGULATED_THERAPY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"ASSISTED_DYING","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Default signals regulated assisted dying (Euthanasia_And_Assisted_Suicide). Safeguards, waiting periods, and reporting are typically mandatory.","eligibility_requirements":"Capacity, voluntariness, medical criteria per national/provincial law.","provider_requirements":"Authorized assessors/providers; mandatory reporting.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred regulated MAID pathway may exist — confirm track rules and provider duties.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred from assisted_dying_default=Euthanasia_And_Assisted_Suicide","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Palliative_Care","End_of_Life"],"diseases":["Terminal Illness","Grievous Irremediable Medical Condition","Intolerable Suffering"],"status":"active"},{"id":"8380ae77-d2a2-40db-8121-d543f1f0db38","procedure_id":"proc-maid","jurisdiction_id":"jur-pt","procedure_name":"Medical Assistance in Dying (MAID) / Assisted Death","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"ASSISTED_DYING","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open MAID pathway under jurisdiction default (pending bills may change this).","eligibility_requirements":"No pathway.","provider_requirements":"No pathway.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: MAID not available under current default posture.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred from assisted_dying_default=Pending_Legislation","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Palliative_Care","End_of_Life"],"diseases":["Terminal Illness","Grievous Irremediable Medical Condition","Intolerable Suffering"],"status":"active"},{"id":"b271bd30-aaef-4154-8e2f-048e3671ad06","procedure_id":"proc-peptide-bpc","jurisdiction_id":"jur-us-or","procedure_name":"BPC-157 Pentadecapeptide Therapy","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal","Orthopedic","Wound_Healing"],"diseases":["Tendon/Ligament Injury","Inflammatory Bowel Disease","Gastric Ulcer","Wound Healing Impairment"],"status":"active"},{"id":"7cadc6a3-d0c5-4454-94cc-70e0cf5ba997","procedure_id":"proc-peptide-bpc","jurisdiction_id":"jur-us-co","procedure_name":"BPC-157 Pentadecapeptide Therapy","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal","Orthopedic","Wound_Healing"],"diseases":["Tendon/Ligament Injury","Inflammatory Bowel Disease","Gastric Ulcer","Wound Healing Impairment"],"status":"active"},{"id":"f0c80c0c-8890-435f-ac2b-5ca683249e4c","procedure_id":"proc-peptide-bpc","jurisdiction_id":"jur-us-ca","procedure_name":"BPC-157 Pentadecapeptide Therapy","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal","Orthopedic","Wound_Healing"],"diseases":["Tendon/Ligament Injury","Inflammatory Bowel Disease","Gastric Ulcer","Wound Healing Impairment"],"status":"active"},{"id":"41dd6f76-fa4c-4695-a201-f6eabbb0e660","procedure_id":"proc-peptide-bpc","jurisdiction_id":"jur-us-tx","procedure_name":"BPC-157 Pentadecapeptide Therapy","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal","Orthopedic","Wound_Healing"],"diseases":["Tendon/Ligament Injury","Inflammatory Bowel Disease","Gastric Ulcer","Wound Healing Impairment"],"status":"active"},{"id":"e96f44af-87c2-410e-a7bf-d28cb94112aa","procedure_id":"proc-peptide-bpc","jurisdiction_id":"jur-us-fl","procedure_name":"BPC-157 Pentadecapeptide Therapy","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal","Orthopedic","Wound_Healing"],"diseases":["Tendon/Ligament Injury","Inflammatory Bowel Disease","Gastric Ulcer","Wound Healing Impairment"],"status":"active"},{"id":"d790c808-bb12-4af2-a7fe-65f3f918775d","procedure_id":"proc-peptide-bpc","jurisdiction_id":"jur-jm","procedure_name":"BPC-157 Pentadecapeptide Therapy","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal","Orthopedic","Wound_Healing"],"diseases":["Tendon/Ligament Injury","Inflammatory Bowel Disease","Gastric Ulcer","Wound Healing Impairment"],"status":"active"},{"id":"7bcc74db-109a-4686-85e4-631ff0f33e4e","procedure_id":"proc-peptide-bpc","jurisdiction_id":"jur-tu","procedure_name":"BPC-157 Pentadecapeptide Therapy","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal","Orthopedic","Wound_Healing"],"diseases":["Tendon/Ligament Injury","Inflammatory Bowel Disease","Gastric Ulcer","Wound Healing Impairment"],"status":"active"},{"id":"e985164d-005f-49cd-a3d3-abb9f0055e20","procedure_id":"proc-peptide-bpc","jurisdiction_id":"jur-in","procedure_name":"BPC-157 Pentadecapeptide Therapy","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"COMPOUNDING","oversight_quality":"MINIMAL","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Still may violate advertising/medicine laws. Bulk substance status is critical.","eligibility_requirements":"Medical justification documentation if any.","provider_requirements":"Prescriber + compounder compliance uncertain.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray compounding climate — high legal risk even if local practice is common.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide + relatively open compounding climate → gray compounding risk.","regulatory_authority":"CDSCO","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal","Orthopedic","Wound_Healing"],"diseases":["Tendon/Ligament Injury","Inflammatory Bowel Disease","Gastric Ulcer","Wound Healing Impairment"],"status":"active"},{"id":"f89b7d5f-65bf-499d-8876-2a79bd567716","procedure_id":"proc-peptide-bpc","jurisdiction_id":"jur-br","procedure_name":"BPC-157 Pentadecapeptide Therapy","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"ANVISA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal","Orthopedic","Wound_Healing"],"diseases":["Tendon/Ligament Injury","Inflammatory Bowel Disease","Gastric Ulcer","Wound Healing Impairment"],"status":"active"},{"id":"e5b2b643-b9df-4c10-8e99-371b9070ae7d","procedure_id":"proc-peptide-bpc","jurisdiction_id":"jur-cr","procedure_name":"BPC-157 Pentadecapeptide Therapy","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal","Orthopedic","Wound_Healing"],"diseases":["Tendon/Ligament Injury","Inflammatory Bowel Disease","Gastric Ulcer","Wound Healing Impairment"],"status":"active"},{"id":"6e74db0d-6951-404a-8b34-2e392b3b9457","procedure_id":"proc-peptide-bpc","jurisdiction_id":"jur-gr","procedure_name":"BPC-157 Pentadecapeptide Therapy","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal","Orthopedic","Wound_Healing"],"diseases":["Tendon/Ligament Injury","Inflammatory Bowel Disease","Gastric Ulcer","Wound Healing Impairment"],"status":"active"},{"id":"d3b4536b-0992-4263-b4d6-390ded5d42aa","procedure_id":"proc-peptide-bpc","jurisdiction_id":"jur-cl","procedure_name":"BPC-157 Pentadecapeptide Therapy","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal","Orthopedic","Wound_Healing"],"diseases":["Tendon/Ligament Injury","Inflammatory Bowel Disease","Gastric Ulcer","Wound Healing Impairment"],"status":"active"},{"id":"18e1853f-e7fe-4f51-a48c-2073b715a279","procedure_id":"proc-peptide-bpc","jurisdiction_id":"jur-ar","procedure_name":"BPC-157 Pentadecapeptide Therapy","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal","Orthopedic","Wound_Healing"],"diseases":["Tendon/Ligament Injury","Inflammatory Bowel Disease","Gastric Ulcer","Wound Healing Impairment"],"status":"active"},{"id":"3872d165-df9b-41fc-b140-812d2f84f80f","procedure_id":"proc-peptide-bpc","jurisdiction_id":"jur-za","procedure_name":"BPC-157 Pentadecapeptide Therapy","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal","Orthopedic","Wound_Healing"],"diseases":["Tendon/Ligament Injury","Inflammatory Bowel Disease","Gastric Ulcer","Wound Healing Impairment"],"status":"active"},{"id":"3ede38f6-6014-41ea-a256-aeba8a0dcf86","procedure_id":"proc-peptide-bpc","jurisdiction_id":"jur-ph","procedure_name":"BPC-157 Pentadecapeptide Therapy","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal","Orthopedic","Wound_Healing"],"diseases":["Tendon/Ligament Injury","Inflammatory Bowel Disease","Gastric Ulcer","Wound Healing Impairment"],"status":"active"},{"id":"f001030e-c6ae-4973-8925-f3535542309b","procedure_id":"proc-peptide-bpc","jurisdiction_id":"jur-po","procedure_name":"BPC-157 Pentadecapeptide Therapy","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal","Orthopedic","Wound_Healing"],"diseases":["Tendon/Ligament Injury","Inflammatory Bowel Disease","Gastric Ulcer","Wound Healing Impairment"],"status":"active"},{"id":"b24e4e13-bbf6-4d1b-992b-7da5db0a3e56","procedure_id":"proc-peptide-bpc","jurisdiction_id":"jur-pt","procedure_name":"BPC-157 Pentadecapeptide Therapy","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal","Orthopedic","Wound_Healing"],"diseases":["Tendon/Ligament Injury","Inflammatory Bowel Disease","Gastric Ulcer","Wound Healing Impairment"],"status":"active"},{"id":"0af41843-2ab5-4b33-96f0-5149e113bd2b","procedure_id":"proc-peptide-thymosin","jurisdiction_id":"jur-us-or","procedure_name":"Thymosin Alpha-1 (Thymalfasin) Immunomodulation","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Immunology","Chronic_Infection"],"diseases":["Chronic Hepatitis B","Chronic Hepatitis C","Immune Deficiency","Chronic Viral Infection"],"status":"active"},{"id":"153eb3bb-704a-482d-bdee-42683b27a7d2","procedure_id":"proc-peptide-thymosin","jurisdiction_id":"jur-us-co","procedure_name":"Thymosin Alpha-1 (Thymalfasin) Immunomodulation","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Immunology","Chronic_Infection"],"diseases":["Chronic Hepatitis B","Chronic Hepatitis C","Immune Deficiency","Chronic Viral Infection"],"status":"active"},{"id":"0fa10b87-ced1-4520-b524-9aa4b6b702f0","procedure_id":"proc-peptide-thymosin","jurisdiction_id":"jur-us-ca","procedure_name":"Thymosin Alpha-1 (Thymalfasin) Immunomodulation","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Immunology","Chronic_Infection"],"diseases":["Chronic Hepatitis B","Chronic Hepatitis C","Immune Deficiency","Chronic Viral Infection"],"status":"active"},{"id":"c3672656-f6d6-4941-9c82-9830c4b05b2b","procedure_id":"proc-peptide-thymosin","jurisdiction_id":"jur-us-tx","procedure_name":"Thymosin Alpha-1 (Thymalfasin) Immunomodulation","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Immunology","Chronic_Infection"],"diseases":["Chronic Hepatitis B","Chronic Hepatitis C","Immune Deficiency","Chronic Viral Infection"],"status":"active"},{"id":"02acb247-5493-4324-a1ca-338761c856a4","procedure_id":"proc-peptide-thymosin","jurisdiction_id":"jur-us-fl","procedure_name":"Thymosin Alpha-1 (Thymalfasin) Immunomodulation","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Immunology","Chronic_Infection"],"diseases":["Chronic Hepatitis B","Chronic Hepatitis C","Immune Deficiency","Chronic Viral Infection"],"status":"active"},{"id":"0f604b0f-9124-46cb-9cc7-960f084b57ec","procedure_id":"proc-peptide-thymosin","jurisdiction_id":"jur-au","procedure_name":"Thymosin Alpha-1 (Thymalfasin) Immunomodulation","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"TGA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Immunology","Chronic_Infection"],"diseases":["Chronic Hepatitis B","Chronic Hepatitis C","Immune Deficiency","Chronic Viral Infection"],"status":"active"},{"id":"a145b0d7-e801-4901-8fc6-55eb6d69e3e6","procedure_id":"proc-peptide-thymosin","jurisdiction_id":"jur-ch","procedure_name":"Thymosin Alpha-1 (Thymalfasin) Immunomodulation","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"Swissmedic","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Immunology","Chronic_Infection"],"diseases":["Chronic Hepatitis B","Chronic Hepatitis C","Immune Deficiency","Chronic Viral Infection"],"status":"active"},{"id":"7a5db1f6-6700-4504-99b2-84955a20a032","procedure_id":"proc-peptide-thymosin","jurisdiction_id":"jur-ca","procedure_name":"Thymosin Alpha-1 (Thymalfasin) Immunomodulation","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"Health Canada","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Immunology","Chronic_Infection"],"diseases":["Chronic Hepatitis B","Chronic Hepatitis C","Immune Deficiency","Chronic Viral Infection"],"status":"active"},{"id":"b03b39a7-0525-48f6-b90b-d95b9456f403","procedure_id":"proc-peptide-thymosin","jurisdiction_id":"jur-hn-prospera","procedure_name":"Thymosin Alpha-1 (Thymalfasin) Immunomodulation","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"COMPOUNDING","oversight_quality":"MINIMAL","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Still may violate advertising/medicine laws. Bulk substance status is critical.","eligibility_requirements":"Medical justification documentation if any.","provider_requirements":"Prescriber + compounder compliance uncertain.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray compounding climate — high legal risk even if local practice is common.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide + relatively open compounding climate → gray compounding risk.","regulatory_authority":"Próspera ZEDE health rules (contested)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Immunology","Chronic_Infection"],"diseases":["Chronic Hepatitis B","Chronic Hepatitis C","Immune Deficiency","Chronic Viral Infection"],"status":"active"},{"id":"e703c1ba-abb4-4c8f-ab20-d369f97c78a0","procedure_id":"proc-peptide-thymosin","jurisdiction_id":"jur-nl","procedure_name":"Thymosin Alpha-1 (Thymalfasin) Immunomodulation","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"MEB / IGJ","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Immunology","Chronic_Infection"],"diseases":["Chronic Hepatitis B","Chronic Hepatitis C","Immune Deficiency","Chronic Viral Infection"],"status":"active"},{"id":"025119db-ef29-46c2-ba53-32f540d85cbe","procedure_id":"proc-peptide-thymosin","jurisdiction_id":"jur-uk","procedure_name":"Thymosin Alpha-1 (Thymalfasin) Immunomodulation","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"MHRA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Immunology","Chronic_Infection"],"diseases":["Chronic Hepatitis B","Chronic Hepatitis C","Immune Deficiency","Chronic Viral Infection"],"status":"active"},{"id":"fb4c5989-b65c-4713-b4c9-e2824340709a","procedure_id":"proc-peptide-thymosin","jurisdiction_id":"jur-il","procedure_name":"Thymosin Alpha-1 (Thymalfasin) Immunomodulation","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Immunology","Chronic_Infection"],"diseases":["Chronic Hepatitis B","Chronic Hepatitis C","Immune Deficiency","Chronic Viral Infection"],"status":"active"},{"id":"b176a61c-3097-44af-984c-9930193b22ac","procedure_id":"proc-peptide-thymosin","jurisdiction_id":"jur-jm","procedure_name":"Thymosin Alpha-1 (Thymalfasin) Immunomodulation","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Immunology","Chronic_Infection"],"diseases":["Chronic Hepatitis B","Chronic Hepatitis C","Immune Deficiency","Chronic Viral Infection"],"status":"active"},{"id":"c768d5b7-d06c-46b3-a156-e9210bf71195","procedure_id":"proc-peptide-thymosin","jurisdiction_id":"jur-th","procedure_name":"Thymosin Alpha-1 (Thymalfasin) Immunomodulation","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"Thai FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Immunology","Chronic_Infection"],"diseases":["Chronic Hepatitis B","Chronic Hepatitis C","Immune Deficiency","Chronic Viral Infection"],"status":"active"},{"id":"4d11e7e0-90f5-41e2-a874-17327fe4a3e3","procedure_id":"proc-peptide-thymosin","jurisdiction_id":"jur-es","procedure_name":"Thymosin Alpha-1 (Thymalfasin) Immunomodulation","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"AEMPS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Immunology","Chronic_Infection"],"diseases":["Chronic Hepatitis B","Chronic Hepatitis C","Immune Deficiency","Chronic Viral Infection"],"status":"active"},{"id":"0290ee66-db54-4d8e-9571-ebf1b685a20a","procedure_id":"proc-peptide-thymosin","jurisdiction_id":"jur-tu","procedure_name":"Thymosin Alpha-1 (Thymalfasin) Immunomodulation","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Immunology","Chronic_Infection"],"diseases":["Chronic Hepatitis B","Chronic Hepatitis C","Immune Deficiency","Chronic Viral Infection"],"status":"active"},{"id":"0a5581b1-88e7-497c-bfc5-a6270242d3f8","procedure_id":"proc-peptide-thymosin","jurisdiction_id":"jur-br","procedure_name":"Thymosin Alpha-1 (Thymalfasin) Immunomodulation","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"ANVISA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Immunology","Chronic_Infection"],"diseases":["Chronic Hepatitis B","Chronic Hepatitis C","Immune Deficiency","Chronic Viral Infection"],"status":"active"},{"id":"f1d428b7-de11-4cb9-9865-b01c391be19f","procedure_id":"proc-peptide-thymosin","jurisdiction_id":"jur-cr","procedure_name":"Thymosin Alpha-1 (Thymalfasin) Immunomodulation","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Immunology","Chronic_Infection"],"diseases":["Chronic Hepatitis B","Chronic Hepatitis C","Immune Deficiency","Chronic Viral Infection"],"status":"active"},{"id":"a2a71899-2045-420c-9c92-d1ae1edbd9a5","procedure_id":"proc-peptide-thymosin","jurisdiction_id":"jur-uae","procedure_name":"Thymosin Alpha-1 (Thymalfasin) Immunomodulation","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Immunology","Chronic_Infection"],"diseases":["Chronic Hepatitis B","Chronic Hepatitis C","Immune Deficiency","Chronic Viral Infection"],"status":"active"},{"id":"8ce4e337-e0c7-42f7-a01f-8e711dc7fa2e","procedure_id":"proc-peptide-thymosin","jurisdiction_id":"jur-kr","procedure_name":"Thymosin Alpha-1 (Thymalfasin) Immunomodulation","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"MFDS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Immunology","Chronic_Infection"],"diseases":["Chronic Hepatitis B","Chronic Hepatitis C","Immune Deficiency","Chronic Viral Infection"],"status":"active"},{"id":"ba8e8dd1-6f62-4414-80fa-a1b4c1da09aa","procedure_id":"proc-peptide-thymosin","jurisdiction_id":"jur-gr","procedure_name":"Thymosin Alpha-1 (Thymalfasin) Immunomodulation","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Immunology","Chronic_Infection"],"diseases":["Chronic Hepatitis B","Chronic Hepatitis C","Immune Deficiency","Chronic Viral Infection"],"status":"active"},{"id":"c37e7919-94c9-4f57-8652-4ff977ef9216","procedure_id":"proc-peptide-thymosin","jurisdiction_id":"jur-be","procedure_name":"Thymosin Alpha-1 (Thymalfasin) Immunomodulation","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Immunology","Chronic_Infection"],"diseases":["Chronic Hepatitis B","Chronic Hepatitis C","Immune Deficiency","Chronic Viral Infection"],"status":"active"},{"id":"3f2afb28-e133-4cee-9d62-4cd6437bf86a","procedure_id":"proc-peptide-thymosin","jurisdiction_id":"jur-se","procedure_name":"Thymosin Alpha-1 (Thymalfasin) Immunomodulation","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Immunology","Chronic_Infection"],"diseases":["Chronic Hepatitis B","Chronic Hepatitis C","Immune Deficiency","Chronic Viral Infection"],"status":"active"},{"id":"d4fe6a87-2f95-485e-9f68-3826226747d6","procedure_id":"proc-peptide-thymosin","jurisdiction_id":"jur-jp","procedure_name":"Thymosin Alpha-1 (Thymalfasin) Immunomodulation","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"PMDA / MHLW","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Immunology","Chronic_Infection"],"diseases":["Chronic Hepatitis B","Chronic Hepatitis C","Immune Deficiency","Chronic Viral Infection"],"status":"active"},{"id":"6a80cbca-f53f-4771-8010-d96e4d67b31e","procedure_id":"proc-peptide-thymosin","jurisdiction_id":"jur-cl","procedure_name":"Thymosin Alpha-1 (Thymalfasin) Immunomodulation","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Immunology","Chronic_Infection"],"diseases":["Chronic Hepatitis B","Chronic Hepatitis C","Immune Deficiency","Chronic Viral Infection"],"status":"active"},{"id":"b10d4753-e5ac-414f-8b26-9bfc3ea237c4","procedure_id":"proc-peptide-thymosin","jurisdiction_id":"jur-za","procedure_name":"Thymosin Alpha-1 (Thymalfasin) Immunomodulation","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Immunology","Chronic_Infection"],"diseases":["Chronic Hepatitis B","Chronic Hepatitis C","Immune Deficiency","Chronic Viral Infection"],"status":"active"},{"id":"305300aa-3d90-4b0b-bc2c-7c3264bb66b9","procedure_id":"proc-peptide-thymosin","jurisdiction_id":"jur-po","procedure_name":"Thymosin Alpha-1 (Thymalfasin) Immunomodulation","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Immunology","Chronic_Infection"],"diseases":["Chronic Hepatitis B","Chronic Hepatitis C","Immune Deficiency","Chronic Viral Infection"],"status":"active"},{"id":"bc20780d-de59-47d0-9d21-106f954de3d6","procedure_id":"proc-peptide-thymosin","jurisdiction_id":"jur-pt","procedure_name":"Thymosin Alpha-1 (Thymalfasin) Immunomodulation","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Immunology","Chronic_Infection"],"diseases":["Chronic Hepatitis B","Chronic Hepatitis C","Immune Deficiency","Chronic Viral Infection"],"status":"active"},{"id":"5246d455-ab28-4d98-b856-7068d3807be2","procedure_id":"proc-peptide-thymosin","jurisdiction_id":"jur-fr","procedure_name":"Thymosin Alpha-1 (Thymalfasin) Immunomodulation","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"ANSM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Immunology","Chronic_Infection"],"diseases":["Chronic Hepatitis B","Chronic Hepatitis C","Immune Deficiency","Chronic Viral Infection"],"status":"active"},{"id":"825569e4-7536-4d09-9828-b77df892be10","procedure_id":"proc-repro-ivf","jurisdiction_id":"jur-us-or","procedure_name":"In Vitro Fertilization (IVF) with Genetic Testing (PGT)","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Infertility","Recurrent Pregnancy Loss","Genetic Carrier Status"],"status":"active"},{"id":"c34c769c-18af-4061-b4ae-f6ebd7aee9f7","procedure_id":"proc-repro-ivf","jurisdiction_id":"jur-us-co","procedure_name":"In Vitro Fertilization (IVF) with Genetic Testing (PGT)","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Infertility","Recurrent Pregnancy Loss","Genetic Carrier Status"],"status":"active"},{"id":"9fe37d61-82f6-4813-83e5-c599db51e264","procedure_id":"proc-repro-ivf","jurisdiction_id":"jur-us-ca","procedure_name":"In Vitro Fertilization (IVF) with Genetic Testing (PGT)","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Infertility","Recurrent Pregnancy Loss","Genetic Carrier Status"],"status":"active"},{"id":"9b871a27-00b3-40ab-8ad5-5017e809bf7e","procedure_id":"proc-repro-ivf","jurisdiction_id":"jur-us-tx","procedure_name":"In Vitro Fertilization (IVF) with Genetic Testing (PGT)","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Infertility","Recurrent Pregnancy Loss","Genetic Carrier Status"],"status":"active"},{"id":"53464494-2bec-4a91-a31e-2324cc934eac","procedure_id":"proc-repro-ivf","jurisdiction_id":"jur-us-fl","procedure_name":"In Vitro Fertilization (IVF) with Genetic Testing (PGT)","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Infertility","Recurrent Pregnancy Loss","Genetic Carrier Status"],"status":"active"},{"id":"823da417-245b-4f78-afc4-a135ee9177f5","procedure_id":"proc-repro-ivf","jurisdiction_id":"jur-au","procedure_name":"In Vitro Fertilization (IVF) with Genetic Testing (PGT)","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"TGA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Infertility","Recurrent Pregnancy Loss","Genetic Carrier Status"],"status":"active"},{"id":"780435d4-b213-40ea-a6b5-0dc58341e7a8","procedure_id":"proc-repro-ivf","jurisdiction_id":"jur-ch","procedure_name":"In Vitro Fertilization (IVF) with Genetic Testing (PGT)","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"Swissmedic","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Infertility","Recurrent Pregnancy Loss","Genetic Carrier Status"],"status":"active"},{"id":"5f85aea2-94ae-42b2-9eee-5163b2c29a88","procedure_id":"proc-repro-ivf","jurisdiction_id":"jur-ca","procedure_name":"In Vitro Fertilization (IVF) with Genetic Testing (PGT)","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"Health Canada","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Infertility","Recurrent Pregnancy Loss","Genetic Carrier Status"],"status":"active"},{"id":"3f10e09b-f406-4b93-833c-4b2f8211a983","procedure_id":"proc-repro-ivf","jurisdiction_id":"jur-hn-prospera","procedure_name":"In Vitro Fertilization (IVF) with Genetic Testing (PGT)","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"Próspera ZEDE health rules (contested)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Infertility","Recurrent Pregnancy Loss","Genetic Carrier Status"],"status":"active"},{"id":"6d65ecf2-5f70-405c-953b-dd7385f07797","procedure_id":"proc-repro-ivf","jurisdiction_id":"jur-nl","procedure_name":"In Vitro Fertilization (IVF) with Genetic Testing (PGT)","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"MEB / IGJ","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Infertility","Recurrent Pregnancy Loss","Genetic Carrier Status"],"status":"active"},{"id":"261b3f8e-39b5-4976-aa6f-cb4cc2cb1f77","procedure_id":"proc-repro-ivf","jurisdiction_id":"jur-de","procedure_name":"In Vitro Fertilization (IVF) with Genetic Testing (PGT)","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"BfArM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Infertility","Recurrent Pregnancy Loss","Genetic Carrier Status"],"status":"active"},{"id":"bec716fd-a567-4977-ac76-aa85ab5eac5a","procedure_id":"proc-repro-ivf","jurisdiction_id":"jur-uk","procedure_name":"In Vitro Fertilization (IVF) with Genetic Testing (PGT)","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"MHRA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Infertility","Recurrent Pregnancy Loss","Genetic Carrier Status"],"status":"active"},{"id":"b6d1f999-ecda-4344-9580-8dcf6ea11825","procedure_id":"proc-repro-ivf","jurisdiction_id":"jur-il","procedure_name":"In Vitro Fertilization (IVF) with Genetic Testing (PGT)","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Infertility","Recurrent Pregnancy Loss","Genetic Carrier Status"],"status":"active"},{"id":"31d6d2b1-4e38-44bf-bcba-889f41537251","procedure_id":"proc-repro-ivf","jurisdiction_id":"jur-jm","procedure_name":"In Vitro Fertilization (IVF) with Genetic Testing (PGT)","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Infertility","Recurrent Pregnancy Loss","Genetic Carrier Status"],"status":"active"},{"id":"f8c04cec-3222-4dc9-9122-e2c27969cc35","procedure_id":"proc-repro-ivf","jurisdiction_id":"jur-th","procedure_name":"In Vitro Fertilization (IVF) with Genetic Testing (PGT)","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"Thai FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Infertility","Recurrent Pregnancy Loss","Genetic Carrier Status"],"status":"active"},{"id":"2807ffd8-0fe1-45cb-8ed3-76908eda3e53","procedure_id":"proc-repro-ivf","jurisdiction_id":"jur-es","procedure_name":"In Vitro Fertilization (IVF) with Genetic Testing (PGT)","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"AEMPS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Infertility","Recurrent Pregnancy Loss","Genetic Carrier Status"],"status":"active"},{"id":"b453ed2d-ff37-4b1c-8650-6ddd93ca973a","procedure_id":"proc-repro-ivf","jurisdiction_id":"jur-tu","procedure_name":"In Vitro Fertilization (IVF) with Genetic Testing (PGT)","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Infertility","Recurrent Pregnancy Loss","Genetic Carrier Status"],"status":"active"},{"id":"31b9cfad-c961-4be2-abea-9010a8154476","procedure_id":"proc-repro-ivf","jurisdiction_id":"jur-in","procedure_name":"In Vitro Fertilization (IVF) with Genetic Testing (PGT)","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"CDSCO","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Infertility","Recurrent Pregnancy Loss","Genetic Carrier Status"],"status":"active"},{"id":"59a9e0d0-e779-45fb-a87d-73d831a4b7e7","procedure_id":"proc-repro-ivf","jurisdiction_id":"jur-br","procedure_name":"In Vitro Fertilization (IVF) with Genetic Testing (PGT)","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"ANVISA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Infertility","Recurrent Pregnancy Loss","Genetic Carrier Status"],"status":"active"},{"id":"da55d793-bc54-4674-baee-06fbcb7cdae9","procedure_id":"proc-repro-ivf","jurisdiction_id":"jur-cr","procedure_name":"In Vitro Fertilization (IVF) with Genetic Testing (PGT)","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Infertility","Recurrent Pregnancy Loss","Genetic Carrier Status"],"status":"active"},{"id":"021abc94-ad0d-4f28-a3b5-c9e5f1da3114","procedure_id":"proc-repro-ivf","jurisdiction_id":"jur-uae","procedure_name":"In Vitro Fertilization (IVF) with Genetic Testing (PGT)","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Infertility","Recurrent Pregnancy Loss","Genetic Carrier Status"],"status":"active"},{"id":"da38e24d-aaf9-4795-8a24-df615ff2c2a7","procedure_id":"proc-repro-ivf","jurisdiction_id":"jur-kr","procedure_name":"In Vitro Fertilization (IVF) with Genetic Testing (PGT)","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"MFDS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Infertility","Recurrent Pregnancy Loss","Genetic Carrier Status"],"status":"active"},{"id":"646b4606-dedc-418c-a6ce-df81bd324bc0","procedure_id":"proc-repro-ivf","jurisdiction_id":"jur-gr","procedure_name":"In Vitro Fertilization (IVF) with Genetic Testing (PGT)","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Infertility","Recurrent Pregnancy Loss","Genetic Carrier Status"],"status":"active"},{"id":"a96e5145-c67b-4842-9177-dba4fbf8d2fe","procedure_id":"proc-repro-ivf","jurisdiction_id":"jur-be","procedure_name":"In Vitro Fertilization (IVF) with Genetic Testing (PGT)","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Infertility","Recurrent Pregnancy Loss","Genetic Carrier Status"],"status":"active"},{"id":"9825ca31-bb66-4ca1-b362-dff82f0a34dd","procedure_id":"proc-repro-ivf","jurisdiction_id":"jur-se","procedure_name":"In Vitro Fertilization (IVF) with Genetic Testing (PGT)","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Infertility","Recurrent Pregnancy Loss","Genetic Carrier Status"],"status":"active"},{"id":"f9947b5b-1980-485a-960a-058518736bcb","procedure_id":"proc-repro-ivf","jurisdiction_id":"jur-jp","procedure_name":"In Vitro Fertilization (IVF) with Genetic Testing (PGT)","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"PMDA / MHLW","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Infertility","Recurrent Pregnancy Loss","Genetic Carrier Status"],"status":"active"},{"id":"739d0175-3866-4667-9ec1-9a36405346a2","procedure_id":"proc-repro-ivf","jurisdiction_id":"jur-sg","procedure_name":"In Vitro Fertilization (IVF) with Genetic Testing (PGT)","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"HSA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Infertility","Recurrent Pregnancy Loss","Genetic Carrier Status"],"status":"active"},{"id":"02fc5642-6a16-458b-af32-12da3c3a5963","procedure_id":"proc-repro-ivf","jurisdiction_id":"jur-cl","procedure_name":"In Vitro Fertilization (IVF) with Genetic Testing (PGT)","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Infertility","Recurrent Pregnancy Loss","Genetic Carrier Status"],"status":"active"},{"id":"ab40d20a-f9f1-40e0-af06-37a18d7a7f35","procedure_id":"proc-repro-ivf","jurisdiction_id":"jur-ar","procedure_name":"In Vitro Fertilization (IVF) with Genetic Testing (PGT)","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Infertility","Recurrent Pregnancy Loss","Genetic Carrier Status"],"status":"active"},{"id":"34240092-6c6d-4d7a-b0eb-4fee62a6a36b","procedure_id":"proc-repro-ivf","jurisdiction_id":"jur-za","procedure_name":"In Vitro Fertilization (IVF) with Genetic Testing (PGT)","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Infertility","Recurrent Pregnancy Loss","Genetic Carrier Status"],"status":"active"},{"id":"d605d4d1-2ccb-4489-870d-ad59b27c0979","procedure_id":"proc-repro-ivf","jurisdiction_id":"jur-ph","procedure_name":"In Vitro Fertilization (IVF) with Genetic Testing (PGT)","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Infertility","Recurrent Pregnancy Loss","Genetic Carrier Status"],"status":"active"},{"id":"7e4457fb-e882-4182-a8c6-e1fc0f882301","procedure_id":"proc-repro-ivf","jurisdiction_id":"jur-po","procedure_name":"In Vitro Fertilization (IVF) with Genetic Testing (PGT)","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Infertility","Recurrent Pregnancy Loss","Genetic Carrier Status"],"status":"active"},{"id":"fb2ee26c-4616-455e-8491-343bc4f2ee8e","procedure_id":"proc-repro-ivf","jurisdiction_id":"jur-pt","procedure_name":"In Vitro Fertilization (IVF) with Genetic Testing (PGT)","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Infertility","Recurrent Pregnancy Loss","Genetic Carrier Status"],"status":"active"},{"id":"184bee92-e787-44d8-952d-18f8b53e54fb","procedure_id":"proc-repro-ivf","jurisdiction_id":"jur-fr","procedure_name":"In Vitro Fertilization (IVF) with Genetic Testing (PGT)","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"ANSM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Infertility","Recurrent Pregnancy Loss","Genetic Carrier Status"],"status":"active"},{"id":"6d090ba2-845b-4dc2-8d88-17a9a62e2ef4","procedure_id":"proc-repro-surrogacy","jurisdiction_id":"jur-us-federal","procedure_name":"Gestational Surrogacy","jurisdiction_name":"United States - Federal","jurisdiction_latitude":38.9,"jurisdiction_longitude":-77.0,"jurisdiction_type":"FEDERAL","country_code":"US","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Without an explicit curated cell, do not assume surrogacy is lawful.","eligibility_requirements":"Unknown.","provider_requirements":"Unknown.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred unknown surrogacy posture — requires family-law research.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: surrogacy is highly jurisdiction-specific (ban vs altruistic vs commercial).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Uterine Factor Infertility","Medical Contraindication to Pregnancy","Recurrent IVF Failure"],"status":"active"},{"id":"1db7f146-5d71-4fa2-98ef-bb8abcb8a9fd","procedure_id":"proc-repro-surrogacy","jurisdiction_id":"jur-us-or","procedure_name":"Gestational Surrogacy","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Without an explicit curated cell, do not assume surrogacy is lawful.","eligibility_requirements":"Unknown.","provider_requirements":"Unknown.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred unknown surrogacy posture — requires family-law research.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: surrogacy is highly jurisdiction-specific (ban vs altruistic vs commercial).","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Uterine Factor Infertility","Medical Contraindication to Pregnancy","Recurrent IVF Failure"],"status":"active"},{"id":"220882d7-1680-44a7-a6f5-09004674e9d6","procedure_id":"proc-repro-surrogacy","jurisdiction_id":"jur-us-co","procedure_name":"Gestational Surrogacy","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Without an explicit curated cell, do not assume surrogacy is lawful.","eligibility_requirements":"Unknown.","provider_requirements":"Unknown.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred unknown surrogacy posture — requires family-law research.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: surrogacy is highly jurisdiction-specific (ban vs altruistic vs commercial).","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Uterine Factor Infertility","Medical Contraindication to Pregnancy","Recurrent IVF Failure"],"status":"active"},{"id":"fe1e78e9-4fff-466e-8095-82dba798599c","procedure_id":"proc-repro-surrogacy","jurisdiction_id":"jur-us-ca","procedure_name":"Gestational Surrogacy","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Without an explicit curated cell, do not assume surrogacy is lawful.","eligibility_requirements":"Unknown.","provider_requirements":"Unknown.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred unknown surrogacy posture — requires family-law research.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: surrogacy is highly jurisdiction-specific (ban vs altruistic vs commercial).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Uterine Factor Infertility","Medical Contraindication to Pregnancy","Recurrent IVF Failure"],"status":"active"},{"id":"ea3b5b22-68a3-4c78-a944-6a1949ee1c79","procedure_id":"proc-repro-surrogacy","jurisdiction_id":"jur-us-tx","procedure_name":"Gestational Surrogacy","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Without an explicit curated cell, do not assume surrogacy is lawful.","eligibility_requirements":"Unknown.","provider_requirements":"Unknown.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred unknown surrogacy posture — requires family-law research.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: surrogacy is highly jurisdiction-specific (ban vs altruistic vs commercial).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Uterine Factor Infertility","Medical Contraindication to Pregnancy","Recurrent IVF Failure"],"status":"active"},{"id":"79f991ee-91a4-4431-93b7-9191b92d1202","procedure_id":"proc-repro-surrogacy","jurisdiction_id":"jur-us-fl","procedure_name":"Gestational Surrogacy","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Without an explicit curated cell, do not assume surrogacy is lawful.","eligibility_requirements":"Unknown.","provider_requirements":"Unknown.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred unknown surrogacy posture — requires family-law research.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: surrogacy is highly jurisdiction-specific (ban vs altruistic vs commercial).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Uterine Factor Infertility","Medical Contraindication to Pregnancy","Recurrent IVF Failure"],"status":"active"},{"id":"67a7403e-0c04-46f9-961b-eb73ecc63aa4","procedure_id":"proc-repro-surrogacy","jurisdiction_id":"jur-au","procedure_name":"Gestational Surrogacy","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Without an explicit curated cell, do not assume surrogacy is lawful.","eligibility_requirements":"Unknown.","provider_requirements":"Unknown.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred unknown surrogacy posture — requires family-law research.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: surrogacy is highly jurisdiction-specific (ban vs altruistic vs commercial).","regulatory_authority":"TGA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Uterine Factor Infertility","Medical Contraindication to Pregnancy","Recurrent IVF Failure"],"status":"active"},{"id":"2ad60f8c-9267-4cf1-9764-b17ad930406d","procedure_id":"proc-repro-surrogacy","jurisdiction_id":"jur-mx","procedure_name":"Gestational Surrogacy","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Without an explicit curated cell, do not assume surrogacy is lawful.","eligibility_requirements":"Unknown.","provider_requirements":"Unknown.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred unknown surrogacy posture — requires family-law research.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: surrogacy is highly jurisdiction-specific (ban vs altruistic vs commercial).","regulatory_authority":"COFEPRIS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Uterine Factor Infertility","Medical Contraindication to Pregnancy","Recurrent IVF Failure"],"status":"active"},{"id":"161673be-8828-4dc3-b748-d5434caae189","procedure_id":"proc-repro-surrogacy","jurisdiction_id":"jur-hn-prospera","procedure_name":"Gestational Surrogacy","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Without an explicit curated cell, do not assume surrogacy is lawful.","eligibility_requirements":"Unknown.","provider_requirements":"Unknown.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred unknown surrogacy posture — requires family-law research.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: surrogacy is highly jurisdiction-specific (ban vs altruistic vs commercial).","regulatory_authority":"Próspera ZEDE health rules (contested)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Uterine Factor Infertility","Medical Contraindication to Pregnancy","Recurrent IVF Failure"],"status":"active"},{"id":"775b61c3-e80e-4bb6-8555-e779d84638ff","procedure_id":"proc-repro-surrogacy","jurisdiction_id":"jur-nl","procedure_name":"Gestational Surrogacy","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Without an explicit curated cell, do not assume surrogacy is lawful.","eligibility_requirements":"Unknown.","provider_requirements":"Unknown.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred unknown surrogacy posture — requires family-law research.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: surrogacy is highly jurisdiction-specific (ban vs altruistic vs commercial).","regulatory_authority":"MEB / IGJ","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Uterine Factor Infertility","Medical Contraindication to Pregnancy","Recurrent IVF Failure"],"status":"active"},{"id":"12ab95e8-9610-4646-996b-01cd4e861ad9","procedure_id":"proc-repro-surrogacy","jurisdiction_id":"jur-uk","procedure_name":"Gestational Surrogacy","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Without an explicit curated cell, do not assume surrogacy is lawful.","eligibility_requirements":"Unknown.","provider_requirements":"Unknown.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred unknown surrogacy posture — requires family-law research.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: surrogacy is highly jurisdiction-specific (ban vs altruistic vs commercial).","regulatory_authority":"MHRA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Uterine Factor Infertility","Medical Contraindication to Pregnancy","Recurrent IVF Failure"],"status":"active"},{"id":"25cae1e2-1d33-4a7e-b2ac-f65e3c982739","procedure_id":"proc-repro-surrogacy","jurisdiction_id":"jur-il","procedure_name":"Gestational Surrogacy","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Without an explicit curated cell, do not assume surrogacy is lawful.","eligibility_requirements":"Unknown.","provider_requirements":"Unknown.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred unknown surrogacy posture — requires family-law research.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: surrogacy is highly jurisdiction-specific (ban vs altruistic vs commercial).","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Uterine Factor Infertility","Medical Contraindication to Pregnancy","Recurrent IVF Failure"],"status":"active"},{"id":"5b9a5cc6-c080-4b5f-ba62-60d790d64656","procedure_id":"proc-repro-surrogacy","jurisdiction_id":"jur-jm","procedure_name":"Gestational Surrogacy","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Without an explicit curated cell, do not assume surrogacy is lawful.","eligibility_requirements":"Unknown.","provider_requirements":"Unknown.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred unknown surrogacy posture — requires family-law research.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: surrogacy is highly jurisdiction-specific (ban vs altruistic vs commercial).","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Uterine Factor Infertility","Medical Contraindication to Pregnancy","Recurrent IVF Failure"],"status":"active"},{"id":"6a00cd0c-c4f2-4089-9894-252534ba1946","procedure_id":"proc-repro-surrogacy","jurisdiction_id":"jur-th","procedure_name":"Gestational Surrogacy","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Without an explicit curated cell, do not assume surrogacy is lawful.","eligibility_requirements":"Unknown.","provider_requirements":"Unknown.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred unknown surrogacy posture — requires family-law research.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: surrogacy is highly jurisdiction-specific (ban vs altruistic vs commercial).","regulatory_authority":"Thai FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Uterine Factor Infertility","Medical Contraindication to Pregnancy","Recurrent IVF Failure"],"status":"active"},{"id":"50bd0127-93bb-4078-8562-42b38a4b053d","procedure_id":"proc-repro-surrogacy","jurisdiction_id":"jur-tu","procedure_name":"Gestational Surrogacy","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Without an explicit curated cell, do not assume surrogacy is lawful.","eligibility_requirements":"Unknown.","provider_requirements":"Unknown.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred unknown surrogacy posture — requires family-law research.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: surrogacy is highly jurisdiction-specific (ban vs altruistic vs commercial).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Uterine Factor Infertility","Medical Contraindication to Pregnancy","Recurrent IVF Failure"],"status":"active"},{"id":"7ad95157-6c60-4b66-8f98-f7dcdac9e473","procedure_id":"proc-repro-surrogacy","jurisdiction_id":"jur-in","procedure_name":"Gestational Surrogacy","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Without an explicit curated cell, do not assume surrogacy is lawful.","eligibility_requirements":"Unknown.","provider_requirements":"Unknown.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred unknown surrogacy posture — requires family-law research.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: surrogacy is highly jurisdiction-specific (ban vs altruistic vs commercial).","regulatory_authority":"CDSCO","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Uterine Factor Infertility","Medical Contraindication to Pregnancy","Recurrent IVF Failure"],"status":"active"},{"id":"c307a348-c567-464a-b84c-6a0fe290afa5","procedure_id":"proc-repro-surrogacy","jurisdiction_id":"jur-br","procedure_name":"Gestational Surrogacy","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Without an explicit curated cell, do not assume surrogacy is lawful.","eligibility_requirements":"Unknown.","provider_requirements":"Unknown.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred unknown surrogacy posture — requires family-law research.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: surrogacy is highly jurisdiction-specific (ban vs altruistic vs commercial).","regulatory_authority":"ANVISA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Uterine Factor Infertility","Medical Contraindication to Pregnancy","Recurrent IVF Failure"],"status":"active"},{"id":"8fc2a79a-37c7-42eb-914e-403c9b23dcf4","procedure_id":"proc-repro-surrogacy","jurisdiction_id":"jur-cr","procedure_name":"Gestational Surrogacy","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Without an explicit curated cell, do not assume surrogacy is lawful.","eligibility_requirements":"Unknown.","provider_requirements":"Unknown.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred unknown surrogacy posture — requires family-law research.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: surrogacy is highly jurisdiction-specific (ban vs altruistic vs commercial).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Uterine Factor Infertility","Medical Contraindication to Pregnancy","Recurrent IVF Failure"],"status":"active"},{"id":"1c5aba7c-6335-49f9-8468-11cad9b04c1a","procedure_id":"proc-repro-surrogacy","jurisdiction_id":"jur-uae","procedure_name":"Gestational Surrogacy","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Without an explicit curated cell, do not assume surrogacy is lawful.","eligibility_requirements":"Unknown.","provider_requirements":"Unknown.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred unknown surrogacy posture — requires family-law research.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: surrogacy is highly jurisdiction-specific (ban vs altruistic vs commercial).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Uterine Factor Infertility","Medical Contraindication to Pregnancy","Recurrent IVF Failure"],"status":"active"},{"id":"4db96be0-af6f-43df-8d60-26bb00bffcbc","procedure_id":"proc-repro-surrogacy","jurisdiction_id":"jur-kr","procedure_name":"Gestational Surrogacy","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Without an explicit curated cell, do not assume surrogacy is lawful.","eligibility_requirements":"Unknown.","provider_requirements":"Unknown.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred unknown surrogacy posture — requires family-law research.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: surrogacy is highly jurisdiction-specific (ban vs altruistic vs commercial).","regulatory_authority":"MFDS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Uterine Factor Infertility","Medical Contraindication to Pregnancy","Recurrent IVF Failure"],"status":"active"},{"id":"2c56ba9f-3b5b-4103-a242-5128d92b403f","procedure_id":"proc-repro-surrogacy","jurisdiction_id":"jur-gr","procedure_name":"Gestational Surrogacy","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Without an explicit curated cell, do not assume surrogacy is lawful.","eligibility_requirements":"Unknown.","provider_requirements":"Unknown.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred unknown surrogacy posture — requires family-law research.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: surrogacy is highly jurisdiction-specific (ban vs altruistic vs commercial).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Uterine Factor Infertility","Medical Contraindication to Pregnancy","Recurrent IVF Failure"],"status":"active"},{"id":"5672e8fa-3cf4-478a-9f60-a2d9191aa27e","procedure_id":"proc-repro-surrogacy","jurisdiction_id":"jur-be","procedure_name":"Gestational Surrogacy","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Without an explicit curated cell, do not assume surrogacy is lawful.","eligibility_requirements":"Unknown.","provider_requirements":"Unknown.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred unknown surrogacy posture — requires family-law research.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: surrogacy is highly jurisdiction-specific (ban vs altruistic vs commercial).","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Uterine Factor Infertility","Medical Contraindication to Pregnancy","Recurrent IVF Failure"],"status":"active"},{"id":"21afc0d0-7b51-45a8-acd1-e4ce1cf58446","procedure_id":"proc-repro-surrogacy","jurisdiction_id":"jur-cl","procedure_name":"Gestational Surrogacy","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Without an explicit curated cell, do not assume surrogacy is lawful.","eligibility_requirements":"Unknown.","provider_requirements":"Unknown.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred unknown surrogacy posture — requires family-law research.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: surrogacy is highly jurisdiction-specific (ban vs altruistic vs commercial).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Uterine Factor Infertility","Medical Contraindication to Pregnancy","Recurrent IVF Failure"],"status":"active"},{"id":"f194bc1f-702d-4222-bb91-4e7400fc65f6","procedure_id":"proc-repro-surrogacy","jurisdiction_id":"jur-ar","procedure_name":"Gestational Surrogacy","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Without an explicit curated cell, do not assume surrogacy is lawful.","eligibility_requirements":"Unknown.","provider_requirements":"Unknown.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred unknown surrogacy posture — requires family-law research.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: surrogacy is highly jurisdiction-specific (ban vs altruistic vs commercial).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Uterine Factor Infertility","Medical Contraindication to Pregnancy","Recurrent IVF Failure"],"status":"active"},{"id":"dbe55fa5-d31d-4022-8c45-738f2b70b040","procedure_id":"proc-repro-surrogacy","jurisdiction_id":"jur-za","procedure_name":"Gestational Surrogacy","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Without an explicit curated cell, do not assume surrogacy is lawful.","eligibility_requirements":"Unknown.","provider_requirements":"Unknown.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred unknown surrogacy posture — requires family-law research.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: surrogacy is highly jurisdiction-specific (ban vs altruistic vs commercial).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Uterine Factor Infertility","Medical Contraindication to Pregnancy","Recurrent IVF Failure"],"status":"active"},{"id":"40e650b9-f622-4a45-b6bf-af6bf143f3be","procedure_id":"proc-repro-surrogacy","jurisdiction_id":"jur-ph","procedure_name":"Gestational Surrogacy","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Without an explicit curated cell, do not assume surrogacy is lawful.","eligibility_requirements":"Unknown.","provider_requirements":"Unknown.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred unknown surrogacy posture — requires family-law research.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: surrogacy is highly jurisdiction-specific (ban vs altruistic vs commercial).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Uterine Factor Infertility","Medical Contraindication to Pregnancy","Recurrent IVF Failure"],"status":"active"},{"id":"59f487f5-325b-4f6a-a868-52ace65c7fae","procedure_id":"proc-repurposed-ldn","jurisdiction_id":"jur-us-or","procedure_name":"Low-Dose Naltrexone (LDN) for Chronic Inflammatory/Autoimmune Conditions","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Chronic_Pain","Neurology"],"diseases":["Fibromyalgia","Crohn's Disease","Multiple Sclerosis","ME/CFS","Long COVID","Chronic Pain"],"status":"active"},{"id":"6ee69782-b293-4f9f-a245-76539fd861bd","procedure_id":"proc-repurposed-ldn","jurisdiction_id":"jur-us-co","procedure_name":"Low-Dose Naltrexone (LDN) for Chronic Inflammatory/Autoimmune Conditions","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Chronic_Pain","Neurology"],"diseases":["Fibromyalgia","Crohn's Disease","Multiple Sclerosis","ME/CFS","Long COVID","Chronic Pain"],"status":"active"},{"id":"a85ef1c4-86a4-460c-ac5a-c8e388c46d8b","procedure_id":"proc-repurposed-ldn","jurisdiction_id":"jur-us-ca","procedure_name":"Low-Dose Naltrexone (LDN) for Chronic Inflammatory/Autoimmune Conditions","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Chronic_Pain","Neurology"],"diseases":["Fibromyalgia","Crohn's Disease","Multiple Sclerosis","ME/CFS","Long COVID","Chronic Pain"],"status":"active"},{"id":"35866bfc-bd85-4b65-a2d8-e67115699c50","procedure_id":"proc-repurposed-ldn","jurisdiction_id":"jur-us-tx","procedure_name":"Low-Dose Naltrexone (LDN) for Chronic Inflammatory/Autoimmune Conditions","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Chronic_Pain","Neurology"],"diseases":["Fibromyalgia","Crohn's Disease","Multiple Sclerosis","ME/CFS","Long COVID","Chronic Pain"],"status":"active"},{"id":"c81158a9-9b42-4304-9676-4e99f979c769","procedure_id":"proc-repurposed-ldn","jurisdiction_id":"jur-us-fl","procedure_name":"Low-Dose Naltrexone (LDN) for Chronic Inflammatory/Autoimmune Conditions","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Chronic_Pain","Neurology"],"diseases":["Fibromyalgia","Crohn's Disease","Multiple Sclerosis","ME/CFS","Long COVID","Chronic Pain"],"status":"active"},{"id":"f8b78cee-4baa-44f9-903e-375c01585f41","procedure_id":"proc-repurposed-ldn","jurisdiction_id":"jur-ch","procedure_name":"Low-Dose Naltrexone (LDN) for Chronic Inflammatory/Autoimmune Conditions","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Swissmedic","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Chronic_Pain","Neurology"],"diseases":["Fibromyalgia","Crohn's Disease","Multiple Sclerosis","ME/CFS","Long COVID","Chronic Pain"],"status":"active"},{"id":"f547ca89-9df2-4c31-adda-9ae53290ce4f","procedure_id":"proc-repurposed-ldn","jurisdiction_id":"jur-mx","procedure_name":"Low-Dose Naltrexone (LDN) for Chronic Inflammatory/Autoimmune Conditions","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Permissive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"COFEPRIS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Chronic_Pain","Neurology"],"diseases":["Fibromyalgia","Crohn's Disease","Multiple Sclerosis","ME/CFS","Long COVID","Chronic Pain"],"status":"active"},{"id":"110823d0-31a2-4889-97aa-4669087df758","procedure_id":"proc-repurposed-ldn","jurisdiction_id":"jur-hn-prospera","procedure_name":"Low-Dose Naltrexone (LDN) for Chronic Inflammatory/Autoimmune Conditions","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Permissive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Próspera ZEDE health rules (contested)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Chronic_Pain","Neurology"],"diseases":["Fibromyalgia","Crohn's Disease","Multiple Sclerosis","ME/CFS","Long COVID","Chronic Pain"],"status":"active"},{"id":"1074f459-39ec-4c4b-8bac-ae030794f94f","procedure_id":"proc-repurposed-ldn","jurisdiction_id":"jur-il","procedure_name":"Low-Dose Naltrexone (LDN) for Chronic Inflammatory/Autoimmune Conditions","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Chronic_Pain","Neurology"],"diseases":["Fibromyalgia","Crohn's Disease","Multiple Sclerosis","ME/CFS","Long COVID","Chronic Pain"],"status":"active"},{"id":"a9ee1721-385b-4e0b-8d17-9b87b139cc20","procedure_id":"proc-repurposed-ldn","jurisdiction_id":"jur-jm","procedure_name":"Low-Dose Naltrexone (LDN) for Chronic Inflammatory/Autoimmune Conditions","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Chronic_Pain","Neurology"],"diseases":["Fibromyalgia","Crohn's Disease","Multiple Sclerosis","ME/CFS","Long COVID","Chronic Pain"],"status":"active"},{"id":"b3044bac-2592-4aa3-8464-b1b77d48859f","procedure_id":"proc-repurposed-ldn","jurisdiction_id":"jur-th","procedure_name":"Low-Dose Naltrexone (LDN) for Chronic Inflammatory/Autoimmune Conditions","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Permissive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Thai FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Chronic_Pain","Neurology"],"diseases":["Fibromyalgia","Crohn's Disease","Multiple Sclerosis","ME/CFS","Long COVID","Chronic Pain"],"status":"active"},{"id":"0fd53622-3514-433c-a267-a0a464f0832d","procedure_id":"proc-repurposed-ldn","jurisdiction_id":"jur-es","procedure_name":"Low-Dose Naltrexone (LDN) for Chronic Inflammatory/Autoimmune Conditions","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"AEMPS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Chronic_Pain","Neurology"],"diseases":["Fibromyalgia","Crohn's Disease","Multiple Sclerosis","ME/CFS","Long COVID","Chronic Pain"],"status":"active"},{"id":"2d3fa293-a016-4090-87ce-03510ba57686","procedure_id":"proc-repurposed-ldn","jurisdiction_id":"jur-tu","procedure_name":"Low-Dose Naltrexone (LDN) for Chronic Inflammatory/Autoimmune Conditions","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Chronic_Pain","Neurology"],"diseases":["Fibromyalgia","Crohn's Disease","Multiple Sclerosis","ME/CFS","Long COVID","Chronic Pain"],"status":"active"},{"id":"c4b89a4b-a1d3-46a1-a12e-0299a0683f11","procedure_id":"proc-repurposed-ldn","jurisdiction_id":"jur-in","procedure_name":"Low-Dose Naltrexone (LDN) for Chronic Inflammatory/Autoimmune Conditions","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Permissive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"CDSCO","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Chronic_Pain","Neurology"],"diseases":["Fibromyalgia","Crohn's Disease","Multiple Sclerosis","ME/CFS","Long COVID","Chronic Pain"],"status":"active"},{"id":"5aa1c4dc-381c-4c9f-b11d-b54274428868","procedure_id":"proc-repurposed-ldn","jurisdiction_id":"jur-br","procedure_name":"Low-Dose Naltrexone (LDN) for Chronic Inflammatory/Autoimmune Conditions","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"ANVISA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Chronic_Pain","Neurology"],"diseases":["Fibromyalgia","Crohn's Disease","Multiple Sclerosis","ME/CFS","Long COVID","Chronic Pain"],"status":"active"},{"id":"3baa9b5b-24ca-470b-a5dc-d75ae59117c0","procedure_id":"proc-repurposed-ldn","jurisdiction_id":"jur-cr","procedure_name":"Low-Dose Naltrexone (LDN) for Chronic Inflammatory/Autoimmune Conditions","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Chronic_Pain","Neurology"],"diseases":["Fibromyalgia","Crohn's Disease","Multiple Sclerosis","ME/CFS","Long COVID","Chronic Pain"],"status":"active"},{"id":"b5f975a1-0fc4-4d48-b39e-24c141ff3032","procedure_id":"proc-repurposed-ldn","jurisdiction_id":"jur-uae","procedure_name":"Low-Dose Naltrexone (LDN) for Chronic Inflammatory/Autoimmune Conditions","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Chronic_Pain","Neurology"],"diseases":["Fibromyalgia","Crohn's Disease","Multiple Sclerosis","ME/CFS","Long COVID","Chronic Pain"],"status":"active"},{"id":"4ee83d48-7ee5-47b5-94ef-6c6f9df7ab35","procedure_id":"proc-repurposed-ldn","jurisdiction_id":"jur-kr","procedure_name":"Low-Dose Naltrexone (LDN) for Chronic Inflammatory/Autoimmune Conditions","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"MFDS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Chronic_Pain","Neurology"],"diseases":["Fibromyalgia","Crohn's Disease","Multiple Sclerosis","ME/CFS","Long COVID","Chronic Pain"],"status":"active"},{"id":"b8cfe6f4-c458-4dd4-a6ab-63c8c0c63fe4","procedure_id":"proc-repurposed-ldn","jurisdiction_id":"jur-gr","procedure_name":"Low-Dose Naltrexone (LDN) for Chronic Inflammatory/Autoimmune Conditions","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Chronic_Pain","Neurology"],"diseases":["Fibromyalgia","Crohn's Disease","Multiple Sclerosis","ME/CFS","Long COVID","Chronic Pain"],"status":"active"},{"id":"2dce7d59-da6f-4f71-bd22-e297e28b84ab","procedure_id":"proc-repurposed-ldn","jurisdiction_id":"jur-be","procedure_name":"Low-Dose Naltrexone (LDN) for Chronic Inflammatory/Autoimmune Conditions","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Chronic_Pain","Neurology"],"diseases":["Fibromyalgia","Crohn's Disease","Multiple Sclerosis","ME/CFS","Long COVID","Chronic Pain"],"status":"active"},{"id":"6aa93f29-9939-4817-9958-2ea11d0d6ce4","procedure_id":"proc-repurposed-ldn","jurisdiction_id":"jur-se","procedure_name":"Low-Dose Naltrexone (LDN) for Chronic Inflammatory/Autoimmune Conditions","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Chronic_Pain","Neurology"],"diseases":["Fibromyalgia","Crohn's Disease","Multiple Sclerosis","ME/CFS","Long COVID","Chronic Pain"],"status":"active"},{"id":"fb013c3c-7d8e-4678-aa2a-0bfdfc53069b","procedure_id":"proc-repurposed-ldn","jurisdiction_id":"jur-jp","procedure_name":"Low-Dose Naltrexone (LDN) for Chronic Inflammatory/Autoimmune Conditions","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"PMDA / MHLW","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Chronic_Pain","Neurology"],"diseases":["Fibromyalgia","Crohn's Disease","Multiple Sclerosis","ME/CFS","Long COVID","Chronic Pain"],"status":"active"},{"id":"31244553-4cdd-463f-ae9a-46021db4687d","procedure_id":"proc-repurposed-ldn","jurisdiction_id":"jur-sg","procedure_name":"Low-Dose Naltrexone (LDN) for Chronic Inflammatory/Autoimmune Conditions","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"HSA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Chronic_Pain","Neurology"],"diseases":["Fibromyalgia","Crohn's Disease","Multiple Sclerosis","ME/CFS","Long COVID","Chronic Pain"],"status":"active"},{"id":"4e69a73f-dc73-4717-90c5-7378820d6312","procedure_id":"proc-repurposed-ldn","jurisdiction_id":"jur-cl","procedure_name":"Low-Dose Naltrexone (LDN) for Chronic Inflammatory/Autoimmune Conditions","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Chronic_Pain","Neurology"],"diseases":["Fibromyalgia","Crohn's Disease","Multiple Sclerosis","ME/CFS","Long COVID","Chronic Pain"],"status":"active"},{"id":"d5ef4ce0-2d7d-463d-b5cf-be2b5cd99e65","procedure_id":"proc-repurposed-ldn","jurisdiction_id":"jur-ar","procedure_name":"Low-Dose Naltrexone (LDN) for Chronic Inflammatory/Autoimmune Conditions","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Chronic_Pain","Neurology"],"diseases":["Fibromyalgia","Crohn's Disease","Multiple Sclerosis","ME/CFS","Long COVID","Chronic Pain"],"status":"active"},{"id":"7bbfca62-9759-44bd-8507-6986c527724d","procedure_id":"proc-repurposed-ldn","jurisdiction_id":"jur-za","procedure_name":"Low-Dose Naltrexone (LDN) for Chronic Inflammatory/Autoimmune Conditions","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Chronic_Pain","Neurology"],"diseases":["Fibromyalgia","Crohn's Disease","Multiple Sclerosis","ME/CFS","Long COVID","Chronic Pain"],"status":"active"},{"id":"4b2a2dd3-6659-4946-a068-d757f93f2f61","procedure_id":"proc-repurposed-ldn","jurisdiction_id":"jur-ph","procedure_name":"Low-Dose Naltrexone (LDN) for Chronic Inflammatory/Autoimmune Conditions","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Chronic_Pain","Neurology"],"diseases":["Fibromyalgia","Crohn's Disease","Multiple Sclerosis","ME/CFS","Long COVID","Chronic Pain"],"status":"active"},{"id":"cd3e21ea-bee0-4d79-95d5-b3ab8256b61d","procedure_id":"proc-repurposed-ldn","jurisdiction_id":"jur-po","procedure_name":"Low-Dose Naltrexone (LDN) for Chronic Inflammatory/Autoimmune Conditions","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Chronic_Pain","Neurology"],"diseases":["Fibromyalgia","Crohn's Disease","Multiple Sclerosis","ME/CFS","Long COVID","Chronic Pain"],"status":"active"},{"id":"e8efc4f9-1a6c-4b71-ba84-b7e03dfb4771","procedure_id":"proc-repurposed-ldn","jurisdiction_id":"jur-pt","procedure_name":"Low-Dose Naltrexone (LDN) for Chronic Inflammatory/Autoimmune Conditions","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Chronic_Pain","Neurology"],"diseases":["Fibromyalgia","Crohn's Disease","Multiple Sclerosis","ME/CFS","Long COVID","Chronic Pain"],"status":"active"},{"id":"5b97e9ed-10b5-445b-914c-6c93e0b42919","procedure_id":"proc-repurposed-ldn","jurisdiction_id":"jur-fr","procedure_name":"Low-Dose Naltrexone (LDN) for Chronic Inflammatory/Autoimmune Conditions","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"ANSM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Chronic_Pain","Neurology"],"diseases":["Fibromyalgia","Crohn's Disease","Multiple Sclerosis","ME/CFS","Long COVID","Chronic Pain"],"status":"active"},{"id":"85a47dd1-1a53-4f05-a92a-987e65698703","procedure_id":"proc-repurposed-methylene","jurisdiction_id":"jur-us-or","procedure_name":"Methylene Blue (Pharmaceutical Grade) for Neuroprotection/Mitochondrial Dysfunction","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Mitochondrial_Health"],"diseases":["Mild Cognitive Impairment","Bipolar Depression","Mitochondrial Dysfunction","Methemoglobinemia"],"status":"active"},{"id":"09b79206-2e98-4bd9-be65-41b504ee7364","procedure_id":"proc-repurposed-methylene","jurisdiction_id":"jur-us-co","procedure_name":"Methylene Blue (Pharmaceutical Grade) for Neuroprotection/Mitochondrial Dysfunction","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Mitochondrial_Health"],"diseases":["Mild Cognitive Impairment","Bipolar Depression","Mitochondrial Dysfunction","Methemoglobinemia"],"status":"active"},{"id":"c6657887-b28b-4bdc-a193-8b39426aae9c","procedure_id":"proc-repurposed-methylene","jurisdiction_id":"jur-us-ca","procedure_name":"Methylene Blue (Pharmaceutical Grade) for Neuroprotection/Mitochondrial Dysfunction","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Mitochondrial_Health"],"diseases":["Mild Cognitive Impairment","Bipolar Depression","Mitochondrial Dysfunction","Methemoglobinemia"],"status":"active"},{"id":"7c9cef8a-f717-44be-9d4d-a5dcb7ed4dee","procedure_id":"proc-repurposed-methylene","jurisdiction_id":"jur-us-tx","procedure_name":"Methylene Blue (Pharmaceutical Grade) for Neuroprotection/Mitochondrial Dysfunction","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Mitochondrial_Health"],"diseases":["Mild Cognitive Impairment","Bipolar Depression","Mitochondrial Dysfunction","Methemoglobinemia"],"status":"active"},{"id":"1250d2da-0c74-4ae8-9c1e-21ba6dd0d681","procedure_id":"proc-repurposed-methylene","jurisdiction_id":"jur-us-fl","procedure_name":"Methylene Blue (Pharmaceutical Grade) for Neuroprotection/Mitochondrial Dysfunction","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Mitochondrial_Health"],"diseases":["Mild Cognitive Impairment","Bipolar Depression","Mitochondrial Dysfunction","Methemoglobinemia"],"status":"active"},{"id":"d2faef01-75cb-48bb-bc01-b7b9e5b29980","procedure_id":"proc-repurposed-methylene","jurisdiction_id":"jur-au","procedure_name":"Methylene Blue (Pharmaceutical Grade) for Neuroprotection/Mitochondrial Dysfunction","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"TGA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Mitochondrial_Health"],"diseases":["Mild Cognitive Impairment","Bipolar Depression","Mitochondrial Dysfunction","Methemoglobinemia"],"status":"active"},{"id":"066f63ec-de71-4487-8c12-7fa3148dc07e","procedure_id":"proc-repurposed-methylene","jurisdiction_id":"jur-ch","procedure_name":"Methylene Blue (Pharmaceutical Grade) for Neuroprotection/Mitochondrial Dysfunction","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Swissmedic","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Mitochondrial_Health"],"diseases":["Mild Cognitive Impairment","Bipolar Depression","Mitochondrial Dysfunction","Methemoglobinemia"],"status":"active"},{"id":"abe08283-4b21-4500-9d22-bd5540c43698","procedure_id":"proc-repurposed-methylene","jurisdiction_id":"jur-hn-prospera","procedure_name":"Methylene Blue (Pharmaceutical Grade) for Neuroprotection/Mitochondrial Dysfunction","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Permissive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Próspera ZEDE health rules (contested)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Mitochondrial_Health"],"diseases":["Mild Cognitive Impairment","Bipolar Depression","Mitochondrial Dysfunction","Methemoglobinemia"],"status":"active"},{"id":"752c497c-0cad-46fd-b7b7-9e2c0ea3a606","procedure_id":"proc-repurposed-methylene","jurisdiction_id":"jur-nl","procedure_name":"Methylene Blue (Pharmaceutical Grade) for Neuroprotection/Mitochondrial Dysfunction","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"MEB / IGJ","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Mitochondrial_Health"],"diseases":["Mild Cognitive Impairment","Bipolar Depression","Mitochondrial Dysfunction","Methemoglobinemia"],"status":"active"},{"id":"73064082-b83d-48bf-b983-3a541cb320ea","procedure_id":"proc-repurposed-methylene","jurisdiction_id":"jur-il","procedure_name":"Methylene Blue (Pharmaceutical Grade) for Neuroprotection/Mitochondrial Dysfunction","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Mitochondrial_Health"],"diseases":["Mild Cognitive Impairment","Bipolar Depression","Mitochondrial Dysfunction","Methemoglobinemia"],"status":"active"},{"id":"47874ba2-8c99-4159-b883-e9971459fa2e","procedure_id":"proc-repurposed-methylene","jurisdiction_id":"jur-jm","procedure_name":"Methylene Blue (Pharmaceutical Grade) for Neuroprotection/Mitochondrial Dysfunction","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Mitochondrial_Health"],"diseases":["Mild Cognitive Impairment","Bipolar Depression","Mitochondrial Dysfunction","Methemoglobinemia"],"status":"active"},{"id":"e7676e05-0442-463e-8e8b-f758f0d52c6e","procedure_id":"proc-repurposed-methylene","jurisdiction_id":"jur-th","procedure_name":"Methylene Blue (Pharmaceutical Grade) for Neuroprotection/Mitochondrial Dysfunction","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Permissive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Thai FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Mitochondrial_Health"],"diseases":["Mild Cognitive Impairment","Bipolar Depression","Mitochondrial Dysfunction","Methemoglobinemia"],"status":"active"},{"id":"3c887d4e-e9b8-4487-b1f1-65a908c80234","procedure_id":"proc-repurposed-methylene","jurisdiction_id":"jur-es","procedure_name":"Methylene Blue (Pharmaceutical Grade) for Neuroprotection/Mitochondrial Dysfunction","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"AEMPS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Mitochondrial_Health"],"diseases":["Mild Cognitive Impairment","Bipolar Depression","Mitochondrial Dysfunction","Methemoglobinemia"],"status":"active"},{"id":"ee60a3d8-5255-464b-979e-2bbe2d0f0513","procedure_id":"proc-repurposed-methylene","jurisdiction_id":"jur-tu","procedure_name":"Methylene Blue (Pharmaceutical Grade) for Neuroprotection/Mitochondrial Dysfunction","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Mitochondrial_Health"],"diseases":["Mild Cognitive Impairment","Bipolar Depression","Mitochondrial Dysfunction","Methemoglobinemia"],"status":"active"},{"id":"79588194-c2ad-4d23-bc90-2b524ad2cc1e","procedure_id":"proc-repurposed-methylene","jurisdiction_id":"jur-in","procedure_name":"Methylene Blue (Pharmaceutical Grade) for Neuroprotection/Mitochondrial Dysfunction","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Permissive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"CDSCO","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Mitochondrial_Health"],"diseases":["Mild Cognitive Impairment","Bipolar Depression","Mitochondrial Dysfunction","Methemoglobinemia"],"status":"active"},{"id":"e144b0d5-8a4a-4b89-9480-963d6ba4931f","procedure_id":"proc-repurposed-methylene","jurisdiction_id":"jur-br","procedure_name":"Methylene Blue (Pharmaceutical Grade) for Neuroprotection/Mitochondrial Dysfunction","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"ANVISA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Mitochondrial_Health"],"diseases":["Mild Cognitive Impairment","Bipolar Depression","Mitochondrial Dysfunction","Methemoglobinemia"],"status":"active"},{"id":"b59a392b-a551-489f-baea-4d0a90ea7e21","procedure_id":"proc-repurposed-methylene","jurisdiction_id":"jur-cr","procedure_name":"Methylene Blue (Pharmaceutical Grade) for Neuroprotection/Mitochondrial Dysfunction","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Mitochondrial_Health"],"diseases":["Mild Cognitive Impairment","Bipolar Depression","Mitochondrial Dysfunction","Methemoglobinemia"],"status":"active"},{"id":"81f37ccb-128a-4ae3-bba5-1e11a94f90c5","procedure_id":"proc-repurposed-methylene","jurisdiction_id":"jur-uae","procedure_name":"Methylene Blue (Pharmaceutical Grade) for Neuroprotection/Mitochondrial Dysfunction","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Mitochondrial_Health"],"diseases":["Mild Cognitive Impairment","Bipolar Depression","Mitochondrial Dysfunction","Methemoglobinemia"],"status":"active"},{"id":"75794cad-93f6-48a1-8e9a-cb6f1797065d","procedure_id":"proc-repurposed-methylene","jurisdiction_id":"jur-kr","procedure_name":"Methylene Blue (Pharmaceutical Grade) for Neuroprotection/Mitochondrial Dysfunction","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"MFDS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Mitochondrial_Health"],"diseases":["Mild Cognitive Impairment","Bipolar Depression","Mitochondrial Dysfunction","Methemoglobinemia"],"status":"active"},{"id":"1f0149ed-5bf7-4c7a-bb3e-7241611b7624","procedure_id":"proc-repurposed-methylene","jurisdiction_id":"jur-gr","procedure_name":"Methylene Blue (Pharmaceutical Grade) for Neuroprotection/Mitochondrial Dysfunction","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Mitochondrial_Health"],"diseases":["Mild Cognitive Impairment","Bipolar Depression","Mitochondrial Dysfunction","Methemoglobinemia"],"status":"active"},{"id":"e4cabbd3-6b90-41ab-a03b-1bd9314c4e65","procedure_id":"proc-repurposed-methylene","jurisdiction_id":"jur-be","procedure_name":"Methylene Blue (Pharmaceutical Grade) for Neuroprotection/Mitochondrial Dysfunction","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Mitochondrial_Health"],"diseases":["Mild Cognitive Impairment","Bipolar Depression","Mitochondrial Dysfunction","Methemoglobinemia"],"status":"active"},{"id":"1b1bea56-758a-4744-8e09-ffb004e9e679","procedure_id":"proc-repurposed-methylene","jurisdiction_id":"jur-se","procedure_name":"Methylene Blue (Pharmaceutical Grade) for Neuroprotection/Mitochondrial Dysfunction","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Mitochondrial_Health"],"diseases":["Mild Cognitive Impairment","Bipolar Depression","Mitochondrial Dysfunction","Methemoglobinemia"],"status":"active"},{"id":"01bf0733-e7db-491d-aef1-5d75bf75abd1","procedure_id":"proc-repurposed-methylene","jurisdiction_id":"jur-jp","procedure_name":"Methylene Blue (Pharmaceutical Grade) for Neuroprotection/Mitochondrial Dysfunction","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"PMDA / MHLW","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Mitochondrial_Health"],"diseases":["Mild Cognitive Impairment","Bipolar Depression","Mitochondrial Dysfunction","Methemoglobinemia"],"status":"active"},{"id":"af0a28e5-ffe4-4a70-8258-0088ab5fc47f","procedure_id":"proc-repurposed-methylene","jurisdiction_id":"jur-sg","procedure_name":"Methylene Blue (Pharmaceutical Grade) for Neuroprotection/Mitochondrial Dysfunction","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"HSA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Mitochondrial_Health"],"diseases":["Mild Cognitive Impairment","Bipolar Depression","Mitochondrial Dysfunction","Methemoglobinemia"],"status":"active"},{"id":"617b11d4-1187-4add-a00a-136e546696cf","procedure_id":"proc-repurposed-methylene","jurisdiction_id":"jur-cl","procedure_name":"Methylene Blue (Pharmaceutical Grade) for Neuroprotection/Mitochondrial Dysfunction","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Mitochondrial_Health"],"diseases":["Mild Cognitive Impairment","Bipolar Depression","Mitochondrial Dysfunction","Methemoglobinemia"],"status":"active"},{"id":"20507ed3-780f-42cb-ab1d-43b5bf0a2866","procedure_id":"proc-repurposed-methylene","jurisdiction_id":"jur-ar","procedure_name":"Methylene Blue (Pharmaceutical Grade) for Neuroprotection/Mitochondrial Dysfunction","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Mitochondrial_Health"],"diseases":["Mild Cognitive Impairment","Bipolar Depression","Mitochondrial Dysfunction","Methemoglobinemia"],"status":"active"},{"id":"6d15cdee-47c0-40f7-b719-e9d5709a4eeb","procedure_id":"proc-repurposed-methylene","jurisdiction_id":"jur-za","procedure_name":"Methylene Blue (Pharmaceutical Grade) for Neuroprotection/Mitochondrial Dysfunction","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Mitochondrial_Health"],"diseases":["Mild Cognitive Impairment","Bipolar Depression","Mitochondrial Dysfunction","Methemoglobinemia"],"status":"active"},{"id":"c99cd2ab-02ec-4b4f-93c9-51780b0bc5c4","procedure_id":"proc-repurposed-methylene","jurisdiction_id":"jur-ph","procedure_name":"Methylene Blue (Pharmaceutical Grade) for Neuroprotection/Mitochondrial Dysfunction","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Mitochondrial_Health"],"diseases":["Mild Cognitive Impairment","Bipolar Depression","Mitochondrial Dysfunction","Methemoglobinemia"],"status":"active"},{"id":"13f377be-c9c6-4d06-8497-cd9071d39b3a","procedure_id":"proc-repurposed-methylene","jurisdiction_id":"jur-po","procedure_name":"Methylene Blue (Pharmaceutical Grade) for Neuroprotection/Mitochondrial Dysfunction","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Mitochondrial_Health"],"diseases":["Mild Cognitive Impairment","Bipolar Depression","Mitochondrial Dysfunction","Methemoglobinemia"],"status":"active"},{"id":"4760b9db-b6ac-4675-b39f-28a42f1f2222","procedure_id":"proc-repurposed-methylene","jurisdiction_id":"jur-pt","procedure_name":"Methylene Blue (Pharmaceutical Grade) for Neuroprotection/Mitochondrial Dysfunction","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Mitochondrial_Health"],"diseases":["Mild Cognitive Impairment","Bipolar Depression","Mitochondrial Dysfunction","Methemoglobinemia"],"status":"active"},{"id":"2e472883-e182-4833-ad60-dc9fb60ba685","procedure_id":"proc-repurposed-methylene","jurisdiction_id":"jur-fr","procedure_name":"Methylene Blue (Pharmaceutical Grade) for Neuroprotection/Mitochondrial Dysfunction","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"ANSM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Mitochondrial_Health"],"diseases":["Mild Cognitive Impairment","Bipolar Depression","Mitochondrial Dysfunction","Methemoglobinemia"],"status":"active"},{"id":"1b50a018-ff1a-453c-bed5-71a6ffea8569","procedure_id":"proc-repurposed-semaglutide","jurisdiction_id":"jur-us-or","procedure_name":"GLP-1 Receptor Agonists (Semaglutide / Tirzepatide) Beyond Diabetes","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","Addiction","Cardiovascular"],"diseases":["Obesity","Type 2 Diabetes","Cardiovascular Disease Risk","NAFLD/NASH"],"status":"active"},{"id":"256d238e-fab4-4051-88b3-9fc5d2b3faf3","procedure_id":"proc-repurposed-semaglutide","jurisdiction_id":"jur-us-co","procedure_name":"GLP-1 Receptor Agonists (Semaglutide / Tirzepatide) Beyond Diabetes","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","Addiction","Cardiovascular"],"diseases":["Obesity","Type 2 Diabetes","Cardiovascular Disease Risk","NAFLD/NASH"],"status":"active"},{"id":"890119a9-c851-40cc-88a9-de9cc4a9fdd5","procedure_id":"proc-repurposed-semaglutide","jurisdiction_id":"jur-us-ca","procedure_name":"GLP-1 Receptor Agonists (Semaglutide / Tirzepatide) Beyond Diabetes","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","Addiction","Cardiovascular"],"diseases":["Obesity","Type 2 Diabetes","Cardiovascular Disease Risk","NAFLD/NASH"],"status":"active"},{"id":"81fca099-493a-45ff-9092-4461408fcc68","procedure_id":"proc-repurposed-semaglutide","jurisdiction_id":"jur-us-tx","procedure_name":"GLP-1 Receptor Agonists (Semaglutide / Tirzepatide) Beyond Diabetes","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","Addiction","Cardiovascular"],"diseases":["Obesity","Type 2 Diabetes","Cardiovascular Disease Risk","NAFLD/NASH"],"status":"active"},{"id":"e4c4eb83-229b-4fbf-83ea-016a2604aaab","procedure_id":"proc-repurposed-semaglutide","jurisdiction_id":"jur-us-fl","procedure_name":"GLP-1 Receptor Agonists (Semaglutide / Tirzepatide) Beyond Diabetes","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","Addiction","Cardiovascular"],"diseases":["Obesity","Type 2 Diabetes","Cardiovascular Disease Risk","NAFLD/NASH"],"status":"active"},{"id":"f80f4e83-43a2-481e-92b8-067f68cb0254","procedure_id":"proc-repurposed-semaglutide","jurisdiction_id":"jur-au","procedure_name":"GLP-1 Receptor Agonists (Semaglutide / Tirzepatide) Beyond Diabetes","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"TGA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","Addiction","Cardiovascular"],"diseases":["Obesity","Type 2 Diabetes","Cardiovascular Disease Risk","NAFLD/NASH"],"status":"active"},{"id":"f9ae3f98-ba47-4c3b-83de-1247cde26e25","procedure_id":"proc-repurposed-semaglutide","jurisdiction_id":"jur-ch","procedure_name":"GLP-1 Receptor Agonists (Semaglutide / Tirzepatide) Beyond Diabetes","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Swissmedic","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","Addiction","Cardiovascular"],"diseases":["Obesity","Type 2 Diabetes","Cardiovascular Disease Risk","NAFLD/NASH"],"status":"active"},{"id":"5759f0e1-1bee-4f7c-90a9-7d3180ccf9d2","procedure_id":"proc-repurposed-semaglutide","jurisdiction_id":"jur-ca","procedure_name":"GLP-1 Receptor Agonists (Semaglutide / Tirzepatide) Beyond Diabetes","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Health Canada","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","Addiction","Cardiovascular"],"diseases":["Obesity","Type 2 Diabetes","Cardiovascular Disease Risk","NAFLD/NASH"],"status":"active"},{"id":"b3399292-30bd-407c-bae5-2cdd178a786b","procedure_id":"proc-repurposed-semaglutide","jurisdiction_id":"jur-mx","procedure_name":"GLP-1 Receptor Agonists (Semaglutide / Tirzepatide) Beyond Diabetes","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Permissive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"COFEPRIS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","Addiction","Cardiovascular"],"diseases":["Obesity","Type 2 Diabetes","Cardiovascular Disease Risk","NAFLD/NASH"],"status":"active"},{"id":"7b50eae4-ec74-453f-a5a6-a3513381953e","procedure_id":"proc-repurposed-semaglutide","jurisdiction_id":"jur-hn-prospera","procedure_name":"GLP-1 Receptor Agonists (Semaglutide / Tirzepatide) Beyond Diabetes","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Permissive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Próspera ZEDE health rules (contested)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","Addiction","Cardiovascular"],"diseases":["Obesity","Type 2 Diabetes","Cardiovascular Disease Risk","NAFLD/NASH"],"status":"active"},{"id":"05253e65-9d8f-445c-b601-544efb28eba6","procedure_id":"proc-repurposed-semaglutide","jurisdiction_id":"jur-nl","procedure_name":"GLP-1 Receptor Agonists (Semaglutide / Tirzepatide) Beyond Diabetes","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"MEB / IGJ","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","Addiction","Cardiovascular"],"diseases":["Obesity","Type 2 Diabetes","Cardiovascular Disease Risk","NAFLD/NASH"],"status":"active"},{"id":"caae4455-84bf-41e4-b7ec-74fefb74f348","procedure_id":"proc-repurposed-semaglutide","jurisdiction_id":"jur-de","procedure_name":"GLP-1 Receptor Agonists (Semaglutide / Tirzepatide) Beyond Diabetes","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"BfArM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","Addiction","Cardiovascular"],"diseases":["Obesity","Type 2 Diabetes","Cardiovascular Disease Risk","NAFLD/NASH"],"status":"active"},{"id":"1814fd9e-9c7e-4a80-95f8-4e3147032dec","procedure_id":"proc-repurposed-semaglutide","jurisdiction_id":"jur-uk","procedure_name":"GLP-1 Receptor Agonists (Semaglutide / Tirzepatide) Beyond Diabetes","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"MHRA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","Addiction","Cardiovascular"],"diseases":["Obesity","Type 2 Diabetes","Cardiovascular Disease Risk","NAFLD/NASH"],"status":"active"},{"id":"2c9c0667-4057-4931-97c3-28e1e8d7882c","procedure_id":"proc-repurposed-semaglutide","jurisdiction_id":"jur-il","procedure_name":"GLP-1 Receptor Agonists (Semaglutide / Tirzepatide) Beyond Diabetes","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","Addiction","Cardiovascular"],"diseases":["Obesity","Type 2 Diabetes","Cardiovascular Disease Risk","NAFLD/NASH"],"status":"active"},{"id":"3c348620-b282-477c-9aee-3a749fdfe76e","procedure_id":"proc-repurposed-semaglutide","jurisdiction_id":"jur-jm","procedure_name":"GLP-1 Receptor Agonists (Semaglutide / Tirzepatide) Beyond Diabetes","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","Addiction","Cardiovascular"],"diseases":["Obesity","Type 2 Diabetes","Cardiovascular Disease Risk","NAFLD/NASH"],"status":"active"},{"id":"41d76a7e-5338-4b12-99ff-b962701cf22b","procedure_id":"proc-repurposed-semaglutide","jurisdiction_id":"jur-th","procedure_name":"GLP-1 Receptor Agonists (Semaglutide / Tirzepatide) Beyond Diabetes","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Permissive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Thai FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","Addiction","Cardiovascular"],"diseases":["Obesity","Type 2 Diabetes","Cardiovascular Disease Risk","NAFLD/NASH"],"status":"active"},{"id":"3372e554-57da-46ed-acdd-92080e0fb6a8","procedure_id":"proc-repurposed-semaglutide","jurisdiction_id":"jur-es","procedure_name":"GLP-1 Receptor Agonists (Semaglutide / Tirzepatide) Beyond Diabetes","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"AEMPS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","Addiction","Cardiovascular"],"diseases":["Obesity","Type 2 Diabetes","Cardiovascular Disease Risk","NAFLD/NASH"],"status":"active"},{"id":"6d19268d-c47d-4c1d-9e4c-23a8c667770a","procedure_id":"proc-repurposed-semaglutide","jurisdiction_id":"jur-tu","procedure_name":"GLP-1 Receptor Agonists (Semaglutide / Tirzepatide) Beyond Diabetes","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","Addiction","Cardiovascular"],"diseases":["Obesity","Type 2 Diabetes","Cardiovascular Disease Risk","NAFLD/NASH"],"status":"active"},{"id":"f9356d0c-438a-48bc-b0fa-9c8372a3ec8b","procedure_id":"proc-repurposed-semaglutide","jurisdiction_id":"jur-in","procedure_name":"GLP-1 Receptor Agonists (Semaglutide / Tirzepatide) Beyond Diabetes","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Permissive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"CDSCO","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","Addiction","Cardiovascular"],"diseases":["Obesity","Type 2 Diabetes","Cardiovascular Disease Risk","NAFLD/NASH"],"status":"active"},{"id":"9ceaa6e1-98ce-4af0-82e7-b8f5615b2c7b","procedure_id":"proc-repurposed-semaglutide","jurisdiction_id":"jur-br","procedure_name":"GLP-1 Receptor Agonists (Semaglutide / Tirzepatide) Beyond Diabetes","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"ANVISA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","Addiction","Cardiovascular"],"diseases":["Obesity","Type 2 Diabetes","Cardiovascular Disease Risk","NAFLD/NASH"],"status":"active"},{"id":"db319376-e011-48e3-ac18-553590b142fd","procedure_id":"proc-repurposed-semaglutide","jurisdiction_id":"jur-cr","procedure_name":"GLP-1 Receptor Agonists (Semaglutide / Tirzepatide) Beyond Diabetes","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","Addiction","Cardiovascular"],"diseases":["Obesity","Type 2 Diabetes","Cardiovascular Disease Risk","NAFLD/NASH"],"status":"active"},{"id":"2da9b99a-7a57-4c95-b66f-c3ff152d310b","procedure_id":"proc-repurposed-semaglutide","jurisdiction_id":"jur-uae","procedure_name":"GLP-1 Receptor Agonists (Semaglutide / Tirzepatide) Beyond Diabetes","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","Addiction","Cardiovascular"],"diseases":["Obesity","Type 2 Diabetes","Cardiovascular Disease Risk","NAFLD/NASH"],"status":"active"},{"id":"4d72b722-dfa2-4fd5-8267-e9980505f8c5","procedure_id":"proc-repurposed-semaglutide","jurisdiction_id":"jur-kr","procedure_name":"GLP-1 Receptor Agonists (Semaglutide / Tirzepatide) Beyond Diabetes","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"MFDS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","Addiction","Cardiovascular"],"diseases":["Obesity","Type 2 Diabetes","Cardiovascular Disease Risk","NAFLD/NASH"],"status":"active"},{"id":"bf14efce-2af4-49be-badc-08543c72a7b3","procedure_id":"proc-repurposed-semaglutide","jurisdiction_id":"jur-gr","procedure_name":"GLP-1 Receptor Agonists (Semaglutide / Tirzepatide) Beyond Diabetes","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","Addiction","Cardiovascular"],"diseases":["Obesity","Type 2 Diabetes","Cardiovascular Disease Risk","NAFLD/NASH"],"status":"active"},{"id":"cf790c4c-7ece-411d-8943-c9c324ff08b3","procedure_id":"proc-repurposed-semaglutide","jurisdiction_id":"jur-be","procedure_name":"GLP-1 Receptor Agonists (Semaglutide / Tirzepatide) Beyond Diabetes","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","Addiction","Cardiovascular"],"diseases":["Obesity","Type 2 Diabetes","Cardiovascular Disease Risk","NAFLD/NASH"],"status":"active"},{"id":"91d92d9d-acac-4362-8a24-88fca5aa4f31","procedure_id":"proc-repurposed-semaglutide","jurisdiction_id":"jur-se","procedure_name":"GLP-1 Receptor Agonists (Semaglutide / Tirzepatide) Beyond Diabetes","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","Addiction","Cardiovascular"],"diseases":["Obesity","Type 2 Diabetes","Cardiovascular Disease Risk","NAFLD/NASH"],"status":"active"},{"id":"8602036b-f46d-45c1-8b95-b9b376cb00ff","procedure_id":"proc-repurposed-semaglutide","jurisdiction_id":"jur-jp","procedure_name":"GLP-1 Receptor Agonists (Semaglutide / Tirzepatide) Beyond Diabetes","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"PMDA / MHLW","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","Addiction","Cardiovascular"],"diseases":["Obesity","Type 2 Diabetes","Cardiovascular Disease Risk","NAFLD/NASH"],"status":"active"},{"id":"f95eaa3e-c6d1-4196-9d64-9fb6b5f3d028","procedure_id":"proc-repurposed-semaglutide","jurisdiction_id":"jur-sg","procedure_name":"GLP-1 Receptor Agonists (Semaglutide / Tirzepatide) Beyond Diabetes","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"HSA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","Addiction","Cardiovascular"],"diseases":["Obesity","Type 2 Diabetes","Cardiovascular Disease Risk","NAFLD/NASH"],"status":"active"},{"id":"147b4953-1d15-4343-ad3e-8817f3a14001","procedure_id":"proc-repurposed-semaglutide","jurisdiction_id":"jur-cl","procedure_name":"GLP-1 Receptor Agonists (Semaglutide / Tirzepatide) Beyond Diabetes","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","Addiction","Cardiovascular"],"diseases":["Obesity","Type 2 Diabetes","Cardiovascular Disease Risk","NAFLD/NASH"],"status":"active"},{"id":"68793f96-b01b-4163-9e8a-14fe479221dc","procedure_id":"proc-repurposed-semaglutide","jurisdiction_id":"jur-ar","procedure_name":"GLP-1 Receptor Agonists (Semaglutide / Tirzepatide) Beyond Diabetes","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","Addiction","Cardiovascular"],"diseases":["Obesity","Type 2 Diabetes","Cardiovascular Disease Risk","NAFLD/NASH"],"status":"active"},{"id":"038a75a6-5429-4fba-abc9-4a8e224cb78d","procedure_id":"proc-repurposed-semaglutide","jurisdiction_id":"jur-za","procedure_name":"GLP-1 Receptor Agonists (Semaglutide / Tirzepatide) Beyond Diabetes","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","Addiction","Cardiovascular"],"diseases":["Obesity","Type 2 Diabetes","Cardiovascular Disease Risk","NAFLD/NASH"],"status":"active"},{"id":"9114704d-5edf-4ff2-9313-8663b126b3e9","procedure_id":"proc-repurposed-semaglutide","jurisdiction_id":"jur-ph","procedure_name":"GLP-1 Receptor Agonists (Semaglutide / Tirzepatide) Beyond Diabetes","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","Addiction","Cardiovascular"],"diseases":["Obesity","Type 2 Diabetes","Cardiovascular Disease Risk","NAFLD/NASH"],"status":"active"},{"id":"7c181fd6-1eba-4ba1-9dc8-17a1e57a6466","procedure_id":"proc-repurposed-semaglutide","jurisdiction_id":"jur-po","procedure_name":"GLP-1 Receptor Agonists (Semaglutide / Tirzepatide) Beyond Diabetes","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","Addiction","Cardiovascular"],"diseases":["Obesity","Type 2 Diabetes","Cardiovascular Disease Risk","NAFLD/NASH"],"status":"active"},{"id":"40f32d09-48f1-4aca-a1a7-89827ac4e1e0","procedure_id":"proc-repurposed-semaglutide","jurisdiction_id":"jur-pt","procedure_name":"GLP-1 Receptor Agonists (Semaglutide / Tirzepatide) Beyond Diabetes","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","Addiction","Cardiovascular"],"diseases":["Obesity","Type 2 Diabetes","Cardiovascular Disease Risk","NAFLD/NASH"],"status":"active"},{"id":"12b19664-40a0-47f2-bcf6-180583b70a30","procedure_id":"proc-repurposed-semaglutide","jurisdiction_id":"jur-fr","procedure_name":"GLP-1 Receptor Agonists (Semaglutide / Tirzepatide) Beyond Diabetes","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"ANSM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","Addiction","Cardiovascular"],"diseases":["Obesity","Type 2 Diabetes","Cardiovascular Disease Risk","NAFLD/NASH"],"status":"active"},{"id":"fe08a5d4-f785-416a-bbde-e25b88d2c9da","procedure_id":"proc-repurposed-rapamycin","jurisdiction_id":"jur-us-or","procedure_name":"Rapamycin (Sirolimus) for Longevity/Healthspan","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Aging","Immunology"],"diseases":["Age-Related Functional Decline","Lymphangioleiomyomatosis (LAM)","Transplant Rejection (labeled)"],"status":"active"},{"id":"55cdfdc7-9499-402a-ba49-8e9ec8ec8628","procedure_id":"proc-repurposed-rapamycin","jurisdiction_id":"jur-us-co","procedure_name":"Rapamycin (Sirolimus) for Longevity/Healthspan","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Aging","Immunology"],"diseases":["Age-Related Functional Decline","Lymphangioleiomyomatosis (LAM)","Transplant Rejection (labeled)"],"status":"active"},{"id":"46205e50-7dc8-4cb4-be5f-4a96b4f67bfd","procedure_id":"proc-repurposed-rapamycin","jurisdiction_id":"jur-us-ca","procedure_name":"Rapamycin (Sirolimus) for Longevity/Healthspan","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Aging","Immunology"],"diseases":["Age-Related Functional Decline","Lymphangioleiomyomatosis (LAM)","Transplant Rejection (labeled)"],"status":"active"},{"id":"998c5997-8e4e-4f4d-ab6d-c43846310484","procedure_id":"proc-repurposed-rapamycin","jurisdiction_id":"jur-us-tx","procedure_name":"Rapamycin (Sirolimus) for Longevity/Healthspan","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Aging","Immunology"],"diseases":["Age-Related Functional Decline","Lymphangioleiomyomatosis (LAM)","Transplant Rejection (labeled)"],"status":"active"},{"id":"a7abe08e-5bf4-4b46-bcef-a09cc9e41a65","procedure_id":"proc-repurposed-rapamycin","jurisdiction_id":"jur-us-fl","procedure_name":"Rapamycin (Sirolimus) for Longevity/Healthspan","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Aging","Immunology"],"diseases":["Age-Related Functional Decline","Lymphangioleiomyomatosis (LAM)","Transplant Rejection (labeled)"],"status":"active"},{"id":"977952d0-9568-438b-a6c1-3c0cbfc652da","procedure_id":"proc-repurposed-rapamycin","jurisdiction_id":"jur-au","procedure_name":"Rapamycin (Sirolimus) for Longevity/Healthspan","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"TGA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Aging","Immunology"],"diseases":["Age-Related Functional Decline","Lymphangioleiomyomatosis (LAM)","Transplant Rejection (labeled)"],"status":"active"},{"id":"c63ef716-c8aa-4845-abfb-0242028365ab","procedure_id":"proc-repurposed-rapamycin","jurisdiction_id":"jur-ch","procedure_name":"Rapamycin (Sirolimus) for Longevity/Healthspan","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Swissmedic","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Aging","Immunology"],"diseases":["Age-Related Functional Decline","Lymphangioleiomyomatosis (LAM)","Transplant Rejection (labeled)"],"status":"active"},{"id":"841c1e31-c852-4dab-9192-80229fba6010","procedure_id":"proc-repurposed-rapamycin","jurisdiction_id":"jur-ca","procedure_name":"Rapamycin (Sirolimus) for Longevity/Healthspan","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Health Canada","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Aging","Immunology"],"diseases":["Age-Related Functional Decline","Lymphangioleiomyomatosis (LAM)","Transplant Rejection (labeled)"],"status":"active"},{"id":"dec55695-4e5c-4e91-9ae3-768931d26186","procedure_id":"proc-repurposed-rapamycin","jurisdiction_id":"jur-mx","procedure_name":"Rapamycin (Sirolimus) for Longevity/Healthspan","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Permissive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"COFEPRIS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Aging","Immunology"],"diseases":["Age-Related Functional Decline","Lymphangioleiomyomatosis (LAM)","Transplant Rejection (labeled)"],"status":"active"},{"id":"0baa6284-0e2a-4afb-9eee-7eb70757b897","procedure_id":"proc-repurposed-rapamycin","jurisdiction_id":"jur-hn-prospera","procedure_name":"Rapamycin (Sirolimus) for Longevity/Healthspan","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Permissive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Próspera ZEDE health rules (contested)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Aging","Immunology"],"diseases":["Age-Related Functional Decline","Lymphangioleiomyomatosis (LAM)","Transplant Rejection (labeled)"],"status":"active"},{"id":"1e3a2394-7132-4472-bf21-d022fc1e0857","procedure_id":"proc-repurposed-rapamycin","jurisdiction_id":"jur-nl","procedure_name":"Rapamycin (Sirolimus) for Longevity/Healthspan","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"MEB / IGJ","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Aging","Immunology"],"diseases":["Age-Related Functional Decline","Lymphangioleiomyomatosis (LAM)","Transplant Rejection (labeled)"],"status":"active"},{"id":"c67aab67-a3f4-4990-a8e2-3c769b685cc5","procedure_id":"proc-repurposed-rapamycin","jurisdiction_id":"jur-de","procedure_name":"Rapamycin (Sirolimus) for Longevity/Healthspan","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"BfArM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Aging","Immunology"],"diseases":["Age-Related Functional Decline","Lymphangioleiomyomatosis (LAM)","Transplant Rejection (labeled)"],"status":"active"},{"id":"316e36df-e743-45b9-bcf5-e110ddd707d2","procedure_id":"proc-repurposed-rapamycin","jurisdiction_id":"jur-uk","procedure_name":"Rapamycin (Sirolimus) for Longevity/Healthspan","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"MHRA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Aging","Immunology"],"diseases":["Age-Related Functional Decline","Lymphangioleiomyomatosis (LAM)","Transplant Rejection (labeled)"],"status":"active"},{"id":"31e22066-2d77-458a-894d-9435e9e4eada","procedure_id":"proc-repurposed-rapamycin","jurisdiction_id":"jur-il","procedure_name":"Rapamycin (Sirolimus) for Longevity/Healthspan","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Aging","Immunology"],"diseases":["Age-Related Functional Decline","Lymphangioleiomyomatosis (LAM)","Transplant Rejection (labeled)"],"status":"active"},{"id":"a4ec922b-7270-457e-858a-dec6dcb038d2","procedure_id":"proc-repurposed-rapamycin","jurisdiction_id":"jur-jm","procedure_name":"Rapamycin (Sirolimus) for Longevity/Healthspan","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Aging","Immunology"],"diseases":["Age-Related Functional Decline","Lymphangioleiomyomatosis (LAM)","Transplant Rejection (labeled)"],"status":"active"},{"id":"d26a836a-63a2-43ab-8033-a5d95762c918","procedure_id":"proc-repurposed-rapamycin","jurisdiction_id":"jur-th","procedure_name":"Rapamycin (Sirolimus) for Longevity/Healthspan","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Permissive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Thai FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Aging","Immunology"],"diseases":["Age-Related Functional Decline","Lymphangioleiomyomatosis (LAM)","Transplant Rejection (labeled)"],"status":"active"},{"id":"ec1becf6-0e5b-41a9-a38a-1730405aa702","procedure_id":"proc-repurposed-rapamycin","jurisdiction_id":"jur-es","procedure_name":"Rapamycin (Sirolimus) for Longevity/Healthspan","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"AEMPS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Aging","Immunology"],"diseases":["Age-Related Functional Decline","Lymphangioleiomyomatosis (LAM)","Transplant Rejection (labeled)"],"status":"active"},{"id":"1f16eb69-d543-42bf-8833-cb57053a8c40","procedure_id":"proc-repurposed-rapamycin","jurisdiction_id":"jur-tu","procedure_name":"Rapamycin (Sirolimus) for Longevity/Healthspan","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Aging","Immunology"],"diseases":["Age-Related Functional Decline","Lymphangioleiomyomatosis (LAM)","Transplant Rejection (labeled)"],"status":"active"},{"id":"d68d6d9c-6b29-4a50-89c2-b95132548c88","procedure_id":"proc-repurposed-rapamycin","jurisdiction_id":"jur-in","procedure_name":"Rapamycin (Sirolimus) for Longevity/Healthspan","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Permissive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"CDSCO","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Aging","Immunology"],"diseases":["Age-Related Functional Decline","Lymphangioleiomyomatosis (LAM)","Transplant Rejection (labeled)"],"status":"active"},{"id":"c44bbb69-ec0a-435a-9050-76fabb233b54","procedure_id":"proc-repurposed-rapamycin","jurisdiction_id":"jur-br","procedure_name":"Rapamycin (Sirolimus) for Longevity/Healthspan","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"ANVISA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Aging","Immunology"],"diseases":["Age-Related Functional Decline","Lymphangioleiomyomatosis (LAM)","Transplant Rejection (labeled)"],"status":"active"},{"id":"96e9fb14-9a93-4051-b6fb-1178d22e7efe","procedure_id":"proc-repurposed-rapamycin","jurisdiction_id":"jur-cr","procedure_name":"Rapamycin (Sirolimus) for Longevity/Healthspan","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Aging","Immunology"],"diseases":["Age-Related Functional Decline","Lymphangioleiomyomatosis (LAM)","Transplant Rejection (labeled)"],"status":"active"},{"id":"b2ce242a-f5a5-4368-a934-f9ad66aeb253","procedure_id":"proc-repurposed-rapamycin","jurisdiction_id":"jur-uae","procedure_name":"Rapamycin (Sirolimus) for Longevity/Healthspan","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Aging","Immunology"],"diseases":["Age-Related Functional Decline","Lymphangioleiomyomatosis (LAM)","Transplant Rejection (labeled)"],"status":"active"},{"id":"326af3a2-a279-49a2-b6ba-bf45a4aa7be6","procedure_id":"proc-repurposed-rapamycin","jurisdiction_id":"jur-kr","procedure_name":"Rapamycin (Sirolimus) for Longevity/Healthspan","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"MFDS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Aging","Immunology"],"diseases":["Age-Related Functional Decline","Lymphangioleiomyomatosis (LAM)","Transplant Rejection (labeled)"],"status":"active"},{"id":"62744875-4909-472b-bd49-eef9798ef384","procedure_id":"proc-repurposed-rapamycin","jurisdiction_id":"jur-gr","procedure_name":"Rapamycin (Sirolimus) for Longevity/Healthspan","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Aging","Immunology"],"diseases":["Age-Related Functional Decline","Lymphangioleiomyomatosis (LAM)","Transplant Rejection (labeled)"],"status":"active"},{"id":"52cb7761-9df1-4d64-9436-573c7b5234cd","procedure_id":"proc-repurposed-rapamycin","jurisdiction_id":"jur-be","procedure_name":"Rapamycin (Sirolimus) for Longevity/Healthspan","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Aging","Immunology"],"diseases":["Age-Related Functional Decline","Lymphangioleiomyomatosis (LAM)","Transplant Rejection (labeled)"],"status":"active"},{"id":"3b755c2a-441e-4eff-9f8f-0d8bd380a165","procedure_id":"proc-repurposed-rapamycin","jurisdiction_id":"jur-se","procedure_name":"Rapamycin (Sirolimus) for Longevity/Healthspan","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Aging","Immunology"],"diseases":["Age-Related Functional Decline","Lymphangioleiomyomatosis (LAM)","Transplant Rejection (labeled)"],"status":"active"},{"id":"65ffcd68-36a2-4fdd-bdff-f9c0426df61d","procedure_id":"proc-repurposed-rapamycin","jurisdiction_id":"jur-jp","procedure_name":"Rapamycin (Sirolimus) for Longevity/Healthspan","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"PMDA / MHLW","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Aging","Immunology"],"diseases":["Age-Related Functional Decline","Lymphangioleiomyomatosis (LAM)","Transplant Rejection (labeled)"],"status":"active"},{"id":"83204e22-a46c-46fb-b76d-31d3defecf73","procedure_id":"proc-repurposed-rapamycin","jurisdiction_id":"jur-sg","procedure_name":"Rapamycin (Sirolimus) for Longevity/Healthspan","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"HSA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Aging","Immunology"],"diseases":["Age-Related Functional Decline","Lymphangioleiomyomatosis (LAM)","Transplant Rejection (labeled)"],"status":"active"},{"id":"24453cd2-df11-4a2a-9f89-37f1e48acadb","procedure_id":"proc-repurposed-rapamycin","jurisdiction_id":"jur-cl","procedure_name":"Rapamycin (Sirolimus) for Longevity/Healthspan","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Aging","Immunology"],"diseases":["Age-Related Functional Decline","Lymphangioleiomyomatosis (LAM)","Transplant Rejection (labeled)"],"status":"active"},{"id":"3dadf428-7a2c-410a-be98-3280b3cacd39","procedure_id":"proc-repurposed-rapamycin","jurisdiction_id":"jur-ar","procedure_name":"Rapamycin (Sirolimus) for Longevity/Healthspan","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Aging","Immunology"],"diseases":["Age-Related Functional Decline","Lymphangioleiomyomatosis (LAM)","Transplant Rejection (labeled)"],"status":"active"},{"id":"0973ffbb-bd0d-4f07-8919-7b8deb4908d2","procedure_id":"proc-repurposed-rapamycin","jurisdiction_id":"jur-za","procedure_name":"Rapamycin (Sirolimus) for Longevity/Healthspan","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Aging","Immunology"],"diseases":["Age-Related Functional Decline","Lymphangioleiomyomatosis (LAM)","Transplant Rejection (labeled)"],"status":"active"},{"id":"aaaf6396-576a-46b1-8723-9603e964ee2c","procedure_id":"proc-repurposed-rapamycin","jurisdiction_id":"jur-ph","procedure_name":"Rapamycin (Sirolimus) for Longevity/Healthspan","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Aging","Immunology"],"diseases":["Age-Related Functional Decline","Lymphangioleiomyomatosis (LAM)","Transplant Rejection (labeled)"],"status":"active"},{"id":"5e413a4a-6fba-4271-a146-284a053c1973","procedure_id":"proc-repurposed-rapamycin","jurisdiction_id":"jur-po","procedure_name":"Rapamycin (Sirolimus) for Longevity/Healthspan","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Aging","Immunology"],"diseases":["Age-Related Functional Decline","Lymphangioleiomyomatosis (LAM)","Transplant Rejection (labeled)"],"status":"active"},{"id":"b3909c68-80a8-479b-aa26-e3ab27e988dd","procedure_id":"proc-repurposed-rapamycin","jurisdiction_id":"jur-pt","procedure_name":"Rapamycin (Sirolimus) for Longevity/Healthspan","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Aging","Immunology"],"diseases":["Age-Related Functional Decline","Lymphangioleiomyomatosis (LAM)","Transplant Rejection (labeled)"],"status":"active"},{"id":"527b2a48-c035-4208-b7bf-a750e47db20b","procedure_id":"proc-repurposed-rapamycin","jurisdiction_id":"jur-fr","procedure_name":"Rapamycin (Sirolimus) for Longevity/Healthspan","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"ANSM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Aging","Immunology"],"diseases":["Age-Related Functional Decline","Lymphangioleiomyomatosis (LAM)","Transplant Rejection (labeled)"],"status":"active"},{"id":"161d2e61-8c44-4eff-96a9-9d050313b682","procedure_id":"proc-stem-exosome","jurisdiction_id":"jur-us-or","procedure_name":"Exosome Therapy (Stem Cell-Derived) for Regeneration","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Regeneration","Anti_Aging","Orthopedic"],"diseases":["Osteoarthritis","Androgenetic Alopecia","Skin Aging","Soft Tissue Injury"],"status":"active"},{"id":"ec34ae88-5279-497d-8233-a5699b7ce996","procedure_id":"proc-stem-exosome","jurisdiction_id":"jur-us-co","procedure_name":"Exosome Therapy (Stem Cell-Derived) for Regeneration","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Regeneration","Anti_Aging","Orthopedic"],"diseases":["Osteoarthritis","Androgenetic Alopecia","Skin Aging","Soft Tissue Injury"],"status":"active"},{"id":"e312c783-3330-4595-9956-7cce2887ab93","procedure_id":"proc-stem-exosome","jurisdiction_id":"jur-us-ca","procedure_name":"Exosome Therapy (Stem Cell-Derived) for Regeneration","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Regeneration","Anti_Aging","Orthopedic"],"diseases":["Osteoarthritis","Androgenetic Alopecia","Skin Aging","Soft Tissue Injury"],"status":"active"},{"id":"7ad77e98-e1e7-45e1-ac7b-af753987d788","procedure_id":"proc-stem-exosome","jurisdiction_id":"jur-us-tx","procedure_name":"Exosome Therapy (Stem Cell-Derived) for Regeneration","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Regeneration","Anti_Aging","Orthopedic"],"diseases":["Osteoarthritis","Androgenetic Alopecia","Skin Aging","Soft Tissue Injury"],"status":"active"},{"id":"aa176803-15bb-44d2-b7d8-c4c263186cf9","procedure_id":"proc-stem-exosome","jurisdiction_id":"jur-us-fl","procedure_name":"Exosome Therapy (Stem Cell-Derived) for Regeneration","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Regeneration","Anti_Aging","Orthopedic"],"diseases":["Osteoarthritis","Androgenetic Alopecia","Skin Aging","Soft Tissue Injury"],"status":"active"},{"id":"8f1c4112-47cd-4de6-a12f-61bca363d04a","procedure_id":"proc-stem-exosome","jurisdiction_id":"jur-au","procedure_name":"Exosome Therapy (Stem Cell-Derived) for Regeneration","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"TGA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Regeneration","Anti_Aging","Orthopedic"],"diseases":["Osteoarthritis","Androgenetic Alopecia","Skin Aging","Soft Tissue Injury"],"status":"active"},{"id":"cecd3207-abaa-407b-a504-94a1d0688126","procedure_id":"proc-stem-exosome","jurisdiction_id":"jur-ch","procedure_name":"Exosome Therapy (Stem Cell-Derived) for Regeneration","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"Swissmedic","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Regeneration","Anti_Aging","Orthopedic"],"diseases":["Osteoarthritis","Androgenetic Alopecia","Skin Aging","Soft Tissue Injury"],"status":"active"},{"id":"63b6b858-e5b5-4ce0-85b5-b294dff981fc","procedure_id":"proc-stem-exosome","jurisdiction_id":"jur-ca","procedure_name":"Exosome Therapy (Stem Cell-Derived) for Regeneration","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"Health Canada","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Regeneration","Anti_Aging","Orthopedic"],"diseases":["Osteoarthritis","Androgenetic Alopecia","Skin Aging","Soft Tissue Injury"],"status":"active"},{"id":"f5ddd46c-ec6c-4a65-b716-cb5e58d03e7c","procedure_id":"proc-stem-exosome","jurisdiction_id":"jur-nl","procedure_name":"Exosome Therapy (Stem Cell-Derived) for Regeneration","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"MEB / IGJ","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Regeneration","Anti_Aging","Orthopedic"],"diseases":["Osteoarthritis","Androgenetic Alopecia","Skin Aging","Soft Tissue Injury"],"status":"active"},{"id":"726ecd70-540c-458a-9275-cf72c3f8fbac","procedure_id":"proc-stem-exosome","jurisdiction_id":"jur-de","procedure_name":"Exosome Therapy (Stem Cell-Derived) for Regeneration","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"BfArM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Regeneration","Anti_Aging","Orthopedic"],"diseases":["Osteoarthritis","Androgenetic Alopecia","Skin Aging","Soft Tissue Injury"],"status":"active"},{"id":"70a60e24-4999-46e8-afd8-cc84bca15030","procedure_id":"proc-stem-exosome","jurisdiction_id":"jur-uk","procedure_name":"Exosome Therapy (Stem Cell-Derived) for Regeneration","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"MHRA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Regeneration","Anti_Aging","Orthopedic"],"diseases":["Osteoarthritis","Androgenetic Alopecia","Skin Aging","Soft Tissue Injury"],"status":"active"},{"id":"5bf58161-a572-4a33-a59f-4dc12d9c0208","procedure_id":"proc-stem-exosome","jurisdiction_id":"jur-il","procedure_name":"Exosome Therapy (Stem Cell-Derived) for Regeneration","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Regeneration","Anti_Aging","Orthopedic"],"diseases":["Osteoarthritis","Androgenetic Alopecia","Skin Aging","Soft Tissue Injury"],"status":"active"},{"id":"25f67602-e479-4fdb-87f6-902e31792dea","procedure_id":"proc-stem-exosome","jurisdiction_id":"jur-jm","procedure_name":"Exosome Therapy (Stem Cell-Derived) for Regeneration","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Regeneration","Anti_Aging","Orthopedic"],"diseases":["Osteoarthritis","Androgenetic Alopecia","Skin Aging","Soft Tissue Injury"],"status":"active"},{"id":"26c71af8-e1d2-495b-9fca-cf209c986b48","procedure_id":"proc-stem-exosome","jurisdiction_id":"jur-es","procedure_name":"Exosome Therapy (Stem Cell-Derived) for Regeneration","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"AEMPS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Regeneration","Anti_Aging","Orthopedic"],"diseases":["Osteoarthritis","Androgenetic Alopecia","Skin Aging","Soft Tissue Injury"],"status":"active"},{"id":"ecbfc4bb-460a-401a-b4b5-e3d360ba9284","procedure_id":"proc-stem-exosome","jurisdiction_id":"jur-tu","procedure_name":"Exosome Therapy (Stem Cell-Derived) for Regeneration","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Regeneration","Anti_Aging","Orthopedic"],"diseases":["Osteoarthritis","Androgenetic Alopecia","Skin Aging","Soft Tissue Injury"],"status":"active"},{"id":"3f6f76b3-a661-4dba-8638-9efea43a452e","procedure_id":"proc-stem-exosome","jurisdiction_id":"jur-in","procedure_name":"Exosome Therapy (Stem Cell-Derived) for Regeneration","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"CDSCO","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Regeneration","Anti_Aging","Orthopedic"],"diseases":["Osteoarthritis","Androgenetic Alopecia","Skin Aging","Soft Tissue Injury"],"status":"active"},{"id":"a340565d-937b-4731-8542-bfaccc137e47","procedure_id":"proc-stem-exosome","jurisdiction_id":"jur-br","procedure_name":"Exosome Therapy (Stem Cell-Derived) for Regeneration","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"ANVISA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Regeneration","Anti_Aging","Orthopedic"],"diseases":["Osteoarthritis","Androgenetic Alopecia","Skin Aging","Soft Tissue Injury"],"status":"active"},{"id":"dbb249ec-203f-499f-a1f1-f6e6a8e59891","procedure_id":"proc-stem-exosome","jurisdiction_id":"jur-cr","procedure_name":"Exosome Therapy (Stem Cell-Derived) for Regeneration","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Regeneration","Anti_Aging","Orthopedic"],"diseases":["Osteoarthritis","Androgenetic Alopecia","Skin Aging","Soft Tissue Injury"],"status":"active"},{"id":"4b07f8f2-6cb2-45f5-bc0b-53ed3d418a51","procedure_id":"proc-stem-exosome","jurisdiction_id":"jur-gr","procedure_name":"Exosome Therapy (Stem Cell-Derived) for Regeneration","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Regeneration","Anti_Aging","Orthopedic"],"diseases":["Osteoarthritis","Androgenetic Alopecia","Skin Aging","Soft Tissue Injury"],"status":"active"},{"id":"b768bee4-56d0-42c9-b6b3-3114bf788586","procedure_id":"proc-stem-exosome","jurisdiction_id":"jur-be","procedure_name":"Exosome Therapy (Stem Cell-Derived) for Regeneration","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Regeneration","Anti_Aging","Orthopedic"],"diseases":["Osteoarthritis","Androgenetic Alopecia","Skin Aging","Soft Tissue Injury"],"status":"active"},{"id":"8951e9aa-450b-4474-8795-fea871fa0299","procedure_id":"proc-stem-exosome","jurisdiction_id":"jur-se","procedure_name":"Exosome Therapy (Stem Cell-Derived) for Regeneration","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Regeneration","Anti_Aging","Orthopedic"],"diseases":["Osteoarthritis","Androgenetic Alopecia","Skin Aging","Soft Tissue Injury"],"status":"active"},{"id":"a19d2ebe-d9a2-4ea0-991c-bdfca926b2d7","procedure_id":"proc-stem-exosome","jurisdiction_id":"jur-jp","procedure_name":"Exosome Therapy (Stem Cell-Derived) for Regeneration","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"PMDA / MHLW","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Regeneration","Anti_Aging","Orthopedic"],"diseases":["Osteoarthritis","Androgenetic Alopecia","Skin Aging","Soft Tissue Injury"],"status":"active"},{"id":"a507942c-db2f-4483-b614-1f4512cae254","procedure_id":"proc-stem-exosome","jurisdiction_id":"jur-sg","procedure_name":"Exosome Therapy (Stem Cell-Derived) for Regeneration","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"HSA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Regeneration","Anti_Aging","Orthopedic"],"diseases":["Osteoarthritis","Androgenetic Alopecia","Skin Aging","Soft Tissue Injury"],"status":"active"},{"id":"e8ead469-5016-4b80-9f85-d2c5c4c9dd68","procedure_id":"proc-stem-exosome","jurisdiction_id":"jur-cl","procedure_name":"Exosome Therapy (Stem Cell-Derived) for Regeneration","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Regeneration","Anti_Aging","Orthopedic"],"diseases":["Osteoarthritis","Androgenetic Alopecia","Skin Aging","Soft Tissue Injury"],"status":"active"},{"id":"15e8bdb1-3fc4-4b3e-a6f9-2bfad5511e7b","procedure_id":"proc-stem-exosome","jurisdiction_id":"jur-ar","procedure_name":"Exosome Therapy (Stem Cell-Derived) for Regeneration","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Regeneration","Anti_Aging","Orthopedic"],"diseases":["Osteoarthritis","Androgenetic Alopecia","Skin Aging","Soft Tissue Injury"],"status":"active"},{"id":"c7111c6d-999f-4827-9948-2ce9b9a8ecfe","procedure_id":"proc-stem-exosome","jurisdiction_id":"jur-za","procedure_name":"Exosome Therapy (Stem Cell-Derived) for Regeneration","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Regeneration","Anti_Aging","Orthopedic"],"diseases":["Osteoarthritis","Androgenetic Alopecia","Skin Aging","Soft Tissue Injury"],"status":"active"},{"id":"ef6fae01-3048-4a33-8e19-7d5e6959f6f1","procedure_id":"proc-stem-exosome","jurisdiction_id":"jur-ph","procedure_name":"Exosome Therapy (Stem Cell-Derived) for Regeneration","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Regeneration","Anti_Aging","Orthopedic"],"diseases":["Osteoarthritis","Androgenetic Alopecia","Skin Aging","Soft Tissue Injury"],"status":"active"},{"id":"0297595c-059e-41f0-a144-a1c1259df7cc","procedure_id":"proc-stem-exosome","jurisdiction_id":"jur-po","procedure_name":"Exosome Therapy (Stem Cell-Derived) for Regeneration","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Regeneration","Anti_Aging","Orthopedic"],"diseases":["Osteoarthritis","Androgenetic Alopecia","Skin Aging","Soft Tissue Injury"],"status":"active"},{"id":"9dffc830-6cdc-4190-a9e3-46d89d0ddfc9","procedure_id":"proc-stem-exosome","jurisdiction_id":"jur-pt","procedure_name":"Exosome Therapy (Stem Cell-Derived) for Regeneration","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Regeneration","Anti_Aging","Orthopedic"],"diseases":["Osteoarthritis","Androgenetic Alopecia","Skin Aging","Soft Tissue Injury"],"status":"active"},{"id":"d8b52821-a8e3-49c1-9faa-cf8702e8d85a","procedure_id":"proc-stem-exosome","jurisdiction_id":"jur-fr","procedure_name":"Exosome Therapy (Stem Cell-Derived) for Regeneration","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"ANSM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Regeneration","Anti_Aging","Orthopedic"],"diseases":["Osteoarthritis","Androgenetic Alopecia","Skin Aging","Soft Tissue Injury"],"status":"active"},{"id":"7d9ce929-364b-4936-98e5-a004ef4266aa","procedure_id":"proc-dmt-depression","jurisdiction_id":"jur-us-or","procedure_name":"DMT (N,N-Dimethyltryptamine) Assisted Therapy for Depression","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"REGULATED_THERAPY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Jurisdiction signals a regulated therapy-program model for psychedelics.","eligibility_requirements":"Program-specific screening (age, contraindications).","provider_requirements":"Program licenses / facilitator or medical credentials per local scheme.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred regulated program pathway may exist — still confirm license classes and product rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: Jurisdiction psychedelic_default=Regulated_Therapy_Program.","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Major Depressive Disorder","Treatment-Resistant Depression"],"status":"active"},{"id":"4f573a7c-36af-4e18-b698-281e5b3884b7","procedure_id":"proc-dmt-depression","jurisdiction_id":"jur-jm","procedure_name":"DMT (N,N-Dimethyltryptamine) Assisted Therapy for Depression","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"UNREGULATED_PERMITTED","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Default allows relatively open practice — quality and consumer protection still apply.","eligibility_requirements":"Operator-defined; local consumer law applies.","provider_requirements":"Local business/medical rules may still apply even if substance posture is open.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred permissive/unregulated posture — high variance in quality; diligence essential.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: Jurisdiction psychedelic_default=Unregulated_Permitted.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Major Depressive Disorder","Treatment-Resistant Depression"],"status":"active"},{"id":"cbec0e81-eaae-4f8c-bce6-0cb719898fb8","procedure_id":"proc-dmt-depression","jurisdiction_id":"jur-gr","procedure_name":"DMT (N,N-Dimethyltryptamine) Assisted Therapy for Depression","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Classical/atypical psychedelic therapy for DMT (N,N-Dimethyltryptamine) Assisted Therapy for Depression treated as prohibited outside narrow research under default national posture.","eligibility_requirements":"No lawful general patient pathway under inferred default.","provider_requirements":"Cannot lawfully open a commercial program without an explicit statutory exception.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Criminal liability risk if default is accurate; always verify current schedule.","arbitrage_summary":"Inferred prohibited under jurisdiction psychedelic default / UN-style scheduling. Not a lawful commercial therapy market.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: No jurisdiction psychedelic_default on file — applied conservative Schedule-I-class default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Major Depressive Disorder","Treatment-Resistant Depression"],"status":"active"},{"id":"780abacc-9e37-440a-9f2d-69d8ce5fc294","procedure_id":"proc-lsd-anxiety","jurisdiction_id":"jur-us-or","procedure_name":"LSD-Assisted Psychotherapy for Anxiety Disorders","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"REGULATED_THERAPY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Jurisdiction signals a regulated therapy-program model for psychedelics.","eligibility_requirements":"Program-specific screening (age, contraindications).","provider_requirements":"Program licenses / facilitator or medical credentials per local scheme.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred regulated program pathway may exist — still confirm license classes and product rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: Jurisdiction psychedelic_default=Regulated_Therapy_Program.","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Anxiety"],"diseases":["Generalized Anxiety Disorder","Illness-Related Anxiety"],"status":"active"},{"id":"894928b8-e88d-4394-b90d-2522aa46ac7c","procedure_id":"proc-lsd-anxiety","jurisdiction_id":"jur-us-co","procedure_name":"LSD-Assisted Psychotherapy for Anxiety Disorders","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"DECRIMINALIZED_NO_SUPPLY","access_pathway":"NONE","oversight_quality":"VARIABLE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Personal use may be decriminalized; commercial therapy supply not inferred as lawful.","eligibility_requirements":"No licensed therapy supply inferred.","provider_requirements":"No commercial pathway inferred.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred decrim-without-supply. Not a clinic destination under default rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: Jurisdiction psychedelic_default=Decriminalized_No_Supply.","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Anxiety"],"diseases":["Generalized Anxiety Disorder","Illness-Related Anxiety"],"status":"active"},{"id":"54252377-4df2-4d7c-9abf-1466d1605816","procedure_id":"proc-lsd-anxiety","jurisdiction_id":"jur-jm","procedure_name":"LSD-Assisted Psychotherapy for Anxiety Disorders","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"UNREGULATED_PERMITTED","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Default allows relatively open practice — quality and consumer protection still apply.","eligibility_requirements":"Operator-defined; local consumer law applies.","provider_requirements":"Local business/medical rules may still apply even if substance posture is open.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred permissive/unregulated posture — high variance in quality; diligence essential.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: Jurisdiction psychedelic_default=Unregulated_Permitted.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Anxiety"],"diseases":["Generalized Anxiety Disorder","Illness-Related Anxiety"],"status":"active"},{"id":"73ed02ee-1cf3-46f9-960b-6824cd50bc3b","procedure_id":"proc-lsd-anxiety","jurisdiction_id":"jur-gr","procedure_name":"LSD-Assisted Psychotherapy for Anxiety Disorders","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Classical/atypical psychedelic therapy for LSD-Assisted Psychotherapy for Anxiety Disorders treated as prohibited outside narrow research under default national posture.","eligibility_requirements":"No lawful general patient pathway under inferred default.","provider_requirements":"Cannot lawfully open a commercial program without an explicit statutory exception.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Criminal liability risk if default is accurate; always verify current schedule.","arbitrage_summary":"Inferred prohibited under jurisdiction psychedelic default / UN-style scheduling. Not a lawful commercial therapy market.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: No jurisdiction psychedelic_default on file — applied conservative Schedule-I-class default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Anxiety"],"diseases":["Generalized Anxiety Disorder","Illness-Related Anxiety"],"status":"active"},{"id":"c83f8df1-4275-487e-ac3e-719fe36b5569","procedure_id":"proc-mescaline-therapy","jurisdiction_id":"jur-us-or","procedure_name":"Mescaline-Assisted Therapy (San Pedro) for Depression/Addiction","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"REGULATED_THERAPY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Jurisdiction signals a regulated therapy-program model for psychedelics.","eligibility_requirements":"Program-specific screening (age, contraindications).","provider_requirements":"Program licenses / facilitator or medical credentials per local scheme.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred regulated program pathway may exist — still confirm license classes and product rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: Jurisdiction psychedelic_default=Regulated_Therapy_Program.","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression","Addiction"],"diseases":["Depression","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"12df6bbc-dd0d-4abe-9a50-82dd6d1e2a70","procedure_id":"proc-mescaline-therapy","jurisdiction_id":"jur-us-co","procedure_name":"Mescaline-Assisted Therapy (San Pedro) for Depression/Addiction","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"DECRIMINALIZED_NO_SUPPLY","access_pathway":"NONE","oversight_quality":"VARIABLE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Personal use may be decriminalized; commercial therapy supply not inferred as lawful.","eligibility_requirements":"No licensed therapy supply inferred.","provider_requirements":"No commercial pathway inferred.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred decrim-without-supply. Not a clinic destination under default rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: Jurisdiction psychedelic_default=Decriminalized_No_Supply.","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression","Addiction"],"diseases":["Depression","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"e64abc7e-373f-4c80-b7f3-f0834b2d2664","procedure_id":"proc-mescaline-therapy","jurisdiction_id":"jur-jm","procedure_name":"Mescaline-Assisted Therapy (San Pedro) for Depression/Addiction","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"UNREGULATED_PERMITTED","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Default allows relatively open practice — quality and consumer protection still apply.","eligibility_requirements":"Operator-defined; local consumer law applies.","provider_requirements":"Local business/medical rules may still apply even if substance posture is open.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred permissive/unregulated posture — high variance in quality; diligence essential.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: Jurisdiction psychedelic_default=Unregulated_Permitted.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression","Addiction"],"diseases":["Depression","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"20030af1-6663-4f90-ad6c-e76fb1da87f0","procedure_id":"proc-mescaline-therapy","jurisdiction_id":"jur-gr","procedure_name":"Mescaline-Assisted Therapy (San Pedro) for Depression/Addiction","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Classical/atypical psychedelic therapy for Mescaline-Assisted Therapy (San Pedro) for Depression/Addiction treated as prohibited outside narrow research under default national posture.","eligibility_requirements":"No lawful general patient pathway under inferred default.","provider_requirements":"Cannot lawfully open a commercial program without an explicit statutory exception.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Criminal liability risk if default is accurate; always verify current schedule.","arbitrage_summary":"Inferred prohibited under jurisdiction psychedelic default / UN-style scheduling. Not a lawful commercial therapy market.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: No jurisdiction psychedelic_default on file — applied conservative Schedule-I-class default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression","Addiction"],"diseases":["Depression","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"cd2f6000-592e-43dc-bd00-f914bf3a39e0","procedure_id":"proc-nad-iv","jurisdiction_id":"jur-us-or","procedure_name":"NAD+ IV Infusion for Mitochondrial Health/Longevity","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Energy","Neurological"],"diseases":["Chronic Fatigue","Long COVID","Mitochondrial Dysfunction","Age-Related Decline"],"status":"active"},{"id":"c71aa6cc-64cd-46ad-9d80-3dc4c4601f45","procedure_id":"proc-nad-iv","jurisdiction_id":"jur-us-co","procedure_name":"NAD+ IV Infusion for Mitochondrial Health/Longevity","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Energy","Neurological"],"diseases":["Chronic Fatigue","Long COVID","Mitochondrial Dysfunction","Age-Related Decline"],"status":"active"},{"id":"2af1aefb-d69b-4d84-9b31-c46d21a8af68","procedure_id":"proc-nad-iv","jurisdiction_id":"jur-us-ca","procedure_name":"NAD+ IV Infusion for Mitochondrial Health/Longevity","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Energy","Neurological"],"diseases":["Chronic Fatigue","Long COVID","Mitochondrial Dysfunction","Age-Related Decline"],"status":"active"},{"id":"50145362-4dd1-4486-bfdb-f03b24f1857d","procedure_id":"proc-nad-iv","jurisdiction_id":"jur-us-tx","procedure_name":"NAD+ IV Infusion for Mitochondrial Health/Longevity","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Energy","Neurological"],"diseases":["Chronic Fatigue","Long COVID","Mitochondrial Dysfunction","Age-Related Decline"],"status":"active"},{"id":"7dc9ffaf-0888-46dc-94dc-292533448e78","procedure_id":"proc-nad-iv","jurisdiction_id":"jur-us-fl","procedure_name":"NAD+ IV Infusion for Mitochondrial Health/Longevity","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Energy","Neurological"],"diseases":["Chronic Fatigue","Long COVID","Mitochondrial Dysfunction","Age-Related Decline"],"status":"active"},{"id":"868d1268-8133-46fa-a674-6d2ef1351107","procedure_id":"proc-nad-iv","jurisdiction_id":"jur-au","procedure_name":"NAD+ IV Infusion for Mitochondrial Health/Longevity","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"TGA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Energy","Neurological"],"diseases":["Chronic Fatigue","Long COVID","Mitochondrial Dysfunction","Age-Related Decline"],"status":"active"},{"id":"94ff88c1-ebc3-484e-b741-f2ecb9ff1742","procedure_id":"proc-nad-iv","jurisdiction_id":"jur-ch","procedure_name":"NAD+ IV Infusion for Mitochondrial Health/Longevity","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"Swissmedic","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Energy","Neurological"],"diseases":["Chronic Fatigue","Long COVID","Mitochondrial Dysfunction","Age-Related Decline"],"status":"active"},{"id":"39939887-a314-420e-a594-015d049ad450","procedure_id":"proc-nad-iv","jurisdiction_id":"jur-ca","procedure_name":"NAD+ IV Infusion for Mitochondrial Health/Longevity","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"Health Canada","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Energy","Neurological"],"diseases":["Chronic Fatigue","Long COVID","Mitochondrial Dysfunction","Age-Related Decline"],"status":"active"},{"id":"e234374d-e9e5-4ca6-a535-60d1a236154c","procedure_id":"proc-nad-iv","jurisdiction_id":"jur-mx","procedure_name":"NAD+ IV Infusion for Mitochondrial Health/Longevity","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"COFEPRIS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Energy","Neurological"],"diseases":["Chronic Fatigue","Long COVID","Mitochondrial Dysfunction","Age-Related Decline"],"status":"active"},{"id":"53cb71f6-7c66-4c52-920b-75b02971c4e3","procedure_id":"proc-nad-iv","jurisdiction_id":"jur-hn-prospera","procedure_name":"NAD+ IV Infusion for Mitochondrial Health/Longevity","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"Próspera ZEDE health rules (contested)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Energy","Neurological"],"diseases":["Chronic Fatigue","Long COVID","Mitochondrial Dysfunction","Age-Related Decline"],"status":"active"},{"id":"5a51d5f0-7dd8-4df3-9661-12b7b4606be6","procedure_id":"proc-nad-iv","jurisdiction_id":"jur-nl","procedure_name":"NAD+ IV Infusion for Mitochondrial Health/Longevity","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"MEB / IGJ","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Energy","Neurological"],"diseases":["Chronic Fatigue","Long COVID","Mitochondrial Dysfunction","Age-Related Decline"],"status":"active"},{"id":"7049857f-63ec-47b1-98f4-8202288bfb50","procedure_id":"proc-nad-iv","jurisdiction_id":"jur-de","procedure_name":"NAD+ IV Infusion for Mitochondrial Health/Longevity","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"BfArM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Energy","Neurological"],"diseases":["Chronic Fatigue","Long COVID","Mitochondrial Dysfunction","Age-Related Decline"],"status":"active"},{"id":"c852afce-4260-4d3c-9964-76097d84b8e8","procedure_id":"proc-nad-iv","jurisdiction_id":"jur-uk","procedure_name":"NAD+ IV Infusion for Mitochondrial Health/Longevity","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"MHRA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Energy","Neurological"],"diseases":["Chronic Fatigue","Long COVID","Mitochondrial Dysfunction","Age-Related Decline"],"status":"active"},{"id":"4da5df5c-4a6c-4037-a2a3-1aa1fd048555","procedure_id":"proc-nad-iv","jurisdiction_id":"jur-il","procedure_name":"NAD+ IV Infusion for Mitochondrial Health/Longevity","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Energy","Neurological"],"diseases":["Chronic Fatigue","Long COVID","Mitochondrial Dysfunction","Age-Related Decline"],"status":"active"},{"id":"ffd113a4-c979-45df-b85c-e1781ff8fcdd","procedure_id":"proc-nad-iv","jurisdiction_id":"jur-jm","procedure_name":"NAD+ IV Infusion for Mitochondrial Health/Longevity","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Energy","Neurological"],"diseases":["Chronic Fatigue","Long COVID","Mitochondrial Dysfunction","Age-Related Decline"],"status":"active"},{"id":"f537dcf9-0d1c-4125-ba12-bbea9fce9877","procedure_id":"proc-nad-iv","jurisdiction_id":"jur-th","procedure_name":"NAD+ IV Infusion for Mitochondrial Health/Longevity","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"Thai FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Energy","Neurological"],"diseases":["Chronic Fatigue","Long COVID","Mitochondrial Dysfunction","Age-Related Decline"],"status":"active"},{"id":"9740004f-9c35-4fc1-959f-fd75418442d4","procedure_id":"proc-nad-iv","jurisdiction_id":"jur-es","procedure_name":"NAD+ IV Infusion for Mitochondrial Health/Longevity","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"AEMPS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Energy","Neurological"],"diseases":["Chronic Fatigue","Long COVID","Mitochondrial Dysfunction","Age-Related Decline"],"status":"active"},{"id":"f4a8f3d9-886f-4415-91eb-1c6eacc187a6","procedure_id":"proc-nad-iv","jurisdiction_id":"jur-tu","procedure_name":"NAD+ IV Infusion for Mitochondrial Health/Longevity","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Energy","Neurological"],"diseases":["Chronic Fatigue","Long COVID","Mitochondrial Dysfunction","Age-Related Decline"],"status":"active"},{"id":"a3dcf908-5ef6-43bc-9fbf-10e7648fd357","procedure_id":"proc-nad-iv","jurisdiction_id":"jur-in","procedure_name":"NAD+ IV Infusion for Mitochondrial Health/Longevity","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"CDSCO","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Energy","Neurological"],"diseases":["Chronic Fatigue","Long COVID","Mitochondrial Dysfunction","Age-Related Decline"],"status":"active"},{"id":"60e05753-e22f-4b5a-9bad-0b743c694fd7","procedure_id":"proc-nad-iv","jurisdiction_id":"jur-br","procedure_name":"NAD+ IV Infusion for Mitochondrial Health/Longevity","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"ANVISA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Energy","Neurological"],"diseases":["Chronic Fatigue","Long COVID","Mitochondrial Dysfunction","Age-Related Decline"],"status":"active"},{"id":"42d7c44d-3df8-4a55-8d8d-10bf817d4f4c","procedure_id":"proc-nad-iv","jurisdiction_id":"jur-cr","procedure_name":"NAD+ IV Infusion for Mitochondrial Health/Longevity","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Energy","Neurological"],"diseases":["Chronic Fatigue","Long COVID","Mitochondrial Dysfunction","Age-Related Decline"],"status":"active"},{"id":"d61c8242-3d49-4c39-8e7b-9e5f527599e5","procedure_id":"proc-nad-iv","jurisdiction_id":"jur-uae","procedure_name":"NAD+ IV Infusion for Mitochondrial Health/Longevity","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Energy","Neurological"],"diseases":["Chronic Fatigue","Long COVID","Mitochondrial Dysfunction","Age-Related Decline"],"status":"active"},{"id":"81ab45cc-9b5c-4935-9beb-a78ed0ac75b5","procedure_id":"proc-nad-iv","jurisdiction_id":"jur-kr","procedure_name":"NAD+ IV Infusion for Mitochondrial Health/Longevity","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"MFDS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Energy","Neurological"],"diseases":["Chronic Fatigue","Long COVID","Mitochondrial Dysfunction","Age-Related Decline"],"status":"active"},{"id":"8f074ff6-f5eb-46e6-9e6f-a76fbca37434","procedure_id":"proc-nad-iv","jurisdiction_id":"jur-gr","procedure_name":"NAD+ IV Infusion for Mitochondrial Health/Longevity","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Energy","Neurological"],"diseases":["Chronic Fatigue","Long COVID","Mitochondrial Dysfunction","Age-Related Decline"],"status":"active"},{"id":"0efce36c-94ee-4519-a608-51e9df84f23d","procedure_id":"proc-nad-iv","jurisdiction_id":"jur-be","procedure_name":"NAD+ IV Infusion for Mitochondrial Health/Longevity","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Energy","Neurological"],"diseases":["Chronic Fatigue","Long COVID","Mitochondrial Dysfunction","Age-Related Decline"],"status":"active"},{"id":"a1d87b95-b386-4c57-9eb4-14f466906f4f","procedure_id":"proc-nad-iv","jurisdiction_id":"jur-se","procedure_name":"NAD+ IV Infusion for Mitochondrial Health/Longevity","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Energy","Neurological"],"diseases":["Chronic Fatigue","Long COVID","Mitochondrial Dysfunction","Age-Related Decline"],"status":"active"},{"id":"7f76916b-7e10-4f36-b8db-066fa63b18ee","procedure_id":"proc-nad-iv","jurisdiction_id":"jur-jp","procedure_name":"NAD+ IV Infusion for Mitochondrial Health/Longevity","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"PMDA / MHLW","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Energy","Neurological"],"diseases":["Chronic Fatigue","Long COVID","Mitochondrial Dysfunction","Age-Related Decline"],"status":"active"},{"id":"914772fa-83f7-4522-8041-67b50dc88ace","procedure_id":"proc-nad-iv","jurisdiction_id":"jur-sg","procedure_name":"NAD+ IV Infusion for Mitochondrial Health/Longevity","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"HSA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Energy","Neurological"],"diseases":["Chronic Fatigue","Long COVID","Mitochondrial Dysfunction","Age-Related Decline"],"status":"active"},{"id":"6e9b4c41-22a5-4852-ad4a-dcd3130aa270","procedure_id":"proc-nad-iv","jurisdiction_id":"jur-cl","procedure_name":"NAD+ IV Infusion for Mitochondrial Health/Longevity","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Energy","Neurological"],"diseases":["Chronic Fatigue","Long COVID","Mitochondrial Dysfunction","Age-Related Decline"],"status":"active"},{"id":"d3ce0562-e1f7-4465-8c01-2a146b365483","procedure_id":"proc-nad-iv","jurisdiction_id":"jur-ar","procedure_name":"NAD+ IV Infusion for Mitochondrial Health/Longevity","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Energy","Neurological"],"diseases":["Chronic Fatigue","Long COVID","Mitochondrial Dysfunction","Age-Related Decline"],"status":"active"},{"id":"495500a2-4047-4c7f-ab3e-e297b13b3194","procedure_id":"proc-nad-iv","jurisdiction_id":"jur-za","procedure_name":"NAD+ IV Infusion for Mitochondrial Health/Longevity","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Energy","Neurological"],"diseases":["Chronic Fatigue","Long COVID","Mitochondrial Dysfunction","Age-Related Decline"],"status":"active"},{"id":"92a9f9f6-307c-4988-a517-660bc4b6a78d","procedure_id":"proc-nad-iv","jurisdiction_id":"jur-ph","procedure_name":"NAD+ IV Infusion for Mitochondrial Health/Longevity","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Energy","Neurological"],"diseases":["Chronic Fatigue","Long COVID","Mitochondrial Dysfunction","Age-Related Decline"],"status":"active"},{"id":"1153289f-fac1-4fef-822a-71340933325e","procedure_id":"proc-nad-iv","jurisdiction_id":"jur-po","procedure_name":"NAD+ IV Infusion for Mitochondrial Health/Longevity","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Energy","Neurological"],"diseases":["Chronic Fatigue","Long COVID","Mitochondrial Dysfunction","Age-Related Decline"],"status":"active"},{"id":"729df337-3d30-46e9-a79a-b36b623595c1","procedure_id":"proc-nad-iv","jurisdiction_id":"jur-pt","procedure_name":"NAD+ IV Infusion for Mitochondrial Health/Longevity","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Energy","Neurological"],"diseases":["Chronic Fatigue","Long COVID","Mitochondrial Dysfunction","Age-Related Decline"],"status":"active"},{"id":"42722b92-ce60-4de6-aa11-76de5f20ec92","procedure_id":"proc-nad-iv","jurisdiction_id":"jur-fr","procedure_name":"NAD+ IV Infusion for Mitochondrial Health/Longevity","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"ANSM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Energy","Neurological"],"diseases":["Chronic Fatigue","Long COVID","Mitochondrial Dysfunction","Age-Related Decline"],"status":"active"},{"id":"0fa115e5-74e1-4f87-9031-cc1eb9a6066c","procedure_id":"proc-hbot","jurisdiction_id":"jur-us-or","procedure_name":"Hyperbaric Oxygen Therapy for Chronic Wounds/TBI/Lyme","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Wound_Healing","Neurological","Chronic_Infection"],"diseases":["Diabetic Foot Ulcer","Chronic Osteomyelitis","Traumatic Brain Injury (off-label)","Chronic Lyme (off-label)"],"status":"active"},{"id":"bfc83567-87be-4b70-b1b4-b4765f2cde76","procedure_id":"proc-hbot","jurisdiction_id":"jur-us-co","procedure_name":"Hyperbaric Oxygen Therapy for Chronic Wounds/TBI/Lyme","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Wound_Healing","Neurological","Chronic_Infection"],"diseases":["Diabetic Foot Ulcer","Chronic Osteomyelitis","Traumatic Brain Injury (off-label)","Chronic Lyme (off-label)"],"status":"active"},{"id":"d9a3ecdd-96ec-4512-8af7-387230ff7f2d","procedure_id":"proc-hbot","jurisdiction_id":"jur-us-ca","procedure_name":"Hyperbaric Oxygen Therapy for Chronic Wounds/TBI/Lyme","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Wound_Healing","Neurological","Chronic_Infection"],"diseases":["Diabetic Foot Ulcer","Chronic Osteomyelitis","Traumatic Brain Injury (off-label)","Chronic Lyme (off-label)"],"status":"active"},{"id":"a250c432-4520-4f3d-b4b8-77e06a2354cf","procedure_id":"proc-hbot","jurisdiction_id":"jur-us-tx","procedure_name":"Hyperbaric Oxygen Therapy for Chronic Wounds/TBI/Lyme","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Wound_Healing","Neurological","Chronic_Infection"],"diseases":["Diabetic Foot Ulcer","Chronic Osteomyelitis","Traumatic Brain Injury (off-label)","Chronic Lyme (off-label)"],"status":"active"},{"id":"9d910473-6688-4b50-9db4-e817e4374277","procedure_id":"proc-hbot","jurisdiction_id":"jur-us-fl","procedure_name":"Hyperbaric Oxygen Therapy for Chronic Wounds/TBI/Lyme","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Wound_Healing","Neurological","Chronic_Infection"],"diseases":["Diabetic Foot Ulcer","Chronic Osteomyelitis","Traumatic Brain Injury (off-label)","Chronic Lyme (off-label)"],"status":"active"},{"id":"e08243c1-8086-481e-b49c-43d1fc9cda01","procedure_id":"proc-hbot","jurisdiction_id":"jur-au","procedure_name":"Hyperbaric Oxygen Therapy for Chronic Wounds/TBI/Lyme","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"TGA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Wound_Healing","Neurological","Chronic_Infection"],"diseases":["Diabetic Foot Ulcer","Chronic Osteomyelitis","Traumatic Brain Injury (off-label)","Chronic Lyme (off-label)"],"status":"active"},{"id":"285de8ac-3335-4ef7-a580-f2b9ae1e25f7","procedure_id":"proc-hbot","jurisdiction_id":"jur-ch","procedure_name":"Hyperbaric Oxygen Therapy for Chronic Wounds/TBI/Lyme","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Swissmedic","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Wound_Healing","Neurological","Chronic_Infection"],"diseases":["Diabetic Foot Ulcer","Chronic Osteomyelitis","Traumatic Brain Injury (off-label)","Chronic Lyme (off-label)"],"status":"active"},{"id":"9d7f4427-f2f5-4f21-a5b4-2d3d705c7239","procedure_id":"proc-hbot","jurisdiction_id":"jur-ca","procedure_name":"Hyperbaric Oxygen Therapy for Chronic Wounds/TBI/Lyme","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Health Canada","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Wound_Healing","Neurological","Chronic_Infection"],"diseases":["Diabetic Foot Ulcer","Chronic Osteomyelitis","Traumatic Brain Injury (off-label)","Chronic Lyme (off-label)"],"status":"active"},{"id":"095dcd9d-1080-490a-8005-830e1846364f","procedure_id":"proc-hbot","jurisdiction_id":"jur-mx","procedure_name":"Hyperbaric Oxygen Therapy for Chronic Wounds/TBI/Lyme","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"COFEPRIS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Wound_Healing","Neurological","Chronic_Infection"],"diseases":["Diabetic Foot Ulcer","Chronic Osteomyelitis","Traumatic Brain Injury (off-label)","Chronic Lyme (off-label)"],"status":"active"},{"id":"03bef094-9371-4f01-9bae-d38139dded11","procedure_id":"proc-hbot","jurisdiction_id":"jur-hn-prospera","procedure_name":"Hyperbaric Oxygen Therapy for Chronic Wounds/TBI/Lyme","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Próspera ZEDE health rules (contested)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Wound_Healing","Neurological","Chronic_Infection"],"diseases":["Diabetic Foot Ulcer","Chronic Osteomyelitis","Traumatic Brain Injury (off-label)","Chronic Lyme (off-label)"],"status":"active"},{"id":"5eed750d-b656-4e44-a037-746089900675","procedure_id":"proc-hbot","jurisdiction_id":"jur-nl","procedure_name":"Hyperbaric Oxygen Therapy for Chronic Wounds/TBI/Lyme","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"MEB / IGJ","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Wound_Healing","Neurological","Chronic_Infection"],"diseases":["Diabetic Foot Ulcer","Chronic Osteomyelitis","Traumatic Brain Injury (off-label)","Chronic Lyme (off-label)"],"status":"active"},{"id":"325b9080-9787-4480-86b4-f02e97d3e247","procedure_id":"proc-hbot","jurisdiction_id":"jur-de","procedure_name":"Hyperbaric Oxygen Therapy for Chronic Wounds/TBI/Lyme","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"BfArM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Wound_Healing","Neurological","Chronic_Infection"],"diseases":["Diabetic Foot Ulcer","Chronic Osteomyelitis","Traumatic Brain Injury (off-label)","Chronic Lyme (off-label)"],"status":"active"},{"id":"d75321be-dd96-46b4-a92d-14b03bdbe470","procedure_id":"proc-hbot","jurisdiction_id":"jur-uk","procedure_name":"Hyperbaric Oxygen Therapy for Chronic Wounds/TBI/Lyme","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"MHRA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Wound_Healing","Neurological","Chronic_Infection"],"diseases":["Diabetic Foot Ulcer","Chronic Osteomyelitis","Traumatic Brain Injury (off-label)","Chronic Lyme (off-label)"],"status":"active"},{"id":"183c1935-50a8-4f4a-85af-d3c75f2c5a42","procedure_id":"proc-hbot","jurisdiction_id":"jur-il","procedure_name":"Hyperbaric Oxygen Therapy for Chronic Wounds/TBI/Lyme","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Wound_Healing","Neurological","Chronic_Infection"],"diseases":["Diabetic Foot Ulcer","Chronic Osteomyelitis","Traumatic Brain Injury (off-label)","Chronic Lyme (off-label)"],"status":"active"},{"id":"a03982b4-c8d8-4c27-952c-e6d792f6a5a2","procedure_id":"proc-hbot","jurisdiction_id":"jur-jm","procedure_name":"Hyperbaric Oxygen Therapy for Chronic Wounds/TBI/Lyme","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Wound_Healing","Neurological","Chronic_Infection"],"diseases":["Diabetic Foot Ulcer","Chronic Osteomyelitis","Traumatic Brain Injury (off-label)","Chronic Lyme (off-label)"],"status":"active"},{"id":"fa171d61-f5fc-4c46-82bb-60858d30a5ee","procedure_id":"proc-hbot","jurisdiction_id":"jur-th","procedure_name":"Hyperbaric Oxygen Therapy for Chronic Wounds/TBI/Lyme","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Thai FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Wound_Healing","Neurological","Chronic_Infection"],"diseases":["Diabetic Foot Ulcer","Chronic Osteomyelitis","Traumatic Brain Injury (off-label)","Chronic Lyme (off-label)"],"status":"active"},{"id":"e9b4a2fd-0a27-455c-8b38-cccbbdbb92d3","procedure_id":"proc-hbot","jurisdiction_id":"jur-es","procedure_name":"Hyperbaric Oxygen Therapy for Chronic Wounds/TBI/Lyme","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"AEMPS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Wound_Healing","Neurological","Chronic_Infection"],"diseases":["Diabetic Foot Ulcer","Chronic Osteomyelitis","Traumatic Brain Injury (off-label)","Chronic Lyme (off-label)"],"status":"active"},{"id":"b1af78fe-1b31-4d3f-b622-510f8d5bb3e9","procedure_id":"proc-hbot","jurisdiction_id":"jur-tu","procedure_name":"Hyperbaric Oxygen Therapy for Chronic Wounds/TBI/Lyme","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Wound_Healing","Neurological","Chronic_Infection"],"diseases":["Diabetic Foot Ulcer","Chronic Osteomyelitis","Traumatic Brain Injury (off-label)","Chronic Lyme (off-label)"],"status":"active"},{"id":"132a99ca-9026-496f-87e1-578c933795e2","procedure_id":"proc-hbot","jurisdiction_id":"jur-in","procedure_name":"Hyperbaric Oxygen Therapy for Chronic Wounds/TBI/Lyme","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"CDSCO","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Wound_Healing","Neurological","Chronic_Infection"],"diseases":["Diabetic Foot Ulcer","Chronic Osteomyelitis","Traumatic Brain Injury (off-label)","Chronic Lyme (off-label)"],"status":"active"},{"id":"dc099f9d-34ab-42d9-9f72-de09e5c97adf","procedure_id":"proc-hbot","jurisdiction_id":"jur-br","procedure_name":"Hyperbaric Oxygen Therapy for Chronic Wounds/TBI/Lyme","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"ANVISA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Wound_Healing","Neurological","Chronic_Infection"],"diseases":["Diabetic Foot Ulcer","Chronic Osteomyelitis","Traumatic Brain Injury (off-label)","Chronic Lyme (off-label)"],"status":"active"},{"id":"c17256ee-544d-4cba-b6f8-89149cd1e699","procedure_id":"proc-hbot","jurisdiction_id":"jur-cr","procedure_name":"Hyperbaric Oxygen Therapy for Chronic Wounds/TBI/Lyme","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Wound_Healing","Neurological","Chronic_Infection"],"diseases":["Diabetic Foot Ulcer","Chronic Osteomyelitis","Traumatic Brain Injury (off-label)","Chronic Lyme (off-label)"],"status":"active"},{"id":"2308f010-ddb5-4bfa-9173-590e10e6dd0e","procedure_id":"proc-hbot","jurisdiction_id":"jur-uae","procedure_name":"Hyperbaric Oxygen Therapy for Chronic Wounds/TBI/Lyme","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Wound_Healing","Neurological","Chronic_Infection"],"diseases":["Diabetic Foot Ulcer","Chronic Osteomyelitis","Traumatic Brain Injury (off-label)","Chronic Lyme (off-label)"],"status":"active"},{"id":"332a6151-db84-4dd2-993e-92a861267182","procedure_id":"proc-hbot","jurisdiction_id":"jur-kr","procedure_name":"Hyperbaric Oxygen Therapy for Chronic Wounds/TBI/Lyme","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"MFDS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Wound_Healing","Neurological","Chronic_Infection"],"diseases":["Diabetic Foot Ulcer","Chronic Osteomyelitis","Traumatic Brain Injury (off-label)","Chronic Lyme (off-label)"],"status":"active"},{"id":"075c5f6f-cd68-4e45-b507-812a1cccb97e","procedure_id":"proc-hbot","jurisdiction_id":"jur-gr","procedure_name":"Hyperbaric Oxygen Therapy for Chronic Wounds/TBI/Lyme","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Wound_Healing","Neurological","Chronic_Infection"],"diseases":["Diabetic Foot Ulcer","Chronic Osteomyelitis","Traumatic Brain Injury (off-label)","Chronic Lyme (off-label)"],"status":"active"},{"id":"219f52c3-eb95-4886-9ccb-72cefd6cbd6a","procedure_id":"proc-hbot","jurisdiction_id":"jur-be","procedure_name":"Hyperbaric Oxygen Therapy for Chronic Wounds/TBI/Lyme","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Wound_Healing","Neurological","Chronic_Infection"],"diseases":["Diabetic Foot Ulcer","Chronic Osteomyelitis","Traumatic Brain Injury (off-label)","Chronic Lyme (off-label)"],"status":"active"},{"id":"71badcfc-2bb0-4909-b17a-bea8f14345cc","procedure_id":"proc-hbot","jurisdiction_id":"jur-se","procedure_name":"Hyperbaric Oxygen Therapy for Chronic Wounds/TBI/Lyme","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Wound_Healing","Neurological","Chronic_Infection"],"diseases":["Diabetic Foot Ulcer","Chronic Osteomyelitis","Traumatic Brain Injury (off-label)","Chronic Lyme (off-label)"],"status":"active"},{"id":"ce4caf34-b5b0-427b-ad10-f0df37f405d1","procedure_id":"proc-hbot","jurisdiction_id":"jur-jp","procedure_name":"Hyperbaric Oxygen Therapy for Chronic Wounds/TBI/Lyme","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"PMDA / MHLW","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Wound_Healing","Neurological","Chronic_Infection"],"diseases":["Diabetic Foot Ulcer","Chronic Osteomyelitis","Traumatic Brain Injury (off-label)","Chronic Lyme (off-label)"],"status":"active"},{"id":"a4d8499e-aaff-4acd-baab-b34bc578d5fb","procedure_id":"proc-hbot","jurisdiction_id":"jur-sg","procedure_name":"Hyperbaric Oxygen Therapy for Chronic Wounds/TBI/Lyme","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"HSA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Wound_Healing","Neurological","Chronic_Infection"],"diseases":["Diabetic Foot Ulcer","Chronic Osteomyelitis","Traumatic Brain Injury (off-label)","Chronic Lyme (off-label)"],"status":"active"},{"id":"d2f2208c-86a6-46e3-8f9c-f81b08509473","procedure_id":"proc-hbot","jurisdiction_id":"jur-cl","procedure_name":"Hyperbaric Oxygen Therapy for Chronic Wounds/TBI/Lyme","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Wound_Healing","Neurological","Chronic_Infection"],"diseases":["Diabetic Foot Ulcer","Chronic Osteomyelitis","Traumatic Brain Injury (off-label)","Chronic Lyme (off-label)"],"status":"active"},{"id":"b74a77ae-4f14-419d-9432-cf1a238f37c0","procedure_id":"proc-hbot","jurisdiction_id":"jur-ar","procedure_name":"Hyperbaric Oxygen Therapy for Chronic Wounds/TBI/Lyme","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Wound_Healing","Neurological","Chronic_Infection"],"diseases":["Diabetic Foot Ulcer","Chronic Osteomyelitis","Traumatic Brain Injury (off-label)","Chronic Lyme (off-label)"],"status":"active"},{"id":"9c6998ab-dbbb-4b3a-b835-4d0850fd8647","procedure_id":"proc-hbot","jurisdiction_id":"jur-za","procedure_name":"Hyperbaric Oxygen Therapy for Chronic Wounds/TBI/Lyme","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Wound_Healing","Neurological","Chronic_Infection"],"diseases":["Diabetic Foot Ulcer","Chronic Osteomyelitis","Traumatic Brain Injury (off-label)","Chronic Lyme (off-label)"],"status":"active"},{"id":"93835c75-f931-45c8-9792-29811efbd527","procedure_id":"proc-hbot","jurisdiction_id":"jur-ph","procedure_name":"Hyperbaric Oxygen Therapy for Chronic Wounds/TBI/Lyme","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Wound_Healing","Neurological","Chronic_Infection"],"diseases":["Diabetic Foot Ulcer","Chronic Osteomyelitis","Traumatic Brain Injury (off-label)","Chronic Lyme (off-label)"],"status":"active"},{"id":"c04ab5bd-d355-43d7-8ce8-641c8068a9e8","procedure_id":"proc-hbot","jurisdiction_id":"jur-po","procedure_name":"Hyperbaric Oxygen Therapy for Chronic Wounds/TBI/Lyme","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Wound_Healing","Neurological","Chronic_Infection"],"diseases":["Diabetic Foot Ulcer","Chronic Osteomyelitis","Traumatic Brain Injury (off-label)","Chronic Lyme (off-label)"],"status":"active"},{"id":"22dacdde-4f0f-4627-95fc-b32b54af9a35","procedure_id":"proc-hbot","jurisdiction_id":"jur-pt","procedure_name":"Hyperbaric Oxygen Therapy for Chronic Wounds/TBI/Lyme","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Wound_Healing","Neurological","Chronic_Infection"],"diseases":["Diabetic Foot Ulcer","Chronic Osteomyelitis","Traumatic Brain Injury (off-label)","Chronic Lyme (off-label)"],"status":"active"},{"id":"ec5635bc-c918-4669-b7db-e38bc219c02e","procedure_id":"proc-hbot","jurisdiction_id":"jur-fr","procedure_name":"Hyperbaric Oxygen Therapy for Chronic Wounds/TBI/Lyme","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"ANSM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Wound_Healing","Neurological","Chronic_Infection"],"diseases":["Diabetic Foot Ulcer","Chronic Osteomyelitis","Traumatic Brain Injury (off-label)","Chronic Lyme (off-label)"],"status":"active"},{"id":"58102bf2-0603-45fa-a87c-1b9b9585411a","procedure_id":"proc-fmt","jurisdiction_id":"jur-us-or","procedure_name":"Fecal Microbiota Transplantation (FMT) for CDI/IBD","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_ON_LABEL","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Do not assume IBD/SIBO commercial FMT is authorized.","eligibility_requirements":"Primarily recurrent C. difficile where products exist.","provider_requirements":"GI/ID scope + product labeling.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: labeled microbiota products where registered; else trial/expanded access.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: cleared microbiota products for rCDI exist in some markets; other indications often trial-only.","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal","Autoimmune"],"diseases":["Recurrent C. difficile Infection","Ulcerative Colitis (off-label)","Crohn's Disease (off-label)"],"status":"active"},{"id":"b2e66e7c-88d9-4d65-a9bf-4bfac08c25fe","procedure_id":"proc-fmt","jurisdiction_id":"jur-us-co","procedure_name":"Fecal Microbiota Transplantation (FMT) for CDI/IBD","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_ON_LABEL","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Do not assume IBD/SIBO commercial FMT is authorized.","eligibility_requirements":"Primarily recurrent C. difficile where products exist.","provider_requirements":"GI/ID scope + product labeling.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: labeled microbiota products where registered; else trial/expanded access.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: cleared microbiota products for rCDI exist in some markets; other indications often trial-only.","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal","Autoimmune"],"diseases":["Recurrent C. difficile Infection","Ulcerative Colitis (off-label)","Crohn's Disease (off-label)"],"status":"active"},{"id":"66616fd0-6242-4344-a3da-1db69f4a9195","procedure_id":"proc-fmt","jurisdiction_id":"jur-us-ca","procedure_name":"Fecal Microbiota Transplantation (FMT) for CDI/IBD","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_ON_LABEL","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Do not assume IBD/SIBO commercial FMT is authorized.","eligibility_requirements":"Primarily recurrent C. difficile where products exist.","provider_requirements":"GI/ID scope + product labeling.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: labeled microbiota products where registered; else trial/expanded access.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: cleared microbiota products for rCDI exist in some markets; other indications often trial-only.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal","Autoimmune"],"diseases":["Recurrent C. difficile Infection","Ulcerative Colitis (off-label)","Crohn's Disease (off-label)"],"status":"active"},{"id":"ecc58ea9-5e51-4812-b35a-270484257ec3","procedure_id":"proc-fmt","jurisdiction_id":"jur-us-tx","procedure_name":"Fecal Microbiota Transplantation (FMT) for CDI/IBD","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_ON_LABEL","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Do not assume IBD/SIBO commercial FMT is authorized.","eligibility_requirements":"Primarily recurrent C. difficile where products exist.","provider_requirements":"GI/ID scope + product labeling.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: labeled microbiota products where registered; else trial/expanded access.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: cleared microbiota products for rCDI exist in some markets; other indications often trial-only.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal","Autoimmune"],"diseases":["Recurrent C. difficile Infection","Ulcerative Colitis (off-label)","Crohn's Disease (off-label)"],"status":"active"},{"id":"ed165fb4-c22b-451b-8c06-626949b167cc","procedure_id":"proc-fmt","jurisdiction_id":"jur-us-fl","procedure_name":"Fecal Microbiota Transplantation (FMT) for CDI/IBD","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_ON_LABEL","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Do not assume IBD/SIBO commercial FMT is authorized.","eligibility_requirements":"Primarily recurrent C. difficile where products exist.","provider_requirements":"GI/ID scope + product labeling.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: labeled microbiota products where registered; else trial/expanded access.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: cleared microbiota products for rCDI exist in some markets; other indications often trial-only.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal","Autoimmune"],"diseases":["Recurrent C. difficile Infection","Ulcerative Colitis (off-label)","Crohn's Disease (off-label)"],"status":"active"},{"id":"1e269cbe-6e72-4c2e-b7a2-d9ad9e06ef8c","procedure_id":"proc-fmt","jurisdiction_id":"jur-au","procedure_name":"Fecal Microbiota Transplantation (FMT) for CDI/IBD","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"APPROVED_ON_LABEL","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Do not assume IBD/SIBO commercial FMT is authorized.","eligibility_requirements":"Primarily recurrent C. difficile where products exist.","provider_requirements":"GI/ID scope + product labeling.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: labeled microbiota products where registered; else trial/expanded access.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: cleared microbiota products for rCDI exist in some markets; other indications often trial-only.","regulatory_authority":"TGA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal","Autoimmune"],"diseases":["Recurrent C. difficile Infection","Ulcerative Colitis (off-label)","Crohn's Disease (off-label)"],"status":"active"},{"id":"2929ba03-cd24-41b0-ab50-acf3079a28c4","procedure_id":"proc-fmt","jurisdiction_id":"jur-ch","procedure_name":"Fecal Microbiota Transplantation (FMT) for CDI/IBD","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"APPROVED_ON_LABEL","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Do not assume IBD/SIBO commercial FMT is authorized.","eligibility_requirements":"Primarily recurrent C. difficile where products exist.","provider_requirements":"GI/ID scope + product labeling.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: labeled microbiota products where registered; else trial/expanded access.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: cleared microbiota products for rCDI exist in some markets; other indications often trial-only.","regulatory_authority":"Swissmedic","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal","Autoimmune"],"diseases":["Recurrent C. difficile Infection","Ulcerative Colitis (off-label)","Crohn's Disease (off-label)"],"status":"active"},{"id":"8e996088-e933-4a43-b8cb-d11ebc10490a","procedure_id":"proc-fmt","jurisdiction_id":"jur-ca","procedure_name":"Fecal Microbiota Transplantation (FMT) for CDI/IBD","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"APPROVED_ON_LABEL","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Do not assume IBD/SIBO commercial FMT is authorized.","eligibility_requirements":"Primarily recurrent C. difficile where products exist.","provider_requirements":"GI/ID scope + product labeling.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: labeled microbiota products where registered; else trial/expanded access.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: cleared microbiota products for rCDI exist in some markets; other indications often trial-only.","regulatory_authority":"Health Canada","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal","Autoimmune"],"diseases":["Recurrent C. difficile Infection","Ulcerative Colitis (off-label)","Crohn's Disease (off-label)"],"status":"active"},{"id":"20604f75-f786-428b-9432-ccfae2105f3b","procedure_id":"proc-fmt","jurisdiction_id":"jur-mx","procedure_name":"Fecal Microbiota Transplantation (FMT) for CDI/IBD","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"REGULATED_MODERATE","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Do not assume IBD/SIBO commercial FMT is authorized.","eligibility_requirements":"Primarily recurrent C. difficile where products exist.","provider_requirements":"GI/ID scope + product labeling.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: labeled microbiota products where registered; else trial/expanded access.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: cleared microbiota products for rCDI exist in some markets; other indications often trial-only.","regulatory_authority":"COFEPRIS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal","Autoimmune"],"diseases":["Recurrent C. difficile Infection","Ulcerative Colitis (off-label)","Crohn's Disease (off-label)"],"status":"active"},{"id":"305a4ac5-a42d-4fd5-acd9-fe6ee9f420e7","procedure_id":"proc-fmt","jurisdiction_id":"jur-hn-prospera","procedure_name":"Fecal Microbiota Transplantation (FMT) for CDI/IBD","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"REGULATED_MODERATE","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Do not assume IBD/SIBO commercial FMT is authorized.","eligibility_requirements":"Primarily recurrent C. difficile where products exist.","provider_requirements":"GI/ID scope + product labeling.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: labeled microbiota products where registered; else trial/expanded access.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: cleared microbiota products for rCDI exist in some markets; other indications often trial-only.","regulatory_authority":"Próspera ZEDE health rules (contested)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal","Autoimmune"],"diseases":["Recurrent C. difficile Infection","Ulcerative Colitis (off-label)","Crohn's Disease (off-label)"],"status":"active"},{"id":"6248ed24-8591-4002-81c7-bc02516f6ad7","procedure_id":"proc-fmt","jurisdiction_id":"jur-nl","procedure_name":"Fecal Microbiota Transplantation (FMT) for CDI/IBD","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"APPROVED_ON_LABEL","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Do not assume IBD/SIBO commercial FMT is authorized.","eligibility_requirements":"Primarily recurrent C. difficile where products exist.","provider_requirements":"GI/ID scope + product labeling.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: labeled microbiota products where registered; else trial/expanded access.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: cleared microbiota products for rCDI exist in some markets; other indications often trial-only.","regulatory_authority":"MEB / IGJ","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal","Autoimmune"],"diseases":["Recurrent C. difficile Infection","Ulcerative Colitis (off-label)","Crohn's Disease (off-label)"],"status":"active"},{"id":"3afa2aea-38f3-4c12-837f-bfbc249601bc","procedure_id":"proc-fmt","jurisdiction_id":"jur-de","procedure_name":"Fecal Microbiota Transplantation (FMT) for CDI/IBD","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"APPROVED_ON_LABEL","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Do not assume IBD/SIBO commercial FMT is authorized.","eligibility_requirements":"Primarily recurrent C. difficile where products exist.","provider_requirements":"GI/ID scope + product labeling.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: labeled microbiota products where registered; else trial/expanded access.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: cleared microbiota products for rCDI exist in some markets; other indications often trial-only.","regulatory_authority":"BfArM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal","Autoimmune"],"diseases":["Recurrent C. difficile Infection","Ulcerative Colitis (off-label)","Crohn's Disease (off-label)"],"status":"active"},{"id":"10d806bb-eb0c-4c12-8246-1f61c14bddd8","procedure_id":"proc-fmt","jurisdiction_id":"jur-uk","procedure_name":"Fecal Microbiota Transplantation (FMT) for CDI/IBD","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"APPROVED_ON_LABEL","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Do not assume IBD/SIBO commercial FMT is authorized.","eligibility_requirements":"Primarily recurrent C. difficile where products exist.","provider_requirements":"GI/ID scope + product labeling.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: labeled microbiota products where registered; else trial/expanded access.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: cleared microbiota products for rCDI exist in some markets; other indications often trial-only.","regulatory_authority":"MHRA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal","Autoimmune"],"diseases":["Recurrent C. difficile Infection","Ulcerative Colitis (off-label)","Crohn's Disease (off-label)"],"status":"active"},{"id":"0e68fa6c-0b75-4d8a-80de-10d2627b56de","procedure_id":"proc-fmt","jurisdiction_id":"jur-il","procedure_name":"Fecal Microbiota Transplantation (FMT) for CDI/IBD","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"REGULATED_MODERATE","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Do not assume IBD/SIBO commercial FMT is authorized.","eligibility_requirements":"Primarily recurrent C. difficile where products exist.","provider_requirements":"GI/ID scope + product labeling.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: labeled microbiota products where registered; else trial/expanded access.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: cleared microbiota products for rCDI exist in some markets; other indications often trial-only.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal","Autoimmune"],"diseases":["Recurrent C. difficile Infection","Ulcerative Colitis (off-label)","Crohn's Disease (off-label)"],"status":"active"},{"id":"ce132a51-2efc-42f6-83e5-6d15e2dfdc68","procedure_id":"proc-fmt","jurisdiction_id":"jur-jm","procedure_name":"Fecal Microbiota Transplantation (FMT) for CDI/IBD","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"REGULATED_MODERATE","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Do not assume IBD/SIBO commercial FMT is authorized.","eligibility_requirements":"Primarily recurrent C. difficile where products exist.","provider_requirements":"GI/ID scope + product labeling.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: labeled microbiota products where registered; else trial/expanded access.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: cleared microbiota products for rCDI exist in some markets; other indications often trial-only.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal","Autoimmune"],"diseases":["Recurrent C. difficile Infection","Ulcerative Colitis (off-label)","Crohn's Disease (off-label)"],"status":"active"},{"id":"85e37283-4df9-4270-933e-aa01e6f95054","procedure_id":"proc-fmt","jurisdiction_id":"jur-th","procedure_name":"Fecal Microbiota Transplantation (FMT) for CDI/IBD","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"APPROVED_ON_LABEL","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Do not assume IBD/SIBO commercial FMT is authorized.","eligibility_requirements":"Primarily recurrent C. difficile where products exist.","provider_requirements":"GI/ID scope + product labeling.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: labeled microbiota products where registered; else trial/expanded access.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: cleared microbiota products for rCDI exist in some markets; other indications often trial-only.","regulatory_authority":"Thai FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal","Autoimmune"],"diseases":["Recurrent C. difficile Infection","Ulcerative Colitis (off-label)","Crohn's Disease (off-label)"],"status":"active"},{"id":"018975e2-a9d8-45cf-b70b-77f1610ae368","procedure_id":"proc-fmt","jurisdiction_id":"jur-es","procedure_name":"Fecal Microbiota Transplantation (FMT) for CDI/IBD","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"APPROVED_ON_LABEL","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Do not assume IBD/SIBO commercial FMT is authorized.","eligibility_requirements":"Primarily recurrent C. difficile where products exist.","provider_requirements":"GI/ID scope + product labeling.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: labeled microbiota products where registered; else trial/expanded access.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: cleared microbiota products for rCDI exist in some markets; other indications often trial-only.","regulatory_authority":"AEMPS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal","Autoimmune"],"diseases":["Recurrent C. difficile Infection","Ulcerative Colitis (off-label)","Crohn's Disease (off-label)"],"status":"active"},{"id":"82e56bbc-e1b4-43bb-b58f-9b51fb3c1f8a","procedure_id":"proc-fmt","jurisdiction_id":"jur-tu","procedure_name":"Fecal Microbiota Transplantation (FMT) for CDI/IBD","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"REGULATED_MODERATE","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Do not assume IBD/SIBO commercial FMT is authorized.","eligibility_requirements":"Primarily recurrent C. difficile where products exist.","provider_requirements":"GI/ID scope + product labeling.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: labeled microbiota products where registered; else trial/expanded access.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: cleared microbiota products for rCDI exist in some markets; other indications often trial-only.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal","Autoimmune"],"diseases":["Recurrent C. difficile Infection","Ulcerative Colitis (off-label)","Crohn's Disease (off-label)"],"status":"active"},{"id":"8afc971d-db0e-412e-b87d-f69c84c60a61","procedure_id":"proc-fmt","jurisdiction_id":"jur-in","procedure_name":"Fecal Microbiota Transplantation (FMT) for CDI/IBD","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"REGULATED_MODERATE","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Do not assume IBD/SIBO commercial FMT is authorized.","eligibility_requirements":"Primarily recurrent C. difficile where products exist.","provider_requirements":"GI/ID scope + product labeling.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: labeled microbiota products where registered; else trial/expanded access.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: cleared microbiota products for rCDI exist in some markets; other indications often trial-only.","regulatory_authority":"CDSCO","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal","Autoimmune"],"diseases":["Recurrent C. difficile Infection","Ulcerative Colitis (off-label)","Crohn's Disease (off-label)"],"status":"active"},{"id":"5b3c1b3e-5a19-44e4-afd4-61a8f45f4828","procedure_id":"proc-fmt","jurisdiction_id":"jur-br","procedure_name":"Fecal Microbiota Transplantation (FMT) for CDI/IBD","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"REGULATED_MODERATE","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Do not assume IBD/SIBO commercial FMT is authorized.","eligibility_requirements":"Primarily recurrent C. difficile where products exist.","provider_requirements":"GI/ID scope + product labeling.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: labeled microbiota products where registered; else trial/expanded access.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: cleared microbiota products for rCDI exist in some markets; other indications often trial-only.","regulatory_authority":"ANVISA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal","Autoimmune"],"diseases":["Recurrent C. difficile Infection","Ulcerative Colitis (off-label)","Crohn's Disease (off-label)"],"status":"active"},{"id":"35e79c8a-04fd-4c23-a5aa-c6367b425cc5","procedure_id":"proc-fmt","jurisdiction_id":"jur-cr","procedure_name":"Fecal Microbiota Transplantation (FMT) for CDI/IBD","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"REGULATED_MODERATE","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Do not assume IBD/SIBO commercial FMT is authorized.","eligibility_requirements":"Primarily recurrent C. difficile where products exist.","provider_requirements":"GI/ID scope + product labeling.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: labeled microbiota products where registered; else trial/expanded access.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: cleared microbiota products for rCDI exist in some markets; other indications often trial-only.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal","Autoimmune"],"diseases":["Recurrent C. difficile Infection","Ulcerative Colitis (off-label)","Crohn's Disease (off-label)"],"status":"active"},{"id":"db120a96-5462-42f3-9e9f-caea70f960d9","procedure_id":"proc-fmt","jurisdiction_id":"jur-uae","procedure_name":"Fecal Microbiota Transplantation (FMT) for CDI/IBD","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"REGULATED_MODERATE","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Do not assume IBD/SIBO commercial FMT is authorized.","eligibility_requirements":"Primarily recurrent C. difficile where products exist.","provider_requirements":"GI/ID scope + product labeling.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: labeled microbiota products where registered; else trial/expanded access.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: cleared microbiota products for rCDI exist in some markets; other indications often trial-only.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal","Autoimmune"],"diseases":["Recurrent C. difficile Infection","Ulcerative Colitis (off-label)","Crohn's Disease (off-label)"],"status":"active"},{"id":"73bc4596-90ce-455a-b685-7eb5a568e03d","procedure_id":"proc-fmt","jurisdiction_id":"jur-kr","procedure_name":"Fecal Microbiota Transplantation (FMT) for CDI/IBD","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"APPROVED_ON_LABEL","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Do not assume IBD/SIBO commercial FMT is authorized.","eligibility_requirements":"Primarily recurrent C. difficile where products exist.","provider_requirements":"GI/ID scope + product labeling.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: labeled microbiota products where registered; else trial/expanded access.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: cleared microbiota products for rCDI exist in some markets; other indications often trial-only.","regulatory_authority":"MFDS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal","Autoimmune"],"diseases":["Recurrent C. difficile Infection","Ulcerative Colitis (off-label)","Crohn's Disease (off-label)"],"status":"active"},{"id":"26ca759d-6045-453a-b8d8-b63b8fb120c8","procedure_id":"proc-fmt","jurisdiction_id":"jur-gr","procedure_name":"Fecal Microbiota Transplantation (FMT) for CDI/IBD","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"REGULATED_MODERATE","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Do not assume IBD/SIBO commercial FMT is authorized.","eligibility_requirements":"Primarily recurrent C. difficile where products exist.","provider_requirements":"GI/ID scope + product labeling.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: labeled microbiota products where registered; else trial/expanded access.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: cleared microbiota products for rCDI exist in some markets; other indications often trial-only.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal","Autoimmune"],"diseases":["Recurrent C. difficile Infection","Ulcerative Colitis (off-label)","Crohn's Disease (off-label)"],"status":"active"},{"id":"e3af945f-4550-4b25-92a9-027aec8f89b4","procedure_id":"proc-fmt","jurisdiction_id":"jur-be","procedure_name":"Fecal Microbiota Transplantation (FMT) for CDI/IBD","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"APPROVED_ON_LABEL","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Do not assume IBD/SIBO commercial FMT is authorized.","eligibility_requirements":"Primarily recurrent C. difficile where products exist.","provider_requirements":"GI/ID scope + product labeling.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: labeled microbiota products where registered; else trial/expanded access.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: cleared microbiota products for rCDI exist in some markets; other indications often trial-only.","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal","Autoimmune"],"diseases":["Recurrent C. difficile Infection","Ulcerative Colitis (off-label)","Crohn's Disease (off-label)"],"status":"active"},{"id":"f713d903-278f-4cd5-8226-693b39621cdc","procedure_id":"proc-fmt","jurisdiction_id":"jur-se","procedure_name":"Fecal Microbiota Transplantation (FMT) for CDI/IBD","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"REGULATED_MODERATE","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Do not assume IBD/SIBO commercial FMT is authorized.","eligibility_requirements":"Primarily recurrent C. difficile where products exist.","provider_requirements":"GI/ID scope + product labeling.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: labeled microbiota products where registered; else trial/expanded access.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: cleared microbiota products for rCDI exist in some markets; other indications often trial-only.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal","Autoimmune"],"diseases":["Recurrent C. difficile Infection","Ulcerative Colitis (off-label)","Crohn's Disease (off-label)"],"status":"active"},{"id":"0cc0bd11-9472-48db-ac36-5a307bcd69a9","procedure_id":"proc-fmt","jurisdiction_id":"jur-jp","procedure_name":"Fecal Microbiota Transplantation (FMT) for CDI/IBD","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"APPROVED_ON_LABEL","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Do not assume IBD/SIBO commercial FMT is authorized.","eligibility_requirements":"Primarily recurrent C. difficile where products exist.","provider_requirements":"GI/ID scope + product labeling.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: labeled microbiota products where registered; else trial/expanded access.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: cleared microbiota products for rCDI exist in some markets; other indications often trial-only.","regulatory_authority":"PMDA / MHLW","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal","Autoimmune"],"diseases":["Recurrent C. difficile Infection","Ulcerative Colitis (off-label)","Crohn's Disease (off-label)"],"status":"active"},{"id":"c7422daa-4e15-4998-902e-b0230d619c62","procedure_id":"proc-fmt","jurisdiction_id":"jur-sg","procedure_name":"Fecal Microbiota Transplantation (FMT) for CDI/IBD","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"APPROVED_ON_LABEL","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Do not assume IBD/SIBO commercial FMT is authorized.","eligibility_requirements":"Primarily recurrent C. difficile where products exist.","provider_requirements":"GI/ID scope + product labeling.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: labeled microbiota products where registered; else trial/expanded access.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: cleared microbiota products for rCDI exist in some markets; other indications often trial-only.","regulatory_authority":"HSA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal","Autoimmune"],"diseases":["Recurrent C. difficile Infection","Ulcerative Colitis (off-label)","Crohn's Disease (off-label)"],"status":"active"},{"id":"36522964-301a-46ed-bf64-c62bdc0d1169","procedure_id":"proc-fmt","jurisdiction_id":"jur-cl","procedure_name":"Fecal Microbiota Transplantation (FMT) for CDI/IBD","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"REGULATED_MODERATE","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Do not assume IBD/SIBO commercial FMT is authorized.","eligibility_requirements":"Primarily recurrent C. difficile where products exist.","provider_requirements":"GI/ID scope + product labeling.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: labeled microbiota products where registered; else trial/expanded access.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: cleared microbiota products for rCDI exist in some markets; other indications often trial-only.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal","Autoimmune"],"diseases":["Recurrent C. difficile Infection","Ulcerative Colitis (off-label)","Crohn's Disease (off-label)"],"status":"active"},{"id":"1409e6d7-0572-4e53-9ad4-d6afb3b97bf6","procedure_id":"proc-fmt","jurisdiction_id":"jur-ar","procedure_name":"Fecal Microbiota Transplantation (FMT) for CDI/IBD","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"REGULATED_MODERATE","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Do not assume IBD/SIBO commercial FMT is authorized.","eligibility_requirements":"Primarily recurrent C. difficile where products exist.","provider_requirements":"GI/ID scope + product labeling.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: labeled microbiota products where registered; else trial/expanded access.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: cleared microbiota products for rCDI exist in some markets; other indications often trial-only.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal","Autoimmune"],"diseases":["Recurrent C. difficile Infection","Ulcerative Colitis (off-label)","Crohn's Disease (off-label)"],"status":"active"},{"id":"35882965-9002-4aa4-bc31-601f628f41d0","procedure_id":"proc-fmt","jurisdiction_id":"jur-za","procedure_name":"Fecal Microbiota Transplantation (FMT) for CDI/IBD","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"REGULATED_MODERATE","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Do not assume IBD/SIBO commercial FMT is authorized.","eligibility_requirements":"Primarily recurrent C. difficile where products exist.","provider_requirements":"GI/ID scope + product labeling.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: labeled microbiota products where registered; else trial/expanded access.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: cleared microbiota products for rCDI exist in some markets; other indications often trial-only.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal","Autoimmune"],"diseases":["Recurrent C. difficile Infection","Ulcerative Colitis (off-label)","Crohn's Disease (off-label)"],"status":"active"},{"id":"fa359c3f-7c4a-4430-936f-74490cf4e3c2","procedure_id":"proc-fmt","jurisdiction_id":"jur-ph","procedure_name":"Fecal Microbiota Transplantation (FMT) for CDI/IBD","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"REGULATED_MODERATE","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Do not assume IBD/SIBO commercial FMT is authorized.","eligibility_requirements":"Primarily recurrent C. difficile where products exist.","provider_requirements":"GI/ID scope + product labeling.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: labeled microbiota products where registered; else trial/expanded access.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: cleared microbiota products for rCDI exist in some markets; other indications often trial-only.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal","Autoimmune"],"diseases":["Recurrent C. difficile Infection","Ulcerative Colitis (off-label)","Crohn's Disease (off-label)"],"status":"active"},{"id":"9f05e95d-14df-4cc9-a6d0-8c751a712453","procedure_id":"proc-fmt","jurisdiction_id":"jur-po","procedure_name":"Fecal Microbiota Transplantation (FMT) for CDI/IBD","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"REGULATED_MODERATE","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Do not assume IBD/SIBO commercial FMT is authorized.","eligibility_requirements":"Primarily recurrent C. difficile where products exist.","provider_requirements":"GI/ID scope + product labeling.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: labeled microbiota products where registered; else trial/expanded access.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: cleared microbiota products for rCDI exist in some markets; other indications often trial-only.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal","Autoimmune"],"diseases":["Recurrent C. difficile Infection","Ulcerative Colitis (off-label)","Crohn's Disease (off-label)"],"status":"active"},{"id":"38c34437-06c7-4c26-bb80-780f641d585e","procedure_id":"proc-fmt","jurisdiction_id":"jur-pt","procedure_name":"Fecal Microbiota Transplantation (FMT) for CDI/IBD","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"REGULATED_MODERATE","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Do not assume IBD/SIBO commercial FMT is authorized.","eligibility_requirements":"Primarily recurrent C. difficile where products exist.","provider_requirements":"GI/ID scope + product labeling.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: labeled microbiota products where registered; else trial/expanded access.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: cleared microbiota products for rCDI exist in some markets; other indications often trial-only.","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal","Autoimmune"],"diseases":["Recurrent C. difficile Infection","Ulcerative Colitis (off-label)","Crohn's Disease (off-label)"],"status":"active"},{"id":"94f9070e-00ca-4252-9df8-6519057bba75","procedure_id":"proc-fmt","jurisdiction_id":"jur-fr","procedure_name":"Fecal Microbiota Transplantation (FMT) for CDI/IBD","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"APPROVED_ON_LABEL","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Do not assume IBD/SIBO commercial FMT is authorized.","eligibility_requirements":"Primarily recurrent C. difficile where products exist.","provider_requirements":"GI/ID scope + product labeling.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: labeled microbiota products where registered; else trial/expanded access.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: cleared microbiota products for rCDI exist in some markets; other indications often trial-only.","regulatory_authority":"ANSM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal","Autoimmune"],"diseases":["Recurrent C. difficile Infection","Ulcerative Colitis (off-label)","Crohn's Disease (off-label)"],"status":"active"},{"id":"df8f4aa2-efdc-4056-b803-ab574170c127","procedure_id":"proc-pt-141","jurisdiction_id":"jur-us-or","procedure_name":"PT-141 (Bremelanotide) for Sexual Dysfunction","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_ON_LABEL","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Sexual_Health"],"diseases":["Hypoactive Sexual Desire Disorder (HSDD)","Erectile Dysfunction (off-label)"],"status":"active"},{"id":"2964d340-cade-4de1-b14b-fb53753b86f9","procedure_id":"proc-pt-141","jurisdiction_id":"jur-us-co","procedure_name":"PT-141 (Bremelanotide) for Sexual Dysfunction","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_ON_LABEL","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Sexual_Health"],"diseases":["Hypoactive Sexual Desire Disorder (HSDD)","Erectile Dysfunction (off-label)"],"status":"active"},{"id":"2b25fe90-dfb2-4503-98bb-7afbcb17af5d","procedure_id":"proc-pt-141","jurisdiction_id":"jur-us-ca","procedure_name":"PT-141 (Bremelanotide) for Sexual Dysfunction","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_ON_LABEL","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Sexual_Health"],"diseases":["Hypoactive Sexual Desire Disorder (HSDD)","Erectile Dysfunction (off-label)"],"status":"active"},{"id":"c2372dac-4d0c-457b-a225-f008a0fa0258","procedure_id":"proc-pt-141","jurisdiction_id":"jur-us-tx","procedure_name":"PT-141 (Bremelanotide) for Sexual Dysfunction","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_ON_LABEL","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Sexual_Health"],"diseases":["Hypoactive Sexual Desire Disorder (HSDD)","Erectile Dysfunction (off-label)"],"status":"active"},{"id":"3327d0ca-ab8c-47f6-91eb-da2649cdddd1","procedure_id":"proc-pt-141","jurisdiction_id":"jur-us-fl","procedure_name":"PT-141 (Bremelanotide) for Sexual Dysfunction","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_ON_LABEL","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Sexual_Health"],"diseases":["Hypoactive Sexual Desire Disorder (HSDD)","Erectile Dysfunction (off-label)"],"status":"active"},{"id":"1cdcf5c2-7893-4a71-b8cd-1f655816e9b6","procedure_id":"proc-pt-141","jurisdiction_id":"jur-ch","procedure_name":"PT-141 (Bremelanotide) for Sexual Dysfunction","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"APPROVED_ON_LABEL","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"Swissmedic","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Sexual_Health"],"diseases":["Hypoactive Sexual Desire Disorder (HSDD)","Erectile Dysfunction (off-label)"],"status":"active"},{"id":"36f3d7c4-6463-4a3d-984d-ea4d2994a901","procedure_id":"proc-pt-141","jurisdiction_id":"jur-hn-prospera","procedure_name":"PT-141 (Bremelanotide) for Sexual Dysfunction","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"Próspera ZEDE health rules (contested)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Sexual_Health"],"diseases":["Hypoactive Sexual Desire Disorder (HSDD)","Erectile Dysfunction (off-label)"],"status":"active"},{"id":"8ed43451-5223-4034-a952-13cf37036f6c","procedure_id":"proc-pt-141","jurisdiction_id":"jur-nl","procedure_name":"PT-141 (Bremelanotide) for Sexual Dysfunction","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"APPROVED_ON_LABEL","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"MEB / IGJ","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Sexual_Health"],"diseases":["Hypoactive Sexual Desire Disorder (HSDD)","Erectile Dysfunction (off-label)"],"status":"active"},{"id":"f9776a8e-468b-41e0-b5a3-c41d51fef415","procedure_id":"proc-pt-141","jurisdiction_id":"jur-de","procedure_name":"PT-141 (Bremelanotide) for Sexual Dysfunction","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"APPROVED_ON_LABEL","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"BfArM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Sexual_Health"],"diseases":["Hypoactive Sexual Desire Disorder (HSDD)","Erectile Dysfunction (off-label)"],"status":"active"},{"id":"04069236-1923-4cbe-8536-7554ff1698a7","procedure_id":"proc-pt-141","jurisdiction_id":"jur-il","procedure_name":"PT-141 (Bremelanotide) for Sexual Dysfunction","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Sexual_Health"],"diseases":["Hypoactive Sexual Desire Disorder (HSDD)","Erectile Dysfunction (off-label)"],"status":"active"},{"id":"b70a64ef-7203-47ca-bc22-951e3007bdad","procedure_id":"proc-pt-141","jurisdiction_id":"jur-jm","procedure_name":"PT-141 (Bremelanotide) for Sexual Dysfunction","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Sexual_Health"],"diseases":["Hypoactive Sexual Desire Disorder (HSDD)","Erectile Dysfunction (off-label)"],"status":"active"},{"id":"ce0aa2b9-02e2-4c29-8cdc-72531f913064","procedure_id":"proc-pt-141","jurisdiction_id":"jur-th","procedure_name":"PT-141 (Bremelanotide) for Sexual Dysfunction","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"APPROVED_ON_LABEL","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"Thai FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Sexual_Health"],"diseases":["Hypoactive Sexual Desire Disorder (HSDD)","Erectile Dysfunction (off-label)"],"status":"active"},{"id":"9e9f2fc3-0ec3-46b7-86fd-056e0893c002","procedure_id":"proc-pt-141","jurisdiction_id":"jur-es","procedure_name":"PT-141 (Bremelanotide) for Sexual Dysfunction","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"APPROVED_ON_LABEL","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"AEMPS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Sexual_Health"],"diseases":["Hypoactive Sexual Desire Disorder (HSDD)","Erectile Dysfunction (off-label)"],"status":"active"},{"id":"59dc25b5-f11d-418a-8ffe-33673bf2c15a","procedure_id":"proc-pt-141","jurisdiction_id":"jur-tu","procedure_name":"PT-141 (Bremelanotide) for Sexual Dysfunction","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Sexual_Health"],"diseases":["Hypoactive Sexual Desire Disorder (HSDD)","Erectile Dysfunction (off-label)"],"status":"active"},{"id":"c744fe9c-1385-4bc5-a804-0b41cf1002a9","procedure_id":"proc-pt-141","jurisdiction_id":"jur-in","procedure_name":"PT-141 (Bremelanotide) for Sexual Dysfunction","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"CDSCO","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Sexual_Health"],"diseases":["Hypoactive Sexual Desire Disorder (HSDD)","Erectile Dysfunction (off-label)"],"status":"active"},{"id":"1e3455d8-ed64-467b-9ba9-d52d6e3a4461","procedure_id":"proc-pt-141","jurisdiction_id":"jur-br","procedure_name":"PT-141 (Bremelanotide) for Sexual Dysfunction","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"ANVISA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Sexual_Health"],"diseases":["Hypoactive Sexual Desire Disorder (HSDD)","Erectile Dysfunction (off-label)"],"status":"active"},{"id":"cfa9748f-a54a-4810-a730-b4da074395af","procedure_id":"proc-pt-141","jurisdiction_id":"jur-cr","procedure_name":"PT-141 (Bremelanotide) for Sexual Dysfunction","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Sexual_Health"],"diseases":["Hypoactive Sexual Desire Disorder (HSDD)","Erectile Dysfunction (off-label)"],"status":"active"},{"id":"530a3222-b086-4f13-ad35-459c6ddb3cd9","procedure_id":"proc-pt-141","jurisdiction_id":"jur-uae","procedure_name":"PT-141 (Bremelanotide) for Sexual Dysfunction","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Sexual_Health"],"diseases":["Hypoactive Sexual Desire Disorder (HSDD)","Erectile Dysfunction (off-label)"],"status":"active"},{"id":"c89f96a7-3d9b-438a-83b1-533a7a7e9dc0","procedure_id":"proc-pt-141","jurisdiction_id":"jur-kr","procedure_name":"PT-141 (Bremelanotide) for Sexual Dysfunction","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"APPROVED_ON_LABEL","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"MFDS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Sexual_Health"],"diseases":["Hypoactive Sexual Desire Disorder (HSDD)","Erectile Dysfunction (off-label)"],"status":"active"},{"id":"755e1f87-9b59-4f77-86dc-6c7d105f95e4","procedure_id":"proc-pt-141","jurisdiction_id":"jur-gr","procedure_name":"PT-141 (Bremelanotide) for Sexual Dysfunction","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Sexual_Health"],"diseases":["Hypoactive Sexual Desire Disorder (HSDD)","Erectile Dysfunction (off-label)"],"status":"active"},{"id":"b96b9124-4be9-46c3-ab02-36e93f174cfb","procedure_id":"proc-pt-141","jurisdiction_id":"jur-be","procedure_name":"PT-141 (Bremelanotide) for Sexual Dysfunction","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"APPROVED_ON_LABEL","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Sexual_Health"],"diseases":["Hypoactive Sexual Desire Disorder (HSDD)","Erectile Dysfunction (off-label)"],"status":"active"},{"id":"0b90fd5c-4e57-4746-9d6c-b1c7317d8ef4","procedure_id":"proc-pt-141","jurisdiction_id":"jur-se","procedure_name":"PT-141 (Bremelanotide) for Sexual Dysfunction","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Sexual_Health"],"diseases":["Hypoactive Sexual Desire Disorder (HSDD)","Erectile Dysfunction (off-label)"],"status":"active"},{"id":"ad0a25a7-5040-41e8-9898-576cd82a077f","procedure_id":"proc-pt-141","jurisdiction_id":"jur-jp","procedure_name":"PT-141 (Bremelanotide) for Sexual Dysfunction","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"APPROVED_ON_LABEL","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"PMDA / MHLW","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Sexual_Health"],"diseases":["Hypoactive Sexual Desire Disorder (HSDD)","Erectile Dysfunction (off-label)"],"status":"active"},{"id":"15453fa2-93ea-4824-8af8-32370a7eb486","procedure_id":"proc-pt-141","jurisdiction_id":"jur-sg","procedure_name":"PT-141 (Bremelanotide) for Sexual Dysfunction","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"APPROVED_ON_LABEL","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"HSA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Sexual_Health"],"diseases":["Hypoactive Sexual Desire Disorder (HSDD)","Erectile Dysfunction (off-label)"],"status":"active"},{"id":"a8e9552b-1c96-4059-b836-303c2bdcca5d","procedure_id":"proc-pt-141","jurisdiction_id":"jur-cl","procedure_name":"PT-141 (Bremelanotide) for Sexual Dysfunction","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Sexual_Health"],"diseases":["Hypoactive Sexual Desire Disorder (HSDD)","Erectile Dysfunction (off-label)"],"status":"active"},{"id":"99b84d02-87e8-4108-b02d-5c51ccd67e28","procedure_id":"proc-pt-141","jurisdiction_id":"jur-ar","procedure_name":"PT-141 (Bremelanotide) for Sexual Dysfunction","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Sexual_Health"],"diseases":["Hypoactive Sexual Desire Disorder (HSDD)","Erectile Dysfunction (off-label)"],"status":"active"},{"id":"d67af78f-ede5-451f-9d3c-f6ec5a752568","procedure_id":"proc-pt-141","jurisdiction_id":"jur-za","procedure_name":"PT-141 (Bremelanotide) for Sexual Dysfunction","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Sexual_Health"],"diseases":["Hypoactive Sexual Desire Disorder (HSDD)","Erectile Dysfunction (off-label)"],"status":"active"},{"id":"02799bf3-e365-4daf-8c5e-9e528dba394f","procedure_id":"proc-pt-141","jurisdiction_id":"jur-ph","procedure_name":"PT-141 (Bremelanotide) for Sexual Dysfunction","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Sexual_Health"],"diseases":["Hypoactive Sexual Desire Disorder (HSDD)","Erectile Dysfunction (off-label)"],"status":"active"},{"id":"bd4ace4b-4b3f-43dd-a3f1-9c935ca80a26","procedure_id":"proc-pt-141","jurisdiction_id":"jur-po","procedure_name":"PT-141 (Bremelanotide) for Sexual Dysfunction","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Sexual_Health"],"diseases":["Hypoactive Sexual Desire Disorder (HSDD)","Erectile Dysfunction (off-label)"],"status":"active"},{"id":"58bcef08-4b98-4cde-b87e-38a8a8f12da7","procedure_id":"proc-pt-141","jurisdiction_id":"jur-pt","procedure_name":"PT-141 (Bremelanotide) for Sexual Dysfunction","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Sexual_Health"],"diseases":["Hypoactive Sexual Desire Disorder (HSDD)","Erectile Dysfunction (off-label)"],"status":"active"},{"id":"9fed474a-f27b-4979-8404-3b90c56bf113","procedure_id":"proc-pt-141","jurisdiction_id":"jur-fr","procedure_name":"PT-141 (Bremelanotide) for Sexual Dysfunction","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"APPROVED_ON_LABEL","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"ANSM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Sexual_Health"],"diseases":["Hypoactive Sexual Desire Disorder (HSDD)","Erectile Dysfunction (off-label)"],"status":"active"},{"id":"c2d52e53-47d7-4156-8de7-5d92ba353ff6","procedure_id":"proc-cryotherapy","jurisdiction_id":"jur-us-or","procedure_name":"Whole-Body Cryotherapy (WBC) for Recovery/Inflammation","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Recovery"],"diseases":["Muscle Recovery","Chronic Inflammation","Sports Injury Recovery"],"status":"active"},{"id":"31ea4021-c09f-4e69-8316-ec72d22929f8","procedure_id":"proc-cryotherapy","jurisdiction_id":"jur-us-co","procedure_name":"Whole-Body Cryotherapy (WBC) for Recovery/Inflammation","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Recovery"],"diseases":["Muscle Recovery","Chronic Inflammation","Sports Injury Recovery"],"status":"active"},{"id":"45ed7c1d-2705-4d2d-bc2c-5438418446b7","procedure_id":"proc-cryotherapy","jurisdiction_id":"jur-us-ca","procedure_name":"Whole-Body Cryotherapy (WBC) for Recovery/Inflammation","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Recovery"],"diseases":["Muscle Recovery","Chronic Inflammation","Sports Injury Recovery"],"status":"active"},{"id":"28700bfe-9a0b-4531-871c-ea00bac9ba75","procedure_id":"proc-cryotherapy","jurisdiction_id":"jur-us-tx","procedure_name":"Whole-Body Cryotherapy (WBC) for Recovery/Inflammation","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Recovery"],"diseases":["Muscle Recovery","Chronic Inflammation","Sports Injury Recovery"],"status":"active"},{"id":"0d489cf0-2232-4fa9-97a9-e9bbfa83ae9a","procedure_id":"proc-cryotherapy","jurisdiction_id":"jur-us-fl","procedure_name":"Whole-Body Cryotherapy (WBC) for Recovery/Inflammation","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Recovery"],"diseases":["Muscle Recovery","Chronic Inflammation","Sports Injury Recovery"],"status":"active"},{"id":"15523ddf-2e69-4b01-9b37-7b175dc86d4a","procedure_id":"proc-cryotherapy","jurisdiction_id":"jur-au","procedure_name":"Whole-Body Cryotherapy (WBC) for Recovery/Inflammation","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"TGA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Recovery"],"diseases":["Muscle Recovery","Chronic Inflammation","Sports Injury Recovery"],"status":"active"},{"id":"9758f8cb-93cc-4a2f-9d08-83fc0e4ce257","procedure_id":"proc-cryotherapy","jurisdiction_id":"jur-ch","procedure_name":"Whole-Body Cryotherapy (WBC) for Recovery/Inflammation","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Swissmedic","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Recovery"],"diseases":["Muscle Recovery","Chronic Inflammation","Sports Injury Recovery"],"status":"active"},{"id":"e5d2e8e9-d5a3-460e-a991-ff7ca2ac1e23","procedure_id":"proc-cryotherapy","jurisdiction_id":"jur-ca","procedure_name":"Whole-Body Cryotherapy (WBC) for Recovery/Inflammation","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Health Canada","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Recovery"],"diseases":["Muscle Recovery","Chronic Inflammation","Sports Injury Recovery"],"status":"active"},{"id":"57ae9a71-c017-438f-88d3-dfd9a92293ea","procedure_id":"proc-cryotherapy","jurisdiction_id":"jur-mx","procedure_name":"Whole-Body Cryotherapy (WBC) for Recovery/Inflammation","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"COFEPRIS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Recovery"],"diseases":["Muscle Recovery","Chronic Inflammation","Sports Injury Recovery"],"status":"active"},{"id":"b228d756-be00-43db-993e-0ef2f4b52827","procedure_id":"proc-cryotherapy","jurisdiction_id":"jur-hn-prospera","procedure_name":"Whole-Body Cryotherapy (WBC) for Recovery/Inflammation","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Próspera ZEDE health rules (contested)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Recovery"],"diseases":["Muscle Recovery","Chronic Inflammation","Sports Injury Recovery"],"status":"active"},{"id":"2f180ac6-3368-4dc4-91f2-d780cac17d29","procedure_id":"proc-cryotherapy","jurisdiction_id":"jur-nl","procedure_name":"Whole-Body Cryotherapy (WBC) for Recovery/Inflammation","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"MEB / IGJ","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Recovery"],"diseases":["Muscle Recovery","Chronic Inflammation","Sports Injury Recovery"],"status":"active"},{"id":"e16607e5-2c7a-4ec2-8d7f-ddf64ba5b7cc","procedure_id":"proc-cryotherapy","jurisdiction_id":"jur-uk","procedure_name":"Whole-Body Cryotherapy (WBC) for Recovery/Inflammation","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"MHRA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Recovery"],"diseases":["Muscle Recovery","Chronic Inflammation","Sports Injury Recovery"],"status":"active"},{"id":"8f9cfe74-b6c5-43ef-aa49-854bbc1dedc2","procedure_id":"proc-cryotherapy","jurisdiction_id":"jur-il","procedure_name":"Whole-Body Cryotherapy (WBC) for Recovery/Inflammation","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Recovery"],"diseases":["Muscle Recovery","Chronic Inflammation","Sports Injury Recovery"],"status":"active"},{"id":"4971a260-b223-485b-885b-8c154ff24e4d","procedure_id":"proc-cryotherapy","jurisdiction_id":"jur-jm","procedure_name":"Whole-Body Cryotherapy (WBC) for Recovery/Inflammation","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Recovery"],"diseases":["Muscle Recovery","Chronic Inflammation","Sports Injury Recovery"],"status":"active"},{"id":"e1be3f0f-5bfb-4104-85d8-ddf3dfa776d0","procedure_id":"proc-cryotherapy","jurisdiction_id":"jur-th","procedure_name":"Whole-Body Cryotherapy (WBC) for Recovery/Inflammation","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Thai FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Recovery"],"diseases":["Muscle Recovery","Chronic Inflammation","Sports Injury Recovery"],"status":"active"},{"id":"3c74ee97-c8a9-4d1c-b986-d39a475013dd","procedure_id":"proc-cryotherapy","jurisdiction_id":"jur-es","procedure_name":"Whole-Body Cryotherapy (WBC) for Recovery/Inflammation","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"AEMPS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Recovery"],"diseases":["Muscle Recovery","Chronic Inflammation","Sports Injury Recovery"],"status":"active"},{"id":"78053711-7a85-48e2-b8de-d191e7906ae2","procedure_id":"proc-cryotherapy","jurisdiction_id":"jur-tu","procedure_name":"Whole-Body Cryotherapy (WBC) for Recovery/Inflammation","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Recovery"],"diseases":["Muscle Recovery","Chronic Inflammation","Sports Injury Recovery"],"status":"active"},{"id":"4a1cb319-2407-40af-9557-1ec0d62f55b2","procedure_id":"proc-cryotherapy","jurisdiction_id":"jur-in","procedure_name":"Whole-Body Cryotherapy (WBC) for Recovery/Inflammation","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"CDSCO","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Recovery"],"diseases":["Muscle Recovery","Chronic Inflammation","Sports Injury Recovery"],"status":"active"},{"id":"db5eea0a-99b7-405e-9b03-948c866e6531","procedure_id":"proc-cryotherapy","jurisdiction_id":"jur-br","procedure_name":"Whole-Body Cryotherapy (WBC) for Recovery/Inflammation","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"ANVISA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Recovery"],"diseases":["Muscle Recovery","Chronic Inflammation","Sports Injury Recovery"],"status":"active"},{"id":"dbd34ec2-e553-48f6-9f92-bfa05bbabee1","procedure_id":"proc-cryotherapy","jurisdiction_id":"jur-cr","procedure_name":"Whole-Body Cryotherapy (WBC) for Recovery/Inflammation","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Recovery"],"diseases":["Muscle Recovery","Chronic Inflammation","Sports Injury Recovery"],"status":"active"},{"id":"e366a1be-d6de-49d4-b649-5b6cfe07c20c","procedure_id":"proc-cryotherapy","jurisdiction_id":"jur-kr","procedure_name":"Whole-Body Cryotherapy (WBC) for Recovery/Inflammation","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"MFDS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Recovery"],"diseases":["Muscle Recovery","Chronic Inflammation","Sports Injury Recovery"],"status":"active"},{"id":"3ac56428-245a-4fe5-bedb-d132c9a42e1e","procedure_id":"proc-cryotherapy","jurisdiction_id":"jur-gr","procedure_name":"Whole-Body Cryotherapy (WBC) for Recovery/Inflammation","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Recovery"],"diseases":["Muscle Recovery","Chronic Inflammation","Sports Injury Recovery"],"status":"active"},{"id":"af19012b-2408-416d-989f-f1fce7d47159","procedure_id":"proc-cryotherapy","jurisdiction_id":"jur-be","procedure_name":"Whole-Body Cryotherapy (WBC) for Recovery/Inflammation","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Recovery"],"diseases":["Muscle Recovery","Chronic Inflammation","Sports Injury Recovery"],"status":"active"},{"id":"c14778d3-8604-4514-9d20-13c0244411db","procedure_id":"proc-cryotherapy","jurisdiction_id":"jur-se","procedure_name":"Whole-Body Cryotherapy (WBC) for Recovery/Inflammation","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Recovery"],"diseases":["Muscle Recovery","Chronic Inflammation","Sports Injury Recovery"],"status":"active"},{"id":"b4e3d561-769f-45d9-a0b5-3270adda8a53","procedure_id":"proc-cryotherapy","jurisdiction_id":"jur-sg","procedure_name":"Whole-Body Cryotherapy (WBC) for Recovery/Inflammation","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"HSA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Recovery"],"diseases":["Muscle Recovery","Chronic Inflammation","Sports Injury Recovery"],"status":"active"},{"id":"81c2264d-2d29-454f-93ba-163262dddc4d","procedure_id":"proc-cryotherapy","jurisdiction_id":"jur-cl","procedure_name":"Whole-Body Cryotherapy (WBC) for Recovery/Inflammation","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Recovery"],"diseases":["Muscle Recovery","Chronic Inflammation","Sports Injury Recovery"],"status":"active"},{"id":"ef6e52b3-dfbb-4401-b528-3827ac703101","procedure_id":"proc-cryotherapy","jurisdiction_id":"jur-ar","procedure_name":"Whole-Body Cryotherapy (WBC) for Recovery/Inflammation","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Recovery"],"diseases":["Muscle Recovery","Chronic Inflammation","Sports Injury Recovery"],"status":"active"},{"id":"763e1f1c-4593-448e-ac72-513776ae8aa7","procedure_id":"proc-cryotherapy","jurisdiction_id":"jur-za","procedure_name":"Whole-Body Cryotherapy (WBC) for Recovery/Inflammation","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Recovery"],"diseases":["Muscle Recovery","Chronic Inflammation","Sports Injury Recovery"],"status":"active"},{"id":"1c12de14-0ab8-4703-80f2-026a969d27db","procedure_id":"proc-cryotherapy","jurisdiction_id":"jur-ph","procedure_name":"Whole-Body Cryotherapy (WBC) for Recovery/Inflammation","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Recovery"],"diseases":["Muscle Recovery","Chronic Inflammation","Sports Injury Recovery"],"status":"active"},{"id":"c6874cec-0840-40ae-96e5-56663b138fbd","procedure_id":"proc-cryotherapy","jurisdiction_id":"jur-pt","procedure_name":"Whole-Body Cryotherapy (WBC) for Recovery/Inflammation","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Recovery"],"diseases":["Muscle Recovery","Chronic Inflammation","Sports Injury Recovery"],"status":"active"},{"id":"a74454aa-3c24-49b0-bfb2-db0ebf735ddb","procedure_id":"proc-cryotherapy","jurisdiction_id":"jur-fr","procedure_name":"Whole-Body Cryotherapy (WBC) for Recovery/Inflammation","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"ANSM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Recovery"],"diseases":["Muscle Recovery","Chronic Inflammation","Sports Injury Recovery"],"status":"active"},{"id":"d69ee1b7-d64e-41a8-9b8c-d32efe82de1a","procedure_id":"proc-prp-therapy","jurisdiction_id":"jur-us-or","procedure_name":"Platelet-Rich Plasma (PRP) Therapy for Joint/Tissue Repair","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Orthopedic","Sports_Medicine","Anti_Aging"],"diseases":["Knee Osteoarthritis","Tendinopathy","Rotator Cuff Injury","Androgenetic Alopecia"],"status":"active"},{"id":"4c3deb00-798c-4d63-9eb5-3dd09559480e","procedure_id":"proc-prp-therapy","jurisdiction_id":"jur-us-co","procedure_name":"Platelet-Rich Plasma (PRP) Therapy for Joint/Tissue Repair","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Orthopedic","Sports_Medicine","Anti_Aging"],"diseases":["Knee Osteoarthritis","Tendinopathy","Rotator Cuff Injury","Androgenetic Alopecia"],"status":"active"},{"id":"b19fd774-4ad5-482d-b062-2e8f9041f78d","procedure_id":"proc-prp-therapy","jurisdiction_id":"jur-us-ca","procedure_name":"Platelet-Rich Plasma (PRP) Therapy for Joint/Tissue Repair","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Orthopedic","Sports_Medicine","Anti_Aging"],"diseases":["Knee Osteoarthritis","Tendinopathy","Rotator Cuff Injury","Androgenetic Alopecia"],"status":"active"},{"id":"bae6dc86-e326-4335-953f-496d27ea6c9b","procedure_id":"proc-prp-therapy","jurisdiction_id":"jur-us-tx","procedure_name":"Platelet-Rich Plasma (PRP) Therapy for Joint/Tissue Repair","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Orthopedic","Sports_Medicine","Anti_Aging"],"diseases":["Knee Osteoarthritis","Tendinopathy","Rotator Cuff Injury","Androgenetic Alopecia"],"status":"active"},{"id":"1ea730e2-3d42-48a9-b632-9b9213698739","procedure_id":"proc-prp-therapy","jurisdiction_id":"jur-us-fl","procedure_name":"Platelet-Rich Plasma (PRP) Therapy for Joint/Tissue Repair","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Orthopedic","Sports_Medicine","Anti_Aging"],"diseases":["Knee Osteoarthritis","Tendinopathy","Rotator Cuff Injury","Androgenetic Alopecia"],"status":"active"},{"id":"5ccb193e-e8dd-4d58-86f1-6300e6d9ffef","procedure_id":"proc-prp-therapy","jurisdiction_id":"jur-au","procedure_name":"Platelet-Rich Plasma (PRP) Therapy for Joint/Tissue Repair","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"TGA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Orthopedic","Sports_Medicine","Anti_Aging"],"diseases":["Knee Osteoarthritis","Tendinopathy","Rotator Cuff Injury","Androgenetic Alopecia"],"status":"active"},{"id":"69791f50-7f9d-48f5-a7c5-bc5089b97ab7","procedure_id":"proc-prp-therapy","jurisdiction_id":"jur-ch","procedure_name":"Platelet-Rich Plasma (PRP) Therapy for Joint/Tissue Repair","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"Swissmedic","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Orthopedic","Sports_Medicine","Anti_Aging"],"diseases":["Knee Osteoarthritis","Tendinopathy","Rotator Cuff Injury","Androgenetic Alopecia"],"status":"active"},{"id":"c6a194b3-c32c-4717-8e13-3e0919969bcd","procedure_id":"proc-prp-therapy","jurisdiction_id":"jur-ca","procedure_name":"Platelet-Rich Plasma (PRP) Therapy for Joint/Tissue Repair","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"Health Canada","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Orthopedic","Sports_Medicine","Anti_Aging"],"diseases":["Knee Osteoarthritis","Tendinopathy","Rotator Cuff Injury","Androgenetic Alopecia"],"status":"active"},{"id":"d04ca47c-d853-4e5e-9000-97fbcec99d47","procedure_id":"proc-prp-therapy","jurisdiction_id":"jur-hn-prospera","procedure_name":"Platelet-Rich Plasma (PRP) Therapy for Joint/Tissue Repair","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"Próspera ZEDE health rules (contested)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Orthopedic","Sports_Medicine","Anti_Aging"],"diseases":["Knee Osteoarthritis","Tendinopathy","Rotator Cuff Injury","Androgenetic Alopecia"],"status":"active"},{"id":"222002c5-8633-45bf-b321-5642399669bc","procedure_id":"proc-prp-therapy","jurisdiction_id":"jur-nl","procedure_name":"Platelet-Rich Plasma (PRP) Therapy for Joint/Tissue Repair","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"MEB / IGJ","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Orthopedic","Sports_Medicine","Anti_Aging"],"diseases":["Knee Osteoarthritis","Tendinopathy","Rotator Cuff Injury","Androgenetic Alopecia"],"status":"active"},{"id":"9a5e8bcd-3041-40b9-8f14-40f434741cad","procedure_id":"proc-prp-therapy","jurisdiction_id":"jur-uk","procedure_name":"Platelet-Rich Plasma (PRP) Therapy for Joint/Tissue Repair","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"MHRA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Orthopedic","Sports_Medicine","Anti_Aging"],"diseases":["Knee Osteoarthritis","Tendinopathy","Rotator Cuff Injury","Androgenetic Alopecia"],"status":"active"},{"id":"68edf59f-009d-4071-acd2-d2a521f2f9aa","procedure_id":"proc-prp-therapy","jurisdiction_id":"jur-il","procedure_name":"Platelet-Rich Plasma (PRP) Therapy for Joint/Tissue Repair","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Orthopedic","Sports_Medicine","Anti_Aging"],"diseases":["Knee Osteoarthritis","Tendinopathy","Rotator Cuff Injury","Androgenetic Alopecia"],"status":"active"},{"id":"28343ac1-3454-4484-8e3c-99d66029b66a","procedure_id":"proc-prp-therapy","jurisdiction_id":"jur-jm","procedure_name":"Platelet-Rich Plasma (PRP) Therapy for Joint/Tissue Repair","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Orthopedic","Sports_Medicine","Anti_Aging"],"diseases":["Knee Osteoarthritis","Tendinopathy","Rotator Cuff Injury","Androgenetic Alopecia"],"status":"active"},{"id":"f3859c73-0ef8-4b82-a34b-6db27481a12f","procedure_id":"proc-prp-therapy","jurisdiction_id":"jur-es","procedure_name":"Platelet-Rich Plasma (PRP) Therapy for Joint/Tissue Repair","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"AEMPS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Orthopedic","Sports_Medicine","Anti_Aging"],"diseases":["Knee Osteoarthritis","Tendinopathy","Rotator Cuff Injury","Androgenetic Alopecia"],"status":"active"},{"id":"76387908-5d53-46d0-90c5-0d0554ebb3ba","procedure_id":"proc-prp-therapy","jurisdiction_id":"jur-tu","procedure_name":"Platelet-Rich Plasma (PRP) Therapy for Joint/Tissue Repair","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Orthopedic","Sports_Medicine","Anti_Aging"],"diseases":["Knee Osteoarthritis","Tendinopathy","Rotator Cuff Injury","Androgenetic Alopecia"],"status":"active"},{"id":"055de132-31c9-456a-80ad-4265e39cf359","procedure_id":"proc-prp-therapy","jurisdiction_id":"jur-in","procedure_name":"Platelet-Rich Plasma (PRP) Therapy for Joint/Tissue Repair","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"CDSCO","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Orthopedic","Sports_Medicine","Anti_Aging"],"diseases":["Knee Osteoarthritis","Tendinopathy","Rotator Cuff Injury","Androgenetic Alopecia"],"status":"active"},{"id":"bdde4faa-10e4-4587-b6c6-51b61e938cf2","procedure_id":"proc-prp-therapy","jurisdiction_id":"jur-br","procedure_name":"Platelet-Rich Plasma (PRP) Therapy for Joint/Tissue Repair","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"ANVISA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Orthopedic","Sports_Medicine","Anti_Aging"],"diseases":["Knee Osteoarthritis","Tendinopathy","Rotator Cuff Injury","Androgenetic Alopecia"],"status":"active"},{"id":"36ebd529-7cf7-4793-b295-4f11f33e7f8c","procedure_id":"proc-prp-therapy","jurisdiction_id":"jur-cr","procedure_name":"Platelet-Rich Plasma (PRP) Therapy for Joint/Tissue Repair","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Orthopedic","Sports_Medicine","Anti_Aging"],"diseases":["Knee Osteoarthritis","Tendinopathy","Rotator Cuff Injury","Androgenetic Alopecia"],"status":"active"},{"id":"5378e8a8-bdf3-46da-a3ed-b4d7caea1188","procedure_id":"proc-prp-therapy","jurisdiction_id":"jur-uae","procedure_name":"Platelet-Rich Plasma (PRP) Therapy for Joint/Tissue Repair","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Orthopedic","Sports_Medicine","Anti_Aging"],"diseases":["Knee Osteoarthritis","Tendinopathy","Rotator Cuff Injury","Androgenetic Alopecia"],"status":"active"},{"id":"5ec3c942-f836-43d8-9578-35d6393195f8","procedure_id":"proc-prp-therapy","jurisdiction_id":"jur-gr","procedure_name":"Platelet-Rich Plasma (PRP) Therapy for Joint/Tissue Repair","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Orthopedic","Sports_Medicine","Anti_Aging"],"diseases":["Knee Osteoarthritis","Tendinopathy","Rotator Cuff Injury","Androgenetic Alopecia"],"status":"active"},{"id":"89bb40b5-3b65-4b1e-a39e-db9f8d6ec901","procedure_id":"proc-prp-therapy","jurisdiction_id":"jur-be","procedure_name":"Platelet-Rich Plasma (PRP) Therapy for Joint/Tissue Repair","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Orthopedic","Sports_Medicine","Anti_Aging"],"diseases":["Knee Osteoarthritis","Tendinopathy","Rotator Cuff Injury","Androgenetic Alopecia"],"status":"active"},{"id":"c2546c5a-fa85-4429-b721-603241726601","procedure_id":"proc-prp-therapy","jurisdiction_id":"jur-se","procedure_name":"Platelet-Rich Plasma (PRP) Therapy for Joint/Tissue Repair","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Orthopedic","Sports_Medicine","Anti_Aging"],"diseases":["Knee Osteoarthritis","Tendinopathy","Rotator Cuff Injury","Androgenetic Alopecia"],"status":"active"},{"id":"00f02fdc-2da8-4f9b-b58f-41eb96cc6c22","procedure_id":"proc-prp-therapy","jurisdiction_id":"jur-sg","procedure_name":"Platelet-Rich Plasma (PRP) Therapy for Joint/Tissue Repair","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"HSA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Orthopedic","Sports_Medicine","Anti_Aging"],"diseases":["Knee Osteoarthritis","Tendinopathy","Rotator Cuff Injury","Androgenetic Alopecia"],"status":"active"},{"id":"7af52205-bc26-4418-9fbe-1d285c3ea13e","procedure_id":"proc-prp-therapy","jurisdiction_id":"jur-cl","procedure_name":"Platelet-Rich Plasma (PRP) Therapy for Joint/Tissue Repair","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Orthopedic","Sports_Medicine","Anti_Aging"],"diseases":["Knee Osteoarthritis","Tendinopathy","Rotator Cuff Injury","Androgenetic Alopecia"],"status":"active"},{"id":"55c0a452-e47d-44c5-a853-2feae9c831f3","procedure_id":"proc-prp-therapy","jurisdiction_id":"jur-ar","procedure_name":"Platelet-Rich Plasma (PRP) Therapy for Joint/Tissue Repair","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Orthopedic","Sports_Medicine","Anti_Aging"],"diseases":["Knee Osteoarthritis","Tendinopathy","Rotator Cuff Injury","Androgenetic Alopecia"],"status":"active"},{"id":"5ab4a029-e511-4ab6-8422-7b68ebfe7fef","procedure_id":"proc-prp-therapy","jurisdiction_id":"jur-za","procedure_name":"Platelet-Rich Plasma (PRP) Therapy for Joint/Tissue Repair","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Orthopedic","Sports_Medicine","Anti_Aging"],"diseases":["Knee Osteoarthritis","Tendinopathy","Rotator Cuff Injury","Androgenetic Alopecia"],"status":"active"},{"id":"d2006d66-5e38-4b36-8d51-f8ebaca61d1e","procedure_id":"proc-prp-therapy","jurisdiction_id":"jur-ph","procedure_name":"Platelet-Rich Plasma (PRP) Therapy for Joint/Tissue Repair","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Orthopedic","Sports_Medicine","Anti_Aging"],"diseases":["Knee Osteoarthritis","Tendinopathy","Rotator Cuff Injury","Androgenetic Alopecia"],"status":"active"},{"id":"bdcb5b3e-696f-4694-b734-a3acd03b7049","procedure_id":"proc-prp-therapy","jurisdiction_id":"jur-po","procedure_name":"Platelet-Rich Plasma (PRP) Therapy for Joint/Tissue Repair","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Orthopedic","Sports_Medicine","Anti_Aging"],"diseases":["Knee Osteoarthritis","Tendinopathy","Rotator Cuff Injury","Androgenetic Alopecia"],"status":"active"},{"id":"b9e3bdc2-d2ad-4d3e-99eb-9e7b4b3f1529","procedure_id":"proc-prp-therapy","jurisdiction_id":"jur-pt","procedure_name":"Platelet-Rich Plasma (PRP) Therapy for Joint/Tissue Repair","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Orthopedic","Sports_Medicine","Anti_Aging"],"diseases":["Knee Osteoarthritis","Tendinopathy","Rotator Cuff Injury","Androgenetic Alopecia"],"status":"active"},{"id":"9f393eff-e2b6-40b0-9f99-48e73ac74665","procedure_id":"proc-prp-therapy","jurisdiction_id":"jur-fr","procedure_name":"Platelet-Rich Plasma (PRP) Therapy for Joint/Tissue Repair","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"ANSM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Orthopedic","Sports_Medicine","Anti_Aging"],"diseases":["Knee Osteoarthritis","Tendinopathy","Rotator Cuff Injury","Androgenetic Alopecia"],"status":"active"},{"id":"efb641f0-2e54-4f69-b358-ba0d52dd2aee","procedure_id":"proc-nmn-nmad","jurisdiction_id":"jur-us-or","procedure_name":"NMN/NR Oral Supplementation for Longevity","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity","Metabolic_Health"],"diseases":["Age-Related Functional Decline","Metabolic Syndrome"],"status":"active"},{"id":"073dff2e-3e38-4334-a6e6-2c825eb4ea72","procedure_id":"proc-nmn-nmad","jurisdiction_id":"jur-us-co","procedure_name":"NMN/NR Oral Supplementation for Longevity","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity","Metabolic_Health"],"diseases":["Age-Related Functional Decline","Metabolic Syndrome"],"status":"active"},{"id":"a46f979c-7ece-4f7d-9dfc-94fa33b0fb12","procedure_id":"proc-nmn-nmad","jurisdiction_id":"jur-us-ca","procedure_name":"NMN/NR Oral Supplementation for Longevity","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity","Metabolic_Health"],"diseases":["Age-Related Functional Decline","Metabolic Syndrome"],"status":"active"},{"id":"0b36fd59-b9b7-4a98-82b6-97c8856fd456","procedure_id":"proc-nmn-nmad","jurisdiction_id":"jur-us-tx","procedure_name":"NMN/NR Oral Supplementation for Longevity","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity","Metabolic_Health"],"diseases":["Age-Related Functional Decline","Metabolic Syndrome"],"status":"active"},{"id":"256a623a-4c99-4679-9b41-1f16f8b16c1b","procedure_id":"proc-nmn-nmad","jurisdiction_id":"jur-us-fl","procedure_name":"NMN/NR Oral Supplementation for Longevity","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity","Metabolic_Health"],"diseases":["Age-Related Functional Decline","Metabolic Syndrome"],"status":"active"},{"id":"5bcdbd7c-f902-4777-8602-a1523f4de0c8","procedure_id":"proc-nmn-nmad","jurisdiction_id":"jur-ch","procedure_name":"NMN/NR Oral Supplementation for Longevity","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"Swissmedic","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity","Metabolic_Health"],"diseases":["Age-Related Functional Decline","Metabolic Syndrome"],"status":"active"},{"id":"17763ed4-e99d-4c5f-8728-0e47745da65c","procedure_id":"proc-nmn-nmad","jurisdiction_id":"jur-ca","procedure_name":"NMN/NR Oral Supplementation for Longevity","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"Health Canada","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity","Metabolic_Health"],"diseases":["Age-Related Functional Decline","Metabolic Syndrome"],"status":"active"},{"id":"f4faaafb-d97c-4570-9d52-5d885a2712ad","procedure_id":"proc-nmn-nmad","jurisdiction_id":"jur-mx","procedure_name":"NMN/NR Oral Supplementation for Longevity","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"COFEPRIS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity","Metabolic_Health"],"diseases":["Age-Related Functional Decline","Metabolic Syndrome"],"status":"active"},{"id":"cff2e715-9814-46de-9f5f-6df26e1a87f6","procedure_id":"proc-nmn-nmad","jurisdiction_id":"jur-hn-prospera","procedure_name":"NMN/NR Oral Supplementation for Longevity","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"Próspera ZEDE health rules (contested)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity","Metabolic_Health"],"diseases":["Age-Related Functional Decline","Metabolic Syndrome"],"status":"active"},{"id":"82591efb-a86d-4c78-8a62-783517a24741","procedure_id":"proc-nmn-nmad","jurisdiction_id":"jur-nl","procedure_name":"NMN/NR Oral Supplementation for Longevity","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"MEB / IGJ","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity","Metabolic_Health"],"diseases":["Age-Related Functional Decline","Metabolic Syndrome"],"status":"active"},{"id":"204ac1c7-4192-4586-9bd7-8895d2321527","procedure_id":"proc-nmn-nmad","jurisdiction_id":"jur-uk","procedure_name":"NMN/NR Oral Supplementation for Longevity","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"MHRA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity","Metabolic_Health"],"diseases":["Age-Related Functional Decline","Metabolic Syndrome"],"status":"active"},{"id":"237322c3-7ef9-4729-b097-987416b1c420","procedure_id":"proc-nmn-nmad","jurisdiction_id":"jur-il","procedure_name":"NMN/NR Oral Supplementation for Longevity","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity","Metabolic_Health"],"diseases":["Age-Related Functional Decline","Metabolic Syndrome"],"status":"active"},{"id":"6953ae40-6772-4f26-aa3d-66c35dd9cdd4","procedure_id":"proc-nmn-nmad","jurisdiction_id":"jur-jm","procedure_name":"NMN/NR Oral Supplementation for Longevity","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity","Metabolic_Health"],"diseases":["Age-Related Functional Decline","Metabolic Syndrome"],"status":"active"},{"id":"de97a771-88e4-4b13-b49b-e8cff40571b3","procedure_id":"proc-nmn-nmad","jurisdiction_id":"jur-th","procedure_name":"NMN/NR Oral Supplementation for Longevity","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"Thai FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity","Metabolic_Health"],"diseases":["Age-Related Functional Decline","Metabolic Syndrome"],"status":"active"},{"id":"0bc66925-5108-450d-bf0b-28ecb0c96729","procedure_id":"proc-nmn-nmad","jurisdiction_id":"jur-es","procedure_name":"NMN/NR Oral Supplementation for Longevity","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"AEMPS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity","Metabolic_Health"],"diseases":["Age-Related Functional Decline","Metabolic Syndrome"],"status":"active"},{"id":"0e8e3dcf-09dc-45fe-b0a8-81f95a17d2f9","procedure_id":"proc-nmn-nmad","jurisdiction_id":"jur-tu","procedure_name":"NMN/NR Oral Supplementation for Longevity","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity","Metabolic_Health"],"diseases":["Age-Related Functional Decline","Metabolic Syndrome"],"status":"active"},{"id":"e9eb4f1e-b02e-4aa2-80d7-bdb26179bc59","procedure_id":"proc-nmn-nmad","jurisdiction_id":"jur-in","procedure_name":"NMN/NR Oral Supplementation for Longevity","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"CDSCO","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity","Metabolic_Health"],"diseases":["Age-Related Functional Decline","Metabolic Syndrome"],"status":"active"},{"id":"eb2043d6-df0e-4c6f-8df1-83fc9a8a2277","procedure_id":"proc-nmn-nmad","jurisdiction_id":"jur-br","procedure_name":"NMN/NR Oral Supplementation for Longevity","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"ANVISA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity","Metabolic_Health"],"diseases":["Age-Related Functional Decline","Metabolic Syndrome"],"status":"active"},{"id":"2208da90-05d8-4d4b-bf5e-1c67eb66f21c","procedure_id":"proc-nmn-nmad","jurisdiction_id":"jur-cr","procedure_name":"NMN/NR Oral Supplementation for Longevity","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity","Metabolic_Health"],"diseases":["Age-Related Functional Decline","Metabolic Syndrome"],"status":"active"},{"id":"a0a0de64-48dd-420f-9367-c8f898cb446b","procedure_id":"proc-nmn-nmad","jurisdiction_id":"jur-uae","procedure_name":"NMN/NR Oral Supplementation for Longevity","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity","Metabolic_Health"],"diseases":["Age-Related Functional Decline","Metabolic Syndrome"],"status":"active"},{"id":"278a1822-c10e-43aa-8bc0-cd80b5ec0c5e","procedure_id":"proc-nmn-nmad","jurisdiction_id":"jur-kr","procedure_name":"NMN/NR Oral Supplementation for Longevity","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"MFDS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity","Metabolic_Health"],"diseases":["Age-Related Functional Decline","Metabolic Syndrome"],"status":"active"},{"id":"ea73a29e-988a-477d-850a-2f002002fc1c","procedure_id":"proc-nmn-nmad","jurisdiction_id":"jur-gr","procedure_name":"NMN/NR Oral Supplementation for Longevity","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity","Metabolic_Health"],"diseases":["Age-Related Functional Decline","Metabolic Syndrome"],"status":"active"},{"id":"8baa15a6-8740-443a-8005-4aec2c6ff171","procedure_id":"proc-nmn-nmad","jurisdiction_id":"jur-be","procedure_name":"NMN/NR Oral Supplementation for Longevity","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity","Metabolic_Health"],"diseases":["Age-Related Functional Decline","Metabolic Syndrome"],"status":"active"},{"id":"78eebbba-ed58-4d20-8c3d-5b34376859a4","procedure_id":"proc-nmn-nmad","jurisdiction_id":"jur-se","procedure_name":"NMN/NR Oral Supplementation for Longevity","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity","Metabolic_Health"],"diseases":["Age-Related Functional Decline","Metabolic Syndrome"],"status":"active"},{"id":"6d7b3cd7-eb98-4bcb-b4d9-208fa5f9ccd2","procedure_id":"proc-nmn-nmad","jurisdiction_id":"jur-cl","procedure_name":"NMN/NR Oral Supplementation for Longevity","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity","Metabolic_Health"],"diseases":["Age-Related Functional Decline","Metabolic Syndrome"],"status":"active"},{"id":"78ee3a78-4394-4dc1-b399-a7abdffc9b78","procedure_id":"proc-nmn-nmad","jurisdiction_id":"jur-ar","procedure_name":"NMN/NR Oral Supplementation for Longevity","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity","Metabolic_Health"],"diseases":["Age-Related Functional Decline","Metabolic Syndrome"],"status":"active"},{"id":"45832d3e-f8a9-41ae-a5cc-07d7850eb590","procedure_id":"proc-nmn-nmad","jurisdiction_id":"jur-za","procedure_name":"NMN/NR Oral Supplementation for Longevity","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity","Metabolic_Health"],"diseases":["Age-Related Functional Decline","Metabolic Syndrome"],"status":"active"},{"id":"f44c2db5-b720-4ce3-86f0-d620e7ad0f38","procedure_id":"proc-nmn-nmad","jurisdiction_id":"jur-ph","procedure_name":"NMN/NR Oral Supplementation for Longevity","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity","Metabolic_Health"],"diseases":["Age-Related Functional Decline","Metabolic Syndrome"],"status":"active"},{"id":"9376e67e-661f-4b4f-ae4e-beaff78bce2b","procedure_id":"proc-nmn-nmad","jurisdiction_id":"jur-po","procedure_name":"NMN/NR Oral Supplementation for Longevity","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity","Metabolic_Health"],"diseases":["Age-Related Functional Decline","Metabolic Syndrome"],"status":"active"},{"id":"1a254a96-2971-4e71-9801-942d917b8374","procedure_id":"proc-nmn-nmad","jurisdiction_id":"jur-pt","procedure_name":"NMN/NR Oral Supplementation for Longevity","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity","Metabolic_Health"],"diseases":["Age-Related Functional Decline","Metabolic Syndrome"],"status":"active"},{"id":"ec947f1c-2bc2-4efb-a9e0-32576de3fc3f","procedure_id":"proc-nmn-nmad","jurisdiction_id":"jur-fr","procedure_name":"NMN/NR Oral Supplementation for Longevity","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Disease claims convert products into unapproved drugs. Facility/IV rules still apply.","eligibility_requirements":"Clinic screening; not a regulated disease indication pathway.","provider_requirements":"Medical director + IV competency where injections/infusions used.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray/cash wellness pathway — compliance is advertising and scope-of-practice driven.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: wellness infusions/supplements sit in a gray zone — medical board + advertising + sterile compounding rules dominate.","regulatory_authority":"ANSM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity","Metabolic_Health"],"diseases":["Age-Related Functional Decline","Metabolic Syndrome"],"status":"active"},{"id":"19e12eeb-260a-45c9-bfc9-0a45810eceda","procedure_id":"proc-ayahuasca","jurisdiction_id":"jur-us-or","procedure_name":"Ayahuasca-Assisted Therapy for Depression/Addiction/Spiritual Growth","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"REGULATED_THERAPY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Jurisdiction signals a regulated therapy-program model for psychedelics.","eligibility_requirements":"Program-specific screening (age, contraindications).","provider_requirements":"Program licenses / facilitator or medical credentials per local scheme.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred regulated program pathway may exist — still confirm license classes and product rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: Jurisdiction psychedelic_default=Regulated_Therapy_Program.","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Addiction","Spirituality"],"diseases":["Depression","Substance Use Disorder","PTSD","Existential Distress"],"status":"active"},{"id":"9a0bf46e-1464-44f8-ae08-052ed87eb7ca","procedure_id":"proc-ayahuasca","jurisdiction_id":"jur-jm","procedure_name":"Ayahuasca-Assisted Therapy for Depression/Addiction/Spiritual Growth","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"UNREGULATED_PERMITTED","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Default allows relatively open practice — quality and consumer protection still apply.","eligibility_requirements":"Operator-defined; local consumer law applies.","provider_requirements":"Local business/medical rules may still apply even if substance posture is open.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred permissive/unregulated posture — high variance in quality; diligence essential.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: Jurisdiction psychedelic_default=Unregulated_Permitted.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Addiction","Spirituality"],"diseases":["Depression","Substance Use Disorder","PTSD","Existential Distress"],"status":"active"},{"id":"ea1f2e09-731d-48f7-8de2-957990f7d566","procedure_id":"proc-ayahuasca","jurisdiction_id":"jur-gr","procedure_name":"Ayahuasca-Assisted Therapy for Depression/Addiction/Spiritual Growth","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Classical/atypical psychedelic therapy for Ayahuasca-Assisted Therapy for Depression/Addiction/Spiritual Growth treated as prohibited outside narrow research under default national posture.","eligibility_requirements":"No lawful general patient pathway under inferred default.","provider_requirements":"Cannot lawfully open a commercial program without an explicit statutory exception.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Criminal liability risk if default is accurate; always verify current schedule.","arbitrage_summary":"Inferred prohibited under jurisdiction psychedelic default / UN-style scheduling. Not a lawful commercial therapy market.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: No jurisdiction psychedelic_default on file — applied conservative Schedule-I-class default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Addiction","Spirituality"],"diseases":["Depression","Substance Use Disorder","PTSD","Existential Distress"],"status":"active"},{"id":"f13d66e3-64e5-44d2-a687-d2e7545ff31c","procedure_id":"proc-medical-cannabis","jurisdiction_id":"jur-us-co","procedure_name":"Medical Cannabis for Chronic Pain / Seizures / PTSD","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"REGULATED_THERAPY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"PHYTOCANNABINOID","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Medical and adult-use both signalled — medical channel still distinct for clinical practice.","eligibility_requirements":"Medical programme or adult-use age rules depending on channel.","provider_requirements":"Recommend-only vs retail licenses are different tracks.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred multi-channel cannabis market; medical practice still needs programme compliance.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred from cannabis_default=Medical_And_Adult_Use","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Pain","Neurology","Mental_Health"],"diseases":["Chronic Pain","Epilepsy","PTSD","Chemotherapy-Induced Nausea","Anxiety"],"status":"active"},{"id":"b93400af-c90d-4182-ab27-da51a310890c","procedure_id":"proc-medical-cannabis","jurisdiction_id":"jur-us-tx","procedure_name":"Medical Cannabis for Chronic Pain / Seizures / PTSD","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PHYTOCANNABINOID","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Medical cannabis programme not inferred under prohibited default.","eligibility_requirements":"No pathway.","provider_requirements":"No pathway.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful medical cannabis market under jurisdiction default.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred from cannabis_default=Prohibited","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Pain","Neurology","Mental_Health"],"diseases":["Chronic Pain","Epilepsy","PTSD","Chemotherapy-Induced Nausea","Anxiety"],"status":"active"},{"id":"70527726-2ec3-46b1-88f2-7c8c5cb67703","procedure_id":"proc-medical-cannabis","jurisdiction_id":"jur-us-fl","procedure_name":"Medical Cannabis for Chronic Pain / Seizures / PTSD","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PHYTOCANNABINOID","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Medical cannabis programme not inferred under prohibited default.","eligibility_requirements":"No pathway.","provider_requirements":"No pathway.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful medical cannabis market under jurisdiction default.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred from cannabis_default=Prohibited","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Pain","Neurology","Mental_Health"],"diseases":["Chronic Pain","Epilepsy","PTSD","Chemotherapy-Induced Nausea","Anxiety"],"status":"active"},{"id":"7bbcb40e-3fc9-4116-9125-f2ffc3153529","procedure_id":"proc-medical-cannabis","jurisdiction_id":"jur-ch","procedure_name":"Medical Cannabis for Chronic Pain / Seizures / PTSD","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"REGULATED_THERAPY","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PHYTOCANNABINOID","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Medical-only default: prescription/authorization + licensed supply chain typically required.","eligibility_requirements":"Qualifying medical indication under national programme (verify list).","provider_requirements":"Authorized prescriber + licensed pharmacy/dispensary channel.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred medical-only cannabis pathway (prescription/authorization model).","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred from cannabis_default=Medical_Only","regulatory_authority":"Swissmedic","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Pain","Neurology","Mental_Health"],"diseases":["Chronic Pain","Epilepsy","PTSD","Chemotherapy-Induced Nausea","Anxiety"],"status":"active"},{"id":"1983c1b8-10ac-49b0-93c8-9a853b8b1b31","procedure_id":"proc-medical-cannabis","jurisdiction_id":"jur-mx","procedure_name":"Medical Cannabis for Chronic Pain / Seizures / PTSD","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"VARIABLE","modality":"PHYTOCANNABINOID","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cannabis rules highly variable; no safe single pathway inference.","eligibility_requirements":"Unknown.","provider_requirements":"Unknown.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred variable cannabis posture — research required.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred from cannabis_default=Highly_Variable","regulatory_authority":"COFEPRIS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Pain","Neurology","Mental_Health"],"diseases":["Chronic Pain","Epilepsy","PTSD","Chemotherapy-Induced Nausea","Anxiety"],"status":"active"},{"id":"41187a39-d135-435c-b118-e8f28f7a881e","procedure_id":"proc-medical-cannabis","jurisdiction_id":"jur-hn-prospera","procedure_name":"Medical Cannabis for Chronic Pain / Seizures / PTSD","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"VARIABLE","modality":"PHYTOCANNABINOID","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cannabis rules highly variable; no safe single pathway inference.","eligibility_requirements":"Unknown.","provider_requirements":"Unknown.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred variable cannabis posture — research required.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred from cannabis_default=Highly_Variable","regulatory_authority":"Próspera ZEDE health rules (contested)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Pain","Neurology","Mental_Health"],"diseases":["Chronic Pain","Epilepsy","PTSD","Chemotherapy-Induced Nausea","Anxiety"],"status":"active"},{"id":"076d17c9-bf0b-4739-a879-b738b7513b91","procedure_id":"proc-medical-cannabis","jurisdiction_id":"jur-jm","procedure_name":"Medical Cannabis for Chronic Pain / Seizures / PTSD","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"REGULATED_THERAPY","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PHYTOCANNABINOID","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Medical-only default: prescription/authorization + licensed supply chain typically required.","eligibility_requirements":"Qualifying medical indication under national programme (verify list).","provider_requirements":"Authorized prescriber + licensed pharmacy/dispensary channel.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred medical-only cannabis pathway (prescription/authorization model).","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred from cannabis_default=Medical_Only","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Pain","Neurology","Mental_Health"],"diseases":["Chronic Pain","Epilepsy","PTSD","Chemotherapy-Induced Nausea","Anxiety"],"status":"active"},{"id":"23847f7f-a598-431e-9706-548969b113c5","procedure_id":"proc-medical-cannabis","jurisdiction_id":"jur-tu","procedure_name":"Medical Cannabis for Chronic Pain / Seizures / PTSD","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PHYTOCANNABINOID","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Medical cannabis programme not inferred under prohibited default.","eligibility_requirements":"No pathway.","provider_requirements":"No pathway.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful medical cannabis market under jurisdiction default.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred from cannabis_default=Prohibited (defaulted; no profile field).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Pain","Neurology","Mental_Health"],"diseases":["Chronic Pain","Epilepsy","PTSD","Chemotherapy-Induced Nausea","Anxiety"],"status":"active"},{"id":"22b9e40b-ebc3-4680-a97a-2d4d5fdcdd5b","procedure_id":"proc-medical-cannabis","jurisdiction_id":"jur-br","procedure_name":"Medical Cannabis for Chronic Pain / Seizures / PTSD","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"REGULATED_THERAPY","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PHYTOCANNABINOID","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Medical-only default: prescription/authorization + licensed supply chain typically required.","eligibility_requirements":"Qualifying medical indication under national programme (verify list).","provider_requirements":"Authorized prescriber + licensed pharmacy/dispensary channel.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred medical-only cannabis pathway (prescription/authorization model).","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred from cannabis_default=Medical_Only","regulatory_authority":"ANVISA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Pain","Neurology","Mental_Health"],"diseases":["Chronic Pain","Epilepsy","PTSD","Chemotherapy-Induced Nausea","Anxiety"],"status":"active"},{"id":"6b45604f-39a7-4d93-b917-2559a5f7161d","procedure_id":"proc-medical-cannabis","jurisdiction_id":"jur-cr","procedure_name":"Medical Cannabis for Chronic Pain / Seizures / PTSD","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PHYTOCANNABINOID","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Medical cannabis programme not inferred under prohibited default.","eligibility_requirements":"No pathway.","provider_requirements":"No pathway.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful medical cannabis market under jurisdiction default.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred from cannabis_default=Prohibited (defaulted; no profile field).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Pain","Neurology","Mental_Health"],"diseases":["Chronic Pain","Epilepsy","PTSD","Chemotherapy-Induced Nausea","Anxiety"],"status":"active"},{"id":"67159203-8050-41c9-a213-a7ab580d3134","procedure_id":"proc-medical-cannabis","jurisdiction_id":"jur-gr","procedure_name":"Medical Cannabis for Chronic Pain / Seizures / PTSD","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PHYTOCANNABINOID","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Medical cannabis programme not inferred under prohibited default.","eligibility_requirements":"No pathway.","provider_requirements":"No pathway.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful medical cannabis market under jurisdiction default.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred from cannabis_default=Prohibited (defaulted; no profile field).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Pain","Neurology","Mental_Health"],"diseases":["Chronic Pain","Epilepsy","PTSD","Chemotherapy-Induced Nausea","Anxiety"],"status":"active"},{"id":"65d590a1-d163-46aa-b906-3a2e8d184c43","procedure_id":"proc-medical-cannabis","jurisdiction_id":"jur-be","procedure_name":"Medical Cannabis for Chronic Pain / Seizures / PTSD","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"REGULATED_THERAPY","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PHYTOCANNABINOID","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Medical-only default: prescription/authorization + licensed supply chain typically required.","eligibility_requirements":"Qualifying medical indication under national programme (verify list).","provider_requirements":"Authorized prescriber + licensed pharmacy/dispensary channel.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred medical-only cannabis pathway (prescription/authorization model).","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred from cannabis_default=Medical_Only","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Pain","Neurology","Mental_Health"],"diseases":["Chronic Pain","Epilepsy","PTSD","Chemotherapy-Induced Nausea","Anxiety"],"status":"active"},{"id":"cbc321c3-52f1-415d-afec-62cf4b5fefa6","procedure_id":"proc-medical-cannabis","jurisdiction_id":"jur-se","procedure_name":"Medical Cannabis for Chronic Pain / Seizures / PTSD","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PHYTOCANNABINOID","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Medical cannabis programme not inferred under prohibited default.","eligibility_requirements":"No pathway.","provider_requirements":"No pathway.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful medical cannabis market under jurisdiction default.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred from cannabis_default=Prohibited (defaulted; no profile field).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Pain","Neurology","Mental_Health"],"diseases":["Chronic Pain","Epilepsy","PTSD","Chemotherapy-Induced Nausea","Anxiety"],"status":"active"},{"id":"17701372-b753-48c7-a1b0-8a0d09b619de","procedure_id":"proc-medical-cannabis","jurisdiction_id":"jur-cl","procedure_name":"Medical Cannabis for Chronic Pain / Seizures / PTSD","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PHYTOCANNABINOID","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Medical cannabis programme not inferred under prohibited default.","eligibility_requirements":"No pathway.","provider_requirements":"No pathway.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful medical cannabis market under jurisdiction default.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred from cannabis_default=Prohibited (defaulted; no profile field).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Pain","Neurology","Mental_Health"],"diseases":["Chronic Pain","Epilepsy","PTSD","Chemotherapy-Induced Nausea","Anxiety"],"status":"active"},{"id":"2d1fa534-ee5d-4c4f-be32-9fffcbd7a84f","procedure_id":"proc-medical-cannabis","jurisdiction_id":"jur-ar","procedure_name":"Medical Cannabis for Chronic Pain / Seizures / PTSD","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PHYTOCANNABINOID","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Medical cannabis programme not inferred under prohibited default.","eligibility_requirements":"No pathway.","provider_requirements":"No pathway.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful medical cannabis market under jurisdiction default.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred from cannabis_default=Prohibited (defaulted; no profile field).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Pain","Neurology","Mental_Health"],"diseases":["Chronic Pain","Epilepsy","PTSD","Chemotherapy-Induced Nausea","Anxiety"],"status":"active"},{"id":"05f1414a-3d19-4174-a8ce-154454b57ab8","procedure_id":"proc-medical-cannabis","jurisdiction_id":"jur-za","procedure_name":"Medical Cannabis for Chronic Pain / Seizures / PTSD","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PHYTOCANNABINOID","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Medical cannabis programme not inferred under prohibited default.","eligibility_requirements":"No pathway.","provider_requirements":"No pathway.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful medical cannabis market under jurisdiction default.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred from cannabis_default=Prohibited (defaulted; no profile field).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Pain","Neurology","Mental_Health"],"diseases":["Chronic Pain","Epilepsy","PTSD","Chemotherapy-Induced Nausea","Anxiety"],"status":"active"},{"id":"5c24c0d9-af88-46ca-8259-667f5d314cbd","procedure_id":"proc-medical-cannabis","jurisdiction_id":"jur-po","procedure_name":"Medical Cannabis for Chronic Pain / Seizures / PTSD","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PHYTOCANNABINOID","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Medical cannabis programme not inferred under prohibited default.","eligibility_requirements":"No pathway.","provider_requirements":"No pathway.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful medical cannabis market under jurisdiction default.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred from cannabis_default=Prohibited (defaulted; no profile field).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Pain","Neurology","Mental_Health"],"diseases":["Chronic Pain","Epilepsy","PTSD","Chemotherapy-Induced Nausea","Anxiety"],"status":"active"},{"id":"f498d511-4673-4cf5-aa76-5270d5b91a2a","procedure_id":"proc-medical-cannabis","jurisdiction_id":"jur-pt","procedure_name":"Medical Cannabis for Chronic Pain / Seizures / PTSD","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"REGULATED_THERAPY","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PHYTOCANNABINOID","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Medical-only default: prescription/authorization + licensed supply chain typically required.","eligibility_requirements":"Qualifying medical indication under national programme (verify list).","provider_requirements":"Authorized prescriber + licensed pharmacy/dispensary channel.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred medical-only cannabis pathway (prescription/authorization model).","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred from cannabis_default=Medical_Only","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Pain","Neurology","Mental_Health"],"diseases":["Chronic Pain","Epilepsy","PTSD","Chemotherapy-Induced Nausea","Anxiety"],"status":"active"},{"id":"27f99662-d15e-4e7b-a663-846ca55a5e78","procedure_id":"proc-medical-cannabis","jurisdiction_id":"jur-fr","procedure_name":"Medical Cannabis for Chronic Pain / Seizures / PTSD","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"REGULATED_THERAPY","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PHYTOCANNABINOID","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Medical-only default: prescription/authorization + licensed supply chain typically required.","eligibility_requirements":"Qualifying medical indication under national programme (verify list).","provider_requirements":"Authorized prescriber + licensed pharmacy/dispensary channel.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred medical-only cannabis pathway (prescription/authorization model).","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred from cannabis_default=Medical_Only","regulatory_authority":"ANSM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Pain","Neurology","Mental_Health"],"diseases":["Chronic Pain","Epilepsy","PTSD","Chemotherapy-Induced Nausea","Anxiety"],"status":"active"},{"id":"de55f77a-7dd5-4995-9afe-68726e2a92ae","procedure_id":"proc-ozone-therapy","jurisdiction_id":"jur-hn-prospera","procedure_name":"Ozone Therapy for Infection / Inflammation / Wound Healing","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"US FDA has warned against ozone therapy for disease treatment.","eligibility_requirements":"None in strict markets.","provider_requirements":"No lawful medical therapy pathway inferred in ICH-class systems.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred unlawful or non-recognized as medical therapy in strict markets.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ozone therapy is generally not an approved medical therapy in strict regulators; gray abroad.","regulatory_authority":"Próspera ZEDE health rules (contested)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Infection","Wound_Healing","Orthopedic"],"diseases":["Chronic Wound","Chronic Infection","Osteoarthritis (off-label)"],"status":"active"},{"id":"4bd96175-ef02-4f93-b101-f7fa6593fc24","procedure_id":"proc-ozone-therapy","jurisdiction_id":"jur-nl","procedure_name":"Ozone Therapy for Infection / Inflammation / Wound Healing","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"US FDA has warned against ozone therapy for disease treatment.","eligibility_requirements":"None in strict markets.","provider_requirements":"No lawful medical therapy pathway inferred in ICH-class systems.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred unlawful or non-recognized as medical therapy in strict markets.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ozone therapy is generally not an approved medical therapy in strict regulators; gray abroad.","regulatory_authority":"MEB / IGJ","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Infection","Wound_Healing","Orthopedic"],"diseases":["Chronic Wound","Chronic Infection","Osteoarthritis (off-label)"],"status":"active"},{"id":"0c6e2497-25f0-4220-8429-7398f4784094","procedure_id":"proc-ozone-therapy","jurisdiction_id":"jur-il","procedure_name":"Ozone Therapy for Infection / Inflammation / Wound Healing","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"US FDA has warned against ozone therapy for disease treatment.","eligibility_requirements":"None in strict markets.","provider_requirements":"No lawful medical therapy pathway inferred in ICH-class systems.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred unlawful or non-recognized as medical therapy in strict markets.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ozone therapy is generally not an approved medical therapy in strict regulators; gray abroad.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Infection","Wound_Healing","Orthopedic"],"diseases":["Chronic Wound","Chronic Infection","Osteoarthritis (off-label)"],"status":"active"},{"id":"b6977648-4553-47ca-8071-4592b941b793","procedure_id":"proc-ozone-therapy","jurisdiction_id":"jur-jm","procedure_name":"Ozone Therapy for Infection / Inflammation / Wound Healing","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"US FDA has warned against ozone therapy for disease treatment.","eligibility_requirements":"None in strict markets.","provider_requirements":"No lawful medical therapy pathway inferred in ICH-class systems.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred unlawful or non-recognized as medical therapy in strict markets.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ozone therapy is generally not an approved medical therapy in strict regulators; gray abroad.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Infection","Wound_Healing","Orthopedic"],"diseases":["Chronic Wound","Chronic Infection","Osteoarthritis (off-label)"],"status":"active"},{"id":"eeb54b0a-c534-4df1-a5f1-aa0c7eac3f5a","procedure_id":"proc-ozone-therapy","jurisdiction_id":"jur-th","procedure_name":"Ozone Therapy for Infection / Inflammation / Wound Healing","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"US FDA has warned against ozone therapy for disease treatment.","eligibility_requirements":"None in strict markets.","provider_requirements":"No lawful medical therapy pathway inferred in ICH-class systems.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred unlawful or non-recognized as medical therapy in strict markets.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ozone therapy is generally not an approved medical therapy in strict regulators; gray abroad.","regulatory_authority":"Thai FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Infection","Wound_Healing","Orthopedic"],"diseases":["Chronic Wound","Chronic Infection","Osteoarthritis (off-label)"],"status":"active"},{"id":"984732e5-d16d-4354-971e-9b5a4d7a2964","procedure_id":"proc-ozone-therapy","jurisdiction_id":"jur-es","procedure_name":"Ozone Therapy for Infection / Inflammation / Wound Healing","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"US FDA has warned against ozone therapy for disease treatment.","eligibility_requirements":"None in strict markets.","provider_requirements":"No lawful medical therapy pathway inferred in ICH-class systems.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred unlawful or non-recognized as medical therapy in strict markets.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ozone therapy is generally not an approved medical therapy in strict regulators; gray abroad.","regulatory_authority":"AEMPS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Infection","Wound_Healing","Orthopedic"],"diseases":["Chronic Wound","Chronic Infection","Osteoarthritis (off-label)"],"status":"active"},{"id":"c03c4e18-8526-46ee-9a68-a5a4614334b6","procedure_id":"proc-ozone-therapy","jurisdiction_id":"jur-in","procedure_name":"Ozone Therapy for Infection / Inflammation / Wound Healing","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"US FDA has warned against ozone therapy for disease treatment.","eligibility_requirements":"None in strict markets.","provider_requirements":"No lawful medical therapy pathway inferred in ICH-class systems.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred unlawful or non-recognized as medical therapy in strict markets.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ozone therapy is generally not an approved medical therapy in strict regulators; gray abroad.","regulatory_authority":"CDSCO","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Infection","Wound_Healing","Orthopedic"],"diseases":["Chronic Wound","Chronic Infection","Osteoarthritis (off-label)"],"status":"active"},{"id":"c51fc9ae-5b7b-4557-9e3a-bac78d8696c5","procedure_id":"proc-ozone-therapy","jurisdiction_id":"jur-br","procedure_name":"Ozone Therapy for Infection / Inflammation / Wound Healing","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"US FDA has warned against ozone therapy for disease treatment.","eligibility_requirements":"None in strict markets.","provider_requirements":"No lawful medical therapy pathway inferred in ICH-class systems.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred unlawful or non-recognized as medical therapy in strict markets.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ozone therapy is generally not an approved medical therapy in strict regulators; gray abroad.","regulatory_authority":"ANVISA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Infection","Wound_Healing","Orthopedic"],"diseases":["Chronic Wound","Chronic Infection","Osteoarthritis (off-label)"],"status":"active"},{"id":"fc9393e9-2469-46ab-847a-3009afd36a12","procedure_id":"proc-ozone-therapy","jurisdiction_id":"jur-cr","procedure_name":"Ozone Therapy for Infection / Inflammation / Wound Healing","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"US FDA has warned against ozone therapy for disease treatment.","eligibility_requirements":"None in strict markets.","provider_requirements":"No lawful medical therapy pathway inferred in ICH-class systems.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred unlawful or non-recognized as medical therapy in strict markets.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ozone therapy is generally not an approved medical therapy in strict regulators; gray abroad.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Infection","Wound_Healing","Orthopedic"],"diseases":["Chronic Wound","Chronic Infection","Osteoarthritis (off-label)"],"status":"active"},{"id":"e59e7347-6fe0-4ec3-b127-9685afe7b60c","procedure_id":"proc-ozone-therapy","jurisdiction_id":"jur-uae","procedure_name":"Ozone Therapy for Infection / Inflammation / Wound Healing","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"US FDA has warned against ozone therapy for disease treatment.","eligibility_requirements":"None in strict markets.","provider_requirements":"No lawful medical therapy pathway inferred in ICH-class systems.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred unlawful or non-recognized as medical therapy in strict markets.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ozone therapy is generally not an approved medical therapy in strict regulators; gray abroad.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Infection","Wound_Healing","Orthopedic"],"diseases":["Chronic Wound","Chronic Infection","Osteoarthritis (off-label)"],"status":"active"},{"id":"8f9424e3-cb7e-440a-ae5e-86b7c49a9a15","procedure_id":"proc-ozone-therapy","jurisdiction_id":"jur-kr","procedure_name":"Ozone Therapy for Infection / Inflammation / Wound Healing","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"US FDA has warned against ozone therapy for disease treatment.","eligibility_requirements":"None in strict markets.","provider_requirements":"No lawful medical therapy pathway inferred in ICH-class systems.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred unlawful or non-recognized as medical therapy in strict markets.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ozone therapy is generally not an approved medical therapy in strict regulators; gray abroad.","regulatory_authority":"MFDS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Infection","Wound_Healing","Orthopedic"],"diseases":["Chronic Wound","Chronic Infection","Osteoarthritis (off-label)"],"status":"active"},{"id":"598eaa6d-fc34-4d2c-8306-830a3b21be54","procedure_id":"proc-ozone-therapy","jurisdiction_id":"jur-gr","procedure_name":"Ozone Therapy for Infection / Inflammation / Wound Healing","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"US FDA has warned against ozone therapy for disease treatment.","eligibility_requirements":"None in strict markets.","provider_requirements":"No lawful medical therapy pathway inferred in ICH-class systems.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred unlawful or non-recognized as medical therapy in strict markets.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ozone therapy is generally not an approved medical therapy in strict regulators; gray abroad.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Infection","Wound_Healing","Orthopedic"],"diseases":["Chronic Wound","Chronic Infection","Osteoarthritis (off-label)"],"status":"active"},{"id":"639238b1-7b9f-4429-8993-9fcac499f409","procedure_id":"proc-ozone-therapy","jurisdiction_id":"jur-be","procedure_name":"Ozone Therapy for Infection / Inflammation / Wound Healing","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"US FDA has warned against ozone therapy for disease treatment.","eligibility_requirements":"None in strict markets.","provider_requirements":"No lawful medical therapy pathway inferred in ICH-class systems.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred unlawful or non-recognized as medical therapy in strict markets.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ozone therapy is generally not an approved medical therapy in strict regulators; gray abroad.","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Infection","Wound_Healing","Orthopedic"],"diseases":["Chronic Wound","Chronic Infection","Osteoarthritis (off-label)"],"status":"active"},{"id":"7221e055-39b2-4323-afb8-54c83d9f787b","procedure_id":"proc-ozone-therapy","jurisdiction_id":"jur-se","procedure_name":"Ozone Therapy for Infection / Inflammation / Wound Healing","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"US FDA has warned against ozone therapy for disease treatment.","eligibility_requirements":"None in strict markets.","provider_requirements":"No lawful medical therapy pathway inferred in ICH-class systems.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred unlawful or non-recognized as medical therapy in strict markets.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ozone therapy is generally not an approved medical therapy in strict regulators; gray abroad.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Infection","Wound_Healing","Orthopedic"],"diseases":["Chronic Wound","Chronic Infection","Osteoarthritis (off-label)"],"status":"active"},{"id":"3dba87f4-f87e-4de6-8efe-d36360748382","procedure_id":"proc-ozone-therapy","jurisdiction_id":"jur-cl","procedure_name":"Ozone Therapy for Infection / Inflammation / Wound Healing","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"US FDA has warned against ozone therapy for disease treatment.","eligibility_requirements":"None in strict markets.","provider_requirements":"No lawful medical therapy pathway inferred in ICH-class systems.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred unlawful or non-recognized as medical therapy in strict markets.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ozone therapy is generally not an approved medical therapy in strict regulators; gray abroad.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Infection","Wound_Healing","Orthopedic"],"diseases":["Chronic Wound","Chronic Infection","Osteoarthritis (off-label)"],"status":"active"},{"id":"8ee23738-e596-4215-aa2e-c80a8d940026","procedure_id":"proc-ozone-therapy","jurisdiction_id":"jur-ar","procedure_name":"Ozone Therapy for Infection / Inflammation / Wound Healing","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"US FDA has warned against ozone therapy for disease treatment.","eligibility_requirements":"None in strict markets.","provider_requirements":"No lawful medical therapy pathway inferred in ICH-class systems.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred unlawful or non-recognized as medical therapy in strict markets.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ozone therapy is generally not an approved medical therapy in strict regulators; gray abroad.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Infection","Wound_Healing","Orthopedic"],"diseases":["Chronic Wound","Chronic Infection","Osteoarthritis (off-label)"],"status":"active"},{"id":"98852f78-767d-4f10-9014-be61599ae66f","procedure_id":"proc-ozone-therapy","jurisdiction_id":"jur-za","procedure_name":"Ozone Therapy for Infection / Inflammation / Wound Healing","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"US FDA has warned against ozone therapy for disease treatment.","eligibility_requirements":"None in strict markets.","provider_requirements":"No lawful medical therapy pathway inferred in ICH-class systems.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred unlawful or non-recognized as medical therapy in strict markets.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ozone therapy is generally not an approved medical therapy in strict regulators; gray abroad.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Infection","Wound_Healing","Orthopedic"],"diseases":["Chronic Wound","Chronic Infection","Osteoarthritis (off-label)"],"status":"active"},{"id":"41217c0e-5b46-4b6b-a8b8-0c17985c4a4b","procedure_id":"proc-ozone-therapy","jurisdiction_id":"jur-ph","procedure_name":"Ozone Therapy for Infection / Inflammation / Wound Healing","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"US FDA has warned against ozone therapy for disease treatment.","eligibility_requirements":"None in strict markets.","provider_requirements":"No lawful medical therapy pathway inferred in ICH-class systems.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred unlawful or non-recognized as medical therapy in strict markets.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ozone therapy is generally not an approved medical therapy in strict regulators; gray abroad.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Infection","Wound_Healing","Orthopedic"],"diseases":["Chronic Wound","Chronic Infection","Osteoarthritis (off-label)"],"status":"active"},{"id":"02057186-1a42-4b0e-9bad-1046c0250b38","procedure_id":"proc-ozone-therapy","jurisdiction_id":"jur-po","procedure_name":"Ozone Therapy for Infection / Inflammation / Wound Healing","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"US FDA has warned against ozone therapy for disease treatment.","eligibility_requirements":"None in strict markets.","provider_requirements":"No lawful medical therapy pathway inferred in ICH-class systems.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred unlawful or non-recognized as medical therapy in strict markets.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ozone therapy is generally not an approved medical therapy in strict regulators; gray abroad.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Infection","Wound_Healing","Orthopedic"],"diseases":["Chronic Wound","Chronic Infection","Osteoarthritis (off-label)"],"status":"active"},{"id":"6477d65f-a3a8-4bd6-bbc6-9bf5ce5a7092","procedure_id":"proc-ozone-therapy","jurisdiction_id":"jur-pt","procedure_name":"Ozone Therapy for Infection / Inflammation / Wound Healing","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"US FDA has warned against ozone therapy for disease treatment.","eligibility_requirements":"None in strict markets.","provider_requirements":"No lawful medical therapy pathway inferred in ICH-class systems.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred unlawful or non-recognized as medical therapy in strict markets.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ozone therapy is generally not an approved medical therapy in strict regulators; gray abroad.","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Infection","Wound_Healing","Orthopedic"],"diseases":["Chronic Wound","Chronic Infection","Osteoarthritis (off-label)"],"status":"active"},{"id":"184a4495-f047-4957-95cc-3905c9181b60","procedure_id":"proc-ozone-therapy","jurisdiction_id":"jur-fr","procedure_name":"Ozone Therapy for Infection / Inflammation / Wound Healing","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"US FDA has warned against ozone therapy for disease treatment.","eligibility_requirements":"None in strict markets.","provider_requirements":"No lawful medical therapy pathway inferred in ICH-class systems.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred unlawful or non-recognized as medical therapy in strict markets.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ozone therapy is generally not an approved medical therapy in strict regulators; gray abroad.","regulatory_authority":"ANSM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Infection","Wound_Healing","Orthopedic"],"diseases":["Chronic Wound","Chronic Infection","Osteoarthritis (off-label)"],"status":"active"},{"id":"9a50a28a-18b8-4a8f-a4ae-180ade5583a2","procedure_id":"proc-stem-nsc","jurisdiction_id":"jur-us-or","procedure_name":"Neural Stem Cell Therapy for Neurodegeneration / Spinal Cord Injury","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Spinal_Cord_Injury"],"diseases":["Parkinson's Disease","ALS","Spinal Cord Injury","Alzheimer's Disease"],"status":"active"},{"id":"f4880488-e84d-400a-a4cc-519c26e7747d","procedure_id":"proc-stem-nsc","jurisdiction_id":"jur-us-co","procedure_name":"Neural Stem Cell Therapy for Neurodegeneration / Spinal Cord Injury","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Spinal_Cord_Injury"],"diseases":["Parkinson's Disease","ALS","Spinal Cord Injury","Alzheimer's Disease"],"status":"active"},{"id":"963f5df1-da58-4a0d-81f3-759fed92f343","procedure_id":"proc-stem-nsc","jurisdiction_id":"jur-us-ca","procedure_name":"Neural Stem Cell Therapy for Neurodegeneration / Spinal Cord Injury","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Spinal_Cord_Injury"],"diseases":["Parkinson's Disease","ALS","Spinal Cord Injury","Alzheimer's Disease"],"status":"active"},{"id":"ddec308f-25d2-4057-a2ce-0239a8640fd3","procedure_id":"proc-stem-nsc","jurisdiction_id":"jur-us-tx","procedure_name":"Neural Stem Cell Therapy for Neurodegeneration / Spinal Cord Injury","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Spinal_Cord_Injury"],"diseases":["Parkinson's Disease","ALS","Spinal Cord Injury","Alzheimer's Disease"],"status":"active"},{"id":"22c98e80-7e67-4380-9e00-5be438996602","procedure_id":"proc-stem-nsc","jurisdiction_id":"jur-us-fl","procedure_name":"Neural Stem Cell Therapy for Neurodegeneration / Spinal Cord Injury","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Spinal_Cord_Injury"],"diseases":["Parkinson's Disease","ALS","Spinal Cord Injury","Alzheimer's Disease"],"status":"active"},{"id":"61123089-1ca4-4085-9d13-ca4dd6691075","procedure_id":"proc-stem-nsc","jurisdiction_id":"jur-au","procedure_name":"Neural Stem Cell Therapy for Neurodegeneration / Spinal Cord Injury","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"TGA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Spinal_Cord_Injury"],"diseases":["Parkinson's Disease","ALS","Spinal Cord Injury","Alzheimer's Disease"],"status":"active"},{"id":"b0dbde31-9b52-4685-83d0-adacbfecfae8","procedure_id":"proc-stem-nsc","jurisdiction_id":"jur-ch","procedure_name":"Neural Stem Cell Therapy for Neurodegeneration / Spinal Cord Injury","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"Swissmedic","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Spinal_Cord_Injury"],"diseases":["Parkinson's Disease","ALS","Spinal Cord Injury","Alzheimer's Disease"],"status":"active"},{"id":"d7d9c964-7695-4694-9aec-555e698f65b5","procedure_id":"proc-stem-nsc","jurisdiction_id":"jur-ca","procedure_name":"Neural Stem Cell Therapy for Neurodegeneration / Spinal Cord Injury","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"Health Canada","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Spinal_Cord_Injury"],"diseases":["Parkinson's Disease","ALS","Spinal Cord Injury","Alzheimer's Disease"],"status":"active"},{"id":"66cbccc2-d56a-470a-b61e-6d58c2cf2115","procedure_id":"proc-stem-nsc","jurisdiction_id":"jur-nl","procedure_name":"Neural Stem Cell Therapy for Neurodegeneration / Spinal Cord Injury","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"MEB / IGJ","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Spinal_Cord_Injury"],"diseases":["Parkinson's Disease","ALS","Spinal Cord Injury","Alzheimer's Disease"],"status":"active"},{"id":"711b4191-a224-4fb6-aeec-1d1ea87ac4ce","procedure_id":"proc-stem-nsc","jurisdiction_id":"jur-de","procedure_name":"Neural Stem Cell Therapy for Neurodegeneration / Spinal Cord Injury","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"BfArM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Spinal_Cord_Injury"],"diseases":["Parkinson's Disease","ALS","Spinal Cord Injury","Alzheimer's Disease"],"status":"active"},{"id":"a86dfbe4-9e01-4690-a895-08bbae34a930","procedure_id":"proc-stem-nsc","jurisdiction_id":"jur-uk","procedure_name":"Neural Stem Cell Therapy for Neurodegeneration / Spinal Cord Injury","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"MHRA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Spinal_Cord_Injury"],"diseases":["Parkinson's Disease","ALS","Spinal Cord Injury","Alzheimer's Disease"],"status":"active"},{"id":"88fa953f-3aca-4e68-b813-d31a88614424","procedure_id":"proc-stem-nsc","jurisdiction_id":"jur-il","procedure_name":"Neural Stem Cell Therapy for Neurodegeneration / Spinal Cord Injury","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Spinal_Cord_Injury"],"diseases":["Parkinson's Disease","ALS","Spinal Cord Injury","Alzheimer's Disease"],"status":"active"},{"id":"703bb0de-24f3-4c06-848d-6c634ed091a9","procedure_id":"proc-stem-nsc","jurisdiction_id":"jur-jm","procedure_name":"Neural Stem Cell Therapy for Neurodegeneration / Spinal Cord Injury","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Spinal_Cord_Injury"],"diseases":["Parkinson's Disease","ALS","Spinal Cord Injury","Alzheimer's Disease"],"status":"active"},{"id":"cdd5cc8b-9a72-49b1-924f-87aab1f08b48","procedure_id":"proc-stem-nsc","jurisdiction_id":"jur-th","procedure_name":"Neural Stem Cell Therapy for Neurodegeneration / Spinal Cord Injury","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"Thai FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Spinal_Cord_Injury"],"diseases":["Parkinson's Disease","ALS","Spinal Cord Injury","Alzheimer's Disease"],"status":"active"},{"id":"8cb5f719-a042-49bb-93c9-a551bd5bd1e1","procedure_id":"proc-stem-nsc","jurisdiction_id":"jur-es","procedure_name":"Neural Stem Cell Therapy for Neurodegeneration / Spinal Cord Injury","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"AEMPS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Spinal_Cord_Injury"],"diseases":["Parkinson's Disease","ALS","Spinal Cord Injury","Alzheimer's Disease"],"status":"active"},{"id":"8bd8292e-b078-44dd-a696-068df8450419","procedure_id":"proc-stem-nsc","jurisdiction_id":"jur-tu","procedure_name":"Neural Stem Cell Therapy for Neurodegeneration / Spinal Cord Injury","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Spinal_Cord_Injury"],"diseases":["Parkinson's Disease","ALS","Spinal Cord Injury","Alzheimer's Disease"],"status":"active"},{"id":"ca4b632e-76dd-46e9-b155-8363abad3361","procedure_id":"proc-stem-nsc","jurisdiction_id":"jur-in","procedure_name":"Neural Stem Cell Therapy for Neurodegeneration / Spinal Cord Injury","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"CDSCO","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Spinal_Cord_Injury"],"diseases":["Parkinson's Disease","ALS","Spinal Cord Injury","Alzheimer's Disease"],"status":"active"},{"id":"c9844b61-4e16-4640-9f11-95b0f5ad4ede","procedure_id":"proc-stem-nsc","jurisdiction_id":"jur-br","procedure_name":"Neural Stem Cell Therapy for Neurodegeneration / Spinal Cord Injury","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"ANVISA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Spinal_Cord_Injury"],"diseases":["Parkinson's Disease","ALS","Spinal Cord Injury","Alzheimer's Disease"],"status":"active"},{"id":"fb1c9f91-d701-4bbf-99ef-0f7ed74c3206","procedure_id":"proc-stem-nsc","jurisdiction_id":"jur-cr","procedure_name":"Neural Stem Cell Therapy for Neurodegeneration / Spinal Cord Injury","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Spinal_Cord_Injury"],"diseases":["Parkinson's Disease","ALS","Spinal Cord Injury","Alzheimer's Disease"],"status":"active"},{"id":"d8d2faaa-9aed-4c7a-8d33-931bff5c8ac9","procedure_id":"proc-stem-nsc","jurisdiction_id":"jur-uae","procedure_name":"Neural Stem Cell Therapy for Neurodegeneration / Spinal Cord Injury","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Spinal_Cord_Injury"],"diseases":["Parkinson's Disease","ALS","Spinal Cord Injury","Alzheimer's Disease"],"status":"active"},{"id":"efafa8a5-d28a-46b6-8fb5-6af30f408b27","procedure_id":"proc-stem-nsc","jurisdiction_id":"jur-gr","procedure_name":"Neural Stem Cell Therapy for Neurodegeneration / Spinal Cord Injury","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Spinal_Cord_Injury"],"diseases":["Parkinson's Disease","ALS","Spinal Cord Injury","Alzheimer's Disease"],"status":"active"},{"id":"efab1f1b-09e4-4ce0-97ba-6fed00cf068f","procedure_id":"proc-stem-nsc","jurisdiction_id":"jur-be","procedure_name":"Neural Stem Cell Therapy for Neurodegeneration / Spinal Cord Injury","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Spinal_Cord_Injury"],"diseases":["Parkinson's Disease","ALS","Spinal Cord Injury","Alzheimer's Disease"],"status":"active"},{"id":"ee20d30e-8de2-4da5-8e43-7fb28492d161","procedure_id":"proc-stem-nsc","jurisdiction_id":"jur-se","procedure_name":"Neural Stem Cell Therapy for Neurodegeneration / Spinal Cord Injury","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Spinal_Cord_Injury"],"diseases":["Parkinson's Disease","ALS","Spinal Cord Injury","Alzheimer's Disease"],"status":"active"},{"id":"e4260ffc-998f-43f4-9003-658be0acc1c1","procedure_id":"proc-stem-nsc","jurisdiction_id":"jur-sg","procedure_name":"Neural Stem Cell Therapy for Neurodegeneration / Spinal Cord Injury","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"HSA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Spinal_Cord_Injury"],"diseases":["Parkinson's Disease","ALS","Spinal Cord Injury","Alzheimer's Disease"],"status":"active"},{"id":"e3aabcf9-435d-49c0-8667-b1879f41755c","procedure_id":"proc-stem-nsc","jurisdiction_id":"jur-cl","procedure_name":"Neural Stem Cell Therapy for Neurodegeneration / Spinal Cord Injury","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Spinal_Cord_Injury"],"diseases":["Parkinson's Disease","ALS","Spinal Cord Injury","Alzheimer's Disease"],"status":"active"},{"id":"181acffb-5259-4b6f-bc4e-d6dfa132d1e6","procedure_id":"proc-stem-nsc","jurisdiction_id":"jur-ar","procedure_name":"Neural Stem Cell Therapy for Neurodegeneration / Spinal Cord Injury","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Spinal_Cord_Injury"],"diseases":["Parkinson's Disease","ALS","Spinal Cord Injury","Alzheimer's Disease"],"status":"active"},{"id":"cf754d3c-af0c-429d-bc86-0e054d2a8658","procedure_id":"proc-stem-nsc","jurisdiction_id":"jur-za","procedure_name":"Neural Stem Cell Therapy for Neurodegeneration / Spinal Cord Injury","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Spinal_Cord_Injury"],"diseases":["Parkinson's Disease","ALS","Spinal Cord Injury","Alzheimer's Disease"],"status":"active"},{"id":"798c1c4d-7d02-48d4-b92f-ff39d37b22da","procedure_id":"proc-stem-nsc","jurisdiction_id":"jur-ph","procedure_name":"Neural Stem Cell Therapy for Neurodegeneration / Spinal Cord Injury","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Spinal_Cord_Injury"],"diseases":["Parkinson's Disease","ALS","Spinal Cord Injury","Alzheimer's Disease"],"status":"active"},{"id":"6172c07c-0a38-457f-972a-765dceae248f","procedure_id":"proc-stem-nsc","jurisdiction_id":"jur-po","procedure_name":"Neural Stem Cell Therapy for Neurodegeneration / Spinal Cord Injury","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Spinal_Cord_Injury"],"diseases":["Parkinson's Disease","ALS","Spinal Cord Injury","Alzheimer's Disease"],"status":"active"},{"id":"bbb4a3f6-f83b-4941-8006-b57eef440fdb","procedure_id":"proc-stem-nsc","jurisdiction_id":"jur-pt","procedure_name":"Neural Stem Cell Therapy for Neurodegeneration / Spinal Cord Injury","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Spinal_Cord_Injury"],"diseases":["Parkinson's Disease","ALS","Spinal Cord Injury","Alzheimer's Disease"],"status":"active"},{"id":"9ddf6e75-9cd7-46b3-b86a-01dfebe89707","procedure_id":"proc-stem-nsc","jurisdiction_id":"jur-fr","procedure_name":"Neural Stem Cell Therapy for Neurodegeneration / Spinal Cord Injury","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"VARIABLE","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Homologous use / minimal manipulation exceptions are narrow. Commercial 'stem cell tourism' frequently unlawful for disease claims in ICH markets.","eligibility_requirements":"If any, under trial/expanded access — not wellness claims.","provider_requirements":"Legitimate path is trial/IND-class; cash clinics often non-compliant.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Enforcement actions common for disease claims without approval.","arbitrage_summary":"Inferred high regulatory risk for commercial unproven cell therapy — trial or foreign gray market only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unproven regenerative marketing is often enforcement-priority in strict regulators; gray abroad.","regulatory_authority":"ANSM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Spinal_Cord_Injury"],"diseases":["Parkinson's Disease","ALS","Spinal Cord Injury","Alzheimer's Disease"],"status":"active"},{"id":"2388e5a4-2dd9-4fd9-84f5-f6d2793a0efb","procedure_id":"proc-proton-therapy","jurisdiction_id":"jur-us-or","procedure_name":"Proton Beam Radiotherapy for Cancer","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Pediatric Cancer","CNS Tumors","Prostate Cancer","Base-of-Skull Tumors"],"status":"active"},{"id":"ab89c706-1ce2-45b2-ba5a-9cb1c13f20fa","procedure_id":"proc-proton-therapy","jurisdiction_id":"jur-us-co","procedure_name":"Proton Beam Radiotherapy for Cancer","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Pediatric Cancer","CNS Tumors","Prostate Cancer","Base-of-Skull Tumors"],"status":"active"},{"id":"a1c1e898-e89e-403a-b736-bdb6a6197284","procedure_id":"proc-proton-therapy","jurisdiction_id":"jur-us-ca","procedure_name":"Proton Beam Radiotherapy for Cancer","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Pediatric Cancer","CNS Tumors","Prostate Cancer","Base-of-Skull Tumors"],"status":"active"},{"id":"22b05c4c-f8d6-450e-877b-a6fcc33b9929","procedure_id":"proc-proton-therapy","jurisdiction_id":"jur-us-tx","procedure_name":"Proton Beam Radiotherapy for Cancer","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Pediatric Cancer","CNS Tumors","Prostate Cancer","Base-of-Skull Tumors"],"status":"active"},{"id":"9bf2ef9e-266a-4711-a20b-84cb40c1a371","procedure_id":"proc-proton-therapy","jurisdiction_id":"jur-us-fl","procedure_name":"Proton Beam Radiotherapy for Cancer","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Pediatric Cancer","CNS Tumors","Prostate Cancer","Base-of-Skull Tumors"],"status":"active"},{"id":"a41d705b-921a-4d87-b6cc-d9cd05615f43","procedure_id":"proc-proton-therapy","jurisdiction_id":"jur-au","procedure_name":"Proton Beam Radiotherapy for Cancer","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"TGA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Pediatric Cancer","CNS Tumors","Prostate Cancer","Base-of-Skull Tumors"],"status":"active"},{"id":"80db8051-4532-47e5-9850-7814f4ce8df5","procedure_id":"proc-proton-therapy","jurisdiction_id":"jur-ca","procedure_name":"Proton Beam Radiotherapy for Cancer","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Health Canada","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Pediatric Cancer","CNS Tumors","Prostate Cancer","Base-of-Skull Tumors"],"status":"active"},{"id":"8f856fa9-f48b-4085-a402-6c3752415c7d","procedure_id":"proc-proton-therapy","jurisdiction_id":"jur-mx","procedure_name":"Proton Beam Radiotherapy for Cancer","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"COFEPRIS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Pediatric Cancer","CNS Tumors","Prostate Cancer","Base-of-Skull Tumors"],"status":"active"},{"id":"c145fbe1-09b0-443e-a979-bd3d767e6e02","procedure_id":"proc-proton-therapy","jurisdiction_id":"jur-hn-prospera","procedure_name":"Proton Beam Radiotherapy for Cancer","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Próspera ZEDE health rules (contested)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Pediatric Cancer","CNS Tumors","Prostate Cancer","Base-of-Skull Tumors"],"status":"active"},{"id":"77aa9a64-dd04-44ef-88f2-080b18c94cf6","procedure_id":"proc-proton-therapy","jurisdiction_id":"jur-nl","procedure_name":"Proton Beam Radiotherapy for Cancer","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"MEB / IGJ","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Pediatric Cancer","CNS Tumors","Prostate Cancer","Base-of-Skull Tumors"],"status":"active"},{"id":"64d7806d-1786-4c8d-ad55-c321dc236d84","procedure_id":"proc-proton-therapy","jurisdiction_id":"jur-il","procedure_name":"Proton Beam Radiotherapy for Cancer","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Pediatric Cancer","CNS Tumors","Prostate Cancer","Base-of-Skull Tumors"],"status":"active"},{"id":"fcb13c49-9b23-42c2-9dd4-d790f91f09c3","procedure_id":"proc-proton-therapy","jurisdiction_id":"jur-jm","procedure_name":"Proton Beam Radiotherapy for Cancer","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Pediatric Cancer","CNS Tumors","Prostate Cancer","Base-of-Skull Tumors"],"status":"active"},{"id":"8fe34c2e-0670-4683-8168-dad846b99ad3","procedure_id":"proc-proton-therapy","jurisdiction_id":"jur-th","procedure_name":"Proton Beam Radiotherapy for Cancer","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Thai FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Pediatric Cancer","CNS Tumors","Prostate Cancer","Base-of-Skull Tumors"],"status":"active"},{"id":"244dd112-8565-40cf-9afe-8cea0088a59f","procedure_id":"proc-proton-therapy","jurisdiction_id":"jur-es","procedure_name":"Proton Beam Radiotherapy for Cancer","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"AEMPS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Pediatric Cancer","CNS Tumors","Prostate Cancer","Base-of-Skull Tumors"],"status":"active"},{"id":"9be67625-23fe-439c-aa4d-8d50df9d8e40","procedure_id":"proc-proton-therapy","jurisdiction_id":"jur-tu","procedure_name":"Proton Beam Radiotherapy for Cancer","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Pediatric Cancer","CNS Tumors","Prostate Cancer","Base-of-Skull Tumors"],"status":"active"},{"id":"4338091f-f2af-4163-8746-bd531f585898","procedure_id":"proc-proton-therapy","jurisdiction_id":"jur-in","procedure_name":"Proton Beam Radiotherapy for Cancer","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"CDSCO","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Pediatric Cancer","CNS Tumors","Prostate Cancer","Base-of-Skull Tumors"],"status":"active"},{"id":"2fb47d62-4bdd-4641-b1c8-3070623c1f2d","procedure_id":"proc-proton-therapy","jurisdiction_id":"jur-br","procedure_name":"Proton Beam Radiotherapy for Cancer","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"ANVISA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Pediatric Cancer","CNS Tumors","Prostate Cancer","Base-of-Skull Tumors"],"status":"active"},{"id":"ab2863f3-1cd1-4526-96ee-e50f501aeaa7","procedure_id":"proc-proton-therapy","jurisdiction_id":"jur-cr","procedure_name":"Proton Beam Radiotherapy for Cancer","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Pediatric Cancer","CNS Tumors","Prostate Cancer","Base-of-Skull Tumors"],"status":"active"},{"id":"f422e7d3-05d9-4e6d-a968-c731111b3968","procedure_id":"proc-proton-therapy","jurisdiction_id":"jur-uae","procedure_name":"Proton Beam Radiotherapy for Cancer","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Pediatric Cancer","CNS Tumors","Prostate Cancer","Base-of-Skull Tumors"],"status":"active"},{"id":"87c22d6a-afaa-4a64-9b2b-53bbeaf26d29","procedure_id":"proc-proton-therapy","jurisdiction_id":"jur-gr","procedure_name":"Proton Beam Radiotherapy for Cancer","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Pediatric Cancer","CNS Tumors","Prostate Cancer","Base-of-Skull Tumors"],"status":"active"},{"id":"71fcf08a-5221-4c6f-be99-0f66f113b32b","procedure_id":"proc-proton-therapy","jurisdiction_id":"jur-be","procedure_name":"Proton Beam Radiotherapy for Cancer","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Pediatric Cancer","CNS Tumors","Prostate Cancer","Base-of-Skull Tumors"],"status":"active"},{"id":"c524d4bb-b29a-42b6-bc3a-41a86221a85f","procedure_id":"proc-proton-therapy","jurisdiction_id":"jur-se","procedure_name":"Proton Beam Radiotherapy for Cancer","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Pediatric Cancer","CNS Tumors","Prostate Cancer","Base-of-Skull Tumors"],"status":"active"},{"id":"5498a0bb-c7a5-4342-a44d-8850a0d69e49","procedure_id":"proc-proton-therapy","jurisdiction_id":"jur-sg","procedure_name":"Proton Beam Radiotherapy for Cancer","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"HSA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Pediatric Cancer","CNS Tumors","Prostate Cancer","Base-of-Skull Tumors"],"status":"active"},{"id":"299f42d6-34e2-47a5-8613-5d62f0dcc68f","procedure_id":"proc-proton-therapy","jurisdiction_id":"jur-cl","procedure_name":"Proton Beam Radiotherapy for Cancer","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Pediatric Cancer","CNS Tumors","Prostate Cancer","Base-of-Skull Tumors"],"status":"active"},{"id":"8c809760-6f7f-41c7-85ed-9bcd9fb1f233","procedure_id":"proc-proton-therapy","jurisdiction_id":"jur-ar","procedure_name":"Proton Beam Radiotherapy for Cancer","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Pediatric Cancer","CNS Tumors","Prostate Cancer","Base-of-Skull Tumors"],"status":"active"},{"id":"541b3ecd-f005-4668-b91c-c414954c35bf","procedure_id":"proc-proton-therapy","jurisdiction_id":"jur-za","procedure_name":"Proton Beam Radiotherapy for Cancer","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Pediatric Cancer","CNS Tumors","Prostate Cancer","Base-of-Skull Tumors"],"status":"active"},{"id":"5ad63a85-868c-4eb9-a45b-1a151ca2a236","procedure_id":"proc-proton-therapy","jurisdiction_id":"jur-ph","procedure_name":"Proton Beam Radiotherapy for Cancer","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Pediatric Cancer","CNS Tumors","Prostate Cancer","Base-of-Skull Tumors"],"status":"active"},{"id":"f5dd3327-9c85-4316-9d6f-e3d91028a73b","procedure_id":"proc-proton-therapy","jurisdiction_id":"jur-po","procedure_name":"Proton Beam Radiotherapy for Cancer","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Pediatric Cancer","CNS Tumors","Prostate Cancer","Base-of-Skull Tumors"],"status":"active"},{"id":"f2ddc16e-f68b-4236-8dfe-8af4093fed1f","procedure_id":"proc-proton-therapy","jurisdiction_id":"jur-pt","procedure_name":"Proton Beam Radiotherapy for Cancer","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Pediatric Cancer","CNS Tumors","Prostate Cancer","Base-of-Skull Tumors"],"status":"active"},{"id":"e577790f-d08d-4698-af7f-f0622bfde27d","procedure_id":"proc-proton-therapy","jurisdiction_id":"jur-fr","procedure_name":"Proton Beam Radiotherapy for Cancer","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"ANSM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Pediatric Cancer","CNS Tumors","Prostate Cancer","Base-of-Skull Tumors"],"status":"active"},{"id":"b78ff9ef-3abd-4087-95bf-6ab24d2d209c","procedure_id":"proc-senolytics","jurisdiction_id":"jur-us-or","procedure_name":"Senolytic Therapy (Dasatinib + Quercetin) for Cellular Aging","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Frailty","Age-Related Functional Decline","Cellular Senescence"],"status":"active"},{"id":"b0d05ae9-c3ce-4f5a-9af8-484b4b27f695","procedure_id":"proc-senolytics","jurisdiction_id":"jur-us-co","procedure_name":"Senolytic Therapy (Dasatinib + Quercetin) for Cellular Aging","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Frailty","Age-Related Functional Decline","Cellular Senescence"],"status":"active"},{"id":"0e06bbd5-60e5-4cbc-99be-80c3414f78b5","procedure_id":"proc-senolytics","jurisdiction_id":"jur-us-ca","procedure_name":"Senolytic Therapy (Dasatinib + Quercetin) for Cellular Aging","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Frailty","Age-Related Functional Decline","Cellular Senescence"],"status":"active"},{"id":"8ab0b004-c990-4142-9bdf-981c99a69a06","procedure_id":"proc-senolytics","jurisdiction_id":"jur-us-tx","procedure_name":"Senolytic Therapy (Dasatinib + Quercetin) for Cellular Aging","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Frailty","Age-Related Functional Decline","Cellular Senescence"],"status":"active"},{"id":"fca4f34f-0968-45ac-961c-a12c73d03fee","procedure_id":"proc-senolytics","jurisdiction_id":"jur-us-fl","procedure_name":"Senolytic Therapy (Dasatinib + Quercetin) for Cellular Aging","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Frailty","Age-Related Functional Decline","Cellular Senescence"],"status":"active"},{"id":"be9f421d-2dec-4ce4-9278-20a5ab64d81e","procedure_id":"proc-senolytics","jurisdiction_id":"jur-au","procedure_name":"Senolytic Therapy (Dasatinib + Quercetin) for Cellular Aging","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"TGA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Frailty","Age-Related Functional Decline","Cellular Senescence"],"status":"active"},{"id":"93e12c75-6652-43a6-8dd1-ab7ca718c159","procedure_id":"proc-senolytics","jurisdiction_id":"jur-ch","procedure_name":"Senolytic Therapy (Dasatinib + Quercetin) for Cellular Aging","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Swissmedic","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Frailty","Age-Related Functional Decline","Cellular Senescence"],"status":"active"},{"id":"352dc523-b2ff-40c5-9971-44b434849774","procedure_id":"proc-senolytics","jurisdiction_id":"jur-hn-prospera","procedure_name":"Senolytic Therapy (Dasatinib + Quercetin) for Cellular Aging","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Permissive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Próspera ZEDE health rules (contested)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Frailty","Age-Related Functional Decline","Cellular Senescence"],"status":"active"},{"id":"65dd12cb-33ba-4d31-b27c-7876ca3d6428","procedure_id":"proc-senolytics","jurisdiction_id":"jur-nl","procedure_name":"Senolytic Therapy (Dasatinib + Quercetin) for Cellular Aging","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"MEB / IGJ","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Frailty","Age-Related Functional Decline","Cellular Senescence"],"status":"active"},{"id":"0416eb44-0a9c-4f4c-9a90-90230ca124cf","procedure_id":"proc-senolytics","jurisdiction_id":"jur-de","procedure_name":"Senolytic Therapy (Dasatinib + Quercetin) for Cellular Aging","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"BfArM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Frailty","Age-Related Functional Decline","Cellular Senescence"],"status":"active"},{"id":"350a4c8a-0ed6-4163-bdb7-b6b4ea04caed","procedure_id":"proc-senolytics","jurisdiction_id":"jur-il","procedure_name":"Senolytic Therapy (Dasatinib + Quercetin) for Cellular Aging","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Frailty","Age-Related Functional Decline","Cellular Senescence"],"status":"active"},{"id":"c4de7722-bf4d-4a13-a3dd-d39d191469a6","procedure_id":"proc-senolytics","jurisdiction_id":"jur-jm","procedure_name":"Senolytic Therapy (Dasatinib + Quercetin) for Cellular Aging","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Frailty","Age-Related Functional Decline","Cellular Senescence"],"status":"active"},{"id":"1a42ca16-9578-4a79-aa2b-17af489e5591","procedure_id":"proc-senolytics","jurisdiction_id":"jur-th","procedure_name":"Senolytic Therapy (Dasatinib + Quercetin) for Cellular Aging","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Permissive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Thai FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Frailty","Age-Related Functional Decline","Cellular Senescence"],"status":"active"},{"id":"7a5b7dcf-dbf5-470a-90f8-5a178285b358","procedure_id":"proc-senolytics","jurisdiction_id":"jur-es","procedure_name":"Senolytic Therapy (Dasatinib + Quercetin) for Cellular Aging","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"AEMPS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Frailty","Age-Related Functional Decline","Cellular Senescence"],"status":"active"},{"id":"f789c80a-f79d-4333-8b94-1b95dab8cbb2","procedure_id":"proc-senolytics","jurisdiction_id":"jur-tu","procedure_name":"Senolytic Therapy (Dasatinib + Quercetin) for Cellular Aging","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Frailty","Age-Related Functional Decline","Cellular Senescence"],"status":"active"},{"id":"b0afbfad-bdbe-4b5a-b705-fa6c04fb48d7","procedure_id":"proc-senolytics","jurisdiction_id":"jur-in","procedure_name":"Senolytic Therapy (Dasatinib + Quercetin) for Cellular Aging","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Permissive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"CDSCO","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Frailty","Age-Related Functional Decline","Cellular Senescence"],"status":"active"},{"id":"e6be53b4-40d0-4a15-9749-86d0ad58dc18","procedure_id":"proc-senolytics","jurisdiction_id":"jur-br","procedure_name":"Senolytic Therapy (Dasatinib + Quercetin) for Cellular Aging","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"ANVISA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Frailty","Age-Related Functional Decline","Cellular Senescence"],"status":"active"},{"id":"596764a4-c890-47f1-abe8-dba03ae67cf7","procedure_id":"proc-senolytics","jurisdiction_id":"jur-cr","procedure_name":"Senolytic Therapy (Dasatinib + Quercetin) for Cellular Aging","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Frailty","Age-Related Functional Decline","Cellular Senescence"],"status":"active"},{"id":"1da24322-7572-4f7a-83b5-999dc4b0104c","procedure_id":"proc-senolytics","jurisdiction_id":"jur-uae","procedure_name":"Senolytic Therapy (Dasatinib + Quercetin) for Cellular Aging","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Frailty","Age-Related Functional Decline","Cellular Senescence"],"status":"active"},{"id":"856d40d6-2742-4512-b916-752dd055e81d","procedure_id":"proc-senolytics","jurisdiction_id":"jur-kr","procedure_name":"Senolytic Therapy (Dasatinib + Quercetin) for Cellular Aging","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"MFDS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Frailty","Age-Related Functional Decline","Cellular Senescence"],"status":"active"},{"id":"9205532e-4816-442b-9e54-71efe96906d4","procedure_id":"proc-senolytics","jurisdiction_id":"jur-gr","procedure_name":"Senolytic Therapy (Dasatinib + Quercetin) for Cellular Aging","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Frailty","Age-Related Functional Decline","Cellular Senescence"],"status":"active"},{"id":"be34a5e9-4322-40f8-b326-afac75afa1b8","procedure_id":"proc-senolytics","jurisdiction_id":"jur-be","procedure_name":"Senolytic Therapy (Dasatinib + Quercetin) for Cellular Aging","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Frailty","Age-Related Functional Decline","Cellular Senescence"],"status":"active"},{"id":"f6bfef7c-d52c-44f9-9c38-f5c71e54da61","procedure_id":"proc-senolytics","jurisdiction_id":"jur-se","procedure_name":"Senolytic Therapy (Dasatinib + Quercetin) for Cellular Aging","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Frailty","Age-Related Functional Decline","Cellular Senescence"],"status":"active"},{"id":"72681662-fa91-48f4-81f4-2c3905381e66","procedure_id":"proc-senolytics","jurisdiction_id":"jur-jp","procedure_name":"Senolytic Therapy (Dasatinib + Quercetin) for Cellular Aging","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"PMDA / MHLW","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Frailty","Age-Related Functional Decline","Cellular Senescence"],"status":"active"},{"id":"8699b558-81b7-4671-a7a3-37ba2437ce1f","procedure_id":"proc-senolytics","jurisdiction_id":"jur-sg","procedure_name":"Senolytic Therapy (Dasatinib + Quercetin) for Cellular Aging","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"HSA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Frailty","Age-Related Functional Decline","Cellular Senescence"],"status":"active"},{"id":"70c1d1b5-6dcd-4b06-8190-112cc88ddd69","procedure_id":"proc-senolytics","jurisdiction_id":"jur-cl","procedure_name":"Senolytic Therapy (Dasatinib + Quercetin) for Cellular Aging","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Frailty","Age-Related Functional Decline","Cellular Senescence"],"status":"active"},{"id":"c0d1fc64-b60d-4c99-87fc-66bba91969dc","procedure_id":"proc-senolytics","jurisdiction_id":"jur-ar","procedure_name":"Senolytic Therapy (Dasatinib + Quercetin) for Cellular Aging","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Frailty","Age-Related Functional Decline","Cellular Senescence"],"status":"active"},{"id":"c8c8db12-e8bf-424a-8bc4-fc6c6009064f","procedure_id":"proc-senolytics","jurisdiction_id":"jur-za","procedure_name":"Senolytic Therapy (Dasatinib + Quercetin) for Cellular Aging","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Frailty","Age-Related Functional Decline","Cellular Senescence"],"status":"active"},{"id":"f441681e-5839-4935-8b6c-40668c0b6342","procedure_id":"proc-senolytics","jurisdiction_id":"jur-ph","procedure_name":"Senolytic Therapy (Dasatinib + Quercetin) for Cellular Aging","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Frailty","Age-Related Functional Decline","Cellular Senescence"],"status":"active"},{"id":"7dbac8b0-3a4b-45c6-b881-03a3d7db0656","procedure_id":"proc-senolytics","jurisdiction_id":"jur-po","procedure_name":"Senolytic Therapy (Dasatinib + Quercetin) for Cellular Aging","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Frailty","Age-Related Functional Decline","Cellular Senescence"],"status":"active"},{"id":"022c9058-db2b-4130-af38-98a8151877e5","procedure_id":"proc-senolytics","jurisdiction_id":"jur-pt","procedure_name":"Senolytic Therapy (Dasatinib + Quercetin) for Cellular Aging","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Frailty","Age-Related Functional Decline","Cellular Senescence"],"status":"active"},{"id":"eb2d1a99-1076-4911-a3e9-6d35fbd92b90","procedure_id":"proc-senolytics","jurisdiction_id":"jur-fr","procedure_name":"Senolytic Therapy (Dasatinib + Quercetin) for Cellular Aging","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"ANSM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Frailty","Age-Related Functional Decline","Cellular Senescence"],"status":"active"},{"id":"3c4666b0-5fa6-43fe-88a4-5b927686cc13","procedure_id":"proc-chelation","jurisdiction_id":"jur-us-or","procedure_name":"IV Chelation Therapy for Heavy Metal Detoxification","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Detoxification","Anti_Aging"],"diseases":["Lead Poisoning","Heavy Metal Toxicity","Iron Overload"],"status":"active"},{"id":"f94d1e0c-efc1-4288-89d5-76c3d2da54c5","procedure_id":"proc-chelation","jurisdiction_id":"jur-us-co","procedure_name":"IV Chelation Therapy for Heavy Metal Detoxification","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Detoxification","Anti_Aging"],"diseases":["Lead Poisoning","Heavy Metal Toxicity","Iron Overload"],"status":"active"},{"id":"2756fbf2-5d9e-408e-b763-20707bfebbd5","procedure_id":"proc-chelation","jurisdiction_id":"jur-us-ca","procedure_name":"IV Chelation Therapy for Heavy Metal Detoxification","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Detoxification","Anti_Aging"],"diseases":["Lead Poisoning","Heavy Metal Toxicity","Iron Overload"],"status":"active"},{"id":"030ea147-e8a2-4d62-9ab5-6755000fda53","procedure_id":"proc-chelation","jurisdiction_id":"jur-us-tx","procedure_name":"IV Chelation Therapy for Heavy Metal Detoxification","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Detoxification","Anti_Aging"],"diseases":["Lead Poisoning","Heavy Metal Toxicity","Iron Overload"],"status":"active"},{"id":"48c66221-d72b-46a3-bc4a-9983643acc97","procedure_id":"proc-chelation","jurisdiction_id":"jur-us-fl","procedure_name":"IV Chelation Therapy for Heavy Metal Detoxification","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Detoxification","Anti_Aging"],"diseases":["Lead Poisoning","Heavy Metal Toxicity","Iron Overload"],"status":"active"},{"id":"7fc74cdb-1ddb-4cdb-99e2-82e0f9bd8605","procedure_id":"proc-chelation","jurisdiction_id":"jur-au","procedure_name":"IV Chelation Therapy for Heavy Metal Detoxification","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"TGA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Detoxification","Anti_Aging"],"diseases":["Lead Poisoning","Heavy Metal Toxicity","Iron Overload"],"status":"active"},{"id":"69fcb832-e4ba-46b8-a548-4383cc6c19fc","procedure_id":"proc-chelation","jurisdiction_id":"jur-ch","procedure_name":"IV Chelation Therapy for Heavy Metal Detoxification","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Swissmedic","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Detoxification","Anti_Aging"],"diseases":["Lead Poisoning","Heavy Metal Toxicity","Iron Overload"],"status":"active"},{"id":"53b04c3a-bc81-4d99-be67-b88b3a4b627b","procedure_id":"proc-chelation","jurisdiction_id":"jur-ca","procedure_name":"IV Chelation Therapy for Heavy Metal Detoxification","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Health Canada","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Detoxification","Anti_Aging"],"diseases":["Lead Poisoning","Heavy Metal Toxicity","Iron Overload"],"status":"active"},{"id":"be71e368-9c54-4072-94ee-bc8dc1aff8d7","procedure_id":"proc-chelation","jurisdiction_id":"jur-hn-prospera","procedure_name":"IV Chelation Therapy for Heavy Metal Detoxification","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Permissive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Próspera ZEDE health rules (contested)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Detoxification","Anti_Aging"],"diseases":["Lead Poisoning","Heavy Metal Toxicity","Iron Overload"],"status":"active"},{"id":"b3665b5f-9f83-4cba-9c61-ead55216e6ae","procedure_id":"proc-chelation","jurisdiction_id":"jur-nl","procedure_name":"IV Chelation Therapy for Heavy Metal Detoxification","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"MEB / IGJ","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Detoxification","Anti_Aging"],"diseases":["Lead Poisoning","Heavy Metal Toxicity","Iron Overload"],"status":"active"},{"id":"0f105b23-20c0-4bb5-978b-7f2e155a8af9","procedure_id":"proc-chelation","jurisdiction_id":"jur-uk","procedure_name":"IV Chelation Therapy for Heavy Metal Detoxification","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"MHRA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Detoxification","Anti_Aging"],"diseases":["Lead Poisoning","Heavy Metal Toxicity","Iron Overload"],"status":"active"},{"id":"8741b027-3ef6-4f4f-ac65-68a1cd854b89","procedure_id":"proc-chelation","jurisdiction_id":"jur-il","procedure_name":"IV Chelation Therapy for Heavy Metal Detoxification","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Detoxification","Anti_Aging"],"diseases":["Lead Poisoning","Heavy Metal Toxicity","Iron Overload"],"status":"active"},{"id":"d451efe5-5be1-4252-99b3-0fb2b70a5871","procedure_id":"proc-chelation","jurisdiction_id":"jur-jm","procedure_name":"IV Chelation Therapy for Heavy Metal Detoxification","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Detoxification","Anti_Aging"],"diseases":["Lead Poisoning","Heavy Metal Toxicity","Iron Overload"],"status":"active"},{"id":"e3ee7d59-fb33-4c03-9411-10326b48ac12","procedure_id":"proc-chelation","jurisdiction_id":"jur-es","procedure_name":"IV Chelation Therapy for Heavy Metal Detoxification","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"AEMPS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Detoxification","Anti_Aging"],"diseases":["Lead Poisoning","Heavy Metal Toxicity","Iron Overload"],"status":"active"},{"id":"a2bc8b1e-f6cd-465c-86e2-2d00cf122e1a","procedure_id":"proc-chelation","jurisdiction_id":"jur-tu","procedure_name":"IV Chelation Therapy for Heavy Metal Detoxification","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Detoxification","Anti_Aging"],"diseases":["Lead Poisoning","Heavy Metal Toxicity","Iron Overload"],"status":"active"},{"id":"d2a9ec58-45ce-42a3-a19c-81451c6f1f85","procedure_id":"proc-chelation","jurisdiction_id":"jur-in","procedure_name":"IV Chelation Therapy for Heavy Metal Detoxification","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Permissive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"CDSCO","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Detoxification","Anti_Aging"],"diseases":["Lead Poisoning","Heavy Metal Toxicity","Iron Overload"],"status":"active"},{"id":"e2459f36-8b47-4561-b354-fd6eb396a377","procedure_id":"proc-chelation","jurisdiction_id":"jur-br","procedure_name":"IV Chelation Therapy for Heavy Metal Detoxification","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"ANVISA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Detoxification","Anti_Aging"],"diseases":["Lead Poisoning","Heavy Metal Toxicity","Iron Overload"],"status":"active"},{"id":"20202d1f-b0ab-4738-8315-555e7f4e038f","procedure_id":"proc-chelation","jurisdiction_id":"jur-cr","procedure_name":"IV Chelation Therapy for Heavy Metal Detoxification","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Detoxification","Anti_Aging"],"diseases":["Lead Poisoning","Heavy Metal Toxicity","Iron Overload"],"status":"active"},{"id":"361e56cb-3df3-4c3e-8934-26c9e86c173b","procedure_id":"proc-chelation","jurisdiction_id":"jur-uae","procedure_name":"IV Chelation Therapy for Heavy Metal Detoxification","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Detoxification","Anti_Aging"],"diseases":["Lead Poisoning","Heavy Metal Toxicity","Iron Overload"],"status":"active"},{"id":"c0491e94-ddf2-4fa2-b8cc-79604b75b56b","procedure_id":"proc-chelation","jurisdiction_id":"jur-kr","procedure_name":"IV Chelation Therapy for Heavy Metal Detoxification","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"MFDS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Detoxification","Anti_Aging"],"diseases":["Lead Poisoning","Heavy Metal Toxicity","Iron Overload"],"status":"active"},{"id":"a85a5898-4cac-4807-ba76-620aa392918b","procedure_id":"proc-chelation","jurisdiction_id":"jur-gr","procedure_name":"IV Chelation Therapy for Heavy Metal Detoxification","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Detoxification","Anti_Aging"],"diseases":["Lead Poisoning","Heavy Metal Toxicity","Iron Overload"],"status":"active"},{"id":"3c638d73-fad3-4a03-ad0f-5e1cc48a8b74","procedure_id":"proc-chelation","jurisdiction_id":"jur-be","procedure_name":"IV Chelation Therapy for Heavy Metal Detoxification","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Detoxification","Anti_Aging"],"diseases":["Lead Poisoning","Heavy Metal Toxicity","Iron Overload"],"status":"active"},{"id":"dfc8b533-915e-4550-a493-52c772ccd390","procedure_id":"proc-chelation","jurisdiction_id":"jur-se","procedure_name":"IV Chelation Therapy for Heavy Metal Detoxification","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Detoxification","Anti_Aging"],"diseases":["Lead Poisoning","Heavy Metal Toxicity","Iron Overload"],"status":"active"},{"id":"94af45a6-cffc-45f1-8185-ca6f21169593","procedure_id":"proc-chelation","jurisdiction_id":"jur-jp","procedure_name":"IV Chelation Therapy for Heavy Metal Detoxification","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"PMDA / MHLW","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Detoxification","Anti_Aging"],"diseases":["Lead Poisoning","Heavy Metal Toxicity","Iron Overload"],"status":"active"},{"id":"1a6c7057-00a7-4a71-bea8-dda0ae206dd0","procedure_id":"proc-chelation","jurisdiction_id":"jur-sg","procedure_name":"IV Chelation Therapy for Heavy Metal Detoxification","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"HSA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Detoxification","Anti_Aging"],"diseases":["Lead Poisoning","Heavy Metal Toxicity","Iron Overload"],"status":"active"},{"id":"a1da99f2-19c8-41de-b496-b13d83ff3345","procedure_id":"proc-chelation","jurisdiction_id":"jur-cl","procedure_name":"IV Chelation Therapy for Heavy Metal Detoxification","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Detoxification","Anti_Aging"],"diseases":["Lead Poisoning","Heavy Metal Toxicity","Iron Overload"],"status":"active"},{"id":"2296009a-e16e-4286-b6e0-206cb2a07356","procedure_id":"proc-chelation","jurisdiction_id":"jur-ar","procedure_name":"IV Chelation Therapy for Heavy Metal Detoxification","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Detoxification","Anti_Aging"],"diseases":["Lead Poisoning","Heavy Metal Toxicity","Iron Overload"],"status":"active"},{"id":"f6b58bff-bed0-482d-8725-14650a7f0b8d","procedure_id":"proc-chelation","jurisdiction_id":"jur-za","procedure_name":"IV Chelation Therapy for Heavy Metal Detoxification","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Detoxification","Anti_Aging"],"diseases":["Lead Poisoning","Heavy Metal Toxicity","Iron Overload"],"status":"active"},{"id":"89943b26-cd03-445e-86c6-3ad91560bde0","procedure_id":"proc-chelation","jurisdiction_id":"jur-ph","procedure_name":"IV Chelation Therapy for Heavy Metal Detoxification","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Detoxification","Anti_Aging"],"diseases":["Lead Poisoning","Heavy Metal Toxicity","Iron Overload"],"status":"active"},{"id":"adea3642-1538-41a7-b0f0-1c167787b56b","procedure_id":"proc-chelation","jurisdiction_id":"jur-po","procedure_name":"IV Chelation Therapy for Heavy Metal Detoxification","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Detoxification","Anti_Aging"],"diseases":["Lead Poisoning","Heavy Metal Toxicity","Iron Overload"],"status":"active"},{"id":"37edd0e6-518f-427a-b847-2e4b1a9ea768","procedure_id":"proc-chelation","jurisdiction_id":"jur-pt","procedure_name":"IV Chelation Therapy for Heavy Metal Detoxification","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Detoxification","Anti_Aging"],"diseases":["Lead Poisoning","Heavy Metal Toxicity","Iron Overload"],"status":"active"},{"id":"73910e3b-623d-49af-8b05-1c21d057532c","procedure_id":"proc-chelation","jurisdiction_id":"jur-fr","procedure_name":"IV Chelation Therapy for Heavy Metal Detoxification","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"ANSM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Detoxification","Anti_Aging"],"diseases":["Lead Poisoning","Heavy Metal Toxicity","Iron Overload"],"status":"active"},{"id":"1284acc9-fa00-4bb3-9828-802b7f2afca4","procedure_id":"proc-metformin-longevity","jurisdiction_id":"jur-us-or","procedure_name":"Metformin for Longevity / Aging Prevention","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Type 2 Diabetes (labeled)","Age-Related Functional Decline","Prediabetes"],"status":"active"},{"id":"4ad0305b-1e32-4774-9d5a-f60a7d8dc1b0","procedure_id":"proc-metformin-longevity","jurisdiction_id":"jur-us-co","procedure_name":"Metformin for Longevity / Aging Prevention","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Type 2 Diabetes (labeled)","Age-Related Functional Decline","Prediabetes"],"status":"active"},{"id":"ef33253e-8511-411c-9470-d5b94d302a01","procedure_id":"proc-metformin-longevity","jurisdiction_id":"jur-us-ca","procedure_name":"Metformin for Longevity / Aging Prevention","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Type 2 Diabetes (labeled)","Age-Related Functional Decline","Prediabetes"],"status":"active"},{"id":"76e071d8-0150-456f-83d7-b5a5459293a1","procedure_id":"proc-metformin-longevity","jurisdiction_id":"jur-us-tx","procedure_name":"Metformin for Longevity / Aging Prevention","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Type 2 Diabetes (labeled)","Age-Related Functional Decline","Prediabetes"],"status":"active"},{"id":"c19a556e-992c-4d9f-b491-cf7aa11b57e1","procedure_id":"proc-metformin-longevity","jurisdiction_id":"jur-us-fl","procedure_name":"Metformin for Longevity / Aging Prevention","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Type 2 Diabetes (labeled)","Age-Related Functional Decline","Prediabetes"],"status":"active"},{"id":"e9cfeef8-98ca-46d8-b04a-176823222a77","procedure_id":"proc-metformin-longevity","jurisdiction_id":"jur-ch","procedure_name":"Metformin for Longevity / Aging Prevention","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Swissmedic","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Type 2 Diabetes (labeled)","Age-Related Functional Decline","Prediabetes"],"status":"active"},{"id":"84a00d36-45bf-4e6b-a2f0-eb4508e0e815","procedure_id":"proc-metformin-longevity","jurisdiction_id":"jur-hn-prospera","procedure_name":"Metformin for Longevity / Aging Prevention","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Permissive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Próspera ZEDE health rules (contested)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Type 2 Diabetes (labeled)","Age-Related Functional Decline","Prediabetes"],"status":"active"},{"id":"0f6aa3a5-2d1d-4f55-bd7e-fda8bd065a33","procedure_id":"proc-metformin-longevity","jurisdiction_id":"jur-nl","procedure_name":"Metformin for Longevity / Aging Prevention","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"MEB / IGJ","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Type 2 Diabetes (labeled)","Age-Related Functional Decline","Prediabetes"],"status":"active"},{"id":"c3f8336e-a72d-42ed-bc70-14458c07d30a","procedure_id":"proc-metformin-longevity","jurisdiction_id":"jur-il","procedure_name":"Metformin for Longevity / Aging Prevention","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Type 2 Diabetes (labeled)","Age-Related Functional Decline","Prediabetes"],"status":"active"},{"id":"d6acd0b8-242a-4e1a-b0ca-9ae610809047","procedure_id":"proc-metformin-longevity","jurisdiction_id":"jur-jm","procedure_name":"Metformin for Longevity / Aging Prevention","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Type 2 Diabetes (labeled)","Age-Related Functional Decline","Prediabetes"],"status":"active"},{"id":"4a680464-a7e0-4669-850c-a75074200a7e","procedure_id":"proc-metformin-longevity","jurisdiction_id":"jur-th","procedure_name":"Metformin for Longevity / Aging Prevention","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Permissive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Thai FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Type 2 Diabetes (labeled)","Age-Related Functional Decline","Prediabetes"],"status":"active"},{"id":"aff591d5-c4ef-4b71-be7a-decf48906dfb","procedure_id":"proc-metformin-longevity","jurisdiction_id":"jur-es","procedure_name":"Metformin for Longevity / Aging Prevention","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"AEMPS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Type 2 Diabetes (labeled)","Age-Related Functional Decline","Prediabetes"],"status":"active"},{"id":"d0a4a1c0-5916-4d97-b98e-bab3f1fdac7f","procedure_id":"proc-metformin-longevity","jurisdiction_id":"jur-tu","procedure_name":"Metformin for Longevity / Aging Prevention","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Type 2 Diabetes (labeled)","Age-Related Functional Decline","Prediabetes"],"status":"active"},{"id":"231f92c6-0c89-4d96-963e-0cce3b9e72d2","procedure_id":"proc-metformin-longevity","jurisdiction_id":"jur-br","procedure_name":"Metformin for Longevity / Aging Prevention","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"ANVISA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Type 2 Diabetes (labeled)","Age-Related Functional Decline","Prediabetes"],"status":"active"},{"id":"7300f13c-508e-4b8f-aaa1-7056ed3e5351","procedure_id":"proc-metformin-longevity","jurisdiction_id":"jur-cr","procedure_name":"Metformin for Longevity / Aging Prevention","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Type 2 Diabetes (labeled)","Age-Related Functional Decline","Prediabetes"],"status":"active"},{"id":"322b4a9d-b1b2-4a1f-9f08-c0feec3ecf5a","procedure_id":"proc-metformin-longevity","jurisdiction_id":"jur-uae","procedure_name":"Metformin for Longevity / Aging Prevention","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Type 2 Diabetes (labeled)","Age-Related Functional Decline","Prediabetes"],"status":"active"},{"id":"d9f313a6-d68d-46d8-a1dd-cfb2614e5c4b","procedure_id":"proc-metformin-longevity","jurisdiction_id":"jur-kr","procedure_name":"Metformin for Longevity / Aging Prevention","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"MFDS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Type 2 Diabetes (labeled)","Age-Related Functional Decline","Prediabetes"],"status":"active"},{"id":"d2d3dad3-9817-4f4d-a285-caa14855bb65","procedure_id":"proc-metformin-longevity","jurisdiction_id":"jur-gr","procedure_name":"Metformin for Longevity / Aging Prevention","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Type 2 Diabetes (labeled)","Age-Related Functional Decline","Prediabetes"],"status":"active"},{"id":"9907f9b6-9939-4cd2-8c0b-6059a50560b7","procedure_id":"proc-metformin-longevity","jurisdiction_id":"jur-be","procedure_name":"Metformin for Longevity / Aging Prevention","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Type 2 Diabetes (labeled)","Age-Related Functional Decline","Prediabetes"],"status":"active"},{"id":"cdebfc9a-e80e-4cff-a4ef-5f221dd42f90","procedure_id":"proc-metformin-longevity","jurisdiction_id":"jur-se","procedure_name":"Metformin for Longevity / Aging Prevention","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Type 2 Diabetes (labeled)","Age-Related Functional Decline","Prediabetes"],"status":"active"},{"id":"e248f804-7ea0-4ece-8a65-873d089343c4","procedure_id":"proc-metformin-longevity","jurisdiction_id":"jur-jp","procedure_name":"Metformin for Longevity / Aging Prevention","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"PMDA / MHLW","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Type 2 Diabetes (labeled)","Age-Related Functional Decline","Prediabetes"],"status":"active"},{"id":"0972a5e9-ed75-4182-8992-f594770ea06d","procedure_id":"proc-metformin-longevity","jurisdiction_id":"jur-sg","procedure_name":"Metformin for Longevity / Aging Prevention","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"HSA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Type 2 Diabetes (labeled)","Age-Related Functional Decline","Prediabetes"],"status":"active"},{"id":"42169c45-c186-4211-b030-e367799c8afd","procedure_id":"proc-metformin-longevity","jurisdiction_id":"jur-cl","procedure_name":"Metformin for Longevity / Aging Prevention","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Type 2 Diabetes (labeled)","Age-Related Functional Decline","Prediabetes"],"status":"active"},{"id":"940c38e2-e9bb-4853-9dce-75a2f3a5fc34","procedure_id":"proc-metformin-longevity","jurisdiction_id":"jur-ar","procedure_name":"Metformin for Longevity / Aging Prevention","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Type 2 Diabetes (labeled)","Age-Related Functional Decline","Prediabetes"],"status":"active"},{"id":"d839f2ad-515a-4ed2-9a08-75cd2a762b55","procedure_id":"proc-metformin-longevity","jurisdiction_id":"jur-za","procedure_name":"Metformin for Longevity / Aging Prevention","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Type 2 Diabetes (labeled)","Age-Related Functional Decline","Prediabetes"],"status":"active"},{"id":"a9926544-40d4-4c0e-a3a7-d043e22dda41","procedure_id":"proc-metformin-longevity","jurisdiction_id":"jur-ph","procedure_name":"Metformin for Longevity / Aging Prevention","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Type 2 Diabetes (labeled)","Age-Related Functional Decline","Prediabetes"],"status":"active"},{"id":"31d6d939-4ff5-435e-84c9-52d1f8a12150","procedure_id":"proc-metformin-longevity","jurisdiction_id":"jur-po","procedure_name":"Metformin for Longevity / Aging Prevention","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Type 2 Diabetes (labeled)","Age-Related Functional Decline","Prediabetes"],"status":"active"},{"id":"264edb7d-7932-4e81-b064-9a63e1fa0057","procedure_id":"proc-metformin-longevity","jurisdiction_id":"jur-pt","procedure_name":"Metformin for Longevity / Aging Prevention","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Type 2 Diabetes (labeled)","Age-Related Functional Decline","Prediabetes"],"status":"active"},{"id":"daca4577-4309-4930-8ac1-85205c1511f0","procedure_id":"proc-metformin-longevity","jurisdiction_id":"jur-fr","procedure_name":"Metformin for Longevity / Aging Prevention","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"ANSM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Longevity"],"diseases":["Type 2 Diabetes (labeled)","Age-Related Functional Decline","Prediabetes"],"status":"active"},{"id":"41204a46-d494-4117-8d63-7366a67725f0","procedure_id":"proc-tms-depression","jurisdiction_id":"jur-us-or","procedure_name":"Transcranial Magnetic Stimulation (TMS) for Depression","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"cdb36830-d6d0-4139-81db-f10f8b7a3106","procedure_id":"proc-tms-depression","jurisdiction_id":"jur-us-co","procedure_name":"Transcranial Magnetic Stimulation (TMS) for Depression","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"a58bbbd0-5d81-4fd0-8595-390743e6ad55","procedure_id":"proc-tms-depression","jurisdiction_id":"jur-us-ca","procedure_name":"Transcranial Magnetic Stimulation (TMS) for Depression","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"0d59f2f2-aef9-4683-8ef3-309c9834642b","procedure_id":"proc-tms-depression","jurisdiction_id":"jur-us-tx","procedure_name":"Transcranial Magnetic Stimulation (TMS) for Depression","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"5172339a-17d8-4284-9779-150b5df541d6","procedure_id":"proc-tms-depression","jurisdiction_id":"jur-us-fl","procedure_name":"Transcranial Magnetic Stimulation (TMS) for Depression","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"b6b3e37b-5f52-4692-8591-c8c491a04184","procedure_id":"proc-tms-depression","jurisdiction_id":"jur-ch","procedure_name":"Transcranial Magnetic Stimulation (TMS) for Depression","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Swissmedic","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"469e8f33-ade8-45f6-b1df-9074e0d73711","procedure_id":"proc-tms-depression","jurisdiction_id":"jur-mx","procedure_name":"Transcranial Magnetic Stimulation (TMS) for Depression","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"COFEPRIS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"5ac0d108-2447-4bc7-b755-a3d1114c99b8","procedure_id":"proc-tms-depression","jurisdiction_id":"jur-hn-prospera","procedure_name":"Transcranial Magnetic Stimulation (TMS) for Depression","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Próspera ZEDE health rules (contested)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"28aa65ae-30d7-4961-912a-47c11690933f","procedure_id":"proc-tms-depression","jurisdiction_id":"jur-nl","procedure_name":"Transcranial Magnetic Stimulation (TMS) for Depression","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"MEB / IGJ","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"ff264805-9c31-442c-89ea-113712eed28a","procedure_id":"proc-tms-depression","jurisdiction_id":"jur-il","procedure_name":"Transcranial Magnetic Stimulation (TMS) for Depression","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"b045878c-540c-4f8f-b2c3-78f6c72dde50","procedure_id":"proc-tms-depression","jurisdiction_id":"jur-jm","procedure_name":"Transcranial Magnetic Stimulation (TMS) for Depression","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"a87c7b07-a313-4174-85e1-b79a238642ba","procedure_id":"proc-tms-depression","jurisdiction_id":"jur-th","procedure_name":"Transcranial Magnetic Stimulation (TMS) for Depression","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Thai FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"9d82a3b5-0a04-4097-bdb4-b75a43218f8e","procedure_id":"proc-tms-depression","jurisdiction_id":"jur-es","procedure_name":"Transcranial Magnetic Stimulation (TMS) for Depression","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"AEMPS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"ffde834e-be35-4d5f-ad6b-9e587016f268","procedure_id":"proc-tms-depression","jurisdiction_id":"jur-tu","procedure_name":"Transcranial Magnetic Stimulation (TMS) for Depression","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"fc3cf42c-e61b-4ece-bb95-d4ac28399012","procedure_id":"proc-tms-depression","jurisdiction_id":"jur-in","procedure_name":"Transcranial Magnetic Stimulation (TMS) for Depression","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"CDSCO","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"98146a26-04fe-46f8-9214-720ae449632d","procedure_id":"proc-tms-depression","jurisdiction_id":"jur-br","procedure_name":"Transcranial Magnetic Stimulation (TMS) for Depression","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"ANVISA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"4d174534-042e-4ea7-a213-afbc9ef51307","procedure_id":"proc-tms-depression","jurisdiction_id":"jur-cr","procedure_name":"Transcranial Magnetic Stimulation (TMS) for Depression","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"3d6b966f-81da-4280-9fa3-4bd9f7aee75b","procedure_id":"proc-tms-depression","jurisdiction_id":"jur-uae","procedure_name":"Transcranial Magnetic Stimulation (TMS) for Depression","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"0cb95cff-c949-4332-b70e-e3de94d0d3bb","procedure_id":"proc-tms-depression","jurisdiction_id":"jur-kr","procedure_name":"Transcranial Magnetic Stimulation (TMS) for Depression","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"MFDS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"91d36574-a8fb-4e4d-bda3-718a4b8b1a43","procedure_id":"proc-tms-depression","jurisdiction_id":"jur-gr","procedure_name":"Transcranial Magnetic Stimulation (TMS) for Depression","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"8e1f8cf8-7f10-4af8-a558-47837504f257","procedure_id":"proc-tms-depression","jurisdiction_id":"jur-be","procedure_name":"Transcranial Magnetic Stimulation (TMS) for Depression","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"7be6821f-2629-4a56-9e96-774603a08364","procedure_id":"proc-tms-depression","jurisdiction_id":"jur-se","procedure_name":"Transcranial Magnetic Stimulation (TMS) for Depression","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"53935747-1b85-420d-b8d8-5fb542f3a9ce","procedure_id":"proc-tms-depression","jurisdiction_id":"jur-jp","procedure_name":"Transcranial Magnetic Stimulation (TMS) for Depression","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"PMDA / MHLW","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"1b64d40e-6182-4e23-a859-2989990cb8a0","procedure_id":"proc-tms-depression","jurisdiction_id":"jur-sg","procedure_name":"Transcranial Magnetic Stimulation (TMS) for Depression","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"HSA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"692071a2-9f31-4c92-bf66-961fba3c7266","procedure_id":"proc-tms-depression","jurisdiction_id":"jur-cl","procedure_name":"Transcranial Magnetic Stimulation (TMS) for Depression","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"461fe9e6-ee1d-46f3-9f1a-bb9ae562e5bd","procedure_id":"proc-tms-depression","jurisdiction_id":"jur-ar","procedure_name":"Transcranial Magnetic Stimulation (TMS) for Depression","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"47fe4085-3f9b-4266-9d32-1b920c2f9720","procedure_id":"proc-tms-depression","jurisdiction_id":"jur-za","procedure_name":"Transcranial Magnetic Stimulation (TMS) for Depression","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"952765a2-08e8-4b66-bbec-26736fadc989","procedure_id":"proc-tms-depression","jurisdiction_id":"jur-ph","procedure_name":"Transcranial Magnetic Stimulation (TMS) for Depression","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"e630c4b3-b868-4400-9f3d-1284d0c39b42","procedure_id":"proc-tms-depression","jurisdiction_id":"jur-po","procedure_name":"Transcranial Magnetic Stimulation (TMS) for Depression","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"12600944-c84f-441f-9b00-262f31962806","procedure_id":"proc-tms-depression","jurisdiction_id":"jur-pt","procedure_name":"Transcranial Magnetic Stimulation (TMS) for Depression","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"1843cb3c-035b-410b-ab62-536861b1853d","procedure_id":"proc-tms-depression","jurisdiction_id":"jur-fr","procedure_name":"Transcranial Magnetic Stimulation (TMS) for Depression","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"ANSM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Major Depressive Disorder"],"status":"active"},{"id":"843a6a2e-fea6-457f-b1e2-abb2e394256b","procedure_id":"proc-tms-ocd","jurisdiction_id":"jur-us-or","procedure_name":"Deep TMS / TMS for Obsessive-Compulsive Disorder","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","OCD"],"diseases":["Obsessive-Compulsive Disorder"],"status":"active"},{"id":"cf2af797-5952-40ae-8277-3bf334fec698","procedure_id":"proc-tms-ocd","jurisdiction_id":"jur-us-co","procedure_name":"Deep TMS / TMS for Obsessive-Compulsive Disorder","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","OCD"],"diseases":["Obsessive-Compulsive Disorder"],"status":"active"},{"id":"9296f218-37dd-4f8f-a38c-5e1dcc53762a","procedure_id":"proc-tms-ocd","jurisdiction_id":"jur-us-ca","procedure_name":"Deep TMS / TMS for Obsessive-Compulsive Disorder","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","OCD"],"diseases":["Obsessive-Compulsive Disorder"],"status":"active"},{"id":"60a582f5-ded4-4599-b1b9-281ece27a3fa","procedure_id":"proc-tms-ocd","jurisdiction_id":"jur-us-tx","procedure_name":"Deep TMS / TMS for Obsessive-Compulsive Disorder","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","OCD"],"diseases":["Obsessive-Compulsive Disorder"],"status":"active"},{"id":"991fa936-5aa3-4777-ae42-c36fa14a9743","procedure_id":"proc-tms-ocd","jurisdiction_id":"jur-us-fl","procedure_name":"Deep TMS / TMS for Obsessive-Compulsive Disorder","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","OCD"],"diseases":["Obsessive-Compulsive Disorder"],"status":"active"},{"id":"c6eb6822-d55e-4524-9272-5055dee4c3b0","procedure_id":"proc-tms-ocd","jurisdiction_id":"jur-au","procedure_name":"Deep TMS / TMS for Obsessive-Compulsive Disorder","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"TGA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","OCD"],"diseases":["Obsessive-Compulsive Disorder"],"status":"active"},{"id":"78112a27-289f-4f79-b86d-0572eebf2178","procedure_id":"proc-tms-ocd","jurisdiction_id":"jur-ch","procedure_name":"Deep TMS / TMS for Obsessive-Compulsive Disorder","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Swissmedic","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","OCD"],"diseases":["Obsessive-Compulsive Disorder"],"status":"active"},{"id":"6f62b51b-c4bb-4227-98ae-20f61ad15030","procedure_id":"proc-tms-ocd","jurisdiction_id":"jur-ca","procedure_name":"Deep TMS / TMS for Obsessive-Compulsive Disorder","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Health Canada","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","OCD"],"diseases":["Obsessive-Compulsive Disorder"],"status":"active"},{"id":"e8457916-514d-4d24-8a63-1352796b34d1","procedure_id":"proc-tms-ocd","jurisdiction_id":"jur-mx","procedure_name":"Deep TMS / TMS for Obsessive-Compulsive Disorder","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"COFEPRIS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","OCD"],"diseases":["Obsessive-Compulsive Disorder"],"status":"active"},{"id":"049723c9-2d96-4d3f-8518-81da6bd426c8","procedure_id":"proc-tms-ocd","jurisdiction_id":"jur-hn-prospera","procedure_name":"Deep TMS / TMS for Obsessive-Compulsive Disorder","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Próspera ZEDE health rules (contested)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","OCD"],"diseases":["Obsessive-Compulsive Disorder"],"status":"active"},{"id":"9fe11079-6307-42b1-8038-3bd524296b9d","procedure_id":"proc-tms-ocd","jurisdiction_id":"jur-nl","procedure_name":"Deep TMS / TMS for Obsessive-Compulsive Disorder","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"MEB / IGJ","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","OCD"],"diseases":["Obsessive-Compulsive Disorder"],"status":"active"},{"id":"d18c116d-4922-477c-8249-c366df98b6be","procedure_id":"proc-tms-ocd","jurisdiction_id":"jur-de","procedure_name":"Deep TMS / TMS for Obsessive-Compulsive Disorder","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"BfArM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","OCD"],"diseases":["Obsessive-Compulsive Disorder"],"status":"active"},{"id":"1e5a1e97-486b-4f0c-bfd8-e2efa297091a","procedure_id":"proc-tms-ocd","jurisdiction_id":"jur-uk","procedure_name":"Deep TMS / TMS for Obsessive-Compulsive Disorder","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"MHRA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","OCD"],"diseases":["Obsessive-Compulsive Disorder"],"status":"active"},{"id":"bda74ba6-6767-481b-84ec-747b051da735","procedure_id":"proc-tms-ocd","jurisdiction_id":"jur-jm","procedure_name":"Deep TMS / TMS for Obsessive-Compulsive Disorder","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","OCD"],"diseases":["Obsessive-Compulsive Disorder"],"status":"active"},{"id":"7c6024dc-36bd-474c-9133-8b91ad04b679","procedure_id":"proc-tms-ocd","jurisdiction_id":"jur-th","procedure_name":"Deep TMS / TMS for Obsessive-Compulsive Disorder","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Thai FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","OCD"],"diseases":["Obsessive-Compulsive Disorder"],"status":"active"},{"id":"c17fc03d-2e36-4a55-992d-afb09ac3dbb2","procedure_id":"proc-tms-ocd","jurisdiction_id":"jur-es","procedure_name":"Deep TMS / TMS for Obsessive-Compulsive Disorder","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"AEMPS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","OCD"],"diseases":["Obsessive-Compulsive Disorder"],"status":"active"},{"id":"7f7e15d5-c770-42f1-99f1-bdad62ff21f4","procedure_id":"proc-tms-ocd","jurisdiction_id":"jur-tu","procedure_name":"Deep TMS / TMS for Obsessive-Compulsive Disorder","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","OCD"],"diseases":["Obsessive-Compulsive Disorder"],"status":"active"},{"id":"a2719bef-d0ec-4a8b-8adf-2525241735f6","procedure_id":"proc-tms-ocd","jurisdiction_id":"jur-in","procedure_name":"Deep TMS / TMS for Obsessive-Compulsive Disorder","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"CDSCO","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","OCD"],"diseases":["Obsessive-Compulsive Disorder"],"status":"active"},{"id":"1c75463f-7d2a-4756-b23d-63e498153a1f","procedure_id":"proc-tms-ocd","jurisdiction_id":"jur-br","procedure_name":"Deep TMS / TMS for Obsessive-Compulsive Disorder","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"ANVISA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","OCD"],"diseases":["Obsessive-Compulsive Disorder"],"status":"active"},{"id":"6d1b1c6f-29ad-4837-9e4b-70edfdd0e132","procedure_id":"proc-tms-ocd","jurisdiction_id":"jur-cr","procedure_name":"Deep TMS / TMS for Obsessive-Compulsive Disorder","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","OCD"],"diseases":["Obsessive-Compulsive Disorder"],"status":"active"},{"id":"d6b6b18d-4ce6-4292-b27b-a0dad45877a6","procedure_id":"proc-tms-ocd","jurisdiction_id":"jur-uae","procedure_name":"Deep TMS / TMS for Obsessive-Compulsive Disorder","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","OCD"],"diseases":["Obsessive-Compulsive Disorder"],"status":"active"},{"id":"2435be08-3a24-497a-a439-f0c0922f09a9","procedure_id":"proc-tms-ocd","jurisdiction_id":"jur-kr","procedure_name":"Deep TMS / TMS for Obsessive-Compulsive Disorder","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"MFDS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","OCD"],"diseases":["Obsessive-Compulsive Disorder"],"status":"active"},{"id":"e63b42c2-944b-4905-ad02-76e96a4f1223","procedure_id":"proc-tms-ocd","jurisdiction_id":"jur-gr","procedure_name":"Deep TMS / TMS for Obsessive-Compulsive Disorder","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","OCD"],"diseases":["Obsessive-Compulsive Disorder"],"status":"active"},{"id":"ab8e399b-ce1a-4987-9edb-db4fe602d8e8","procedure_id":"proc-tms-ocd","jurisdiction_id":"jur-be","procedure_name":"Deep TMS / TMS for Obsessive-Compulsive Disorder","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","OCD"],"diseases":["Obsessive-Compulsive Disorder"],"status":"active"},{"id":"ca66ac0b-8a5f-4ab8-99bc-7140d6029095","procedure_id":"proc-tms-ocd","jurisdiction_id":"jur-se","procedure_name":"Deep TMS / TMS for Obsessive-Compulsive Disorder","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","OCD"],"diseases":["Obsessive-Compulsive Disorder"],"status":"active"},{"id":"b62b1274-a8a6-41ac-bdb0-fc42f149267a","procedure_id":"proc-tms-ocd","jurisdiction_id":"jur-jp","procedure_name":"Deep TMS / TMS for Obsessive-Compulsive Disorder","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"PMDA / MHLW","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","OCD"],"diseases":["Obsessive-Compulsive Disorder"],"status":"active"},{"id":"450b0940-1f6f-4d03-8b1c-e0960b884ca7","procedure_id":"proc-tms-ocd","jurisdiction_id":"jur-sg","procedure_name":"Deep TMS / TMS for Obsessive-Compulsive Disorder","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"HSA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","OCD"],"diseases":["Obsessive-Compulsive Disorder"],"status":"active"},{"id":"e2c4bb92-1e3c-4a00-983b-a13c6ed5f483","procedure_id":"proc-tms-ocd","jurisdiction_id":"jur-cl","procedure_name":"Deep TMS / TMS for Obsessive-Compulsive Disorder","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","OCD"],"diseases":["Obsessive-Compulsive Disorder"],"status":"active"},{"id":"df371f92-1479-41a2-836f-8d1e607bedbe","procedure_id":"proc-tms-ocd","jurisdiction_id":"jur-ar","procedure_name":"Deep TMS / TMS for Obsessive-Compulsive Disorder","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","OCD"],"diseases":["Obsessive-Compulsive Disorder"],"status":"active"},{"id":"335fa1c2-1e97-4dfc-8dd2-69cc891b1adb","procedure_id":"proc-tms-ocd","jurisdiction_id":"jur-za","procedure_name":"Deep TMS / TMS for Obsessive-Compulsive Disorder","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","OCD"],"diseases":["Obsessive-Compulsive Disorder"],"status":"active"},{"id":"51259a37-43a1-4f4b-99ce-f056a92972d8","procedure_id":"proc-tms-ocd","jurisdiction_id":"jur-ph","procedure_name":"Deep TMS / TMS for Obsessive-Compulsive Disorder","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","OCD"],"diseases":["Obsessive-Compulsive Disorder"],"status":"active"},{"id":"a369ce8f-10f6-476e-a3f3-d5c3f38c373b","procedure_id":"proc-tms-ocd","jurisdiction_id":"jur-po","procedure_name":"Deep TMS / TMS for Obsessive-Compulsive Disorder","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","OCD"],"diseases":["Obsessive-Compulsive Disorder"],"status":"active"},{"id":"493846cb-c615-4abf-8cfa-7810c61eeaa4","procedure_id":"proc-tms-ocd","jurisdiction_id":"jur-pt","procedure_name":"Deep TMS / TMS for Obsessive-Compulsive Disorder","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","OCD"],"diseases":["Obsessive-Compulsive Disorder"],"status":"active"},{"id":"934c2ddf-06d7-41a1-8239-4474db3ed5a0","procedure_id":"proc-tms-ocd","jurisdiction_id":"jur-fr","procedure_name":"Deep TMS / TMS for Obsessive-Compulsive Disorder","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"ANSM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","OCD"],"diseases":["Obsessive-Compulsive Disorder"],"status":"active"},{"id":"40b09576-949d-4808-b98e-c24eccf57173","procedure_id":"proc-vns-depression","jurisdiction_id":"jur-us-or","procedure_name":"Vagus Nerve Stimulation (VNS) for Depression","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Epilepsy"],"status":"active"},{"id":"b05ce7ff-4526-43ad-8dc5-e407d310b3b1","procedure_id":"proc-vns-depression","jurisdiction_id":"jur-us-co","procedure_name":"Vagus Nerve Stimulation (VNS) for Depression","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Epilepsy"],"status":"active"},{"id":"d6c74b17-57ab-4cd3-bcf2-615a796aebb7","procedure_id":"proc-vns-depression","jurisdiction_id":"jur-us-ca","procedure_name":"Vagus Nerve Stimulation (VNS) for Depression","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Epilepsy"],"status":"active"},{"id":"e82d3325-bcca-484a-8560-39dc99baa839","procedure_id":"proc-vns-depression","jurisdiction_id":"jur-us-tx","procedure_name":"Vagus Nerve Stimulation (VNS) for Depression","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Epilepsy"],"status":"active"},{"id":"a9eea88e-086b-452e-8262-ab630dabfb00","procedure_id":"proc-vns-depression","jurisdiction_id":"jur-us-fl","procedure_name":"Vagus Nerve Stimulation (VNS) for Depression","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Epilepsy"],"status":"active"},{"id":"9dcf338e-4205-4e38-a1e1-baf0c822a30e","procedure_id":"proc-vns-depression","jurisdiction_id":"jur-au","procedure_name":"Vagus Nerve Stimulation (VNS) for Depression","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"TGA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Epilepsy"],"status":"active"},{"id":"6c5df51d-6944-4f28-861f-4c9e246b3bf9","procedure_id":"proc-vns-depression","jurisdiction_id":"jur-ch","procedure_name":"Vagus Nerve Stimulation (VNS) for Depression","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Swissmedic","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Epilepsy"],"status":"active"},{"id":"5caad6b4-fdd7-47f3-a402-e9261ce14498","procedure_id":"proc-vns-depression","jurisdiction_id":"jur-ca","procedure_name":"Vagus Nerve Stimulation (VNS) for Depression","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Health Canada","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Epilepsy"],"status":"active"},{"id":"2b4f0b20-0fea-4c46-90f5-cceeebcd5a45","procedure_id":"proc-vns-depression","jurisdiction_id":"jur-mx","procedure_name":"Vagus Nerve Stimulation (VNS) for Depression","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"COFEPRIS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Epilepsy"],"status":"active"},{"id":"189bafae-8482-4c06-bd60-0ca3f5273740","procedure_id":"proc-vns-depression","jurisdiction_id":"jur-hn-prospera","procedure_name":"Vagus Nerve Stimulation (VNS) for Depression","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Próspera ZEDE health rules (contested)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Epilepsy"],"status":"active"},{"id":"5d025092-2526-400b-be70-14423a67cbc5","procedure_id":"proc-vns-depression","jurisdiction_id":"jur-nl","procedure_name":"Vagus Nerve Stimulation (VNS) for Depression","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"MEB / IGJ","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Epilepsy"],"status":"active"},{"id":"078f5a6b-e6f2-4ce1-aa8c-1d9a6664c5a7","procedure_id":"proc-vns-depression","jurisdiction_id":"jur-uk","procedure_name":"Vagus Nerve Stimulation (VNS) for Depression","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"MHRA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Epilepsy"],"status":"active"},{"id":"6b7ff363-b843-4e16-a552-63e8a0a21bae","procedure_id":"proc-vns-depression","jurisdiction_id":"jur-il","procedure_name":"Vagus Nerve Stimulation (VNS) for Depression","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Epilepsy"],"status":"active"},{"id":"b18d1a79-ff4b-43ad-8525-aabc90e445c0","procedure_id":"proc-vns-depression","jurisdiction_id":"jur-jm","procedure_name":"Vagus Nerve Stimulation (VNS) for Depression","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Epilepsy"],"status":"active"},{"id":"7b41e858-9e26-47f5-82f1-61f91b63e9f0","procedure_id":"proc-vns-depression","jurisdiction_id":"jur-th","procedure_name":"Vagus Nerve Stimulation (VNS) for Depression","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Thai FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Epilepsy"],"status":"active"},{"id":"8bd9996a-194d-4735-ad98-5cc9e1a3d35c","procedure_id":"proc-vns-depression","jurisdiction_id":"jur-es","procedure_name":"Vagus Nerve Stimulation (VNS) for Depression","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"AEMPS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Epilepsy"],"status":"active"},{"id":"4370e462-6204-4fc4-ab7b-329881b075eb","procedure_id":"proc-vns-depression","jurisdiction_id":"jur-tu","procedure_name":"Vagus Nerve Stimulation (VNS) for Depression","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Epilepsy"],"status":"active"},{"id":"b6554e6b-6b16-42b0-bbe9-7452afc47373","procedure_id":"proc-vns-depression","jurisdiction_id":"jur-in","procedure_name":"Vagus Nerve Stimulation (VNS) for Depression","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"CDSCO","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Epilepsy"],"status":"active"},{"id":"4fba9643-d3d0-43ab-ac1b-a30ae79cd9fd","procedure_id":"proc-vns-depression","jurisdiction_id":"jur-br","procedure_name":"Vagus Nerve Stimulation (VNS) for Depression","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"ANVISA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Epilepsy"],"status":"active"},{"id":"c0adbefe-ab07-4869-8cd9-c5eb475dd13d","procedure_id":"proc-vns-depression","jurisdiction_id":"jur-cr","procedure_name":"Vagus Nerve Stimulation (VNS) for Depression","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Epilepsy"],"status":"active"},{"id":"1feeac9a-9958-492d-af98-a12182b7f2ac","procedure_id":"proc-vns-depression","jurisdiction_id":"jur-uae","procedure_name":"Vagus Nerve Stimulation (VNS) for Depression","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Epilepsy"],"status":"active"},{"id":"01f3f0ff-bae3-461b-a354-13c591ee3ba1","procedure_id":"proc-vns-depression","jurisdiction_id":"jur-kr","procedure_name":"Vagus Nerve Stimulation (VNS) for Depression","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"MFDS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Epilepsy"],"status":"active"},{"id":"ff88f265-0f95-40f8-85bc-006ea4ca8dbf","procedure_id":"proc-vns-depression","jurisdiction_id":"jur-gr","procedure_name":"Vagus Nerve Stimulation (VNS) for Depression","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Epilepsy"],"status":"active"},{"id":"63cf6504-ac73-4d75-954f-e26a28f72b46","procedure_id":"proc-vns-depression","jurisdiction_id":"jur-be","procedure_name":"Vagus Nerve Stimulation (VNS) for Depression","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Epilepsy"],"status":"active"},{"id":"f44edff2-1044-4671-b563-e8a4fff6d88f","procedure_id":"proc-vns-depression","jurisdiction_id":"jur-se","procedure_name":"Vagus Nerve Stimulation (VNS) for Depression","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Epilepsy"],"status":"active"},{"id":"4bbb58e9-9ac5-4b0e-9814-05b692e57d5a","procedure_id":"proc-vns-depression","jurisdiction_id":"jur-jp","procedure_name":"Vagus Nerve Stimulation (VNS) for Depression","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"PMDA / MHLW","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Epilepsy"],"status":"active"},{"id":"26420b63-5317-4065-878c-fbe187cff105","procedure_id":"proc-vns-depression","jurisdiction_id":"jur-sg","procedure_name":"Vagus Nerve Stimulation (VNS) for Depression","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"HSA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Epilepsy"],"status":"active"},{"id":"fad12320-4722-4031-96e9-566faf1c3f94","procedure_id":"proc-vns-depression","jurisdiction_id":"jur-cl","procedure_name":"Vagus Nerve Stimulation (VNS) for Depression","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Epilepsy"],"status":"active"},{"id":"68362dd5-e9c5-47ed-af83-78e75a4b2e69","procedure_id":"proc-vns-depression","jurisdiction_id":"jur-ar","procedure_name":"Vagus Nerve Stimulation (VNS) for Depression","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Epilepsy"],"status":"active"},{"id":"265e9840-ff6a-4602-984f-ccc23f166d22","procedure_id":"proc-vns-depression","jurisdiction_id":"jur-za","procedure_name":"Vagus Nerve Stimulation (VNS) for Depression","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Epilepsy"],"status":"active"},{"id":"4f76e23e-198d-4cab-b64f-7adc12aa7dfe","procedure_id":"proc-vns-depression","jurisdiction_id":"jur-ph","procedure_name":"Vagus Nerve Stimulation (VNS) for Depression","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Epilepsy"],"status":"active"},{"id":"da1f5375-3541-4b3e-98be-3d8838daea4c","procedure_id":"proc-vns-depression","jurisdiction_id":"jur-po","procedure_name":"Vagus Nerve Stimulation (VNS) for Depression","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Epilepsy"],"status":"active"},{"id":"1e7fc071-666a-4344-8aac-7eccef6f1345","procedure_id":"proc-vns-depression","jurisdiction_id":"jur-pt","procedure_name":"Vagus Nerve Stimulation (VNS) for Depression","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Epilepsy"],"status":"active"},{"id":"0fa88918-da6e-44f1-8dd8-e4cf084862a6","procedure_id":"proc-vns-depression","jurisdiction_id":"jur-fr","procedure_name":"Vagus Nerve Stimulation (VNS) for Depression","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"ANSM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression"],"diseases":["Treatment-Resistant Depression","Epilepsy"],"status":"active"},{"id":"8f9a270b-f24f-4f2c-ac0d-1bf8bbe7afd9","procedure_id":"proc-dbs-parkinson","jurisdiction_id":"jur-us-or","procedure_name":"Deep Brain Stimulation (DBS) for Parkinson's Disease","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Parkinson's Disease","Essential Tremor (selected targets)"],"status":"active"},{"id":"5113de05-5d05-4963-9a8e-47063d314f34","procedure_id":"proc-dbs-parkinson","jurisdiction_id":"jur-us-co","procedure_name":"Deep Brain Stimulation (DBS) for Parkinson's Disease","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Parkinson's Disease","Essential Tremor (selected targets)"],"status":"active"},{"id":"cab188c3-5a78-4089-a930-b998b93857d1","procedure_id":"proc-dbs-parkinson","jurisdiction_id":"jur-us-ca","procedure_name":"Deep Brain Stimulation (DBS) for Parkinson's Disease","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Parkinson's Disease","Essential Tremor (selected targets)"],"status":"active"},{"id":"e1c9b8a0-5963-4c54-9f40-003afcf75b82","procedure_id":"proc-dbs-parkinson","jurisdiction_id":"jur-us-tx","procedure_name":"Deep Brain Stimulation (DBS) for Parkinson's Disease","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Parkinson's Disease","Essential Tremor (selected targets)"],"status":"active"},{"id":"00b922f5-0c26-4f01-b2f9-2cf1eacee980","procedure_id":"proc-dbs-parkinson","jurisdiction_id":"jur-us-fl","procedure_name":"Deep Brain Stimulation (DBS) for Parkinson's Disease","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Parkinson's Disease","Essential Tremor (selected targets)"],"status":"active"},{"id":"79c48af3-ee6f-48f2-990a-3a63948e8b58","procedure_id":"proc-dbs-parkinson","jurisdiction_id":"jur-au","procedure_name":"Deep Brain Stimulation (DBS) for Parkinson's Disease","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"TGA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Parkinson's Disease","Essential Tremor (selected targets)"],"status":"active"},{"id":"97005a96-22ba-4ffa-b73f-08ad6778fcc7","procedure_id":"proc-dbs-parkinson","jurisdiction_id":"jur-ch","procedure_name":"Deep Brain Stimulation (DBS) for Parkinson's Disease","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Swissmedic","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Parkinson's Disease","Essential Tremor (selected targets)"],"status":"active"},{"id":"f26b6867-9afd-414f-828a-5fbe68553d40","procedure_id":"proc-dbs-parkinson","jurisdiction_id":"jur-ca","procedure_name":"Deep Brain Stimulation (DBS) for Parkinson's Disease","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Health Canada","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Parkinson's Disease","Essential Tremor (selected targets)"],"status":"active"},{"id":"1eaff756-e539-44be-b4d6-f3396ac2422c","procedure_id":"proc-dbs-parkinson","jurisdiction_id":"jur-mx","procedure_name":"Deep Brain Stimulation (DBS) for Parkinson's Disease","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"COFEPRIS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Parkinson's Disease","Essential Tremor (selected targets)"],"status":"active"},{"id":"61810dee-398a-4132-a68a-e9dd95642d0a","procedure_id":"proc-dbs-parkinson","jurisdiction_id":"jur-hn-prospera","procedure_name":"Deep Brain Stimulation (DBS) for Parkinson's Disease","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Próspera ZEDE health rules (contested)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Parkinson's Disease","Essential Tremor (selected targets)"],"status":"active"},{"id":"0574eac5-ca35-407a-8e8b-730d78f0d150","procedure_id":"proc-dbs-parkinson","jurisdiction_id":"jur-nl","procedure_name":"Deep Brain Stimulation (DBS) for Parkinson's Disease","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"MEB / IGJ","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Parkinson's Disease","Essential Tremor (selected targets)"],"status":"active"},{"id":"43aa3a2c-af8a-444c-b22b-1bb4fd719594","procedure_id":"proc-dbs-parkinson","jurisdiction_id":"jur-uk","procedure_name":"Deep Brain Stimulation (DBS) for Parkinson's Disease","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"MHRA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Parkinson's Disease","Essential Tremor (selected targets)"],"status":"active"},{"id":"f9a4361b-bc34-47c3-85d4-1e0626f37207","procedure_id":"proc-dbs-parkinson","jurisdiction_id":"jur-il","procedure_name":"Deep Brain Stimulation (DBS) for Parkinson's Disease","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Parkinson's Disease","Essential Tremor (selected targets)"],"status":"active"},{"id":"dd4dd2b2-e6fb-4981-a530-3a2214430bd4","procedure_id":"proc-dbs-parkinson","jurisdiction_id":"jur-jm","procedure_name":"Deep Brain Stimulation (DBS) for Parkinson's Disease","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Parkinson's Disease","Essential Tremor (selected targets)"],"status":"active"},{"id":"7caabd51-d7ca-48d8-b706-1aa3fcc20a0a","procedure_id":"proc-dbs-parkinson","jurisdiction_id":"jur-th","procedure_name":"Deep Brain Stimulation (DBS) for Parkinson's Disease","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Thai FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Parkinson's Disease","Essential Tremor (selected targets)"],"status":"active"},{"id":"639b5ccf-a0b6-4132-a9aa-f2fe8212a27f","procedure_id":"proc-dbs-parkinson","jurisdiction_id":"jur-es","procedure_name":"Deep Brain Stimulation (DBS) for Parkinson's Disease","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"AEMPS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Parkinson's Disease","Essential Tremor (selected targets)"],"status":"active"},{"id":"717f1193-35d1-46a0-a12d-8dbd09ae4c83","procedure_id":"proc-dbs-parkinson","jurisdiction_id":"jur-tu","procedure_name":"Deep Brain Stimulation (DBS) for Parkinson's Disease","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Parkinson's Disease","Essential Tremor (selected targets)"],"status":"active"},{"id":"45cc4877-5eb6-451a-8f91-4470c929f7ed","procedure_id":"proc-dbs-parkinson","jurisdiction_id":"jur-br","procedure_name":"Deep Brain Stimulation (DBS) for Parkinson's Disease","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"ANVISA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Parkinson's Disease","Essential Tremor (selected targets)"],"status":"active"},{"id":"adc1efa5-9b64-4fe5-b4f4-eb958338cd75","procedure_id":"proc-dbs-parkinson","jurisdiction_id":"jur-cr","procedure_name":"Deep Brain Stimulation (DBS) for Parkinson's Disease","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Parkinson's Disease","Essential Tremor (selected targets)"],"status":"active"},{"id":"8090bbee-46f9-4ea0-a502-25bfd4577af6","procedure_id":"proc-dbs-parkinson","jurisdiction_id":"jur-uae","procedure_name":"Deep Brain Stimulation (DBS) for Parkinson's Disease","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Parkinson's Disease","Essential Tremor (selected targets)"],"status":"active"},{"id":"47cf4950-0cef-4cbf-9ea9-c8c973ad8aa2","procedure_id":"proc-dbs-parkinson","jurisdiction_id":"jur-kr","procedure_name":"Deep Brain Stimulation (DBS) for Parkinson's Disease","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"MFDS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Parkinson's Disease","Essential Tremor (selected targets)"],"status":"active"},{"id":"ac7b38b0-4979-4dcd-9308-8631a2483857","procedure_id":"proc-dbs-parkinson","jurisdiction_id":"jur-gr","procedure_name":"Deep Brain Stimulation (DBS) for Parkinson's Disease","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Parkinson's Disease","Essential Tremor (selected targets)"],"status":"active"},{"id":"3e52ce5a-b6bd-48e2-a0bf-0b54966a0832","procedure_id":"proc-dbs-parkinson","jurisdiction_id":"jur-be","procedure_name":"Deep Brain Stimulation (DBS) for Parkinson's Disease","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Parkinson's Disease","Essential Tremor (selected targets)"],"status":"active"},{"id":"508528b2-0282-4a5b-a136-6c15ac81d6e6","procedure_id":"proc-dbs-parkinson","jurisdiction_id":"jur-se","procedure_name":"Deep Brain Stimulation (DBS) for Parkinson's Disease","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Parkinson's Disease","Essential Tremor (selected targets)"],"status":"active"},{"id":"cd2ac35c-18b7-41c8-b9ff-cd3757b4b4f3","procedure_id":"proc-dbs-parkinson","jurisdiction_id":"jur-sg","procedure_name":"Deep Brain Stimulation (DBS) for Parkinson's Disease","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"HSA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Parkinson's Disease","Essential Tremor (selected targets)"],"status":"active"},{"id":"9c92330e-43c1-4e93-9fc8-af691affcf64","procedure_id":"proc-dbs-parkinson","jurisdiction_id":"jur-cl","procedure_name":"Deep Brain Stimulation (DBS) for Parkinson's Disease","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Parkinson's Disease","Essential Tremor (selected targets)"],"status":"active"},{"id":"cf2820f2-21ed-429c-8340-8c3af97be7b9","procedure_id":"proc-dbs-parkinson","jurisdiction_id":"jur-ar","procedure_name":"Deep Brain Stimulation (DBS) for Parkinson's Disease","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Parkinson's Disease","Essential Tremor (selected targets)"],"status":"active"},{"id":"3382a21c-0b36-4698-9138-a2a476e39bcf","procedure_id":"proc-dbs-parkinson","jurisdiction_id":"jur-za","procedure_name":"Deep Brain Stimulation (DBS) for Parkinson's Disease","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Parkinson's Disease","Essential Tremor (selected targets)"],"status":"active"},{"id":"3e5bb7df-bfe6-4b65-967f-f2f9ff5426a8","procedure_id":"proc-dbs-parkinson","jurisdiction_id":"jur-ph","procedure_name":"Deep Brain Stimulation (DBS) for Parkinson's Disease","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Parkinson's Disease","Essential Tremor (selected targets)"],"status":"active"},{"id":"f7660ab2-9f9b-4609-ace1-9b8cb00df35f","procedure_id":"proc-dbs-parkinson","jurisdiction_id":"jur-po","procedure_name":"Deep Brain Stimulation (DBS) for Parkinson's Disease","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Parkinson's Disease","Essential Tremor (selected targets)"],"status":"active"},{"id":"5a39dad8-5b6b-41e5-b0fb-772d6697009c","procedure_id":"proc-dbs-parkinson","jurisdiction_id":"jur-pt","procedure_name":"Deep Brain Stimulation (DBS) for Parkinson's Disease","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Parkinson's Disease","Essential Tremor (selected targets)"],"status":"active"},{"id":"cfd7a9d8-5978-471a-ba8f-823c13028924","procedure_id":"proc-dbs-parkinson","jurisdiction_id":"jur-fr","procedure_name":"Deep Brain Stimulation (DBS) for Parkinson's Disease","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"ANSM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Parkinson's Disease","Essential Tremor (selected targets)"],"status":"active"},{"id":"814a7fb8-6fca-41c7-98f6-6154c7c5b633","procedure_id":"proc-fus-tremor","jurisdiction_id":"jur-us-or","procedure_name":"MR-Guided Focused Ultrasound for Essential Tremor / PD Tremor","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Essential Tremor","Parkinson's Disease Tremor"],"status":"active"},{"id":"c93fa1e0-5b06-45e4-ad97-62acf2a9d988","procedure_id":"proc-fus-tremor","jurisdiction_id":"jur-us-co","procedure_name":"MR-Guided Focused Ultrasound for Essential Tremor / PD Tremor","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Essential Tremor","Parkinson's Disease Tremor"],"status":"active"},{"id":"4c7ac6fa-3931-4a4e-bcf7-1ea749eb0533","procedure_id":"proc-fus-tremor","jurisdiction_id":"jur-us-ca","procedure_name":"MR-Guided Focused Ultrasound for Essential Tremor / PD Tremor","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Essential Tremor","Parkinson's Disease Tremor"],"status":"active"},{"id":"19ff6531-6986-45a2-bdef-788c3f943bd8","procedure_id":"proc-fus-tremor","jurisdiction_id":"jur-us-tx","procedure_name":"MR-Guided Focused Ultrasound for Essential Tremor / PD Tremor","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Essential Tremor","Parkinson's Disease Tremor"],"status":"active"},{"id":"21c39314-8920-4d0d-a701-762e3da5f00a","procedure_id":"proc-fus-tremor","jurisdiction_id":"jur-us-fl","procedure_name":"MR-Guided Focused Ultrasound for Essential Tremor / PD Tremor","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Essential Tremor","Parkinson's Disease Tremor"],"status":"active"},{"id":"8e7d87b2-0750-4a25-80c6-15a87fef0a7b","procedure_id":"proc-fus-tremor","jurisdiction_id":"jur-au","procedure_name":"MR-Guided Focused Ultrasound for Essential Tremor / PD Tremor","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"TGA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Essential Tremor","Parkinson's Disease Tremor"],"status":"active"},{"id":"44dab2e3-c9a5-4cfc-8ee5-ea320ee6a3d1","procedure_id":"proc-fus-tremor","jurisdiction_id":"jur-ch","procedure_name":"MR-Guided Focused Ultrasound for Essential Tremor / PD Tremor","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Swissmedic","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Essential Tremor","Parkinson's Disease Tremor"],"status":"active"},{"id":"cf411da7-9d83-4a5e-ab7f-4172dfd0dbf5","procedure_id":"proc-fus-tremor","jurisdiction_id":"jur-ca","procedure_name":"MR-Guided Focused Ultrasound for Essential Tremor / PD Tremor","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Health Canada","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Essential Tremor","Parkinson's Disease Tremor"],"status":"active"},{"id":"4961a559-c8cd-4fe1-82c5-91a7909e3ad8","procedure_id":"proc-fus-tremor","jurisdiction_id":"jur-mx","procedure_name":"MR-Guided Focused Ultrasound for Essential Tremor / PD Tremor","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"COFEPRIS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Essential Tremor","Parkinson's Disease Tremor"],"status":"active"},{"id":"da33d152-81d4-47e8-98c3-d42789ffa3e6","procedure_id":"proc-fus-tremor","jurisdiction_id":"jur-hn-prospera","procedure_name":"MR-Guided Focused Ultrasound for Essential Tremor / PD Tremor","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Próspera ZEDE health rules (contested)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Essential Tremor","Parkinson's Disease Tremor"],"status":"active"},{"id":"60e08a47-960a-481d-a18f-e67ec6f4611d","procedure_id":"proc-fus-tremor","jurisdiction_id":"jur-nl","procedure_name":"MR-Guided Focused Ultrasound for Essential Tremor / PD Tremor","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"MEB / IGJ","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Essential Tremor","Parkinson's Disease Tremor"],"status":"active"},{"id":"4dcdf6b4-c89d-41ff-b479-077d99c0af73","procedure_id":"proc-fus-tremor","jurisdiction_id":"jur-de","procedure_name":"MR-Guided Focused Ultrasound for Essential Tremor / PD Tremor","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"BfArM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Essential Tremor","Parkinson's Disease Tremor"],"status":"active"},{"id":"407daba7-3075-4765-a9e6-f492fbf03afe","procedure_id":"proc-fus-tremor","jurisdiction_id":"jur-uk","procedure_name":"MR-Guided Focused Ultrasound for Essential Tremor / PD Tremor","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"MHRA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Essential Tremor","Parkinson's Disease Tremor"],"status":"active"},{"id":"65ced30c-d4ac-4283-9d53-595fe2d2d339","procedure_id":"proc-fus-tremor","jurisdiction_id":"jur-jm","procedure_name":"MR-Guided Focused Ultrasound for Essential Tremor / PD Tremor","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Essential Tremor","Parkinson's Disease Tremor"],"status":"active"},{"id":"4f9a995f-7ec5-4689-9b0a-52f63e632b90","procedure_id":"proc-fus-tremor","jurisdiction_id":"jur-th","procedure_name":"MR-Guided Focused Ultrasound for Essential Tremor / PD Tremor","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Thai FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Essential Tremor","Parkinson's Disease Tremor"],"status":"active"},{"id":"e4c513ed-59b3-4b2d-a43b-501c1e73a3b2","procedure_id":"proc-fus-tremor","jurisdiction_id":"jur-es","procedure_name":"MR-Guided Focused Ultrasound for Essential Tremor / PD Tremor","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"AEMPS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Essential Tremor","Parkinson's Disease Tremor"],"status":"active"},{"id":"7cf75a40-3630-4f3e-8767-35ff4d9eca67","procedure_id":"proc-fus-tremor","jurisdiction_id":"jur-tu","procedure_name":"MR-Guided Focused Ultrasound for Essential Tremor / PD Tremor","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Essential Tremor","Parkinson's Disease Tremor"],"status":"active"},{"id":"39d146c4-3317-407c-8bd1-d86b24538edc","procedure_id":"proc-fus-tremor","jurisdiction_id":"jur-in","procedure_name":"MR-Guided Focused Ultrasound for Essential Tremor / PD Tremor","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"CDSCO","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Essential Tremor","Parkinson's Disease Tremor"],"status":"active"},{"id":"48cf90e9-443d-4987-94b4-475a3de51bfd","procedure_id":"proc-fus-tremor","jurisdiction_id":"jur-br","procedure_name":"MR-Guided Focused Ultrasound for Essential Tremor / PD Tremor","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"ANVISA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Essential Tremor","Parkinson's Disease Tremor"],"status":"active"},{"id":"b74e3875-a262-40bd-ae13-23ae7c2caa54","procedure_id":"proc-fus-tremor","jurisdiction_id":"jur-cr","procedure_name":"MR-Guided Focused Ultrasound for Essential Tremor / PD Tremor","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Essential Tremor","Parkinson's Disease Tremor"],"status":"active"},{"id":"fc03d936-4682-4241-ba2d-4d55684bff03","procedure_id":"proc-fus-tremor","jurisdiction_id":"jur-uae","procedure_name":"MR-Guided Focused Ultrasound for Essential Tremor / PD Tremor","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Essential Tremor","Parkinson's Disease Tremor"],"status":"active"},{"id":"948446ee-93c9-4e7f-b6d2-d5bc6bcfdcad","procedure_id":"proc-fus-tremor","jurisdiction_id":"jur-kr","procedure_name":"MR-Guided Focused Ultrasound for Essential Tremor / PD Tremor","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"MFDS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Essential Tremor","Parkinson's Disease Tremor"],"status":"active"},{"id":"153da70b-e3bd-4502-b02b-f2bc092dcf3b","procedure_id":"proc-fus-tremor","jurisdiction_id":"jur-gr","procedure_name":"MR-Guided Focused Ultrasound for Essential Tremor / PD Tremor","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Essential Tremor","Parkinson's Disease Tremor"],"status":"active"},{"id":"867ee9ba-4f20-4930-ad51-b1081958f990","procedure_id":"proc-fus-tremor","jurisdiction_id":"jur-be","procedure_name":"MR-Guided Focused Ultrasound for Essential Tremor / PD Tremor","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Essential Tremor","Parkinson's Disease Tremor"],"status":"active"},{"id":"c7c77038-46f2-447f-bda2-5ce3af97144b","procedure_id":"proc-fus-tremor","jurisdiction_id":"jur-se","procedure_name":"MR-Guided Focused Ultrasound for Essential Tremor / PD Tremor","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Essential Tremor","Parkinson's Disease Tremor"],"status":"active"},{"id":"5229acd1-681a-444a-8451-882ec41c10e6","procedure_id":"proc-fus-tremor","jurisdiction_id":"jur-sg","procedure_name":"MR-Guided Focused Ultrasound for Essential Tremor / PD Tremor","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"HSA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Essential Tremor","Parkinson's Disease Tremor"],"status":"active"},{"id":"16b6ae4f-c988-4716-bdc5-7ee0b063d051","procedure_id":"proc-fus-tremor","jurisdiction_id":"jur-cl","procedure_name":"MR-Guided Focused Ultrasound for Essential Tremor / PD Tremor","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Essential Tremor","Parkinson's Disease Tremor"],"status":"active"},{"id":"f058e0e0-b2f7-4f12-8992-776a6b0cd1ae","procedure_id":"proc-fus-tremor","jurisdiction_id":"jur-ar","procedure_name":"MR-Guided Focused Ultrasound for Essential Tremor / PD Tremor","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Essential Tremor","Parkinson's Disease Tremor"],"status":"active"},{"id":"10282128-2a6c-488e-b29f-889df84e4998","procedure_id":"proc-fus-tremor","jurisdiction_id":"jur-za","procedure_name":"MR-Guided Focused Ultrasound for Essential Tremor / PD Tremor","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Essential Tremor","Parkinson's Disease Tremor"],"status":"active"},{"id":"c9f0479c-680a-45bf-9e00-0b9056795329","procedure_id":"proc-fus-tremor","jurisdiction_id":"jur-ph","procedure_name":"MR-Guided Focused Ultrasound for Essential Tremor / PD Tremor","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Essential Tremor","Parkinson's Disease Tremor"],"status":"active"},{"id":"907b4423-b313-406e-acb1-75db9d703311","procedure_id":"proc-fus-tremor","jurisdiction_id":"jur-po","procedure_name":"MR-Guided Focused Ultrasound for Essential Tremor / PD Tremor","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Essential Tremor","Parkinson's Disease Tremor"],"status":"active"},{"id":"3669a415-1a22-4135-8abe-88a4fcc8433b","procedure_id":"proc-fus-tremor","jurisdiction_id":"jur-pt","procedure_name":"MR-Guided Focused Ultrasound for Essential Tremor / PD Tremor","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Essential Tremor","Parkinson's Disease Tremor"],"status":"active"},{"id":"e219b251-25a0-4d05-86a4-74019d38018f","procedure_id":"proc-fus-tremor","jurisdiction_id":"jur-fr","procedure_name":"MR-Guided Focused Ultrasound for Essential Tremor / PD Tremor","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"ANSM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Movement_Disorders"],"diseases":["Essential Tremor","Parkinson's Disease Tremor"],"status":"active"},{"id":"a5aaf8c8-8632-4369-aaa8-507d0cfa99af","procedure_id":"proc-til-melanoma","jurisdiction_id":"jur-us-or","procedure_name":"Tumor-Infiltrating Lymphocyte (TIL) Therapy for Melanoma","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Melanoma"],"diseases":["Advanced Melanoma","Metastatic Melanoma"],"status":"active"},{"id":"abcb4e9f-ba26-42e8-9407-ce150e490f12","procedure_id":"proc-til-melanoma","jurisdiction_id":"jur-us-co","procedure_name":"Tumor-Infiltrating Lymphocyte (TIL) Therapy for Melanoma","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Melanoma"],"diseases":["Advanced Melanoma","Metastatic Melanoma"],"status":"active"},{"id":"8826c545-010e-4243-b05a-f53eef6d45a6","procedure_id":"proc-til-melanoma","jurisdiction_id":"jur-us-ca","procedure_name":"Tumor-Infiltrating Lymphocyte (TIL) Therapy for Melanoma","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Melanoma"],"diseases":["Advanced Melanoma","Metastatic Melanoma"],"status":"active"},{"id":"2359a268-dc2f-490a-adf5-d0f069b76594","procedure_id":"proc-til-melanoma","jurisdiction_id":"jur-us-tx","procedure_name":"Tumor-Infiltrating Lymphocyte (TIL) Therapy for Melanoma","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Melanoma"],"diseases":["Advanced Melanoma","Metastatic Melanoma"],"status":"active"},{"id":"e732ec94-ba95-4226-85df-036257c6d2a3","procedure_id":"proc-til-melanoma","jurisdiction_id":"jur-us-fl","procedure_name":"Tumor-Infiltrating Lymphocyte (TIL) Therapy for Melanoma","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Melanoma"],"diseases":["Advanced Melanoma","Metastatic Melanoma"],"status":"active"},{"id":"f4154acc-abc6-47cc-9cd5-1a126dc32385","procedure_id":"proc-til-melanoma","jurisdiction_id":"jur-au","procedure_name":"Tumor-Infiltrating Lymphocyte (TIL) Therapy for Melanoma","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"TGA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Melanoma"],"diseases":["Advanced Melanoma","Metastatic Melanoma"],"status":"active"},{"id":"ef9fae25-da85-46d5-a051-a14309c0aa14","procedure_id":"proc-til-melanoma","jurisdiction_id":"jur-ch","procedure_name":"Tumor-Infiltrating Lymphocyte (TIL) Therapy for Melanoma","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"Swissmedic","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Melanoma"],"diseases":["Advanced Melanoma","Metastatic Melanoma"],"status":"active"},{"id":"1e82eef3-0d62-42b6-874b-d6963c354cb1","procedure_id":"proc-til-melanoma","jurisdiction_id":"jur-ca","procedure_name":"Tumor-Infiltrating Lymphocyte (TIL) Therapy for Melanoma","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"Health Canada","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Melanoma"],"diseases":["Advanced Melanoma","Metastatic Melanoma"],"status":"active"},{"id":"b34ef308-4fe8-41dc-bcb1-b59df936ddbf","procedure_id":"proc-til-melanoma","jurisdiction_id":"jur-mx","procedure_name":"Tumor-Infiltrating Lymphocyte (TIL) Therapy for Melanoma","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"COFEPRIS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Melanoma"],"diseases":["Advanced Melanoma","Metastatic Melanoma"],"status":"active"},{"id":"80b9adb6-b31e-4edd-b340-6e9d547742b0","procedure_id":"proc-til-melanoma","jurisdiction_id":"jur-hn-prospera","procedure_name":"Tumor-Infiltrating Lymphocyte (TIL) Therapy for Melanoma","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"Próspera ZEDE health rules (contested)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Melanoma"],"diseases":["Advanced Melanoma","Metastatic Melanoma"],"status":"active"},{"id":"571ade74-3ee3-48d4-a0ba-13e8ee8f05fb","procedure_id":"proc-til-melanoma","jurisdiction_id":"jur-nl","procedure_name":"Tumor-Infiltrating Lymphocyte (TIL) Therapy for Melanoma","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"MEB / IGJ","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Melanoma"],"diseases":["Advanced Melanoma","Metastatic Melanoma"],"status":"active"},{"id":"6a1ada6d-32ba-42eb-8ed7-d01927a47118","procedure_id":"proc-til-melanoma","jurisdiction_id":"jur-uk","procedure_name":"Tumor-Infiltrating Lymphocyte (TIL) Therapy for Melanoma","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"MHRA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Melanoma"],"diseases":["Advanced Melanoma","Metastatic Melanoma"],"status":"active"},{"id":"0c1450d4-7de2-4d22-8ba8-3412b737e715","procedure_id":"proc-til-melanoma","jurisdiction_id":"jur-il","procedure_name":"Tumor-Infiltrating Lymphocyte (TIL) Therapy for Melanoma","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Melanoma"],"diseases":["Advanced Melanoma","Metastatic Melanoma"],"status":"active"},{"id":"e8d03a64-dae0-40e5-8771-1f7e05f8359d","procedure_id":"proc-til-melanoma","jurisdiction_id":"jur-jm","procedure_name":"Tumor-Infiltrating Lymphocyte (TIL) Therapy for Melanoma","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Melanoma"],"diseases":["Advanced Melanoma","Metastatic Melanoma"],"status":"active"},{"id":"47b4bf71-fc44-4672-b0b0-54b82085e38b","procedure_id":"proc-til-melanoma","jurisdiction_id":"jur-th","procedure_name":"Tumor-Infiltrating Lymphocyte (TIL) Therapy for Melanoma","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"Thai FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Melanoma"],"diseases":["Advanced Melanoma","Metastatic Melanoma"],"status":"active"},{"id":"39f134d8-ffdb-4196-a5ca-9a569021754f","procedure_id":"proc-til-melanoma","jurisdiction_id":"jur-es","procedure_name":"Tumor-Infiltrating Lymphocyte (TIL) Therapy for Melanoma","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"AEMPS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Melanoma"],"diseases":["Advanced Melanoma","Metastatic Melanoma"],"status":"active"},{"id":"0e733c9a-702d-41e0-ad00-5b027c71406b","procedure_id":"proc-til-melanoma","jurisdiction_id":"jur-tu","procedure_name":"Tumor-Infiltrating Lymphocyte (TIL) Therapy for Melanoma","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial centre pathway inferred.","eligibility_requirements":"Trial criteria.","provider_requirements":"Trial site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial-only for advanced cell/gene therapy.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: advanced cell/gene therapy without clear commercial authorization → trial-only default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Melanoma"],"diseases":["Advanced Melanoma","Metastatic Melanoma"],"status":"active"},{"id":"a6f021ed-73a1-4728-beb5-e5c4b2a0bacf","procedure_id":"proc-til-melanoma","jurisdiction_id":"jur-in","procedure_name":"Tumor-Infiltrating Lymphocyte (TIL) Therapy for Melanoma","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"CDSCO","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Melanoma"],"diseases":["Advanced Melanoma","Metastatic Melanoma"],"status":"active"},{"id":"7ca35f76-659b-458d-b12e-d06a2fe4fc7d","procedure_id":"proc-til-melanoma","jurisdiction_id":"jur-br","procedure_name":"Tumor-Infiltrating Lymphocyte (TIL) Therapy for Melanoma","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"ANVISA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Melanoma"],"diseases":["Advanced Melanoma","Metastatic Melanoma"],"status":"active"},{"id":"02baecf6-195f-4baa-94a5-56677980c953","procedure_id":"proc-til-melanoma","jurisdiction_id":"jur-cr","procedure_name":"Tumor-Infiltrating Lymphocyte (TIL) Therapy for Melanoma","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial centre pathway inferred.","eligibility_requirements":"Trial criteria.","provider_requirements":"Trial site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial-only for advanced cell/gene therapy.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: advanced cell/gene therapy without clear commercial authorization → trial-only default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Melanoma"],"diseases":["Advanced Melanoma","Metastatic Melanoma"],"status":"active"},{"id":"97025dd5-35f3-410c-ad27-175756d57aa2","procedure_id":"proc-til-melanoma","jurisdiction_id":"jur-uae","procedure_name":"Tumor-Infiltrating Lymphocyte (TIL) Therapy for Melanoma","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial centre pathway inferred.","eligibility_requirements":"Trial criteria.","provider_requirements":"Trial site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial-only for advanced cell/gene therapy.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: advanced cell/gene therapy without clear commercial authorization → trial-only default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Melanoma"],"diseases":["Advanced Melanoma","Metastatic Melanoma"],"status":"active"},{"id":"6e4ff75a-9ee3-4edc-b66e-36cea1944dc0","procedure_id":"proc-til-melanoma","jurisdiction_id":"jur-kr","procedure_name":"Tumor-Infiltrating Lymphocyte (TIL) Therapy for Melanoma","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"MFDS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Melanoma"],"diseases":["Advanced Melanoma","Metastatic Melanoma"],"status":"active"},{"id":"415834dd-e46f-49bc-bf78-8a07f018d14f","procedure_id":"proc-til-melanoma","jurisdiction_id":"jur-gr","procedure_name":"Tumor-Infiltrating Lymphocyte (TIL) Therapy for Melanoma","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial centre pathway inferred.","eligibility_requirements":"Trial criteria.","provider_requirements":"Trial site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial-only for advanced cell/gene therapy.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: advanced cell/gene therapy without clear commercial authorization → trial-only default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Melanoma"],"diseases":["Advanced Melanoma","Metastatic Melanoma"],"status":"active"},{"id":"5869071c-b447-4bfa-be54-b8f1defc1627","procedure_id":"proc-til-melanoma","jurisdiction_id":"jur-be","procedure_name":"Tumor-Infiltrating Lymphocyte (TIL) Therapy for Melanoma","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Melanoma"],"diseases":["Advanced Melanoma","Metastatic Melanoma"],"status":"active"},{"id":"92e7f938-5402-4fc1-a9c1-5ee011bc3971","procedure_id":"proc-til-melanoma","jurisdiction_id":"jur-se","procedure_name":"Tumor-Infiltrating Lymphocyte (TIL) Therapy for Melanoma","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial centre pathway inferred.","eligibility_requirements":"Trial criteria.","provider_requirements":"Trial site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial-only for advanced cell/gene therapy.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: advanced cell/gene therapy without clear commercial authorization → trial-only default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Melanoma"],"diseases":["Advanced Melanoma","Metastatic Melanoma"],"status":"active"},{"id":"8c6787e8-72ae-4178-96ee-60fbfb289d29","procedure_id":"proc-til-melanoma","jurisdiction_id":"jur-jp","procedure_name":"Tumor-Infiltrating Lymphocyte (TIL) Therapy for Melanoma","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"PMDA / MHLW","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Melanoma"],"diseases":["Advanced Melanoma","Metastatic Melanoma"],"status":"active"},{"id":"45e7d381-0f00-47b0-a085-878d43710e8b","procedure_id":"proc-til-melanoma","jurisdiction_id":"jur-sg","procedure_name":"Tumor-Infiltrating Lymphocyte (TIL) Therapy for Melanoma","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"HSA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Melanoma"],"diseases":["Advanced Melanoma","Metastatic Melanoma"],"status":"active"},{"id":"579f7a17-ad78-4ef7-9e96-2a4fd00a81c7","procedure_id":"proc-til-melanoma","jurisdiction_id":"jur-cl","procedure_name":"Tumor-Infiltrating Lymphocyte (TIL) Therapy for Melanoma","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial centre pathway inferred.","eligibility_requirements":"Trial criteria.","provider_requirements":"Trial site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial-only for advanced cell/gene therapy.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: advanced cell/gene therapy without clear commercial authorization → trial-only default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Melanoma"],"diseases":["Advanced Melanoma","Metastatic Melanoma"],"status":"active"},{"id":"f96a3180-dc08-402b-9dd7-fc830ecd2a2f","procedure_id":"proc-til-melanoma","jurisdiction_id":"jur-ar","procedure_name":"Tumor-Infiltrating Lymphocyte (TIL) Therapy for Melanoma","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial centre pathway inferred.","eligibility_requirements":"Trial criteria.","provider_requirements":"Trial site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial-only for advanced cell/gene therapy.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: advanced cell/gene therapy without clear commercial authorization → trial-only default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Melanoma"],"diseases":["Advanced Melanoma","Metastatic Melanoma"],"status":"active"},{"id":"9f00e7de-00df-49f7-bd21-3ef2011e9bd2","procedure_id":"proc-til-melanoma","jurisdiction_id":"jur-za","procedure_name":"Tumor-Infiltrating Lymphocyte (TIL) Therapy for Melanoma","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial centre pathway inferred.","eligibility_requirements":"Trial criteria.","provider_requirements":"Trial site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial-only for advanced cell/gene therapy.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: advanced cell/gene therapy without clear commercial authorization → trial-only default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Melanoma"],"diseases":["Advanced Melanoma","Metastatic Melanoma"],"status":"active"},{"id":"ce7b5860-f408-4a94-b7ed-c0aa40dddee0","procedure_id":"proc-til-melanoma","jurisdiction_id":"jur-ph","procedure_name":"Tumor-Infiltrating Lymphocyte (TIL) Therapy for Melanoma","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial centre pathway inferred.","eligibility_requirements":"Trial criteria.","provider_requirements":"Trial site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial-only for advanced cell/gene therapy.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: advanced cell/gene therapy without clear commercial authorization → trial-only default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Melanoma"],"diseases":["Advanced Melanoma","Metastatic Melanoma"],"status":"active"},{"id":"6ae535fe-9770-4a8c-a014-c5896fb6be60","procedure_id":"proc-til-melanoma","jurisdiction_id":"jur-po","procedure_name":"Tumor-Infiltrating Lymphocyte (TIL) Therapy for Melanoma","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial centre pathway inferred.","eligibility_requirements":"Trial criteria.","provider_requirements":"Trial site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial-only for advanced cell/gene therapy.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: advanced cell/gene therapy without clear commercial authorization → trial-only default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Melanoma"],"diseases":["Advanced Melanoma","Metastatic Melanoma"],"status":"active"},{"id":"7912c6bf-d5f0-44e2-959e-967982749461","procedure_id":"proc-til-melanoma","jurisdiction_id":"jur-pt","procedure_name":"Tumor-Infiltrating Lymphocyte (TIL) Therapy for Melanoma","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Melanoma"],"diseases":["Advanced Melanoma","Metastatic Melanoma"],"status":"active"},{"id":"114586ba-c227-4f06-a52c-abf01ef7cd89","procedure_id":"proc-til-melanoma","jurisdiction_id":"jur-fr","procedure_name":"Tumor-Infiltrating Lymphocyte (TIL) Therapy for Melanoma","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"FULLY_APPROVED","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Very high — product + inpatient (not estimated here)","price_usd":null,"access_pathway_details":"Inferred hospital/centre-only delivery. Product-specific authorization and REMS/centre networks usually required.","eligibility_requirements":"Labeled indication + centre eligibility.","provider_requirements":"Manufacturer-authorized / FACT-class centre; hospital privileges.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: authorized treatment-centre pathway in regulated markets — not outpatient startup.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: commercial ATMP/gene-therapy products are typically authorized only via national regulator + designated centres in ICH-class systems.","regulatory_authority":"ANSM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology","Melanoma"],"diseases":["Advanced Melanoma","Metastatic Melanoma"],"status":"active"},{"id":"e935854f-ca25-4d33-9aa0-1447547def8e","procedure_id":"proc-car-t-solid","jurisdiction_id":"jur-us-or","procedure_name":"Experimental CAR-T / TCR Therapy for Solid Tumors","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Advanced Solid Tumors","Gastric Cancer (trial)","Neuroblastoma (trial)"],"status":"active"},{"id":"35a38a1f-c13f-4eae-ab5f-1ddb38708a5a","procedure_id":"proc-car-t-solid","jurisdiction_id":"jur-us-co","procedure_name":"Experimental CAR-T / TCR Therapy for Solid Tumors","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Advanced Solid Tumors","Gastric Cancer (trial)","Neuroblastoma (trial)"],"status":"active"},{"id":"ee3a15d1-f530-4e64-8914-625bdaffee48","procedure_id":"proc-car-t-solid","jurisdiction_id":"jur-us-ca","procedure_name":"Experimental CAR-T / TCR Therapy for Solid Tumors","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Advanced Solid Tumors","Gastric Cancer (trial)","Neuroblastoma (trial)"],"status":"active"},{"id":"bbd7ee04-c97b-4f61-b744-a5e50e792aa6","procedure_id":"proc-car-t-solid","jurisdiction_id":"jur-us-tx","procedure_name":"Experimental CAR-T / TCR Therapy for Solid Tumors","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Advanced Solid Tumors","Gastric Cancer (trial)","Neuroblastoma (trial)"],"status":"active"},{"id":"e13102a5-efb4-464b-a4c4-771fbba6f690","procedure_id":"proc-car-t-solid","jurisdiction_id":"jur-us-fl","procedure_name":"Experimental CAR-T / TCR Therapy for Solid Tumors","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Advanced Solid Tumors","Gastric Cancer (trial)","Neuroblastoma (trial)"],"status":"active"},{"id":"cee8b092-35de-4b04-b9ba-3f9675e81330","procedure_id":"proc-car-t-solid","jurisdiction_id":"jur-au","procedure_name":"Experimental CAR-T / TCR Therapy for Solid Tumors","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"TGA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Advanced Solid Tumors","Gastric Cancer (trial)","Neuroblastoma (trial)"],"status":"active"},{"id":"14ab464a-c76b-460f-8323-2e53edaa11d8","procedure_id":"proc-car-t-solid","jurisdiction_id":"jur-ch","procedure_name":"Experimental CAR-T / TCR Therapy for Solid Tumors","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"Swissmedic","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Advanced Solid Tumors","Gastric Cancer (trial)","Neuroblastoma (trial)"],"status":"active"},{"id":"f46b5c89-bf62-4ad0-9a9b-48eaf0643c4e","procedure_id":"proc-car-t-solid","jurisdiction_id":"jur-ca","procedure_name":"Experimental CAR-T / TCR Therapy for Solid Tumors","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"Health Canada","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Advanced Solid Tumors","Gastric Cancer (trial)","Neuroblastoma (trial)"],"status":"active"},{"id":"eb8a1501-6120-4b7e-812f-d65f54d93345","procedure_id":"proc-car-t-solid","jurisdiction_id":"jur-mx","procedure_name":"Experimental CAR-T / TCR Therapy for Solid Tumors","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"COFEPRIS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Advanced Solid Tumors","Gastric Cancer (trial)","Neuroblastoma (trial)"],"status":"active"},{"id":"5e8d9914-9842-4b84-8b4f-2f8ebf662534","procedure_id":"proc-car-t-solid","jurisdiction_id":"jur-hn-prospera","procedure_name":"Experimental CAR-T / TCR Therapy for Solid Tumors","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"Próspera ZEDE health rules (contested)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Advanced Solid Tumors","Gastric Cancer (trial)","Neuroblastoma (trial)"],"status":"active"},{"id":"e2156545-bd86-4691-a0d3-df58e02b107c","procedure_id":"proc-car-t-solid","jurisdiction_id":"jur-nl","procedure_name":"Experimental CAR-T / TCR Therapy for Solid Tumors","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"MEB / IGJ","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Advanced Solid Tumors","Gastric Cancer (trial)","Neuroblastoma (trial)"],"status":"active"},{"id":"6d08f935-aec2-4ad0-bcf4-46a299c221a2","procedure_id":"proc-car-t-solid","jurisdiction_id":"jur-de","procedure_name":"Experimental CAR-T / TCR Therapy for Solid Tumors","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"BfArM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Advanced Solid Tumors","Gastric Cancer (trial)","Neuroblastoma (trial)"],"status":"active"},{"id":"11a98bc1-3fb1-4c31-8181-120a595d5ba7","procedure_id":"proc-car-t-solid","jurisdiction_id":"jur-uk","procedure_name":"Experimental CAR-T / TCR Therapy for Solid Tumors","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"MHRA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Advanced Solid Tumors","Gastric Cancer (trial)","Neuroblastoma (trial)"],"status":"active"},{"id":"aec4b025-f1b6-4ee5-be0d-48f03e3b786f","procedure_id":"proc-car-t-solid","jurisdiction_id":"jur-il","procedure_name":"Experimental CAR-T / TCR Therapy for Solid Tumors","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Advanced Solid Tumors","Gastric Cancer (trial)","Neuroblastoma (trial)"],"status":"active"},{"id":"97f31f7b-a4f1-4517-b701-e06c6d2645d3","procedure_id":"proc-car-t-solid","jurisdiction_id":"jur-jm","procedure_name":"Experimental CAR-T / TCR Therapy for Solid Tumors","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Advanced Solid Tumors","Gastric Cancer (trial)","Neuroblastoma (trial)"],"status":"active"},{"id":"f39053df-5a31-4a22-a30d-4ca58db179f7","procedure_id":"proc-car-t-solid","jurisdiction_id":"jur-th","procedure_name":"Experimental CAR-T / TCR Therapy for Solid Tumors","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"Thai FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Advanced Solid Tumors","Gastric Cancer (trial)","Neuroblastoma (trial)"],"status":"active"},{"id":"3e2cfa08-ae35-42e3-84f4-913ee7f339f1","procedure_id":"proc-car-t-solid","jurisdiction_id":"jur-es","procedure_name":"Experimental CAR-T / TCR Therapy for Solid Tumors","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"AEMPS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Advanced Solid Tumors","Gastric Cancer (trial)","Neuroblastoma (trial)"],"status":"active"},{"id":"4003b849-f8da-4c77-99d0-f80d07fb9e23","procedure_id":"proc-car-t-solid","jurisdiction_id":"jur-tu","procedure_name":"Experimental CAR-T / TCR Therapy for Solid Tumors","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Advanced Solid Tumors","Gastric Cancer (trial)","Neuroblastoma (trial)"],"status":"active"},{"id":"ab692185-2348-4912-8726-776058fe4d8d","procedure_id":"proc-car-t-solid","jurisdiction_id":"jur-in","procedure_name":"Experimental CAR-T / TCR Therapy for Solid Tumors","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"CDSCO","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Advanced Solid Tumors","Gastric Cancer (trial)","Neuroblastoma (trial)"],"status":"active"},{"id":"1e58cfd8-b4a3-44cb-846b-c8fb98dfc1e2","procedure_id":"proc-car-t-solid","jurisdiction_id":"jur-br","procedure_name":"Experimental CAR-T / TCR Therapy for Solid Tumors","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"ANVISA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Advanced Solid Tumors","Gastric Cancer (trial)","Neuroblastoma (trial)"],"status":"active"},{"id":"979010b4-1299-45de-a048-aec1862311fd","procedure_id":"proc-car-t-solid","jurisdiction_id":"jur-cr","procedure_name":"Experimental CAR-T / TCR Therapy for Solid Tumors","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Advanced Solid Tumors","Gastric Cancer (trial)","Neuroblastoma (trial)"],"status":"active"},{"id":"993c3b2c-36df-4588-8133-3294854f8165","procedure_id":"proc-car-t-solid","jurisdiction_id":"jur-uae","procedure_name":"Experimental CAR-T / TCR Therapy for Solid Tumors","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Advanced Solid Tumors","Gastric Cancer (trial)","Neuroblastoma (trial)"],"status":"active"},{"id":"1c299b39-633c-407b-9a1e-9c4ad1b88ca6","procedure_id":"proc-car-t-solid","jurisdiction_id":"jur-gr","procedure_name":"Experimental CAR-T / TCR Therapy for Solid Tumors","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Advanced Solid Tumors","Gastric Cancer (trial)","Neuroblastoma (trial)"],"status":"active"},{"id":"e58f58fc-660c-4b3e-b505-1cee2096e8a3","procedure_id":"proc-car-t-solid","jurisdiction_id":"jur-be","procedure_name":"Experimental CAR-T / TCR Therapy for Solid Tumors","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Advanced Solid Tumors","Gastric Cancer (trial)","Neuroblastoma (trial)"],"status":"active"},{"id":"30a38a57-d2e3-4094-8b52-3666a15b028d","procedure_id":"proc-car-t-solid","jurisdiction_id":"jur-se","procedure_name":"Experimental CAR-T / TCR Therapy for Solid Tumors","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Advanced Solid Tumors","Gastric Cancer (trial)","Neuroblastoma (trial)"],"status":"active"},{"id":"0bb26f20-13d5-4734-8d15-0e49526cad34","procedure_id":"proc-car-t-solid","jurisdiction_id":"jur-sg","procedure_name":"Experimental CAR-T / TCR Therapy for Solid Tumors","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"HSA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Advanced Solid Tumors","Gastric Cancer (trial)","Neuroblastoma (trial)"],"status":"active"},{"id":"7ccbb767-23e5-4155-8460-5794b734c6a5","procedure_id":"proc-car-t-solid","jurisdiction_id":"jur-cl","procedure_name":"Experimental CAR-T / TCR Therapy for Solid Tumors","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Advanced Solid Tumors","Gastric Cancer (trial)","Neuroblastoma (trial)"],"status":"active"},{"id":"07deda57-b7a6-457e-9a15-776cb1567b8d","procedure_id":"proc-car-t-solid","jurisdiction_id":"jur-ar","procedure_name":"Experimental CAR-T / TCR Therapy for Solid Tumors","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Advanced Solid Tumors","Gastric Cancer (trial)","Neuroblastoma (trial)"],"status":"active"},{"id":"4250d9f6-7fc4-4f70-9297-701e35185f0e","procedure_id":"proc-car-t-solid","jurisdiction_id":"jur-za","procedure_name":"Experimental CAR-T / TCR Therapy for Solid Tumors","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Advanced Solid Tumors","Gastric Cancer (trial)","Neuroblastoma (trial)"],"status":"active"},{"id":"cc421d20-0b95-41ff-88c4-48612d15ee1c","procedure_id":"proc-car-t-solid","jurisdiction_id":"jur-ph","procedure_name":"Experimental CAR-T / TCR Therapy for Solid Tumors","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Advanced Solid Tumors","Gastric Cancer (trial)","Neuroblastoma (trial)"],"status":"active"},{"id":"010b9016-b07f-4921-ad1d-4a1729efac73","procedure_id":"proc-car-t-solid","jurisdiction_id":"jur-po","procedure_name":"Experimental CAR-T / TCR Therapy for Solid Tumors","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Advanced Solid Tumors","Gastric Cancer (trial)","Neuroblastoma (trial)"],"status":"active"},{"id":"80263bf7-367d-431c-a2d1-233ff7ebe1ea","procedure_id":"proc-car-t-solid","jurisdiction_id":"jur-pt","procedure_name":"Experimental CAR-T / TCR Therapy for Solid Tumors","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Advanced Solid Tumors","Gastric Cancer (trial)","Neuroblastoma (trial)"],"status":"active"},{"id":"287bab4c-dd61-477c-911c-3222e8d89e90","procedure_id":"proc-car-t-solid","jurisdiction_id":"jur-fr","procedure_name":"Experimental CAR-T / TCR Therapy for Solid Tumors","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"ANSM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Advanced Solid Tumors","Gastric Cancer (trial)","Neuroblastoma (trial)"],"status":"active"},{"id":"6026dee5-6543-483c-9d54-8231dd91b724","procedure_id":"proc-dendritic-vaccine","jurisdiction_id":"jur-us-or","procedure_name":"Dendritic Cell Cancer Vaccines (Personalized)","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Metastatic Castration-Resistant Prostate Cancer","Solid Tumors (clinic variable)"],"status":"active"},{"id":"3871fad1-4737-4669-b1cf-3c087bc4b43e","procedure_id":"proc-dendritic-vaccine","jurisdiction_id":"jur-us-co","procedure_name":"Dendritic Cell Cancer Vaccines (Personalized)","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Metastatic Castration-Resistant Prostate Cancer","Solid Tumors (clinic variable)"],"status":"active"},{"id":"e3a8a47e-753a-4c7e-a252-3849c197e3fd","procedure_id":"proc-dendritic-vaccine","jurisdiction_id":"jur-us-ca","procedure_name":"Dendritic Cell Cancer Vaccines (Personalized)","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Metastatic Castration-Resistant Prostate Cancer","Solid Tumors (clinic variable)"],"status":"active"},{"id":"94484cee-3e09-4702-b56f-27861029a675","procedure_id":"proc-dendritic-vaccine","jurisdiction_id":"jur-us-tx","procedure_name":"Dendritic Cell Cancer Vaccines (Personalized)","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Metastatic Castration-Resistant Prostate Cancer","Solid Tumors (clinic variable)"],"status":"active"},{"id":"c5ec986c-6d7b-46c3-b3b2-4f1235c48a00","procedure_id":"proc-dendritic-vaccine","jurisdiction_id":"jur-us-fl","procedure_name":"Dendritic Cell Cancer Vaccines (Personalized)","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Metastatic Castration-Resistant Prostate Cancer","Solid Tumors (clinic variable)"],"status":"active"},{"id":"ec6f2068-6eac-4538-831b-c8982c6309a0","procedure_id":"proc-dendritic-vaccine","jurisdiction_id":"jur-au","procedure_name":"Dendritic Cell Cancer Vaccines (Personalized)","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"TGA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Metastatic Castration-Resistant Prostate Cancer","Solid Tumors (clinic variable)"],"status":"active"},{"id":"5e244577-d83c-4bed-8d7a-05d639666cfa","procedure_id":"proc-dendritic-vaccine","jurisdiction_id":"jur-ch","procedure_name":"Dendritic Cell Cancer Vaccines (Personalized)","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"Swissmedic","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Metastatic Castration-Resistant Prostate Cancer","Solid Tumors (clinic variable)"],"status":"active"},{"id":"c627fca7-2869-495c-aeaf-31ec04dbf57b","procedure_id":"proc-dendritic-vaccine","jurisdiction_id":"jur-ca","procedure_name":"Dendritic Cell Cancer Vaccines (Personalized)","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"Health Canada","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Metastatic Castration-Resistant Prostate Cancer","Solid Tumors (clinic variable)"],"status":"active"},{"id":"2bc0e8cc-c891-4179-98e7-38b86de2ab29","procedure_id":"proc-dendritic-vaccine","jurisdiction_id":"jur-hn-prospera","procedure_name":"Dendritic Cell Cancer Vaccines (Personalized)","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"Próspera ZEDE health rules (contested)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Metastatic Castration-Resistant Prostate Cancer","Solid Tumors (clinic variable)"],"status":"active"},{"id":"825541d7-dbd3-4e5a-8099-0f64e8c8840e","procedure_id":"proc-dendritic-vaccine","jurisdiction_id":"jur-nl","procedure_name":"Dendritic Cell Cancer Vaccines (Personalized)","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"MEB / IGJ","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Metastatic Castration-Resistant Prostate Cancer","Solid Tumors (clinic variable)"],"status":"active"},{"id":"a53e8649-6ca3-43c8-9c50-a0539dfa5ac1","procedure_id":"proc-dendritic-vaccine","jurisdiction_id":"jur-uk","procedure_name":"Dendritic Cell Cancer Vaccines (Personalized)","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"MHRA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Metastatic Castration-Resistant Prostate Cancer","Solid Tumors (clinic variable)"],"status":"active"},{"id":"decc3fb5-819b-439e-ad57-7821e4f495b4","procedure_id":"proc-dendritic-vaccine","jurisdiction_id":"jur-il","procedure_name":"Dendritic Cell Cancer Vaccines (Personalized)","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Metastatic Castration-Resistant Prostate Cancer","Solid Tumors (clinic variable)"],"status":"active"},{"id":"6f722d25-5f5d-4dfd-8843-54a42b85503f","procedure_id":"proc-dendritic-vaccine","jurisdiction_id":"jur-jm","procedure_name":"Dendritic Cell Cancer Vaccines (Personalized)","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Metastatic Castration-Resistant Prostate Cancer","Solid Tumors (clinic variable)"],"status":"active"},{"id":"8c924073-691c-4a12-8e19-828cf0525ace","procedure_id":"proc-dendritic-vaccine","jurisdiction_id":"jur-th","procedure_name":"Dendritic Cell Cancer Vaccines (Personalized)","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"Thai FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Metastatic Castration-Resistant Prostate Cancer","Solid Tumors (clinic variable)"],"status":"active"},{"id":"bfa4e2cd-0c7d-4ed6-a860-89aea80144ba","procedure_id":"proc-dendritic-vaccine","jurisdiction_id":"jur-es","procedure_name":"Dendritic Cell Cancer Vaccines (Personalized)","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"AEMPS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Metastatic Castration-Resistant Prostate Cancer","Solid Tumors (clinic variable)"],"status":"active"},{"id":"9d84263c-f73a-425f-8989-56e456a9f08d","procedure_id":"proc-dendritic-vaccine","jurisdiction_id":"jur-tu","procedure_name":"Dendritic Cell Cancer Vaccines (Personalized)","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Metastatic Castration-Resistant Prostate Cancer","Solid Tumors (clinic variable)"],"status":"active"},{"id":"d1516625-fa23-47bf-9b79-8369496942ab","procedure_id":"proc-dendritic-vaccine","jurisdiction_id":"jur-in","procedure_name":"Dendritic Cell Cancer Vaccines (Personalized)","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"CDSCO","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Metastatic Castration-Resistant Prostate Cancer","Solid Tumors (clinic variable)"],"status":"active"},{"id":"fb24cb6c-00aa-4192-abf3-65161328ae91","procedure_id":"proc-dendritic-vaccine","jurisdiction_id":"jur-br","procedure_name":"Dendritic Cell Cancer Vaccines (Personalized)","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"ANVISA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Metastatic Castration-Resistant Prostate Cancer","Solid Tumors (clinic variable)"],"status":"active"},{"id":"3295f6a8-ec88-487d-8dfa-ee412df28c80","procedure_id":"proc-dendritic-vaccine","jurisdiction_id":"jur-cr","procedure_name":"Dendritic Cell Cancer Vaccines (Personalized)","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Metastatic Castration-Resistant Prostate Cancer","Solid Tumors (clinic variable)"],"status":"active"},{"id":"6d1f2503-0872-418c-b830-2cac457c8148","procedure_id":"proc-dendritic-vaccine","jurisdiction_id":"jur-uae","procedure_name":"Dendritic Cell Cancer Vaccines (Personalized)","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Metastatic Castration-Resistant Prostate Cancer","Solid Tumors (clinic variable)"],"status":"active"},{"id":"26ee5d53-3862-44c4-a7c9-a60d477156d8","procedure_id":"proc-dendritic-vaccine","jurisdiction_id":"jur-kr","procedure_name":"Dendritic Cell Cancer Vaccines (Personalized)","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"MFDS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Metastatic Castration-Resistant Prostate Cancer","Solid Tumors (clinic variable)"],"status":"active"},{"id":"bd5f89c1-59b9-4de1-b99b-719ef9e58275","procedure_id":"proc-dendritic-vaccine","jurisdiction_id":"jur-gr","procedure_name":"Dendritic Cell Cancer Vaccines (Personalized)","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Metastatic Castration-Resistant Prostate Cancer","Solid Tumors (clinic variable)"],"status":"active"},{"id":"038b3bd4-c471-427b-85b1-bfec65e15638","procedure_id":"proc-dendritic-vaccine","jurisdiction_id":"jur-be","procedure_name":"Dendritic Cell Cancer Vaccines (Personalized)","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Metastatic Castration-Resistant Prostate Cancer","Solid Tumors (clinic variable)"],"status":"active"},{"id":"40f44448-83e2-42fd-a179-5ec16a9e5831","procedure_id":"proc-dendritic-vaccine","jurisdiction_id":"jur-se","procedure_name":"Dendritic Cell Cancer Vaccines (Personalized)","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Metastatic Castration-Resistant Prostate Cancer","Solid Tumors (clinic variable)"],"status":"active"},{"id":"0738e3e9-ed5d-4636-8fc9-cd52127d72c8","procedure_id":"proc-dendritic-vaccine","jurisdiction_id":"jur-jp","procedure_name":"Dendritic Cell Cancer Vaccines (Personalized)","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"PMDA / MHLW","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Metastatic Castration-Resistant Prostate Cancer","Solid Tumors (clinic variable)"],"status":"active"},{"id":"6e439435-ed33-422d-a26f-b60727024524","procedure_id":"proc-dendritic-vaccine","jurisdiction_id":"jur-sg","procedure_name":"Dendritic Cell Cancer Vaccines (Personalized)","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"HSA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Metastatic Castration-Resistant Prostate Cancer","Solid Tumors (clinic variable)"],"status":"active"},{"id":"b26ed85d-8efa-4b38-b5af-a82eea947c15","procedure_id":"proc-dendritic-vaccine","jurisdiction_id":"jur-cl","procedure_name":"Dendritic Cell Cancer Vaccines (Personalized)","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Metastatic Castration-Resistant Prostate Cancer","Solid Tumors (clinic variable)"],"status":"active"},{"id":"df7de17c-d20e-47d9-9fad-7ea8f67d9e74","procedure_id":"proc-dendritic-vaccine","jurisdiction_id":"jur-ar","procedure_name":"Dendritic Cell Cancer Vaccines (Personalized)","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Metastatic Castration-Resistant Prostate Cancer","Solid Tumors (clinic variable)"],"status":"active"},{"id":"24808a8f-6afd-41f2-b1a3-e821009037f0","procedure_id":"proc-dendritic-vaccine","jurisdiction_id":"jur-za","procedure_name":"Dendritic Cell Cancer Vaccines (Personalized)","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Metastatic Castration-Resistant Prostate Cancer","Solid Tumors (clinic variable)"],"status":"active"},{"id":"2b15e9aa-b0d5-4be4-a77b-f5a77ed25acd","procedure_id":"proc-dendritic-vaccine","jurisdiction_id":"jur-ph","procedure_name":"Dendritic Cell Cancer Vaccines (Personalized)","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Metastatic Castration-Resistant Prostate Cancer","Solid Tumors (clinic variable)"],"status":"active"},{"id":"0affcfc7-025c-433a-b360-2b2838907309","procedure_id":"proc-dendritic-vaccine","jurisdiction_id":"jur-po","procedure_name":"Dendritic Cell Cancer Vaccines (Personalized)","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Metastatic Castration-Resistant Prostate Cancer","Solid Tumors (clinic variable)"],"status":"active"},{"id":"5138f1d4-65a0-4364-9a86-593b9742ccaa","procedure_id":"proc-dendritic-vaccine","jurisdiction_id":"jur-pt","procedure_name":"Dendritic Cell Cancer Vaccines (Personalized)","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Metastatic Castration-Resistant Prostate Cancer","Solid Tumors (clinic variable)"],"status":"active"},{"id":"e7c63ddb-0484-42ed-b2c3-ebd873dbf0d4","procedure_id":"proc-dendritic-vaccine","jurisdiction_id":"jur-fr","procedure_name":"Dendritic Cell Cancer Vaccines (Personalized)","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"ANSM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Metastatic Castration-Resistant Prostate Cancer","Solid Tumors (clinic variable)"],"status":"active"},{"id":"04ee35a3-03e6-442b-ab5c-fa2f9676749e","procedure_id":"proc-apheresis-longcovid","jurisdiction_id":"jur-us-or","procedure_name":"Therapeutic Apheresis / HELP Apheresis for Long COVID & Microclot Protocols","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Long_COVID","Cardiovascular"],"diseases":["Long COVID","ME/CFS-like Post-Viral Syndrome","Hyperviscosity Syndromes (labeled apheresis)"],"status":"active"},{"id":"172d45fe-2d4d-4cbe-ae70-5306b82ca0ee","procedure_id":"proc-apheresis-longcovid","jurisdiction_id":"jur-us-co","procedure_name":"Therapeutic Apheresis / HELP Apheresis for Long COVID & Microclot Protocols","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Long_COVID","Cardiovascular"],"diseases":["Long COVID","ME/CFS-like Post-Viral Syndrome","Hyperviscosity Syndromes (labeled apheresis)"],"status":"active"},{"id":"1321831f-d255-49e9-9791-b0b33995c6dd","procedure_id":"proc-apheresis-longcovid","jurisdiction_id":"jur-us-ca","procedure_name":"Therapeutic Apheresis / HELP Apheresis for Long COVID & Microclot Protocols","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Long_COVID","Cardiovascular"],"diseases":["Long COVID","ME/CFS-like Post-Viral Syndrome","Hyperviscosity Syndromes (labeled apheresis)"],"status":"active"},{"id":"426c4421-a956-4d4c-b829-99e46bd93dfc","procedure_id":"proc-apheresis-longcovid","jurisdiction_id":"jur-us-tx","procedure_name":"Therapeutic Apheresis / HELP Apheresis for Long COVID & Microclot Protocols","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Long_COVID","Cardiovascular"],"diseases":["Long COVID","ME/CFS-like Post-Viral Syndrome","Hyperviscosity Syndromes (labeled apheresis)"],"status":"active"},{"id":"e6f99323-1fa0-46d9-91c2-2571ab474f27","procedure_id":"proc-apheresis-longcovid","jurisdiction_id":"jur-us-fl","procedure_name":"Therapeutic Apheresis / HELP Apheresis for Long COVID & Microclot Protocols","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Long_COVID","Cardiovascular"],"diseases":["Long COVID","ME/CFS-like Post-Viral Syndrome","Hyperviscosity Syndromes (labeled apheresis)"],"status":"active"},{"id":"8cc76b0b-e61b-487d-aeef-d6c467ed76a9","procedure_id":"proc-apheresis-longcovid","jurisdiction_id":"jur-au","procedure_name":"Therapeutic Apheresis / HELP Apheresis for Long COVID & Microclot Protocols","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"TGA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Long_COVID","Cardiovascular"],"diseases":["Long COVID","ME/CFS-like Post-Viral Syndrome","Hyperviscosity Syndromes (labeled apheresis)"],"status":"active"},{"id":"c2ef55ca-6a5c-48b3-bca6-b582267cc76d","procedure_id":"proc-apheresis-longcovid","jurisdiction_id":"jur-ca","procedure_name":"Therapeutic Apheresis / HELP Apheresis for Long COVID & Microclot Protocols","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"Health Canada","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Long_COVID","Cardiovascular"],"diseases":["Long COVID","ME/CFS-like Post-Viral Syndrome","Hyperviscosity Syndromes (labeled apheresis)"],"status":"active"},{"id":"dd94d0f5-5c4e-44ee-8362-72ad3c6acf8b","procedure_id":"proc-apheresis-longcovid","jurisdiction_id":"jur-mx","procedure_name":"Therapeutic Apheresis / HELP Apheresis for Long COVID & Microclot Protocols","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"COFEPRIS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Long_COVID","Cardiovascular"],"diseases":["Long COVID","ME/CFS-like Post-Viral Syndrome","Hyperviscosity Syndromes (labeled apheresis)"],"status":"active"},{"id":"efd78b16-f54e-44d1-b9eb-e4944bef3090","procedure_id":"proc-apheresis-longcovid","jurisdiction_id":"jur-hn-prospera","procedure_name":"Therapeutic Apheresis / HELP Apheresis for Long COVID & Microclot Protocols","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"Próspera ZEDE health rules (contested)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Long_COVID","Cardiovascular"],"diseases":["Long COVID","ME/CFS-like Post-Viral Syndrome","Hyperviscosity Syndromes (labeled apheresis)"],"status":"active"},{"id":"80b7a372-39e6-4854-b59b-2a0637429783","procedure_id":"proc-apheresis-longcovid","jurisdiction_id":"jur-nl","procedure_name":"Therapeutic Apheresis / HELP Apheresis for Long COVID & Microclot Protocols","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"MEB / IGJ","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Long_COVID","Cardiovascular"],"diseases":["Long COVID","ME/CFS-like Post-Viral Syndrome","Hyperviscosity Syndromes (labeled apheresis)"],"status":"active"},{"id":"4e1a63cc-12a9-4814-91d3-dac9d49ce9e8","procedure_id":"proc-apheresis-longcovid","jurisdiction_id":"jur-uk","procedure_name":"Therapeutic Apheresis / HELP Apheresis for Long COVID & Microclot Protocols","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"MHRA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Long_COVID","Cardiovascular"],"diseases":["Long COVID","ME/CFS-like Post-Viral Syndrome","Hyperviscosity Syndromes (labeled apheresis)"],"status":"active"},{"id":"f86d5d74-1599-4a28-9a9e-2e4427df79eb","procedure_id":"proc-apheresis-longcovid","jurisdiction_id":"jur-il","procedure_name":"Therapeutic Apheresis / HELP Apheresis for Long COVID & Microclot Protocols","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Long_COVID","Cardiovascular"],"diseases":["Long COVID","ME/CFS-like Post-Viral Syndrome","Hyperviscosity Syndromes (labeled apheresis)"],"status":"active"},{"id":"58060dd1-9595-4bcf-84c6-79e23f35b6aa","procedure_id":"proc-apheresis-longcovid","jurisdiction_id":"jur-jm","procedure_name":"Therapeutic Apheresis / HELP Apheresis for Long COVID & Microclot Protocols","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Long_COVID","Cardiovascular"],"diseases":["Long COVID","ME/CFS-like Post-Viral Syndrome","Hyperviscosity Syndromes (labeled apheresis)"],"status":"active"},{"id":"c8236c59-9489-4262-94cc-b315de03b3c7","procedure_id":"proc-apheresis-longcovid","jurisdiction_id":"jur-th","procedure_name":"Therapeutic Apheresis / HELP Apheresis for Long COVID & Microclot Protocols","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"Thai FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Long_COVID","Cardiovascular"],"diseases":["Long COVID","ME/CFS-like Post-Viral Syndrome","Hyperviscosity Syndromes (labeled apheresis)"],"status":"active"},{"id":"2744950e-f195-4412-98d0-e618051baaf6","procedure_id":"proc-apheresis-longcovid","jurisdiction_id":"jur-es","procedure_name":"Therapeutic Apheresis / HELP Apheresis for Long COVID & Microclot Protocols","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"AEMPS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Long_COVID","Cardiovascular"],"diseases":["Long COVID","ME/CFS-like Post-Viral Syndrome","Hyperviscosity Syndromes (labeled apheresis)"],"status":"active"},{"id":"b1cbc276-8cef-4297-98dc-3fdcd34123e4","procedure_id":"proc-apheresis-longcovid","jurisdiction_id":"jur-tu","procedure_name":"Therapeutic Apheresis / HELP Apheresis for Long COVID & Microclot Protocols","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Long_COVID","Cardiovascular"],"diseases":["Long COVID","ME/CFS-like Post-Viral Syndrome","Hyperviscosity Syndromes (labeled apheresis)"],"status":"active"},{"id":"857b7552-b5f8-4138-ad17-617ee4463f3a","procedure_id":"proc-apheresis-longcovid","jurisdiction_id":"jur-in","procedure_name":"Therapeutic Apheresis / HELP Apheresis for Long COVID & Microclot Protocols","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"CDSCO","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Long_COVID","Cardiovascular"],"diseases":["Long COVID","ME/CFS-like Post-Viral Syndrome","Hyperviscosity Syndromes (labeled apheresis)"],"status":"active"},{"id":"00e712a4-23bb-4d87-a66f-8224be6d3347","procedure_id":"proc-apheresis-longcovid","jurisdiction_id":"jur-br","procedure_name":"Therapeutic Apheresis / HELP Apheresis for Long COVID & Microclot Protocols","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"ANVISA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Long_COVID","Cardiovascular"],"diseases":["Long COVID","ME/CFS-like Post-Viral Syndrome","Hyperviscosity Syndromes (labeled apheresis)"],"status":"active"},{"id":"12e60f57-997a-4e29-bdab-a1ac827c02ba","procedure_id":"proc-apheresis-longcovid","jurisdiction_id":"jur-cr","procedure_name":"Therapeutic Apheresis / HELP Apheresis for Long COVID & Microclot Protocols","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Long_COVID","Cardiovascular"],"diseases":["Long COVID","ME/CFS-like Post-Viral Syndrome","Hyperviscosity Syndromes (labeled apheresis)"],"status":"active"},{"id":"a0f31a1c-a46f-483d-8dc4-407d8c42522b","procedure_id":"proc-apheresis-longcovid","jurisdiction_id":"jur-uae","procedure_name":"Therapeutic Apheresis / HELP Apheresis for Long COVID & Microclot Protocols","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Long_COVID","Cardiovascular"],"diseases":["Long COVID","ME/CFS-like Post-Viral Syndrome","Hyperviscosity Syndromes (labeled apheresis)"],"status":"active"},{"id":"d4125c0a-8312-42d4-b213-578b789741cc","procedure_id":"proc-apheresis-longcovid","jurisdiction_id":"jur-kr","procedure_name":"Therapeutic Apheresis / HELP Apheresis for Long COVID & Microclot Protocols","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"MFDS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Long_COVID","Cardiovascular"],"diseases":["Long COVID","ME/CFS-like Post-Viral Syndrome","Hyperviscosity Syndromes (labeled apheresis)"],"status":"active"},{"id":"bf464978-4d75-4ede-9e20-c014b75f7e0d","procedure_id":"proc-apheresis-longcovid","jurisdiction_id":"jur-gr","procedure_name":"Therapeutic Apheresis / HELP Apheresis for Long COVID & Microclot Protocols","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Long_COVID","Cardiovascular"],"diseases":["Long COVID","ME/CFS-like Post-Viral Syndrome","Hyperviscosity Syndromes (labeled apheresis)"],"status":"active"},{"id":"0a85ec60-d22d-4d3e-b71d-a2c37699caf9","procedure_id":"proc-apheresis-longcovid","jurisdiction_id":"jur-be","procedure_name":"Therapeutic Apheresis / HELP Apheresis for Long COVID & Microclot Protocols","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Long_COVID","Cardiovascular"],"diseases":["Long COVID","ME/CFS-like Post-Viral Syndrome","Hyperviscosity Syndromes (labeled apheresis)"],"status":"active"},{"id":"e1e9072e-e30e-4046-8ac7-1c0ab7407d3f","procedure_id":"proc-apheresis-longcovid","jurisdiction_id":"jur-se","procedure_name":"Therapeutic Apheresis / HELP Apheresis for Long COVID & Microclot Protocols","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Long_COVID","Cardiovascular"],"diseases":["Long COVID","ME/CFS-like Post-Viral Syndrome","Hyperviscosity Syndromes (labeled apheresis)"],"status":"active"},{"id":"e92986f3-185c-4262-ab35-e051ea2b241a","procedure_id":"proc-apheresis-longcovid","jurisdiction_id":"jur-jp","procedure_name":"Therapeutic Apheresis / HELP Apheresis for Long COVID & Microclot Protocols","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"PMDA / MHLW","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Long_COVID","Cardiovascular"],"diseases":["Long COVID","ME/CFS-like Post-Viral Syndrome","Hyperviscosity Syndromes (labeled apheresis)"],"status":"active"},{"id":"15e349b8-5f46-42ac-b6f0-2ba0e8c3c87e","procedure_id":"proc-apheresis-longcovid","jurisdiction_id":"jur-sg","procedure_name":"Therapeutic Apheresis / HELP Apheresis for Long COVID & Microclot Protocols","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"HSA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Long_COVID","Cardiovascular"],"diseases":["Long COVID","ME/CFS-like Post-Viral Syndrome","Hyperviscosity Syndromes (labeled apheresis)"],"status":"active"},{"id":"085db5a3-ffad-44c2-848e-42ad96d58706","procedure_id":"proc-apheresis-longcovid","jurisdiction_id":"jur-cl","procedure_name":"Therapeutic Apheresis / HELP Apheresis for Long COVID & Microclot Protocols","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Long_COVID","Cardiovascular"],"diseases":["Long COVID","ME/CFS-like Post-Viral Syndrome","Hyperviscosity Syndromes (labeled apheresis)"],"status":"active"},{"id":"bae61c50-0b6f-4b45-a841-15e34e1153b0","procedure_id":"proc-apheresis-longcovid","jurisdiction_id":"jur-ar","procedure_name":"Therapeutic Apheresis / HELP Apheresis for Long COVID & Microclot Protocols","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Long_COVID","Cardiovascular"],"diseases":["Long COVID","ME/CFS-like Post-Viral Syndrome","Hyperviscosity Syndromes (labeled apheresis)"],"status":"active"},{"id":"01f8ea21-badf-4a29-ad8d-e32ed7195cf3","procedure_id":"proc-apheresis-longcovid","jurisdiction_id":"jur-za","procedure_name":"Therapeutic Apheresis / HELP Apheresis for Long COVID & Microclot Protocols","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Long_COVID","Cardiovascular"],"diseases":["Long COVID","ME/CFS-like Post-Viral Syndrome","Hyperviscosity Syndromes (labeled apheresis)"],"status":"active"},{"id":"c851128d-622b-4fe7-863a-5a828061b6ac","procedure_id":"proc-apheresis-longcovid","jurisdiction_id":"jur-ph","procedure_name":"Therapeutic Apheresis / HELP Apheresis for Long COVID & Microclot Protocols","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Long_COVID","Cardiovascular"],"diseases":["Long COVID","ME/CFS-like Post-Viral Syndrome","Hyperviscosity Syndromes (labeled apheresis)"],"status":"active"},{"id":"16db6873-4101-43b8-bc23-32697a8ce1b3","procedure_id":"proc-apheresis-longcovid","jurisdiction_id":"jur-po","procedure_name":"Therapeutic Apheresis / HELP Apheresis for Long COVID & Microclot Protocols","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Long_COVID","Cardiovascular"],"diseases":["Long COVID","ME/CFS-like Post-Viral Syndrome","Hyperviscosity Syndromes (labeled apheresis)"],"status":"active"},{"id":"0f7fb659-f78d-4134-80e6-3f42395c8d71","procedure_id":"proc-apheresis-longcovid","jurisdiction_id":"jur-pt","procedure_name":"Therapeutic Apheresis / HELP Apheresis for Long COVID & Microclot Protocols","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Long_COVID","Cardiovascular"],"diseases":["Long COVID","ME/CFS-like Post-Viral Syndrome","Hyperviscosity Syndromes (labeled apheresis)"],"status":"active"},{"id":"9fe63792-aa83-4507-961d-654a2aecd6a8","procedure_id":"proc-apheresis-longcovid","jurisdiction_id":"jur-fr","procedure_name":"Therapeutic Apheresis / HELP Apheresis for Long COVID & Microclot Protocols","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"CELLULAR","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"ANSM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Long_COVID","Cardiovascular"],"diseases":["Long COVID","ME/CFS-like Post-Viral Syndrome","Hyperviscosity Syndromes (labeled apheresis)"],"status":"active"},{"id":"5da49684-ce80-4029-971a-581641e83896","procedure_id":"proc-ivig","jurisdiction_id":"jur-us-or","procedure_name":"Intravenous Immunoglobulin (IVIG) for Autoimmune / Neuroimmune Disease","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Neurology","Immunology"],"diseases":["Primary Immunodeficiency","CIDP","ITP","Autoimmune Encephalitis (off-label)","Long COVID (off-label)"],"status":"active"},{"id":"a5707682-4d74-489e-8dd8-b91a27f53d9f","procedure_id":"proc-ivig","jurisdiction_id":"jur-us-co","procedure_name":"Intravenous Immunoglobulin (IVIG) for Autoimmune / Neuroimmune Disease","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Neurology","Immunology"],"diseases":["Primary Immunodeficiency","CIDP","ITP","Autoimmune Encephalitis (off-label)","Long COVID (off-label)"],"status":"active"},{"id":"f3ca18e3-3984-4dac-b6a7-ec18e443e5a9","procedure_id":"proc-ivig","jurisdiction_id":"jur-us-ca","procedure_name":"Intravenous Immunoglobulin (IVIG) for Autoimmune / Neuroimmune Disease","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Neurology","Immunology"],"diseases":["Primary Immunodeficiency","CIDP","ITP","Autoimmune Encephalitis (off-label)","Long COVID (off-label)"],"status":"active"},{"id":"f28b3cc7-933a-4407-9258-e305309e2f23","procedure_id":"proc-ivig","jurisdiction_id":"jur-us-tx","procedure_name":"Intravenous Immunoglobulin (IVIG) for Autoimmune / Neuroimmune Disease","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Neurology","Immunology"],"diseases":["Primary Immunodeficiency","CIDP","ITP","Autoimmune Encephalitis (off-label)","Long COVID (off-label)"],"status":"active"},{"id":"3a7a4d9d-e746-47da-adf2-363effecd8c8","procedure_id":"proc-ivig","jurisdiction_id":"jur-us-fl","procedure_name":"Intravenous Immunoglobulin (IVIG) for Autoimmune / Neuroimmune Disease","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Neurology","Immunology"],"diseases":["Primary Immunodeficiency","CIDP","ITP","Autoimmune Encephalitis (off-label)","Long COVID (off-label)"],"status":"active"},{"id":"e7821892-4d88-453f-92e9-7ad37c8779f6","procedure_id":"proc-ivig","jurisdiction_id":"jur-au","procedure_name":"Intravenous Immunoglobulin (IVIG) for Autoimmune / Neuroimmune Disease","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"TGA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Neurology","Immunology"],"diseases":["Primary Immunodeficiency","CIDP","ITP","Autoimmune Encephalitis (off-label)","Long COVID (off-label)"],"status":"active"},{"id":"f6fb3036-16cd-4764-91d6-2921391d5ebd","procedure_id":"proc-ivig","jurisdiction_id":"jur-ch","procedure_name":"Intravenous Immunoglobulin (IVIG) for Autoimmune / Neuroimmune Disease","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Swissmedic","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Neurology","Immunology"],"diseases":["Primary Immunodeficiency","CIDP","ITP","Autoimmune Encephalitis (off-label)","Long COVID (off-label)"],"status":"active"},{"id":"e6931c66-c895-450b-bb2c-25c459d38db6","procedure_id":"proc-ivig","jurisdiction_id":"jur-ca","procedure_name":"Intravenous Immunoglobulin (IVIG) for Autoimmune / Neuroimmune Disease","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Health Canada","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Neurology","Immunology"],"diseases":["Primary Immunodeficiency","CIDP","ITP","Autoimmune Encephalitis (off-label)","Long COVID (off-label)"],"status":"active"},{"id":"900ac649-7eb3-4e64-a147-14dd75cb60e3","procedure_id":"proc-ivig","jurisdiction_id":"jur-mx","procedure_name":"Intravenous Immunoglobulin (IVIG) for Autoimmune / Neuroimmune Disease","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Permissive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"COFEPRIS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Neurology","Immunology"],"diseases":["Primary Immunodeficiency","CIDP","ITP","Autoimmune Encephalitis (off-label)","Long COVID (off-label)"],"status":"active"},{"id":"42e5dc2b-429a-4796-b57e-57da55c0b1e3","procedure_id":"proc-ivig","jurisdiction_id":"jur-hn-prospera","procedure_name":"Intravenous Immunoglobulin (IVIG) for Autoimmune / Neuroimmune Disease","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Permissive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Próspera ZEDE health rules (contested)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Neurology","Immunology"],"diseases":["Primary Immunodeficiency","CIDP","ITP","Autoimmune Encephalitis (off-label)","Long COVID (off-label)"],"status":"active"},{"id":"e4f19393-4e07-4198-80dc-6a4ebf215486","procedure_id":"proc-ivig","jurisdiction_id":"jur-nl","procedure_name":"Intravenous Immunoglobulin (IVIG) for Autoimmune / Neuroimmune Disease","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"MEB / IGJ","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Neurology","Immunology"],"diseases":["Primary Immunodeficiency","CIDP","ITP","Autoimmune Encephalitis (off-label)","Long COVID (off-label)"],"status":"active"},{"id":"44c57c95-0d91-4e86-9e10-51451bb24992","procedure_id":"proc-ivig","jurisdiction_id":"jur-uk","procedure_name":"Intravenous Immunoglobulin (IVIG) for Autoimmune / Neuroimmune Disease","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"MHRA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Neurology","Immunology"],"diseases":["Primary Immunodeficiency","CIDP","ITP","Autoimmune Encephalitis (off-label)","Long COVID (off-label)"],"status":"active"},{"id":"becfd405-219e-4459-a528-e851605fa1db","procedure_id":"proc-ivig","jurisdiction_id":"jur-il","procedure_name":"Intravenous Immunoglobulin (IVIG) for Autoimmune / Neuroimmune Disease","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Neurology","Immunology"],"diseases":["Primary Immunodeficiency","CIDP","ITP","Autoimmune Encephalitis (off-label)","Long COVID (off-label)"],"status":"active"},{"id":"a5c97b11-ca34-40f2-9fcc-8246512f170a","procedure_id":"proc-ivig","jurisdiction_id":"jur-jm","procedure_name":"Intravenous Immunoglobulin (IVIG) for Autoimmune / Neuroimmune Disease","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Neurology","Immunology"],"diseases":["Primary Immunodeficiency","CIDP","ITP","Autoimmune Encephalitis (off-label)","Long COVID (off-label)"],"status":"active"},{"id":"87bb91ed-6183-43e8-b4b9-8be9d2e80309","procedure_id":"proc-ivig","jurisdiction_id":"jur-th","procedure_name":"Intravenous Immunoglobulin (IVIG) for Autoimmune / Neuroimmune Disease","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Permissive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Thai FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Neurology","Immunology"],"diseases":["Primary Immunodeficiency","CIDP","ITP","Autoimmune Encephalitis (off-label)","Long COVID (off-label)"],"status":"active"},{"id":"03215acd-83aa-4a48-9d8a-6cf1dc3c138f","procedure_id":"proc-ivig","jurisdiction_id":"jur-es","procedure_name":"Intravenous Immunoglobulin (IVIG) for Autoimmune / Neuroimmune Disease","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"AEMPS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Neurology","Immunology"],"diseases":["Primary Immunodeficiency","CIDP","ITP","Autoimmune Encephalitis (off-label)","Long COVID (off-label)"],"status":"active"},{"id":"eaf9eb5f-5312-4cd6-a94c-46fabaee3582","procedure_id":"proc-ivig","jurisdiction_id":"jur-tu","procedure_name":"Intravenous Immunoglobulin (IVIG) for Autoimmune / Neuroimmune Disease","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Neurology","Immunology"],"diseases":["Primary Immunodeficiency","CIDP","ITP","Autoimmune Encephalitis (off-label)","Long COVID (off-label)"],"status":"active"},{"id":"d0779324-8352-4bb4-96a7-2543d536e1c9","procedure_id":"proc-ivig","jurisdiction_id":"jur-br","procedure_name":"Intravenous Immunoglobulin (IVIG) for Autoimmune / Neuroimmune Disease","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"ANVISA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Neurology","Immunology"],"diseases":["Primary Immunodeficiency","CIDP","ITP","Autoimmune Encephalitis (off-label)","Long COVID (off-label)"],"status":"active"},{"id":"678d089d-a6d0-4169-a9e9-df3e0914912c","procedure_id":"proc-ivig","jurisdiction_id":"jur-cr","procedure_name":"Intravenous Immunoglobulin (IVIG) for Autoimmune / Neuroimmune Disease","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Neurology","Immunology"],"diseases":["Primary Immunodeficiency","CIDP","ITP","Autoimmune Encephalitis (off-label)","Long COVID (off-label)"],"status":"active"},{"id":"d0f256bf-fc40-43fd-854e-50e86a4709f5","procedure_id":"proc-ivig","jurisdiction_id":"jur-uae","procedure_name":"Intravenous Immunoglobulin (IVIG) for Autoimmune / Neuroimmune Disease","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Neurology","Immunology"],"diseases":["Primary Immunodeficiency","CIDP","ITP","Autoimmune Encephalitis (off-label)","Long COVID (off-label)"],"status":"active"},{"id":"ca2095af-e458-4eaf-aef1-dad98040db62","procedure_id":"proc-ivig","jurisdiction_id":"jur-kr","procedure_name":"Intravenous Immunoglobulin (IVIG) for Autoimmune / Neuroimmune Disease","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"MFDS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Neurology","Immunology"],"diseases":["Primary Immunodeficiency","CIDP","ITP","Autoimmune Encephalitis (off-label)","Long COVID (off-label)"],"status":"active"},{"id":"7014a4b5-cc23-420a-840f-6a91edefd32d","procedure_id":"proc-ivig","jurisdiction_id":"jur-gr","procedure_name":"Intravenous Immunoglobulin (IVIG) for Autoimmune / Neuroimmune Disease","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Neurology","Immunology"],"diseases":["Primary Immunodeficiency","CIDP","ITP","Autoimmune Encephalitis (off-label)","Long COVID (off-label)"],"status":"active"},{"id":"96fe71f8-d12b-4233-8827-29a9ecd046c0","procedure_id":"proc-ivig","jurisdiction_id":"jur-be","procedure_name":"Intravenous Immunoglobulin (IVIG) for Autoimmune / Neuroimmune Disease","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Neurology","Immunology"],"diseases":["Primary Immunodeficiency","CIDP","ITP","Autoimmune Encephalitis (off-label)","Long COVID (off-label)"],"status":"active"},{"id":"e81934b8-390e-428c-a310-b2f0ff601ad2","procedure_id":"proc-ivig","jurisdiction_id":"jur-se","procedure_name":"Intravenous Immunoglobulin (IVIG) for Autoimmune / Neuroimmune Disease","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Neurology","Immunology"],"diseases":["Primary Immunodeficiency","CIDP","ITP","Autoimmune Encephalitis (off-label)","Long COVID (off-label)"],"status":"active"},{"id":"29ebee72-d5b5-4ae2-ac9e-363c971eebdb","procedure_id":"proc-ivig","jurisdiction_id":"jur-jp","procedure_name":"Intravenous Immunoglobulin (IVIG) for Autoimmune / Neuroimmune Disease","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"PMDA / MHLW","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Neurology","Immunology"],"diseases":["Primary Immunodeficiency","CIDP","ITP","Autoimmune Encephalitis (off-label)","Long COVID (off-label)"],"status":"active"},{"id":"d11801d4-2fc4-45b6-b307-75a7a9ee043f","procedure_id":"proc-ivig","jurisdiction_id":"jur-sg","procedure_name":"Intravenous Immunoglobulin (IVIG) for Autoimmune / Neuroimmune Disease","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"HSA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Neurology","Immunology"],"diseases":["Primary Immunodeficiency","CIDP","ITP","Autoimmune Encephalitis (off-label)","Long COVID (off-label)"],"status":"active"},{"id":"a2de8d64-5282-4130-8331-8d75f97d752a","procedure_id":"proc-ivig","jurisdiction_id":"jur-cl","procedure_name":"Intravenous Immunoglobulin (IVIG) for Autoimmune / Neuroimmune Disease","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Neurology","Immunology"],"diseases":["Primary Immunodeficiency","CIDP","ITP","Autoimmune Encephalitis (off-label)","Long COVID (off-label)"],"status":"active"},{"id":"acf8596b-b35a-49a6-9594-a91862c7e706","procedure_id":"proc-ivig","jurisdiction_id":"jur-ar","procedure_name":"Intravenous Immunoglobulin (IVIG) for Autoimmune / Neuroimmune Disease","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Neurology","Immunology"],"diseases":["Primary Immunodeficiency","CIDP","ITP","Autoimmune Encephalitis (off-label)","Long COVID (off-label)"],"status":"active"},{"id":"36e667ab-b977-4a86-bf38-6849ca5c8ecd","procedure_id":"proc-ivig","jurisdiction_id":"jur-za","procedure_name":"Intravenous Immunoglobulin (IVIG) for Autoimmune / Neuroimmune Disease","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Neurology","Immunology"],"diseases":["Primary Immunodeficiency","CIDP","ITP","Autoimmune Encephalitis (off-label)","Long COVID (off-label)"],"status":"active"},{"id":"b8fcfb57-e19a-412f-b85f-e2531daeaf30","procedure_id":"proc-ivig","jurisdiction_id":"jur-ph","procedure_name":"Intravenous Immunoglobulin (IVIG) for Autoimmune / Neuroimmune Disease","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Neurology","Immunology"],"diseases":["Primary Immunodeficiency","CIDP","ITP","Autoimmune Encephalitis (off-label)","Long COVID (off-label)"],"status":"active"},{"id":"7bd9b17d-c5f6-4c84-8fb6-65470e1d442d","procedure_id":"proc-ivig","jurisdiction_id":"jur-po","procedure_name":"Intravenous Immunoglobulin (IVIG) for Autoimmune / Neuroimmune Disease","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Neurology","Immunology"],"diseases":["Primary Immunodeficiency","CIDP","ITP","Autoimmune Encephalitis (off-label)","Long COVID (off-label)"],"status":"active"},{"id":"7b3afe25-1b8b-4f68-b875-7200abd1b6af","procedure_id":"proc-ivig","jurisdiction_id":"jur-pt","procedure_name":"Intravenous Immunoglobulin (IVIG) for Autoimmune / Neuroimmune Disease","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Neurology","Immunology"],"diseases":["Primary Immunodeficiency","CIDP","ITP","Autoimmune Encephalitis (off-label)","Long COVID (off-label)"],"status":"active"},{"id":"4209f0e6-3d4c-47ab-b06b-c86906754a96","procedure_id":"proc-ivig","jurisdiction_id":"jur-fr","procedure_name":"Intravenous Immunoglobulin (IVIG) for Autoimmune / Neuroimmune Disease","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"ANSM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Autoimmune","Neurology","Immunology"],"diseases":["Primary Immunodeficiency","CIDP","ITP","Autoimmune Encephalitis (off-label)","Long COVID (off-label)"],"status":"active"},{"id":"f7529a69-5d0d-4135-961f-8a2b0b459084","procedure_id":"proc-sglt2-hf","jurisdiction_id":"jur-us-or","procedure_name":"SGLT2 Inhibitors for Heart Failure & CKD Beyond Diabetes","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Kidney"],"diseases":["Heart Failure","Chronic Kidney Disease","Type 2 Diabetes"],"status":"active"},{"id":"fa68bf2c-8249-4716-b831-91ed3548d34b","procedure_id":"proc-sglt2-hf","jurisdiction_id":"jur-us-co","procedure_name":"SGLT2 Inhibitors for Heart Failure & CKD Beyond Diabetes","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Kidney"],"diseases":["Heart Failure","Chronic Kidney Disease","Type 2 Diabetes"],"status":"active"},{"id":"83b84d2e-3b94-4338-a4bf-35647e06de80","procedure_id":"proc-sglt2-hf","jurisdiction_id":"jur-us-ca","procedure_name":"SGLT2 Inhibitors for Heart Failure & CKD Beyond Diabetes","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Kidney"],"diseases":["Heart Failure","Chronic Kidney Disease","Type 2 Diabetes"],"status":"active"},{"id":"7bd70346-45ce-401f-883c-e0d97ce45b79","procedure_id":"proc-sglt2-hf","jurisdiction_id":"jur-us-tx","procedure_name":"SGLT2 Inhibitors for Heart Failure & CKD Beyond Diabetes","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Kidney"],"diseases":["Heart Failure","Chronic Kidney Disease","Type 2 Diabetes"],"status":"active"},{"id":"872e8796-9df1-4c6b-b050-2c4531b34065","procedure_id":"proc-sglt2-hf","jurisdiction_id":"jur-us-fl","procedure_name":"SGLT2 Inhibitors for Heart Failure & CKD Beyond Diabetes","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Kidney"],"diseases":["Heart Failure","Chronic Kidney Disease","Type 2 Diabetes"],"status":"active"},{"id":"e4ba7055-362a-47ac-834a-fda26164eb5b","procedure_id":"proc-sglt2-hf","jurisdiction_id":"jur-au","procedure_name":"SGLT2 Inhibitors for Heart Failure & CKD Beyond Diabetes","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"TGA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Kidney"],"diseases":["Heart Failure","Chronic Kidney Disease","Type 2 Diabetes"],"status":"active"},{"id":"7edb5ea4-eec3-4fa6-a93c-9c6947e740b7","procedure_id":"proc-sglt2-hf","jurisdiction_id":"jur-ch","procedure_name":"SGLT2 Inhibitors for Heart Failure & CKD Beyond Diabetes","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Swissmedic","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Kidney"],"diseases":["Heart Failure","Chronic Kidney Disease","Type 2 Diabetes"],"status":"active"},{"id":"f02b7715-6c91-43bd-9a37-d83eeead8615","procedure_id":"proc-sglt2-hf","jurisdiction_id":"jur-ca","procedure_name":"SGLT2 Inhibitors for Heart Failure & CKD Beyond Diabetes","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Health Canada","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Kidney"],"diseases":["Heart Failure","Chronic Kidney Disease","Type 2 Diabetes"],"status":"active"},{"id":"e0fb2b02-10b5-43cd-be8f-3388e31264f7","procedure_id":"proc-sglt2-hf","jurisdiction_id":"jur-mx","procedure_name":"SGLT2 Inhibitors for Heart Failure & CKD Beyond Diabetes","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Permissive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"COFEPRIS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Kidney"],"diseases":["Heart Failure","Chronic Kidney Disease","Type 2 Diabetes"],"status":"active"},{"id":"9997f519-9793-4a57-8d54-3db97ed45315","procedure_id":"proc-sglt2-hf","jurisdiction_id":"jur-hn-prospera","procedure_name":"SGLT2 Inhibitors for Heart Failure & CKD Beyond Diabetes","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Permissive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Próspera ZEDE health rules (contested)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Kidney"],"diseases":["Heart Failure","Chronic Kidney Disease","Type 2 Diabetes"],"status":"active"},{"id":"b7c5ab16-0e05-4628-8578-c7098c5708c1","procedure_id":"proc-sglt2-hf","jurisdiction_id":"jur-nl","procedure_name":"SGLT2 Inhibitors for Heart Failure & CKD Beyond Diabetes","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"MEB / IGJ","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Kidney"],"diseases":["Heart Failure","Chronic Kidney Disease","Type 2 Diabetes"],"status":"active"},{"id":"8a6b1ee4-4473-412f-9f06-e52590c8da69","procedure_id":"proc-sglt2-hf","jurisdiction_id":"jur-il","procedure_name":"SGLT2 Inhibitors for Heart Failure & CKD Beyond Diabetes","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Kidney"],"diseases":["Heart Failure","Chronic Kidney Disease","Type 2 Diabetes"],"status":"active"},{"id":"684dee8a-3872-49b5-a428-f4e828bb0f63","procedure_id":"proc-sglt2-hf","jurisdiction_id":"jur-jm","procedure_name":"SGLT2 Inhibitors for Heart Failure & CKD Beyond Diabetes","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Kidney"],"diseases":["Heart Failure","Chronic Kidney Disease","Type 2 Diabetes"],"status":"active"},{"id":"c3bd8359-632e-401e-827d-2470eb3810a6","procedure_id":"proc-sglt2-hf","jurisdiction_id":"jur-th","procedure_name":"SGLT2 Inhibitors for Heart Failure & CKD Beyond Diabetes","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Permissive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Thai FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Kidney"],"diseases":["Heart Failure","Chronic Kidney Disease","Type 2 Diabetes"],"status":"active"},{"id":"9372ea1c-58a2-43ef-8446-c061d1c8d3a4","procedure_id":"proc-sglt2-hf","jurisdiction_id":"jur-es","procedure_name":"SGLT2 Inhibitors for Heart Failure & CKD Beyond Diabetes","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"AEMPS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Kidney"],"diseases":["Heart Failure","Chronic Kidney Disease","Type 2 Diabetes"],"status":"active"},{"id":"f1384fdb-b5ef-4ba0-bfc0-378e02f58b5a","procedure_id":"proc-sglt2-hf","jurisdiction_id":"jur-tu","procedure_name":"SGLT2 Inhibitors for Heart Failure & CKD Beyond Diabetes","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Kidney"],"diseases":["Heart Failure","Chronic Kidney Disease","Type 2 Diabetes"],"status":"active"},{"id":"be284f2e-b5bf-4501-a398-85ee85336f94","procedure_id":"proc-sglt2-hf","jurisdiction_id":"jur-br","procedure_name":"SGLT2 Inhibitors for Heart Failure & CKD Beyond Diabetes","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"ANVISA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Kidney"],"diseases":["Heart Failure","Chronic Kidney Disease","Type 2 Diabetes"],"status":"active"},{"id":"a7800534-e01d-4d78-8bb1-2094cd6620b6","procedure_id":"proc-sglt2-hf","jurisdiction_id":"jur-cr","procedure_name":"SGLT2 Inhibitors for Heart Failure & CKD Beyond Diabetes","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Kidney"],"diseases":["Heart Failure","Chronic Kidney Disease","Type 2 Diabetes"],"status":"active"},{"id":"a3d0b176-16e2-46b6-9536-b5624a84e620","procedure_id":"proc-sglt2-hf","jurisdiction_id":"jur-uae","procedure_name":"SGLT2 Inhibitors for Heart Failure & CKD Beyond Diabetes","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Kidney"],"diseases":["Heart Failure","Chronic Kidney Disease","Type 2 Diabetes"],"status":"active"},{"id":"1f5fdbcd-f46e-4e9b-9181-b8e99736c829","procedure_id":"proc-sglt2-hf","jurisdiction_id":"jur-kr","procedure_name":"SGLT2 Inhibitors for Heart Failure & CKD Beyond Diabetes","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"MFDS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Kidney"],"diseases":["Heart Failure","Chronic Kidney Disease","Type 2 Diabetes"],"status":"active"},{"id":"0682d7a2-02d6-4f3e-8186-95dbb3b803fa","procedure_id":"proc-sglt2-hf","jurisdiction_id":"jur-gr","procedure_name":"SGLT2 Inhibitors for Heart Failure & CKD Beyond Diabetes","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Kidney"],"diseases":["Heart Failure","Chronic Kidney Disease","Type 2 Diabetes"],"status":"active"},{"id":"cb0f96d6-ea36-4128-80ef-179c5205b496","procedure_id":"proc-sglt2-hf","jurisdiction_id":"jur-be","procedure_name":"SGLT2 Inhibitors for Heart Failure & CKD Beyond Diabetes","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Kidney"],"diseases":["Heart Failure","Chronic Kidney Disease","Type 2 Diabetes"],"status":"active"},{"id":"3e32e807-e806-4557-a561-00b11cf554c6","procedure_id":"proc-sglt2-hf","jurisdiction_id":"jur-se","procedure_name":"SGLT2 Inhibitors for Heart Failure & CKD Beyond Diabetes","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Kidney"],"diseases":["Heart Failure","Chronic Kidney Disease","Type 2 Diabetes"],"status":"active"},{"id":"970b3bfd-8c3c-4259-8d67-6348d05461c5","procedure_id":"proc-sglt2-hf","jurisdiction_id":"jur-jp","procedure_name":"SGLT2 Inhibitors for Heart Failure & CKD Beyond Diabetes","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"PMDA / MHLW","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Kidney"],"diseases":["Heart Failure","Chronic Kidney Disease","Type 2 Diabetes"],"status":"active"},{"id":"96321b9b-d869-4065-b3b0-7fe351b80825","procedure_id":"proc-sglt2-hf","jurisdiction_id":"jur-sg","procedure_name":"SGLT2 Inhibitors for Heart Failure & CKD Beyond Diabetes","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"HSA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Kidney"],"diseases":["Heart Failure","Chronic Kidney Disease","Type 2 Diabetes"],"status":"active"},{"id":"41f019f2-c07c-44a5-875c-7f5bb22bdfab","procedure_id":"proc-sglt2-hf","jurisdiction_id":"jur-cl","procedure_name":"SGLT2 Inhibitors for Heart Failure & CKD Beyond Diabetes","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Kidney"],"diseases":["Heart Failure","Chronic Kidney Disease","Type 2 Diabetes"],"status":"active"},{"id":"67585efd-6aff-458e-9384-b2d4236ced4c","procedure_id":"proc-sglt2-hf","jurisdiction_id":"jur-ar","procedure_name":"SGLT2 Inhibitors for Heart Failure & CKD Beyond Diabetes","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Kidney"],"diseases":["Heart Failure","Chronic Kidney Disease","Type 2 Diabetes"],"status":"active"},{"id":"c6c591c0-6a10-418b-9da9-2c9095fcd836","procedure_id":"proc-sglt2-hf","jurisdiction_id":"jur-za","procedure_name":"SGLT2 Inhibitors for Heart Failure & CKD Beyond Diabetes","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Kidney"],"diseases":["Heart Failure","Chronic Kidney Disease","Type 2 Diabetes"],"status":"active"},{"id":"ad48287b-0c7f-497e-b80b-0fe6aa4fffc4","procedure_id":"proc-sglt2-hf","jurisdiction_id":"jur-ph","procedure_name":"SGLT2 Inhibitors for Heart Failure & CKD Beyond Diabetes","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Kidney"],"diseases":["Heart Failure","Chronic Kidney Disease","Type 2 Diabetes"],"status":"active"},{"id":"5733d41b-5664-414e-a38a-b508509f5c1f","procedure_id":"proc-sglt2-hf","jurisdiction_id":"jur-po","procedure_name":"SGLT2 Inhibitors for Heart Failure & CKD Beyond Diabetes","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Kidney"],"diseases":["Heart Failure","Chronic Kidney Disease","Type 2 Diabetes"],"status":"active"},{"id":"6c3b8c17-815f-41aa-96a8-c9231ca51d31","procedure_id":"proc-sglt2-hf","jurisdiction_id":"jur-pt","procedure_name":"SGLT2 Inhibitors for Heart Failure & CKD Beyond Diabetes","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Kidney"],"diseases":["Heart Failure","Chronic Kidney Disease","Type 2 Diabetes"],"status":"active"},{"id":"a06bce04-48ba-44f5-8218-c8eb6dd789d7","procedure_id":"proc-sglt2-hf","jurisdiction_id":"jur-fr","procedure_name":"SGLT2 Inhibitors for Heart Failure & CKD Beyond Diabetes","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"ANSM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Kidney"],"diseases":["Heart Failure","Chronic Kidney Disease","Type 2 Diabetes"],"status":"active"},{"id":"b3736940-91ef-4b14-ab15-2756f855b1ef","procedure_id":"proc-glp1-addiction","jurisdiction_id":"jur-us-or","procedure_name":"GLP-1 Agonists for Alcohol / Substance Use Disorder (Emerging)","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction","Mental_Health"],"diseases":["Alcohol Use Disorder","Obesity","Type 2 Diabetes"],"status":"active"},{"id":"2963d46e-66d8-4217-ab8c-dfb774002758","procedure_id":"proc-glp1-addiction","jurisdiction_id":"jur-us-co","procedure_name":"GLP-1 Agonists for Alcohol / Substance Use Disorder (Emerging)","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction","Mental_Health"],"diseases":["Alcohol Use Disorder","Obesity","Type 2 Diabetes"],"status":"active"},{"id":"55926987-fcc0-451d-b415-eb10cf9a7884","procedure_id":"proc-glp1-addiction","jurisdiction_id":"jur-us-ca","procedure_name":"GLP-1 Agonists for Alcohol / Substance Use Disorder (Emerging)","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction","Mental_Health"],"diseases":["Alcohol Use Disorder","Obesity","Type 2 Diabetes"],"status":"active"},{"id":"2f972a1b-abfb-42fb-a03a-44130610fff4","procedure_id":"proc-glp1-addiction","jurisdiction_id":"jur-us-tx","procedure_name":"GLP-1 Agonists for Alcohol / Substance Use Disorder (Emerging)","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction","Mental_Health"],"diseases":["Alcohol Use Disorder","Obesity","Type 2 Diabetes"],"status":"active"},{"id":"dc37e3ea-b0a0-4600-85c5-69b268a40ef4","procedure_id":"proc-glp1-addiction","jurisdiction_id":"jur-us-fl","procedure_name":"GLP-1 Agonists for Alcohol / Substance Use Disorder (Emerging)","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction","Mental_Health"],"diseases":["Alcohol Use Disorder","Obesity","Type 2 Diabetes"],"status":"active"},{"id":"036f4fb2-41a4-4d01-926c-f2d832cc7280","procedure_id":"proc-glp1-addiction","jurisdiction_id":"jur-au","procedure_name":"GLP-1 Agonists for Alcohol / Substance Use Disorder (Emerging)","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"TGA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction","Mental_Health"],"diseases":["Alcohol Use Disorder","Obesity","Type 2 Diabetes"],"status":"active"},{"id":"0e937389-7fed-4c81-9814-f9f2f0896d8e","procedure_id":"proc-glp1-addiction","jurisdiction_id":"jur-ch","procedure_name":"GLP-1 Agonists for Alcohol / Substance Use Disorder (Emerging)","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Swissmedic","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction","Mental_Health"],"diseases":["Alcohol Use Disorder","Obesity","Type 2 Diabetes"],"status":"active"},{"id":"a6cec9e4-7c52-4fa0-89ec-7e6a04b7b86d","procedure_id":"proc-glp1-addiction","jurisdiction_id":"jur-ca","procedure_name":"GLP-1 Agonists for Alcohol / Substance Use Disorder (Emerging)","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Health Canada","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction","Mental_Health"],"diseases":["Alcohol Use Disorder","Obesity","Type 2 Diabetes"],"status":"active"},{"id":"ee7d8665-1c86-44ca-a328-4924f6dbd4ef","procedure_id":"proc-glp1-addiction","jurisdiction_id":"jur-mx","procedure_name":"GLP-1 Agonists for Alcohol / Substance Use Disorder (Emerging)","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Permissive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"COFEPRIS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction","Mental_Health"],"diseases":["Alcohol Use Disorder","Obesity","Type 2 Diabetes"],"status":"active"},{"id":"83ea9c61-6e2a-4a58-b231-5a0c0a8bb57f","procedure_id":"proc-glp1-addiction","jurisdiction_id":"jur-hn-prospera","procedure_name":"GLP-1 Agonists for Alcohol / Substance Use Disorder (Emerging)","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Permissive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Próspera ZEDE health rules (contested)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction","Mental_Health"],"diseases":["Alcohol Use Disorder","Obesity","Type 2 Diabetes"],"status":"active"},{"id":"1b2ef2fd-f868-4354-a49e-5c0077a2997a","procedure_id":"proc-glp1-addiction","jurisdiction_id":"jur-nl","procedure_name":"GLP-1 Agonists for Alcohol / Substance Use Disorder (Emerging)","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"MEB / IGJ","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction","Mental_Health"],"diseases":["Alcohol Use Disorder","Obesity","Type 2 Diabetes"],"status":"active"},{"id":"a933593a-8283-42f4-83ea-d7e568e1ee10","procedure_id":"proc-glp1-addiction","jurisdiction_id":"jur-de","procedure_name":"GLP-1 Agonists for Alcohol / Substance Use Disorder (Emerging)","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"BfArM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction","Mental_Health"],"diseases":["Alcohol Use Disorder","Obesity","Type 2 Diabetes"],"status":"active"},{"id":"615fe9a1-099d-49a4-aa8c-78dd775b7a6e","procedure_id":"proc-glp1-addiction","jurisdiction_id":"jur-il","procedure_name":"GLP-1 Agonists for Alcohol / Substance Use Disorder (Emerging)","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction","Mental_Health"],"diseases":["Alcohol Use Disorder","Obesity","Type 2 Diabetes"],"status":"active"},{"id":"bc7157a0-60ce-470a-b42d-b86f18568435","procedure_id":"proc-glp1-addiction","jurisdiction_id":"jur-jm","procedure_name":"GLP-1 Agonists for Alcohol / Substance Use Disorder (Emerging)","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction","Mental_Health"],"diseases":["Alcohol Use Disorder","Obesity","Type 2 Diabetes"],"status":"active"},{"id":"1de409c2-7d13-4c03-843d-7d5d81607c7a","procedure_id":"proc-glp1-addiction","jurisdiction_id":"jur-th","procedure_name":"GLP-1 Agonists for Alcohol / Substance Use Disorder (Emerging)","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Permissive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Thai FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction","Mental_Health"],"diseases":["Alcohol Use Disorder","Obesity","Type 2 Diabetes"],"status":"active"},{"id":"47933bd5-97bc-43b0-8643-2af50cefe261","procedure_id":"proc-glp1-addiction","jurisdiction_id":"jur-es","procedure_name":"GLP-1 Agonists for Alcohol / Substance Use Disorder (Emerging)","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"AEMPS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction","Mental_Health"],"diseases":["Alcohol Use Disorder","Obesity","Type 2 Diabetes"],"status":"active"},{"id":"f9a31745-c736-4afb-bfc9-bb708e386392","procedure_id":"proc-glp1-addiction","jurisdiction_id":"jur-tu","procedure_name":"GLP-1 Agonists for Alcohol / Substance Use Disorder (Emerging)","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction","Mental_Health"],"diseases":["Alcohol Use Disorder","Obesity","Type 2 Diabetes"],"status":"active"},{"id":"1e7aeeb5-0bbb-4578-93fa-87f3e879cc92","procedure_id":"proc-glp1-addiction","jurisdiction_id":"jur-in","procedure_name":"GLP-1 Agonists for Alcohol / Substance Use Disorder (Emerging)","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Permissive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"CDSCO","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction","Mental_Health"],"diseases":["Alcohol Use Disorder","Obesity","Type 2 Diabetes"],"status":"active"},{"id":"f0cb1767-29a8-4009-9017-41feb7edc486","procedure_id":"proc-glp1-addiction","jurisdiction_id":"jur-br","procedure_name":"GLP-1 Agonists for Alcohol / Substance Use Disorder (Emerging)","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"ANVISA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction","Mental_Health"],"diseases":["Alcohol Use Disorder","Obesity","Type 2 Diabetes"],"status":"active"},{"id":"3b44f390-c72e-4b55-aa70-88978c3e2a54","procedure_id":"proc-glp1-addiction","jurisdiction_id":"jur-cr","procedure_name":"GLP-1 Agonists for Alcohol / Substance Use Disorder (Emerging)","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction","Mental_Health"],"diseases":["Alcohol Use Disorder","Obesity","Type 2 Diabetes"],"status":"active"},{"id":"5a1fcb7e-55d2-4725-a893-3ce219df94db","procedure_id":"proc-glp1-addiction","jurisdiction_id":"jur-uae","procedure_name":"GLP-1 Agonists for Alcohol / Substance Use Disorder (Emerging)","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction","Mental_Health"],"diseases":["Alcohol Use Disorder","Obesity","Type 2 Diabetes"],"status":"active"},{"id":"85be64b7-409f-45a6-a5a8-592109f196c5","procedure_id":"proc-glp1-addiction","jurisdiction_id":"jur-kr","procedure_name":"GLP-1 Agonists for Alcohol / Substance Use Disorder (Emerging)","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"MFDS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction","Mental_Health"],"diseases":["Alcohol Use Disorder","Obesity","Type 2 Diabetes"],"status":"active"},{"id":"3b4e8234-ddd8-4f77-8558-08c41716e09c","procedure_id":"proc-glp1-addiction","jurisdiction_id":"jur-gr","procedure_name":"GLP-1 Agonists for Alcohol / Substance Use Disorder (Emerging)","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction","Mental_Health"],"diseases":["Alcohol Use Disorder","Obesity","Type 2 Diabetes"],"status":"active"},{"id":"7409e637-c0d7-4424-8037-08f749dbca4d","procedure_id":"proc-glp1-addiction","jurisdiction_id":"jur-be","procedure_name":"GLP-1 Agonists for Alcohol / Substance Use Disorder (Emerging)","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction","Mental_Health"],"diseases":["Alcohol Use Disorder","Obesity","Type 2 Diabetes"],"status":"active"},{"id":"2d1aae34-3550-4376-8b5e-8ff4a8f8d95d","procedure_id":"proc-glp1-addiction","jurisdiction_id":"jur-se","procedure_name":"GLP-1 Agonists for Alcohol / Substance Use Disorder (Emerging)","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction","Mental_Health"],"diseases":["Alcohol Use Disorder","Obesity","Type 2 Diabetes"],"status":"active"},{"id":"891604f5-aef9-4646-8535-a5b25560375a","procedure_id":"proc-glp1-addiction","jurisdiction_id":"jur-jp","procedure_name":"GLP-1 Agonists for Alcohol / Substance Use Disorder (Emerging)","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"PMDA / MHLW","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction","Mental_Health"],"diseases":["Alcohol Use Disorder","Obesity","Type 2 Diabetes"],"status":"active"},{"id":"5baeafc5-ad1c-4e51-8127-62566264dede","procedure_id":"proc-glp1-addiction","jurisdiction_id":"jur-sg","procedure_name":"GLP-1 Agonists for Alcohol / Substance Use Disorder (Emerging)","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"HSA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction","Mental_Health"],"diseases":["Alcohol Use Disorder","Obesity","Type 2 Diabetes"],"status":"active"},{"id":"cc1eaf5e-08bf-469e-b102-1fa2728b44ef","procedure_id":"proc-glp1-addiction","jurisdiction_id":"jur-cl","procedure_name":"GLP-1 Agonists for Alcohol / Substance Use Disorder (Emerging)","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction","Mental_Health"],"diseases":["Alcohol Use Disorder","Obesity","Type 2 Diabetes"],"status":"active"},{"id":"caeac99f-befb-43fe-98c7-912821cbd024","procedure_id":"proc-glp1-addiction","jurisdiction_id":"jur-ar","procedure_name":"GLP-1 Agonists for Alcohol / Substance Use Disorder (Emerging)","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction","Mental_Health"],"diseases":["Alcohol Use Disorder","Obesity","Type 2 Diabetes"],"status":"active"},{"id":"ca3b0908-d482-45f0-a7f1-69b5d1bc0a26","procedure_id":"proc-glp1-addiction","jurisdiction_id":"jur-za","procedure_name":"GLP-1 Agonists for Alcohol / Substance Use Disorder (Emerging)","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction","Mental_Health"],"diseases":["Alcohol Use Disorder","Obesity","Type 2 Diabetes"],"status":"active"},{"id":"14c75134-50c7-4098-91f9-58b026f72f45","procedure_id":"proc-glp1-addiction","jurisdiction_id":"jur-ph","procedure_name":"GLP-1 Agonists for Alcohol / Substance Use Disorder (Emerging)","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction","Mental_Health"],"diseases":["Alcohol Use Disorder","Obesity","Type 2 Diabetes"],"status":"active"},{"id":"ee3b0532-ebf8-4905-a440-f5d17c22e837","procedure_id":"proc-glp1-addiction","jurisdiction_id":"jur-po","procedure_name":"GLP-1 Agonists for Alcohol / Substance Use Disorder (Emerging)","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction","Mental_Health"],"diseases":["Alcohol Use Disorder","Obesity","Type 2 Diabetes"],"status":"active"},{"id":"71c56aac-f3ab-4e69-a50e-28e281be15a1","procedure_id":"proc-glp1-addiction","jurisdiction_id":"jur-pt","procedure_name":"GLP-1 Agonists for Alcohol / Substance Use Disorder (Emerging)","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction","Mental_Health"],"diseases":["Alcohol Use Disorder","Obesity","Type 2 Diabetes"],"status":"active"},{"id":"8ff883fc-86ea-443c-b0e5-46d1a3cb9a2f","procedure_id":"proc-glp1-addiction","jurisdiction_id":"jur-fr","procedure_name":"GLP-1 Agonists for Alcohol / Substance Use Disorder (Emerging)","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"ANSM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction","Mental_Health"],"diseases":["Alcohol Use Disorder","Obesity","Type 2 Diabetes"],"status":"active"},{"id":"11c75e46-a2bb-4b71-9f3c-0103fe167d92","procedure_id":"proc-prazosin-ptsd","jurisdiction_id":"jur-us-or","procedure_name":"Prazosin for PTSD Nightmares","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["PTSD Nightmares","Hypertension (labeled)"],"status":"active"},{"id":"559f6fb1-239c-45cb-9f9a-e13e5296031e","procedure_id":"proc-prazosin-ptsd","jurisdiction_id":"jur-us-co","procedure_name":"Prazosin for PTSD Nightmares","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["PTSD Nightmares","Hypertension (labeled)"],"status":"active"},{"id":"83650ce0-4523-454d-bcaa-9993e56ed79a","procedure_id":"proc-prazosin-ptsd","jurisdiction_id":"jur-us-ca","procedure_name":"Prazosin for PTSD Nightmares","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["PTSD Nightmares","Hypertension (labeled)"],"status":"active"},{"id":"d303514b-6bd9-4c05-b75b-ca42ab8fa5e0","procedure_id":"proc-prazosin-ptsd","jurisdiction_id":"jur-us-tx","procedure_name":"Prazosin for PTSD Nightmares","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["PTSD Nightmares","Hypertension (labeled)"],"status":"active"},{"id":"a88ae63d-7d9c-4377-a2fe-d6ffe4930850","procedure_id":"proc-prazosin-ptsd","jurisdiction_id":"jur-us-fl","procedure_name":"Prazosin for PTSD Nightmares","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["PTSD Nightmares","Hypertension (labeled)"],"status":"active"},{"id":"de97a31f-759f-48bd-8b44-8d801da8ebae","procedure_id":"proc-prazosin-ptsd","jurisdiction_id":"jur-au","procedure_name":"Prazosin for PTSD Nightmares","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"TGA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["PTSD Nightmares","Hypertension (labeled)"],"status":"active"},{"id":"2b05df88-764f-44dd-890b-f3ec13b462c0","procedure_id":"proc-prazosin-ptsd","jurisdiction_id":"jur-ch","procedure_name":"Prazosin for PTSD Nightmares","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Swissmedic","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["PTSD Nightmares","Hypertension (labeled)"],"status":"active"},{"id":"c5e3c4d8-7091-4ef5-b89a-a7176c6ccfc3","procedure_id":"proc-prazosin-ptsd","jurisdiction_id":"jur-mx","procedure_name":"Prazosin for PTSD Nightmares","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Permissive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"COFEPRIS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["PTSD Nightmares","Hypertension (labeled)"],"status":"active"},{"id":"1e77d8af-ede0-401e-a076-9ad33c820047","procedure_id":"proc-prazosin-ptsd","jurisdiction_id":"jur-hn-prospera","procedure_name":"Prazosin for PTSD Nightmares","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Permissive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Próspera ZEDE health rules (contested)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["PTSD Nightmares","Hypertension (labeled)"],"status":"active"},{"id":"8745852e-6c76-438f-9245-cd2fb1649d19","procedure_id":"proc-prazosin-ptsd","jurisdiction_id":"jur-nl","procedure_name":"Prazosin for PTSD Nightmares","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"MEB / IGJ","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["PTSD Nightmares","Hypertension (labeled)"],"status":"active"},{"id":"d96d5f03-9cd3-4cc9-b296-0fe692746167","procedure_id":"proc-prazosin-ptsd","jurisdiction_id":"jur-de","procedure_name":"Prazosin for PTSD Nightmares","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"BfArM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["PTSD Nightmares","Hypertension (labeled)"],"status":"active"},{"id":"e49cc6a7-cacb-4919-aa94-f9926b343a9c","procedure_id":"proc-prazosin-ptsd","jurisdiction_id":"jur-il","procedure_name":"Prazosin for PTSD Nightmares","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["PTSD Nightmares","Hypertension (labeled)"],"status":"active"},{"id":"edcb3c4e-ac9d-4294-8491-3bafadcd2100","procedure_id":"proc-prazosin-ptsd","jurisdiction_id":"jur-jm","procedure_name":"Prazosin for PTSD Nightmares","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["PTSD Nightmares","Hypertension (labeled)"],"status":"active"},{"id":"dfcd58d7-e00c-4027-8b92-4e705f23cd7a","procedure_id":"proc-prazosin-ptsd","jurisdiction_id":"jur-th","procedure_name":"Prazosin for PTSD Nightmares","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Permissive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Thai FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["PTSD Nightmares","Hypertension (labeled)"],"status":"active"},{"id":"963e9398-3142-469c-b94e-9a49c83fede1","procedure_id":"proc-prazosin-ptsd","jurisdiction_id":"jur-es","procedure_name":"Prazosin for PTSD Nightmares","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"AEMPS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["PTSD Nightmares","Hypertension (labeled)"],"status":"active"},{"id":"c7511529-5f03-4bac-82e5-99be4e4eaee5","procedure_id":"proc-prazosin-ptsd","jurisdiction_id":"jur-tu","procedure_name":"Prazosin for PTSD Nightmares","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["PTSD Nightmares","Hypertension (labeled)"],"status":"active"},{"id":"0e749ecf-5277-4823-914f-66b34a8718f6","procedure_id":"proc-prazosin-ptsd","jurisdiction_id":"jur-in","procedure_name":"Prazosin for PTSD Nightmares","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Permissive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"CDSCO","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["PTSD Nightmares","Hypertension (labeled)"],"status":"active"},{"id":"ed318be9-fc61-4af8-88da-3f6fae70f24c","procedure_id":"proc-prazosin-ptsd","jurisdiction_id":"jur-br","procedure_name":"Prazosin for PTSD Nightmares","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"ANVISA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["PTSD Nightmares","Hypertension (labeled)"],"status":"active"},{"id":"bda5d2db-6808-466a-84e2-cb315d28e90e","procedure_id":"proc-prazosin-ptsd","jurisdiction_id":"jur-cr","procedure_name":"Prazosin for PTSD Nightmares","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["PTSD Nightmares","Hypertension (labeled)"],"status":"active"},{"id":"16f14816-1c03-4fb4-96aa-8162d9d9c31a","procedure_id":"proc-prazosin-ptsd","jurisdiction_id":"jur-uae","procedure_name":"Prazosin for PTSD Nightmares","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["PTSD Nightmares","Hypertension (labeled)"],"status":"active"},{"id":"b004bd85-24c7-408d-870b-5bf0b504c189","procedure_id":"proc-prazosin-ptsd","jurisdiction_id":"jur-kr","procedure_name":"Prazosin for PTSD Nightmares","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"MFDS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["PTSD Nightmares","Hypertension (labeled)"],"status":"active"},{"id":"8c3fb76b-e158-4399-8796-fa0451d6cb5b","procedure_id":"proc-prazosin-ptsd","jurisdiction_id":"jur-gr","procedure_name":"Prazosin for PTSD Nightmares","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["PTSD Nightmares","Hypertension (labeled)"],"status":"active"},{"id":"1524e982-5e6c-4285-94ed-a2e61c1ea0dd","procedure_id":"proc-prazosin-ptsd","jurisdiction_id":"jur-be","procedure_name":"Prazosin for PTSD Nightmares","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["PTSD Nightmares","Hypertension (labeled)"],"status":"active"},{"id":"abec86fe-fd03-44ee-ba26-6ba269a817cc","procedure_id":"proc-prazosin-ptsd","jurisdiction_id":"jur-se","procedure_name":"Prazosin for PTSD Nightmares","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["PTSD Nightmares","Hypertension (labeled)"],"status":"active"},{"id":"44afeb77-7a4a-4895-9687-ee1c694f3ba4","procedure_id":"proc-prazosin-ptsd","jurisdiction_id":"jur-jp","procedure_name":"Prazosin for PTSD Nightmares","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"PMDA / MHLW","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["PTSD Nightmares","Hypertension (labeled)"],"status":"active"},{"id":"ddd948d4-6001-4753-89bd-daa8bd56c433","procedure_id":"proc-prazosin-ptsd","jurisdiction_id":"jur-sg","procedure_name":"Prazosin for PTSD Nightmares","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"HSA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["PTSD Nightmares","Hypertension (labeled)"],"status":"active"},{"id":"285335ce-d023-45a5-99cd-99ab255ecd20","procedure_id":"proc-prazosin-ptsd","jurisdiction_id":"jur-cl","procedure_name":"Prazosin for PTSD Nightmares","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["PTSD Nightmares","Hypertension (labeled)"],"status":"active"},{"id":"72cd8f19-a7d4-4944-868f-d1abdc583cae","procedure_id":"proc-prazosin-ptsd","jurisdiction_id":"jur-ar","procedure_name":"Prazosin for PTSD Nightmares","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["PTSD Nightmares","Hypertension (labeled)"],"status":"active"},{"id":"e658eabf-6958-4222-8f1d-1d4c6685f349","procedure_id":"proc-prazosin-ptsd","jurisdiction_id":"jur-za","procedure_name":"Prazosin for PTSD Nightmares","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["PTSD Nightmares","Hypertension (labeled)"],"status":"active"},{"id":"930d07ed-e7ef-4a64-8271-c8b59fe78fad","procedure_id":"proc-prazosin-ptsd","jurisdiction_id":"jur-ph","procedure_name":"Prazosin for PTSD Nightmares","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["PTSD Nightmares","Hypertension (labeled)"],"status":"active"},{"id":"d27c03b0-3cee-495d-9715-736053e1b884","procedure_id":"proc-prazosin-ptsd","jurisdiction_id":"jur-po","procedure_name":"Prazosin for PTSD Nightmares","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["PTSD Nightmares","Hypertension (labeled)"],"status":"active"},{"id":"d104b50e-d937-492d-9cdc-5cb7e7cfe7a5","procedure_id":"proc-prazosin-ptsd","jurisdiction_id":"jur-pt","procedure_name":"Prazosin for PTSD Nightmares","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["PTSD Nightmares","Hypertension (labeled)"],"status":"active"},{"id":"86cb3e86-c149-4235-b678-86eb77fe4a96","procedure_id":"proc-prazosin-ptsd","jurisdiction_id":"jur-fr","procedure_name":"Prazosin for PTSD Nightmares","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"ANSM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","PTSD"],"diseases":["PTSD Nightmares","Hypertension (labeled)"],"status":"active"},{"id":"8e0f4c4d-b031-4db1-824b-3e123756c09d","procedure_id":"proc-baclofen-aud","jurisdiction_id":"jur-us-or","procedure_name":"High-Dose Baclofen for Alcohol Use Disorder","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction"],"diseases":["Alcohol Use Disorder"],"status":"active"},{"id":"9a68dc0a-d780-48cb-a613-def74ac6f67f","procedure_id":"proc-baclofen-aud","jurisdiction_id":"jur-us-co","procedure_name":"High-Dose Baclofen for Alcohol Use Disorder","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction"],"diseases":["Alcohol Use Disorder"],"status":"active"},{"id":"2ae64322-0799-4d5e-a605-84a764ed4d59","procedure_id":"proc-baclofen-aud","jurisdiction_id":"jur-us-ca","procedure_name":"High-Dose Baclofen for Alcohol Use Disorder","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction"],"diseases":["Alcohol Use Disorder"],"status":"active"},{"id":"44293329-ebc6-41b0-83bc-adef9aca3f62","procedure_id":"proc-baclofen-aud","jurisdiction_id":"jur-us-tx","procedure_name":"High-Dose Baclofen for Alcohol Use Disorder","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction"],"diseases":["Alcohol Use Disorder"],"status":"active"},{"id":"7e58acf0-11b5-4980-adc8-8cf4503d4e48","procedure_id":"proc-baclofen-aud","jurisdiction_id":"jur-us-fl","procedure_name":"High-Dose Baclofen for Alcohol Use Disorder","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction"],"diseases":["Alcohol Use Disorder"],"status":"active"},{"id":"9659c58c-2233-4c90-a0ee-883bc92765e3","procedure_id":"proc-baclofen-aud","jurisdiction_id":"jur-au","procedure_name":"High-Dose Baclofen for Alcohol Use Disorder","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"TGA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction"],"diseases":["Alcohol Use Disorder"],"status":"active"},{"id":"34ff8169-aa72-4d63-9e4c-858553fb18ce","procedure_id":"proc-baclofen-aud","jurisdiction_id":"jur-ch","procedure_name":"High-Dose Baclofen for Alcohol Use Disorder","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Swissmedic","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction"],"diseases":["Alcohol Use Disorder"],"status":"active"},{"id":"d10ca808-1d15-410e-927d-ca8e524ddcf6","procedure_id":"proc-baclofen-aud","jurisdiction_id":"jur-ca","procedure_name":"High-Dose Baclofen for Alcohol Use Disorder","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Health Canada","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction"],"diseases":["Alcohol Use Disorder"],"status":"active"},{"id":"399f9078-bdb3-44b5-a445-c8ac089f9402","procedure_id":"proc-baclofen-aud","jurisdiction_id":"jur-mx","procedure_name":"High-Dose Baclofen for Alcohol Use Disorder","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Permissive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"COFEPRIS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction"],"diseases":["Alcohol Use Disorder"],"status":"active"},{"id":"79ea362d-a49d-428a-90a5-e1256990b12c","procedure_id":"proc-baclofen-aud","jurisdiction_id":"jur-hn-prospera","procedure_name":"High-Dose Baclofen for Alcohol Use Disorder","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Permissive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Próspera ZEDE health rules (contested)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction"],"diseases":["Alcohol Use Disorder"],"status":"active"},{"id":"628a3787-5879-48d0-a660-1e0b11198ccb","procedure_id":"proc-baclofen-aud","jurisdiction_id":"jur-nl","procedure_name":"High-Dose Baclofen for Alcohol Use Disorder","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"MEB / IGJ","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction"],"diseases":["Alcohol Use Disorder"],"status":"active"},{"id":"d0f8dcf4-df16-4daa-aa09-c105b7a8bfcc","procedure_id":"proc-baclofen-aud","jurisdiction_id":"jur-uk","procedure_name":"High-Dose Baclofen for Alcohol Use Disorder","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"MHRA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction"],"diseases":["Alcohol Use Disorder"],"status":"active"},{"id":"7828ab9a-dc7f-4d40-a312-504f16b9c1e6","procedure_id":"proc-baclofen-aud","jurisdiction_id":"jur-il","procedure_name":"High-Dose Baclofen for Alcohol Use Disorder","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction"],"diseases":["Alcohol Use Disorder"],"status":"active"},{"id":"5b941166-af61-4d16-9289-682bd522819c","procedure_id":"proc-baclofen-aud","jurisdiction_id":"jur-jm","procedure_name":"High-Dose Baclofen for Alcohol Use Disorder","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction"],"diseases":["Alcohol Use Disorder"],"status":"active"},{"id":"417cc20a-80ea-4f82-bf15-a82d92bc3d2f","procedure_id":"proc-baclofen-aud","jurisdiction_id":"jur-th","procedure_name":"High-Dose Baclofen for Alcohol Use Disorder","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Permissive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Thai FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction"],"diseases":["Alcohol Use Disorder"],"status":"active"},{"id":"523393d7-7427-4f71-878c-08c75bc87872","procedure_id":"proc-baclofen-aud","jurisdiction_id":"jur-es","procedure_name":"High-Dose Baclofen for Alcohol Use Disorder","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"AEMPS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction"],"diseases":["Alcohol Use Disorder"],"status":"active"},{"id":"8d6f52b8-eb10-42f9-99d3-1acf93cf7e50","procedure_id":"proc-baclofen-aud","jurisdiction_id":"jur-tu","procedure_name":"High-Dose Baclofen for Alcohol Use Disorder","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction"],"diseases":["Alcohol Use Disorder"],"status":"active"},{"id":"69af2cd8-8d04-49c3-a896-d0a9b1806424","procedure_id":"proc-baclofen-aud","jurisdiction_id":"jur-in","procedure_name":"High-Dose Baclofen for Alcohol Use Disorder","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Permissive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"CDSCO","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction"],"diseases":["Alcohol Use Disorder"],"status":"active"},{"id":"da2a5e00-4bae-4cde-8e21-4214745dd432","procedure_id":"proc-baclofen-aud","jurisdiction_id":"jur-br","procedure_name":"High-Dose Baclofen for Alcohol Use Disorder","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"ANVISA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction"],"diseases":["Alcohol Use Disorder"],"status":"active"},{"id":"b32ee233-4453-4470-b119-ed42c20b13d2","procedure_id":"proc-baclofen-aud","jurisdiction_id":"jur-cr","procedure_name":"High-Dose Baclofen for Alcohol Use Disorder","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction"],"diseases":["Alcohol Use Disorder"],"status":"active"},{"id":"f73f8215-72c6-4941-b008-0eb3a22a6c4c","procedure_id":"proc-baclofen-aud","jurisdiction_id":"jur-uae","procedure_name":"High-Dose Baclofen for Alcohol Use Disorder","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction"],"diseases":["Alcohol Use Disorder"],"status":"active"},{"id":"b1f8820f-5d6b-47aa-8e4d-d0042dfacd65","procedure_id":"proc-baclofen-aud","jurisdiction_id":"jur-kr","procedure_name":"High-Dose Baclofen for Alcohol Use Disorder","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"MFDS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction"],"diseases":["Alcohol Use Disorder"],"status":"active"},{"id":"f1a932ee-6238-4ba7-ba61-1bbbf556ea8a","procedure_id":"proc-baclofen-aud","jurisdiction_id":"jur-gr","procedure_name":"High-Dose Baclofen for Alcohol Use Disorder","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction"],"diseases":["Alcohol Use Disorder"],"status":"active"},{"id":"4cef97e2-f53f-4e88-953d-359d8c744872","procedure_id":"proc-baclofen-aud","jurisdiction_id":"jur-be","procedure_name":"High-Dose Baclofen for Alcohol Use Disorder","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction"],"diseases":["Alcohol Use Disorder"],"status":"active"},{"id":"bae657aa-df1d-43a7-aa2b-86f5bfceaffa","procedure_id":"proc-baclofen-aud","jurisdiction_id":"jur-se","procedure_name":"High-Dose Baclofen for Alcohol Use Disorder","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction"],"diseases":["Alcohol Use Disorder"],"status":"active"},{"id":"5aae7f44-3298-4c46-a5b1-bf8e86d21864","procedure_id":"proc-baclofen-aud","jurisdiction_id":"jur-jp","procedure_name":"High-Dose Baclofen for Alcohol Use Disorder","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"PMDA / MHLW","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction"],"diseases":["Alcohol Use Disorder"],"status":"active"},{"id":"468ea400-6e36-4072-8566-c09dce0ab48e","procedure_id":"proc-baclofen-aud","jurisdiction_id":"jur-sg","procedure_name":"High-Dose Baclofen for Alcohol Use Disorder","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"HSA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction"],"diseases":["Alcohol Use Disorder"],"status":"active"},{"id":"e4ac396c-2a82-4be8-b085-aea4a6d00bbe","procedure_id":"proc-baclofen-aud","jurisdiction_id":"jur-cl","procedure_name":"High-Dose Baclofen for Alcohol Use Disorder","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction"],"diseases":["Alcohol Use Disorder"],"status":"active"},{"id":"da72be83-ea66-4514-a8bf-3bbc26b88b98","procedure_id":"proc-baclofen-aud","jurisdiction_id":"jur-ar","procedure_name":"High-Dose Baclofen for Alcohol Use Disorder","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction"],"diseases":["Alcohol Use Disorder"],"status":"active"},{"id":"ac78472e-5580-4d00-8b8f-a5363456028d","procedure_id":"proc-baclofen-aud","jurisdiction_id":"jur-za","procedure_name":"High-Dose Baclofen for Alcohol Use Disorder","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction"],"diseases":["Alcohol Use Disorder"],"status":"active"},{"id":"71fa6331-1b03-4602-8f64-5a174ff9d932","procedure_id":"proc-baclofen-aud","jurisdiction_id":"jur-ph","procedure_name":"High-Dose Baclofen for Alcohol Use Disorder","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction"],"diseases":["Alcohol Use Disorder"],"status":"active"},{"id":"d23f24ec-f4af-4ddb-89e9-2176c324601b","procedure_id":"proc-baclofen-aud","jurisdiction_id":"jur-po","procedure_name":"High-Dose Baclofen for Alcohol Use Disorder","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction"],"diseases":["Alcohol Use Disorder"],"status":"active"},{"id":"3c0df1eb-85b8-48b9-b7e6-e14a607aa3d8","procedure_id":"proc-baclofen-aud","jurisdiction_id":"jur-pt","procedure_name":"High-Dose Baclofen for Alcohol Use Disorder","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Addiction"],"diseases":["Alcohol Use Disorder"],"status":"active"},{"id":"9318f331-df23-4331-9dd7-e17c9739df37","procedure_id":"proc-peptide-cjc-ipa","jurisdiction_id":"jur-us-or","procedure_name":"CJC-1295 / Ipamorelin Growth Hormone Secretagogue Peptides","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Performance"],"diseases":["Age-Related Sarcopenia","Growth Hormone Deficiency (not labeled for secretagogues)"],"status":"active"},{"id":"96c36682-e9c5-47bf-932b-37a29c1712b0","procedure_id":"proc-peptide-cjc-ipa","jurisdiction_id":"jur-us-co","procedure_name":"CJC-1295 / Ipamorelin Growth Hormone Secretagogue Peptides","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Performance"],"diseases":["Age-Related Sarcopenia","Growth Hormone Deficiency (not labeled for secretagogues)"],"status":"active"},{"id":"4040d31e-cb0b-4ece-ab99-991e21e32586","procedure_id":"proc-peptide-cjc-ipa","jurisdiction_id":"jur-us-ca","procedure_name":"CJC-1295 / Ipamorelin Growth Hormone Secretagogue Peptides","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Performance"],"diseases":["Age-Related Sarcopenia","Growth Hormone Deficiency (not labeled for secretagogues)"],"status":"active"},{"id":"131cc61c-d8a5-4b32-9ea9-28f53e38091c","procedure_id":"proc-peptide-cjc-ipa","jurisdiction_id":"jur-us-tx","procedure_name":"CJC-1295 / Ipamorelin Growth Hormone Secretagogue Peptides","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Performance"],"diseases":["Age-Related Sarcopenia","Growth Hormone Deficiency (not labeled for secretagogues)"],"status":"active"},{"id":"c0abfaae-b770-4438-a789-ac55d00be82a","procedure_id":"proc-peptide-cjc-ipa","jurisdiction_id":"jur-us-fl","procedure_name":"CJC-1295 / Ipamorelin Growth Hormone Secretagogue Peptides","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Performance"],"diseases":["Age-Related Sarcopenia","Growth Hormone Deficiency (not labeled for secretagogues)"],"status":"active"},{"id":"d19ad1fb-ea63-4d6a-b4c4-ff7a5886dfdf","procedure_id":"proc-peptide-cjc-ipa","jurisdiction_id":"jur-ch","procedure_name":"CJC-1295 / Ipamorelin Growth Hormone Secretagogue Peptides","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"Swissmedic","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Performance"],"diseases":["Age-Related Sarcopenia","Growth Hormone Deficiency (not labeled for secretagogues)"],"status":"active"},{"id":"4276abdf-0ab1-4ffd-8e70-3cd2a03acba1","procedure_id":"proc-peptide-cjc-ipa","jurisdiction_id":"jur-hn-prospera","procedure_name":"CJC-1295 / Ipamorelin Growth Hormone Secretagogue Peptides","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"COMPOUNDING","oversight_quality":"MINIMAL","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Still may violate advertising/medicine laws. Bulk substance status is critical.","eligibility_requirements":"Medical justification documentation if any.","provider_requirements":"Prescriber + compounder compliance uncertain.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray compounding climate — high legal risk even if local practice is common.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide + relatively open compounding climate → gray compounding risk.","regulatory_authority":"Próspera ZEDE health rules (contested)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Performance"],"diseases":["Age-Related Sarcopenia","Growth Hormone Deficiency (not labeled for secretagogues)"],"status":"active"},{"id":"928204ba-b88c-415d-9761-db9c3b636ba0","procedure_id":"proc-peptide-cjc-ipa","jurisdiction_id":"jur-nl","procedure_name":"CJC-1295 / Ipamorelin Growth Hormone Secretagogue Peptides","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"MEB / IGJ","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Performance"],"diseases":["Age-Related Sarcopenia","Growth Hormone Deficiency (not labeled for secretagogues)"],"status":"active"},{"id":"e73e061c-8434-4c7e-8ed3-5566ec18ca53","procedure_id":"proc-peptide-cjc-ipa","jurisdiction_id":"jur-il","procedure_name":"CJC-1295 / Ipamorelin Growth Hormone Secretagogue Peptides","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Performance"],"diseases":["Age-Related Sarcopenia","Growth Hormone Deficiency (not labeled for secretagogues)"],"status":"active"},{"id":"b3fb73e1-74bd-4aca-b4da-4c2ddb283d0f","procedure_id":"proc-peptide-cjc-ipa","jurisdiction_id":"jur-jm","procedure_name":"CJC-1295 / Ipamorelin Growth Hormone Secretagogue Peptides","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Performance"],"diseases":["Age-Related Sarcopenia","Growth Hormone Deficiency (not labeled for secretagogues)"],"status":"active"},{"id":"14c23726-984f-4863-88d7-e467b024955c","procedure_id":"proc-peptide-cjc-ipa","jurisdiction_id":"jur-es","procedure_name":"CJC-1295 / Ipamorelin Growth Hormone Secretagogue Peptides","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"AEMPS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Performance"],"diseases":["Age-Related Sarcopenia","Growth Hormone Deficiency (not labeled for secretagogues)"],"status":"active"},{"id":"a3276571-d971-405d-9437-73fe95540e78","procedure_id":"proc-peptide-cjc-ipa","jurisdiction_id":"jur-tu","procedure_name":"CJC-1295 / Ipamorelin Growth Hormone Secretagogue Peptides","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Performance"],"diseases":["Age-Related Sarcopenia","Growth Hormone Deficiency (not labeled for secretagogues)"],"status":"active"},{"id":"9368b13c-3d94-4c1b-a914-ed019fd2cc05","procedure_id":"proc-peptide-cjc-ipa","jurisdiction_id":"jur-in","procedure_name":"CJC-1295 / Ipamorelin Growth Hormone Secretagogue Peptides","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"COMPOUNDING","oversight_quality":"MINIMAL","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Still may violate advertising/medicine laws. Bulk substance status is critical.","eligibility_requirements":"Medical justification documentation if any.","provider_requirements":"Prescriber + compounder compliance uncertain.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray compounding climate — high legal risk even if local practice is common.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide + relatively open compounding climate → gray compounding risk.","regulatory_authority":"CDSCO","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Performance"],"diseases":["Age-Related Sarcopenia","Growth Hormone Deficiency (not labeled for secretagogues)"],"status":"active"},{"id":"0dbf10e4-85e5-4db3-9bce-0fd2587ae2a4","procedure_id":"proc-peptide-cjc-ipa","jurisdiction_id":"jur-br","procedure_name":"CJC-1295 / Ipamorelin Growth Hormone Secretagogue Peptides","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"ANVISA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Performance"],"diseases":["Age-Related Sarcopenia","Growth Hormone Deficiency (not labeled for secretagogues)"],"status":"active"},{"id":"91032311-e6b0-49bf-9a1e-7516dde4c33f","procedure_id":"proc-peptide-cjc-ipa","jurisdiction_id":"jur-cr","procedure_name":"CJC-1295 / Ipamorelin Growth Hormone Secretagogue Peptides","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Performance"],"diseases":["Age-Related Sarcopenia","Growth Hormone Deficiency (not labeled for secretagogues)"],"status":"active"},{"id":"85b1fc13-f399-4371-98fb-7b9fff9a92fd","procedure_id":"proc-peptide-cjc-ipa","jurisdiction_id":"jur-uae","procedure_name":"CJC-1295 / Ipamorelin Growth Hormone Secretagogue Peptides","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Performance"],"diseases":["Age-Related Sarcopenia","Growth Hormone Deficiency (not labeled for secretagogues)"],"status":"active"},{"id":"c0cf388e-9114-4638-a935-6511880ee5ba","procedure_id":"proc-peptide-cjc-ipa","jurisdiction_id":"jur-kr","procedure_name":"CJC-1295 / Ipamorelin Growth Hormone Secretagogue Peptides","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"MFDS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Performance"],"diseases":["Age-Related Sarcopenia","Growth Hormone Deficiency (not labeled for secretagogues)"],"status":"active"},{"id":"8db76ac7-a984-47a1-ae9e-df14198ad802","procedure_id":"proc-peptide-cjc-ipa","jurisdiction_id":"jur-gr","procedure_name":"CJC-1295 / Ipamorelin Growth Hormone Secretagogue Peptides","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Performance"],"diseases":["Age-Related Sarcopenia","Growth Hormone Deficiency (not labeled for secretagogues)"],"status":"active"},{"id":"effa09dd-bfe2-436f-b275-a06ab8b5e20a","procedure_id":"proc-peptide-cjc-ipa","jurisdiction_id":"jur-be","procedure_name":"CJC-1295 / Ipamorelin Growth Hormone Secretagogue Peptides","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Performance"],"diseases":["Age-Related Sarcopenia","Growth Hormone Deficiency (not labeled for secretagogues)"],"status":"active"},{"id":"a4d610b6-df6a-4049-ad4e-a803020ea9e0","procedure_id":"proc-peptide-cjc-ipa","jurisdiction_id":"jur-se","procedure_name":"CJC-1295 / Ipamorelin Growth Hormone Secretagogue Peptides","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Performance"],"diseases":["Age-Related Sarcopenia","Growth Hormone Deficiency (not labeled for secretagogues)"],"status":"active"},{"id":"2e71a028-4a6e-4b82-a742-15971e8bae6a","procedure_id":"proc-peptide-cjc-ipa","jurisdiction_id":"jur-cl","procedure_name":"CJC-1295 / Ipamorelin Growth Hormone Secretagogue Peptides","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Performance"],"diseases":["Age-Related Sarcopenia","Growth Hormone Deficiency (not labeled for secretagogues)"],"status":"active"},{"id":"653b0c21-ca5f-4709-8a76-0bff590044b2","procedure_id":"proc-peptide-cjc-ipa","jurisdiction_id":"jur-ar","procedure_name":"CJC-1295 / Ipamorelin Growth Hormone Secretagogue Peptides","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Performance"],"diseases":["Age-Related Sarcopenia","Growth Hormone Deficiency (not labeled for secretagogues)"],"status":"active"},{"id":"0969c584-7db4-479e-9feb-0d6fe37666c1","procedure_id":"proc-peptide-cjc-ipa","jurisdiction_id":"jur-za","procedure_name":"CJC-1295 / Ipamorelin Growth Hormone Secretagogue Peptides","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Performance"],"diseases":["Age-Related Sarcopenia","Growth Hormone Deficiency (not labeled for secretagogues)"],"status":"active"},{"id":"83c49b5f-17ad-4505-9346-2867cec217b8","procedure_id":"proc-peptide-cjc-ipa","jurisdiction_id":"jur-ph","procedure_name":"CJC-1295 / Ipamorelin Growth Hormone Secretagogue Peptides","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Performance"],"diseases":["Age-Related Sarcopenia","Growth Hormone Deficiency (not labeled for secretagogues)"],"status":"active"},{"id":"85a0ba9a-9f88-4a8f-b451-c38bbf97b024","procedure_id":"proc-peptide-cjc-ipa","jurisdiction_id":"jur-po","procedure_name":"CJC-1295 / Ipamorelin Growth Hormone Secretagogue Peptides","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Performance"],"diseases":["Age-Related Sarcopenia","Growth Hormone Deficiency (not labeled for secretagogues)"],"status":"active"},{"id":"8369f29f-3e20-43c7-8fa7-d24bb309c1f5","procedure_id":"proc-peptide-cjc-ipa","jurisdiction_id":"jur-pt","procedure_name":"CJC-1295 / Ipamorelin Growth Hormone Secretagogue Peptides","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Anti_Aging","Performance"],"diseases":["Age-Related Sarcopenia","Growth Hormone Deficiency (not labeled for secretagogues)"],"status":"active"},{"id":"a5b52f72-1b85-4fd9-8e7e-438a4bcd6d75","procedure_id":"proc-peptide-tesamorelin","jurisdiction_id":"jur-us-or","procedure_name":"Tesamorelin (Egrifta) for HIV Lipodystrophy / Off-Label Visceral Fat","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_ON_LABEL","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","HIV"],"diseases":["HIV-Associated Lipodystrophy","Visceral Adiposity (off-label)"],"status":"active"},{"id":"4ed5a656-8dd1-4e4e-bbc5-af55b74bb862","procedure_id":"proc-peptide-tesamorelin","jurisdiction_id":"jur-us-co","procedure_name":"Tesamorelin (Egrifta) for HIV Lipodystrophy / Off-Label Visceral Fat","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_ON_LABEL","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","HIV"],"diseases":["HIV-Associated Lipodystrophy","Visceral Adiposity (off-label)"],"status":"active"},{"id":"607fac6e-c3bb-4702-ae7b-8b38f19186e9","procedure_id":"proc-peptide-tesamorelin","jurisdiction_id":"jur-us-ca","procedure_name":"Tesamorelin (Egrifta) for HIV Lipodystrophy / Off-Label Visceral Fat","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_ON_LABEL","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","HIV"],"diseases":["HIV-Associated Lipodystrophy","Visceral Adiposity (off-label)"],"status":"active"},{"id":"03fd2f05-bcd1-4ba4-946d-e5951631baf6","procedure_id":"proc-peptide-tesamorelin","jurisdiction_id":"jur-us-tx","procedure_name":"Tesamorelin (Egrifta) for HIV Lipodystrophy / Off-Label Visceral Fat","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_ON_LABEL","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","HIV"],"diseases":["HIV-Associated Lipodystrophy","Visceral Adiposity (off-label)"],"status":"active"},{"id":"25540810-9550-4f6a-82c8-8c28d2368579","procedure_id":"proc-peptide-tesamorelin","jurisdiction_id":"jur-us-fl","procedure_name":"Tesamorelin (Egrifta) for HIV Lipodystrophy / Off-Label Visceral Fat","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_ON_LABEL","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","HIV"],"diseases":["HIV-Associated Lipodystrophy","Visceral Adiposity (off-label)"],"status":"active"},{"id":"aa8251fc-7a3a-4689-8709-10d134132251","procedure_id":"proc-peptide-tesamorelin","jurisdiction_id":"jur-au","procedure_name":"Tesamorelin (Egrifta) for HIV Lipodystrophy / Off-Label Visceral Fat","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"APPROVED_ON_LABEL","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"TGA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","HIV"],"diseases":["HIV-Associated Lipodystrophy","Visceral Adiposity (off-label)"],"status":"active"},{"id":"08641326-4fd5-439e-a62e-0bda6fbe4e44","procedure_id":"proc-peptide-tesamorelin","jurisdiction_id":"jur-ch","procedure_name":"Tesamorelin (Egrifta) for HIV Lipodystrophy / Off-Label Visceral Fat","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"APPROVED_ON_LABEL","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"Swissmedic","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","HIV"],"diseases":["HIV-Associated Lipodystrophy","Visceral Adiposity (off-label)"],"status":"active"},{"id":"6a230c12-89e1-4469-a713-81b41ec7aedd","procedure_id":"proc-peptide-tesamorelin","jurisdiction_id":"jur-mx","procedure_name":"Tesamorelin (Egrifta) for HIV Lipodystrophy / Off-Label Visceral Fat","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"COFEPRIS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","HIV"],"diseases":["HIV-Associated Lipodystrophy","Visceral Adiposity (off-label)"],"status":"active"},{"id":"5969c744-1d96-4794-b5a3-a5d5633121cb","procedure_id":"proc-peptide-tesamorelin","jurisdiction_id":"jur-hn-prospera","procedure_name":"Tesamorelin (Egrifta) for HIV Lipodystrophy / Off-Label Visceral Fat","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"Próspera ZEDE health rules (contested)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","HIV"],"diseases":["HIV-Associated Lipodystrophy","Visceral Adiposity (off-label)"],"status":"active"},{"id":"1921114e-cb41-464c-950f-2a7720ac64ff","procedure_id":"proc-peptide-tesamorelin","jurisdiction_id":"jur-nl","procedure_name":"Tesamorelin (Egrifta) for HIV Lipodystrophy / Off-Label Visceral Fat","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"APPROVED_ON_LABEL","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"MEB / IGJ","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","HIV"],"diseases":["HIV-Associated Lipodystrophy","Visceral Adiposity (off-label)"],"status":"active"},{"id":"0e18cf52-d461-449b-b3a8-093430a46354","procedure_id":"proc-peptide-tesamorelin","jurisdiction_id":"jur-de","procedure_name":"Tesamorelin (Egrifta) for HIV Lipodystrophy / Off-Label Visceral Fat","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"APPROVED_ON_LABEL","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"BfArM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","HIV"],"diseases":["HIV-Associated Lipodystrophy","Visceral Adiposity (off-label)"],"status":"active"},{"id":"705eb9b4-2c14-4c53-91f9-e11f68ec435f","procedure_id":"proc-peptide-tesamorelin","jurisdiction_id":"jur-uk","procedure_name":"Tesamorelin (Egrifta) for HIV Lipodystrophy / Off-Label Visceral Fat","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"APPROVED_ON_LABEL","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"MHRA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","HIV"],"diseases":["HIV-Associated Lipodystrophy","Visceral Adiposity (off-label)"],"status":"active"},{"id":"22863c35-1ecc-4a84-bd59-e6513616ac36","procedure_id":"proc-peptide-tesamorelin","jurisdiction_id":"jur-il","procedure_name":"Tesamorelin (Egrifta) for HIV Lipodystrophy / Off-Label Visceral Fat","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","HIV"],"diseases":["HIV-Associated Lipodystrophy","Visceral Adiposity (off-label)"],"status":"active"},{"id":"335d4982-d6f2-4718-9036-e613916f0ca7","procedure_id":"proc-peptide-tesamorelin","jurisdiction_id":"jur-jm","procedure_name":"Tesamorelin (Egrifta) for HIV Lipodystrophy / Off-Label Visceral Fat","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","HIV"],"diseases":["HIV-Associated Lipodystrophy","Visceral Adiposity (off-label)"],"status":"active"},{"id":"841eca2d-4fa9-48ad-afef-39cb3857ac15","procedure_id":"proc-peptide-tesamorelin","jurisdiction_id":"jur-th","procedure_name":"Tesamorelin (Egrifta) for HIV Lipodystrophy / Off-Label Visceral Fat","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"APPROVED_ON_LABEL","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"Thai FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","HIV"],"diseases":["HIV-Associated Lipodystrophy","Visceral Adiposity (off-label)"],"status":"active"},{"id":"52a30d95-eb9f-4c2c-a9da-50999c8f7914","procedure_id":"proc-peptide-tesamorelin","jurisdiction_id":"jur-es","procedure_name":"Tesamorelin (Egrifta) for HIV Lipodystrophy / Off-Label Visceral Fat","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"APPROVED_ON_LABEL","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"AEMPS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","HIV"],"diseases":["HIV-Associated Lipodystrophy","Visceral Adiposity (off-label)"],"status":"active"},{"id":"373ead84-9c60-4f6a-bd5e-4045673d3d2f","procedure_id":"proc-peptide-tesamorelin","jurisdiction_id":"jur-tu","procedure_name":"Tesamorelin (Egrifta) for HIV Lipodystrophy / Off-Label Visceral Fat","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","HIV"],"diseases":["HIV-Associated Lipodystrophy","Visceral Adiposity (off-label)"],"status":"active"},{"id":"a170936b-dba2-4966-bf36-2072a3220718","procedure_id":"proc-peptide-tesamorelin","jurisdiction_id":"jur-in","procedure_name":"Tesamorelin (Egrifta) for HIV Lipodystrophy / Off-Label Visceral Fat","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"CDSCO","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","HIV"],"diseases":["HIV-Associated Lipodystrophy","Visceral Adiposity (off-label)"],"status":"active"},{"id":"3b03e9aa-e092-4005-89d7-84c1ede5b975","procedure_id":"proc-peptide-tesamorelin","jurisdiction_id":"jur-br","procedure_name":"Tesamorelin (Egrifta) for HIV Lipodystrophy / Off-Label Visceral Fat","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"ANVISA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","HIV"],"diseases":["HIV-Associated Lipodystrophy","Visceral Adiposity (off-label)"],"status":"active"},{"id":"91f642b1-6010-47a9-a238-03754a2e1e7d","procedure_id":"proc-peptide-tesamorelin","jurisdiction_id":"jur-cr","procedure_name":"Tesamorelin (Egrifta) for HIV Lipodystrophy / Off-Label Visceral Fat","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","HIV"],"diseases":["HIV-Associated Lipodystrophy","Visceral Adiposity (off-label)"],"status":"active"},{"id":"f875d988-1829-45ee-a34b-c9357ba77f7e","procedure_id":"proc-peptide-tesamorelin","jurisdiction_id":"jur-uae","procedure_name":"Tesamorelin (Egrifta) for HIV Lipodystrophy / Off-Label Visceral Fat","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","HIV"],"diseases":["HIV-Associated Lipodystrophy","Visceral Adiposity (off-label)"],"status":"active"},{"id":"d7c3ca10-abc2-4cb0-a960-83b4532f9111","procedure_id":"proc-peptide-tesamorelin","jurisdiction_id":"jur-kr","procedure_name":"Tesamorelin (Egrifta) for HIV Lipodystrophy / Off-Label Visceral Fat","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"APPROVED_ON_LABEL","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"MFDS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","HIV"],"diseases":["HIV-Associated Lipodystrophy","Visceral Adiposity (off-label)"],"status":"active"},{"id":"9a77e373-2af7-4c4a-8484-f71dd6eea9f8","procedure_id":"proc-peptide-tesamorelin","jurisdiction_id":"jur-gr","procedure_name":"Tesamorelin (Egrifta) for HIV Lipodystrophy / Off-Label Visceral Fat","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","HIV"],"diseases":["HIV-Associated Lipodystrophy","Visceral Adiposity (off-label)"],"status":"active"},{"id":"b19defe9-22da-44d2-97e3-b9d1dc48d221","procedure_id":"proc-peptide-tesamorelin","jurisdiction_id":"jur-be","procedure_name":"Tesamorelin (Egrifta) for HIV Lipodystrophy / Off-Label Visceral Fat","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"APPROVED_ON_LABEL","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","HIV"],"diseases":["HIV-Associated Lipodystrophy","Visceral Adiposity (off-label)"],"status":"active"},{"id":"fd1a7611-b766-4ebc-bf44-0f901c81111a","procedure_id":"proc-peptide-tesamorelin","jurisdiction_id":"jur-se","procedure_name":"Tesamorelin (Egrifta) for HIV Lipodystrophy / Off-Label Visceral Fat","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","HIV"],"diseases":["HIV-Associated Lipodystrophy","Visceral Adiposity (off-label)"],"status":"active"},{"id":"965d3371-76fb-44fe-813a-9746c7920b01","procedure_id":"proc-peptide-tesamorelin","jurisdiction_id":"jur-jp","procedure_name":"Tesamorelin (Egrifta) for HIV Lipodystrophy / Off-Label Visceral Fat","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"APPROVED_ON_LABEL","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"PMDA / MHLW","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","HIV"],"diseases":["HIV-Associated Lipodystrophy","Visceral Adiposity (off-label)"],"status":"active"},{"id":"2eb6ffe0-215a-4be0-8122-c857fa168f45","procedure_id":"proc-peptide-tesamorelin","jurisdiction_id":"jur-sg","procedure_name":"Tesamorelin (Egrifta) for HIV Lipodystrophy / Off-Label Visceral Fat","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"APPROVED_ON_LABEL","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"HSA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","HIV"],"diseases":["HIV-Associated Lipodystrophy","Visceral Adiposity (off-label)"],"status":"active"},{"id":"f393c80d-401f-459d-b4dd-02e3a5e298f5","procedure_id":"proc-peptide-tesamorelin","jurisdiction_id":"jur-cl","procedure_name":"Tesamorelin (Egrifta) for HIV Lipodystrophy / Off-Label Visceral Fat","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","HIV"],"diseases":["HIV-Associated Lipodystrophy","Visceral Adiposity (off-label)"],"status":"active"},{"id":"0176b85e-fe3f-4417-9c20-8b2c916ce2a3","procedure_id":"proc-peptide-tesamorelin","jurisdiction_id":"jur-ar","procedure_name":"Tesamorelin (Egrifta) for HIV Lipodystrophy / Off-Label Visceral Fat","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","HIV"],"diseases":["HIV-Associated Lipodystrophy","Visceral Adiposity (off-label)"],"status":"active"},{"id":"2771e0cb-43cc-4163-adeb-19f596b18cf8","procedure_id":"proc-peptide-tesamorelin","jurisdiction_id":"jur-za","procedure_name":"Tesamorelin (Egrifta) for HIV Lipodystrophy / Off-Label Visceral Fat","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","HIV"],"diseases":["HIV-Associated Lipodystrophy","Visceral Adiposity (off-label)"],"status":"active"},{"id":"64d42a19-3b0e-4138-a300-47593aeff79b","procedure_id":"proc-peptide-tesamorelin","jurisdiction_id":"jur-ph","procedure_name":"Tesamorelin (Egrifta) for HIV Lipodystrophy / Off-Label Visceral Fat","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","HIV"],"diseases":["HIV-Associated Lipodystrophy","Visceral Adiposity (off-label)"],"status":"active"},{"id":"8cb3e8ee-d805-44c1-ba86-30680d23a1a4","procedure_id":"proc-peptide-tesamorelin","jurisdiction_id":"jur-po","procedure_name":"Tesamorelin (Egrifta) for HIV Lipodystrophy / Off-Label Visceral Fat","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","HIV"],"diseases":["HIV-Associated Lipodystrophy","Visceral Adiposity (off-label)"],"status":"active"},{"id":"323e07fe-280a-4287-ba46-7c19cad54f85","procedure_id":"proc-peptide-tesamorelin","jurisdiction_id":"jur-pt","procedure_name":"Tesamorelin (Egrifta) for HIV Lipodystrophy / Off-Label Visceral Fat","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"UNKNOWN","access_pathway":"NONE","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","HIV"],"diseases":["HIV-Associated Lipodystrophy","Visceral Adiposity (off-label)"],"status":"active"},{"id":"eda89082-a79e-40a5-a646-979b7ab520fb","procedure_id":"proc-peptide-tesamorelin","jurisdiction_id":"jur-fr","procedure_name":"Tesamorelin (Egrifta) for HIV Lipodystrophy / Off-Label Visceral Fat","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"APPROVED_ON_LABEL","access_pathway":"STANDARD_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only where the product is actually authorized/marketed locally — registration is country-specific.","eligibility_requirements":"Labeled indication criteria.","provider_requirements":"Prescriptive authority + specialty pharmacy as applicable.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred standard Rx pathway if product is registered locally; otherwise unavailable.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: products with originator labels (e.g. tesamorelin, bremelanotide) follow ordinary prescription rules where marketed.","regulatory_authority":"ANSM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Metabolic_Health","HIV"],"diseases":["HIV-Associated Lipodystrophy","Visceral Adiposity (off-label)"],"status":"active"},{"id":"d114c607-2d4b-4a80-963a-d9e823f18012","procedure_id":"proc-mito-replacement","jurisdiction_id":"jur-hn-prospera","procedure_name":"Mitochondrial Replacement Therapy (MRT / Three-Person IVF)","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only a handful of regimes authorize mitochondrial donation.","eligibility_requirements":"None under default inference.","provider_requirements":"None under default inference.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred prohibited/unavailable for MRT outside known licensed programmes.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: MRT is rare and usually banned outside dedicated UK-class licences; default prohibited unless explicit programme exists.","regulatory_authority":"Próspera ZEDE health rules (contested)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Mitochondrial DNA Disease","Leigh Syndrome Risk","Mitochondrial Inheritance Risk"],"status":"active"},{"id":"ba6495be-5296-4a47-b6ce-c63c30013f36","procedure_id":"proc-mito-replacement","jurisdiction_id":"jur-gr","procedure_name":"Mitochondrial Replacement Therapy (MRT / Three-Person IVF)","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Only a handful of regimes authorize mitochondrial donation.","eligibility_requirements":"None under default inference.","provider_requirements":"None under default inference.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred prohibited/unavailable for MRT outside known licensed programmes.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: MRT is rare and usually banned outside dedicated UK-class licences; default prohibited unless explicit programme exists.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health","Genetics"],"diseases":["Mitochondrial DNA Disease","Leigh Syndrome Risk","Mitochondrial Inheritance Risk"],"status":"active"},{"id":"22c76f5c-4b7d-425d-8044-0d8e7479bdb2","procedure_id":"proc-egg-freezing","jurisdiction_id":"jur-us-or","procedure_name":"Elective Oocyte Cryopreservation (Social Egg Freezing)","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Age-Related Fertility Decline","Oncofertility","Elective Fertility Preservation"],"status":"active"},{"id":"523f7cec-dbe9-464d-885c-9bfe9d83a3ab","procedure_id":"proc-egg-freezing","jurisdiction_id":"jur-us-co","procedure_name":"Elective Oocyte Cryopreservation (Social Egg Freezing)","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Age-Related Fertility Decline","Oncofertility","Elective Fertility Preservation"],"status":"active"},{"id":"610c3e4e-78ac-4a3f-9d56-2c63987b3b56","procedure_id":"proc-egg-freezing","jurisdiction_id":"jur-us-ca","procedure_name":"Elective Oocyte Cryopreservation (Social Egg Freezing)","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Age-Related Fertility Decline","Oncofertility","Elective Fertility Preservation"],"status":"active"},{"id":"99baad51-bcc5-4113-b33b-06d37470dd8b","procedure_id":"proc-egg-freezing","jurisdiction_id":"jur-us-tx","procedure_name":"Elective Oocyte Cryopreservation (Social Egg Freezing)","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Age-Related Fertility Decline","Oncofertility","Elective Fertility Preservation"],"status":"active"},{"id":"c29552d9-688b-462f-bac2-24163fac56b1","procedure_id":"proc-egg-freezing","jurisdiction_id":"jur-us-fl","procedure_name":"Elective Oocyte Cryopreservation (Social Egg Freezing)","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Age-Related Fertility Decline","Oncofertility","Elective Fertility Preservation"],"status":"active"},{"id":"bd025bf6-4540-44e6-a591-b715a2d92de4","procedure_id":"proc-egg-freezing","jurisdiction_id":"jur-au","procedure_name":"Elective Oocyte Cryopreservation (Social Egg Freezing)","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"TGA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Age-Related Fertility Decline","Oncofertility","Elective Fertility Preservation"],"status":"active"},{"id":"65591eed-f723-4e75-a830-48267e989796","procedure_id":"proc-egg-freezing","jurisdiction_id":"jur-ch","procedure_name":"Elective Oocyte Cryopreservation (Social Egg Freezing)","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"Swissmedic","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Age-Related Fertility Decline","Oncofertility","Elective Fertility Preservation"],"status":"active"},{"id":"1e5fd2bc-4515-4df1-a8c5-d3c3d3e6ac10","procedure_id":"proc-egg-freezing","jurisdiction_id":"jur-ca","procedure_name":"Elective Oocyte Cryopreservation (Social Egg Freezing)","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"Health Canada","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Age-Related Fertility Decline","Oncofertility","Elective Fertility Preservation"],"status":"active"},{"id":"923d86c5-e690-406a-ad14-ee75af2eb2e1","procedure_id":"proc-egg-freezing","jurisdiction_id":"jur-mx","procedure_name":"Elective Oocyte Cryopreservation (Social Egg Freezing)","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"COFEPRIS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Age-Related Fertility Decline","Oncofertility","Elective Fertility Preservation"],"status":"active"},{"id":"cc291266-c9e6-4a68-9be5-51dce8ebf3c6","procedure_id":"proc-egg-freezing","jurisdiction_id":"jur-hn-prospera","procedure_name":"Elective Oocyte Cryopreservation (Social Egg Freezing)","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"Próspera ZEDE health rules (contested)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Age-Related Fertility Decline","Oncofertility","Elective Fertility Preservation"],"status":"active"},{"id":"c2b746ba-eaa1-4d30-883b-e6034a351b6b","procedure_id":"proc-egg-freezing","jurisdiction_id":"jur-nl","procedure_name":"Elective Oocyte Cryopreservation (Social Egg Freezing)","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"MEB / IGJ","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Age-Related Fertility Decline","Oncofertility","Elective Fertility Preservation"],"status":"active"},{"id":"5573687a-c17d-4316-bec0-c314a492830c","procedure_id":"proc-egg-freezing","jurisdiction_id":"jur-uk","procedure_name":"Elective Oocyte Cryopreservation (Social Egg Freezing)","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"MHRA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Age-Related Fertility Decline","Oncofertility","Elective Fertility Preservation"],"status":"active"},{"id":"6cbe42a8-56a9-4505-8b87-9c43feeee076","procedure_id":"proc-egg-freezing","jurisdiction_id":"jur-il","procedure_name":"Elective Oocyte Cryopreservation (Social Egg Freezing)","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Age-Related Fertility Decline","Oncofertility","Elective Fertility Preservation"],"status":"active"},{"id":"10a9c36f-d336-44dd-800e-c8e93f7d340a","procedure_id":"proc-egg-freezing","jurisdiction_id":"jur-jm","procedure_name":"Elective Oocyte Cryopreservation (Social Egg Freezing)","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Age-Related Fertility Decline","Oncofertility","Elective Fertility Preservation"],"status":"active"},{"id":"22756f77-36fd-4815-b312-292a9df5d192","procedure_id":"proc-egg-freezing","jurisdiction_id":"jur-th","procedure_name":"Elective Oocyte Cryopreservation (Social Egg Freezing)","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"Thai FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Age-Related Fertility Decline","Oncofertility","Elective Fertility Preservation"],"status":"active"},{"id":"17e562fb-79f2-4da7-951a-5442c563f1e7","procedure_id":"proc-egg-freezing","jurisdiction_id":"jur-tu","procedure_name":"Elective Oocyte Cryopreservation (Social Egg Freezing)","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Age-Related Fertility Decline","Oncofertility","Elective Fertility Preservation"],"status":"active"},{"id":"631e7cb8-152f-4b60-8a00-2edd4c4e358a","procedure_id":"proc-egg-freezing","jurisdiction_id":"jur-in","procedure_name":"Elective Oocyte Cryopreservation (Social Egg Freezing)","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"CDSCO","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Age-Related Fertility Decline","Oncofertility","Elective Fertility Preservation"],"status":"active"},{"id":"94445aa5-1b01-4895-a940-0a79732fbafb","procedure_id":"proc-egg-freezing","jurisdiction_id":"jur-br","procedure_name":"Elective Oocyte Cryopreservation (Social Egg Freezing)","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"ANVISA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Age-Related Fertility Decline","Oncofertility","Elective Fertility Preservation"],"status":"active"},{"id":"79f2545a-fbf0-45da-93f8-76d4486f1de4","procedure_id":"proc-egg-freezing","jurisdiction_id":"jur-cr","procedure_name":"Elective Oocyte Cryopreservation (Social Egg Freezing)","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Age-Related Fertility Decline","Oncofertility","Elective Fertility Preservation"],"status":"active"},{"id":"93ccd12b-a235-4014-bb87-ded90ac0ae32","procedure_id":"proc-egg-freezing","jurisdiction_id":"jur-uae","procedure_name":"Elective Oocyte Cryopreservation (Social Egg Freezing)","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Age-Related Fertility Decline","Oncofertility","Elective Fertility Preservation"],"status":"active"},{"id":"c0c7f515-f1f7-4949-aeda-e1a4b2a6409f","procedure_id":"proc-egg-freezing","jurisdiction_id":"jur-kr","procedure_name":"Elective Oocyte Cryopreservation (Social Egg Freezing)","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"MFDS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Age-Related Fertility Decline","Oncofertility","Elective Fertility Preservation"],"status":"active"},{"id":"c230bd91-696b-4273-b5bf-4912a3707861","procedure_id":"proc-egg-freezing","jurisdiction_id":"jur-gr","procedure_name":"Elective Oocyte Cryopreservation (Social Egg Freezing)","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Age-Related Fertility Decline","Oncofertility","Elective Fertility Preservation"],"status":"active"},{"id":"d81dd17c-3849-440d-891c-fe131423eb0b","procedure_id":"proc-egg-freezing","jurisdiction_id":"jur-be","procedure_name":"Elective Oocyte Cryopreservation (Social Egg Freezing)","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Age-Related Fertility Decline","Oncofertility","Elective Fertility Preservation"],"status":"active"},{"id":"d72850d6-3c71-4705-9fac-ce2e3ad0e2b0","procedure_id":"proc-egg-freezing","jurisdiction_id":"jur-se","procedure_name":"Elective Oocyte Cryopreservation (Social Egg Freezing)","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Age-Related Fertility Decline","Oncofertility","Elective Fertility Preservation"],"status":"active"},{"id":"d6f124e8-1324-4890-a5af-eac4ae631a4a","procedure_id":"proc-egg-freezing","jurisdiction_id":"jur-sg","procedure_name":"Elective Oocyte Cryopreservation (Social Egg Freezing)","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"HSA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Age-Related Fertility Decline","Oncofertility","Elective Fertility Preservation"],"status":"active"},{"id":"a38bea3c-18dc-4aa4-93fc-d3bb605bea0c","procedure_id":"proc-egg-freezing","jurisdiction_id":"jur-cl","procedure_name":"Elective Oocyte Cryopreservation (Social Egg Freezing)","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Age-Related Fertility Decline","Oncofertility","Elective Fertility Preservation"],"status":"active"},{"id":"a902f5a5-86ae-48a3-b04f-75cfcc8165bb","procedure_id":"proc-egg-freezing","jurisdiction_id":"jur-ar","procedure_name":"Elective Oocyte Cryopreservation (Social Egg Freezing)","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Age-Related Fertility Decline","Oncofertility","Elective Fertility Preservation"],"status":"active"},{"id":"4c1a58be-030a-49f1-b1da-6cc497fe8187","procedure_id":"proc-egg-freezing","jurisdiction_id":"jur-za","procedure_name":"Elective Oocyte Cryopreservation (Social Egg Freezing)","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Age-Related Fertility Decline","Oncofertility","Elective Fertility Preservation"],"status":"active"},{"id":"12dd8c3a-c95e-427a-8a21-d12362eb2c65","procedure_id":"proc-egg-freezing","jurisdiction_id":"jur-ph","procedure_name":"Elective Oocyte Cryopreservation (Social Egg Freezing)","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Age-Related Fertility Decline","Oncofertility","Elective Fertility Preservation"],"status":"active"},{"id":"3f860421-e9a9-4487-b55b-908e707610ca","procedure_id":"proc-egg-freezing","jurisdiction_id":"jur-po","procedure_name":"Elective Oocyte Cryopreservation (Social Egg Freezing)","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Age-Related Fertility Decline","Oncofertility","Elective Fertility Preservation"],"status":"active"},{"id":"1432b295-e901-4091-8923-1dd7c7559efb","procedure_id":"proc-egg-freezing","jurisdiction_id":"jur-pt","procedure_name":"Elective Oocyte Cryopreservation (Social Egg Freezing)","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"VARIABLE","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Age-Related Fertility Decline","Oncofertility","Elective Fertility Preservation"],"status":"active"},{"id":"e3f0c636-f0c0-4869-90a6-a6edccc6c55c","procedure_id":"proc-egg-freezing","jurisdiction_id":"jur-fr","procedure_name":"Elective Oocyte Cryopreservation (Social Egg Freezing)","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Licensing, gamete storage, and embryo rules vary; some ethics limits (e.g. donor, PGT) are jurisdiction-specific.","eligibility_requirements":"Clinic protocols + any national ART act limits.","provider_requirements":"ART clinic license + lab accreditation typically required.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred licensed ART clinic pathway in regulated health systems.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: IVF/ART is widely regulated as licensed medical practice where modern fertility care exists.","regulatory_authority":"ANSM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Age-Related Fertility Decline","Oncofertility","Elective Fertility Preservation"],"status":"active"},{"id":"c75417ab-9ef2-4bc6-8562-99330c992490","procedure_id":"proc-uterine-transplant","jurisdiction_id":"jur-us-or","procedure_name":"Uterus Transplantation for Absolute Uterine Factor Infertility","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Not a standard ART service line.","eligibility_requirements":"Strict transplant criteria.","provider_requirements":"Transplant programme.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/limited transplant-centre only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: uterus transplant remains experimental/limited-centre globally.","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Absolute Uterine Factor Infertility","MRKH Syndrome"],"status":"active"},{"id":"0fa1ff9a-883c-4394-a79e-4f6fb3962965","procedure_id":"proc-uterine-transplant","jurisdiction_id":"jur-us-co","procedure_name":"Uterus Transplantation for Absolute Uterine Factor Infertility","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Not a standard ART service line.","eligibility_requirements":"Strict transplant criteria.","provider_requirements":"Transplant programme.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/limited transplant-centre only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: uterus transplant remains experimental/limited-centre globally.","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Absolute Uterine Factor Infertility","MRKH Syndrome"],"status":"active"},{"id":"d705e61e-3c62-4af3-a00b-a3489b6bbd4a","procedure_id":"proc-uterine-transplant","jurisdiction_id":"jur-us-ca","procedure_name":"Uterus Transplantation for Absolute Uterine Factor Infertility","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Not a standard ART service line.","eligibility_requirements":"Strict transplant criteria.","provider_requirements":"Transplant programme.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/limited transplant-centre only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: uterus transplant remains experimental/limited-centre globally.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Absolute Uterine Factor Infertility","MRKH Syndrome"],"status":"active"},{"id":"426a04ef-0859-4e55-8fa3-c8581910b17d","procedure_id":"proc-uterine-transplant","jurisdiction_id":"jur-us-tx","procedure_name":"Uterus Transplantation for Absolute Uterine Factor Infertility","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Not a standard ART service line.","eligibility_requirements":"Strict transplant criteria.","provider_requirements":"Transplant programme.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/limited transplant-centre only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: uterus transplant remains experimental/limited-centre globally.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Absolute Uterine Factor Infertility","MRKH Syndrome"],"status":"active"},{"id":"bc341396-2d55-4829-8c36-d57db68a8a40","procedure_id":"proc-uterine-transplant","jurisdiction_id":"jur-us-fl","procedure_name":"Uterus Transplantation for Absolute Uterine Factor Infertility","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Not a standard ART service line.","eligibility_requirements":"Strict transplant criteria.","provider_requirements":"Transplant programme.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/limited transplant-centre only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: uterus transplant remains experimental/limited-centre globally.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Absolute Uterine Factor Infertility","MRKH Syndrome"],"status":"active"},{"id":"01260e19-11fa-4b6d-9041-c5d1742bd4cb","procedure_id":"proc-uterine-transplant","jurisdiction_id":"jur-au","procedure_name":"Uterus Transplantation for Absolute Uterine Factor Infertility","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Not a standard ART service line.","eligibility_requirements":"Strict transplant criteria.","provider_requirements":"Transplant programme.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/limited transplant-centre only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: uterus transplant remains experimental/limited-centre globally.","regulatory_authority":"TGA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Absolute Uterine Factor Infertility","MRKH Syndrome"],"status":"active"},{"id":"281148ce-3d92-40ac-91c6-4e914dd9376a","procedure_id":"proc-uterine-transplant","jurisdiction_id":"jur-ch","procedure_name":"Uterus Transplantation for Absolute Uterine Factor Infertility","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Not a standard ART service line.","eligibility_requirements":"Strict transplant criteria.","provider_requirements":"Transplant programme.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/limited transplant-centre only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: uterus transplant remains experimental/limited-centre globally.","regulatory_authority":"Swissmedic","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Absolute Uterine Factor Infertility","MRKH Syndrome"],"status":"active"},{"id":"ef35c77c-2d80-4a8c-b8ea-11b90aa68055","procedure_id":"proc-uterine-transplant","jurisdiction_id":"jur-ca","procedure_name":"Uterus Transplantation for Absolute Uterine Factor Infertility","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Not a standard ART service line.","eligibility_requirements":"Strict transplant criteria.","provider_requirements":"Transplant programme.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/limited transplant-centre only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: uterus transplant remains experimental/limited-centre globally.","regulatory_authority":"Health Canada","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Absolute Uterine Factor Infertility","MRKH Syndrome"],"status":"active"},{"id":"ac3ae646-080a-41a3-8b91-8feeea6080fc","procedure_id":"proc-uterine-transplant","jurisdiction_id":"jur-mx","procedure_name":"Uterus Transplantation for Absolute Uterine Factor Infertility","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Not a standard ART service line.","eligibility_requirements":"Strict transplant criteria.","provider_requirements":"Transplant programme.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/limited transplant-centre only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: uterus transplant remains experimental/limited-centre globally.","regulatory_authority":"COFEPRIS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Absolute Uterine Factor Infertility","MRKH Syndrome"],"status":"active"},{"id":"fbf094b5-fc9b-477f-b88b-bc4bb60bb89c","procedure_id":"proc-uterine-transplant","jurisdiction_id":"jur-hn-prospera","procedure_name":"Uterus Transplantation for Absolute Uterine Factor Infertility","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Not a standard ART service line.","eligibility_requirements":"Strict transplant criteria.","provider_requirements":"Transplant programme.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/limited transplant-centre only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: uterus transplant remains experimental/limited-centre globally.","regulatory_authority":"Próspera ZEDE health rules (contested)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Absolute Uterine Factor Infertility","MRKH Syndrome"],"status":"active"},{"id":"f4fee070-ceaf-42ee-9317-294cf128c529","procedure_id":"proc-uterine-transplant","jurisdiction_id":"jur-nl","procedure_name":"Uterus Transplantation for Absolute Uterine Factor Infertility","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Not a standard ART service line.","eligibility_requirements":"Strict transplant criteria.","provider_requirements":"Transplant programme.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/limited transplant-centre only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: uterus transplant remains experimental/limited-centre globally.","regulatory_authority":"MEB / IGJ","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Absolute Uterine Factor Infertility","MRKH Syndrome"],"status":"active"},{"id":"8f3056e5-b636-47e9-966a-d9238a5c6a3b","procedure_id":"proc-uterine-transplant","jurisdiction_id":"jur-de","procedure_name":"Uterus Transplantation for Absolute Uterine Factor Infertility","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Not a standard ART service line.","eligibility_requirements":"Strict transplant criteria.","provider_requirements":"Transplant programme.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/limited transplant-centre only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: uterus transplant remains experimental/limited-centre globally.","regulatory_authority":"BfArM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Absolute Uterine Factor Infertility","MRKH Syndrome"],"status":"active"},{"id":"b34d1a69-f247-4909-b5fb-71a9be28fdb4","procedure_id":"proc-uterine-transplant","jurisdiction_id":"jur-uk","procedure_name":"Uterus Transplantation for Absolute Uterine Factor Infertility","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Not a standard ART service line.","eligibility_requirements":"Strict transplant criteria.","provider_requirements":"Transplant programme.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/limited transplant-centre only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: uterus transplant remains experimental/limited-centre globally.","regulatory_authority":"MHRA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Absolute Uterine Factor Infertility","MRKH Syndrome"],"status":"active"},{"id":"eaf0b0ad-b9c9-4617-871e-e4c2f8f77b96","procedure_id":"proc-uterine-transplant","jurisdiction_id":"jur-il","procedure_name":"Uterus Transplantation for Absolute Uterine Factor Infertility","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Not a standard ART service line.","eligibility_requirements":"Strict transplant criteria.","provider_requirements":"Transplant programme.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/limited transplant-centre only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: uterus transplant remains experimental/limited-centre globally.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Absolute Uterine Factor Infertility","MRKH Syndrome"],"status":"active"},{"id":"5b2fae68-c388-4548-b33f-003721751169","procedure_id":"proc-uterine-transplant","jurisdiction_id":"jur-jm","procedure_name":"Uterus Transplantation for Absolute Uterine Factor Infertility","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Not a standard ART service line.","eligibility_requirements":"Strict transplant criteria.","provider_requirements":"Transplant programme.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/limited transplant-centre only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: uterus transplant remains experimental/limited-centre globally.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Absolute Uterine Factor Infertility","MRKH Syndrome"],"status":"active"},{"id":"a750c354-ee92-4f7a-9354-170edde59eec","procedure_id":"proc-uterine-transplant","jurisdiction_id":"jur-th","procedure_name":"Uterus Transplantation for Absolute Uterine Factor Infertility","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Not a standard ART service line.","eligibility_requirements":"Strict transplant criteria.","provider_requirements":"Transplant programme.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/limited transplant-centre only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: uterus transplant remains experimental/limited-centre globally.","regulatory_authority":"Thai FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Absolute Uterine Factor Infertility","MRKH Syndrome"],"status":"active"},{"id":"c02c3e7a-8374-43f6-a87b-ee5922a83442","procedure_id":"proc-uterine-transplant","jurisdiction_id":"jur-es","procedure_name":"Uterus Transplantation for Absolute Uterine Factor Infertility","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Not a standard ART service line.","eligibility_requirements":"Strict transplant criteria.","provider_requirements":"Transplant programme.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/limited transplant-centre only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: uterus transplant remains experimental/limited-centre globally.","regulatory_authority":"AEMPS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Absolute Uterine Factor Infertility","MRKH Syndrome"],"status":"active"},{"id":"fc37e66b-7453-4045-ae92-8cda2c4ceef4","procedure_id":"proc-uterine-transplant","jurisdiction_id":"jur-tu","procedure_name":"Uterus Transplantation for Absolute Uterine Factor Infertility","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Not a standard ART service line.","eligibility_requirements":"Strict transplant criteria.","provider_requirements":"Transplant programme.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/limited transplant-centre only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: uterus transplant remains experimental/limited-centre globally.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Absolute Uterine Factor Infertility","MRKH Syndrome"],"status":"active"},{"id":"9f514a7e-1cea-43e4-8ae1-0d7152d2a89d","procedure_id":"proc-uterine-transplant","jurisdiction_id":"jur-in","procedure_name":"Uterus Transplantation for Absolute Uterine Factor Infertility","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Not a standard ART service line.","eligibility_requirements":"Strict transplant criteria.","provider_requirements":"Transplant programme.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/limited transplant-centre only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: uterus transplant remains experimental/limited-centre globally.","regulatory_authority":"CDSCO","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Absolute Uterine Factor Infertility","MRKH Syndrome"],"status":"active"},{"id":"580f40b9-503e-4a75-b13c-1431e4a79680","procedure_id":"proc-uterine-transplant","jurisdiction_id":"jur-br","procedure_name":"Uterus Transplantation for Absolute Uterine Factor Infertility","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Not a standard ART service line.","eligibility_requirements":"Strict transplant criteria.","provider_requirements":"Transplant programme.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/limited transplant-centre only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: uterus transplant remains experimental/limited-centre globally.","regulatory_authority":"ANVISA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Absolute Uterine Factor Infertility","MRKH Syndrome"],"status":"active"},{"id":"cb2e58d8-da1f-4507-b3ae-228c4228396d","procedure_id":"proc-uterine-transplant","jurisdiction_id":"jur-cr","procedure_name":"Uterus Transplantation for Absolute Uterine Factor Infertility","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Not a standard ART service line.","eligibility_requirements":"Strict transplant criteria.","provider_requirements":"Transplant programme.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/limited transplant-centre only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: uterus transplant remains experimental/limited-centre globally.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Absolute Uterine Factor Infertility","MRKH Syndrome"],"status":"active"},{"id":"84cca6f5-4023-4521-943a-53f5c736f593","procedure_id":"proc-uterine-transplant","jurisdiction_id":"jur-uae","procedure_name":"Uterus Transplantation for Absolute Uterine Factor Infertility","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Not a standard ART service line.","eligibility_requirements":"Strict transplant criteria.","provider_requirements":"Transplant programme.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/limited transplant-centre only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: uterus transplant remains experimental/limited-centre globally.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Absolute Uterine Factor Infertility","MRKH Syndrome"],"status":"active"},{"id":"87859068-039b-4b03-ad65-1f722d43934a","procedure_id":"proc-uterine-transplant","jurisdiction_id":"jur-kr","procedure_name":"Uterus Transplantation for Absolute Uterine Factor Infertility","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Not a standard ART service line.","eligibility_requirements":"Strict transplant criteria.","provider_requirements":"Transplant programme.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/limited transplant-centre only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: uterus transplant remains experimental/limited-centre globally.","regulatory_authority":"MFDS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Absolute Uterine Factor Infertility","MRKH Syndrome"],"status":"active"},{"id":"0cef07be-8ecb-46e4-8196-87b2b3fd8af9","procedure_id":"proc-uterine-transplant","jurisdiction_id":"jur-gr","procedure_name":"Uterus Transplantation for Absolute Uterine Factor Infertility","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Not a standard ART service line.","eligibility_requirements":"Strict transplant criteria.","provider_requirements":"Transplant programme.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/limited transplant-centre only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: uterus transplant remains experimental/limited-centre globally.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Absolute Uterine Factor Infertility","MRKH Syndrome"],"status":"active"},{"id":"146c43f1-40cf-4ecd-b80f-19060869752c","procedure_id":"proc-uterine-transplant","jurisdiction_id":"jur-be","procedure_name":"Uterus Transplantation for Absolute Uterine Factor Infertility","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Not a standard ART service line.","eligibility_requirements":"Strict transplant criteria.","provider_requirements":"Transplant programme.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/limited transplant-centre only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: uterus transplant remains experimental/limited-centre globally.","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Absolute Uterine Factor Infertility","MRKH Syndrome"],"status":"active"},{"id":"df80ea06-a1db-48b4-a934-a6a3c6913014","procedure_id":"proc-uterine-transplant","jurisdiction_id":"jur-jp","procedure_name":"Uterus Transplantation for Absolute Uterine Factor Infertility","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Not a standard ART service line.","eligibility_requirements":"Strict transplant criteria.","provider_requirements":"Transplant programme.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/limited transplant-centre only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: uterus transplant remains experimental/limited-centre globally.","regulatory_authority":"PMDA / MHLW","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Absolute Uterine Factor Infertility","MRKH Syndrome"],"status":"active"},{"id":"6b7fd6d7-d105-4b2b-a953-55957bb05d68","procedure_id":"proc-uterine-transplant","jurisdiction_id":"jur-sg","procedure_name":"Uterus Transplantation for Absolute Uterine Factor Infertility","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Not a standard ART service line.","eligibility_requirements":"Strict transplant criteria.","provider_requirements":"Transplant programme.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/limited transplant-centre only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: uterus transplant remains experimental/limited-centre globally.","regulatory_authority":"HSA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Absolute Uterine Factor Infertility","MRKH Syndrome"],"status":"active"},{"id":"43c56c16-ac07-45ce-8d70-dc7b736f0444","procedure_id":"proc-uterine-transplant","jurisdiction_id":"jur-cl","procedure_name":"Uterus Transplantation for Absolute Uterine Factor Infertility","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Not a standard ART service line.","eligibility_requirements":"Strict transplant criteria.","provider_requirements":"Transplant programme.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/limited transplant-centre only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: uterus transplant remains experimental/limited-centre globally.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Absolute Uterine Factor Infertility","MRKH Syndrome"],"status":"active"},{"id":"bed5e2f6-bf9c-4c99-8700-2096740fc649","procedure_id":"proc-uterine-transplant","jurisdiction_id":"jur-ar","procedure_name":"Uterus Transplantation for Absolute Uterine Factor Infertility","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Not a standard ART service line.","eligibility_requirements":"Strict transplant criteria.","provider_requirements":"Transplant programme.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/limited transplant-centre only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: uterus transplant remains experimental/limited-centre globally.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Absolute Uterine Factor Infertility","MRKH Syndrome"],"status":"active"},{"id":"4ca84150-01cb-40d5-a67d-7043433a1c6c","procedure_id":"proc-uterine-transplant","jurisdiction_id":"jur-za","procedure_name":"Uterus Transplantation for Absolute Uterine Factor Infertility","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Not a standard ART service line.","eligibility_requirements":"Strict transplant criteria.","provider_requirements":"Transplant programme.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/limited transplant-centre only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: uterus transplant remains experimental/limited-centre globally.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Absolute Uterine Factor Infertility","MRKH Syndrome"],"status":"active"},{"id":"90f1839e-309d-4de4-9ec2-906433654520","procedure_id":"proc-uterine-transplant","jurisdiction_id":"jur-ph","procedure_name":"Uterus Transplantation for Absolute Uterine Factor Infertility","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Not a standard ART service line.","eligibility_requirements":"Strict transplant criteria.","provider_requirements":"Transplant programme.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/limited transplant-centre only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: uterus transplant remains experimental/limited-centre globally.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Absolute Uterine Factor Infertility","MRKH Syndrome"],"status":"active"},{"id":"64adac79-b075-45d9-8eb2-c920d83bc6e6","procedure_id":"proc-uterine-transplant","jurisdiction_id":"jur-po","procedure_name":"Uterus Transplantation for Absolute Uterine Factor Infertility","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Not a standard ART service line.","eligibility_requirements":"Strict transplant criteria.","provider_requirements":"Transplant programme.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/limited transplant-centre only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: uterus transplant remains experimental/limited-centre globally.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Absolute Uterine Factor Infertility","MRKH Syndrome"],"status":"active"},{"id":"d65172ee-0113-4295-90cb-3e9d5fb4e358","procedure_id":"proc-uterine-transplant","jurisdiction_id":"jur-pt","procedure_name":"Uterus Transplantation for Absolute Uterine Factor Infertility","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Not a standard ART service line.","eligibility_requirements":"Strict transplant criteria.","provider_requirements":"Transplant programme.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/limited transplant-centre only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: uterus transplant remains experimental/limited-centre globally.","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Absolute Uterine Factor Infertility","MRKH Syndrome"],"status":"active"},{"id":"0cd0f8ef-ffca-4969-9bd9-ccf2127c23ff","procedure_id":"proc-uterine-transplant","jurisdiction_id":"jur-fr","procedure_name":"Uterus Transplantation for Absolute Uterine Factor Infertility","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"REPRODUCTIVE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Not a standard ART service line.","eligibility_requirements":"Strict transplant criteria.","provider_requirements":"Transplant programme.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/limited transplant-centre only.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: uterus transplant remains experimental/limited-centre globally.","regulatory_authority":"ANSM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Reproductive_Health"],"diseases":["Absolute Uterine Factor Infertility","MRKH Syndrome"],"status":"active"},{"id":"80219637-7772-4a77-afc0-d0a1582f490d","procedure_id":"proc-5meo-dmt","jurisdiction_id":"jur-us-or","procedure_name":"5-MeO-DMT Assisted Therapy","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"REGULATED_THERAPY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Jurisdiction signals a regulated therapy-program model for psychedelics.","eligibility_requirements":"Program-specific screening (age, contraindications).","provider_requirements":"Program licenses / facilitator or medical credentials per local scheme.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred regulated program pathway may exist — still confirm license classes and product rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: Jurisdiction psychedelic_default=Regulated_Therapy_Program.","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Spirituality"],"diseases":["Depression","Anxiety","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"437b3b58-8f7c-43e1-b65d-506665c40aa5","procedure_id":"proc-5meo-dmt","jurisdiction_id":"jur-jm","procedure_name":"5-MeO-DMT Assisted Therapy","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"UNREGULATED_PERMITTED","access_pathway":"MEDICAL_TOURISM_CASH","oversight_quality":"MINIMAL","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Default allows relatively open practice — quality and consumer protection still apply.","eligibility_requirements":"Operator-defined; local consumer law applies.","provider_requirements":"Local business/medical rules may still apply even if substance posture is open.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred permissive/unregulated posture — high variance in quality; diligence essential.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: Jurisdiction psychedelic_default=Unregulated_Permitted.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Spirituality"],"diseases":["Depression","Anxiety","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"e65e44f0-107a-4bdb-8a9e-07c11b88bc97","procedure_id":"proc-5meo-dmt","jurisdiction_id":"jur-gr","procedure_name":"5-MeO-DMT Assisted Therapy","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Classical/atypical psychedelic therapy for 5-MeO-DMT Assisted Therapy treated as prohibited outside narrow research under default national posture.","eligibility_requirements":"No lawful general patient pathway under inferred default.","provider_requirements":"Cannot lawfully open a commercial program without an explicit statutory exception.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Criminal liability risk if default is accurate; always verify current schedule.","arbitrage_summary":"Inferred prohibited under jurisdiction psychedelic default / UN-style scheduling. Not a lawful commercial therapy market.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: No jurisdiction psychedelic_default on file — applied conservative Schedule-I-class default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Spirituality"],"diseases":["Depression","Anxiety","Substance Use Disorder","Existential Distress"],"status":"active"},{"id":"ca24e83b-4d5e-4696-82e0-927787a64d20","procedure_id":"proc-ketamine-assisted-psychotherapy","jurisdiction_id":"jur-us-or","procedure_name":"Ketamine-Assisted Psychotherapy (KAP)","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (Federal CSA + state Measure 109 programme). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression","PTSD"],"diseases":["Treatment-Resistant Depression","PTSD","Anxiety Disorders"],"status":"active"},{"id":"bd5c7a0d-b88f-4421-9af6-54df94a899c1","procedure_id":"proc-ketamine-assisted-psychotherapy","jurisdiction_id":"jur-us-co","procedure_name":"Ketamine-Assisted Psychotherapy (KAP)","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (Federal CSA + Prop 122 Natural Medicine Health Act). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression","PTSD"],"diseases":["Treatment-Resistant Depression","PTSD","Anxiety Disorders"],"status":"active"},{"id":"d4b6eb81-2773-4ce3-87d5-80424fb8649f","procedure_id":"proc-ketamine-assisted-psychotherapy","jurisdiction_id":"jur-us-ca","procedure_name":"Ketamine-Assisted Psychotherapy (KAP)","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (Controlled Substances Act Schedule I–V). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression","PTSD"],"diseases":["Treatment-Resistant Depression","PTSD","Anxiety Disorders"],"status":"active"},{"id":"05140cb0-c744-4b4c-afba-b589bf1a1b01","procedure_id":"proc-ketamine-assisted-psychotherapy","jurisdiction_id":"jur-us-tx","procedure_name":"Ketamine-Assisted Psychotherapy (KAP)","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (Controlled Substances Act Schedule I–V). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression","PTSD"],"diseases":["Treatment-Resistant Depression","PTSD","Anxiety Disorders"],"status":"active"},{"id":"00d5b4eb-cf32-4229-9286-ffca63f5c4aa","procedure_id":"proc-ketamine-assisted-psychotherapy","jurisdiction_id":"jur-us-fl","procedure_name":"Ketamine-Assisted Psychotherapy (KAP)","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (Controlled Substances Act Schedule I–V). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression","PTSD"],"diseases":["Treatment-Resistant Depression","PTSD","Anxiety Disorders"],"status":"active"},{"id":"e64df334-560a-4aac-a69b-4d7d6160f132","procedure_id":"proc-ketamine-assisted-psychotherapy","jurisdiction_id":"jur-ch","procedure_name":"Ketamine-Assisted Psychotherapy (KAP)","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (Narcotics Act (BetmG)). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"Swissmedic","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression","PTSD"],"diseases":["Treatment-Resistant Depression","PTSD","Anxiety Disorders"],"status":"active"},{"id":"b219b6c0-9047-41a0-b587-a6630477fa94","procedure_id":"proc-ketamine-assisted-psychotherapy","jurisdiction_id":"jur-mx","procedure_name":"Ketamine-Assisted Psychotherapy (KAP)","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (Ley General de Salud psychotropics schedules). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"COFEPRIS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression","PTSD"],"diseases":["Treatment-Resistant Depression","PTSD","Anxiety Disorders"],"status":"active"},{"id":"078b74c1-346d-41b3-a80a-8b05892d7138","procedure_id":"proc-ketamine-assisted-psychotherapy","jurisdiction_id":"jur-hn-prospera","procedure_name":"Ketamine-Assisted Psychotherapy (KAP)","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (Special zone + national law tension). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"Próspera ZEDE health rules (contested)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression","PTSD"],"diseases":["Treatment-Resistant Depression","PTSD","Anxiety Disorders"],"status":"active"},{"id":"55d33726-3e88-467c-b3dc-e9e49669f53a","procedure_id":"proc-ketamine-assisted-psychotherapy","jurisdiction_id":"jur-nl","procedure_name":"Ketamine-Assisted Psychotherapy (KAP)","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (Opium Act (List I/II) — truffle exception for sclerotia). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"MEB / IGJ","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression","PTSD"],"diseases":["Treatment-Resistant Depression","PTSD","Anxiety Disorders"],"status":"active"},{"id":"a5ed375a-9362-44b5-8dc4-f28d668bc3f9","procedure_id":"proc-ketamine-assisted-psychotherapy","jurisdiction_id":"jur-de","procedure_name":"Ketamine-Assisted Psychotherapy (KAP)","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (BtMG (Narcotics Act)). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"BfArM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression","PTSD"],"diseases":["Treatment-Resistant Depression","PTSD","Anxiety Disorders"],"status":"active"},{"id":"dda56c1c-5a1d-4b61-9bf0-e2933628a1e5","procedure_id":"proc-ketamine-assisted-psychotherapy","jurisdiction_id":"jur-uk","procedure_name":"Ketamine-Assisted Psychotherapy (KAP)","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (Misuse of Drugs Act 1971 Class A/B/C). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"MHRA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression","PTSD"],"diseases":["Treatment-Resistant Depression","PTSD","Anxiety Disorders"],"status":"active"},{"id":"d18853c3-9359-42cb-a353-33bee35a68c7","procedure_id":"proc-ketamine-assisted-psychotherapy","jurisdiction_id":"jur-il","procedure_name":"Ketamine-Assisted Psychotherapy (KAP)","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (Dangerous Drugs Ordinance). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression","PTSD"],"diseases":["Treatment-Resistant Depression","PTSD","Anxiety Disorders"],"status":"active"},{"id":"be9037cf-f7f7-4bdd-bf93-1f4507be7e3a","procedure_id":"proc-ketamine-assisted-psychotherapy","jurisdiction_id":"jur-jm","procedure_name":"Ketamine-Assisted Psychotherapy (KAP)","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (Dangerous Drugs Act — psilocybin mushrooms historically unscheduled). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression","PTSD"],"diseases":["Treatment-Resistant Depression","PTSD","Anxiety Disorders"],"status":"active"},{"id":"08b91118-f158-4cf6-a47d-815118aed04e","procedure_id":"proc-ketamine-assisted-psychotherapy","jurisdiction_id":"jur-th","procedure_name":"Ketamine-Assisted Psychotherapy (KAP)","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (Narcotics Act (cannabis reforms in flux)). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"Thai FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression","PTSD"],"diseases":["Treatment-Resistant Depression","PTSD","Anxiety Disorders"],"status":"active"},{"id":"11dc4d69-d4cf-462f-b016-bb41ca55c926","procedure_id":"proc-ketamine-assisted-psychotherapy","jurisdiction_id":"jur-es","procedure_name":"Ketamine-Assisted Psychotherapy (KAP)","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (Spanish narcotics schedules). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"AEMPS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression","PTSD"],"diseases":["Treatment-Resistant Depression","PTSD","Anxiety Disorders"],"status":"active"},{"id":"82962eef-7f58-403e-a2a5-46cae68ef28c","procedure_id":"proc-ketamine-assisted-psychotherapy","jurisdiction_id":"jur-tu","procedure_name":"Ketamine-Assisted Psychotherapy (KAP)","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (national scheduling). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression","PTSD"],"diseases":["Treatment-Resistant Depression","PTSD","Anxiety Disorders"],"status":"active"},{"id":"e8aee075-0cf5-4844-8d0c-97d32c0fbbe8","procedure_id":"proc-ketamine-assisted-psychotherapy","jurisdiction_id":"jur-in","procedure_name":"Ketamine-Assisted Psychotherapy (KAP)","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (NDPS Act 1985). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"CDSCO","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression","PTSD"],"diseases":["Treatment-Resistant Depression","PTSD","Anxiety Disorders"],"status":"active"},{"id":"33fc7128-5b39-47c8-8699-a7b39ada1456","procedure_id":"proc-ketamine-assisted-psychotherapy","jurisdiction_id":"jur-br","procedure_name":"Ketamine-Assisted Psychotherapy (KAP)","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (Portaria SVS/MS controlled lists). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"ANVISA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression","PTSD"],"diseases":["Treatment-Resistant Depression","PTSD","Anxiety Disorders"],"status":"active"},{"id":"d57b8748-40a8-48de-9f8b-f5109632096f","procedure_id":"proc-ketamine-assisted-psychotherapy","jurisdiction_id":"jur-cr","procedure_name":"Ketamine-Assisted Psychotherapy (KAP)","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (national scheduling). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression","PTSD"],"diseases":["Treatment-Resistant Depression","PTSD","Anxiety Disorders"],"status":"active"},{"id":"cf0931e7-5b8d-4bf5-a278-1b501a3faea7","procedure_id":"proc-ketamine-assisted-psychotherapy","jurisdiction_id":"jur-uae","procedure_name":"Ketamine-Assisted Psychotherapy (KAP)","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (national scheduling). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression","PTSD"],"diseases":["Treatment-Resistant Depression","PTSD","Anxiety Disorders"],"status":"active"},{"id":"e57b1868-4c91-4348-8003-392c9c17e7c0","procedure_id":"proc-ketamine-assisted-psychotherapy","jurisdiction_id":"jur-kr","procedure_name":"Ketamine-Assisted Psychotherapy (KAP)","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (Narcotics Control Act). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"MFDS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression","PTSD"],"diseases":["Treatment-Resistant Depression","PTSD","Anxiety Disorders"],"status":"active"},{"id":"aa0e9252-cadc-47fc-b358-26f983f9d4e4","procedure_id":"proc-ketamine-assisted-psychotherapy","jurisdiction_id":"jur-gr","procedure_name":"Ketamine-Assisted Psychotherapy (KAP)","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (national scheduling). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression","PTSD"],"diseases":["Treatment-Resistant Depression","PTSD","Anxiety Disorders"],"status":"active"},{"id":"93a82d06-20fb-46e3-b856-14fbdf7dbecc","procedure_id":"proc-ketamine-assisted-psychotherapy","jurisdiction_id":"jur-be","procedure_name":"Ketamine-Assisted Psychotherapy (KAP)","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (Narcotics legislation). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression","PTSD"],"diseases":["Treatment-Resistant Depression","PTSD","Anxiety Disorders"],"status":"active"},{"id":"ebd42a1b-58de-4974-9809-f00231f3caac","procedure_id":"proc-ketamine-assisted-psychotherapy","jurisdiction_id":"jur-se","procedure_name":"Ketamine-Assisted Psychotherapy (KAP)","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (national scheduling). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression","PTSD"],"diseases":["Treatment-Resistant Depression","PTSD","Anxiety Disorders"],"status":"active"},{"id":"f769bfd3-b696-4c28-a7b9-67db11130f43","procedure_id":"proc-ketamine-assisted-psychotherapy","jurisdiction_id":"jur-jp","procedure_name":"Ketamine-Assisted Psychotherapy (KAP)","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (Narcotics & Stimulants Control Acts — very strict). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"PMDA / MHLW","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression","PTSD"],"diseases":["Treatment-Resistant Depression","PTSD","Anxiety Disorders"],"status":"active"},{"id":"fa54b35c-bd84-48fb-bb06-cbf6de86ecb8","procedure_id":"proc-ketamine-assisted-psychotherapy","jurisdiction_id":"jur-sg","procedure_name":"Ketamine-Assisted Psychotherapy (KAP)","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (Misuse of Drugs Act — severe penalties). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"HSA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression","PTSD"],"diseases":["Treatment-Resistant Depression","PTSD","Anxiety Disorders"],"status":"active"},{"id":"20399845-0cc0-48c6-a0df-8a9f3be5a3c1","procedure_id":"proc-ketamine-assisted-psychotherapy","jurisdiction_id":"jur-cl","procedure_name":"Ketamine-Assisted Psychotherapy (KAP)","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (national scheduling). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression","PTSD"],"diseases":["Treatment-Resistant Depression","PTSD","Anxiety Disorders"],"status":"active"},{"id":"8835218d-478c-44c1-9f8b-514bf1d4418b","procedure_id":"proc-ketamine-assisted-psychotherapy","jurisdiction_id":"jur-ar","procedure_name":"Ketamine-Assisted Psychotherapy (KAP)","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (national scheduling). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression","PTSD"],"diseases":["Treatment-Resistant Depression","PTSD","Anxiety Disorders"],"status":"active"},{"id":"5fab6959-1803-40e9-8d0e-81a9516bdeed","procedure_id":"proc-ketamine-assisted-psychotherapy","jurisdiction_id":"jur-za","procedure_name":"Ketamine-Assisted Psychotherapy (KAP)","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (national scheduling). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression","PTSD"],"diseases":["Treatment-Resistant Depression","PTSD","Anxiety Disorders"],"status":"active"},{"id":"acd13c25-966c-47de-91c5-788b28f7fd68","procedure_id":"proc-ketamine-assisted-psychotherapy","jurisdiction_id":"jur-ph","procedure_name":"Ketamine-Assisted Psychotherapy (KAP)","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (national scheduling). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression","PTSD"],"diseases":["Treatment-Resistant Depression","PTSD","Anxiety Disorders"],"status":"active"},{"id":"1c7ae973-ac89-4030-a394-a5800b098454","procedure_id":"proc-ketamine-assisted-psychotherapy","jurisdiction_id":"jur-po","procedure_name":"Ketamine-Assisted Psychotherapy (KAP)","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (national scheduling). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression","PTSD"],"diseases":["Treatment-Resistant Depression","PTSD","Anxiety Disorders"],"status":"active"},{"id":"2a6d331e-2b96-4ed2-8584-5d2c070707b8","procedure_id":"proc-ketamine-assisted-psychotherapy","jurisdiction_id":"jur-pt","procedure_name":"Ketamine-Assisted Psychotherapy (KAP)","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (Decriminalisation 2001 + trafficking still criminal). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression","PTSD"],"diseases":["Treatment-Resistant Depression","PTSD","Anxiety Disorders"],"status":"active"},{"id":"15cb0a0e-8141-4de2-8449-1a5f84faab8b","procedure_id":"proc-ketamine-assisted-psychotherapy","jurisdiction_id":"jur-fr","procedure_name":"Ketamine-Assisted Psychotherapy (KAP)","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Inferred off-label / clinic model under medical and controlled-substance rules. Esketamine (Spravato) may have separate REMS/label pathway where marketed — not assumed here.","eligibility_requirements":"Medical evaluation; controlled-substance prescribing standards.","provider_requirements":"Licensed prescriber + controlled-substance authority; monitoring protocols.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Diversion controls, monitoring, and off-label consent still apply.","arbitrage_summary":"Inferred: medical controlled-substance clinic pathway likely if medical practice is lawful; still confirm scheduling and clinic rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: ketamine is a scheduled medicine with accepted anesthetic use in most systems (Stupéfiants schedules). Depression/KAP use is typically off-label clinic practice where medical licensing allows.","regulatory_authority":"ANSM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Depression","PTSD"],"diseases":["Treatment-Resistant Depression","PTSD","Anxiety Disorders"],"status":"active"},{"id":"b106fa32-0f8b-4566-900c-298f85df509a","procedure_id":"proc-pef-ablation","jurisdiction_id":"jur-us-or","procedure_name":"Pulsed Field Ablation (PFA) for Atrial Fibrillation","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular"],"diseases":["Atrial Fibrillation"],"status":"active"},{"id":"fc36391d-50f2-4110-bcd1-77df680a41d1","procedure_id":"proc-pef-ablation","jurisdiction_id":"jur-us-co","procedure_name":"Pulsed Field Ablation (PFA) for Atrial Fibrillation","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular"],"diseases":["Atrial Fibrillation"],"status":"active"},{"id":"abf0a77b-924e-4993-a601-0f7261b779d8","procedure_id":"proc-pef-ablation","jurisdiction_id":"jur-us-ca","procedure_name":"Pulsed Field Ablation (PFA) for Atrial Fibrillation","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular"],"diseases":["Atrial Fibrillation"],"status":"active"},{"id":"e79a7fab-d4df-43d9-b3fc-c368910be6a6","procedure_id":"proc-pef-ablation","jurisdiction_id":"jur-us-tx","procedure_name":"Pulsed Field Ablation (PFA) for Atrial Fibrillation","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular"],"diseases":["Atrial Fibrillation"],"status":"active"},{"id":"eb358f5e-59b0-46fb-b819-7781c4dd36b6","procedure_id":"proc-pef-ablation","jurisdiction_id":"jur-us-fl","procedure_name":"Pulsed Field Ablation (PFA) for Atrial Fibrillation","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular"],"diseases":["Atrial Fibrillation"],"status":"active"},{"id":"a5dcf69d-0d85-4eb5-be9c-464beaf52c17","procedure_id":"proc-pef-ablation","jurisdiction_id":"jur-au","procedure_name":"Pulsed Field Ablation (PFA) for Atrial Fibrillation","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"TGA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular"],"diseases":["Atrial Fibrillation"],"status":"active"},{"id":"869d6528-09c9-4f33-a118-47ed76d4d328","procedure_id":"proc-pef-ablation","jurisdiction_id":"jur-ch","procedure_name":"Pulsed Field Ablation (PFA) for Atrial Fibrillation","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Swissmedic","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular"],"diseases":["Atrial Fibrillation"],"status":"active"},{"id":"94d6cfc9-86b9-4cc0-97dc-9e7641cd8f85","procedure_id":"proc-pef-ablation","jurisdiction_id":"jur-ca","procedure_name":"Pulsed Field Ablation (PFA) for Atrial Fibrillation","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Health Canada","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular"],"diseases":["Atrial Fibrillation"],"status":"active"},{"id":"c46cfec8-4dc5-48df-9102-3858fc223bd4","procedure_id":"proc-pef-ablation","jurisdiction_id":"jur-mx","procedure_name":"Pulsed Field Ablation (PFA) for Atrial Fibrillation","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"COFEPRIS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular"],"diseases":["Atrial Fibrillation"],"status":"active"},{"id":"ecafd16d-7ce7-4aaa-96d7-5c5a9ab33e08","procedure_id":"proc-pef-ablation","jurisdiction_id":"jur-hn-prospera","procedure_name":"Pulsed Field Ablation (PFA) for Atrial Fibrillation","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Próspera ZEDE health rules (contested)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular"],"diseases":["Atrial Fibrillation"],"status":"active"},{"id":"8815170c-f8ae-4ffe-95af-ddddbcbd12cc","procedure_id":"proc-pef-ablation","jurisdiction_id":"jur-nl","procedure_name":"Pulsed Field Ablation (PFA) for Atrial Fibrillation","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"MEB / IGJ","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular"],"diseases":["Atrial Fibrillation"],"status":"active"},{"id":"43de337d-e600-4976-b916-4ed18ae02f49","procedure_id":"proc-pef-ablation","jurisdiction_id":"jur-uk","procedure_name":"Pulsed Field Ablation (PFA) for Atrial Fibrillation","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"MHRA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular"],"diseases":["Atrial Fibrillation"],"status":"active"},{"id":"78963d3b-837b-4cd0-b0db-4dfe4bfa8844","procedure_id":"proc-pef-ablation","jurisdiction_id":"jur-il","procedure_name":"Pulsed Field Ablation (PFA) for Atrial Fibrillation","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular"],"diseases":["Atrial Fibrillation"],"status":"active"},{"id":"008c778d-6ef3-469e-8c0f-f7aa6ec627fd","procedure_id":"proc-pef-ablation","jurisdiction_id":"jur-jm","procedure_name":"Pulsed Field Ablation (PFA) for Atrial Fibrillation","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular"],"diseases":["Atrial Fibrillation"],"status":"active"},{"id":"8cda1fcb-a5a7-4b58-a00d-91675022f688","procedure_id":"proc-pef-ablation","jurisdiction_id":"jur-th","procedure_name":"Pulsed Field Ablation (PFA) for Atrial Fibrillation","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Thai FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular"],"diseases":["Atrial Fibrillation"],"status":"active"},{"id":"8bc7617f-a51c-4315-94d5-197ae5542cf6","procedure_id":"proc-pef-ablation","jurisdiction_id":"jur-es","procedure_name":"Pulsed Field Ablation (PFA) for Atrial Fibrillation","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"AEMPS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular"],"diseases":["Atrial Fibrillation"],"status":"active"},{"id":"a588f090-dfef-4569-814b-38b41d2f20db","procedure_id":"proc-pef-ablation","jurisdiction_id":"jur-tu","procedure_name":"Pulsed Field Ablation (PFA) for Atrial Fibrillation","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular"],"diseases":["Atrial Fibrillation"],"status":"active"},{"id":"a516ca85-d0d8-403e-a18d-c33465798680","procedure_id":"proc-pef-ablation","jurisdiction_id":"jur-in","procedure_name":"Pulsed Field Ablation (PFA) for Atrial Fibrillation","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"CDSCO","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular"],"diseases":["Atrial Fibrillation"],"status":"active"},{"id":"1527eeae-756f-4910-b9cd-3e1ca1dbefc3","procedure_id":"proc-pef-ablation","jurisdiction_id":"jur-br","procedure_name":"Pulsed Field Ablation (PFA) for Atrial Fibrillation","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"ANVISA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular"],"diseases":["Atrial Fibrillation"],"status":"active"},{"id":"3a63bc67-4fc4-425e-b700-213187294be2","procedure_id":"proc-pef-ablation","jurisdiction_id":"jur-cr","procedure_name":"Pulsed Field Ablation (PFA) for Atrial Fibrillation","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular"],"diseases":["Atrial Fibrillation"],"status":"active"},{"id":"1672b181-7300-4f3a-aee1-8c060d4680e5","procedure_id":"proc-pef-ablation","jurisdiction_id":"jur-uae","procedure_name":"Pulsed Field Ablation (PFA) for Atrial Fibrillation","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular"],"diseases":["Atrial Fibrillation"],"status":"active"},{"id":"241f7a53-539d-467f-8348-1ce3ba746f62","procedure_id":"proc-pef-ablation","jurisdiction_id":"jur-kr","procedure_name":"Pulsed Field Ablation (PFA) for Atrial Fibrillation","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"MFDS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular"],"diseases":["Atrial Fibrillation"],"status":"active"},{"id":"67c66036-ced0-4d01-9989-d80e6b63c132","procedure_id":"proc-pef-ablation","jurisdiction_id":"jur-gr","procedure_name":"Pulsed Field Ablation (PFA) for Atrial Fibrillation","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular"],"diseases":["Atrial Fibrillation"],"status":"active"},{"id":"a67970ab-6609-4b9a-912f-39cdd6f56170","procedure_id":"proc-pef-ablation","jurisdiction_id":"jur-be","procedure_name":"Pulsed Field Ablation (PFA) for Atrial Fibrillation","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular"],"diseases":["Atrial Fibrillation"],"status":"active"},{"id":"4b651fc4-5eb1-4699-9d75-7535f6fd7de4","procedure_id":"proc-pef-ablation","jurisdiction_id":"jur-se","procedure_name":"Pulsed Field Ablation (PFA) for Atrial Fibrillation","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular"],"diseases":["Atrial Fibrillation"],"status":"active"},{"id":"3104c1b1-145b-4717-ac2d-e23564eddd8d","procedure_id":"proc-pef-ablation","jurisdiction_id":"jur-sg","procedure_name":"Pulsed Field Ablation (PFA) for Atrial Fibrillation","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"HSA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular"],"diseases":["Atrial Fibrillation"],"status":"active"},{"id":"837f04f2-b2cc-4a03-8ff4-30e25241e0a4","procedure_id":"proc-pef-ablation","jurisdiction_id":"jur-cl","procedure_name":"Pulsed Field Ablation (PFA) for Atrial Fibrillation","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular"],"diseases":["Atrial Fibrillation"],"status":"active"},{"id":"9f0b65ed-afa2-4761-9856-62bb5b4b0991","procedure_id":"proc-pef-ablation","jurisdiction_id":"jur-ar","procedure_name":"Pulsed Field Ablation (PFA) for Atrial Fibrillation","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular"],"diseases":["Atrial Fibrillation"],"status":"active"},{"id":"a769669f-3098-42d3-9cf6-b08b860f52ee","procedure_id":"proc-pef-ablation","jurisdiction_id":"jur-za","procedure_name":"Pulsed Field Ablation (PFA) for Atrial Fibrillation","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular"],"diseases":["Atrial Fibrillation"],"status":"active"},{"id":"aab44a4e-fe80-4a84-b521-f09cf1880e31","procedure_id":"proc-pef-ablation","jurisdiction_id":"jur-ph","procedure_name":"Pulsed Field Ablation (PFA) for Atrial Fibrillation","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular"],"diseases":["Atrial Fibrillation"],"status":"active"},{"id":"96889a00-e2fc-4d56-9ac3-eea70e97ae0f","procedure_id":"proc-pef-ablation","jurisdiction_id":"jur-po","procedure_name":"Pulsed Field Ablation (PFA) for Atrial Fibrillation","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular"],"diseases":["Atrial Fibrillation"],"status":"active"},{"id":"cce19788-544b-422f-ac81-4baadcdac9d0","procedure_id":"proc-pef-ablation","jurisdiction_id":"jur-pt","procedure_name":"Pulsed Field Ablation (PFA) for Atrial Fibrillation","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular"],"diseases":["Atrial Fibrillation"],"status":"active"},{"id":"087cf97a-5ba2-4fbf-accb-cc8b849448b4","procedure_id":"proc-pef-ablation","jurisdiction_id":"jur-fr","procedure_name":"Pulsed Field Ablation (PFA) for Atrial Fibrillation","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"ANSM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular"],"diseases":["Atrial Fibrillation"],"status":"active"},{"id":"1b3cbf9c-02f8-4e2d-9040-544d8424ea66","procedure_id":"proc-lecanemab","jurisdiction_id":"jur-us-or","procedure_name":"Anti-Amyloid Monoclonal Antibodies (Lecanemab / Donanemab) for Early Alzheimer's","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Dementia"],"diseases":["Early Alzheimer's Disease","Mild Cognitive Impairment due to AD"],"status":"active"},{"id":"233fc836-c61b-4d13-b9b8-ce8d4327d798","procedure_id":"proc-lecanemab","jurisdiction_id":"jur-us-co","procedure_name":"Anti-Amyloid Monoclonal Antibodies (Lecanemab / Donanemab) for Early Alzheimer's","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Dementia"],"diseases":["Early Alzheimer's Disease","Mild Cognitive Impairment due to AD"],"status":"active"},{"id":"e14d9142-455c-40ee-a77a-36eff8551016","procedure_id":"proc-lecanemab","jurisdiction_id":"jur-us-ca","procedure_name":"Anti-Amyloid Monoclonal Antibodies (Lecanemab / Donanemab) for Early Alzheimer's","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Dementia"],"diseases":["Early Alzheimer's Disease","Mild Cognitive Impairment due to AD"],"status":"active"},{"id":"59927f66-39c6-406b-93fe-936859b955bf","procedure_id":"proc-lecanemab","jurisdiction_id":"jur-us-tx","procedure_name":"Anti-Amyloid Monoclonal Antibodies (Lecanemab / Donanemab) for Early Alzheimer's","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Dementia"],"diseases":["Early Alzheimer's Disease","Mild Cognitive Impairment due to AD"],"status":"active"},{"id":"0cd4de1e-2c82-4352-853a-c95143f377ee","procedure_id":"proc-lecanemab","jurisdiction_id":"jur-us-fl","procedure_name":"Anti-Amyloid Monoclonal Antibodies (Lecanemab / Donanemab) for Early Alzheimer's","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Dementia"],"diseases":["Early Alzheimer's Disease","Mild Cognitive Impairment due to AD"],"status":"active"},{"id":"ce1614e3-3280-40f4-a72e-52ae4d2be7d7","procedure_id":"proc-lecanemab","jurisdiction_id":"jur-au","procedure_name":"Anti-Amyloid Monoclonal Antibodies (Lecanemab / Donanemab) for Early Alzheimer's","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"TGA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Dementia"],"diseases":["Early Alzheimer's Disease","Mild Cognitive Impairment due to AD"],"status":"active"},{"id":"2a24a70d-1ad8-4cce-86cd-e08abe0ab228","procedure_id":"proc-lecanemab","jurisdiction_id":"jur-ch","procedure_name":"Anti-Amyloid Monoclonal Antibodies (Lecanemab / Donanemab) for Early Alzheimer's","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Swissmedic","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Dementia"],"diseases":["Early Alzheimer's Disease","Mild Cognitive Impairment due to AD"],"status":"active"},{"id":"074b38a8-a3b2-428c-be71-5edc7b3635e8","procedure_id":"proc-lecanemab","jurisdiction_id":"jur-ca","procedure_name":"Anti-Amyloid Monoclonal Antibodies (Lecanemab / Donanemab) for Early Alzheimer's","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Health Canada","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Dementia"],"diseases":["Early Alzheimer's Disease","Mild Cognitive Impairment due to AD"],"status":"active"},{"id":"e1af0113-bb31-47bc-ad52-52494f4e7898","procedure_id":"proc-lecanemab","jurisdiction_id":"jur-mx","procedure_name":"Anti-Amyloid Monoclonal Antibodies (Lecanemab / Donanemab) for Early Alzheimer's","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Permissive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"COFEPRIS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Dementia"],"diseases":["Early Alzheimer's Disease","Mild Cognitive Impairment due to AD"],"status":"active"},{"id":"3365fb09-cda3-4b47-b39a-efee0b9877b3","procedure_id":"proc-lecanemab","jurisdiction_id":"jur-hn-prospera","procedure_name":"Anti-Amyloid Monoclonal Antibodies (Lecanemab / Donanemab) for Early Alzheimer's","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Permissive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Próspera ZEDE health rules (contested)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Dementia"],"diseases":["Early Alzheimer's Disease","Mild Cognitive Impairment due to AD"],"status":"active"},{"id":"c092defa-3e6e-4192-b0c4-6542a9e19d31","procedure_id":"proc-lecanemab","jurisdiction_id":"jur-nl","procedure_name":"Anti-Amyloid Monoclonal Antibodies (Lecanemab / Donanemab) for Early Alzheimer's","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"MEB / IGJ","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Dementia"],"diseases":["Early Alzheimer's Disease","Mild Cognitive Impairment due to AD"],"status":"active"},{"id":"b819773e-aef2-4688-978b-00ffee155681","procedure_id":"proc-lecanemab","jurisdiction_id":"jur-de","procedure_name":"Anti-Amyloid Monoclonal Antibodies (Lecanemab / Donanemab) for Early Alzheimer's","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"BfArM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Dementia"],"diseases":["Early Alzheimer's Disease","Mild Cognitive Impairment due to AD"],"status":"active"},{"id":"e4c4469d-c4b3-46a0-9df2-b2f4888a150b","procedure_id":"proc-lecanemab","jurisdiction_id":"jur-il","procedure_name":"Anti-Amyloid Monoclonal Antibodies (Lecanemab / Donanemab) for Early Alzheimer's","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Dementia"],"diseases":["Early Alzheimer's Disease","Mild Cognitive Impairment due to AD"],"status":"active"},{"id":"c2151b96-3ce2-4b7f-85b3-bcad7cff53e0","procedure_id":"proc-lecanemab","jurisdiction_id":"jur-jm","procedure_name":"Anti-Amyloid Monoclonal Antibodies (Lecanemab / Donanemab) for Early Alzheimer's","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Dementia"],"diseases":["Early Alzheimer's Disease","Mild Cognitive Impairment due to AD"],"status":"active"},{"id":"70d569ef-af9e-4f0d-b889-6002eda2a08f","procedure_id":"proc-lecanemab","jurisdiction_id":"jur-th","procedure_name":"Anti-Amyloid Monoclonal Antibodies (Lecanemab / Donanemab) for Early Alzheimer's","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Permissive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Thai FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Dementia"],"diseases":["Early Alzheimer's Disease","Mild Cognitive Impairment due to AD"],"status":"active"},{"id":"e4573645-18f3-41a7-be74-c828ce9bf00b","procedure_id":"proc-lecanemab","jurisdiction_id":"jur-es","procedure_name":"Anti-Amyloid Monoclonal Antibodies (Lecanemab / Donanemab) for Early Alzheimer's","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"AEMPS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Dementia"],"diseases":["Early Alzheimer's Disease","Mild Cognitive Impairment due to AD"],"status":"active"},{"id":"0f4018ad-90d4-43a6-9008-6e9beadb5f78","procedure_id":"proc-lecanemab","jurisdiction_id":"jur-tu","procedure_name":"Anti-Amyloid Monoclonal Antibodies (Lecanemab / Donanemab) for Early Alzheimer's","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Dementia"],"diseases":["Early Alzheimer's Disease","Mild Cognitive Impairment due to AD"],"status":"active"},{"id":"19a54369-f124-4fdd-b4fc-b3c8e8727d20","procedure_id":"proc-lecanemab","jurisdiction_id":"jur-in","procedure_name":"Anti-Amyloid Monoclonal Antibodies (Lecanemab / Donanemab) for Early Alzheimer's","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Permissive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"CDSCO","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Dementia"],"diseases":["Early Alzheimer's Disease","Mild Cognitive Impairment due to AD"],"status":"active"},{"id":"206f2b96-98e8-4339-8749-21ef6a2fb18e","procedure_id":"proc-lecanemab","jurisdiction_id":"jur-br","procedure_name":"Anti-Amyloid Monoclonal Antibodies (Lecanemab / Donanemab) for Early Alzheimer's","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"ANVISA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Dementia"],"diseases":["Early Alzheimer's Disease","Mild Cognitive Impairment due to AD"],"status":"active"},{"id":"3a6843b4-ca4a-4117-9805-f42edfa6dd17","procedure_id":"proc-lecanemab","jurisdiction_id":"jur-cr","procedure_name":"Anti-Amyloid Monoclonal Antibodies (Lecanemab / Donanemab) for Early Alzheimer's","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Dementia"],"diseases":["Early Alzheimer's Disease","Mild Cognitive Impairment due to AD"],"status":"active"},{"id":"2ca46902-b546-4df3-8e02-2752dbe471de","procedure_id":"proc-lecanemab","jurisdiction_id":"jur-uae","procedure_name":"Anti-Amyloid Monoclonal Antibodies (Lecanemab / Donanemab) for Early Alzheimer's","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Dementia"],"diseases":["Early Alzheimer's Disease","Mild Cognitive Impairment due to AD"],"status":"active"},{"id":"c3270782-46a3-4caf-a84d-78e49c68bdb5","procedure_id":"proc-lecanemab","jurisdiction_id":"jur-kr","procedure_name":"Anti-Amyloid Monoclonal Antibodies (Lecanemab / Donanemab) for Early Alzheimer's","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"MFDS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Dementia"],"diseases":["Early Alzheimer's Disease","Mild Cognitive Impairment due to AD"],"status":"active"},{"id":"69d1da88-a233-43c5-a8f2-2a5adf71495d","procedure_id":"proc-lecanemab","jurisdiction_id":"jur-gr","procedure_name":"Anti-Amyloid Monoclonal Antibodies (Lecanemab / Donanemab) for Early Alzheimer's","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Dementia"],"diseases":["Early Alzheimer's Disease","Mild Cognitive Impairment due to AD"],"status":"active"},{"id":"f2cc7067-9ef5-4ca3-a08e-57a0771c643a","procedure_id":"proc-lecanemab","jurisdiction_id":"jur-be","procedure_name":"Anti-Amyloid Monoclonal Antibodies (Lecanemab / Donanemab) for Early Alzheimer's","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Dementia"],"diseases":["Early Alzheimer's Disease","Mild Cognitive Impairment due to AD"],"status":"active"},{"id":"c4e00ea4-b0ba-47cf-9f6f-39bc5cd1b206","procedure_id":"proc-lecanemab","jurisdiction_id":"jur-se","procedure_name":"Anti-Amyloid Monoclonal Antibodies (Lecanemab / Donanemab) for Early Alzheimer's","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Dementia"],"diseases":["Early Alzheimer's Disease","Mild Cognitive Impairment due to AD"],"status":"active"},{"id":"66fc6a82-1c70-4e57-8771-6f9b9f325ad3","procedure_id":"proc-lecanemab","jurisdiction_id":"jur-sg","procedure_name":"Anti-Amyloid Monoclonal Antibodies (Lecanemab / Donanemab) for Early Alzheimer's","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"HSA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Dementia"],"diseases":["Early Alzheimer's Disease","Mild Cognitive Impairment due to AD"],"status":"active"},{"id":"565d9334-e888-4dd0-868e-164f60fd7737","procedure_id":"proc-lecanemab","jurisdiction_id":"jur-cl","procedure_name":"Anti-Amyloid Monoclonal Antibodies (Lecanemab / Donanemab) for Early Alzheimer's","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Dementia"],"diseases":["Early Alzheimer's Disease","Mild Cognitive Impairment due to AD"],"status":"active"},{"id":"71c3fd51-55fe-45a1-a5ee-83463f0c5ce7","procedure_id":"proc-lecanemab","jurisdiction_id":"jur-ar","procedure_name":"Anti-Amyloid Monoclonal Antibodies (Lecanemab / Donanemab) for Early Alzheimer's","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Dementia"],"diseases":["Early Alzheimer's Disease","Mild Cognitive Impairment due to AD"],"status":"active"},{"id":"2abaf59d-70e8-4cd9-9319-b900756a6903","procedure_id":"proc-lecanemab","jurisdiction_id":"jur-za","procedure_name":"Anti-Amyloid Monoclonal Antibodies (Lecanemab / Donanemab) for Early Alzheimer's","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Dementia"],"diseases":["Early Alzheimer's Disease","Mild Cognitive Impairment due to AD"],"status":"active"},{"id":"55d34888-331e-4255-ad3e-931b52b57c75","procedure_id":"proc-lecanemab","jurisdiction_id":"jur-ph","procedure_name":"Anti-Amyloid Monoclonal Antibodies (Lecanemab / Donanemab) for Early Alzheimer's","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Dementia"],"diseases":["Early Alzheimer's Disease","Mild Cognitive Impairment due to AD"],"status":"active"},{"id":"ac2b234b-f39a-4072-bc7d-3ad042ce4f73","procedure_id":"proc-lecanemab","jurisdiction_id":"jur-po","procedure_name":"Anti-Amyloid Monoclonal Antibodies (Lecanemab / Donanemab) for Early Alzheimer's","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Dementia"],"diseases":["Early Alzheimer's Disease","Mild Cognitive Impairment due to AD"],"status":"active"},{"id":"631f6a66-edbc-4541-8b73-cff45d57047b","procedure_id":"proc-lecanemab","jurisdiction_id":"jur-pt","procedure_name":"Anti-Amyloid Monoclonal Antibodies (Lecanemab / Donanemab) for Early Alzheimer's","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Dementia"],"diseases":["Early Alzheimer's Disease","Mild Cognitive Impairment due to AD"],"status":"active"},{"id":"fa997530-b0f1-461d-878c-f7f9bb9c508f","procedure_id":"proc-lecanemab","jurisdiction_id":"jur-fr","procedure_name":"Anti-Amyloid Monoclonal Antibodies (Lecanemab / Donanemab) for Early Alzheimer's","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"ANSM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Neurology","Dementia"],"diseases":["Early Alzheimer's Disease","Mild Cognitive Impairment due to AD"],"status":"active"},{"id":"8a33e830-4911-42dc-a76f-ba2fd63b3721","procedure_id":"proc-trt","jurisdiction_id":"jur-us-or","procedure_name":"Testosterone Replacement Therapy (TRT) for Hypogonadism","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Endocrinology","Men's_Health"],"diseases":["Male Hypogonadism","Testosterone Deficiency"],"status":"active"},{"id":"203eeb30-d590-475b-946b-8101710ab890","procedure_id":"proc-trt","jurisdiction_id":"jur-us-co","procedure_name":"Testosterone Replacement Therapy (TRT) for Hypogonadism","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Endocrinology","Men's_Health"],"diseases":["Male Hypogonadism","Testosterone Deficiency"],"status":"active"},{"id":"85ce8ad7-00a0-40ab-95f8-8528377a78e7","procedure_id":"proc-trt","jurisdiction_id":"jur-us-ca","procedure_name":"Testosterone Replacement Therapy (TRT) for Hypogonadism","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Endocrinology","Men's_Health"],"diseases":["Male Hypogonadism","Testosterone Deficiency"],"status":"active"},{"id":"7c7ee7d4-68eb-4b61-87d7-329c30f29f3e","procedure_id":"proc-trt","jurisdiction_id":"jur-us-tx","procedure_name":"Testosterone Replacement Therapy (TRT) for Hypogonadism","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Endocrinology","Men's_Health"],"diseases":["Male Hypogonadism","Testosterone Deficiency"],"status":"active"},{"id":"733e60c6-437c-4455-9b8e-b4b3c1a5cf56","procedure_id":"proc-trt","jurisdiction_id":"jur-us-fl","procedure_name":"Testosterone Replacement Therapy (TRT) for Hypogonadism","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Endocrinology","Men's_Health"],"diseases":["Male Hypogonadism","Testosterone Deficiency"],"status":"active"},{"id":"16aaccbc-9c41-4100-a172-725db60e5a53","procedure_id":"proc-trt","jurisdiction_id":"jur-au","procedure_name":"Testosterone Replacement Therapy (TRT) for Hypogonadism","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"TGA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Endocrinology","Men's_Health"],"diseases":["Male Hypogonadism","Testosterone Deficiency"],"status":"active"},{"id":"e5d7a9c5-e5e0-4f62-9006-37b69c4d22a8","procedure_id":"proc-trt","jurisdiction_id":"jur-ch","procedure_name":"Testosterone Replacement Therapy (TRT) for Hypogonadism","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Swissmedic","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Endocrinology","Men's_Health"],"diseases":["Male Hypogonadism","Testosterone Deficiency"],"status":"active"},{"id":"45489b50-98e8-43bf-9337-cf1ca1ba3968","procedure_id":"proc-trt","jurisdiction_id":"jur-ca","procedure_name":"Testosterone Replacement Therapy (TRT) for Hypogonadism","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Health Canada","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Endocrinology","Men's_Health"],"diseases":["Male Hypogonadism","Testosterone Deficiency"],"status":"active"},{"id":"d254946c-5476-4f37-ac71-4e014ef2d94e","procedure_id":"proc-trt","jurisdiction_id":"jur-hn-prospera","procedure_name":"Testosterone Replacement Therapy (TRT) for Hypogonadism","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Permissive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Próspera ZEDE health rules (contested)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Endocrinology","Men's_Health"],"diseases":["Male Hypogonadism","Testosterone Deficiency"],"status":"active"},{"id":"451ef019-b6ad-46f0-86f5-83384b9e744e","procedure_id":"proc-trt","jurisdiction_id":"jur-nl","procedure_name":"Testosterone Replacement Therapy (TRT) for Hypogonadism","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"MEB / IGJ","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Endocrinology","Men's_Health"],"diseases":["Male Hypogonadism","Testosterone Deficiency"],"status":"active"},{"id":"db205ef7-94c2-40b6-9cf2-5a96c6f5401d","procedure_id":"proc-trt","jurisdiction_id":"jur-de","procedure_name":"Testosterone Replacement Therapy (TRT) for Hypogonadism","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"BfArM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Endocrinology","Men's_Health"],"diseases":["Male Hypogonadism","Testosterone Deficiency"],"status":"active"},{"id":"1f1b9bfb-8480-4bb0-b05f-05001f283c3f","procedure_id":"proc-trt","jurisdiction_id":"jur-il","procedure_name":"Testosterone Replacement Therapy (TRT) for Hypogonadism","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Endocrinology","Men's_Health"],"diseases":["Male Hypogonadism","Testosterone Deficiency"],"status":"active"},{"id":"0a74d1dd-a004-4c07-a990-7512bb6c2c35","procedure_id":"proc-trt","jurisdiction_id":"jur-jm","procedure_name":"Testosterone Replacement Therapy (TRT) for Hypogonadism","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Endocrinology","Men's_Health"],"diseases":["Male Hypogonadism","Testosterone Deficiency"],"status":"active"},{"id":"d5eb075d-37a7-4c23-b2b0-1d1b811a2228","procedure_id":"proc-trt","jurisdiction_id":"jur-th","procedure_name":"Testosterone Replacement Therapy (TRT) for Hypogonadism","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Permissive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Thai FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Endocrinology","Men's_Health"],"diseases":["Male Hypogonadism","Testosterone Deficiency"],"status":"active"},{"id":"2d5f0a59-e461-47ee-9abd-df5477d4567f","procedure_id":"proc-trt","jurisdiction_id":"jur-es","procedure_name":"Testosterone Replacement Therapy (TRT) for Hypogonadism","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"AEMPS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Endocrinology","Men's_Health"],"diseases":["Male Hypogonadism","Testosterone Deficiency"],"status":"active"},{"id":"c89d52ab-82ec-4ae9-8cf6-7ff517225188","procedure_id":"proc-trt","jurisdiction_id":"jur-tu","procedure_name":"Testosterone Replacement Therapy (TRT) for Hypogonadism","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Endocrinology","Men's_Health"],"diseases":["Male Hypogonadism","Testosterone Deficiency"],"status":"active"},{"id":"46a2d71c-8f73-40d4-82cb-28706cc0b0a7","procedure_id":"proc-trt","jurisdiction_id":"jur-in","procedure_name":"Testosterone Replacement Therapy (TRT) for Hypogonadism","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Permissive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"CDSCO","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Endocrinology","Men's_Health"],"diseases":["Male Hypogonadism","Testosterone Deficiency"],"status":"active"},{"id":"11de9c30-4e3f-4c29-926f-be1c9ed2e33d","procedure_id":"proc-trt","jurisdiction_id":"jur-br","procedure_name":"Testosterone Replacement Therapy (TRT) for Hypogonadism","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"ANVISA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Endocrinology","Men's_Health"],"diseases":["Male Hypogonadism","Testosterone Deficiency"],"status":"active"},{"id":"11772b89-fe70-4de9-916c-83ceed7abb39","procedure_id":"proc-trt","jurisdiction_id":"jur-cr","procedure_name":"Testosterone Replacement Therapy (TRT) for Hypogonadism","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Endocrinology","Men's_Health"],"diseases":["Male Hypogonadism","Testosterone Deficiency"],"status":"active"},{"id":"cd0ad195-35a1-44ba-8d83-531a53836d07","procedure_id":"proc-trt","jurisdiction_id":"jur-uae","procedure_name":"Testosterone Replacement Therapy (TRT) for Hypogonadism","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Endocrinology","Men's_Health"],"diseases":["Male Hypogonadism","Testosterone Deficiency"],"status":"active"},{"id":"d6445b48-9ba5-44ff-8357-9f01737c9c04","procedure_id":"proc-trt","jurisdiction_id":"jur-kr","procedure_name":"Testosterone Replacement Therapy (TRT) for Hypogonadism","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"MFDS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Endocrinology","Men's_Health"],"diseases":["Male Hypogonadism","Testosterone Deficiency"],"status":"active"},{"id":"f85e4bc7-a1ef-41f9-b531-c0e0bbea2702","procedure_id":"proc-trt","jurisdiction_id":"jur-gr","procedure_name":"Testosterone Replacement Therapy (TRT) for Hypogonadism","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Endocrinology","Men's_Health"],"diseases":["Male Hypogonadism","Testosterone Deficiency"],"status":"active"},{"id":"faca0432-6028-460b-9a4e-2e5b693d2649","procedure_id":"proc-trt","jurisdiction_id":"jur-be","procedure_name":"Testosterone Replacement Therapy (TRT) for Hypogonadism","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Endocrinology","Men's_Health"],"diseases":["Male Hypogonadism","Testosterone Deficiency"],"status":"active"},{"id":"373b8e3b-540c-42c3-9a3f-20c9aba2f049","procedure_id":"proc-trt","jurisdiction_id":"jur-se","procedure_name":"Testosterone Replacement Therapy (TRT) for Hypogonadism","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Endocrinology","Men's_Health"],"diseases":["Male Hypogonadism","Testosterone Deficiency"],"status":"active"},{"id":"5e2b773d-1cf9-41b5-8d9d-1eb4feb1a5fc","procedure_id":"proc-trt","jurisdiction_id":"jur-jp","procedure_name":"Testosterone Replacement Therapy (TRT) for Hypogonadism","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"PMDA / MHLW","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Endocrinology","Men's_Health"],"diseases":["Male Hypogonadism","Testosterone Deficiency"],"status":"active"},{"id":"f726e9cd-ccd8-4082-a404-b95deeb44905","procedure_id":"proc-trt","jurisdiction_id":"jur-sg","procedure_name":"Testosterone Replacement Therapy (TRT) for Hypogonadism","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"HSA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Endocrinology","Men's_Health"],"diseases":["Male Hypogonadism","Testosterone Deficiency"],"status":"active"},{"id":"729d841e-c12e-4e3f-b4ee-5d7020fc0387","procedure_id":"proc-trt","jurisdiction_id":"jur-cl","procedure_name":"Testosterone Replacement Therapy (TRT) for Hypogonadism","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Endocrinology","Men's_Health"],"diseases":["Male Hypogonadism","Testosterone Deficiency"],"status":"active"},{"id":"12b14d30-2677-42a5-80b0-428b949a2ffa","procedure_id":"proc-trt","jurisdiction_id":"jur-ar","procedure_name":"Testosterone Replacement Therapy (TRT) for Hypogonadism","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Endocrinology","Men's_Health"],"diseases":["Male Hypogonadism","Testosterone Deficiency"],"status":"active"},{"id":"2e146f08-f3cb-4b1b-a4f7-d04a91f40982","procedure_id":"proc-trt","jurisdiction_id":"jur-za","procedure_name":"Testosterone Replacement Therapy (TRT) for Hypogonadism","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Endocrinology","Men's_Health"],"diseases":["Male Hypogonadism","Testosterone Deficiency"],"status":"active"},{"id":"9c86b58f-dbaa-48fd-86c5-0c95adfd4d90","procedure_id":"proc-trt","jurisdiction_id":"jur-ph","procedure_name":"Testosterone Replacement Therapy (TRT) for Hypogonadism","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Endocrinology","Men's_Health"],"diseases":["Male Hypogonadism","Testosterone Deficiency"],"status":"active"},{"id":"49bb53f1-e107-4cd0-ad2b-e6a7c6dee23a","procedure_id":"proc-trt","jurisdiction_id":"jur-po","procedure_name":"Testosterone Replacement Therapy (TRT) for Hypogonadism","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Endocrinology","Men's_Health"],"diseases":["Male Hypogonadism","Testosterone Deficiency"],"status":"active"},{"id":"ec0cba86-c6b9-40f4-93c2-aac330d280a9","procedure_id":"proc-trt","jurisdiction_id":"jur-pt","procedure_name":"Testosterone Replacement Therapy (TRT) for Hypogonadism","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Endocrinology","Men's_Health"],"diseases":["Male Hypogonadism","Testosterone Deficiency"],"status":"active"},{"id":"66847a88-587c-4d11-b0ab-5376a31f2d5a","procedure_id":"proc-trt","jurisdiction_id":"jur-fr","procedure_name":"Testosterone Replacement Therapy (TRT) for Hypogonadism","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"ANSM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Endocrinology","Men's_Health"],"diseases":["Male Hypogonadism","Testosterone Deficiency"],"status":"active"},{"id":"e5915e7d-d71c-4d88-8c53-8602548c921c","procedure_id":"proc-peptide-ss31","jurisdiction_id":"jur-us-or","procedure_name":"Elamipretide / Mitochondrial-Targeted Peptides (SS-31 Class)","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mitochondrial_Health","Cardiology","Ophthalmology"],"diseases":["Barth Syndrome","Mitochondrial Myopathy","Dry AMD (investigational)"],"status":"active"},{"id":"fc4995e7-f6f8-46a1-8bdc-b6f9a310877f","procedure_id":"proc-peptide-ss31","jurisdiction_id":"jur-us-co","procedure_name":"Elamipretide / Mitochondrial-Targeted Peptides (SS-31 Class)","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mitochondrial_Health","Cardiology","Ophthalmology"],"diseases":["Barth Syndrome","Mitochondrial Myopathy","Dry AMD (investigational)"],"status":"active"},{"id":"31c9794d-1664-4a21-8d39-16cac6c6ea62","procedure_id":"proc-peptide-ss31","jurisdiction_id":"jur-us-ca","procedure_name":"Elamipretide / Mitochondrial-Targeted Peptides (SS-31 Class)","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mitochondrial_Health","Cardiology","Ophthalmology"],"diseases":["Barth Syndrome","Mitochondrial Myopathy","Dry AMD (investigational)"],"status":"active"},{"id":"d176f208-8388-4919-b753-a2f9f660366c","procedure_id":"proc-peptide-ss31","jurisdiction_id":"jur-us-tx","procedure_name":"Elamipretide / Mitochondrial-Targeted Peptides (SS-31 Class)","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mitochondrial_Health","Cardiology","Ophthalmology"],"diseases":["Barth Syndrome","Mitochondrial Myopathy","Dry AMD (investigational)"],"status":"active"},{"id":"4efe4543-7725-4811-b37b-39ba8b7d7f86","procedure_id":"proc-peptide-ss31","jurisdiction_id":"jur-us-fl","procedure_name":"Elamipretide / Mitochondrial-Targeted Peptides (SS-31 Class)","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mitochondrial_Health","Cardiology","Ophthalmology"],"diseases":["Barth Syndrome","Mitochondrial Myopathy","Dry AMD (investigational)"],"status":"active"},{"id":"afd1603c-d434-4611-8e4c-797e1c3db852","procedure_id":"proc-peptide-ss31","jurisdiction_id":"jur-au","procedure_name":"Elamipretide / Mitochondrial-Targeted Peptides (SS-31 Class)","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"TGA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mitochondrial_Health","Cardiology","Ophthalmology"],"diseases":["Barth Syndrome","Mitochondrial Myopathy","Dry AMD (investigational)"],"status":"active"},{"id":"49512216-8597-4017-bb28-3ca9958f25c0","procedure_id":"proc-peptide-ss31","jurisdiction_id":"jur-ch","procedure_name":"Elamipretide / Mitochondrial-Targeted Peptides (SS-31 Class)","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"Swissmedic","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mitochondrial_Health","Cardiology","Ophthalmology"],"diseases":["Barth Syndrome","Mitochondrial Myopathy","Dry AMD (investigational)"],"status":"active"},{"id":"667ff4f5-9b28-4f35-a292-459c16a994f0","procedure_id":"proc-peptide-ss31","jurisdiction_id":"jur-ca","procedure_name":"Elamipretide / Mitochondrial-Targeted Peptides (SS-31 Class)","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"Health Canada","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mitochondrial_Health","Cardiology","Ophthalmology"],"diseases":["Barth Syndrome","Mitochondrial Myopathy","Dry AMD (investigational)"],"status":"active"},{"id":"4b79708d-0452-486a-9da6-2749158c2338","procedure_id":"proc-peptide-ss31","jurisdiction_id":"jur-mx","procedure_name":"Elamipretide / Mitochondrial-Targeted Peptides (SS-31 Class)","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"COMPOUNDING","oversight_quality":"MINIMAL","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Still may violate advertising/medicine laws. Bulk substance status is critical.","eligibility_requirements":"Medical justification documentation if any.","provider_requirements":"Prescriber + compounder compliance uncertain.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray compounding climate — high legal risk even if local practice is common.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide + relatively open compounding climate → gray compounding risk.","regulatory_authority":"COFEPRIS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mitochondrial_Health","Cardiology","Ophthalmology"],"diseases":["Barth Syndrome","Mitochondrial Myopathy","Dry AMD (investigational)"],"status":"active"},{"id":"545d24ad-b8ef-4a98-8e70-eb04a57e1185","procedure_id":"proc-peptide-ss31","jurisdiction_id":"jur-hn-prospera","procedure_name":"Elamipretide / Mitochondrial-Targeted Peptides (SS-31 Class)","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"COMPOUNDING","oversight_quality":"MINIMAL","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Still may violate advertising/medicine laws. Bulk substance status is critical.","eligibility_requirements":"Medical justification documentation if any.","provider_requirements":"Prescriber + compounder compliance uncertain.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray compounding climate — high legal risk even if local practice is common.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide + relatively open compounding climate → gray compounding risk.","regulatory_authority":"Próspera ZEDE health rules (contested)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mitochondrial_Health","Cardiology","Ophthalmology"],"diseases":["Barth Syndrome","Mitochondrial Myopathy","Dry AMD (investigational)"],"status":"active"},{"id":"e731715e-9f6b-467e-aad3-7458062ad57d","procedure_id":"proc-peptide-ss31","jurisdiction_id":"jur-nl","procedure_name":"Elamipretide / Mitochondrial-Targeted Peptides (SS-31 Class)","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"MEB / IGJ","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mitochondrial_Health","Cardiology","Ophthalmology"],"diseases":["Barth Syndrome","Mitochondrial Myopathy","Dry AMD (investigational)"],"status":"active"},{"id":"6c4422c3-0c64-49ca-b35a-8afb9178f2a0","procedure_id":"proc-peptide-ss31","jurisdiction_id":"jur-uk","procedure_name":"Elamipretide / Mitochondrial-Targeted Peptides (SS-31 Class)","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"MHRA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mitochondrial_Health","Cardiology","Ophthalmology"],"diseases":["Barth Syndrome","Mitochondrial Myopathy","Dry AMD (investigational)"],"status":"active"},{"id":"bd69b891-8b56-44fc-baf4-b3938f0c3ac0","procedure_id":"proc-peptide-ss31","jurisdiction_id":"jur-il","procedure_name":"Elamipretide / Mitochondrial-Targeted Peptides (SS-31 Class)","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mitochondrial_Health","Cardiology","Ophthalmology"],"diseases":["Barth Syndrome","Mitochondrial Myopathy","Dry AMD (investigational)"],"status":"active"},{"id":"4d619729-b912-4892-a73d-fb5f05a8beed","procedure_id":"proc-peptide-ss31","jurisdiction_id":"jur-jm","procedure_name":"Elamipretide / Mitochondrial-Targeted Peptides (SS-31 Class)","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mitochondrial_Health","Cardiology","Ophthalmology"],"diseases":["Barth Syndrome","Mitochondrial Myopathy","Dry AMD (investigational)"],"status":"active"},{"id":"2f2fc710-5eca-471d-804b-b0f4174b3157","procedure_id":"proc-peptide-ss31","jurisdiction_id":"jur-th","procedure_name":"Elamipretide / Mitochondrial-Targeted Peptides (SS-31 Class)","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"Thai FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mitochondrial_Health","Cardiology","Ophthalmology"],"diseases":["Barth Syndrome","Mitochondrial Myopathy","Dry AMD (investigational)"],"status":"active"},{"id":"850c31e4-8595-4a7a-98c7-fadcd86159c4","procedure_id":"proc-peptide-ss31","jurisdiction_id":"jur-es","procedure_name":"Elamipretide / Mitochondrial-Targeted Peptides (SS-31 Class)","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"AEMPS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mitochondrial_Health","Cardiology","Ophthalmology"],"diseases":["Barth Syndrome","Mitochondrial Myopathy","Dry AMD (investigational)"],"status":"active"},{"id":"a1e3870b-fe7b-4b74-b283-05726f08edd8","procedure_id":"proc-peptide-ss31","jurisdiction_id":"jur-tu","procedure_name":"Elamipretide / Mitochondrial-Targeted Peptides (SS-31 Class)","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mitochondrial_Health","Cardiology","Ophthalmology"],"diseases":["Barth Syndrome","Mitochondrial Myopathy","Dry AMD (investigational)"],"status":"active"},{"id":"668f4dfc-74d1-47d3-b2ce-13136ec57c3d","procedure_id":"proc-peptide-ss31","jurisdiction_id":"jur-in","procedure_name":"Elamipretide / Mitochondrial-Targeted Peptides (SS-31 Class)","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"COMPOUNDING","oversight_quality":"MINIMAL","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Still may violate advertising/medicine laws. Bulk substance status is critical.","eligibility_requirements":"Medical justification documentation if any.","provider_requirements":"Prescriber + compounder compliance uncertain.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred gray compounding climate — high legal risk even if local practice is common.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide + relatively open compounding climate → gray compounding risk.","regulatory_authority":"CDSCO","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mitochondrial_Health","Cardiology","Ophthalmology"],"diseases":["Barth Syndrome","Mitochondrial Myopathy","Dry AMD (investigational)"],"status":"active"},{"id":"5fb6d55d-2d5d-4a44-9dc7-e1cea7e2d0ec","procedure_id":"proc-peptide-ss31","jurisdiction_id":"jur-br","procedure_name":"Elamipretide / Mitochondrial-Targeted Peptides (SS-31 Class)","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"ANVISA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mitochondrial_Health","Cardiology","Ophthalmology"],"diseases":["Barth Syndrome","Mitochondrial Myopathy","Dry AMD (investigational)"],"status":"active"},{"id":"b4150091-e7c2-473e-a018-fef8dd1b93cf","procedure_id":"proc-peptide-ss31","jurisdiction_id":"jur-cr","procedure_name":"Elamipretide / Mitochondrial-Targeted Peptides (SS-31 Class)","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mitochondrial_Health","Cardiology","Ophthalmology"],"diseases":["Barth Syndrome","Mitochondrial Myopathy","Dry AMD (investigational)"],"status":"active"},{"id":"32014c54-fc8b-4c3d-bc89-40e35bd6c4c9","procedure_id":"proc-peptide-ss31","jurisdiction_id":"jur-uae","procedure_name":"Elamipretide / Mitochondrial-Targeted Peptides (SS-31 Class)","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mitochondrial_Health","Cardiology","Ophthalmology"],"diseases":["Barth Syndrome","Mitochondrial Myopathy","Dry AMD (investigational)"],"status":"active"},{"id":"2c49e6d4-aa09-4d2b-80f7-242128a9aea2","procedure_id":"proc-peptide-ss31","jurisdiction_id":"jur-kr","procedure_name":"Elamipretide / Mitochondrial-Targeted Peptides (SS-31 Class)","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"MFDS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mitochondrial_Health","Cardiology","Ophthalmology"],"diseases":["Barth Syndrome","Mitochondrial Myopathy","Dry AMD (investigational)"],"status":"active"},{"id":"8603bdee-bf3b-4b6b-b8c2-563fb6970327","procedure_id":"proc-peptide-ss31","jurisdiction_id":"jur-gr","procedure_name":"Elamipretide / Mitochondrial-Targeted Peptides (SS-31 Class)","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mitochondrial_Health","Cardiology","Ophthalmology"],"diseases":["Barth Syndrome","Mitochondrial Myopathy","Dry AMD (investigational)"],"status":"active"},{"id":"1b1dd9e5-cd20-41ac-b555-079d4472b264","procedure_id":"proc-peptide-ss31","jurisdiction_id":"jur-be","procedure_name":"Elamipretide / Mitochondrial-Targeted Peptides (SS-31 Class)","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mitochondrial_Health","Cardiology","Ophthalmology"],"diseases":["Barth Syndrome","Mitochondrial Myopathy","Dry AMD (investigational)"],"status":"active"},{"id":"60a9da77-8f30-403d-86ac-4f18effbe72b","procedure_id":"proc-peptide-ss31","jurisdiction_id":"jur-se","procedure_name":"Elamipretide / Mitochondrial-Targeted Peptides (SS-31 Class)","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mitochondrial_Health","Cardiology","Ophthalmology"],"diseases":["Barth Syndrome","Mitochondrial Myopathy","Dry AMD (investigational)"],"status":"active"},{"id":"bc4b7b7c-907a-42c5-ae4d-49cb2d9ff9aa","procedure_id":"proc-peptide-ss31","jurisdiction_id":"jur-jp","procedure_name":"Elamipretide / Mitochondrial-Targeted Peptides (SS-31 Class)","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"PMDA / MHLW","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mitochondrial_Health","Cardiology","Ophthalmology"],"diseases":["Barth Syndrome","Mitochondrial Myopathy","Dry AMD (investigational)"],"status":"active"},{"id":"3193652d-9630-4c5c-b330-36be6756f2bd","procedure_id":"proc-peptide-ss31","jurisdiction_id":"jur-sg","procedure_name":"Elamipretide / Mitochondrial-Targeted Peptides (SS-31 Class)","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"HSA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mitochondrial_Health","Cardiology","Ophthalmology"],"diseases":["Barth Syndrome","Mitochondrial Myopathy","Dry AMD (investigational)"],"status":"active"},{"id":"21fec864-6a69-48c9-99b1-a0e0d5621ae4","procedure_id":"proc-peptide-ss31","jurisdiction_id":"jur-cl","procedure_name":"Elamipretide / Mitochondrial-Targeted Peptides (SS-31 Class)","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mitochondrial_Health","Cardiology","Ophthalmology"],"diseases":["Barth Syndrome","Mitochondrial Myopathy","Dry AMD (investigational)"],"status":"active"},{"id":"fc2e9ee5-510a-4f5f-9f29-4b32006160c2","procedure_id":"proc-peptide-ss31","jurisdiction_id":"jur-ar","procedure_name":"Elamipretide / Mitochondrial-Targeted Peptides (SS-31 Class)","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mitochondrial_Health","Cardiology","Ophthalmology"],"diseases":["Barth Syndrome","Mitochondrial Myopathy","Dry AMD (investigational)"],"status":"active"},{"id":"a103c1e4-6c0a-4dbf-94de-db827443270d","procedure_id":"proc-peptide-ss31","jurisdiction_id":"jur-za","procedure_name":"Elamipretide / Mitochondrial-Targeted Peptides (SS-31 Class)","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mitochondrial_Health","Cardiology","Ophthalmology"],"diseases":["Barth Syndrome","Mitochondrial Myopathy","Dry AMD (investigational)"],"status":"active"},{"id":"eda50a54-6672-4ec3-8408-80a207c38c07","procedure_id":"proc-peptide-ss31","jurisdiction_id":"jur-ph","procedure_name":"Elamipretide / Mitochondrial-Targeted Peptides (SS-31 Class)","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mitochondrial_Health","Cardiology","Ophthalmology"],"diseases":["Barth Syndrome","Mitochondrial Myopathy","Dry AMD (investigational)"],"status":"active"},{"id":"f4da7bb2-df22-4446-8032-381a09cc4530","procedure_id":"proc-peptide-ss31","jurisdiction_id":"jur-po","procedure_name":"Elamipretide / Mitochondrial-Targeted Peptides (SS-31 Class)","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mitochondrial_Health","Cardiology","Ophthalmology"],"diseases":["Barth Syndrome","Mitochondrial Myopathy","Dry AMD (investigational)"],"status":"active"},{"id":"be0f9bd2-44d4-4cb1-9145-30be8e7d6354","procedure_id":"proc-peptide-ss31","jurisdiction_id":"jur-pt","procedure_name":"Elamipretide / Mitochondrial-Targeted Peptides (SS-31 Class)","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mitochondrial_Health","Cardiology","Ophthalmology"],"diseases":["Barth Syndrome","Mitochondrial Myopathy","Dry AMD (investigational)"],"status":"active"},{"id":"5af1f160-9ae8-4fba-a754-0e7c655c7180","procedure_id":"proc-peptide-ss31","jurisdiction_id":"jur-fr","procedure_name":"Elamipretide / Mitochondrial-Targeted Peptides (SS-31 Class)","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PEPTIDE","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"FDA Category 2 / similar concerns in peer regulators. No lawful routine clinic pathway inferred.","eligibility_requirements":"None for commercial therapy claims.","provider_requirements":"Cannot lawfully scale a clinic on unapproved bulk peptides under typical rules.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred: no lawful routine commercial pathway for unapproved research peptides.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: unapproved peptide products generally cannot be marketed as medicines; compounding often restricted (esp. ICH markets).","regulatory_authority":"ANSM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mitochondrial_Health","Cardiology","Ophthalmology"],"diseases":["Barth Syndrome","Mitochondrial Myopathy","Dry AMD (investigational)"],"status":"active"},{"id":"267c3380-e0fd-4f62-a745-225fcc7f3566","procedure_id":"proc-ecmo-bridge","jurisdiction_id":"jur-us-or","procedure_name":"Elective / Bridge ECMO and Advanced Cardiac Support Tourism Pathways","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Critical_Care"],"diseases":["Cardiogenic Shock","Severe ARDS","Bridge to Transplant"],"status":"active"},{"id":"32f7b0de-7d0f-4807-80cc-13acee18f4fd","procedure_id":"proc-ecmo-bridge","jurisdiction_id":"jur-us-co","procedure_name":"Elective / Bridge ECMO and Advanced Cardiac Support Tourism Pathways","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Critical_Care"],"diseases":["Cardiogenic Shock","Severe ARDS","Bridge to Transplant"],"status":"active"},{"id":"78ba57f8-3f60-4f8a-b520-e4e37c08c7f9","procedure_id":"proc-ecmo-bridge","jurisdiction_id":"jur-us-ca","procedure_name":"Elective / Bridge ECMO and Advanced Cardiac Support Tourism Pathways","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Critical_Care"],"diseases":["Cardiogenic Shock","Severe ARDS","Bridge to Transplant"],"status":"active"},{"id":"480692b1-1cb6-4371-bd32-aeb1a13214fb","procedure_id":"proc-ecmo-bridge","jurisdiction_id":"jur-us-tx","procedure_name":"Elective / Bridge ECMO and Advanced Cardiac Support Tourism Pathways","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Critical_Care"],"diseases":["Cardiogenic Shock","Severe ARDS","Bridge to Transplant"],"status":"active"},{"id":"012b5a8f-d255-4ab4-b4f0-b90349e66e5c","procedure_id":"proc-ecmo-bridge","jurisdiction_id":"jur-us-fl","procedure_name":"Elective / Bridge ECMO and Advanced Cardiac Support Tourism Pathways","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Critical_Care"],"diseases":["Cardiogenic Shock","Severe ARDS","Bridge to Transplant"],"status":"active"},{"id":"7a509f70-6235-4252-8c13-3869189f646f","procedure_id":"proc-ecmo-bridge","jurisdiction_id":"jur-au","procedure_name":"Elective / Bridge ECMO and Advanced Cardiac Support Tourism Pathways","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"TGA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Critical_Care"],"diseases":["Cardiogenic Shock","Severe ARDS","Bridge to Transplant"],"status":"active"},{"id":"74c030e9-b902-422b-b0c3-8deeb3ac145a","procedure_id":"proc-ecmo-bridge","jurisdiction_id":"jur-ch","procedure_name":"Elective / Bridge ECMO and Advanced Cardiac Support Tourism Pathways","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Swissmedic","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Critical_Care"],"diseases":["Cardiogenic Shock","Severe ARDS","Bridge to Transplant"],"status":"active"},{"id":"9b9f1e61-f2ff-4f1d-b9e2-61993b702aaf","procedure_id":"proc-ecmo-bridge","jurisdiction_id":"jur-ca","procedure_name":"Elective / Bridge ECMO and Advanced Cardiac Support Tourism Pathways","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Health Canada","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Critical_Care"],"diseases":["Cardiogenic Shock","Severe ARDS","Bridge to Transplant"],"status":"active"},{"id":"a3925300-0be1-42d5-b024-bfa603458859","procedure_id":"proc-ecmo-bridge","jurisdiction_id":"jur-mx","procedure_name":"Elective / Bridge ECMO and Advanced Cardiac Support Tourism Pathways","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"COFEPRIS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Critical_Care"],"diseases":["Cardiogenic Shock","Severe ARDS","Bridge to Transplant"],"status":"active"},{"id":"b12ef1d3-d443-42e0-a0fc-2192e3c45002","procedure_id":"proc-ecmo-bridge","jurisdiction_id":"jur-hn-prospera","procedure_name":"Elective / Bridge ECMO and Advanced Cardiac Support Tourism Pathways","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Próspera ZEDE health rules (contested)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Critical_Care"],"diseases":["Cardiogenic Shock","Severe ARDS","Bridge to Transplant"],"status":"active"},{"id":"0c76f435-89e2-4eaa-89fa-653cfbaf2738","procedure_id":"proc-ecmo-bridge","jurisdiction_id":"jur-nl","procedure_name":"Elective / Bridge ECMO and Advanced Cardiac Support Tourism Pathways","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"MEB / IGJ","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Critical_Care"],"diseases":["Cardiogenic Shock","Severe ARDS","Bridge to Transplant"],"status":"active"},{"id":"b009de18-736a-495e-9cc5-74c541848ccc","procedure_id":"proc-ecmo-bridge","jurisdiction_id":"jur-uk","procedure_name":"Elective / Bridge ECMO and Advanced Cardiac Support Tourism Pathways","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"MHRA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Critical_Care"],"diseases":["Cardiogenic Shock","Severe ARDS","Bridge to Transplant"],"status":"active"},{"id":"c4347744-dfb1-4768-b8c0-c26103ac552f","procedure_id":"proc-ecmo-bridge","jurisdiction_id":"jur-il","procedure_name":"Elective / Bridge ECMO and Advanced Cardiac Support Tourism Pathways","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Critical_Care"],"diseases":["Cardiogenic Shock","Severe ARDS","Bridge to Transplant"],"status":"active"},{"id":"ec5ada06-bd6a-4c2f-8e43-18f0114b7ad5","procedure_id":"proc-ecmo-bridge","jurisdiction_id":"jur-jm","procedure_name":"Elective / Bridge ECMO and Advanced Cardiac Support Tourism Pathways","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Critical_Care"],"diseases":["Cardiogenic Shock","Severe ARDS","Bridge to Transplant"],"status":"active"},{"id":"cfbf2285-9126-4444-a6a1-fc1ec078b1a7","procedure_id":"proc-ecmo-bridge","jurisdiction_id":"jur-th","procedure_name":"Elective / Bridge ECMO and Advanced Cardiac Support Tourism Pathways","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"Thai FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Critical_Care"],"diseases":["Cardiogenic Shock","Severe ARDS","Bridge to Transplant"],"status":"active"},{"id":"69b707a6-e4c2-4830-b272-f64e9ad684ed","procedure_id":"proc-ecmo-bridge","jurisdiction_id":"jur-es","procedure_name":"Elective / Bridge ECMO and Advanced Cardiac Support Tourism Pathways","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"AEMPS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Critical_Care"],"diseases":["Cardiogenic Shock","Severe ARDS","Bridge to Transplant"],"status":"active"},{"id":"0f5d691f-c008-4d75-a6b0-7894fd70500b","procedure_id":"proc-ecmo-bridge","jurisdiction_id":"jur-tu","procedure_name":"Elective / Bridge ECMO and Advanced Cardiac Support Tourism Pathways","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Critical_Care"],"diseases":["Cardiogenic Shock","Severe ARDS","Bridge to Transplant"],"status":"active"},{"id":"5460dc7c-bff2-46e5-816a-81fad8b37611","procedure_id":"proc-ecmo-bridge","jurisdiction_id":"jur-in","procedure_name":"Elective / Bridge ECMO and Advanced Cardiac Support Tourism Pathways","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"CDSCO","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Critical_Care"],"diseases":["Cardiogenic Shock","Severe ARDS","Bridge to Transplant"],"status":"active"},{"id":"55bb9231-2fb9-4242-b154-a10756328c25","procedure_id":"proc-ecmo-bridge","jurisdiction_id":"jur-br","procedure_name":"Elective / Bridge ECMO and Advanced Cardiac Support Tourism Pathways","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"ANVISA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Critical_Care"],"diseases":["Cardiogenic Shock","Severe ARDS","Bridge to Transplant"],"status":"active"},{"id":"8d155729-f0d3-48e5-94ba-f908cf8b7a01","procedure_id":"proc-ecmo-bridge","jurisdiction_id":"jur-cr","procedure_name":"Elective / Bridge ECMO and Advanced Cardiac Support Tourism Pathways","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Critical_Care"],"diseases":["Cardiogenic Shock","Severe ARDS","Bridge to Transplant"],"status":"active"},{"id":"d44eedef-9012-4fd2-ad21-0c206b494415","procedure_id":"proc-ecmo-bridge","jurisdiction_id":"jur-uae","procedure_name":"Elective / Bridge ECMO and Advanced Cardiac Support Tourism Pathways","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Critical_Care"],"diseases":["Cardiogenic Shock","Severe ARDS","Bridge to Transplant"],"status":"active"},{"id":"b48ee4fa-02c8-4a80-b1bc-9697cb4bac1c","procedure_id":"proc-ecmo-bridge","jurisdiction_id":"jur-kr","procedure_name":"Elective / Bridge ECMO and Advanced Cardiac Support Tourism Pathways","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"MFDS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Critical_Care"],"diseases":["Cardiogenic Shock","Severe ARDS","Bridge to Transplant"],"status":"active"},{"id":"91c2aeb7-f51e-4836-9727-e12b30b9a6cb","procedure_id":"proc-ecmo-bridge","jurisdiction_id":"jur-gr","procedure_name":"Elective / Bridge ECMO and Advanced Cardiac Support Tourism Pathways","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Critical_Care"],"diseases":["Cardiogenic Shock","Severe ARDS","Bridge to Transplant"],"status":"active"},{"id":"b32caf84-475d-443c-8e26-fbc8b95a8041","procedure_id":"proc-ecmo-bridge","jurisdiction_id":"jur-be","procedure_name":"Elective / Bridge ECMO and Advanced Cardiac Support Tourism Pathways","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Critical_Care"],"diseases":["Cardiogenic Shock","Severe ARDS","Bridge to Transplant"],"status":"active"},{"id":"6d7ecc56-df2e-4c1e-8345-b0e6dde2ccc1","procedure_id":"proc-ecmo-bridge","jurisdiction_id":"jur-se","procedure_name":"Elective / Bridge ECMO and Advanced Cardiac Support Tourism Pathways","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Critical_Care"],"diseases":["Cardiogenic Shock","Severe ARDS","Bridge to Transplant"],"status":"active"},{"id":"c9e174f5-8867-423c-82f4-e2102b54d62e","procedure_id":"proc-ecmo-bridge","jurisdiction_id":"jur-jp","procedure_name":"Elective / Bridge ECMO and Advanced Cardiac Support Tourism Pathways","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"PMDA / MHLW","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Critical_Care"],"diseases":["Cardiogenic Shock","Severe ARDS","Bridge to Transplant"],"status":"active"},{"id":"f1413ece-2c25-47a5-bffd-520e1be23406","procedure_id":"proc-ecmo-bridge","jurisdiction_id":"jur-sg","procedure_name":"Elective / Bridge ECMO and Advanced Cardiac Support Tourism Pathways","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"HSA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Critical_Care"],"diseases":["Cardiogenic Shock","Severe ARDS","Bridge to Transplant"],"status":"active"},{"id":"e59f7165-8e47-4451-9a73-4f5fb84e1afc","procedure_id":"proc-ecmo-bridge","jurisdiction_id":"jur-cl","procedure_name":"Elective / Bridge ECMO and Advanced Cardiac Support Tourism Pathways","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Critical_Care"],"diseases":["Cardiogenic Shock","Severe ARDS","Bridge to Transplant"],"status":"active"},{"id":"987f0395-3a2a-4577-8ad0-15400220ba35","procedure_id":"proc-ecmo-bridge","jurisdiction_id":"jur-ar","procedure_name":"Elective / Bridge ECMO and Advanced Cardiac Support Tourism Pathways","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Critical_Care"],"diseases":["Cardiogenic Shock","Severe ARDS","Bridge to Transplant"],"status":"active"},{"id":"88f1a9d1-781b-4d13-ade7-182a7b1dd63b","procedure_id":"proc-ecmo-bridge","jurisdiction_id":"jur-za","procedure_name":"Elective / Bridge ECMO and Advanced Cardiac Support Tourism Pathways","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Critical_Care"],"diseases":["Cardiogenic Shock","Severe ARDS","Bridge to Transplant"],"status":"active"},{"id":"ae92b064-41f1-4a19-aa04-91d2b087942b","procedure_id":"proc-ecmo-bridge","jurisdiction_id":"jur-ph","procedure_name":"Elective / Bridge ECMO and Advanced Cardiac Support Tourism Pathways","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Critical_Care"],"diseases":["Cardiogenic Shock","Severe ARDS","Bridge to Transplant"],"status":"active"},{"id":"5dfe37b2-c8fc-42b1-8f57-2733ea0c2396","procedure_id":"proc-ecmo-bridge","jurisdiction_id":"jur-po","procedure_name":"Elective / Bridge ECMO and Advanced Cardiac Support Tourism Pathways","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Critical_Care"],"diseases":["Cardiogenic Shock","Severe ARDS","Bridge to Transplant"],"status":"active"},{"id":"e2195740-2ecf-4b89-b2cb-fcb3d7c5b533","procedure_id":"proc-ecmo-bridge","jurisdiction_id":"jur-pt","procedure_name":"Elective / Bridge ECMO and Advanced Cardiac Support Tourism Pathways","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"PHYSICIAN_DISCRETION_GRAY","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Critical_Care"],"diseases":["Cardiogenic Shock","Severe ARDS","Bridge to Transplant"],"status":"active"},{"id":"de8acade-60fe-4bf9-bddf-081f1c050796","procedure_id":"proc-ecmo-bridge","jurisdiction_id":"jur-fr","procedure_name":"Elective / Bridge ECMO and Advanced Cardiac Support Tourism Pathways","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"FULLY_APPROVED","access_pathway":"LICENSED_PROVIDER_REGIME","oversight_quality":"REGULATED_HIGH","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Cleared/approved device indications vary by country. Hospital privileges often required for implantables.","eligibility_requirements":"Indication-specific selection criteria.","provider_requirements":"Privileged specialists + device training/proctoring.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred specialist/device pathway where medical device regulation exists.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: medical devices require national device registration + facility/operator rules; specialty devices are specialist-delivered.","regulatory_authority":"ANSM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Cardiovascular","Critical_Care"],"diseases":["Cardiogenic Shock","Severe ARDS","Bridge to Transplant"],"status":"active"},{"id":"fb5d49b0-a47e-4f90-b31d-f212c572208c","procedure_id":"proc-fecal-sibo","jurisdiction_id":"jur-us-or","procedure_name":"Elemental Diet / Rifaximin Protocols for SIBO (Access Friction Map)","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal"],"diseases":["SIBO","IBS-D","Hepatic Encephalopathy (rifaximin labeled)"],"status":"active"},{"id":"68133534-9fa7-4b87-a147-d3c1ff976986","procedure_id":"proc-fecal-sibo","jurisdiction_id":"jur-us-co","procedure_name":"Elemental Diet / Rifaximin Protocols for SIBO (Access Friction Map)","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal"],"diseases":["SIBO","IBS-D","Hepatic Encephalopathy (rifaximin labeled)"],"status":"active"},{"id":"83085f51-a02a-4d0c-bc1d-4af346cbd83f","procedure_id":"proc-fecal-sibo","jurisdiction_id":"jur-us-ca","procedure_name":"Elemental Diet / Rifaximin Protocols for SIBO (Access Friction Map)","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal"],"diseases":["SIBO","IBS-D","Hepatic Encephalopathy (rifaximin labeled)"],"status":"active"},{"id":"a11a7152-9a52-45be-9198-91027ae7d31a","procedure_id":"proc-fecal-sibo","jurisdiction_id":"jur-us-tx","procedure_name":"Elemental Diet / Rifaximin Protocols for SIBO (Access Friction Map)","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal"],"diseases":["SIBO","IBS-D","Hepatic Encephalopathy (rifaximin labeled)"],"status":"active"},{"id":"de755837-996f-48d4-af5c-95009096624d","procedure_id":"proc-fecal-sibo","jurisdiction_id":"jur-us-fl","procedure_name":"Elemental Diet / Rifaximin Protocols for SIBO (Access Friction Map)","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal"],"diseases":["SIBO","IBS-D","Hepatic Encephalopathy (rifaximin labeled)"],"status":"active"},{"id":"93d434de-f967-4378-ba2e-4b67a54fc562","procedure_id":"proc-fecal-sibo","jurisdiction_id":"jur-au","procedure_name":"Elemental Diet / Rifaximin Protocols for SIBO (Access Friction Map)","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"TGA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal"],"diseases":["SIBO","IBS-D","Hepatic Encephalopathy (rifaximin labeled)"],"status":"active"},{"id":"21b77489-21a5-497d-be21-35db27cea69a","procedure_id":"proc-fecal-sibo","jurisdiction_id":"jur-ch","procedure_name":"Elemental Diet / Rifaximin Protocols for SIBO (Access Friction Map)","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Swissmedic","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal"],"diseases":["SIBO","IBS-D","Hepatic Encephalopathy (rifaximin labeled)"],"status":"active"},{"id":"61d51935-ca01-4397-96d6-deb5086e1140","procedure_id":"proc-fecal-sibo","jurisdiction_id":"jur-ca","procedure_name":"Elemental Diet / Rifaximin Protocols for SIBO (Access Friction Map)","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Health Canada","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal"],"diseases":["SIBO","IBS-D","Hepatic Encephalopathy (rifaximin labeled)"],"status":"active"},{"id":"ec25bd7f-fdb6-4c3a-afe5-e1cc77b84c2f","procedure_id":"proc-fecal-sibo","jurisdiction_id":"jur-hn-prospera","procedure_name":"Elemental Diet / Rifaximin Protocols for SIBO (Access Friction Map)","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Permissive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Próspera ZEDE health rules (contested)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal"],"diseases":["SIBO","IBS-D","Hepatic Encephalopathy (rifaximin labeled)"],"status":"active"},{"id":"dd1417b9-9fc9-4221-9e97-143588470501","procedure_id":"proc-fecal-sibo","jurisdiction_id":"jur-nl","procedure_name":"Elemental Diet / Rifaximin Protocols for SIBO (Access Friction Map)","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"MEB / IGJ","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal"],"diseases":["SIBO","IBS-D","Hepatic Encephalopathy (rifaximin labeled)"],"status":"active"},{"id":"712dfd67-bbd6-4694-bf22-eedaed4fde62","procedure_id":"proc-fecal-sibo","jurisdiction_id":"jur-de","procedure_name":"Elemental Diet / Rifaximin Protocols for SIBO (Access Friction Map)","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"BfArM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal"],"diseases":["SIBO","IBS-D","Hepatic Encephalopathy (rifaximin labeled)"],"status":"active"},{"id":"14c265ec-53fc-4468-9e13-3735b86b06bf","procedure_id":"proc-fecal-sibo","jurisdiction_id":"jur-uk","procedure_name":"Elemental Diet / Rifaximin Protocols for SIBO (Access Friction Map)","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"MHRA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal"],"diseases":["SIBO","IBS-D","Hepatic Encephalopathy (rifaximin labeled)"],"status":"active"},{"id":"2c7213d6-a44a-4e0c-90a9-8588c5668be2","procedure_id":"proc-fecal-sibo","jurisdiction_id":"jur-il","procedure_name":"Elemental Diet / Rifaximin Protocols for SIBO (Access Friction Map)","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal"],"diseases":["SIBO","IBS-D","Hepatic Encephalopathy (rifaximin labeled)"],"status":"active"},{"id":"201163fa-79f7-440e-bc07-3b0de9713899","procedure_id":"proc-fecal-sibo","jurisdiction_id":"jur-jm","procedure_name":"Elemental Diet / Rifaximin Protocols for SIBO (Access Friction Map)","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal"],"diseases":["SIBO","IBS-D","Hepatic Encephalopathy (rifaximin labeled)"],"status":"active"},{"id":"e5bee9f4-aeb1-46e2-beee-34db70b77d37","procedure_id":"proc-fecal-sibo","jurisdiction_id":"jur-th","procedure_name":"Elemental Diet / Rifaximin Protocols for SIBO (Access Friction Map)","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Permissive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Thai FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal"],"diseases":["SIBO","IBS-D","Hepatic Encephalopathy (rifaximin labeled)"],"status":"active"},{"id":"ae12ec08-c0bd-4dcd-8c0c-47942e63c6e9","procedure_id":"proc-fecal-sibo","jurisdiction_id":"jur-es","procedure_name":"Elemental Diet / Rifaximin Protocols for SIBO (Access Friction Map)","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"AEMPS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal"],"diseases":["SIBO","IBS-D","Hepatic Encephalopathy (rifaximin labeled)"],"status":"active"},{"id":"2886957d-4a89-4882-b4a7-75eee7ac6aeb","procedure_id":"proc-fecal-sibo","jurisdiction_id":"jur-tu","procedure_name":"Elemental Diet / Rifaximin Protocols for SIBO (Access Friction Map)","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal"],"diseases":["SIBO","IBS-D","Hepatic Encephalopathy (rifaximin labeled)"],"status":"active"},{"id":"19f4a0f8-0f26-4ecc-af93-4729c1a5fd52","procedure_id":"proc-fecal-sibo","jurisdiction_id":"jur-br","procedure_name":"Elemental Diet / Rifaximin Protocols for SIBO (Access Friction Map)","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"ANVISA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal"],"diseases":["SIBO","IBS-D","Hepatic Encephalopathy (rifaximin labeled)"],"status":"active"},{"id":"a54b32a8-9f11-4ab7-89a9-5618dfa5af3b","procedure_id":"proc-fecal-sibo","jurisdiction_id":"jur-cr","procedure_name":"Elemental Diet / Rifaximin Protocols for SIBO (Access Friction Map)","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal"],"diseases":["SIBO","IBS-D","Hepatic Encephalopathy (rifaximin labeled)"],"status":"active"},{"id":"db53cd29-6897-44c8-9c4c-40dd2e0fa0a8","procedure_id":"proc-fecal-sibo","jurisdiction_id":"jur-uae","procedure_name":"Elemental Diet / Rifaximin Protocols for SIBO (Access Friction Map)","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal"],"diseases":["SIBO","IBS-D","Hepatic Encephalopathy (rifaximin labeled)"],"status":"active"},{"id":"69ca0b74-1de1-4004-a2c7-c05b13a6defd","procedure_id":"proc-fecal-sibo","jurisdiction_id":"jur-kr","procedure_name":"Elemental Diet / Rifaximin Protocols for SIBO (Access Friction Map)","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"MFDS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal"],"diseases":["SIBO","IBS-D","Hepatic Encephalopathy (rifaximin labeled)"],"status":"active"},{"id":"0be05c26-63fc-421e-8aed-e2d905214617","procedure_id":"proc-fecal-sibo","jurisdiction_id":"jur-gr","procedure_name":"Elemental Diet / Rifaximin Protocols for SIBO (Access Friction Map)","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal"],"diseases":["SIBO","IBS-D","Hepatic Encephalopathy (rifaximin labeled)"],"status":"active"},{"id":"ee5d8df4-de75-4460-bc34-145d42d24839","procedure_id":"proc-fecal-sibo","jurisdiction_id":"jur-be","procedure_name":"Elemental Diet / Rifaximin Protocols for SIBO (Access Friction Map)","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal"],"diseases":["SIBO","IBS-D","Hepatic Encephalopathy (rifaximin labeled)"],"status":"active"},{"id":"e0564a72-d102-4fb9-8096-00bc6437ac66","procedure_id":"proc-fecal-sibo","jurisdiction_id":"jur-se","procedure_name":"Elemental Diet / Rifaximin Protocols for SIBO (Access Friction Map)","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal"],"diseases":["SIBO","IBS-D","Hepatic Encephalopathy (rifaximin labeled)"],"status":"active"},{"id":"950d05bc-a49c-4702-8323-7f98b241b41d","procedure_id":"proc-fecal-sibo","jurisdiction_id":"jur-jp","procedure_name":"Elemental Diet / Rifaximin Protocols for SIBO (Access Friction Map)","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"PMDA / MHLW","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal"],"diseases":["SIBO","IBS-D","Hepatic Encephalopathy (rifaximin labeled)"],"status":"active"},{"id":"868f8a0b-1c94-448f-8a04-c89b9d113f16","procedure_id":"proc-fecal-sibo","jurisdiction_id":"jur-sg","procedure_name":"Elemental Diet / Rifaximin Protocols for SIBO (Access Friction Map)","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"HSA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal"],"diseases":["SIBO","IBS-D","Hepatic Encephalopathy (rifaximin labeled)"],"status":"active"},{"id":"0f622ad9-5732-4a6c-b923-c9b7b2e4ab8a","procedure_id":"proc-fecal-sibo","jurisdiction_id":"jur-cl","procedure_name":"Elemental Diet / Rifaximin Protocols for SIBO (Access Friction Map)","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal"],"diseases":["SIBO","IBS-D","Hepatic Encephalopathy (rifaximin labeled)"],"status":"active"},{"id":"e4ea7e41-82a3-4663-9584-957acb4d0fad","procedure_id":"proc-fecal-sibo","jurisdiction_id":"jur-ar","procedure_name":"Elemental Diet / Rifaximin Protocols for SIBO (Access Friction Map)","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal"],"diseases":["SIBO","IBS-D","Hepatic Encephalopathy (rifaximin labeled)"],"status":"active"},{"id":"cfae0751-343b-405e-b868-32b8f871396a","procedure_id":"proc-fecal-sibo","jurisdiction_id":"jur-za","procedure_name":"Elemental Diet / Rifaximin Protocols for SIBO (Access Friction Map)","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal"],"diseases":["SIBO","IBS-D","Hepatic Encephalopathy (rifaximin labeled)"],"status":"active"},{"id":"7eb133a4-fdde-41e7-9693-5928515b3a74","procedure_id":"proc-fecal-sibo","jurisdiction_id":"jur-ph","procedure_name":"Elemental Diet / Rifaximin Protocols for SIBO (Access Friction Map)","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal"],"diseases":["SIBO","IBS-D","Hepatic Encephalopathy (rifaximin labeled)"],"status":"active"},{"id":"e4e6ef7b-9a14-4f75-8f24-b57bf22a663b","procedure_id":"proc-fecal-sibo","jurisdiction_id":"jur-po","procedure_name":"Elemental Diet / Rifaximin Protocols for SIBO (Access Friction Map)","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal"],"diseases":["SIBO","IBS-D","Hepatic Encephalopathy (rifaximin labeled)"],"status":"active"},{"id":"c4fe5393-6979-4747-bb17-8933ebb53e55","procedure_id":"proc-fecal-sibo","jurisdiction_id":"jur-pt","procedure_name":"Elemental Diet / Rifaximin Protocols for SIBO (Access Friction Map)","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal"],"diseases":["SIBO","IBS-D","Hepatic Encephalopathy (rifaximin labeled)"],"status":"active"},{"id":"81297866-df5e-41f5-8db0-f5dcb628c30f","procedure_id":"proc-fecal-sibo","jurisdiction_id":"jur-fr","procedure_name":"Elemental Diet / Rifaximin Protocols for SIBO (Access Friction Map)","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"ANSM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Gastrointestinal"],"diseases":["SIBO","IBS-D","Hepatic Encephalopathy (rifaximin labeled)"],"status":"active"},{"id":"d6eced26-0c3f-4ae6-97a5-ca8054eb2fca","procedure_id":"proc-low-dose-lithium","jurisdiction_id":"jur-us-or","procedure_name":"Low-Dose Lithium for Neuroprotection / Mood","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Neurology"],"diseases":["Bipolar Disorder (full-dose labeled)","Mood Instability","Dementia Risk Reduction (investigational)"],"status":"active"},{"id":"dbfc08a7-f6f7-4502-b678-c6ace67bf648","procedure_id":"proc-low-dose-lithium","jurisdiction_id":"jur-us-co","procedure_name":"Low-Dose Lithium for Neuroprotection / Mood","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Neurology"],"diseases":["Bipolar Disorder (full-dose labeled)","Mood Instability","Dementia Risk Reduction (investigational)"],"status":"active"},{"id":"617d5aab-1c6d-4027-82e3-833a296a31f4","procedure_id":"proc-low-dose-lithium","jurisdiction_id":"jur-us-ca","procedure_name":"Low-Dose Lithium for Neuroprotection / Mood","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Neurology"],"diseases":["Bipolar Disorder (full-dose labeled)","Mood Instability","Dementia Risk Reduction (investigational)"],"status":"active"},{"id":"559b27c7-76f1-43e8-b8a8-e18a00052530","procedure_id":"proc-low-dose-lithium","jurisdiction_id":"jur-us-tx","procedure_name":"Low-Dose Lithium for Neuroprotection / Mood","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Neurology"],"diseases":["Bipolar Disorder (full-dose labeled)","Mood Instability","Dementia Risk Reduction (investigational)"],"status":"active"},{"id":"66be05d0-f916-497e-bbfb-ee3f0855078c","procedure_id":"proc-low-dose-lithium","jurisdiction_id":"jur-us-fl","procedure_name":"Low-Dose Lithium for Neuroprotection / Mood","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Neurology"],"diseases":["Bipolar Disorder (full-dose labeled)","Mood Instability","Dementia Risk Reduction (investigational)"],"status":"active"},{"id":"2df4a38b-f6ce-4180-9dc3-402f284211bc","procedure_id":"proc-low-dose-lithium","jurisdiction_id":"jur-au","procedure_name":"Low-Dose Lithium for Neuroprotection / Mood","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"TGA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Neurology"],"diseases":["Bipolar Disorder (full-dose labeled)","Mood Instability","Dementia Risk Reduction (investigational)"],"status":"active"},{"id":"15e4bf65-c3f7-4078-8081-a802b6af5571","procedure_id":"proc-low-dose-lithium","jurisdiction_id":"jur-ch","procedure_name":"Low-Dose Lithium for Neuroprotection / Mood","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Swissmedic","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Neurology"],"diseases":["Bipolar Disorder (full-dose labeled)","Mood Instability","Dementia Risk Reduction (investigational)"],"status":"active"},{"id":"9cf697ba-1e96-4b4b-a3ce-ba3bcae137d8","procedure_id":"proc-low-dose-lithium","jurisdiction_id":"jur-ca","procedure_name":"Low-Dose Lithium for Neuroprotection / Mood","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Health Canada","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Neurology"],"diseases":["Bipolar Disorder (full-dose labeled)","Mood Instability","Dementia Risk Reduction (investigational)"],"status":"active"},{"id":"10121242-a139-4a9c-8bc9-9dba24549e0a","procedure_id":"proc-low-dose-lithium","jurisdiction_id":"jur-mx","procedure_name":"Low-Dose Lithium for Neuroprotection / Mood","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Permissive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"COFEPRIS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Neurology"],"diseases":["Bipolar Disorder (full-dose labeled)","Mood Instability","Dementia Risk Reduction (investigational)"],"status":"active"},{"id":"aa50bc06-27af-43dd-b0a2-517021853d08","procedure_id":"proc-low-dose-lithium","jurisdiction_id":"jur-hn-prospera","procedure_name":"Low-Dose Lithium for Neuroprotection / Mood","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Permissive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Próspera ZEDE health rules (contested)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Neurology"],"diseases":["Bipolar Disorder (full-dose labeled)","Mood Instability","Dementia Risk Reduction (investigational)"],"status":"active"},{"id":"f8f7a0a2-3843-4bd4-8e90-9edd1a5a3f6e","procedure_id":"proc-low-dose-lithium","jurisdiction_id":"jur-nl","procedure_name":"Low-Dose Lithium for Neuroprotection / Mood","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"MEB / IGJ","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Neurology"],"diseases":["Bipolar Disorder (full-dose labeled)","Mood Instability","Dementia Risk Reduction (investigational)"],"status":"active"},{"id":"e318479e-5330-450e-8be7-dc5e6d7900f3","procedure_id":"proc-low-dose-lithium","jurisdiction_id":"jur-uk","procedure_name":"Low-Dose Lithium for Neuroprotection / Mood","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"MHRA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Neurology"],"diseases":["Bipolar Disorder (full-dose labeled)","Mood Instability","Dementia Risk Reduction (investigational)"],"status":"active"},{"id":"fc299399-70b5-4b44-beac-8d995258b303","procedure_id":"proc-low-dose-lithium","jurisdiction_id":"jur-il","procedure_name":"Low-Dose Lithium for Neuroprotection / Mood","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Neurology"],"diseases":["Bipolar Disorder (full-dose labeled)","Mood Instability","Dementia Risk Reduction (investigational)"],"status":"active"},{"id":"3621e394-be07-4845-b6f8-c14351a56637","procedure_id":"proc-low-dose-lithium","jurisdiction_id":"jur-jm","procedure_name":"Low-Dose Lithium for Neuroprotection / Mood","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Neurology"],"diseases":["Bipolar Disorder (full-dose labeled)","Mood Instability","Dementia Risk Reduction (investigational)"],"status":"active"},{"id":"3f9bdf48-b8cc-46cd-83bc-943491d768d9","procedure_id":"proc-low-dose-lithium","jurisdiction_id":"jur-th","procedure_name":"Low-Dose Lithium for Neuroprotection / Mood","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Permissive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"Thai FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Neurology"],"diseases":["Bipolar Disorder (full-dose labeled)","Mood Instability","Dementia Risk Reduction (investigational)"],"status":"active"},{"id":"41ea520c-af14-4f48-96b0-da1138f17dc4","procedure_id":"proc-low-dose-lithium","jurisdiction_id":"jur-es","procedure_name":"Low-Dose Lithium for Neuroprotection / Mood","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"AEMPS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Neurology"],"diseases":["Bipolar Disorder (full-dose labeled)","Mood Instability","Dementia Risk Reduction (investigational)"],"status":"active"},{"id":"a7264103-63f1-48c6-8321-6a5d47cdb73a","procedure_id":"proc-low-dose-lithium","jurisdiction_id":"jur-tu","procedure_name":"Low-Dose Lithium for Neuroprotection / Mood","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Neurology"],"diseases":["Bipolar Disorder (full-dose labeled)","Mood Instability","Dementia Risk Reduction (investigational)"],"status":"active"},{"id":"bdbb1dd9-fccc-4d18-b04c-9550b375d678","procedure_id":"proc-low-dose-lithium","jurisdiction_id":"jur-in","procedure_name":"Low-Dose Lithium for Neuroprotection / Mood","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Permissive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"CDSCO","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Neurology"],"diseases":["Bipolar Disorder (full-dose labeled)","Mood Instability","Dementia Risk Reduction (investigational)"],"status":"active"},{"id":"3257222a-5a9c-4688-93f2-dd86777bb8bf","procedure_id":"proc-low-dose-lithium","jurisdiction_id":"jur-br","procedure_name":"Low-Dose Lithium for Neuroprotection / Mood","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"ANVISA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Neurology"],"diseases":["Bipolar Disorder (full-dose labeled)","Mood Instability","Dementia Risk Reduction (investigational)"],"status":"active"},{"id":"87842361-915a-425f-9225-431ca3451515","procedure_id":"proc-low-dose-lithium","jurisdiction_id":"jur-cr","procedure_name":"Low-Dose Lithium for Neuroprotection / Mood","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Neurology"],"diseases":["Bipolar Disorder (full-dose labeled)","Mood Instability","Dementia Risk Reduction (investigational)"],"status":"active"},{"id":"d6c5f0b1-dd41-4ef4-9b82-f9c9442f2451","procedure_id":"proc-low-dose-lithium","jurisdiction_id":"jur-uae","procedure_name":"Low-Dose Lithium for Neuroprotection / Mood","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Neurology"],"diseases":["Bipolar Disorder (full-dose labeled)","Mood Instability","Dementia Risk Reduction (investigational)"],"status":"active"},{"id":"aba7e7ed-fdab-4471-8889-521c0d47ff29","procedure_id":"proc-low-dose-lithium","jurisdiction_id":"jur-kr","procedure_name":"Low-Dose Lithium for Neuroprotection / Mood","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"MFDS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Neurology"],"diseases":["Bipolar Disorder (full-dose labeled)","Mood Instability","Dementia Risk Reduction (investigational)"],"status":"active"},{"id":"5706d51b-2087-4fc9-87ca-1f757b824430","procedure_id":"proc-low-dose-lithium","jurisdiction_id":"jur-gr","procedure_name":"Low-Dose Lithium for Neuroprotection / Mood","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Neurology"],"diseases":["Bipolar Disorder (full-dose labeled)","Mood Instability","Dementia Risk Reduction (investigational)"],"status":"active"},{"id":"712f7c56-98ff-4a87-8b0a-4af0dbb0bed1","procedure_id":"proc-low-dose-lithium","jurisdiction_id":"jur-be","procedure_name":"Low-Dose Lithium for Neuroprotection / Mood","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Neurology"],"diseases":["Bipolar Disorder (full-dose labeled)","Mood Instability","Dementia Risk Reduction (investigational)"],"status":"active"},{"id":"42a4d4c8-b293-443d-92d2-720ee7058968","procedure_id":"proc-low-dose-lithium","jurisdiction_id":"jur-se","procedure_name":"Low-Dose Lithium for Neuroprotection / Mood","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Neurology"],"diseases":["Bipolar Disorder (full-dose labeled)","Mood Instability","Dementia Risk Reduction (investigational)"],"status":"active"},{"id":"c441cd55-3ddb-4c6e-aee7-c73b48d75ff9","procedure_id":"proc-low-dose-lithium","jurisdiction_id":"jur-jp","procedure_name":"Low-Dose Lithium for Neuroprotection / Mood","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"PMDA / MHLW","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Neurology"],"diseases":["Bipolar Disorder (full-dose labeled)","Mood Instability","Dementia Risk Reduction (investigational)"],"status":"active"},{"id":"51d8dd4a-cd9e-4d8d-b9f4-93bf1d055821","procedure_id":"proc-low-dose-lithium","jurisdiction_id":"jur-sg","procedure_name":"Low-Dose Lithium for Neuroprotection / Mood","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"HSA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Neurology"],"diseases":["Bipolar Disorder (full-dose labeled)","Mood Instability","Dementia Risk Reduction (investigational)"],"status":"active"},{"id":"e2d4804c-a5c4-4aa5-95b1-04e5cc2e4ee1","procedure_id":"proc-low-dose-lithium","jurisdiction_id":"jur-cl","procedure_name":"Low-Dose Lithium for Neuroprotection / Mood","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Neurology"],"diseases":["Bipolar Disorder (full-dose labeled)","Mood Instability","Dementia Risk Reduction (investigational)"],"status":"active"},{"id":"19374142-7003-43a9-a7b9-69c25eb5f12c","procedure_id":"proc-low-dose-lithium","jurisdiction_id":"jur-ar","procedure_name":"Low-Dose Lithium for Neuroprotection / Mood","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Neurology"],"diseases":["Bipolar Disorder (full-dose labeled)","Mood Instability","Dementia Risk Reduction (investigational)"],"status":"active"},{"id":"f79e62df-0205-4f13-8b63-64586b9d4c0f","procedure_id":"proc-low-dose-lithium","jurisdiction_id":"jur-za","procedure_name":"Low-Dose Lithium for Neuroprotection / Mood","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Neurology"],"diseases":["Bipolar Disorder (full-dose labeled)","Mood Instability","Dementia Risk Reduction (investigational)"],"status":"active"},{"id":"4e3f0e67-e350-402c-b0e7-d68d686b3731","procedure_id":"proc-low-dose-lithium","jurisdiction_id":"jur-ph","procedure_name":"Low-Dose Lithium for Neuroprotection / Mood","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Neurology"],"diseases":["Bipolar Disorder (full-dose labeled)","Mood Instability","Dementia Risk Reduction (investigational)"],"status":"active"},{"id":"de36a371-5ae2-4e74-ba50-783615f2242c","procedure_id":"proc-low-dose-lithium","jurisdiction_id":"jur-po","procedure_name":"Low-Dose Lithium for Neuroprotection / Mood","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: unknown.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Neurology"],"diseases":["Bipolar Disorder (full-dose labeled)","Mood Instability","Dementia Risk Reduction (investigational)"],"status":"active"},{"id":"010207b6-5bd6-4f8e-b8c2-2c56387ee3a0","procedure_id":"proc-low-dose-lithium","jurisdiction_id":"jur-pt","procedure_name":"Low-Dose Lithium for Neuroprotection / Mood","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"VARIABLE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Moderate.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Neurology"],"diseases":["Bipolar Disorder (full-dose labeled)","Mood Instability","Dementia Risk Reduction (investigational)"],"status":"active"},{"id":"aecd5992-9628-4e03-b6e1-62e675372a01","procedure_id":"proc-low-dose-lithium","jurisdiction_id":"jur-fr","procedure_name":"Low-Dose Lithium for Neuroprotection / Mood","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"APPROVED_OFF_LABEL","access_pathway":"OFF_LABEL_PRESCRIPTION","oversight_quality":"REGULATED_MODERATE","modality":"REPURPOSED","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Assumes a functioning medical licensing system and that the molecule class is registered for some indication. Longevity/addiction uses may be off-label. Compounding environment: Restrictive.","eligibility_requirements":"Clinical judgment + informed consent for off-label use.","provider_requirements":"Licensed prescriber; standard of care documentation.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Payer denial common; advertising disease claims may be illegal.","arbitrage_summary":"Inferred off-label prescribing pathway under ordinary medical practice — confirm local formulary, controlled status, and advertising rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: where physicians may prescribe registered molecules, off-label use is commonly a medical-practice matter (advertising still regulated).","regulatory_authority":"ANSM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Neurology"],"diseases":["Bipolar Disorder (full-dose labeled)","Mood Instability","Dementia Risk Reduction (investigational)"],"status":"active"},{"id":"64bf09d3-7409-403e-bf8c-b54559823055","procedure_id":"proc-psilocybin-microdose","jurisdiction_id":"jur-us-co","procedure_name":"Psilocybin Microdosing Protocols","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"DECRIMINALIZED_NO_SUPPLY","access_pathway":"NONE","oversight_quality":"VARIABLE","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Personal use may be decriminalized; commercial therapy supply not inferred as lawful.","eligibility_requirements":"No licensed therapy supply inferred.","provider_requirements":"No commercial pathway inferred.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred decrim-without-supply. Not a clinic destination under default rules.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: Jurisdiction psychedelic_default=Decriminalized_No_Supply.","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Cognition"],"diseases":["Depression","Anxiety","ADHD Symptoms (self-report)"],"status":"active"},{"id":"570e39dc-d7a5-46d0-98b9-483d6ecfb61d","procedure_id":"proc-psilocybin-microdose","jurisdiction_id":"jur-gr","procedure_name":"Psilocybin Microdosing Protocols","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"PROHIBITED","access_pathway":"NONE","oversight_quality":"HIGH","modality":"PSYCHEDELICS","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"Classical/atypical psychedelic therapy for Psilocybin Microdosing Protocols treated as prohibited outside narrow research under default national posture.","eligibility_requirements":"No lawful general patient pathway under inferred default.","provider_requirements":"Cannot lawfully open a commercial program without an explicit statutory exception.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Criminal liability risk if default is accurate; always verify current schedule.","arbitrage_summary":"Inferred prohibited under jurisdiction psychedelic default / UN-style scheduling. Not a lawful commercial therapy market.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: No jurisdiction psychedelic_default on file — applied conservative Schedule-I-class default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Mental_Health","Cognition"],"diseases":["Depression","Anxiety","ADHD Symptoms (self-report)"],"status":"active"},{"id":"e0417a34-ebfe-4390-a317-e5aeb22a1bb0","procedure_id":"proc-cord-blood","jurisdiction_id":"jur-us-or","procedure_name":"Umbilical Cord Blood / Perinatal Cell Therapies","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Hematology","Regeneration"],"diseases":["Leukemia (transplant)","Lymphoma (transplant)","Cerebral Palsy (investigational clinics)"],"status":"active"},{"id":"d30f1fb4-71e6-43db-a6eb-3834f73f5778","procedure_id":"proc-cord-blood","jurisdiction_id":"jur-us-co","procedure_name":"Umbilical Cord Blood / Perinatal Cell Therapies","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Hematology","Regeneration"],"diseases":["Leukemia (transplant)","Lymphoma (transplant)","Cerebral Palsy (investigational clinics)"],"status":"active"},{"id":"81d97231-6f48-4de8-9496-5dfd22418430","procedure_id":"proc-cord-blood","jurisdiction_id":"jur-us-ca","procedure_name":"Umbilical Cord Blood / Perinatal Cell Therapies","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Hematology","Regeneration"],"diseases":["Leukemia (transplant)","Lymphoma (transplant)","Cerebral Palsy (investigational clinics)"],"status":"active"},{"id":"37779737-dc15-4a86-acaf-c1662a02fdc5","procedure_id":"proc-cord-blood","jurisdiction_id":"jur-us-tx","procedure_name":"Umbilical Cord Blood / Perinatal Cell Therapies","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Hematology","Regeneration"],"diseases":["Leukemia (transplant)","Lymphoma (transplant)","Cerebral Palsy (investigational clinics)"],"status":"active"},{"id":"f5f2d899-41f7-40ac-8088-bcf7029d167a","procedure_id":"proc-cord-blood","jurisdiction_id":"jur-us-fl","procedure_name":"Umbilical Cord Blood / Perinatal Cell Therapies","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Hematology","Regeneration"],"diseases":["Leukemia (transplant)","Lymphoma (transplant)","Cerebral Palsy (investigational clinics)"],"status":"active"},{"id":"0276f6fb-5772-4321-bbfe-709cb04a4cc9","procedure_id":"proc-cord-blood","jurisdiction_id":"jur-au","procedure_name":"Umbilical Cord Blood / Perinatal Cell Therapies","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"TGA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Hematology","Regeneration"],"diseases":["Leukemia (transplant)","Lymphoma (transplant)","Cerebral Palsy (investigational clinics)"],"status":"active"},{"id":"7cf3e732-918f-4507-9322-ac4d66a2b3b5","procedure_id":"proc-cord-blood","jurisdiction_id":"jur-ch","procedure_name":"Umbilical Cord Blood / Perinatal Cell Therapies","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"Swissmedic","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Hematology","Regeneration"],"diseases":["Leukemia (transplant)","Lymphoma (transplant)","Cerebral Palsy (investigational clinics)"],"status":"active"},{"id":"c18dcbb3-cd9c-40d2-8cf4-0563d6b2f5a1","procedure_id":"proc-cord-blood","jurisdiction_id":"jur-ca","procedure_name":"Umbilical Cord Blood / Perinatal Cell Therapies","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"Health Canada","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Hematology","Regeneration"],"diseases":["Leukemia (transplant)","Lymphoma (transplant)","Cerebral Palsy (investigational clinics)"],"status":"active"},{"id":"e75800d4-23dd-4997-a673-8965a53533ef","procedure_id":"proc-cord-blood","jurisdiction_id":"jur-hn-prospera","procedure_name":"Umbilical Cord Blood / Perinatal Cell Therapies","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"Próspera ZEDE health rules (contested)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Hematology","Regeneration"],"diseases":["Leukemia (transplant)","Lymphoma (transplant)","Cerebral Palsy (investigational clinics)"],"status":"active"},{"id":"cb2a2664-d0a5-4ebd-a1a0-cd300764a779","procedure_id":"proc-cord-blood","jurisdiction_id":"jur-nl","procedure_name":"Umbilical Cord Blood / Perinatal Cell Therapies","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"MEB / IGJ","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Hematology","Regeneration"],"diseases":["Leukemia (transplant)","Lymphoma (transplant)","Cerebral Palsy (investigational clinics)"],"status":"active"},{"id":"f6e7f11a-cf5f-44d0-8246-d6511368c466","procedure_id":"proc-cord-blood","jurisdiction_id":"jur-de","procedure_name":"Umbilical Cord Blood / Perinatal Cell Therapies","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"BfArM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Hematology","Regeneration"],"diseases":["Leukemia (transplant)","Lymphoma (transplant)","Cerebral Palsy (investigational clinics)"],"status":"active"},{"id":"a4ddc04a-6b15-4b11-a995-a95ba45e3270","procedure_id":"proc-cord-blood","jurisdiction_id":"jur-uk","procedure_name":"Umbilical Cord Blood / Perinatal Cell Therapies","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"MHRA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Hematology","Regeneration"],"diseases":["Leukemia (transplant)","Lymphoma (transplant)","Cerebral Palsy (investigational clinics)"],"status":"active"},{"id":"1edd5e69-a8dd-4c96-8818-dd3507916ca4","procedure_id":"proc-cord-blood","jurisdiction_id":"jur-il","procedure_name":"Umbilical Cord Blood / Perinatal Cell Therapies","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Hematology","Regeneration"],"diseases":["Leukemia (transplant)","Lymphoma (transplant)","Cerebral Palsy (investigational clinics)"],"status":"active"},{"id":"cb0f9a7b-3e3a-4993-856d-4429fe2ed774","procedure_id":"proc-cord-blood","jurisdiction_id":"jur-jm","procedure_name":"Umbilical Cord Blood / Perinatal Cell Therapies","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Hematology","Regeneration"],"diseases":["Leukemia (transplant)","Lymphoma (transplant)","Cerebral Palsy (investigational clinics)"],"status":"active"},{"id":"25ac0265-a6fe-46db-9162-30a124810bcf","procedure_id":"proc-cord-blood","jurisdiction_id":"jur-th","procedure_name":"Umbilical Cord Blood / Perinatal Cell Therapies","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"Thai FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Hematology","Regeneration"],"diseases":["Leukemia (transplant)","Lymphoma (transplant)","Cerebral Palsy (investigational clinics)"],"status":"active"},{"id":"71723b71-62a9-49de-af4e-22159fe6fde1","procedure_id":"proc-cord-blood","jurisdiction_id":"jur-es","procedure_name":"Umbilical Cord Blood / Perinatal Cell Therapies","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"AEMPS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Hematology","Regeneration"],"diseases":["Leukemia (transplant)","Lymphoma (transplant)","Cerebral Palsy (investigational clinics)"],"status":"active"},{"id":"bdcd9eab-948b-4931-9c83-be6b0a8e1663","procedure_id":"proc-cord-blood","jurisdiction_id":"jur-tu","procedure_name":"Umbilical Cord Blood / Perinatal Cell Therapies","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Hematology","Regeneration"],"diseases":["Leukemia (transplant)","Lymphoma (transplant)","Cerebral Palsy (investigational clinics)"],"status":"active"},{"id":"5360ddea-5a55-48c0-bcd8-8e1c17567c3d","procedure_id":"proc-cord-blood","jurisdiction_id":"jur-in","procedure_name":"Umbilical Cord Blood / Perinatal Cell Therapies","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"CDSCO","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Hematology","Regeneration"],"diseases":["Leukemia (transplant)","Lymphoma (transplant)","Cerebral Palsy (investigational clinics)"],"status":"active"},{"id":"4e85f061-53dd-4ae3-a4ba-7280cb2fc65f","procedure_id":"proc-cord-blood","jurisdiction_id":"jur-br","procedure_name":"Umbilical Cord Blood / Perinatal Cell Therapies","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"ANVISA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Hematology","Regeneration"],"diseases":["Leukemia (transplant)","Lymphoma (transplant)","Cerebral Palsy (investigational clinics)"],"status":"active"},{"id":"90f63d0e-1853-49d8-993e-baa4b0a75bf4","procedure_id":"proc-cord-blood","jurisdiction_id":"jur-cr","procedure_name":"Umbilical Cord Blood / Perinatal Cell Therapies","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Hematology","Regeneration"],"diseases":["Leukemia (transplant)","Lymphoma (transplant)","Cerebral Palsy (investigational clinics)"],"status":"active"},{"id":"34bb510a-a2a5-41b6-a431-5b9b723a7aae","procedure_id":"proc-cord-blood","jurisdiction_id":"jur-uae","procedure_name":"Umbilical Cord Blood / Perinatal Cell Therapies","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Hematology","Regeneration"],"diseases":["Leukemia (transplant)","Lymphoma (transplant)","Cerebral Palsy (investigational clinics)"],"status":"active"},{"id":"1b0c2955-ad5f-45f0-a5ff-ab4963223c32","procedure_id":"proc-cord-blood","jurisdiction_id":"jur-kr","procedure_name":"Umbilical Cord Blood / Perinatal Cell Therapies","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"MFDS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Hematology","Regeneration"],"diseases":["Leukemia (transplant)","Lymphoma (transplant)","Cerebral Palsy (investigational clinics)"],"status":"active"},{"id":"7e471d5e-a237-4c45-b650-efe9c78de827","procedure_id":"proc-cord-blood","jurisdiction_id":"jur-gr","procedure_name":"Umbilical Cord Blood / Perinatal Cell Therapies","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Hematology","Regeneration"],"diseases":["Leukemia (transplant)","Lymphoma (transplant)","Cerebral Palsy (investigational clinics)"],"status":"active"},{"id":"9c4a34ce-97ab-4256-ad25-6ee808dca9f7","procedure_id":"proc-cord-blood","jurisdiction_id":"jur-be","procedure_name":"Umbilical Cord Blood / Perinatal Cell Therapies","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Hematology","Regeneration"],"diseases":["Leukemia (transplant)","Lymphoma (transplant)","Cerebral Palsy (investigational clinics)"],"status":"active"},{"id":"037c1110-3b6e-4e98-a9c9-fc98a73da8b2","procedure_id":"proc-cord-blood","jurisdiction_id":"jur-se","procedure_name":"Umbilical Cord Blood / Perinatal Cell Therapies","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Hematology","Regeneration"],"diseases":["Leukemia (transplant)","Lymphoma (transplant)","Cerebral Palsy (investigational clinics)"],"status":"active"},{"id":"ddcf974f-def1-4e82-ae7d-a7f6d09cad0e","procedure_id":"proc-cord-blood","jurisdiction_id":"jur-jp","procedure_name":"Umbilical Cord Blood / Perinatal Cell Therapies","jurisdiction_name":"Japan","jurisdiction_latitude":36.2,"jurisdiction_longitude":138.2,"jurisdiction_type":"COUNTRY","country_code":"JP","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"PMDA / MHLW","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Hematology","Regeneration"],"diseases":["Leukemia (transplant)","Lymphoma (transplant)","Cerebral Palsy (investigational clinics)"],"status":"active"},{"id":"e5ce1b9b-f25b-409c-b16d-69f4dcda40a4","procedure_id":"proc-cord-blood","jurisdiction_id":"jur-cl","procedure_name":"Umbilical Cord Blood / Perinatal Cell Therapies","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Hematology","Regeneration"],"diseases":["Leukemia (transplant)","Lymphoma (transplant)","Cerebral Palsy (investigational clinics)"],"status":"active"},{"id":"bc627848-4088-44f3-8715-9d30862c4ded","procedure_id":"proc-cord-blood","jurisdiction_id":"jur-ar","procedure_name":"Umbilical Cord Blood / Perinatal Cell Therapies","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Hematology","Regeneration"],"diseases":["Leukemia (transplant)","Lymphoma (transplant)","Cerebral Palsy (investigational clinics)"],"status":"active"},{"id":"37fb77d6-ebb5-45f7-9f9b-8d8bf6ec8e95","procedure_id":"proc-cord-blood","jurisdiction_id":"jur-za","procedure_name":"Umbilical Cord Blood / Perinatal Cell Therapies","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Hematology","Regeneration"],"diseases":["Leukemia (transplant)","Lymphoma (transplant)","Cerebral Palsy (investigational clinics)"],"status":"active"},{"id":"f6a24b4c-5d09-4fa3-a1f0-0efa49dfc783","procedure_id":"proc-cord-blood","jurisdiction_id":"jur-ph","procedure_name":"Umbilical Cord Blood / Perinatal Cell Therapies","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Hematology","Regeneration"],"diseases":["Leukemia (transplant)","Lymphoma (transplant)","Cerebral Palsy (investigational clinics)"],"status":"active"},{"id":"c8c87c20-35ef-47ee-9d53-4bc0bc623e7b","procedure_id":"proc-cord-blood","jurisdiction_id":"jur-po","procedure_name":"Umbilical Cord Blood / Perinatal Cell Therapies","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Hematology","Regeneration"],"diseases":["Leukemia (transplant)","Lymphoma (transplant)","Cerebral Palsy (investigational clinics)"],"status":"active"},{"id":"3b680aa9-c3cf-4efd-bac5-35ad8d6d43b6","procedure_id":"proc-cord-blood","jurisdiction_id":"jur-pt","procedure_name":"Umbilical Cord Blood / Perinatal Cell Therapies","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Hematology","Regeneration"],"diseases":["Leukemia (transplant)","Lymphoma (transplant)","Cerebral Palsy (investigational clinics)"],"status":"active"},{"id":"2bc360d1-231c-4b20-8bb2-f8f97526a222","procedure_id":"proc-cord-blood","jurisdiction_id":"jur-fr","procedure_name":"Umbilical Cord Blood / Perinatal Cell Therapies","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"STEM_CELL","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"ANSM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Hematology","Regeneration"],"diseases":["Leukemia (transplant)","Lymphoma (transplant)","Cerebral Palsy (investigational clinics)"],"status":"active"},{"id":"531755e0-e544-46f1-a1d7-ca9fa8c2bfda","procedure_id":"proc-photoimmunotherapy","jurisdiction_id":"jur-us-or","procedure_name":"Near-Infrared Photoimmunotherapy for Head & Neck Cancer","jurisdiction_name":"United States - Oregon","jurisdiction_latitude":44.0,"jurisdiction_longitude":-120.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"FDA (federal) + OHA Psilocybin Services","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Head and Neck Squamous Cell Carcinoma"],"status":"active"},{"id":"6fd18185-ede5-45f7-abad-4ccf2e1d1d0d","procedure_id":"proc-photoimmunotherapy","jurisdiction_id":"jur-us-co","procedure_name":"Near-Infrared Photoimmunotherapy for Head & Neck Cancer","jurisdiction_name":"United States - Colorado","jurisdiction_latitude":39.0,"jurisdiction_longitude":-105.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"FDA + DORA Natural Medicine Division","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Head and Neck Squamous Cell Carcinoma"],"status":"active"},{"id":"369fe90d-ed45-43c0-bf5f-f6aa2b5aef81","procedure_id":"proc-photoimmunotherapy","jurisdiction_id":"jur-us-ca","procedure_name":"Near-Infrared Photoimmunotherapy for Head & Neck Cancer","jurisdiction_name":"United States - California","jurisdiction_latitude":36.8,"jurisdiction_longitude":-119.4,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Head and Neck Squamous Cell Carcinoma"],"status":"active"},{"id":"208be2dd-9bef-4813-ad0e-022ac790a6df","procedure_id":"proc-photoimmunotherapy","jurisdiction_id":"jur-us-tx","procedure_name":"Near-Infrared Photoimmunotherapy for Head & Neck Cancer","jurisdiction_name":"United States - Texas","jurisdiction_latitude":31.0,"jurisdiction_longitude":-100.0,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Head and Neck Squamous Cell Carcinoma"],"status":"active"},{"id":"b2b65659-6fe7-4f63-b1e4-37756909f7ba","procedure_id":"proc-photoimmunotherapy","jurisdiction_id":"jur-us-fl","procedure_name":"Near-Infrared Photoimmunotherapy for Head & Neck Cancer","jurisdiction_name":"United States - Florida","jurisdiction_latitude":27.7,"jurisdiction_longitude":-81.5,"jurisdiction_type":"US_STATE","country_code":"US","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Head and Neck Squamous Cell Carcinoma"],"status":"active"},{"id":"e9cac6d5-0bcf-4df4-9ac1-9877b92eb7fd","procedure_id":"proc-photoimmunotherapy","jurisdiction_id":"jur-au","procedure_name":"Near-Infrared Photoimmunotherapy for Head & Neck Cancer","jurisdiction_name":"Australia","jurisdiction_latitude":-25.3,"jurisdiction_longitude":133.8,"jurisdiction_type":"COUNTRY","country_code":"AU","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"TGA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Head and Neck Squamous Cell Carcinoma"],"status":"active"},{"id":"f3cd2322-e694-4d2c-8e33-b1a6d1b003c7","procedure_id":"proc-photoimmunotherapy","jurisdiction_id":"jur-ch","procedure_name":"Near-Infrared Photoimmunotherapy for Head & Neck Cancer","jurisdiction_name":"Switzerland","jurisdiction_latitude":46.8,"jurisdiction_longitude":8.2,"jurisdiction_type":"COUNTRY","country_code":"CH","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"Swissmedic","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Head and Neck Squamous Cell Carcinoma"],"status":"active"},{"id":"48d9efb2-64e4-4b6d-85b3-42e58af0a0ab","procedure_id":"proc-photoimmunotherapy","jurisdiction_id":"jur-ca","procedure_name":"Near-Infrared Photoimmunotherapy for Head & Neck Cancer","jurisdiction_name":"Canada","jurisdiction_latitude":56.1,"jurisdiction_longitude":-106.3,"jurisdiction_type":"COUNTRY","country_code":"CA","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"Health Canada","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Head and Neck Squamous Cell Carcinoma"],"status":"active"},{"id":"daa7c177-1a15-4744-acf6-a04f27703124","procedure_id":"proc-photoimmunotherapy","jurisdiction_id":"jur-mx","procedure_name":"Near-Infrared Photoimmunotherapy for Head & Neck Cancer","jurisdiction_name":"Mexico","jurisdiction_latitude":23.6,"jurisdiction_longitude":-102.5,"jurisdiction_type":"COUNTRY","country_code":"MX","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"COFEPRIS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Head and Neck Squamous Cell Carcinoma"],"status":"active"},{"id":"0b823958-592b-4783-91c2-a9672066cecd","procedure_id":"proc-photoimmunotherapy","jurisdiction_id":"jur-hn-prospera","procedure_name":"Near-Infrared Photoimmunotherapy for Head & Neck Cancer","jurisdiction_name":"Honduras - Próspera ZEDE","jurisdiction_latitude":16.2,"jurisdiction_longitude":-86.5,"jurisdiction_type":"ZEDE","country_code":"HN","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"Próspera ZEDE health rules (contested)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Head and Neck Squamous Cell Carcinoma"],"status":"active"},{"id":"30f68a1f-4ae9-49fe-8ec9-e33ba8d65ceb","procedure_id":"proc-photoimmunotherapy","jurisdiction_id":"jur-nl","procedure_name":"Near-Infrared Photoimmunotherapy for Head & Neck Cancer","jurisdiction_name":"Netherlands","jurisdiction_latitude":52.1,"jurisdiction_longitude":5.3,"jurisdiction_type":"COUNTRY","country_code":"NL","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"MEB / IGJ","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Head and Neck Squamous Cell Carcinoma"],"status":"active"},{"id":"f6a1093c-aa72-4f8d-97e5-7e0cde1eddb9","procedure_id":"proc-photoimmunotherapy","jurisdiction_id":"jur-de","procedure_name":"Near-Infrared Photoimmunotherapy for Head & Neck Cancer","jurisdiction_name":"Germany","jurisdiction_latitude":51.2,"jurisdiction_longitude":10.5,"jurisdiction_type":"COUNTRY","country_code":"DE","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"BfArM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Head and Neck Squamous Cell Carcinoma"],"status":"active"},{"id":"67be47ca-4902-4175-ae49-1a8a568d9bc3","procedure_id":"proc-photoimmunotherapy","jurisdiction_id":"jur-uk","procedure_name":"Near-Infrared Photoimmunotherapy for Head & Neck Cancer","jurisdiction_name":"United Kingdom","jurisdiction_latitude":55.4,"jurisdiction_longitude":-3.4,"jurisdiction_type":"COUNTRY","country_code":"GB","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"MHRA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Head and Neck Squamous Cell Carcinoma"],"status":"active"},{"id":"d6c540b5-5955-486c-bbcc-548644386e82","procedure_id":"proc-photoimmunotherapy","jurisdiction_id":"jur-il","procedure_name":"Near-Infrared Photoimmunotherapy for Head & Neck Cancer","jurisdiction_name":"Israel","jurisdiction_latitude":31.0,"jurisdiction_longitude":34.9,"jurisdiction_type":"COUNTRY","country_code":"IL","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Head and Neck Squamous Cell Carcinoma"],"status":"active"},{"id":"805ec5a4-c3ce-4631-abc0-88a74971e767","procedure_id":"proc-photoimmunotherapy","jurisdiction_id":"jur-jm","procedure_name":"Near-Infrared Photoimmunotherapy for Head & Neck Cancer","jurisdiction_name":"Jamaica","jurisdiction_latitude":18.1,"jurisdiction_longitude":-77.3,"jurisdiction_type":"COUNTRY","country_code":"JM","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"Ministry of Health","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Head and Neck Squamous Cell Carcinoma"],"status":"active"},{"id":"7bee5c77-f900-4d08-a5c4-b4bc1304aaeb","procedure_id":"proc-photoimmunotherapy","jurisdiction_id":"jur-th","procedure_name":"Near-Infrared Photoimmunotherapy for Head & Neck Cancer","jurisdiction_name":"Thailand","jurisdiction_latitude":15.9,"jurisdiction_longitude":100.9,"jurisdiction_type":"COUNTRY","country_code":"TH","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"Thai FDA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Head and Neck Squamous Cell Carcinoma"],"status":"active"},{"id":"5908235a-c894-459f-922d-d61b5c7b1c4b","procedure_id":"proc-photoimmunotherapy","jurisdiction_id":"jur-es","procedure_name":"Near-Infrared Photoimmunotherapy for Head & Neck Cancer","jurisdiction_name":"Spain","jurisdiction_latitude":40.5,"jurisdiction_longitude":-3.7,"jurisdiction_type":"COUNTRY","country_code":"ES","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"AEMPS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Head and Neck Squamous Cell Carcinoma"],"status":"active"},{"id":"0f708fde-0535-4586-8750-2c4dc66c8182","procedure_id":"proc-photoimmunotherapy","jurisdiction_id":"jur-tu","procedure_name":"Near-Infrared Photoimmunotherapy for Head & Neck Cancer","jurisdiction_name":"Turkey","jurisdiction_latitude":39.0,"jurisdiction_longitude":35.2,"jurisdiction_type":"COUNTRY","country_code":"TR","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Head and Neck Squamous Cell Carcinoma"],"status":"active"},{"id":"a8a27706-c44d-4a0c-acfd-259459091d8a","procedure_id":"proc-photoimmunotherapy","jurisdiction_id":"jur-in","procedure_name":"Near-Infrared Photoimmunotherapy for Head & Neck Cancer","jurisdiction_name":"India","jurisdiction_latitude":20.6,"jurisdiction_longitude":78.9,"jurisdiction_type":"COUNTRY","country_code":"IN","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"CDSCO","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Head and Neck Squamous Cell Carcinoma"],"status":"active"},{"id":"1ce0ab0e-e0a5-43eb-bd14-3bd089905f20","procedure_id":"proc-photoimmunotherapy","jurisdiction_id":"jur-br","procedure_name":"Near-Infrared Photoimmunotherapy for Head & Neck Cancer","jurisdiction_name":"Brazil","jurisdiction_latitude":-14.2,"jurisdiction_longitude":-51.9,"jurisdiction_type":"COUNTRY","country_code":"BR","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"ANVISA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Head and Neck Squamous Cell Carcinoma"],"status":"active"},{"id":"940f585e-275f-4462-9f90-7bad2b0273f0","procedure_id":"proc-photoimmunotherapy","jurisdiction_id":"jur-cr","procedure_name":"Near-Infrared Photoimmunotherapy for Head & Neck Cancer","jurisdiction_name":"Costa Rica","jurisdiction_latitude":9.7,"jurisdiction_longitude":-83.8,"jurisdiction_type":"COUNTRY","country_code":"CR","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Head and Neck Squamous Cell Carcinoma"],"status":"active"},{"id":"bad2be84-7017-403c-acc9-72fa75e8fea6","procedure_id":"proc-photoimmunotherapy","jurisdiction_id":"jur-uae","procedure_name":"Near-Infrared Photoimmunotherapy for Head & Neck Cancer","jurisdiction_name":"United Arab Emirates (Dubai)","jurisdiction_latitude":24.5,"jurisdiction_longitude":54.4,"jurisdiction_type":"COUNTRY","country_code":"AE","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Head and Neck Squamous Cell Carcinoma"],"status":"active"},{"id":"19f16c1b-c3a8-42e5-b0ea-35b8aaeec056","procedure_id":"proc-photoimmunotherapy","jurisdiction_id":"jur-kr","procedure_name":"Near-Infrared Photoimmunotherapy for Head & Neck Cancer","jurisdiction_name":"South Korea","jurisdiction_latitude":36.2,"jurisdiction_longitude":127.1,"jurisdiction_type":"COUNTRY","country_code":"KR","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"MFDS","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Head and Neck Squamous Cell Carcinoma"],"status":"active"},{"id":"15bc28a6-7be6-4262-af80-6ecf47bb380b","procedure_id":"proc-photoimmunotherapy","jurisdiction_id":"jur-gr","procedure_name":"Near-Infrared Photoimmunotherapy for Head & Neck Cancer","jurisdiction_name":"Greece","jurisdiction_latitude":39.1,"jurisdiction_longitude":21.8,"jurisdiction_type":"COUNTRY","country_code":"GR","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Head and Neck Squamous Cell Carcinoma"],"status":"active"},{"id":"e65756ec-72b9-4d1f-9f3f-b3e6caad3254","procedure_id":"proc-photoimmunotherapy","jurisdiction_id":"jur-be","procedure_name":"Near-Infrared Photoimmunotherapy for Head & Neck Cancer","jurisdiction_name":"Belgium","jurisdiction_latitude":50.5,"jurisdiction_longitude":4.5,"jurisdiction_type":"COUNTRY","country_code":"BE","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"FAMHP","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Head and Neck Squamous Cell Carcinoma"],"status":"active"},{"id":"ddf9b2ac-3d22-4817-9143-140c4295b224","procedure_id":"proc-photoimmunotherapy","jurisdiction_id":"jur-se","procedure_name":"Near-Infrared Photoimmunotherapy for Head & Neck Cancer","jurisdiction_name":"Sweden","jurisdiction_latitude":60.1,"jurisdiction_longitude":18.6,"jurisdiction_type":"COUNTRY","country_code":"SE","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Head and Neck Squamous Cell Carcinoma"],"status":"active"},{"id":"7a204d14-2967-40f5-b37f-4b8e9aea40d6","procedure_id":"proc-photoimmunotherapy","jurisdiction_id":"jur-sg","procedure_name":"Near-Infrared Photoimmunotherapy for Head & Neck Cancer","jurisdiction_name":"Singapore","jurisdiction_latitude":1.3,"jurisdiction_longitude":103.8,"jurisdiction_type":"COUNTRY","country_code":"SG","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"HSA","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Head and Neck Squamous Cell Carcinoma"],"status":"active"},{"id":"3be729ee-c439-458f-8709-8c81cdf6b3d3","procedure_id":"proc-photoimmunotherapy","jurisdiction_id":"jur-cl","procedure_name":"Near-Infrared Photoimmunotherapy for Head & Neck Cancer","jurisdiction_name":"Chile","jurisdiction_latitude":-35.7,"jurisdiction_longitude":-71.5,"jurisdiction_type":"COUNTRY","country_code":"CL","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Head and Neck Squamous Cell Carcinoma"],"status":"active"},{"id":"b34d42ca-4de3-4121-9f52-e194b09a5bbd","procedure_id":"proc-photoimmunotherapy","jurisdiction_id":"jur-ar","procedure_name":"Near-Infrared Photoimmunotherapy for Head & Neck Cancer","jurisdiction_name":"Argentina","jurisdiction_latitude":-38.4,"jurisdiction_longitude":-63.6,"jurisdiction_type":"COUNTRY","country_code":"AR","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Head and Neck Squamous Cell Carcinoma"],"status":"active"},{"id":"a0ab1a8a-6a69-44d4-aed7-5fe159df0b6d","procedure_id":"proc-photoimmunotherapy","jurisdiction_id":"jur-za","procedure_name":"Near-Infrared Photoimmunotherapy for Head & Neck Cancer","jurisdiction_name":"South Africa","jurisdiction_latitude":-30.6,"jurisdiction_longitude":22.9,"jurisdiction_type":"COUNTRY","country_code":"ZA","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Head and Neck Squamous Cell Carcinoma"],"status":"active"},{"id":"96478e35-6326-451b-8d42-e159c2eff513","procedure_id":"proc-photoimmunotherapy","jurisdiction_id":"jur-ph","procedure_name":"Near-Infrared Photoimmunotherapy for Head & Neck Cancer","jurisdiction_name":"Philippines","jurisdiction_latitude":12.9,"jurisdiction_longitude":121.8,"jurisdiction_type":"COUNTRY","country_code":"PH","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Head and Neck Squamous Cell Carcinoma"],"status":"active"},{"id":"79886172-e625-48df-bcfa-d617fd049956","procedure_id":"proc-photoimmunotherapy","jurisdiction_id":"jur-po","procedure_name":"Near-Infrared Photoimmunotherapy for Head & Neck Cancer","jurisdiction_name":"Poland","jurisdiction_latitude":51.9,"jurisdiction_longitude":19.1,"jurisdiction_type":"COUNTRY","country_code":"PL","legal_status":"CLINICAL_TRIAL_ONLY","access_pathway":"CLINICAL_TRIAL_ENROLLMENT","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"National medicines / health authority (inferred)","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Head and Neck Squamous Cell Carcinoma"],"status":"active"},{"id":"424a1561-ad1f-4d2e-a6dd-5fcba7d52c24","procedure_id":"proc-photoimmunotherapy","jurisdiction_id":"jur-pt","procedure_name":"Near-Infrared Photoimmunotherapy for Head & Neck Cancer","jurisdiction_name":"Portugal","jurisdiction_latitude":39.4,"jurisdiction_longitude":-8.2,"jurisdiction_type":"COUNTRY","country_code":"PT","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"INFARMED","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Head and Neck Squamous Cell Carcinoma"],"status":"active"},{"id":"522b0b46-fdac-4ef8-896d-be0481e8676b","procedure_id":"proc-photoimmunotherapy","jurisdiction_id":"jur-fr","procedure_name":"Near-Infrared Photoimmunotherapy for Head & Neck Cancer","jurisdiction_name":"France","jurisdiction_latitude":46.6,"jurisdiction_longitude":2.2,"jurisdiction_type":"COUNTRY","country_code":"FR","legal_status":"PERMITTED_EXPANDED_ACCESS","access_pathway":"EXPANDED_ACCESS","oversight_quality":"HIGH","modality":"ONCOLOGY","estimated_cost_range_usd":"Not priced — inferred cell","price_usd":null,"access_pathway_details":"No open commercial programme inferred.","eligibility_requirements":"Protocol criteria.","provider_requirements":"Authorized research site.","residency_travel_notes":"Residency rules not specifically researched for this inferred cell.","risk_notes":"Inference risk: actual law may be stricter or more permissive than defaults.","arbitrage_summary":"Inferred trial/special-access only for experimental cell/gene modality.","oversight_notes":"INFERRED cell — no explicit curated AccessCell existed for this pair. Derived from jurisdiction defaults (psychedelic/cannabis/MAID/RTT/compounding) and therapy class rules. Confirm primary law before relying.","cost_notes":"No market price research for this inferred cell.","legal_basis":"Inferred: experimental advanced therapy → trial/expanded access default.","regulatory_authority":"ANSM","last_verified":"2026-07-17","sources":[{"title":"Inferred from jurisdiction regulatory profile + therapy class","url":null,"note":"Not an explicit statute-by-statute determination for this pair"}],"therapeutic_areas":["Oncology"],"diseases":["Head and Neck Squamous Cell Carcinoma"],"status":"active"}],"filter_options":{"modalities":["ASSISTED_DYING","CELLULAR","GENE_THERAPY","ONCOLOGY","PEPTIDE","PHYTOCANNABINOID","PSYCHEDELICS","REPRODUCTIVE","REPURPOSED","STEM_CELL"],"legal_statuses":["APPROVED_OFF_LABEL","APPROVED_ON_LABEL","CLINICAL_TRIAL_ONLY","DECRIMINALIZED","DECRIMINALIZED_NO_SUPPLY","FULLY_APPROVED","PERMITTED_EXPANDED_ACCESS","PHYSICIAN_DISCRETION_GRAY","PROHIBITED","REGULATED_THERAPY","RIGHT_TO_TRY","UNKNOWN","UNREGULATED_PERMITTED"],"oversight_qualities":["HIGH","LOW","MEDIUM","MINIMAL","REGULATED_HIGH","REGULATED_MODERATE","VARIABLE"],"therapeutic_areas":["Addiction","Aging","Anti_Aging","Anxiety","Autoimmune","Cardiology","Cardiovascular","Chronic_Infection","Chronic_Pain","Cognition","Critical_Care","Dementia","Depression","Detoxification","End_of_Life","Endocrinology","Energy","Gastrointestinal","Genetics","HIV","Hematology","Immunology","Infection","Kidney","Long_COVID","Longevity","Melanoma","Men's_Health","Mental_Health","Metabolic_Health","Mitochondrial_Health","Movement_Disorders","Neurological","Neurology","OCD","Oncology","Ophthalmology","Orthopedic","PTSD","Pain","Palliative_Care","Performance","Recovery","Regeneration","Reproductive_Health","Sexual_Health","Spinal_Cord_Injury","Spirituality","Sports_Medicine","Wound_Healing"]}}